<SEC-DOCUMENT>0001193125-20-049115.txt : 20200226
<SEC-HEADER>0001193125-20-049115.hdr.sgml : 20200226
<ACCEPTANCE-DATETIME>20200226071729
ACCESSION NUMBER:		0001193125-20-049115
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200226
DATE AS OF CHANGE:		20200226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Karyopharm Therapeutics Inc.
		CENTRAL INDEX KEY:			0001503802
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263931704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36167
		FILM NUMBER:		20653295

	BUSINESS ADDRESS:	
		STREET 1:		85 WELLS AVENUE
		STREET 2:		SECOND FLOOR
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02459
		BUSINESS PHONE:		617-658-0600

	MAIL ADDRESS:	
		STREET 1:		85 WELLS AVENUE
		STREET 2:		SECOND FLOOR
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02459
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d853399d10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:kpti="http://www.karyopharm.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
 <div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="kpti:LicenseAgreementTerminationDescription" id="hidden10185021" contextRef="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">the Ono License Agreement may be terminated earlier by (i) either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Ono on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days' prior notice or (iii) us in the event Ono challenges or assists with a challenge to certain of our patent rights.</ix:nonNumeric><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="hidden11073498" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">9843094</ix:nonFraction><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2019To12_31_2019">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2019To12_31_2019">2019</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2019To12_31_2019">FY </ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2019To12_31_2019">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden10168366" contextRef="P01_01_2019To12_31_2019">Karyopharm Therapeutics Inc.</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2019To12_31_2019">0001503802</ix:nonNumeric><ix:nonNumeric name="kpti:OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" id="hidden10534998" contextRef="P01_01_2019To12_31_2019">P3D</ix:nonNumeric><ix:nonNumeric name="kpti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="hidden10168480" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P6M</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden10173497" contextRef="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="kpti:SaleAgreementTerminationDate" id="hidden10182875" contextRef="P10_02_2018To10_02_2018">2018-08-12</ix:nonNumeric><ix:footnote id="FN_40312" xml:lang="en-US">Represents capitalization of operating lease right-of-use assets, offset by reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</ix:footnote ><ix:footnote id="FN_40313" xml:lang="en-US">Represents reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</ix:footnote ><ix:footnote id="FN_40314" xml:lang="en-US">Represents recognition of operating lease liabilities.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="kpti-20191231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_16_2018To10_16_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-16</xbrli:startDate> <xbrli:endDate>2018-10-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_02_2018To10_02_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-02</xbrli:startDate> <xbrli:endDate>2018-10-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OfficeAndResearchSpaceLeaseMemberusgaapLeaseArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis" >kpti:OfficeAndResearchSpaceLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >kpti:LongTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis" >us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" >kpti:SelinexorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" >kpti:EltanexorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_KPT9274MemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" >kpti:KPT9274Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_VerdinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" >kpti:VerdinexorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:SalesEventsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >kpti:LongTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >kpti:LongTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >kpti:HealthcareRoyaltyPartnersIvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMemberKPTIRoyaltyPaymentDueDateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >kpti:HealthcareRoyaltyPartnersIvLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kpti:RoyaltyPaymentDueDateAxis" >kpti:RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMemberKPTIRoyaltyPaymentDueDateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >kpti:HealthcareRoyaltyPartnersIvLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="kpti:RoyaltyPaymentDueDateAxis" >kpti:RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DeferredRoyaltyObligationMemberusgaapBalanceSheetLocationAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >kpti:DeferredRoyaltyObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >kpti:ConsultingAndContractResearchServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MinimumMembersrtRangeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >kpti:LongTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >kpti:LongTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >kpti:ConsultingAndContractResearchServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_JefferiesLLCMembersrtCounterpartyNameAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:OpenMarketSaleAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >kpti:JefferiesLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseAndAssetPurchaseAgreementsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:LicenseAndAssetPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:BiogenMAIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis" >kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodonememberMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >kpti:VestingperiodonememberMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodtwomemberMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >kpti:VestingperiodtwomemberMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonAreaMaintenanceMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >kpti:CommonAreaMaintenanceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseAndOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:LicenseAndOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_XpovioMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:XpovioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DEsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:DE</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >kpti:ConsultingAndHistopathologyServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >kpti:CantorFitzgeraldAndCoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >kpti:JefferiesLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:OpenMarketSaleAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicenseAndOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:LicenseAndOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >kpti:ConsultingAndHistopathologyServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >kpti:CantorFitzgeraldAndCoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_LicenseAndOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:LicenseAndOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:DevelopmentGoalsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-05-23</xbrli:startDate> <xbrli:endDate>2018-05-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:SalesEventsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-05-23</xbrli:startDate> <xbrli:endDate>2018-05-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis" >us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:DevelopmentMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:SalesEventsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:BiogenMAIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis" >kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-24</xbrli:startDate> <xbrli:endDate>2018-01-24</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis_MaximumMembersrtRangeAxis_SalesMilestoneMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis" >kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:SalesMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:BiogenMAIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-01-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis" >kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:BiogenMAIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-01-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To03_31_2018_BiogenMAIncMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:BiogenMAIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_11_2017To10_11_2017_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:DevelopmentGoalsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-10-11</xbrli:startDate> <xbrli:endDate>2017-10-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_11_2017To10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:SalesEventsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-10-11</xbrli:startDate> <xbrli:endDate>2017-10-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis" >us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-10-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" >kpti:SelinexorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" >kpti:EltanexorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_ClinicalDevelopmentAndRegulatoryMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_ScenarioPlanMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >kpti:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_28_2017To04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-04-28</xbrli:startDate> <xbrli:endDate>2017-04-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-04-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-16</xbrli:startDate> <xbrli:endDate>2018-10-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_16_2018To10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-16</xbrli:startDate> <xbrli:endDate>2018-10-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_26_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >srt:ScenarioForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-15</xbrli:startDate> <xbrli:endDate>2022-10-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2018_AccountingStandardsUpdate201616MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-05-07</xbrli:startDate> <xbrli:endDate>2018-05-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-05-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_07_2015To12_07_2015_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >kpti:CantorFitzgeraldAndCoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-12-07</xbrli:startDate> <xbrli:endDate>2015-12-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >kpti:JefferiesLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >kpti:OpenMarketSaleAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2013-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2013_MaximumMembersrtRangeAxis_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2013-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2013To10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-10-01</xbrli:startDate> <xbrli:endDate>2013-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001503802</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft" > <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_JPY" > <xbrli:measure>iso4217:JPY</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Securities" > <xbrli:measure>kpti:Securities</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Segments" > <xbrli:measure>kpti:Segments</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_D" > <xbrli:measure>utr:D</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Installment" > <xbrli:measure>kpti:Installment</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_10522752" toRefs="FN_40312"/><ix:relationship fromRefs="Fact_10522753" toRefs="FN_40312"/><ix:relationship fromRefs="Fact_10522754" toRefs="FN_40313"/><ix:relationship fromRefs="Fact_10522755" toRefs="FN_40313"/><ix:relationship fromRefs="Fact_10522756" toRefs="FN_40313"/><ix:relationship fromRefs="Fact_10522757" toRefs="FN_40313"/><ix:relationship fromRefs="Fact_10522758" toRefs="FN_40314"/><ix:relationship fromRefs="Fact_10522759" toRefs="FN_40314"/><ix:relationship fromRefs="Fact_10522760" toRefs="FN_40314"/><ix:relationship fromRefs="Fact_10522761" toRefs="FN_40314"/></ix:resources></ix:header></div><div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em; line-height: 12pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: center;"><div style="width: 100%; line-height: 0.5pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center;"><div style="width: 100%; line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: center;"><div style="margin: 6pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2019To12_31_2019">10-K</ix:nonNumeric></div> </div></div></div><div style="text-align: center;"><div style="margin: 6pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(Mark One) </div></div></div><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2019To12_31_2019" format="ixt:booleantrue">&#9746;</ix:nonNumeric></div></div></div> </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; padding: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 11pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center;font-family: &quot;Times New Roman&quot;;font-size: 9pt;font-weight: normal;margin-top: 6pt;margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended: <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2019To12_31_2019" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></div> </div></div></div><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2019To12_31_2019" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></div></div> </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>&#160;to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>&#160;</div></div></div></div><div style="text-align: center;font-family: &quot;Times New Roman&quot;;font-size: 10pt;font-weight: normal;margin-top: 6pt;margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">Commission file number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2019To12_31_2019">001-36167</ix:nonNumeric></div> </div></div></div><div style="text-align: center;"><div style="margin: 6pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden10168366">KARYOPHARM THERAPEUTICS INC</span>.</div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="text-align: center;"><div style="margin: 6pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 6pt auto 0px; width: 100%; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 48%; padding: 0px;"></td></tr>
<tr style="font-size: 9pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2019To12_31_2019" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div> </div></div></div></td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2019To12_31_2019">26-3931704</ix:nonNumeric></div> </div> </div></div></td></tr>
<tr style="font-size: 7pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization) </div></div></div></td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Identification No.) </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2019To12_31_2019">85 Wells Avenue, 2<div style="font-size: 6.66pt; vertical-align: top; line-height: 4.9284pt;;display:inline;">nd</div> Floor</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2019To12_31_2019">Newton</ix:nonNumeric></div>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2019To12_31_2019" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2019To12_31_2019">02459</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(Address of principal executive offices) (zip code) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">Registrant&#8217;s telephone number, including area code: (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2019To12_31_2019">617</ix:nonNumeric></div>)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2019To12_31_2019">658-0600</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 6pt auto 0px; width: 100%; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 33%; padding: 0px;"></td>
<td style="padding: 0px; width: 1%;"></td>
<td style="width: 33%; padding: 0px;"></td></tr>
<tr style="font-size: 7pt; page-break-inside: avoid;">
<td style="text-align: center; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 34%;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(Title of each class) </div></div></div></td>
<td style="vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 33%;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Trading Symbol(s) </div></div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; width: 1%;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 33%;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(Name of each exchange on which listed) </div></div></div></td></tr>
<tr style="font-size: 9pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 34%;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2019To12_31_2019">Common Stock</ix:nonNumeric></div>, $0.0001 par value </div></div></div></td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top; width: 33%;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2019To12_31_2019">KPTI</ix:nonNumeric></div> </div></div></div></td>
<td style="vertical-align: top; padding-left: 0px; width: 1%;">&#160;</td>
<td style="padding: 0px; vertical-align: top; width: 33%;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2019To12_31_2019" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></div> </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: None </div></div></div><div style="text-align: center;"><div style="margin: 6pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2019To12_31_2019">Yes</ix:nonNumeric>&#160;&#160;<div style="font-family: 'Times New Roman'; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> No</div>&#160;&#160;<div style="font-family: 'Times New Roman'; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2019To12_31_2019">No</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2019To12_31_2019">Yes</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;&#160;&#160;No&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;S-T</div> (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2019To12_31_2019">Yes</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div>&#160;&#160;&#160;&#160;No&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 6pt auto 0px; width: 100%; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 14%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 65%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; padding: 0px; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Large accelerated filer</div> </div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2019To12_31_2019" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric></div> </div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div>&#160;filer</div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Smaller&#160;reporting&#160;company </div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2019To12_31_2019" format="ixt:booleantrue">&#9746;</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 4px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Emerging&#160;growth&#160;company </div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2019To12_31_2019" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;">Indicate by check mark whether the registrant is a shell company (as defined in Rule<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;&#160;&#160;No&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2019To12_31_2019" format="ixt:booleanfalse">&#9746;</ix:nonNumeric></div></div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The aggregate market value of the registrant&#8217;s voting and non-voting common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold on June&#160;30, 2019 was </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">343,517,677</ix:nonFraction>. Shares of common </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">stock held by each executive officer and director and by each holder of 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Number of shares outstanding of the registrant&#8217;s Common Stock as of February&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div>, 2020: </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn02_14_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">65,548,095</ix:nonFraction>.</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Documents incorporated by reference: </div></div></div><div style="text-align: left; text-indent: 3%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Portions of our definitive proxy statement to be filed with the Securities and Exchange Commission no later than April 29, 2020 in connection with our 2020 annual meeting of stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K. </div></div><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div><div style="text-align: center;"><div style="width: 100%; line-height: 0.5pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="width: 100%; line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div></div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div></div></div><div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div><div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;"><div style="width: 100%; font-size: 10pt;"><div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 13%; padding: 0px;"></td>
<td style="width: 3%; padding: 0px;"></td>
<td style="width: 78%; padding: 0px;"></td>
<td style="width: 3%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Page&#160;No. </div></div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_1">PART I </a> </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_2">Business</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_3">Risk Factors</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1B. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_4">Unresolved Staff Comments</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_5">Properties</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_6">Legal Proceedings</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_7">Mine Safety Disclosures</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_8">PART II </a> </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;5. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_9">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_10">Selected Financial Data</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;7. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_11">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;7A. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_12">Quantitative and Qualitative Disclosures about Market Risk</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;8. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_13">Financial Statements and Supplementary Data</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9A. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_14">Controls and Procedures</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9B. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_15">Other Information</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_16">PART III </a> </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;10. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_17">Directors, Executive Officers and Corporate Governance</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;11. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_18">Executive Compensation</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;12. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_19">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;13. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_20">Certain Relationships and Related Transactions, and Director Independence</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;14. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_21">Principal Accountant Fees and Services</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_22">PART IV </a> </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;15. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_23">Exhibits and Financial Statement Schedules</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16. </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_24">Form 10-K Summary</a> </div></div></div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx853399_25">SIGNATURES </a> </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div></div><div style="width: 100%;"><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward-Looking Information </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;">This Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> contains forward-looking statements regarding the expectations of Karyopharm Therapeutics Inc., herein referred to as &#8220;Karyopharm,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our,&#8221; with respect to the possible achievement of discovery and development milestones, our future discovery and development efforts, our commercialization efforts, our partnerships with third parties, our future operating results and financial position, our business strategy, and other objectives for future operations. We often use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. You also can identify these forward-looking statements by the fact that they do not relate strictly to historical or current facts. There are a number of important risks and uncertainties that could cause actual results or events to differ materially from those indicated by forward-looking statements. These risks and uncertainties include those inherent in pharmaceutical research and development, such as our ability to successfully commercialize XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (selinexor), adverse results in our drug discovery and clinical development activities, decisions made by the U.S. Food and Drug Administration and other regulatory authorities with respect to the development and commercialization of our drug candidates, our ability to raise additional capital to support our clinical development program and other operations, our ability to develop products of commercial value and to identify, discover and obtain rights to additional potential product candidates, our ability to obtain, maintain and enforce intellectual property rights for our drug candidates, dependence on any collaborators, competition, our ability to obtain any necessary financing to conduct our planned activities, and other risk factors. Please refer to the section entitled &#8220;Risk Factors&#8221; in Part&#160;I of this report for a description of these risks and uncertainties. Unless required by law, we do not undertake any obligation to update any forward-looking statements. </div></div> <div id="tx853399_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 24pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I </div></div></div> <div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;1. </div></td>
<td id="tx853399_2" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Business</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 24pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We are an innovation-driven pharmaceutical company focused on the discovery, development and commercialization of novel, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">S</div></div>elective <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">I</div></div>nhibitor of <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">N</div></div>uclear <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">E</div></div>xport</div></div> (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SINE</div></div>) compounds that inhibit the nuclear export protein exportin 1, or XPO1. These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of high unmet medical need diseases. Our SINE compounds were the first oral XPO1 inhibitors in clinical development. Our lead asset, XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (selinexor) tablets, was the first SINE compound to receive marketing approval by the U.S. Food and Drug Administration, or FDA, on July&#160;3, 2019 and is currently indicated for use in adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, or PIs, at least two immunomodulatory agents, or IMiDs, and an anti-CD38 monoclonal antibody. We refer to myeloma that is refractory to these five agents as penta-refractory myeloma. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing, randomized Phase 3 BOSTON (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Bo</div></div></div></div>rtezomib, <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">S</div></div></div></div>elinexor and Dexame<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">t</div></div></div></div>has<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">on</div></div></div></div>e) study evaluating selinexor in combination with Velcade<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (bortezomib) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> dexamethasone in patients with myeloma treatment with between one and three prior therapies is expected to serve as the confirmatory trial.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our focus is on marketing XPOVIO in its currently approved indication as well as seeking the regulatory approval and potential commercialization of selinexor as an oral agent in additional cancer indications with significant unmet medical need. We plan to conduct additional clinical trials and seek additional approvals for the use of selinexor in combination with other oncology therapies to expand the patient populations that are eligible for selinexor. Thus, we are currently advancing the clinical development of selinexor in multiple hematological malignancies and solid tumor indications. Studies that support submitted applications for regulatory approval include STORM (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div></div>reatment of <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">R</div></div></div>efractory <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">M</div></div></div>yeloma) and SADAL (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>gainst <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">D</div></div></div>iffuse <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>ggressive <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">L</div></div></div>ymphoma). Ongoing clinical trials evaluating selinexor include the pivotal, randomized Phase 3 BOSTON study in multiple myeloma, the Phase 1b/2 STOMP (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor and Backbone <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div></div>reatments <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">o</div></div></div>f <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">M</div></div></div>ultiple Myeloma <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">P</div></div></div>atients) study in combination with standard therapies in multiple myeloma, the Phase 2/3 SEAL (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Se</div></div></div>linexor in <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>dvanced <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">L</div></div></div>iposarcoma) study in liposarcoma, and the Phase 3 SIENDO (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor/Placebo After Combination Chemotherapy <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">I</div></div></div>n Patients with Advanced or Recurrent <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ENDO</div></div></div>metrial Cancer) study evaluating selinexor as maintenance therapy in endometrial cancer. During 2019, final data from the Phase 2b STORM study were published in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New England Journal of Medicine</div></div> (Chari, A. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">et al</div></div>. August 2019). In addition, we reported updated, positive data from the SADAL study as well as updated interim data for the STOMP study at various medical conferences. As a result of the positive results from STORM, in addition to the FDA approval of our first New Drug Application, or NDA, we also filed a Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA, in January 2019 and expect to receive a decision on our application in the middle of 2020.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Based on the positive results of the SADAL study, we submitted a Supplemental New Drug Application, or sNDA, to the FDA in December 2019, with a request for accelerated approval for selinexor as a new treatment for adult patients with relapsed and/or refractory diffuse large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma, or DLBCL, not otherwise specified, who have received at least two prior therapies. The FDA accepted the application for filing on February&#160;18, 2020 and granted Priority Review with a target decision date of June&#160;23, 2020 under the Prescription Drug User Fee Act, or PDUFA. Selinexor has received both Orphan Drug and Fast Track designations from the FDA for this same indication. Provided&#160;that marketing approval is granted by the FDA, we expect to be prepared to commercialize selinexor in the&#160;United States&#160;as a treatment for patients with relapsed and/or refractory DLBCL as early as the middle of 2020.&#160;We also plan to submit a MAA to the EMA in 2020 with a request for conditional approval.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition to selinexor, we are also advancing a pipeline of novel drug candidates including our other oral SINE compounds eltanexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-8602)</div> and verdinexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-335),</div> as well as our oral dual PAK4/NAMPT inhibitor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274.</div> We began clinical testing of eltanexor, a second-generation SINE compound, in late 2015. Our clinical development program for eltanexor includes myelodysplastic syndrome, or MDS, colorectal cancer, or CRC, and metastatic castration-resistant prostate cancer, or CRPC. Based on clinical results to date and resource prioritization, we plan to focus on the development of eltanexor in MDS in 2020. We began clinical testing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in patients with hematologic or solid tumors during 2016 and we plan to study its combination with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD1</div> monoclonal antibody in a phase 1 clinical study in the near future. Finally, verdinexor is our lead compound that is being evaluated as a potential therapy for viral, rare disease and autoimmune indications in humans and by a collaborator as a potential therapy for cancers in companion animals.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA Accelerated Approval of XPOVIO </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the positive outcome from the expanded cohort of the STORM study, on August&#160;6, 2018, we announced the completion of the rolling submission of an NDA to the FDA with a request for accelerated approval for selinexor as a new treatment for patients with heavily pretreated, relapsed or refractory multiple myeloma. On October&#160;5, 2018, the FDA accepted for filing our NDA and also granted our request for priority review of the NDA and assigned an action date of April&#160;6, 2019 under the PDUFA. On February&#160;26, 2019, the Oncologic Drugs Advisory Committee, or ODAC, of the FDA met to review data supporting our NDA requesting accelerated approval for selinexor. The FDA specifically asked the ODAC to vote on whether the </div></div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">committee believed the approval of selinexor should be delayed until the results from the ongoing, randomized Phase 3 BOSTON study are available. In a vote of eight &#8220;Yes&#8221; and five &#8220;No,&#8221; the ODAC recommended that the approval decision for selinexor should be delayed until the results of the BOSTON study are available. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Following the ODAC meeting, and at the FDA&#8217;s request, we submitted additional, existing clinical information that included preliminary data from the BOSTON study as an amendment to the NDA, which allowed the FDA to extend the PDUFA action date by three months to July&#160;6, 2019. On July&#160;3, 2019, the FDA approved oral XPOVIO, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class,</div> nuclear export inhibitor. XPOVIO was approved in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two PIs, at least two IMiDs, and an anti-CD38 monoclonal antibody. XPOVIO is the first SINE compound and is the first ever nuclear export inhibitor approved for human use. The first indication is approved under accelerated approval based on response rate. As with all accelerated approvals, continued approval for the treatment of myeloma may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing Phase 3 BOSTON study is expected to serve as the confirmatory trial for the accelerated approval of XPOVIO. The FDA noted in its press release announcing the approval of XPOVIO that the efficacy evaluation was supported by additional information from the BOSTON study.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization of XPOVIO in the U.S. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2019, XPOVIO became commercially available to patients in the U.S. The commercial launch of XPOVIO is being supported by approximately 70 Karyopharm sales representatives and nurse liaisons as well as KaryForward<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">TM</div>, an extensive patient and healthcare provider support program. Our commercial efforts are also being supplemented by patient support initiatives coordinated by our dedicated network of participating specialty pharmacy providers. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019, approximately 1,400 XPOVIO prescriptions had been fulfilled, driven by strong demand from both academic and community-based oncologists, and XPOVIO had been prescribed by more than 550 unique physicians and healthcare accounts. Net product sales for XPOVIO were $30.5&#160;million through December&#160;31, 2019. XPOVIO sales have been driven by a combination of new patient starts, prescription refills, and initial channel inventory to our distribution partners. Patient demand for XPOVIO continued to increase during 2019 following its accelerated approval by the FDA. Prompt insurance coverage for XPOVIO has been a key contributor to its early commercial success, with XPOVIO being added to numerous national commercial and Medicare formularies and coverage policies. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, we expect to build upon XPOVIO&#8217;s early commercial success in the late-line relapsed refractory multiple myeloma market by educating physicians, healthcare providers and patients about XPOVIO&#8217;s clinical profile and unique mechanism of action. Additionally, if results from the pivotal BOSTON trial, which are expected in early 2020, are positive, our commercial team will begin to prepare for XPOVIO&#8217;s potential expansion into the second line relapsed refractory multiple myeloma market, subject to the FDA&#8217;s review and approval of our expected sNDA. Finally, pending FDA approval of XPOVIO in DLBCL, we expect to begin selling XPOVIO in this indication to hematologists and oncologists in the U.S with our existing field sales force. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">European Marketing Authorization Application </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2019, we submitted a MAA to the EMA requesting conditional approval for selinexor in combination with dexamethasone as a new treatment for patients with triple class refractory multiple myeloma, meaning patients who have received at least three prior therapies and whose disease is refractory to at least one PI, one IMiD, and one anti-CD38 monoclonal antibody. This submission was based on the positive results from the Phase 2b STORM study. We received feedback from EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, including the integrated inspection report, based on site audits and a sponsor inspection. In January 2020, we were granted a three-month extension from CHMP to provide additional time to respond to the </div></div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">CHMP&#8217;s outstanding questions related to the application. We are currently working with CHMP to address the outstanding questions and expect to receive a decision on the application in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To commercialize selinexor following any regulatory approval outside of the U.S., we will either work with existing and potential future partners to establish the appropriate commercial infrastructure outside the U.S., or we may, in certain geographies, elect to establish the commercial infrastructure ourselves. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Randomized Confirmatory BOSTON Study in Multiple Myeloma </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We are currently conducting the pivotal, randomized Phase 3 BOSTON study evaluating once-weekly selinexor in combination with once-weekly Velcade and dexamethasone (SVd) for the treatment of patients with multiple myeloma who have had one to three prior lines of therapy. Enrollment in the BOSTON study was completed in January 2019 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data are expected in early 2020, contingent upon the occurrence of progression-free survival, or PFS, events, the primary endpoint of the study. Data from the BOSTON study, if positive, are expected to be used to support regulatory submissions to the FDA, the EMA and other regulatory agencies requesting the use of selinexor in combination with Velcade and dexamethasone in patients with multiple myeloma who have received at least one prior line of therapy. If approved, this combination of selinexor with Velcade and dexamethasone will be the first approved therapy using once weekly (rather than the standard twice weekly) dosing of Velcade. Given that Velcade must be given in a healthcare setting, we believe that this once-weekly dosing regimen could be substantially more attractive to patients by potentially eliminating a significant percentage of office visits.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Karyopharm&#8217;s Pipeline and Core Clinical Trials </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key clinical trials of selinexor are summarized in the chart below. In addition to these studies, there are several ongoing investigator-sponsored clinical trials in a variety of hematological and solid tumor malignancies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; line-height: 12pt; margin-left: 0in; text-align: center;">
<img alt="" src="g853399g23c59.jpg" style="width: 594px; height: 357px;"/></div> <div style="clear: both; max-height: 0px;">&#160;</div> </div> </div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with hematological and solid tumor malignancies, often in the relapsed and/or refractory setting. In general, relapsed disease refers to disease that progresses following the expiration of a specified period of time after discontinuation of therapy and </div></div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refractory disease refers to disease that progresses while the patient is on therapy or within a specified period of time after discontinuation of therapy. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hematological Malignancies </div></div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple Myeloma </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple myeloma is a hematological malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow, the presence of monoclonal immunoglobulin, also known as M protein, in the serum or urine, bone disease, kidney disease and immunodeficiency. It is more common in elderly patients, with a median age at diagnosis of 69&#160;years. According to the National Cancer Institute, or NCI, multiple myeloma is the second most common cancer of the blood in the U.S. with more than 32,000 new cases each year and over 130,000 patients living with the disease. Despite recent therapeutic advances, there is currently no cure and most patients&#8217; disease will typically progress following treatment with currently available therapies. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The treatment of multiple myeloma has improved in the last 20&#160;years due to the use of high-dose chemotherapy and autologous stem cell transplantation, which is restricted to healthier, often younger patients, and the subsequent introduction of IMiDs, such as Revlimid and Pomalyst, and the PIs Velcade, Kyprolis<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, and Ninlaro<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (ixazomib). Two monoclonal antibodies, Darzalex and Empliciti<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#8482;</div> (elotuzumab), have also been approved, as has the histone deacetylase inhibitor Farydak<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (panobinostat). The introduction of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-chemotherapeutic</div> agents has led to a significant increase in the survival of patients with multiple myeloma. Although a wide variety of newly approved or experimental therapies are being used in relapsed and/or refractory patients, including new proteasome inhibitors (oprozomib and marizomib), monoclonal antibodies (with or without toxin conjugates; belantamab mafodotin, an anti-BCMA antibody-drug conjugate; isatuximab, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-CD38</div> monoclonal antibody) and cellular therapies like chimeric antigen receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell,</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T,</div> therapy, nearly all patients will eventually relapse and succumb to their disease. With about 13,000 deaths from multiple myeloma in the United States alone expected to occur in 2020 according to the American Cancer Society, we believe that there remains a need for therapies for patients whose disease has relapsed after, or is refractory to, available therapy. The approval of XPOVIO in patients with penta-refractory myeloma after four prior therapies further supports this perspective.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to EvaluatePharma (January 2020), the worldwide market for prescription drugs used to treat patients with multiple myeloma exceeded $16&#160;billion in 2018 and is projected to reach over $20&#160;billion by 2024. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phase 2b STORM Study </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The Phase 2b STORM study was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> clinical trial evaluating oral selinexor in combination with standard, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> dexamethasone in patients with heavily pretreated, relapsed or refractory myeloma. Based on the results of the clinical data set for Part 1 of the STORM study, which we reported in 2016, we expanded the STORM study, designated Part 2, which enrolled 122 heavily pretreated patients with triple-class refractory myeloma, of which 83 patients had penta-refractory myeloma.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The results from the STORM study served as the basis for our NDA filing and subsequent accelerated approval from the FDA. The final data from the 122 patients treated on STORM Part 2 were published in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New England Journal of Medicine</div></div> on August&#160;22, 2019. These heavily pretreated patients had a median of seven prior therapeutic regimens, including a median of 10 unique anti-myeloma agents. Specifically, the myeloma patients who were eligible for the study had prior treatment with the two PIs, Velcade and Kyprolis, the two IMiDs, Revlimid and Pomalyst, and the anti-CD38 monoclonal antibody Darzalex, as well as alkylating agents, and their disease was refractory to glucocorticoids, at least one PI, at least one IMiD, Darzalex, and their most recent therapy. In all patients, this myeloma was considered &#8220;triple-class refractory.&#8221; In a subset of 83&#160;patients, their disease was documented to be refractory to all five major agents and is designated penta-refractory myeloma. In addition to multiple-refractory disease, patients in the STORM study had rapidly progressing myeloma, with a median 22% increase in disease burden in the 12 days from screening to initial therapy.</div> </div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Given the rapid progression of triple-class refractory myeloma, the window of opportunity to prevent further illness and death is small. Therefore, the regimen that was used in the STORM study began with a high dose of selinexor to achieve rapid disease control. Each patient began treatment with 80mg oral selinexor twice weekly in combination with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> dexamethasone (20mg twice weekly). This initial dose was chosen to optimize the potential to halt disease progression and reduce tumor load. Because most patients involved in the study had limited <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-organ</div> reserve and were at increased risk for adverse events, dose modifications were anticipated and were specified along with supportive care in the study protocol.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">For the STORM study&#8217;s primary endpoint, oral selinexor achieved an ORR of 26%, including two (2%) stringent complete responses, or sCRs, six (5%) very good partial responses, or VGPRs, and 24 (20%) partial responses, or PRs, and the trial therefore met its primary endpoint. Both patients who had relapsed after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T </div> therapy achieved PRs. Minimal response per International Myeloma Working Group, or IMWG, criteria was observed in 16 (13%) patients and 48 patients (39%) had stable disease. Median time to PR or better was 4.1 weeks. The clinical benefit rate, meaning a minimal response or better, was 39%. All responses were adjudicated by an Independent Review Committee consisting of 4 independent experts in the treatment of multiple myeloma.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Median duration of response, or DOR, was 4.4 months. PFS was 3.7 months and overall survival, or OS, was 8.6 months. In the 39% of patients who achieved a minimal response or better, median OS was 15.6 months, compared to a median OS of 1.7 months in patients whose disease progressed or where response was not evaluable. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The adverse events that were observed in the study appeared to be a function of dose, schedule, and baseline clinical characteristics, including, for example, preexisting cytopenias. The most common treatment-emergent adverse events, or AEs, were thrombocytopenia (73%), fatigue (73%), nausea (72%) and anemia (67%). AEs are classified by severity and graded on a scale of one to five with one being the least severe and five resulting in death. The most common Grade 3/4 treatment-emergent AEs were thrombocytopenia (59%), anemia (44%), hyponatremia (22%) and neutropenia (21%). Importantly, most <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> AEs were limited in severity to Grades 1 or 2, with only 10% experiencing Grade 3 nausea and 3% experiencing Grade 3 vomiting. In all, 18% of patients discontinued study treatment because of an AE considered by the investigator related to the study drug. AEs leading to dose modification or holds occurred in 80% of patients, with the majority occurring in the first two months of treatment. The most common AEs leading to dose reduction or interruption were thrombocytopenia (43%), fatigue (16%), and neutropenia (11%). Supportive care, including granulocyte colony stimulating factors, thrombopoietin receptor agonists, optimization of fluid and caloric intake, appetite stimulants, psychostimulants and/or additional anti-nausea agents usually reduced the intensity and/or duration of AEs. Side effects were reversible without evidence of toxic effects in major organs (treatment-related cardiac, pulmonary, hepatic, or renal dysfunction of Grade 3 or higher) or cumulative toxic effects, with irreversible acute kidney injury reported in one patient (1%). Serious AEs occurred in 63% of patients, with pneumonia (11%) and sepsis (9%) being the most common. Twenty-eight patients died during the study: 16 from disease progression and 12 from an AE. Of these 12 patients, two were assessed by the investigator as related to treatment (one patient having pneumonia with concurrent disease progression and the other having sepsis).</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The complete results of this study were published in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New England Journal of Medicine. </div></div>However, the FDA&#8217;s accelerated approval of XPOVIO was based upon the efficacy and safety in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group </div> analysis of the 83 patients in the STORM study with documented penta-refractory myeloma, as the benefit-risk ratio appeared to be greater in this more heavily <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-treated</div> population than in the overall trial population. The overall response rate in this patient population was 25.3%.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional data and analysis from the STORM study were also presented at key medical conferences in 2019 including the European Hematology Association, or EHA, the International Myeloma Working Group, or IMWG, and the American Society of Hematology, or ASH, annual meetings. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phase 1b/2 STOMP Study </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The STOMP study, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">multi-arm</div> clinical trial in patients with multiple myeloma, is evaluating selinexor and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> dexamethasone plus standard therapies, such as Velcade, Kyprolis, Revlimid, Pomalyst or Darzalex. An additional arm of the study evaluating selinexor in combination with Revlimid in patients with previously untreated myeloma was opened in June 2018. We presented updated clinical data from the STOMP study at both the EHA 2019 annual meeting in June 2019 as well as at the ASH 2019 annual meeting in December 2019 demonstrating that selinexor and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> dexamethasone plus standard anti-myeloma therapies exhibit encouraging response rates when combined with these approved therapies.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor plus Pomalyst and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-dose</div> Dexamethasone (SPd) Presented at the ASH 2019 Annual Meeting </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In this all oral arm of the Phase 1b/2 STOMP study, oral selinexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(60-100mg</div> weekly or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">40-80mg</div> twice weekly) is being evaluated in combination with Pomalyst (3 or 4mg orally, once daily) and low dose dexamethasone (orally, 40mg once weekly or 20mg twice weekly) in patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy, including a PI and an IMiD, or patients with myeloma refractory to both a PI and an IMiD. The following table is a summary of the interim efficacy data:</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 60%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="20" style="height: 5px; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-left-width: 0.5pt; border-top-style: solid; border-left-style: solid;">&#160;</td>
<td style="height: 5px; border-top-color: rgb(0, 0, 0); border-right-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-right-width: 0.5pt; border-top-style: solid; border-right-style: solid;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="20" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid; white-space: nowrap;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Best Responses<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">1</div> in Evaluable SPd Patients as of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Oct-2019</div><div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">2</div></div></div> </td>
<td style="border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: 0.5pt; border-bottom-width: 0.5pt; border-right-style: solid; border-bottom-style: solid;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-right: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); white-space: nowrap; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior Therapy Status </div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">N<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">3</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ORR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">VGPR<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">4</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">PR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Median PFS </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid;"> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">&#160;&#160;<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pomalyst-na&#239;ve</div> and Revlimid refractory or relapsed</div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18&#160;(56%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6&#160;(19%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12&#160;(38%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12.2&#160;months </div></div> </td>
<td colspan="2" style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; border-right: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Pomalyst Treated and Revlimid refractory </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5&#160;(36%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;(7%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4&#160;(29%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5.6&#160;months </div></div> </td>
<td colspan="2" style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key: ORR=Overall Response Rate (VGPR+PR); VGPR=Very Good Partial Response; PR=Partial Response </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">1</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Responses were adjudicated according to the International Myeloma Working Group criteria</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Based on interim unaudited data</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">3</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Five patients not evaluable for response: one death unrelated to myeloma, one <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with study procedures, one withdrawal of consent before disease follow up, one death related to progressive disease, or PD; one PD before completing one cycle of therapy</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">4</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">One unconfirmed VGPR</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Among the patients evaluated for safety as of the data cutoff date, the most common treatment-related AEs were cytopenias, along with gastrointestinal and constitutional symptoms; most were manageable with dose modifications and/or supportive care. The most common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> treatment-related AEs were nausea (52%), fatigue (52%) and weight loss (39%). As expected, the most common treatment-related Grade 3 and 4 AEs were neutropenia (58%), thrombocytopenia (27%) and anemia (27%).</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor plus Kyprolis and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-dose</div> Dexamethasone (SKd) Presented at the ASH 2019 Annual Meeting </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In this arm of the Phase 1b/2 STOMP study, oral selinexor (80 or 100mg once-weekly) is being evaluated in combination with Kyprolis (56mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> or 70mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> once weekly) and low dose dexamethasone (orally, 40mg once weekly or 20mg twice weekly) in patients with relapsed refractory multiple myeloma who have received at least two prior therapies, which can include previous treatment with a PI, one or more IMiDs or Darzalex. The median number of prior treatments was four (with a range of two to eight). The following table is a summary of the interim efficacy data: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 8pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 54%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="20" style="height: 5px; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-left-width: 0.5pt; border-top-style: solid; border-left-style: solid;">&#160;</td>
<td style="height: 5px; border-top-color: rgb(0, 0, 0); border-right-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-right-width: 0.5pt; border-top-style: solid; border-right-style: solid;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="20" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid; white-space: nowrap;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Best Responses<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">1</div> in Evaluable SKd Patients as of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Oct-2019</div><div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">2</div></div></div> </td>
<td style="border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: 0.5pt; border-bottom-width: 0.5pt; border-right-style: solid; border-bottom-style: solid;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-right: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); white-space: nowrap; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Category </div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">N </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ORR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">VGPR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">PR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid;"> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">&#160;&#160;All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Kyprolis-na&#239;ve) </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10&#160;(71%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3&#160;(21%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7&#160;(50%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td colspan="2" style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key: ORR=Overall Response Rate (CR+VGPR+PR); CR=Complete Response; VGPR=Very Good Partial Response; PR=Partial Response </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">1</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Responses were adjudicated according to the International Myeloma Working Group criteria</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Based on interim unaudited data</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">All patients had reductions in myeloma protein, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-protein,</div> from baseline, with 71% of patients experiencing a reduction of 90% or more. As of the data cutoff date, median PFS had not yet been reached.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Among the patients evaluated for safety, the most common treatment-related AEs were cytopenias, along with gastrointestinal and constitutional symptoms; most were manageable with dose modifications and/or supportive care. The most common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> treatment-related AEs were nausea (71%), fatigue (43%), anorexia (36%), vomiting (36%) and weight loss (36%) and were mostly Grade 1 and 2 events. As expected, the most common treatment-related Grade <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div>3 AEs were hematologic AEs and included thrombocytopenia (64%), anemia (14%) and leukopenia (14%). The recommended Phase 2 dose, or RP2D, was identified as selinexor 80mg and Kyprolis 56mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> and enrollment continues using this regimen.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor plus Revlimid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-dose</div> Dexamethasone (SPd) in Newly Diagnosed Patients with Multiple Myeloma Presented at the ASH 2019 Annual Meeting </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In this all oral arm of the Phase 1b/2 STOMP study in patients with newly diagnosed multiple myeloma, selinexor (60mg orally once-weekly) is being combined with Revlimid (25mg orally, once daily) and low dose dexamethasone (orally, 40mg once weekly or 20mg twice weekly). The following table is a summary of the interim efficacy data: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 8pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 63%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="20" style="height: 5px; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-left-width: 0.5pt; border-top-style: solid; border-left-style: solid;">&#160;</td>
<td style="height: 5px; border-top-color: rgb(0, 0, 0); border-right-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-right-width: 0.5pt; border-top-style: solid; border-right-style: solid;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="20" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid; white-space: nowrap;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Best Responses<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">1</div> in Evaluable SRd Patients as of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Oct-2019</div><div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">2</div></div></div> </td>
<td style="border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: 0.5pt; border-bottom-width: 0.5pt; border-right-style: solid; border-bottom-style: solid;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-right: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); white-space: nowrap; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Category </div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">N<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">3</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ORR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">VGPR<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">4</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">PR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid;"> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;All </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6&#160;(86%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;(14%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4&#160;(57%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#160;(14</div></div> </td>
<td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: 0.5pt; border-bottom-width: 0.5pt; border-right-style: solid; border-bottom-style: solid; white-space: nowrap;">%)</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key: ORR=Overall Response Rate (CR+VGPR+PR) </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">1</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Responses were adjudicated according to the International Myeloma Working Group criteria</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Based on interim unaudited data</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">3</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">One patient was not evaluable for response due to withdrawn consent prior to disease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up </div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">4</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">One VGPR was confirmed on Oct 10, 2019 (after data cut); two VGPR are unconfirmed</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The data are early and the median PFS was not reached. Among the patients evaluable for safety, the most common treatment-related AEs were cytopenias, along with gastrointestinal and constitutional symptoms; most were manageable with dose modifications and/or supportive care. The most common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> treatment-related AEs were diarrhea (63%), weight loss (63%), nausea (50%), constipation (38%), fatigue (38%), hypokalemia (38%) and insomnia (38%) and were mostly Grades 1 or 2. The most common Grade <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div>3 AEs were neutropenia (75%), anemia (50%) and thrombocytopenia (25%). Among the five patients evaluable for dose limiting toxicities, or DLTs, as of the data cutoff date, there were no DLTs observed.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor plus Darzalex and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-dose</div> Dexamethasone (SDd) Presented at the EHA 2019 Annual Meeting </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In this arm of the Phase 1b/2 STOMP study, oral selinexor (dose escalated using either 100mg once weekly or 60mg twice weekly) is being evaluated in combination with Darzalex (16mg/kg intravenously once weekly) and low dose dexamethasone (orally, 40mg once weekly or 20mg twice weekly) in patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy, including a PI and an IMiD, or patients with multiple myeloma refractory to both a PI and an IMiD. The following table is a summary of the updated interim efficacy data: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 70%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="16" style="height: 5px; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-left-width: 0.5pt; border-top-style: solid; border-left-style: solid;">&#160;</td>
<td style="height: 5px; border-top-color: rgb(0, 0, 0); border-right-color: rgb(0, 0, 0); border-top-width: 0.5pt; border-right-width: 0.5pt; border-top-style: solid; border-right-style: solid;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="16" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid; white-space: nowrap;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Best Responses<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">1</div> in Evaluable SDd Patients as of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-May-2019</div><div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">2</div></div></div> </td>
<td style="border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: 0.5pt; border-bottom-width: 0.5pt; border-right-style: solid; border-bottom-style: solid;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-right: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); white-space: nowrap; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Category </div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">N<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">3</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ORR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">VGPR </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">PR<div style="font-size: 5.92pt; vertical-align: top; line-height: 4.3808pt;;display:inline;">4</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0);"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-left-width: 0.5pt; border-bottom-style: solid; border-left-style: solid;"> <div style="font-size: 2pt; margin-top: 0px; margin-bottom: 1pt; line-height: normal;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Darzalex na&#239;ve </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22&#160;(73%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11&#160;(37%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11&#160;(37%) </div></div> </td>
<td colspan="2" style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 5px; border-right: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;All </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22&#160;(69%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11&#160;(34%) </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); border-left: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11&#160;(34%) </div></div> </td>
<td colspan="2" style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; border-right: 0.5pt solid rgb(0, 0, 0); border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key: ORR=Overall Response Rate (VGPR+PR); PR= Partial Response </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">1</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Responses were adjudicated according to the International Myeloma Working Group criteria</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Based on interim unaudited data</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">3</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Two patients were not evaluable for response as they withdrew consent prior to disease follow up</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">4</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Two unconfirmed PRs</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Despite the heavily pretreated nature of the patients in the study, with 100% of the patients having disease refractory to both a PI and an IMiD, only one patient (3%) did not have at least a minimal response. As of the data cutoff date, median PFS had not been reached. Among patients with at least a PR, the median time on treatment was 7.7 months, while the median time on study for all evaluable patients was 4.8 months. Median time to response was 1.0 month. Based on published data, the expected ORR for Darzalex therapy without selinexor in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PI-</div> and IMiD-refractory, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Darzalex-na&#239;ve</div> population is approximately 29%, and the anticipated response rate with selinexor-dexamethasone in this population is <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8804;</div>30% based on the STORM and previous studies. Thus, the ORR of 73% continues to provide a basis for further evaluation of the SDd combination. Among the 31 patients evaluated for safety, the most common treatment-related AEs were cytopenias, along with gastrointestinal and constitutional symptoms; most were manageable with dose modifications and/or supportive care. The most common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> treatment-related AEs were nausea (68%), fatigue (58%), anorexia (32%), insomnia (32%), diarrhea (32%), hyponatremia (32%), and vomiting (26%) and were mostly Grade 1 and 2 events. As expected, the most common Grade 3 and 4 treatment-related AEs were hematologic AEs and included thrombocytopenia (42%), anemia (29%), leukopenia (26%) and neutropenia (23%). Based on these tolerability and efficacy data, the recommended RP2D of SDd is selinexor (100mg orally, once weekly), Darzalex (16mg/kg, once weekly) and dexamethasone (40mg orally, once weekly).</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor plus Velcade and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-dose</div> Dexamethasone (SVd) Published in Blood<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div>2018 </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In this arm of the Phase 1b/2 STOMP study, oral selinexor was studied in 42 patients who received selinexor (60, 80, or 100mg orally, once or twice weekly) plus Velcade (1.3mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> subcutaneously) and dexamethasone (20mg orally) once or twice weekly in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21-</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">35-day</div> cycles. In the dose-escalation phase, patients were randomized to one of two treatment cohorts to receive selinexor once weekly or twice weekly in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21-</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">35-day</div> cycles, depending on the bortezomib dosing schedule. Based on long-term tolerability and efficacy, the recommended RP2D of SVd was established at 100 mg selinexor once weekly plus 40 mg dexamethasone once weekly and 1.3 mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> bortezomib once weekly in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">35-day</div> cycles.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Patients had a median of three prior lines of therapy (with a range of one to 11), and 50% were refractory to a PI. Treatment-related Grade 3 or 4 AEs reported in <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div>10% of patients were thrombocytopenia (45%), neutropenia (24%), fatigue (14%), and anemia (12%). The incidence and severity of peripheral neuropathy were low, with four (10%) patients experiencing this AE at a grade limited to two or below. The ORR for the entire population was 63% with an 84% ORR for patients with disease that was not refractory to a PI and 43% in patients with disease refractory to a PI. The median PFS for all patients was 9.0 months; 17.8 months for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PI-nonrefractory,</div> and 6.1 months for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PI-refractory. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The results from the SVd arm of the STOMP study were published in the journal <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Blood</div></div> (2018 Dec 13; 132(24): 2546&#8211;2554). The SVd arm of the STOMP study served as the basis for the design of the Phase 3 BOSTON study evaluating once-weekly selinexor, once-weekly Velcade and dexamethasone in patients who have had one to three lines of prior multiple myeloma therapy.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Hodgkin&#8217;s</div> Lymphoma </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Hodgkin&#8217;s</div> lymphoma, or NHL, is a cancer that starts in cells called lymphocytes, which are part of the body&#8217;s immune system. Lymphocytes are found in the lymph nodes and other lymphoid tissues, such as the spleen and bone marrow, as well as in the blood. NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. In 2020, the American Cancer Society, or ACS, estimates that more than 77,000 patients will be diagnosed with NHL and nearly 20,000 deaths will result from the disease. DLBCL is the most common and the most aggressive of the different forms of NHL, making up approximately 18,000 of the new cases diagnosed annually in the United States. Approximately 50% of newly diagnosed patients are currently cured with front-line (typically <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;R-CHOP&#8221;</div> chemotherapy) and another approximately 10% of patients are cured with second line intensive chemotherapy followed by autologous stem cell transplantation. The remaining patients generally succumb to the disease, with the median OS of patients with relapsed or refractory</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">DLBCL after two prior regimens less than one year, and often less than six months. Despite the recent approval of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy, many patients with relapsed/refractory DLBCL are not medically stable enough to undergo <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. The FDA recently granted accelerated approval to the triplet therapy polatuzumab vedotin, bendamustine, rituximab, known as PBR, for the treatment of adult patients with relapsed or refractory diffuse large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma, not otherwise specified after at least two prior therapies.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phase 2b SADAL Study </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The SADAL study is an open-label Phase&#160;2b clinical trial evaluating single-agent oral selinexor (60mg, twice weekly) in patients that have relapsed or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. At the ASH 2018 annual meeting, we presented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> clinical data from the SADAL study demonstrating that selinexor, when administered as a single-agent, is clinically active and capable of producing durable responses associated with prolonged overall survival. Updated data were presented at the 2019 International Conference on Malignant Lymphoma, or ICML, meeting on June&#160;19, 2019. The results presented at the ICML meeting remain consistent with those reported at the ASH 2018 annual meeting and include efficacy results from the final 12 patients who had not reached their first response assessment in time to be included in the previously released <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> efficacy analyses. Among the 127 patients (median of two prior treatment regimens with a range one to six) who were evaluable for response, as adjudicated by an Independent Central Radiological Review, or ICRR, committee, 36 patients responded (13 CRs and 23 PRs) for an ORR of 28.3%. An additional 11 patients experienced stable disease, or SD, for a disease control rate, or DCR, of 37.0%. Selinexor also demonstrated responses in patients with either GCB or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GCB</div> subtypes of DLBCL: the ORR in the 59 patients with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GCB-subtype</div> was 33.9% and the ORR in the 63 patients with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GCB</div> subtype was 20.6%. In addition, there were five patients enrolled whose subtype was unclassified and one of these patients achieved a CR while two of these patients achieved a PR.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The median DOR across responding patients was 9.2 months and responses tended to occur rapidly, with most documented at the first post-baseline radiological evaluation (weeks <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-9).</div> Median OS for the entire patient population was 9.0 months while median OS has not yet been reached in patients who achieved either a CR or PR. Patients whose disease progressed or had no response to selinexor had a median OS of 4.1 months, which is consistent with the expected poor prognosis (OS &lt;six months) for patients who have relapsed or refractory DLBCL and have been previously treated with two or more lines of therapy.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">All 127 patients were included in the safety analyses. The most common treatment-related AEs were cytopenias along with gastrointestinal and constitutional symptoms and were generally reversible and most were manageable with dose modifications and/or supportive care. The most common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> AEs were nausea (52.8%), fatigue (37.8%), and anorexia (34.6%) and were mostly Grade 1 and 2 events. As expected, the most common Grade 3 and 4 AEs were thrombocytopenia (39.4%), neutropenia (20.5%) and anemia (13.4%) and were generally not associated with clinical sequelae.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2018, the FDA granted Fast Track designation to selinexor for the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. Selinexor has also been granted Orphan Drug designation by the FDA in DLBCL. Based on the positive results of the SADAL study, we submitted an sNDA to the FDA on December&#160;23, 2019, with a request for accelerated approval for selinexor as a new treatment for adult patients with relapsed or refractory DLBCL, not otherwise specified, who have received at least two prior therapies. The FDA filed the application on February&#160;18, 2020 and granted Priority Review with a target decision date of June&#160;23, 2020 under PDUFA. We also plan to submit a MAA to the EMA in 2020 with a request for conditional approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We plan to initiate two studies in DLBCL during 2020. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XPORT-DLBCL-030,</div> which is expected to serve as a confirmatory study for the accelerated approval requested in DLBCL based on the SADAL study, is a Phase 3 trial of selinexor or matching placebo given with the standard combination immunochemotherapy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">R-GDP </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(rituximab, gemcitabine, dexamethasone, cisplatin) to patients with at least one prior therapy and who are ineligible for high dose chemotherapy and stem cell transplantation (or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T).</div> The primary endpoint of the study is PFS, and this study is expected to initiate in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XPORT-DLBCL-025</div> is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">multi-arm</div> study of selinexor in combination with commonly used and approved agents for the treatment of DLBCL; this study is expected to begin in the second half of 2020. This study will inform the use of selinexor with a variety of additional agents for the treatment of DLBCL.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advanced or Metastatic Solid Tumors </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Solid tumors represent the vast majority of cancer incidences. Given the large patient population with solid tumors and the mechanistic activity of selinexor that makes it potentially suitable for treating any type of cancer, we are developing selinexor to potentially play a meaningful role across multiple solid tumor indications, either alone or in combination as a backbone therapy. We have seen encouraging single-agent data for selinexor in a variety of solid tumors including PRs and durable SD with disease control greater than three months. Our Phase 1b study in patients with liposarcoma and other sarcomas demonstrated durable SD with single agent selinexor, and our Phase 2 studies of selinexor in gynecological malignancies and glioblastoma multiforme, or GBM, also demonstrated anti-cancer activity, including bona fide PRs as well as prolonged SD. Given the promising single-agent activity in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">difficult-to-treat</div> indications and the potential to enhance activity in combination with existing therapies, we are currently developing selinexor in unmet needs like liposarcoma and endometrial cancer with plans to expand development in GBM, and to advance combination therapy development with both standard of care and emerging therapies like immune checkpoint inhibitors.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liposarcoma </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liposarcoma represents an area of high unmet need, with currently approved treatments for aggressive disease limited to parenteral chemotherapies. Liposarcoma arises from fat cells or their precursors and represents up to 18% of all soft tissue sarcoma, or approximately 2,500 new cases per year in the United Sates. Liposarcoma most commonly occurs in the thigh, behind the knee, the groin, the gluteal area or behind the abdominal cavity. Dedifferentiated liposarcoma is an aggressive form of soft tissue sarcoma that is resistant to both standard chemotherapy and radiation. Liposarcoma has a particularly high rate of recurrence following surgery, especially in cases involving the abdomen. Except for cases that are cured with surgery, most patients with metastatic liposarcoma will succumb to this disease, and novel therapies are needed. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phase 2/3 SEAL Study in Liposarcoma </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our Phase 1b trial to evaluate the effects of food and formulation on selinexor pharmacokinetics in patients with soft tissue or bone sarcoma, 31 of 54 sarcoma patients (57%)&#160;experienced SD with single agent selinexor treatment. Fifteen of the 54 patients had dedifferentiated liposarcoma. Of these 15 patients with dedifferentiated liposarcoma, 13 (87%)&#160;experienced SD and seven (47%)&#160;experienced SD of four months or longer. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In light of the Phase 1b data, we are conducting the SEAL (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Se</div></div></div>linexor<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>in <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>dvanced<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">L</div></div></div>iposarcoma) study, a multi-center, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating single-agent oral selinexor in patients with advanced unresectable dedifferentiated liposarcoma who received at least one line of prior systemic therapy. Patients are randomized to receive either 60mg of selinexor or placebo, respectively, each given twice weekly until progression or intolerability. Patients on placebo with confirmed progressive disease are permitted to cross over to the selinexor treatment arm. In June 2018, we reported a successful outcome from the Phase 2 portion of the SEAL study of 56 patients with previously treated, advanced unresectable dedifferentiated liposarcoma. The median number of prior treatment regimens was two (range of two to 10 prior treatment regimens). For the study&#8217;s primary endpoint, patients treated with selinexor achieved PFS of 5.5 months, compared to 2.7 months for placebo-treated patients with a hazard ratio of 0.67, representing a 33% reduction in</div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the risk of progression or death. PFS was assessed by an ICRR committee based on RECIST v1.1. In this randomized, blinded Phase 2 portion of the study, selinexor demonstrated a safety and tolerability profile consistent with prior studies with AEs, primarily consisting of nausea, fatigue, anorexia and weight loss, and low levels of Grade 3/4 cytopenias, and no new or unexpected safety signals were identified. The majority of treatment-related AEs were low grade and reversible with dose modifications and/or supportive care. The data from the Phase 2 portion of the SEAL study, which is complete, demonstrate that treatment with selinexor improves PFS (based on the RECIST v1.1 criteria) and supports the currently ongoing Phase 3 portion of the study using RECIST v1.1 response criteria, and for which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data are anticipated in 2020.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Phase 3 portion of the SEAL study is being conducted in North America and Europe. In this blinded, placebo-controlled Phase 3 study, patients are randomized 2:1 to receive either oral selinexor (60mg twice weekly) until disease progression or intolerability, or placebo. Patients whose disease progresses on placebo will be permitted to cross over to the selinexor arm. The primary endpoint of the Phase 3 portion of the study is PFS as assessed by the ICRR committee based on RECIST v1.1. The Phase 3 study design and primary endpoint of PFS were agreed to by the FDA. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Top-line</div> data from the Phase 3 portion of the SEAL study are anticipated in 2020. Assuming a positive outcome, these data are intended to support regulatory submissions requesting approval for oral selinexor as a new treatment for patients with advanced unresectable dedifferentiated liposarcoma. Selinexor received Orphan Drug designation by the FDA for the patient population being evaluated in the SEAL study.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Endometrial Cancer </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Endometrial cancer, also called endometrial carcinoma, occurs when cells in the endometrium, which is the inner lining of uterus, begin to grow out of control. In the United States, endometrial cancer is the most common cancer of the female reproductive organs. The NCI estimates that approximately 62,000 new cases of endometrial cancer will be diagnosed in 2020, with approximately 12,000 deaths. Endometrial cancer affects mainly post-menopausal women and the average age of a women diagnosed with endometrial cancer is 60. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phase 2/3 SIENDO Study in Endometrial Cancer </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIENDO is a randomized, blinded Phase 2/3 trial evaluating selinexor versus placebo as a maintenance therapy in patients with advanced or recurrent endometrial cancer following at least one prior platinum-based combination chemotherapy treatment. During the first quarter of 2019 an Investigational New Drug, or IND, application was submitted by us and accepted by the FDA, resulting in the transition of this study from investigator-sponsored to company-sponsored. The overall objective of SIENDO is to obtain conclusive evidence of efficacy for maintenance selinexor in patients with advanced or recurrent endometrial cancer. This is a multi-national, multi-center trial and is expected to enroll approximately 192 patients. We currently expect to report topline data from the SIENDO study in 2021. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">This trial was designed based on the data from our SIGN study, a Phase 2, open-label study of efficacy and safety of oral selinexor in patients with heavily <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-treated,</div> progressive gynecological cancers. In December 2019, the full results from the SIGN study in patients with recurrent gynecological malignancies were published in<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Gynecologic Oncology</div></div>&#160;(I.B. Vergot et.al., Gynecologic Oncology. December 2019).&#160;According to the published data, the SIGN study showed selinexor&#8217;s promising anti-tumor activity and disease control in gynecological malignancies. Of the&#160;66&#160;patients with ovarian cancer,&#160;20&#160;patients (30%) had disease control, meaning PR or SD for at least 12 weeks, including 7 patients (11%) with a PR. The median duration of response for patients that achieved a PR was 7.4 months. Median PFS for all patients with ovarian cancer was&#160;2.6&#160;months and median OS was&#160;7.3&#160;months. Of the&#160;23 patients with endometrial cancer,&#160;eight (35%) had disease control (three PRs and&#160;five&#160;with SD for at least 12 weeks). Median PFS for the endometrial cancer arm was&#160;2.8&#160;months and median OS was&#160;7.0&#160;months. Across all arms, the most common AEs were nausea (71%), fatigue (68%), decreased appetite (57%), vomiting (53%), weight loss (48%), anemia (36%), and thrombocytopenia (34%), which were managed with supportive care and dose modifications. Notably,&#160;fewer Grade 3 and 4 AEs occurred in patients receiving once weekly compared to twice weekly selinexor, with equivalent efficacy.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Glioblastoma </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Glioblastoma multiforme, or GBM, is an area of high unmet need, with existing treatments having very limited success in increasing overall surviving rates. GBM is the most common and aggressive malignant primary brain tumor in humans, accounting for 60% of brain tumors in adults. Patients facing GBM face significant morbidity and mortality rates, with over 13,000 deaths per year in the United States. Additionally, GBM patients endure poor prognosis rates, with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-year</div> survival rate of 37.2%, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> survival rate of 5.1%, and a median survival rate of roughly 10 months. The current standard of care for GBM patients includes surgery, radiation therapy, and chemotherapy. Approved drug treatments for GBM include temozolomide and Avastin<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (bevacizumab). Despite these treatment options, most patients diagnosed with GBM will quickly succumb to the disease and novel therapies are needed.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phase 2 KING Study in Glioblastoma Multiforme </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The KING study is a Phase 2 study evaluating the efficacy and safety of oral selinexor in patients with recurrent GBM. In June 2016, we presented data at the American Society of Clinical Oncology, or ASCO, annual meeting where we showed that single-agent oral selinexor demonstrated anti-tumor activity in patients with glioblastoma that recurred after temozolomide and radiation therapy, including selinexor brain penetration at clinically relevant levels, leading to durable anti-cancer activity and disease control of up to 6 months. Specifically, data as of May&#160;23, 2016 from 33 surgically ineligible patients with GBM that progressed after treatment with temozolomide and radiation showed that selinexor dosed twice weekly at 50mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> (or approximately 80mg flat dosing) demonstrated anti-tumor activity with a 12% ORR (PR or better) and a 33% DCR (SD or better) with durability of up to six months in two patients. The most common AEs were thrombocytopenia, fatigue, anorexia, and nausea, consistent with the selinexor adverse event profile. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In July 2019, updated data were presented at the ASCO 2019 annual meeting based on 76 total patients enrolled in the study as of May 2019. While multiple doses of selinexor were tested in this study (50mg twice weekly, 60 mg twice weekly and 80mg once weekly), the dose of 80mg once per week was determined to be the recommended dose for further evaluation. In the study, there were 30 patients treated with selinexor 80 mg once per week. In this cohort, the rate of patients who were still alive and did not have their disease progress after six <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">28-day</div> cycles on therapy (called the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-cycle</div> PFS rate) was 30%, the rate of patients who were still alive and did not have their disease progress after six month on therapy (called the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> PFS rate) was 19%, and the ORR was 10%. Additionally, the median OS in this arm of the trial was 9.4 months. The most common AEs in this arm of the trial were nausea, fatigue, anorexia, leukopenia, and neutropenia and were predominately Grade 1 and 2 adverse events. No Grade 4 treatment-related AEs were reported in <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div> 10% of patients and no fatal (Grade 5) treatment-related AEs were reported.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;">The Phase 1/2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XPORT-GBM-029</div> Study in GBM </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Based on these positive findings from the KING study, during the second half of 2020, we plan to initiate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">XPORT-GBM-029,</div> a new Phase 1/2 multi-center, open-label study to evaluate selinexor in combination with standard of care therapies. The Phase 1 portion of the study is expected to evaluate selinexor in combination with radiation with or without&#160;temozolomide in newly diagnosed GBM and selinexor in combination with lomustine chemotherapy in recurrent GBM. The Phase 2 portion of the study is designed to be a randomized study to compare the combinations evaluated in the Phase 1 portion against standard of care therapies alone in patients with recurrent or newly diagnosed GBM.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Other Pipeline Programs </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Eltanexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-8602) </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eltanexor is a second-generation SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1. The mechanism of action for the biological (anti-cancer) activity of eltanexor is believed to be the same as selinexor. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Eltanexor differs from selinexor primarily because it was designed and confirmed to have much lower penetration into the brain in preclinical species compared with selinexor. Following oral administration, animals treated with eltanexor show lower percentage of body weight loss and improved food consumption, as well as less &#8220;fatigue behavior,&#8221; in comparison to animals similarly treated with selinexor. This allows more frequent dosing of eltanexor, enabling a longer period of exposure at higher levels than is possible with selinexor, which allows for greater indication diversification among our SINE compounds.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>In many preclinical model systems, the more intensive dosing regimen leads to superior efficacy in comparison to selinexor treatment.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Therefore, eltanexor may cause fewer side effects which are believed to be mediated through the central nervous system such as nausea, fatigue and anorexia in humans.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>As a result, we believe that eltanexor represents a second-generation SINE compound and are evaluating safety, tolerability and efficacy in humans.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We initiated our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-humans</div> Phase 1/2 clinical trial for eltanexor in patients with relapsed/refractory multiple myeloma in January 2016. At the ASH 2017 annual meeting, we reported positive data from the ongoing Phase 1/2 study demonstrating good tolerability and promising activity in multiple myeloma. The median time on treatment for the overall study population was greater than 130 days, with a range of 10 days to over two years. The ORR across all 34 patients was 21% including one patient with VGPR. No CRs were observed. Among the 14 patients who received a starting dose of eltanexor in combination with dexamethasone, the ORR was 35.7%.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Among the 39 patients evaluable for safety, the most common Grade 1/2 AEs in the multiple myeloma patient population were nausea (54%), fatigue (46%), anemia (38%), diarrhea (38%), dysgeusia (33%), weight loss (33%) and neutropenia (31%). As expected in this patient population, the most common Grade 3/4 AEs were thrombocytopenia (56%), neutropenia (26%), anemia (15%), leukopenia (15%) and hyponatremia (10%). Importantly, nausea, fatigue, diarrhea and vomiting were nearly all Grade 1, generally manageable and transient, and bleeding was uncommon. The maximum tolerated dose was not reached; however, dose escalation was halted as responses were achieved. Based on these data, the RP2D in this patient population has been established as 20mg eltanexor dosed five times per week with 20mg dexamethasone dosed twice weekly.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This Phase 1/2 study has been expanded to include patients with high risk MDS, metastatic CRC or metastatic CRPC to determine the safety, preliminary efficacy, and RP2D of eltanexor in patients with these advanced cancers. These are indications where selinexor and XPO1 inhibition has shown clear activity, but where side effects such as fatigue and anorexia were problematic for patients due to the underlying malignancies. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">At the ASH 2019 annual meeting, positive data was presented from the Phase 1/2 study evaluating the safety, tolerability and anti-tumor activity of single-agent oral eltanexor (10mg or 20mg once-daily for five days per week) in elderly patients with higher-risk MDS with disease refractory to hypomethylating agents. Of the 20 patients evaluable for efficacy, seven patients had a complete response without marrow recovery, or mCR, indicating an ORR of 35%. An additional five patients (25%) achieved SD as their best response. Median OS was 10.6 months. The most common treatment-related AEs were hematologic, gastrointestinal and constitutional. The most common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-hematologic</div> treatment-related AEs were nausea (45%), decreased appetite (40%), fatigue (35%), diarrhea (35%) and dysgeusia (25%); the vast majority were Grade 1 or 2. The most common Grade <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div>3 AEs were anemia (30%), neutropenia (25%), thrombocytopenia (20%) and leukopenia (15%). AEs were dose-dependent and generally managed with supportive care and dose modification. This Phase 1/2 study remains ongoing. Based on these data, we plan to either amend the existing Phase 1/2 study protocol or implement a new protocol to evaluate eltanexor in combination with cedazuridine-decitabine (ASTX727) in patients with newly diagnosed MDS. The dose finding portion of the study evaluating this novel combination is expected to begin during the second half of 2020.&#160;Once the RP2D of this combination is established, the study is expected to expand into a Phase 2/3 study to explore the efficacy of this combination in newly diagnosed MDS.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274 </div> </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> orally bioavailable small molecule that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive</div> dual modulator of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">p21-activated</div> kinase 4, or PAK4, and nicotinamide phosphoribosyltransferase, or NAMPT, which is also known</div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">as PBEF or visfatin. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-inhibition</div> of these targets leads to synergistic anti-tumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, inhibition of proliferation, and ultimately apoptosis. Normal cells are more resistant to inhibition by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> due in part to their relative genomic stability and lower metabolic rates. Hematologic and solid tumor cells become dependent on both PAK4 and NAMPT pathways and are therefore susceptible to single-agent cytotoxic effect of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> has shown broad evidence of anti-cancer activity against hematological and solid tumor malignant cells while showing minimal toxicity to normal cells in vitro. In mouse xenograft studies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274 </div> given orally has shown evidence of anti-cancer activity and tolerability. To our knowledge, we are the only company with an allosteric, PAK4 and/or NAMPT specific inhibitor currently in clinical development.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We initiated a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-humans</div> Phase 1 open-label clinical trial evaluating the safety, tolerability, and efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in patients with advanced solid malignancies or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Hodgkin&#8217;s</div> lymphoma. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Top-line </div> results from this Phase 1 study were presented in September 2017 at the European Society of Medical Oncology, or ESMO, annual meeting. Among the 18 patients evaluable for preliminary efficacy, there were six (33%) with SD, the longest for 7.3 months. Tumor reductions were observed in three out of three patients with NAPRT1 deficient tumors. Among the 21 patients evaluated for safety, the most common Grade 2 AEs across dose levels were arthralgia (43%), anemia (24%) and fatigue (24%). The most common drug-related Grade 3 or higher AEs across dose levels include anemia (38%) and fatigue (5%). Gastrointestinal-related AEs were infrequent and low grade. In addition, it was determined that niacin can be safely administered with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> and may improve tolerability, particularly with respect to anemia. Dose escalation remains ongoing and further evaluation of effects in NAPRT1 deficient tumors is planned. Enrollment is planned to continue based on the patients&#8217; NAPRT1 status in a 2:1 ratio with twice as many patients with negative NAPRT1 enrolled versus those patients with positive NAPRT1. These study findings indicate that in patients whose disease has progressed despite most available therapies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> can induce tumor shrinkage and disease stabilization.</div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition, we plan to evaluate the combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD1</div> monoclonal antibody in a phase 1 clinical study in the near future.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Verdinexor (KPT-335): </div></div></div>Oral SINE Compound for Lymphoma in Companion Canines<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We have used spontaneously occurring canine cancers as a surrogate model for human malignancies. It is widely known that canine lymphomas display a comparable genetic profile and respond to chemotherapy in a fashion similar to their human counterparts (human NHL, most closely DLBCL). Lymphomas are one of the most common tumors in pet dogs. Lymphoma in dogs is very aggressive and, without treatment, the tumors are often fatal within weeks. The majority of dog lymphomas are DLBCL and most of the others are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell </div> lymphomas. Given the similarities of dog and human lymphomas, prior to initiating clinical trials of selinexor in humans, we investigated verdinexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-335),</div> a closely related, orally available SINE compound in pet dogs with lymphomas. Verdinexor received a Minor Use / Minor Species, or MUMS, designation from the FDA&#8217;s Center for Veterinary Medicine, or CVM, for the treatment of newly-diagnosed or first relapse after chemotherapy lymphomas in pet dogs.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Several different dog tumor cell lines, including those derived from lymphomas, exhibited growth inhibition and apoptosis in vitro upon exposure to nanomolar concentrations of verdinexor. Data from a Phase&#160;1 clinical trial of verdinexor as well as dose expansion study involving pet dogs with cancer, primarily with lymphoma, show efficacy of verdinexor to treat dogs with lymphoma. Side effects included anorexia, weight loss, vomiting and diarrhea and were manageable with dose modulation and supportive care. We conducted an owner observation-based survey and the data indicated that the overall quality of life did not change significantly in dogs treated with verdinexor. Based on these findings, a Phase&#160;2b clinical trial, intended to support regulatory approval under the MUMS designation in the United States, was performed in 58 pet dogs with either newly-diagnosed or first relapse after chemotherapy lymphomas. Verdinexor was administered initially at doses ranging from 25mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> to 30mg/m<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">2</div> two or three days per week. Minimal or no supportive care was given. The results of </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">this Phase 2b clinical trial were published in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BMC Veterinary Research</div></div> (Sadowski, A.R., et.al., August 2018). According to the published data, the ORR among the 58 dogs was 37%. The most common AEs related to verdinexor included anorexia, weight loss, vomiting, lethargy and diarrhea. Most events (95%) were considered grade 1 or 2. We submitted the safety and effectiveness sections of a New Animal Drug Application for verdinexor to the CVM in December 2013.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In May 2017, we entered into an exclusive licensing agreement with Anivive Lifesciences, Inc., or Anivive, a privately-held biotech company focused on innovations in the veterinary drug and bioinformatics space, pursuant to which Anivive received worldwide rights to research, develop and commercialize verdinexor for the treatment of cancer in companion animals. In exchange, we received an upfront payment and are eligible to receive future milestone payments and royalties. If approved, we believe that verdinexor would represent the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-chemotherapy-based</div> approval for the treatment of dog lymphoma.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Potential of XPO1 in Settings Beyond Oncology </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In addition to its role in cancer, XPO1 is known to play a role in neurological, inflammatory, viral, wound healing and other diseases. In the hands of academic collaborators, SINE compounds have shown activity in a variety of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-oncology</div> models consistent with the biology of XPO1. In January 2018, we entered into an Asset Purchase Agreement with Biogen MA Inc., a subsidiary of Biogen Inc., or Biogen, pursuant to which Biogen acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350,</div> an investigational new drug application-ready, oral SINE compound with a preclinical data package supporting potential efficacy in a number of neuro-inflammatory conditions, as well as certain related assets with an initial focus in amyotrophic lateral sclerosis, or ALS. According to publicly available information, an IND application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (now BIIB100) was filed in December 2018 and the first patient was dosed in a Phase 1 study of sporadic ALS in June 2019.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">SINE compounds have also demonstrated activity in animal models of viral diseases, certain rare diseases and other indications, and we are continuing to develop programs in these areas largely through academic collaborations and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-dilutive</div> funding opportunities with the intent to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-license</div> these programs for clinical development and future commercialization.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Oncology</div> Drug Candidates </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-style: italic; font-weight: bold; letter-spacing: 0px; top: 0px;;display:inline;">Verdinexor (KPT-335): </div>Oral SINE Compound for Viral, Rare Disease and Autoimmune Indications<div style="font-style: italic; font-weight: bold; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Verdinexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-335)</div> is an oral SINE compound and our lead compound that is being evaluated as a potential therapy for viral, inflammatory, and autoimmune indications, in addition to the canine lymphoma program described above. Several autoimmune indications are driven by aberrant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> responses, particularly uncontrolled <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> cytokine expression and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NF-kB</div> activation. These include systemic lupus erythematosus, or SLE, a primary focus of our work with verdinexor. Funded by a grant under the Small Business Innovation Research program, the work to complete <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> evaluation of verdinexor as a treatment for SLE is expected to finish in early 2020. At such time, we expect to be in position to file an IND application with the FDA. In addition to SLE, we are initiating preclinical research in spinal cord injuries. In September 2019, we and our collaborator were awarded $2.1&#160;million in grant funding from the U.S. Department of Defense to cover all preclinical work required to reach <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-readiness</div> in the field of spinal cord injuries.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition, several viruses exclusively utilize XPO1 to shuttle cargos necessary for viral replication, such as viral and host proteins from the nucleus to the cytoplasm. Due to the stability of host gene targets compared to viruses which rapidly adapt for best fitness in hosts, targeting host genes may offer an approach to limit drug resistance. We intend to extend preclinical research in viruses that may be relevant to patients with compromised immune systems, such as cytomegalovirus, or CMV. As such, we are conducting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> animal studies of verdinexor in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CMV-infected</div> mice with the National Institutes of Health. We also intend to investigate verdinexor to treat inflammation in virally-suppressed antiretroviral therapy-receiving individuals.</div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18</div></div> </div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015, we conducted a randomized, double-blind, placebo-controlled, dose-escalating Phase 1 clinical trial of verdinexor in healthy human volunteers in Australia. This study was designed to evaluate the safety and tolerability of verdinexor in healthy adult subjects. Mild to moderate AEs of similar grade and in an equivalent percentage of patients as placebo were reported, and no serious or severe AEs were observed. We plan to continue to explore strategies to pursue the clinical development of verdinexor as a treatment for viral, inflammatory, and autoimmune indications, including potentially partnering with a collaborator or through government-funded grant or contract opportunities. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As part of the exclusive license agreement we entered into with Antengene Therapeutics Limited, or Antengene, in May 2018, we granted Antengene exclusive rights to develop and commercialize&#160;verdinexor for the diagnosis, treatment and/or prevention of certain human<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;non-oncology</div>&#160;indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Mechanism of Action: Transient XPO1 Inhibition by SINE Compounds </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain functions may only occur within a particular location in the cell, so one of the ways a cell regulates the function of a particular protein is by controlling that protein&#8217;s location within the cell. The nuclear pore is a complex gate between the nucleus and cytoplasm, regulating the import and export of most large molecules, called macromolecules, including many proteins, into and out of the nucleus. In healthy cells, nuclear transport, both into and out of the nucleus, is a normal and regular occurrence that is tightly regulated and requires the presence of specific carrier proteins. XPO1 mediates the export of over 220 mammalian cargo proteins and some growth-promoting mRNAs. Particularly, XPO1 mediates the transport of the majority of tumor suppressor proteins and appears to be the only mediator of nuclear export for these proteins. Cancer cells have increased levels of XPO1, causing the increased export of these tumor suppressor proteins from the nucleus. Since the tumor suppressor proteins must be located in the nucleus to survey for DNA damage and initiate programmed cell death, or apoptosis, XPO1 overexpression in cancer cells neutralizes their tumor suppressing function by removing them from the nucleus. By blocking XPO1, our SINE compounds inhibit the export of tumor suppressor proteins, leading to their accumulation and functional reactivation in the nucleus. The accumulation of tumor suppressor proteins in the nucleus amplifies their natural apoptotic function in cancer cells. Because normal cells have little or no DNA damage, accumulation of tumor suppressor proteins in their nucleus generally does not lead to apoptosis. Further, SINE compounds reduce the translation of certain growth-promoting and anti-apoptosis proteins&#8212;often called oncoproteins&#8212;by inhibiting the XPO1-mediated nuclear to cytoplasmic transport of a protein called eIF4E (eukaryotic protein translation initiation factor 4E), which itself binds to the </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mRNAs that code for these proteins. The figure below depicts the process by which our SINE compounds inhibit the XPO1-mediated nuclear export of tumor suppressor proteins and oncoprotein mRNAs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt; margin-left: 0in; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g853399g91m71.jpg" style="width: 535px; height: 396px;"/></div></div> </div> </div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that the XPO1-inhibiting SINE compounds that we have discovered and developed to date, including selinexor, have the potential to provide novel, oral, targeted therapies that enable tumor suppressor proteins to remain in the nucleus and promote the apoptosis of potentially any type of cancer cell. In multiple cancer types, patient tumor biopsies have confirmed that selinexor treatment induces nuclear localization of tumor suppressor proteins and, subsequently, cancer cell death, or apoptosis. We believe that XPOVIO is the only currently approved cancer treatment selectively targeting the restoration and increase in the levels of multiple tumor suppressor proteins in the nucleus. We believe that selinexor&#8217;s novel mechanism of action and oral administration and low levels of major organ toxicities observed to date in patients treated with selinexor in clinical trials, along with encouraging efficacy data, support the potential for selinexor&#8217;s broad use across many cancer types, including both hematological and solid tumor malignancies. Our SINE compounds were the first oral XPO1 inhibitors in clinical development. We own all intellectual property rights related to the compounds that we are developing, including composition of matter and method of use patents covering selinexor issued by the U.S. Patent and Trademark Office in 2015 and which provide patent protection through at least 2032, prior to any adjustments or extensions. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategy </div></div></div> <div style="text-align: justify; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The critical components of our business strategy are to: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Maximize the Commercial Value of XPOVIO and Our Other Drug Candidates. </div></div></div>We are also executing on our U.S. commercial capabilities and supporting the ongoing launch of XPOVIO in the United States. In 2019 we launched XPOVIO in the U.S. market. As of December&#160;31, 2019, approximately 1,400 XPOVIO prescriptions had been fulfilled, driven by strong demand from both academic and community-based oncologists, and XPOVIO had been prescribed by more than 550</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20</div></div> </div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">unique physicians and healthcare accounts. In 2020, we plan to further penetrate the U.S. commercial market and further educate the medical community about the clinical data that supported the accelerated approval of XPOVIO. Outside of the United States, we will either work with existing and potential partners to establish such commercial infrastructure or may consider establishing this infrastructure ourselves on a case by base basis. To date, we have entered into several strategic arrangements.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div>In October 2017, we entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization of selinexor and eltanexor for all human oncology indications in Japan, South Korea, Taiwan, Hong Kong, and the ASEAN countries. In May 2018, we entered into an exclusive license agreement with Antengene under which we granted Antengene exclusive rights to develop and commercialize selinexor, eltanexor and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> each for the diagnosis, treatment and/or prevention of all human oncology indications, as well as&#160;verdinexor for the diagnosis, treatment and/or prevention of certain human<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;non-oncology</div>&#160;indications. We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the oncology field in mainland China and Macau and licensed the development and commercial rights to Antengene for<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;KPT-9274</div>&#160;in the oncology field and verdinexor in the<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;non-oncology</div>&#160;field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam. We currently hold development, marketing, and commercialization rights for selinexor in all other countries and are developing selinexor and seeking regulatory approval for its use in oncology indications without a collaborator in North America and Europe.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Continue to Develop and Seek Regulatory Approvals of Selinexor, Our Lead Novel Drug Candidate, in North America and Europe.</div></div></div> We plan to seek regulatory approvals of selinexor in North America and Europe for each indication in which we receive favorable results in a trial with a survival endpoint that is registration-enabling. As we did with XPOVIO based on results of the STORM study, we may also seek regulatory approvals where a clinical trial demonstrates significant data in a surrogate endpoint, such as overall response rate, that could allow for accelerated or conditional approval. We or our current or future partners may seek marketing approvals in other geographies as well.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Maintain Our Competitive Advantage and Scientific Expertise in the Field of Nuclear Transport.</div></div></div> To further our understanding of the role nuclear transport plays in the underlying biology of cancer, as well other major diseases, we plan to continue research in the field of nuclear transport and related areas, primarily by fostering relationships with scientific advisors and physicians. We continue to explore a variety of standard and novel combinations of other anti-cancer agents with our SINE inhibitors, and these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies are anticipated to provide support for new clinical investigations. One such example includes the recently initiated combination study of selinexor with Venclexta<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (venetoclax), an oral inhibitor of the oncoprotein <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bcl-2.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> studies have suggested that the combination may be synergistic in killing cancer cells and a new investigator-sponsored study at Vanderbilt University was initiated to evaluate the clinical potential of this combination. Beyond oncology, we have taken this approach in the past with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350,</div> an oral SINE compound for which we developed a preclinical data package supporting potential efficacy in a number of neuro-inflammatory conditions, which Biogen acquired from us in early 2018. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> was renamed BIIB100 and is currently in clinical evaluation to treat ALS. We believe that investing in the recruitment of exceptional advisors, employees, and management is critical to our continued leadership in the nuclear transport field. We are collaborating with leading patient advocacy groups to provide education on the science behind our SINE compounds and to support the development and execution of clinical trials. We have advanced the understanding and potential application of SINE compounds in cancer treatment through a broad range of collaborations with leading institutions engaged in evaluating SINE compounds in clinical trials in the United States, Canada, many European countries, Australia, India, Israel, Singapore and elsewhere.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Continue Developing our Pipeline of Novel Drug Candidates.</div></div></div> To date, we have identified several drug candidates: our oral SINE compounds selinexor, eltanexor and verdinexor and our oral dual</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21</div></div> </div> </div> </div> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">PAK4/NAMPT inhibitor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274.</div> A fifth program, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> for ALS and other neuro-inflammatory conditions, was sold to Biogen in January 2018. We may also identify or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> novel drug candidates for development in oncology in the future.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Maximize the Value of Our Other SINE Compounds in Non-Oncology Indications through Collaborations.</div></div></div> We may seek to enter into global or regional development, marketing, and commercialization collaboration arrangements for our other SINE compounds in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-oncology </div> indications. For example, in May 2018, we licensed the development and commercial rights to Antengene for verdinexor in the<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;non-oncology</div>&#160;field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam. As described above, in January 2018, we entered into an asset purchase agreement with Biogen pursuant to which Biogen acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> as well as certain related assets with an initial focus in ALS.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Focus: Nuclear Transport </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancer is a disease characterized by unregulated cell growth. Cancer cells develop when DNA inside the nucleus of normal cells accumulates damage in genes that regulate cell growth and survival. In healthy cells, proteins called tumor suppressor proteins located in the cell nucleus help prevent accumulation of DNA damage (mutations, chromosomal translocations and other abnormalities) by monitoring DNA for damage, and if damage is detected, the tumor suppressor proteins direct the cell to attempt to repair it. However, if the DNA damage is too severe, the tumor suppressor proteins direct the cell to die in a process called apoptosis. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteins, however, are not made inside the nucleus but rather made outside of the nucleus in an area called the cytoplasm. A membrane, called the nuclear membrane, separates the nucleus from the cytoplasm. Larger nuclear proteins, including tumor suppressor proteins, must be transported from the cytoplasm where they are made into the nucleus to perform their functions in keeping a cell healthy. Similarly, when they have completed their normal functions, these proteins are typically exported back into the cytoplasm. Proteins move between the nucleus from the cytoplasm through a protein complex embedded in the nuclear membrane called the nuclear pore. The nuclear pore works like a gate through which large molecules, including many other proteins and RNAs, enter and exit the nucleus. When molecules enter the nucleus from the cytoplasm, the process is called import, and when molecules exit from the nucleus to the cytoplasm, the process is called export. The import and export of most proteins and other large molecules between the nucleus and cytoplasm require specific carrier proteins to chaperone their cargo molecules through the nuclear pore complex. Carrier proteins which mediate the import of macromolecules into the nucleus are called importins, and those which mediate the export of macromolecules out of the nucleus are called exportins. Therefore, the processes of import and export are carried out separately and are typically regulated independently. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Eight exportins have been identified in human cells. One such export carrier protein was discovered in 1999 and is called exportin 1, or XPO1 or CRM1. XPO1 exports over 220 proteins referred to as its &#8220;cargo proteins.&#8221; In particular, XPO1 appears to be the sole exporter for most of the tumor suppressor proteins including p53, p73, p21, p27, APC, FOXO, pRB and survivin. In addition to exporting tumor suppressor proteins out of the nucleus, XPO1 mediates the nuclear export of a protein called eukaryotic initiation factor 4E, or eIF4E, also called the &#8220;mRNA cap binding protein.&#8221; eIF4E binds to the mRNAs for many growth-regulating proteins, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">c-myc, </div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bcl-2,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bcl-6</div> and cyclin D. eIF4E depends on XPO1 to help carry these growth-promoting mRNAs from the nucleus into the cytoplasm where the mRNAs are efficiently translated into proteins. XPO1 also exports the anti-inflammatory (and anti-tumor) protein I<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B, which inhibits a protein called NF-<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B. NF-<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B is found in the nucleus of most cancer cells and plays a role in cancer metastasis and chemotherapy resistance, as well as in many inflammatory and autoimmune diseases. By exporting I<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B out of the nucleus, XPO1 augments NF-<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B activity.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPO1 levels are reported to be elevated in nearly all cancer cells when compared to their healthy cell counterparts. Therefore, these elevated levels of XPO1 in cancer cells mediate the rapid export of tumor </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22</div></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%;"> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">suppressor proteins as well as I<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B and eIF4E out of the nucleus. When compared to healthy cells, the increased export of tumor suppressor proteins in cancer cells may lead to reduced monitoring for DNA damage, the normal triggering of apoptosis and increased NF-<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B activity. Higher levels of XPO1 expression in cancer cells is also generally correlated with resistance to chemotherapy and poor prognosis of patients.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Inhibiting XPO1 leads to accumulation of tumor suppressor proteins as well as eIF4E and I<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B in the cell nucleus, which has been confirmed in a variety of preclinical models as well as in tumor biopsy tissues from patients treated with selinexor. Nuclear retention of tumor suppressor proteins increases their efficiency in detecting DNA damage and subsequently triggering apoptosis in cancer cells. In addition, blocking XPO1 can cause accumulation of eIF4E-bound growth-promoting mRNAs, which may cause a reduction in the levels of growth-promoting proteins in cancer cells; this has also been confirmed in preclinical models and in patients&#8217; tumor biopsy tissues. Accumulation of I<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B in the nucleus inhibits NF-<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B, which may be beneficial in overcoming chemotherapy resistance and in treating autoimmune, inflammatory, and neuro-inflammatory disease; this too has been detected in both preclinical models and in human cancer tissues from treated patients. For these reasons, we believe blocking XPO1 is a good strategy for treating cancer as well as autoimmune, inflammatory and neuro-inflammatory diseases. The figure below depicts the process by which XPO1 mediates the nuclear transport process.</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 24pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPO1 Mediation of Nuclear Transport </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Approach: Targeting Nuclear Export with SINE Compounds</div></div></div> </div> </div> </div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="clear: both; max-height: 0px;">&#160;</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 0in; text-align: center;">
<img alt="" src="g853399g76b11.jpg" style="width: 443px; height: 328px;"/></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">XPOVIO, our approved XPO1 inhibitor, and our drug candidates are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class,</div> oral, <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">SINE</div></div> compounds. SINE compounds inhibit XPO1-mediated nuclear export by strongly, yet reversibly, binding to the XPO1 cargo binding site, effectively blocking the XPO1-cargo protein interaction. The transient XPO1 inhibition period that we have observed to date with our SINE compounds appears to be sufficient for elevation of tumor suppressor protein levels and I<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">k</div>B in the nucleus. Accumulation of tumor suppressor proteins in the nucleus of cancer cells allows them to perform their normal role of detecting DNA damage, thereby inhibiting a cancer cell&#8217;s ability to divide and promoting apoptosis.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Healthy cells also accumulate tumor suppressor proteins in the presence of a</div> </div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SINE compound, but they do not undergo apoptosis after transient XPO1 inhibition because they have minimal or no DNA damage. The figure below depicts the process by which SINE compounds inhibit the XPO1-mediated nuclear export of tumor suppressor proteins. </div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 24pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transient XPO1 Inhibition by SINE Compounds</div></div></div> </div> </div> </div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 0in; text-align: center;"><div style="font-style:italic;display:inline;">
<img alt="" src="g853399g25t47.jpg" style="width: 508px; height: 376px;"/></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to cancer, our SINE compounds have demonstrated the potential to provide therapeutic benefit in a number of other indications. Specifically, SINE compounds have shown evidence of activity in preclinical models of viral infections, neurological disorders, inflammation and autoimmune diseases. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Initial Indication: Cancer </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the World Health Organization, cancer is the second leading cause of death globally and responsible for an estimated 9.6&#160;million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Additionally, cancer is one of the most important health issues facing patients in the United States. The American Cancer Society estimates that in the United States, more than 16.9&#160;million Americans with a history of cancer were alive on January&#160;1, 2019 and more than 1.8&#160;million new cancer cases are expected to be diagnosed in 2020. Approximately 600,000 Americans are expected to die of cancer in 2020. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The most common methods for treating patients with cancer are a combination of surgery, radiation, and drug therapy. Locoregional therapies, such as surgery and radiation therapy, are particularly effective with localized disease. However, in situations where the cancer has spread beyond the primary site or cannot otherwise be treated through locoregional therapies, physicians generally use systemic drug therapies. In many cases, drug therapy includes combinations of several different drugs. An early approach to cancer treatment was through cytotoxic drugs that kill rapidly proliferating cancer cells by nonspecific mechanisms, such as disrupting cell metabolism or causing damage to cellular components required for survival and rapid growth. While these </div></div> </div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">drugs have been effective in the treatment of some cancers, they act in an indiscriminate manner, killing healthy cells as well as cancer cells. Due to their mechanism of action, many cytotoxic drugs have a narrow dose range above which the toxicity causes unacceptable or even fatal levels of damage and below which the drugs are not effective in promoting cancer cell death. A different approach to pharmacological cancer treatment has been to develop drugs referred to as targeted therapeutics, which target specific biological molecules in the human body that play a role in the rapid cell growth and spread of cancer. Targeted therapeutics are designed specifically to exploit vulnerabilities in cancer cells to improve efficacy and to minimize side effects. The drugs are designed to either attack a target that causes uncontrolled growth of cancer cells because of a genetic alteration more often found in cancer cells than in healthy cells or attack a target that cancer cells are more dependent on for their growth than are healthy cells. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our SINE compounds are novel therapies specifically designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. When tumor suppressor proteins are located in the cell nucleus, they assess the integrity of a cell&#8217;s DNA. In cells with heavily damaged DNA, such as cancer cells, these tumor suppressor proteins induce cell death, or apoptosis.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Unlike many other targeted therapeutic approaches that only work for a specific set of cancers or in a specific subgroup of patients, we believe that by restoring tumor suppressor proteins to the nucleus where they can assess a cell&#8217;s DNA, our SINE compounds have the potential to provide therapeutic benefits across a broad range of both hematological and solid tumor malignancies and benefit a wider range of patients.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Additionally, and as supported by its mechanism of action and preclinical and clinical data, we believe that selinexor has the potential for additive or synergistic benefit with approved and experimental therapies in treating cancer patients.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>As a result, we believe that selinexor has the potential to serve as a backbone therapy across multiple hematological and solid tumor malignancies as part of a variety of combination therapies.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our founding by Dr.&#160;Sharon Shacham in 2008, our goal has been to establish a leading, independent oncology business. We are led by Dr.&#160;Shacham, our President and Chief Scientific Officer, and Dr.&#160;Michael Kauffman, our Chief Executive Officer. Dr.&#160;Kauffman played a leadership role in the development and approval of Velcade at Millennium Pharmaceuticals and of Kyprolis while serving as Chief Medical Officer at Proteolix and then Onyx Pharmaceuticals. Both prior to her founding of Karyopharm and while at Karyopharm, Dr.&#160;Shacham has played a leadership role in the discovery and development of many novel drug candidates, which have been or are being tested in human clinical trials. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our inception, we have devoted most of our efforts to research and development. Beginning in July 2019, we have generated revenue from the commercial sale of XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (selinexor). Net product sales for the year ended December&#160;31, 2019 was $30.5&#160;million. As of December&#160;31, 2019, we had an accumulated deficit of $873.3&#160;million. We had net losses of $199.6&#160;million, $178.4&#160;million and $129.0&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategic Relationships </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On May&#160;23, 2018, we entered into a license agreement with Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong, or Antengene, and a subsidiary of Antengene Corporation Co. Ltd., a corporation organized and existing under the laws of the People&#8217;s Republic of China, pursuant to which we granted Antengene exclusive rights to develop and commercialize, at its own cost, selinexor,&#160;eltanexor and<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;KPT-9274,</div>&#160;each for the diagnosis, treatment and/or prevention of all human oncology indications, as well as&#160;verdinexor for the diagnosis, treatment and/or prevention of certain human<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;non-oncology</div> indications. We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the oncology field in mainland China and Macau and licensed the development and commercial rights to Antengene for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274 </div> in the oncology field, as well as verdinexor in the<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;non-oncology</div>&#160;field in mainland China, Taiwan, Hong Kong, Macau, South Korea, and the ASEAN countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam). Under the terms of the Antengene Agreement, we received an upfront cash payment of $11.7&#160;million and are entitled to receive up to $105.0&#160;million in milestone payments</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">from Antengene if certain development goals are achieved and up to $45.0&#160;million in milestone payments from Antengene if certain sales milestones are achieved. We are further eligible to receive tiered double-digit royalties based on future net sales of selinexor and eltanexor in China and Macau, and tiered single- to double-digit royalties based on future net sales of<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;KPT-9274</div>&#160;and verdinexor in the licensed territories. Antengene&#8217;s obligations under the license agreement have been guaranteed by Antengene Corporation Co. Ltd.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">According to publicly available information, Antengene filed Clinical Trial Applications, or CTAs, in China with the National Medical Products Administration, or NMPA, for selinexor in multiple myeloma and DLBCL in 2019. The multiple myeloma CTA, known as MARCH, supports a clinical study of selinexor plus dexamethasone in patients whose disease is refractory to lenalidomide and bortezomib. The first patient in this study was enrolled in September 2019. The DLBCL CTA, known as SEARCH, supports a clinical study of selinexor both as single agent and in combination with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ATG-008,</div> for the treatment of relapsed/refractory DLBCL. Also, Antengene announced on January&#160;3, 2020 that the Food and Drug Administration, Ministry of Health and Welfare, Taiwan has recently approved the commencement of a phase I open-label clinical trial for the PAK4/NAMPT dual target oral inhibitor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in patients with advanced solid tumors or NHL which have progressed despite standard therapy, for whom no standard therapy exists, or who have refused standard therapy.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On January&#160;24, 2018, we entered into an asset purchase agreement with Biogen pursuant to which Biogen acquired our oral SINE compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> and certain related assets. XPO1 mediates the nuclear export of multiple proteins that impact neurological and inflammatory processes. Consequently, inhibition of XPO1 by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> results in a reduction in inflammation and an increase in anti-inflammatory and neuroprotective responses. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> penetrates the blood brain barrier to a greater degree than other SINE compounds. Preclinical data generated largely by external collaborators show efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> and related SINE compounds in animal models of amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, epilepsy, and other neuro-inflammatory indications. We received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> upfront payment of $10.0&#160;million from Biogen and are eligible to receive additional payments of up to $207&#160;million based on the achievement by Biogen of future specified development and commercial milestones. We are also eligible to receive tiered royalty payments that reach low double digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product or the expiration of specified patent protection for the applicable product, determined on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">county-by-country</div> basis. According to publicly available information, an IND application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> was filed in December 2018 and the first patient was dosed in a Phase 1 study of sporadic ALS in June 2019.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Effective October&#160;11, 2017, we entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., or Ono, whereby Ono received rights to develop and commercialize selinexor and eltanexor at its own cost and expense, for the diagnosis, treatment and/or prevention of all human oncology indications in Japan, South Korea, Taiwan, Hong Kong, and the ASEAN countries, which we refer to as the Ono Territory. In exchange, we received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> upfront payment of &#165;2.5&#160;billion (approximately US$21.9 million) from Ono and retain all rights to selinexor and eltanexor outside the Ono Territory. We are eligible to receive up to an additional &#165;19.15&#160;billion (approximately US$176.2&#160;million at the exchange rate on December&#160;31, 2019) if specified future development and commercial milestones are achieved by Ono. We are also eligible to receive low double-digit royalties based on future net sales of selinexor and eltanexor in the Ono Territory. Ono will have the ability to participate in any global clinical study of selinexor and eltanexor and will bear the cost and expense for patients enrolled in clinical studies in the Ono Territory.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2017, we entered into an exclusive licensing agreement with Anivive Life Sciences, Inc., or Anivive, pursuant to which Anivive received worldwide rights to research, develop and commercialize verdinexor for the treatment of cancer in companion animals. In exchange, we received an upfront payment of $1.0&#160;million and a subsequent milestone of $250,000 and are eligible to receive up to $43.25&#160;million in future regulatory, clinical and commercial milestone payments, assuming approval in both the United States and the European Union. In addition, Anivive agreed to pay us up to low double-digit royalty payments based on future </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">net sales of verdinexor. If approved, we believe that verdinexor would represent the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-chemotherapy-</div>based approval for the treatment of dog lymphoma.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our drug candidates, our core technologies, and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary or intellectual property rights. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the United States and in foreign jurisdictions related to our proprietary technology and drug candidates. We also rely on trade secrets, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We file patent applications directed to the composition of matter and methods of use and manufacture for our drug candidates. As of February&#160;10, 2020, we were the sole owner of 20 patents in the United States and we had 10 pending patent applications in the United States, two pending international applications filed under the Patent Cooperation Treaty, or PCT, 59 granted patents and 96 pending patent applications in foreign jurisdictions. The PCT is an international patent law treaty that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in each of the member states. Although a PCT application is not itself examined and cannot issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. The technology underlying such pending patent applications has been developed by us and was not acquired from any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> agreement.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The intellectual property portfolios for our key drug candidates as of February&#160;10, 2020 are summarized below. </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor (KPT-330)</div></div>: Our selinexor patent portfolio covers the composition of matter and methods of use of selinexor, as well as methods of making selinexor, and consists of five issued U.S. patents (two patents are specific to selinexor, two other patents cover both selinexor and verdinexor and the fifth patent covers polymorphs of selinexor), 23 issued foreign patents, 43 pending foreign patent applications, two pending U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> applications, including one directed to polymorphs of selinexor and one pending U.S. provisional patent application. Any patents that may issue in the United States as part of our selinexor patent portfolio, with the exception of a patent directed to the polymorphs of selinexor, will expire in 2032, absent any terminal disclaimer, patent term adjustment due to administrative delays by the United States Patent and Trademark Office, or USPTO, or patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. Any patents that may issue in foreign jurisdictions will likewise expire in 2032. Any patents that may issue in the United States directed to the polymorphs of selinexor will expire in 2035, absent any terminal disclaimer, patent term adjustment due to administrative delays by the USPTO or patent term extension under the Hatch-Waxman Act. Any patent issued in foreign jurisdictions will likewise expire in 2035. If a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent application claiming the benefit of the pending U.S. provisional patent application referenced above is filed in 2020, any patents that may issue from such applications will expire no earlier than 2040.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selinexor (Wound Healing)</div></div>: Our patent portfolio covering selinexor for wound healing, including acute and chronic wounds, covers methods of using selinexor or verdinexor for wound healing, including systemic and topical uses, and consists of one issued U.S. patent and one granted European patent. The U.S. patent will expire in 2034, absent any terminal disclaimer, patent term adjustment due to administrative delay by the USPTO or patent term extension under the Hatch-Waxman Act. The European patent will likewise expire in 2034.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Verdinexor (KPT-335)</div></div>: Our selinexor patent portfolio described above, with the exception of the applications directed to polymorphs of selinexor, also covers both the composition of matter and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">methods of use of verdinexor, as well as methods of making verdinexor. There are four issued U.S. Patents that cover verdinexor. One patent is specific to verdinexor, two patents cover both verdinexor and selinexor (also referenced above with respect to selinexor) and the other covers veterinary uses of verdinexor.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eltanexor </div></div>(<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">KPT-8602)</div></div>: Our eltanexor patent portfolio covers both the composition of matter and methods of use of eltanexor, and consists of two issued U.S. patents, one pending <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> U.S. patent application, nine issued foreign patents, 20 pending foreign patent applications and one pending PCT application. The PCT application provides the opportunity for seeking protection in all PCT member states. Any patents that may issue in the United States as part of our eltanexor patent portfolio, with the exception of a patent based on the pending PCT application, will expire in 2034, absent any terminal disclaimer, patent term adjustment due to administrative delays by the USPTO or patent term extension under the Hatch-Waxman Act. Any patents issued in foreign jurisdictions will likewise expire in 2034. Any patents that may issue in the United States based on the pending PCT application will expire in 2039, absent any terminal disclaimer, patent term adjustment due to administrative delays by the USPTO or patent term extension under the Hatch-Waxman Act. Any patents issued in foreign jurisdictions will likewise expire in 2039.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PAK4/NAMPT Inhibitors</div></div>: Our PAK4/NAMPT inhibitors patent portfolio covers both the composition of matter and methods of use of the PAK4/NAMPT inhibitors described therein, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> and consists of five patent families with nine issued U.S. patents, five issued foreign patents, two pending U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent applications, and 28 pending foreign patent applications in total. Any patents that may issue in the United States based on the pending U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> applications will expire in 2034 for the earliest filed application and 2036&#160;for the remaining application, absent any terminal disclaimer, patent term adjustment due to administrative delays by the USPTO or patent term extension under the Hatch-Waxman Act. Any patents that may issue based on the pending foreign patent applications will likewise expire in 2034 or 2036. Foreign patent applications covering the composition of matter and methods of use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> have been filed in 21 countries/regions.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition to the patent portfolios covering our key drug candidates, as of February&#160;10, 2020, our patent portfolio also includes five patents (U.S. Patent Nos.&#160;8,513,230, 9,303,000, 9,428,490, 9,550,757 and 10,526,295) and 17 granted foreign patents and pending patent applications in the U.S. and foreign jurisdictions relating to other XPO1 inhibitors and their use in targeted therapeutics and combination therapies and biomarkers for XPO1 inhibitors. In the United States, we have trademark registrations for our name and logo, and a combination of the two, XPOVIO, and PORE for our online portal.&#160;We also have pending applications to register two additional possible drug names (examination is currently suspended), and KARYFORWARD and a KARYFORWARD logo for our financial aid and charitable services.&#160;Outside the United States, XPOVIO is registered or pending in thirty additional jurisdictions, and is registered or pending in Katakana in Japan, Hangul in South Korea, and Chinese characters in Taiwan.&#160;We also have registrations or applications for eight additional possible drug names in numerous foreign jurisdictions. The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. See &#8220;&#8212;Government Regulation&#8212;Patent Term Restoration and Extension&#8221; below for additional information on such extensions. In the future, if and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each drug candidate and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our drug candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, patent applications that we may file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Our issued patents and any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, we cannot be certain of the priority of inventions covered by pending third-party patent applications. If third parties prepare and file patent applications that also claim technology or therapeutics to which we have rights, we may have to participate in interference proceedings to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us. In addition, because of the extensive time required for clinical development and regulatory review of a drug candidate we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition to patents, we rely upon unpatented trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees. We also have agreements with selected consultants, scientific advisors and collaborators requiring assignment of inventions. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed through our relationship with a third party.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">With respect to our proprietary drug discovery and optimization platform, we consider trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to be our primary intellectual property. Trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> can be difficult to protect. We anticipate that with respect to this technology platform, these trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> may over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any drug candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">There are several companies developing or marketing treatments for cancer and the other indications on which we currently plan to focus, including many major pharmaceutical and biotechnology companies. To our knowledge, only one other company with an XPO1 inhibitor has enrolled patients in clinical trials at the present time. Stemline Therapeutics, Inc. announced in January 2015 that it had exclusively licensed the rights to develop and commercialize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SL-801</div> (felezonexor), an oral XPO1 inhibitor, from CanBas&#160;Co.,&#160;Ltd. In December 2015, Stemline announced the opening of its IND and planned initiation of a clinical development program in multiple cancer types. Stemline currently has a Phase 1 trial that is open and enrolling patients with advanced solid tumors. Updates were provided at the ESMO 2019 annual meeting indicating one patient had realized a partial response and some other patients had experienced stable disease.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key competitive factors affecting the success of any approved oncology drug product, including our drug candidates, if approved, are likely to be their efficacy, safety, convenience and price, the availability of alternative cancer therapies and the availability of reimbursement from government and other third-party payors. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs, or commercialize existing drugs in new indications, and those drugs are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. Generic drugs for the treatment of cancer and the other indications on which we currently plan to initially focus are currently on the market, and additional drugs are expected to become available on a generic basis over the coming years. As we have seen with XPOVIO, and in multiple myeloma, if we obtain marketing approval for our other drug candidates or for selinexor in other indications, we expect that they will be priced at a significant premium over generic versions of older chemotherapy agents and other cancer therapies. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our drug candidates may compete with many existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our drug candidates will be complimentary with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to currently marketed therapies, there are also a number of drugs in late stage clinical development to treat cancer and the other indications on which we plan to initially focus. These drugs in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our drug candidates for which we obtain marketing approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPOVIO and, if approved, our other lead drug candidates may compete with the investigational therapies and currently marketed drugs discussed below. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple Myeloma </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Over the past 15 years, ten agents have been approved in the United States for the treatment of patients with multiple myeloma: bortezomib (Velcade<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Takeda), lenalidomide (Revlimid<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Celgene), thalidomide (Thalomid<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Celgene), liposomal doxorubicin (Doxil<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Janssen), carfilzomib (Kyprolis<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Amgen), pomalidomide (Pomalyst<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;<div style="font-size: 5.476pt; line-height: 4.05224pt;;display:inline;vertical-align: top;"> </div></div>, Celgene), panobinostat (Farydak<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Novartis), daratumumab (Darzalex<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Janssen), elotuzumab (Empliciti<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, BMS), and ixazomib (Ninlaro<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Takeda). Approved indications range from the treatment of newly diagnosed patients to those with relapsed and/or refractory multiple myeloma. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Several other anti-cancer agents are in late-stage development for the treatment of patients with multiple myeloma, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-B</div> cell maturation antigen (BCMA), based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies such as bb2121 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CC-93269</div> (Bluebird Bio/Celgene/BMS), JCHARHI25 (Juno Therapeutics/Celgene), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-BCMA-101</div> (Johnson&#160;&amp;</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Johnson/Poseida Therapeutics), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">JNJ-4528</div> (LCAR-B38M, Johnson&#160;&amp; Johnson/Legend BioTech) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T-BCMA</div> (Novartis); monocolonal antibodies such as isatuximab (Sanofi), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TAK-079</div> (Takeda); antibody-drug conjugates such as belantamab mafodotin (GSK2857916, GlaxoSmithKline); <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies such as AMG420 (Amgen), REGN5458 (Regeneron) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PF-06863135</div> (Pfizer); and other novel agents such as ibrutinib (Imbruvica<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> , Abbvie/Roche), venetoclax (Venclexta<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Abbvie), plitidepsin (PharMar), masitinib (AB Sciences), filanesib (Array Biopharma), oprozomib (Amgen), ricolinostat (Celgene) and melflufen (Oncopeptides).</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Hodgkin&#8217;s</div> Lymphoma (NHL) </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The initial therapy for DLBCL typically consists of multi-agent cytotoxic drugs in combination with the monoclonal antibody rituximab (Rituxan<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Roche). In patients with DLBCL who are not elderly and who have good organ function, high dose chemotherapy with stem cell transplantation is often used. Over the past two years, three therapeutic interventions have been approved in the United States for the treatment of patients with relapsed refractory DLBCL, or RR DLBCL, who have received at least two prior therapies: tisagenlecleucel (Kymriah<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Novartis) and axicabtagene ciloleucel (Yescarta<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Kite/Gilead), both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies, and polatuzumab vedotin (Policy<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Genentech/Roche). On December&#160;30, 2019, MorphoSys announced its submission of a biologics license application (BLA) to the FDA for tafasitamab in RR DLBCL. Newer targeted agents such as the BTK inhibitor ibrutinib (Imbruvica<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Pharmacyclics) and the immunomodulatory drug lenalidomide (Revlimid<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Celgene) have also shown activity in DLBCL. There are also a number of other widely used anti-cancer agents that have broad labels which include NHL, and some of these are being evaluated alone or in combination for the treatment of patients with DLBCL that have relapsed after treatment with chemotherapy. Other anti-cancer agents are also being evaluated in the treatment of DLBCL, including but not limited to, tafasitamab <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(MOR-208,</div> MorphoSys), polatuzumab vedotin (Polivy<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;"><div style="font-size: 5.476pt; vertical-align: top; line-height: 4.05224pt;;display:inline;">&#8482;</div></div>, Roche), magrolimab <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Hu5F9-G4,</div> Forty Seven, Inc.), umbralisib/ublituximab (TG Therapeutics), mosunetuzumab (Roche), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ADCT-402 </div> (ADC Therapeutics), zanubrutinib (Brukinsa<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;"><div style="font-size: 5.476pt; vertical-align: top; line-height: 4.05224pt;;display:inline;">&#8482;</div></div>, Beigene), everolimus (Afinitor<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Novartis), venetoclax (Venclexta<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Abbvie), acalabrutinib (Calquence<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Acerta Pharma), blinatumomab (Blincyto<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Amgen), durvalumab (Imfinzi<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, AstraZeneca), nivolumab (Opdivo<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, BMS), pembrolizumab (Keytruda<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Merck), avelumab (Bavencio<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Pfizer/EMD Serono) and brentuximab vendotin (Adcetris<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Seattle Genetics). In addition, other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies are currently in clinical development.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dedifferentiated Liposarcoma (DDLS) </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sarcomas are a group of cancers which arise from connective tissue and bone, of which more than 50 subtypes exist. Liposarcoma is one of the more common types of soft tissue sarcoma. The initial treatment for liposarcoma is surgery with or without radiotherapy when possible. When liposarcoma is not amenable to surgery (i.e., unresectable), various systemic treatments, including multiagent and sometimes single agent chemotherapy are used. Agents used in combination therapies include: doxorubicin, ifosfamide, epirubicin, gemcitabine, dacarbazine, docetaxel and vinorelbine. There are a number of anti-cancer agents that have board soft tissue sarcoma labels and are typically used as single agents after initial systemic therapy, which include liposomal doxorubicin, temozolomide, vinorelbine, pazopanib (Votrient<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> Novartis), larotrectinib (for neurotrophic tyrosine receptor kinase, or NTRK, gene fusion-positive sarcomas&#8212;Vitrakvi<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Bayer) and entrectinib (for NTRK gene fusion-positive sarcomas&#8212;Rozlytrek<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Genentech/Roche). </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selinexor in being evaluated in patients with advanced, unresectable, dedifferentiated relapsed or refractory liposarcoma who have received at least two prior therapies. Two agents have been approved in the United States for the management of unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen: eribulin (Halaven<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;<div style="font-size: 5.476pt; line-height: 4.05224pt;;display:inline;vertical-align: top;"> </div></div>, Eisai Inc. 2017) and trabectedin (Yondelis<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Janseen 2019). Other anti-cancer agents are also being evaluated in the treatment of dedifferentiated liposarcoma, including but not limited to HDM201 and LEE011 (Novartis), cabazitaxel (Jevtana<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Sanofi), abemaciclib (Verzenio<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Lilly), plitidepsin (PharmaMar), Ipilimumab/Nivolumab (BMS), and Pembrolizumab (Keytruda<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, Merck). The effectiveness of existing treatments for unresectable or metastatic liposarcoma remains limited and few trials have specifically evaluated dedifferentiated liposarcoma at an advanced stage. </div></div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition with XPO1 Inhibitors </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Drug compounds currently in preclinical studies, if developed and approved, could also be competitive with our drug candidates, if approved. In January 2015, Stemline Therapeutics, Inc. announced that it had exclusively licensed the rights to develop and commercialize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SL-801,</div> an XPO1 inhibitor, from CanBas&#160;Co.,&#160;Ltd. Stemline currently has a Phase 1 trial that is open and enrolling patients with advanced solid tumors and updates were provided at the 2019 ESMO annual meeting indicating one patient had realized a partial response and some other patients had experienced stable disease. Additionally, Kosan Biosciences&#160;Inc. (acquired by Bristol-Myers Squibb Company) had evaluated compounds derived from leptomycin B in preclinical studies. To our knowledge, the Kosan compounds are not currently being developed and have never entered human studies.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">With respect to indications other than cancer, there are many currently marketed therapies and drugs in late-stage clinical development to treat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-oncology</div> indications which we may develop of our XPO1 inhibitors. However, to our knowledge, there are no other XPO1 inhibitors in clinical development for the treatment of any diseases other than cancer, including indications such as autoimmune and inflammatory diseases or wound healing. There is no published information on the use of the preclinical compounds that have been developed by Kosan Biosciences or CanBas&#160;Co./Stemline in models other than cancer.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition with PAK4/NAMPT Dual Inhibitors </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> PAK4/NAMPT dual inhibitor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> if developed and approved, would compete with currently marketed therapies and drugs in clinical development to treat cancer. However, there are currently no marketed therapies that target PAK4 and/or NAMPT.&#160;We are not aware of any company focusing on the development of a PAK4/NAMPT dual inhibitor.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;KPT-9274</div> is orally bioavailable and has demonstrated in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies consistent pharmacokinetics properties, minimal brain penetration, and minimal inhibition of cytochrome P450 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(CYP-450)</div> enzymes.&#160;In early animal models, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> has not shown the retinal and cardiac effects observed with certain NAMPT inhibitors.&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pfizer&#160;Inc. developed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PF-03758309,</div> a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-selective</div> PAK inhibitor, meaning that this compound inhibited several of the PAK family members, and not solely PAK4, through Phase&#160;1 clinical development, but that compound had poor oral bioavailability in both animals and humans and, to our knowledge, development has been discontinued. We are aware that PAK4 biology is being evaluated preclinically by AstraZeneca&#160;plc and Genentech,&#160;Inc. (acquired by Roche Holding AG). We are aware of a possible first in human clinical trial by Arcus Bioscience for its PAK inhibitor in 2020.&#160;We are not aware of any other PAK4 inhibitors that are in clinical development at the present time.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> we are aware of three NAMPT inhibitors that have entered phase 1/2 human clinical trials in patients with solid tumors or lymphomas. These compounds include GMX1778 (also known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CHS-828,</div> Teva), GMX1777 (water-soluble derivative of GMX1778, Teva), and APO866 (also known as FK866 and WK175).&#160;APO866 and GMX1777 was delivered as parenteral infusions, while GMX1778 was evaluated by oral dosing. The safety and preliminary efficacy of these inhibitors as reported in the literature appeared to show unfavorable pharmacokinetics properties (limited/no oral bioavailability, poor plasma stability, high inter- and intra-patient variability, and drug-drug interactions).&#160;To our knowledge, development of these inhibitors were discontinued. We are also aware that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">OT-82</div> (OncoTartis) has advanced to first in human clinical development stage. We are aware that NAMPT biology is being evaluated by Genentech, Inc., Eli Lilly&#160;&amp; Company, Millennium/Takeda Pharmaceutical Company Ltd., OncoTartis, Inc., Arcus Bioscience, Aurigene Discovery Technologies Limited, and at some academic institutions. We are not aware of any other NAMPT inhibitors in clinical development.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have any manufacturing facilities or personnel. We currently utilize and expect to continue to utilize third parties for the manufacture and testing of our preclinical, clinical, and commercial drug products. We </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">have engaged one third-party manufacturer to obtain the active pharmaceutical ingredient for selinexor for clinical and commercial testing. We have engaged a separate third-party manufacturer for<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;fill-and-finish</div>&#160;(tableting) services and have entered into a three-year supply agreement for the manufacture of selinexor 20 mg tablets with this manufacturer. We obtain all other selinexor supplies or materials on a purchase order basis and do not have a long-term supply arrangement in place at this time. We currently maintain sufficient inventories to exceed our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> forecasts for selinexor and do not have arrangements in place for a redundant supply. For all of our drug candidates, we intend to identify and qualify additional manufacturers to provide the active pharmaceutical ingredient and<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;fill-and-finish</div>&#160;services as part of our long-term commercial supply plans.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our drug products/candidates are small molecules and are manufactured in reliable and reproducible synthetic processes from readily available starting materials. The chemistry and formulation processes of selinexor has been developed to meet our large-scale manufacturing needs and do not require unusual equipment in the manufacturing process. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Review and Approval of Drugs in the United States </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The failure to comply with applicable requirements under the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">submission to the FDA of an IND, which must take effect before human clinical trials may begin;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">preparation and submission to the FDA of an NDA;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">review of the product by an FDA advisory committee, where appropriate or if applicable;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">payment of user fees and securing FDA approval of the NDA; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical Studies </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug product, as well as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. In addition, companies usually must also develop additional information about the chemistry and physical characteristics of the investigational product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the candidate product and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the candidate product does not undergo unacceptable deterioration over its shelf life.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The IND and IRB Processes </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug that is not the subject of an approved NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&#160;days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with FDA certain regulatory requirements in order to use the study as support for an IND or application for marketing approval. Specifically, on April&#160;28, 2008, the FDA amended its regulations governing the acceptance of foreign clinical studies not conducted under an investigational new drug application as support for an IND or an NDA. The final rule provides that such studies must be conducted in accordance with GCP, including review and approval by an independent ethics committee and informed consent from subjects. The GCP requirements in the final rule encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-IND</div> foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-IND</div> foreign studies are conducted in a manner comparable to that required for IND studies.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct a continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee or DSMB. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov website. Similar requirements for posting clinical trial information are present in the European Union (EudraCT) website: https://eudract.ema.europa.eu/ and other countries, as well. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expanded Access to an Investigational Drug for Treatment Use </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div> basis for: individual patients (single-patient IND applications for treatment in emergency settings and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emergency</div> settings); <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">intermediate-size</div> patient populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;13, 2016, the 21st Century Cures Act established (and the 2017 Food and Drug Administration Reauthorization Act later amended) a requirement that sponsors of one or more investigational drugs for the treatment of a serious disease(s) or condition(s) make publicly available their policy for evaluating and responding to requests for expanded access for individual patients. Although these requirements were rolled out over time, they have now come into full effect. This provision requires drug and biologic companies to make publicly available their policies for expanded access for individual patient access to products intended for serious diseases. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study; or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, on May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human Clinical Trials in Support of an NDA </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human clinical trials are typically conducted in four sequential phases, which may overlap or be combined: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top; white-space: nowrap;">Phase&#160;1:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The drug is initially introduced into a small number of healthy human subjects or patients with the target disease (e.g. cancer) or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top; white-space: nowrap;">Phase&#160;2:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top; white-space: nowrap;">Phase&#160;3:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. These clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which denotes a study that presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a drug.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top; white-space: nowrap;">Phase&#160;4:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Post-approval studies may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Submission of an NDA to the FDA </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2020 is $2,942,965 for an application requiring clinical data. The sponsor of an approved NDA is also subject to a program fee for fiscal year 2020 of $325,424. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for drugs with orphan designation and a waiver for certain small businesses. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The FDA conducts a preliminary review of an NDA within 60&#160;days of its receipt and strives to inform the sponsor by the 74th&#160;day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> substantive review. The FDA has agreed to certain performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspections may cover all facilities associated with an NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. The FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain drug</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">applications, including applications for drugs in a shortage or drugs for which approval is dependent on remediation of conditions identified in the inspection report. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fast Track, Breakthrough Therapy, Priority Review and Regenerative Advanced Therapy Designations </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation, priority review designation and regenerative advanced therapy designation. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Specifically, the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Second, a product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div> basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finally, with passage of the 21st&#160;Century Cures Act, or Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy (as defined in the Cures Act) that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accelerated Approval Pathway </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s Decision on an NDA </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&#160;4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-Approval Requirements </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">fines, warning letters or holds on post-approval clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">product seizure or detention, or refusal to permit the import or export of products; or</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">injunctions or the imposition of civil or criminal penalties.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">direct-to-consumer</div> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-misleading</div> communication regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label </div> information, such as distributing scientific or medical journal information. If a company is found to have promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementation regulations, as well as the Drug Supply Chain Security Act, or DSCSA, which regulates the distribution of and tracing of prescription drugs and prescription drug samples at the federal level, and sets minimum standards for the regulation of drug distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;505(b)(2) NDAs </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new product. These applications are submitted under Section&#160;505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section&#160;505(b)(2) of the FDCA. This type of application allows the applicant to rely, in part, on the FDA&#8217;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section&#160;505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied upon by the applicant for approval of the application &#8220;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221; </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thus, Section&#160;505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. NDAs filed under Section&#160;505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the Section&#160;505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b)(2) applicant. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Abbreviated New Drug Applications for Generic Drugs </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug...&#8221; </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. Clinicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing clinicians or patient. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent</div> exclusivity for the RLD has expired. The FDCA provides a period of five years of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent</div> data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&#160;IV certification, in which case the applicant may submit its application four years following the original product approval.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA must establish a priority review track for certain generic drugs, requiring the FDA to review a drug application within eight months for a drug that has three or fewer approved drugs listed in the Orange Book and is no longer protected by any patent or regulatory exclusivities, or is on the FDA&#8217;s drug shortage list. The new legislation also authorizes FDA to expedite review of competitor generic therapies or drugs with inadequate generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of the application. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Hatch-Waxman Patent Certification and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-Month</div> Stay </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section&#160;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Specifically, the applicant must certify with respect to each patent that: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the required patent information has not been filed;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the listed patent has expired;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph&#160;IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the ANDA applicant is not seeking approval). </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the ANDA applicant has provided a Paragraph&#160;IV certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days after the receipt of a Paragraph&#160;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months after the receipt of the Paragraph&#160;IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">To the extent that the Section&#160;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a Section&#160;505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent </div> exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph&#160;IV certification and subsequent patent infringement suit, until the earlier of 30&#160;months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section&#160;505(b)(2) applicant.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric Studies and Exclusivity </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. For drugs intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric study plans with drug sponsors. The legislation requires FDA to meet with drug sponsors by no later than the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-of-phase</div> 1 meeting for serious or life-threatening diseases and by no later than ninety days after FDA&#8217;s receipt of the study plan.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pediatric exclusivity is another type of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent</div> marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent</div> and orphan exclusivity. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. With regard to patents, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> pediatric exclusivity period will not attach to any patents for which a generic (ANDA or 505(b)(2) NDA) applicant submitted a paragraph IV patent certification, unless the NDA sponsor or patent owner first obtains a court determination that the patent is valid and infringed by a proposed generic product.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan Drug Designation and Exclusivity </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug exclusivity will not bar approval of another orphan drug under certain circumstances, including if a subsequent product with the same drug for the same indication is shown to be clinically superior to the </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Legislation reverses prior precedent holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity regardless of a showing of clinical superiority. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent Term Restoration and Extension </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. We cannot provide any assurance that any patent term extension with respect to any U.S. patent will be obtained and, if obtained, the duration of such extension, in connection with any of our product candidates.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Review and Approval of Animal Drugs in the United States </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to pursuing approval of our drug candidates for use in human beings, we may also seek approval of certain drug candidates for veterinary applications. As with new drug products for human beings, new animal drugs may not be marketed in the United States until they have been approved by the FDA as safe and effective. The requirements and phases governing approval of a new animal drug are analogous to those for new human drugs. Specifically, the Center for Veterinary Medicine or CVM at FDA is responsible for determining whether a new veterinary product should be approved on the basis of a NADA filed by the applicant. A NADA must contain substantial evidence of the safety and effectiveness of the animal drug, as well as data and controls demonstrating that the product will be manufactured and studied in compliance with, among other things, applicable cGMP and GLP practices. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">To begin this process, an applicant must file an Investigational New Animal Drug application, or INAD, with the CVM. The applicant will hold a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-development</div> meeting with the CVM to reach general agreement on the plans for providing the data necessary to fulfill requirements for a NADA. In this context, an applicant must submit pivotal protocols to the CVM for review and concurrence prior to conducting the required studies. The applicant will gather and submit data on safety, efficacy and chemistry, manufacturing and controls or CMC to the CVM for review, as below:</div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top; white-space: nowrap;">Safety:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The design and review of the safety study and the study protocol are completed prior to initiation of the study to help assure that the data generated will meet FDA requirements. These studies are conducted under rigorous quality control, including GLP, to assure integrity of the data. They are designed to clearly define a safety margin, identify any potential safety concerns, and establish a safe dose for the product. This dose and effectiveness is then evaluated in the pivotal field efficacy study where the product is studied in the animal patient population in which the product is intended to be used.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top; white-space: nowrap;">Efficacy:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Early pilot studies may be done in laboratory cats or dogs to establish effectiveness and the dose range for each product. When an effective dose is established, a study protocol to test the product in real world conditions is developed prior to beginning the study. The pivotal field efficacy study protocol is submitted for review and concurrence prior to study initiation, to help assure that the data generated will meet requirements. This study must be conducted with the formulation of the product that is intended to be commercialized, and is a multi-site, randomized, controlled study, generally with a placebo control.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; vertical-align: top; white-space: nowrap;">CMC:</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">To assure that the new animal drug product can be manufactured consistently, FDA will require applicants to provide documentation of the process by which the active ingredient is made and the controls applicable to that process that assure the active ingredient and the formulation of the final commercial product meet certain criteria, including purity and stability. After a product is approved, applicants will be required to communicate with FDA before any changes are made to these procedures or at the manufacturing site. Both the active ingredient and commercial formulations are required to be manufactured at facilities that practice cGMP.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once all data have been submitted and reviewed for each technical section&#8212;safety, efficacy and CMC&#8212;the CVM will issue a technical section complete letter as each section review is completed. When the three letters have been issued, the applicant will compile a draft of the Freedom of Information Summary, the proposed labeling, and all other relevant information, and submit these as an administrative NADA for CVM review. Generally, if there are no deficiencies in the submission, the NADA will be issued within four to six months after submission of the administrative NADA. This review will be conducted according to timelines specified in the Animal Drug User Fee Act. The FDA&#8217;s basis for approving a NADA is documented in a Freedom of Information Summary. Post-approval monitoring of products is required by law, with reports being provided to the CVM&#8217;s Surveillance and Compliance group. Reports of product quality defects, AEs or unexpected results must also be produced in accordance with the relevant regulatory requirements. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Review and Approval of Drug Products in the European Union </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Procedures Governing Approval of Drug Products in the European Union </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the EU has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a EU member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To obtain marketing approval of a product under EU regulatory systems, an applicant must submit a marketing authorization application, or MAA, either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or EMA, is responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210&#160;days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150&#160;days. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The decentralized procedure is available to applicants who wish to market a product in various EU member states where such product has not received marketing approval in any EU member states before. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member state designated by the applicant, known as the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment report and drafts of the related materials within 210&#160;days after receipt of a valid application. Within 90&#160;days of receiving the reference member state&#8217;s assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related materials. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Within this framework, manufacturers may seek approval of hybrid medicinal products under Article&#160;10(3) of Directive 2001/83/EC. Hybrid applications rely, in part, on information and data from a reference product and new data from appropriate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> tests and clinical trials. Such applications are necessary when the proposed product does not meet the strict definition of a generic medicinal product, or bioavailability studies cannot be used to demonstrate bioequivalence, or there are changes in the active substance(s), therapeutic indications, strength, pharmaceutical form or route of administration of the generic product compared to the reference medicinal product. In such cases the results of tests and trials must be consistent with the data content standards required in the Annex to the Directive 2001/83/EC, as amended by Directive 2003/63/EC.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hybrid medicinal product applications have automatic access to the centralized procedure when the reference product was authorized for marketing via that procedure. Where the reference product was authorized via the decentralized procedure, a hybrid application may be accepted for consideration under the centralized procedure if the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical innovation, or the granting of a community authorization for the medicinal product is in the interest of patients at the community level. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical Trial Approval in the European Union </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Requirements for the conduct of clinical trials in the EU including Good Clinical Practice, or GCP, are set forth in the Clinical Trials Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of clinical trials in the EU has been implemented through national legislation of the EU member states. Under this system, approval must be obtained from the competent national authority of each EU member state in which a study is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application in that country. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2014, the EU passed the new Clinical Trials Regulation, (EU) No 536/2014, which will replace the current Clinical Trials Directive 2001/20/EC. To ensure that the rules for clinical trials are identical throughout the EU, the new EU clinical trials legislation was passed as a regulation that is directly applicable in all EU member states. All clinical trials performed in the EU are required to be conducted in accordance with the Clinical Trials Directive 2001/20/EC until the new Clinical Trials Regulation (EU) No 536/2014 becomes applicable.. The Clinical Trials Directive 2001/20/EC will, however, still apply three years from the date of entry into application of the Clinical Trials Regulation to (i)&#160;clinical trials applications submitted before the entry into application and (ii)&#160;clinical trials applications submitted within one year after the entry into application if the sponsor opts for old system. As of January&#160;1, 2020, the website of the European Commission reported that the implementation of the Clinical Trials Regulation was dependent on the development of a fully functional clinical trials portal and database, which would be confirmed by an independent audit, and that the new legislation would come into effect six months after the European Commission publishes a notice of this confirmation. The website indicated that the audit was expected to commence in December 2020. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trial in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the EU portal; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures that will spare sponsors from submitting broadly identical information separately to various bodies and different member states; a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part&#160;I is assessed jointly by all member states concerned, and Part&#160;II is assessed separately by each member state concerned); strictly defined deadlines for the assessment of clinical trial applications; and the involvement of the ethics committees in the assessment procedure in accordance with the national law of the member state concerned but within the overall timelines defined by the Clinical Trials Regulation. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRIME Designation in the EU </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">medium-sized</div> enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the CHMP or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">kick-off</div> meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Periods of Authorization and Renewals </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> sunset clause).</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Data and Market Exclusivity in the European Union </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In the EU, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but not approved for two years. The overall <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company can complete a full MAA with a complete database of pharmaceutical test, preclinical tests and clinical trials and obtain marketing approval of its product.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan Drug Designation and Exclusivity </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulation&#160;141/2000 provides that a drug shall be designated as an orphan drug if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Community when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Community and that without incentives it is unlikely that the marketing of the drug in the European Community would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Community or, if such method exists, the drug will be of significant benefit to those affected by that condition. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Regulation&#160;847/2000 sets out criteria and procedures governing designation of orphan drugs in the EU. Specifically, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year </div> period of market exclusivity. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinically relevant superiority&#8221; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs pursuant to Regulation&#160;141/2000 shall be eligible for incentives made available by the European Community and by the member states to support research into, and the development and availability of, orphan drugs.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Requirements after Marketing Authorization </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As in the United States, both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. The holder of an EU marketing authorization for a medicinal product must, for example, comply with EU pharmacovigilance legislation and its related regulations and guidelines which entail many requirements for conducting </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the EU is also highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, including compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In the EU, the advertising and promotion of approved products are subject to EU Member States&#8217; laws governing promotion of medicinal products, interactions with clinicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion, which is prohibited in the EU.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General Data Protection Regulation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to <div style="font-family: &quot;Euro Serif&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8364;</div>20&#160;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brexit and the Regulatory Framework in the United Kingdom </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;23, 2016, the electorate in the United Kingdom, or UK, voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted negotiations, the UK left the EU on January&#160;31, 2020. Under the withdrawal agreement, there is a transitional period until December&#160;31, 2020 (extendable up to two years). Under the withdrawal agreement, there is a transitional period until December&#160;31, 2020 (extendable up to two years). Discussions between the UK and the UK have so far mainly focused on finalizing withdrawal issues and transition agreements but have been extremely difficult to date. To date, only an outline of a trade agreement has been reached.&#160;Much remains open but the Prime Minister has indicated that the UK will not seek to extend the transitional period beyond the end of 2020.&#160;If no trade agreement has been reached before the end of the transitional period, there may be significant market and economic disruption. The Prime Minister has also indicated that the UK will not accept high regulatory alignment with the EU. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the regulatory framework for pharmaceutical products in the UK covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the UK. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the United Kingdom. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pricing Decisions for Approved Products </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-priced</div> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceutical Coverage, Pricing and Reimbursement </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. Additionally, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, we participate in, and have certain price reporting obligations to, the Medicaid Drug Rebate program, several state Medicaid supplemental rebate programs, and other governmental pricing programs. We also have obligations to report the average sales price for certain of our drugs to the Medicare program. Under the Medicaid Drug Rebate program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Medicaid rebates are based on pricing data reported by us on a monthly and quarterly basis to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency that administers the Medicaid and Medicare programs. These data include the average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the U.S. in any pricing structure, calculated to include all sales and associated rebates, discounts, and other price concessions. The amount of the rebate is adjusted upward if average manufacture price increases more than inflation (measured by reference to the Consumer Price Index - Urban). If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due, which revisions could affect our rebate liability for prior quarters.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare is a federal program that is administered by the federal government that covers individuals age 65 and over or that are disabled as well as those with certain health conditions. Manufacturer-submitted information is used by CMS to calculate Medicare payment rates. Civil monetary penalties can be applied if we are found to have knowingly submitted any false pricing or other information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, or if we fail to submit the required data on a timely basis. Such conduct also could be grounds for CMS to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid for our covered outpatient drugs.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal law requires that any company that participates in the Medicaid Drug Rebate program also participate in the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid. The 340B program, which is administered by the Health Resources and Services Administration, or HRSA, requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. Covered entities include hospitals that serve a disproportionate share of financially needy patients, community health clinics, and other entities that receive certain types of grants under the Public Health Service Act. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and Medicaid rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate program. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. HRSA requires the federal ceiling price to be reported quarterly.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. It is currently unclear how HRSA will apply its enforcement authority under the new regulation. Any charge by HRSA that we have violated the requirements of the regulation could result in civil monetary penalties. HRSA also implemented a new price reporting system during the first quarter of 2019, under which manufacturers are now required to report their 340B ceiling prices to HRSA on a quarterly basis. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside the United States, ensuring adequate coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-priced</div> markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Law and Regulation </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted regulatory approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Such restrictions under applicable federal and state healthcare laws and regulations, include the following: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the federal civil monetary penalty and false statement laws and regulations relating to pricing and submission of pricing information for government programs, including penalties for knowingly and intentionally overcharging 340B eligible entities and the submission of false or fraudulent pricing information to government entities;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willingly executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other transfers of value to clinicians and teaching hospitals (and beginning in 2022, additional non-physician clinicians including physician assistants and nurse practitioners) and clinician ownership and investment interests; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> third-party payors, including private insurers.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to clinicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Reform </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A primary trend in the United States healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, Congress enacted the Patient Protection and Affordable Care Act, or ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. Among the provisions of the ACA of importance to our potential drug candidates are: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage plans;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expanded the types of entities eligible for the 340B drug discount program;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 50% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale-discount</div> off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation has been not been clearly defined. The ACA provided that under certain circumstances, IPAB recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2029 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Since enactment of the ACA, there have been and continue to be numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December&#160;22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, will become effective in 2019. Additionally, the 2020 federal spending package permanently eliminated, effective January&#160;1, 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACA-mandated</div> &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50&#160;percent to 70&#160;percent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. The Congress will likely consider other legislation to replace elements of the ACA during the next Congressional session.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, on December&#160;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. The Trump administration and CMS have both stated that the ruling will have no immediate effect, and on December&#160;30, 2018 the same judge issued an order staying the judgment pending appeal. The Trump Administration recently represented to the Court of Appeals considering this judgment that it does not oppose the lower court&#8217;s ruling. On July&#160;10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. On December&#160;18, 2019, that court affirmed the lower court&#8217;s ruling that the individual mandate portion of the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. On January&#160;21, 2020, the U.S. Supreme Court declined to review this decision on an expedited basis. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Trump Administration has also taken executive actions to undermine or delay implementation of the ACA. Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October&#160;25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, on June&#160;14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12&#160;billion in ACA risk corridor payments to third-party payors who argued were owed to them. This decision is under review by the U.S. Supreme Court during its current term. The full effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our business, are not yet known. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. For example, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">For example, on May&#160;11, 2018, the Trump Administration issued a plan to lower drug prices. Under this blueprint for action, the Trump Administration indicated that the Department of Health and Human Services, or HHS, will: take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies; advance biosimilars and generics to boost price competition; evaluate the inclusion of prices in drug makers&#8217; ads to enhance price competition; speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers; avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid; work to give Part D plan sponsors more negotiation power with drug makers; examine which Medicare Part B drugs could be negotiated for a lower price by Part D plans, and improving the design of the Part B Competitive Acquisition Program; update Medicare&#8217;s drug-pricing dashboard to increase transparency; prohibit Part D contracts that include &#8220;gag rules&#8221; that prevent pharmacists from informing patients when they could pay less <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div> by not using insurance; and require that Part D plan members be provided with an annual statement of plan payments, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div> spending, and drug price increases. In addition, on December&#160;23, 2019, the Trump Administration published a proposed rulemaking that, if finalized, would allow states or certain other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-federal</div> government entities to submit importation program proposals to FDA for review and approval. Applicants would be required to demonstrate their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. At the same time, FDA issued draft guidance that would allow manufacturers to import their own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> drugs that are authorized for sale in other countries (multi-market approved products).</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;14, 2020, we had 347 full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement, nor have we experienced work stoppages. We believe that relations with our employees are good. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information about our Executive Officers </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table lists the positions, names and ages of our current executive officers: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 47%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 43%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Age </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Position </div></div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael&#160;G.&#160;Kauffman,&#160;M.D.,&#160;Ph.D. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer and Director </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sharon Shacham, Ph.D., M.B.A. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">President and Chief Scientific Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher&#160;B.&#160;Primiano,&#160;J.D.,&#160;M.B.A. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Vice President, Chief Business Officer, General Counsel and Secretary </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ran Frenkel, RPh. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Development Operations Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jatin Shah, M.D.. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Vice President, Chief Medical Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tanya Lewis, M.S. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Vice President, Chief Regulatory Officer and Quality Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael Mason </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top;">&#160;</td>
<td style="padding: 0px; text-align: right; vertical-align: top; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior Vice President, Chief Financial Officer and Treasurer </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michael G. Kauffman, M.D., Ph.D</div></div>. Dr.&#160;Kauffman has served as Karyopharm&#8217;s Chief Executive Officer since January 2011 and has been one of our directors since 2008. Dr.&#160;Kauffman <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founded</div> Karyopharm with Dr.&#160;Sharon Shacham in 2008 and served as our President from January 2011 to December 2013 and as Chief Medical Officer from December 2012 to December 2013. Prior to joining Karyopharm, he was Chief Medical Officer of Onyx Pharmaceuticals&#160;Inc., a biopharmaceutical company, from November 2009 to December 2010. From November 2008 to November 2009, Dr.&#160;Kauffman was Chief Medical Officer of Proteolix&#160;Inc., which was acquired by Onyx Pharmaceuticals. At Proteolix, he led the development of Kyprolis<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma by the Food and Drug Administration in July 2012. Dr.&#160;Kauffman was an operating partner at Bessemer Venture Partners from 2006 to 2008, where he led investments in biotechnology companies. From 2006 to 2008, he was President and Chief Executive Officer of Epix Pharmaceuticals,&#160;Inc., a biopharmaceutical company that underwent liquidation proceedings through an assignment for the benefit of creditors under Massachusetts law in 2009. Dr.&#160;Kauffman was President and Chief Executive Officer of Predix Pharmaceuticals,&#160;Inc., a private biopharmaceutical company focused on G protein-coupled receptors (GPCR), from 2002 until its merger into Epix Pharmaceuticals in 2006. In that role, he led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, oversaw the discovery and development of four new clinical candidates and led collaboration transactions with Amgen and GlaxoSmithKline. From March 2000 to September 2002, Dr.&#160;Kauffman was Vice President, Clinical at Millennium Pharmaceuticals,&#160;Inc., a biopharmaceutical company, where he led the Velcade<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> development program. From September 1997 to March 2000, Dr.&#160;Kauffman held a number of senior positions at Millennium Predictive Medicine,&#160;Inc., a biopharmaceutical company and a subsidiary of Millennium Pharmaceuticals, where he led the discovery and development of novel molecular diagnostics for major cancers, including melanoma and led transactions with Becton-Dickenson and Bristol Myers Squibb. From August 1995 to September 1997, Dr.&#160;Kauffman held a number of senior positions at Biogen Idec,&#160;Inc., a biopharmaceutical company, where he led the clinical development of anti-CD40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group. Dr.&#160;Kauffman currently serves on the board of directors, nominating and governance committee and research and development committee of Infinity Pharmaceuticals, Inc., a public biopharmaceutical company, on the board of directors and audit committee and as chairman of the compensation committee of Kezar Life Sciences, Inc., also a public biopharmaceutical company, and is the lead director and serves on the board of directors and compensation committee of Verastem&#160;Inc., also a public biopharmaceutical company. Dr.&#160;Kauffman previously served on the board of directors and compensation and audit committees of Zalicus Inc., a biotechnology company. Dr.&#160;Kauffman received his B.A. in Biochemistry</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">from Amherst College and his M.D.&#160;and Ph.D. from Johns Hopkins Medical School, and he trained in internal medicine and rheumatology at Beth Israel Hospital (now Beth Israel Deaconess Medical Center) and Massachusetts General Hospital. He is board certified in internal medicine. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sharon Shacham, Ph.D., M.B.A.</div></div> Dr.&#160;Shacham founded Karyopharm in 2008 and has served as our President since December 2013, and as our Chief Scientific Officer since October 2010. Dr.&#160;Shacham served as our President of Research and Development from December 2012 to December 2013, as our Head of Research and Development from October 2010 to December 2012 and as our President and Chief Executive Officer from October 2010 to January 2011. Dr.&#160;Shacham established the company to focus on the discovery and development of small molecule inhibitors of nuclear export and has led our scientific progress since inception. Her computational drug discovery algorithms formed a critical part of the technological basis for our drug discovery and optimization expertise, which was used for the discovery of selinexor, our lead drug candidate. Dr.&#160;Shacham <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-chairs</div> our Scientific Advisory Board. Prior to founding Karyopharm, from 2006 to April 2009, she was Senior Vice President of Drug Development at Epix Pharmaceuticals,&#160;Inc., a biopharmaceutical company that underwent liquidation proceedings through an assignment for the benefit of creditors under Massachusetts law in 2009. She was Director, Algorithm and Software Development at Predix Pharmaceuticals&#160;Inc. from July 2000 until Predix&#8217;s merger into Epix Pharmaceuticals in 2006, where she led the company&#8217;s efforts in&#160;GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr.&#160;Shacham received her B.Sc. in Chemistry, Ph.D. and M.B.A. from Tel Aviv University.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Christopher B. Primiano, J.D., M.B.A.</div></div> Mr.&#160;Primiano joined Karyopharm in March 2014 as Vice President, Corporate Development, General Counsel and Secretary, and was appointed Senior Vice President, Corporate Development, General Counsel and Secretary in September 2015; Senior Vice President, Operations, Business Development, General Counsel and Secretary in November 2016 and Executive Vice President, Chief Business Officer, General Counsel and Secretary in January 2018. Prior to joining Karyopharm, Mr.&#160;Primiano was a Counsel at Wilmer Cutler Pickering Hale and Dorr LLP, where he had practiced law since October 2012. From August 2010 to August 2012, he served as Vice President, Corporate Development, General Counsel and Secretary of GlassHouse Technologies, Inc., an information technology consulting company, where he led global legal operations and managed asset and subsidiary acquisition and sale activity. Mr.&#160;Primiano began his career at Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian LLP, where he practiced law from August 2006 to July 2010. Mr.&#160;Primiano received a B.A. in Political Economy and English from Georgetown University, an M.B.A. from the Boston College Carroll School of Management and a J.D. from Boston College Law School.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ran Frenkel, RPh.</div></div> Mr.&#160;Frenkel was appointed Executive Vice President, Worldwide Development Operations of Karyopharm in October 2014 and was appointed Chief Development Operations Officer in January 2015. Prior to joining Karyopharm, Mr.&#160;Frenkel held a number of senior management roles in Europe, Israel and the United States, most recently as Managing Director EMEA from January 2013 to October 2014 for Clinipace Worldwide, an international clinical research organization, where he had responsibility for the overall management of the organization in Europe, the Middle East and Africa. Prior to becoming Managing Director EMEA, Mr.&#160;Frenkel was VP International Business Development at Clinipace Worldwide from July 2011 to January 2013. Prior to joining Clinipace Worldwide, from January 2007 to August 2011, Mr.&#160;Frenkel established and managed the Israeli office of PFC Pharma Focus AG, which was acquired by Clinipace Worldwide in 2011, and from 2004 to 2007, he held the position of Managing Director at Actelion Pharmaceuticals with responsibility for all science and business affairs of the company in Israel. Mr.&#160;Frenkel received a BPharm from Hebrew University.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jatin Shah, M.D.</div></div> Dr.&#160;Shah joined Karyopharm in May 2017 as Vice President, Clinical Strategy, and was appointed Senior Vice President, Clinical Development in April 2018 and Executive Vice President, Chief Medical Officer in July 2019. Prior to joining Karyopharm, Dr.&#160;Shah held numerous roles at The University of Texas MD Anderson Cancer Center. From September 2007 to August 2016, Dr.&#160;Shah served as an Assistant Professor, Associate Professor, and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine. Dr.&#160;Shah received his M.D. from The Ohio State University College of Medicine, Columbus, Ohio and holds a degree in Mechanical Engineering from The Ohio State University. Dr.&#160;Shah</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completed his residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr.&#160;Shah holds board certification in hematology and oncology from the American Board of Internal Medicine. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tanya Lewis, M.S. </div></div>Ms.&#160;Lewis joined Karyopharm in October 2018 as Senior Vice President, Regulatory and Quality Affairs and was appointed Executive Vice President, Chief Regulatory Officer and Quality Officer in November 2019. Prior to joining Karyopharm, Ms.&#160;Lewis held several leadership roles across the biopharmaceutical industry where she was instrumental in the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, VARUBI<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>, INTEGRILIN<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>&#160;and ZEJULA<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div>. Most recently Ms.&#160;Lewis served as Vice President, Regulatory and Quality Affairs for Syros Pharmaceuticals, a pharmaceutical company, from January 2017 to July 2018. Prior to joining Syros Pharmaceuticals, Inc., Ms.&#160;Lewis served as Vice President, Regulatory Affairs and Quality Assurance for Idera Pharmaceuticals, Inc., a pharmaceutical company, from October 2015 to December 2016. Prior to joining Idera Pharmaceuticals, Ms.&#160;Lewis served as Vice President, Regulatory Affairs for Tesaro, Inc., a pharmaceutical company, from October 2011 to June 2015. Ms.&#160;Lewis holds a B.S. in Biology from Northeastern University and a M.S. in Regulatory Affairs and Public Health from Massachusetts College of Pharmacy and Allied Health Science.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michael Mason, C.P.A., M.B.A. </div></div>Mr.&#160;Mason has served as our Senior Vice President, Chief Financial Officer and Treasurer since February&#160;2019. Mr.&#160;Mason served as Vice President of Finance and Treasurer of Alnylam Pharmaceuticals, Inc., a public biopharmaceutical company, from February 2011 until February 2019, as its Principal Accounting Officer from February 2011 to October 2018, and as its Principal Financial Officer from February 2011 to June 2016 and from January 2017 to May 2017. From December 2005 to February 2011, Mr.&#160;Mason served as Alynylam&#8217;s Corporate Controller. From May 2000 through November 2005, Mr.&#160;Mason served in several finance and commercial roles at Praecis Pharmaceuticals Incorporated, a public biotechnology company, most recently as Corporate Controller. Prior to Praecis, Mr.&#160;Mason worked in the audit practice at KPMG LLP, a national audit, tax and advisory services firm. Mr.&#160;Mason received a B.A. in Business Administration from Stetson University and an M.B.A. from Babson College and is a certified public accountant.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Corporate Information </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Karyopharm was incorporated under the laws of the state of Delaware on December&#160;22, 2008 under the name Karyopharm Therapeutics&#160;Inc. Our principal executive offices are located at 85 Wells Avenue, 2<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">nd</div> Floor, Newton, Massachusetts 02459. Our telephone number is (617)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;658-0600,</div> and our website is located at www.karyopharm.com. References to our website are inactive textual references only and the content of our website should not be deemed incorporated by reference into this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Available Information </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Our Internet website is http://www.karyopharm.com. We make available free of charge through our website our annual report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K,</div> quarterly reports on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-Q,</div> current reports on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;8-K</div> and amendments to those reports filed or furnished pursuant to Sections&#160;13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the U.S. Securities and Exchange Commission, or SEC. In addition, we regularly use our website to post information regarding our business, development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors&#8221; as a source of information about us.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Code of Business Conduct and Ethics, Corporate Governance Guidelines and the charters of the Audit, Compensation, Nominating and Corporate Governance and Compliance Committees of our board of directors are all available on our website at http://www.karyopharm.com at the &#8220;Investors&#8221; section under &#8220;Corporate Governance&#8221;. Stockholders may request a free copy of any of these documents by writing to Investor Relations, Karyopharm Therapeutics&#160;Inc., 85 Wells Avenue, 2<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">nd</div> floor, Newton, Massachusetts 02459, U.S.A. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">ITEM&#160;1A. </div></td>
<td id="tx853399_3" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">RISK FACTORS</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;">Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and in other documents that we file with the SEC, in evaluating us and our business. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Discovery, Development and Commercialization of Our Drugs and Drug Candidates </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We depend heavily on the success of XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (selinexor). If we are unable to successfully commercialize XPOVIO or successfully develop selinexor for additional indications, or if we experience significant delays in doing so, our business will be materially harmed. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have invested a significant portion of our efforts and financial resources in the research and development of our lead drug candidate, selinexor. Our ability to generate revenues from the sale of drugs that treat cancer and other diseases in humans will depend heavily on the successful development, regulatory approval and commercialization of selinexor. On July&#160;3, 2019, the U.S. Food and Drug Administration, or FDA, granted accelerated approval for XPOVIO in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma, or RRMM, who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Our ability to generate product revenues will depend on our successful commercialization of XPOVIO and our obtaining additional marketing approvals for, and successfully commercializing, selinexor for additional indications. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commercial success of XPOVIO and the successful clinical development of selinexor and our other drug candidates will depend on several factors, including the following: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">successful commercialization of XPOVIO in the United States, including establishing and maintaining sales, marketing and distribution capabilities for XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the consistency of any new data we collect and analyses we conduct with prior results, whether they support a favorable safety, efficacy and effectiveness profile of XPOVIO and any potential impact on our FDA accelerated approval and/or FDA package insert for XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our ability to comply with FDA post-marketing requirements and commitments, including through successfully conducting additional studies that confirm clinical efficacy, effectiveness and safety of XPOVIO and acceptance of the same by the FDA and medical community since continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">acceptance of XPOVIO and, if and when approved, our other drug candidates, by patients, the medical community and third-party payors;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtaining and maintaining coverage, adequate pricing and adequate reimbursement by third-party payors, including government payors, for XPOVIO and our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">successful completion of preclinical studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">acceptance by the FDA of investigational new drug applications, or INDs, for our drug candidates prior to commencing clinical studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">successful enrollment in, and completion of, clinical trials, including demonstration of a favorable risk-benefit ratio;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">receipt of marketing approvals from applicable regulatory authorities;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establishing sales, marketing, manufacturing and distribution capabilities to commercialize any drug candidates for which we may obtain marketing approval, whether alone or in collaboration with others;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">launching commercial sales of any drug candidates for which we obtain marketing approval, whether alone or in collaboration with others;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">effectively competing with other therapies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">maintaining an acceptable safety profile of the drugs following approval;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">compliance with existing and new health care laws and regulations currently being considered or implemented in the United States, including price reporting and other disclosure requirements of such laws and regulations and the potential impact of such requirements on physician prescribing practices and payor coverage;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">enforcing and defending intellectual property rights and claims; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">maintaining and growing an organization of scientists and business people, including collaborators, who can develop and commercialize our drug candidates.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize XPOVIO or our drug candidates, which would materially harm our business. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our drug candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. Success in early-stage clinical trials does not mean that future larger registration clinical trials will be successful because drug candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities despite having progressed through early-stage clinical trials. Drug candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials, and interim results of a clinical trial are not necessarily indicative of final results.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the design of a clinical trial can determine whether its results will support approval of a drug, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and conduct a clinical trial to support regulatory approval. Further, if our drug candidates are found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for them and our business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same drug candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase&#160;2, Phase&#160;3 or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to market our drug candidates. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Further, our drug candidates may not be approved even if they achieve their primary endpoints in Phase&#160;3 clinical trials or other registration trials. The FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a drug candidate even after providing a positive opinion on, or otherwise reviewing and providing comments or advice on, a protocol for a clinical trial that has the potential to result in approval by the FDA or another regulatory authority. In addition, any of these regulatory authorities may also approve a drug candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. Furthermore, the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our drug candidates.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">To date, we have had several discussions with the FDA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities regarding the design of our later phase clinical trials for selinexor, including the BOSTON, STORM, SADAL and SEAL studies. In July 2019, the FDA approved, under accelerated approval based on response rate from the STORM study, XPOVIO in combination with dexamethasone for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. We plan to seek additional regulatory approvals of selinexor in North America and Europe in each indication with respect to which such later phase clinical trial is being conducted and with respect to which we receive positive results that may support full or accelerated approval, as the case may be. We or our current or future partners may also seek such approvals in other geographies. We cannot be certain that we will commence additional later phase trials or complete ongoing later phase trials as anticipated. Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and well-controlled clinical studies, and, with respect to approval in the United States, to the satisfaction of the FDA, that the drug candidate is safe and effective for use for that target indication. There is no assurance that the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities would consider our current and planned later phase clinical trials to be sufficient to serve as the basis for filing for approval or to gain approval of selinexor for any indication. The FDA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that selinexor is safe and effective. If we are required to conduct additional clinical trials of selinexor prior to approval, including additional earlier phase clinical trials that may be required prior to commencing any later phase clinical trials, or additional clinical trials following completion of our current and planned later phase clinical trials, we will need substantial additional funds, and there is no assurance that the results of any such additional clinical trials will be sufficient for approval.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The results to date in preclinical and early clinical studies conducted by us or our academic collaborators and in Phase&#160;1 and Phase&#160;2 clinical trials that we are currently conducting include the response of tumors to selinexor. We expect that in any later phase clinical trial where patients are randomized to receive either selinexor on the one hand, or standard of care, supportive care or placebo on the other hand, the primary endpoint will be either progression free survival, meaning the length of time on treatment until objective tumor progression, or overall survival, while the primary endpoint in any later phase clinical trial that is not similarly randomized may be different. For example, the primary endpoint of our Phase&#160;2/3 SEAL study, the clinical trial of selinexor in patients with dedifferentiated liposarcoma, and of our Phase&#160;3 BOSTON study, the clinical trial of selinexor in combination with Velcade (bortezomib) and dexamethasone in patients with multiple myeloma, is progression free survival. In some instances, the FDA and other regulatory bodies have accepted overall response rate as a surrogate for a clinical benefit and have granted regulatory approvals based on this or other surrogate endpoints. Overall response rate is defined as the portion of patients with tumor size reduction of a predefined amount for a minimum time period. For some types of cancer, we may use overall response rate as a primary endpoint, as we did in our SADAL study and our STORM study. These clinical trials will not be randomized against control arms and the primary endpoints of these trials are overall response rate. If selinexor does not demonstrate sufficient overall response rates in these indications, or any other indication for which a clinical trial has overall response rate as a primary endpoint, or if the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities do not deem overall response rate a sufficient endpoint, or deem a positive overall response rate to be insufficient, it will</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">likely not be approved for that indication based on the applicable study. With respect to the STORM and SADAL studies, the FDA has reiterated to us that it recommends, in general, a randomized trial with a progression-free survival endpoint as an initial registration approach. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finally, independent review committees are typically implemented to adjudicate efficacy outcomes in clinical studies that are intended to support requests for marketing authorization. For example, in our STORM study, the primary endpoint of overall response rate was determined based on efficacy adjudications by an independent review committee, or IRC, comprised of physicians who are expert in treating and evaluating patients with multiple myeloma. While the FDA agreed with the assessments of the IRC for the STORM study in conducting its review of those data, we cannot be certain that other regulatory authorities will agree with the assessments of the IRC for STORM or any other study for which we may submit data to support a request for marketing authorization. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be successful in our efforts to identify or discover additional potential drug candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Part of our strategy involves identifying and developing drug candidates to build a pipeline of novel drug candidates. Our drug discovery efforts may not be successful in identifying compounds that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential drug candidates, yet fail to yield drug candidates for clinical development for a number of reasons, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the research methodology used may not be successful in identifying potential drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">potential drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; or</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">potential drug candidates may not be effective in treating their targeted diseases.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research programs to identify new drug candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential drug candidate that ultimately proves to be unsuccessful. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain revenues from sale of drugs in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical drug development is a lengthy and expensive process, with an uncertain outcome. If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such drug candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before obtaining marketing approval from regulatory authorities for the sale of our drug candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later stage clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, certain data from our Phase&#160;1 and Phase&#160;2 clinical trials of selinexor to date are based on unaudited data provided by our clinical trial investigators. An audit of this data may change the conclusions drawn from this unaudited data provided by our clinical trial investigators indicating less promising results than we currently anticipate. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drug candidates. Furthermore, the </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of any drug candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other drug candidates and/or cause the FDA or other regulatory authorities to require additional testing before any of our drug candidates are approved. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our drug candidates, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulatory authorities or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">feedback from regulatory authorities that requires us to modify the design of our clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or contract research organizations;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, suspend ongoing clinical trials or abandon drug development programs;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our third-party contractors, including those manufacturing our drug candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">we or our investigators might have to suspend or terminate clinical trials of our drug candidates for various reasons, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory requirements, a finding that our drug candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulators may recommend or require us to perform additional or unanticipated clinical trials to obtain approval;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the cost of clinical trials of our drug candidates may be greater than we anticipate;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">any partners and collaborators that help conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">be delayed in obtaining marketing approval for our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">not obtain marketing approval at all;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtain marketing approval in some countries and not in others;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">be subject to additional post-marketing testing requirements; or</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">have the drug removed from the market after obtaining marketing approval.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates, allow our competitors to bring drugs to market before we do or impair our ability to successfully commercialize our drug candidates, which would harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of regulatory approval of our drug candidates. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we experience delays or difficulties in the enrollment of patients in clinical trials, or we are otherwise delayed in our ability to conduct clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United&#160;States. In addition, some of our competitors may have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; drug candidates. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient enrollment is affected by other factors, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">severity of the disease under investigation;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">availability and efficacy of approved drugs for the disease under investigation;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">patient eligibility criteria for the study in question;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">competing drugs in clinical development;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">perceived risks and benefits of the drug candidate under study;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">efforts to facilitate timely enrollment in clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">patient referral practices of physicians;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the ability to monitor patients adequately during and after treatment; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">proximity and availability of clinical trial sites for prospective patients.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, patient enrollment may be affected by future regulatory actions, such as Form&#160;483 observations or the partial clinical hold we were subject to previously. In February 2017, following the conclusion of a joint inspection conducted by the FDA and Danish Medicines Agency at our corporate headquarters, the FDA issued a Form&#160;483 noting certain deficiencies in procedures and documentation that were identified in our selinexor development program. We implemented corrective actions, preventative actions and other initiatives directed at resolving the deficiencies identified in the Form&#160;483 observations and provided the FDA with our responses to the Form&#160;483 observations in February 2017. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in March 2017, the FDA notified us that it had placed the clinical trials under our IND for selinexor on partial clinical hold, which is an order by the FDA to delay or suspend part of a sponsor&#8217;s clinical </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">work requested under its IND as well as investigator-sponsored trials. The partial clinical hold was due to incomplete information in the existing version of the investigator&#8217;s brochure, including an incomplete list of serious adverse events, or SAEs, associated with selinexor, and not as a result of any new information regarding the safety profile of selinexor. The partial clinical holds on the clinical trials of selinexor were lifted by the FDA Division of Hematology Products (effective March&#160;30, 2017), Division of Oncology Products&#160;1 (effective April&#160;5, 2017) and Division of Oncology Products&#160;2 (effective March&#160;31, 2017). However, if in the future we are delayed in addressing, or unable to address, any concerns of the FDA or other regulators, we could be delayed or prevented from enrolling patients in our clinical trials. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If serious adverse or unacceptable side effects are identified or we observe limited efficacy of our drug candidates, we may need to abandon or limit the development or commercialization of one or more of our drug candidates, and such findings may delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If XPOVIO or any of our drug candidates are associated with undesirable side effects or have characteristics that are unexpected in clinical trials or following approval and/or commercialization, we may need to abandon their development or limit development or marketing to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Adverse events, or AEs, in our clinical trials to date have been generally predictable and manageable, although some patients have experienced more serious AEs. The most common drug-related AEs were gastrointestinal, such as nausea, anorexia, diarrhea and vomiting, and fatigue. These side effects were generally mild or moderate in severity. The most common AEs that were Grade&#160;3 or Grade&#160;4, meaning they were more than mild or moderate in severity, were thrombocytopenia, or low count of platelets in the blood, and neutropenia, or low neutrophil counts. To date, the most common AEs have been managed with supportive care and dose modifications. However, a number of patients have withdrawn from our clinical trials as a result of AEs. For example, amongst the 202 patients enrolled in Parts 1 and 2 of the STORM study who were treated with selinexor in combination with dexamethasone, the most common AEs (incidence <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div>20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infections. The treatment discontinuation rate due to AEs was 27%; 53% of patients had a reduction in the selinexor dose, and 65.3% had the dose of selinexor interrupted. In this group of patients, the most frequent AEs requiring permanent discontinuation in 4% or greater of patients who received selinexor included fatigue, nausea, and thrombocytopenia. Similarly, in the SADAL study, as of April&#160;3, 2019, among the 127 patients included in the safety analysis, the most common AEs (incidence <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#8805;</div>20%) were thrombocytopenia, nausea, fatigue, anemia, anorexia, diarrhea, constipation, weight loss, neutropenia, vomiting, pyrexia and asthenia. Some patients across our clinical trials have experienced SAEs deemed by us and the clinical investigator to be related to selinexor. SAEs generally refer to AEs that result in death, are life threatening, require hospitalization or prolonging of hospitalization, or cause a significant and permanent disruption of normal life functions, congenital anomalies or birth defects, or require intervention to prevent such an outcome.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These AEs and the resulting dose modification and/or treatment discontinuation rates or safety or toxicity issues that we may experience in our clinical trials in the future could result in a more restrictive label for any drug candidates approved for marketing or could result in the delay or denial of approval to market any drug candidates by the FDA or comparable foreign regulatory authorities, which could prevent us from ever generating revenue from the sale of drugs or achieving profitability. Results of our trials could reveal an </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unacceptably high severity and prevalence of side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our drug candidates for any or all targeted indications. Many compounds that initially showed promise in early-stage trials for treating cancer or other diseases have later been found to cause side effects that prevented further development of the compound. If such an event occurs after any of our drug candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulatory authorities may withdraw the approval of such drug;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulatory authorities may require one or more post-marketing studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">we could be sued and held liable for harm caused to patients; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our reputation may suffer.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected drug candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenues from the sale of our drugs and harm our business and results of operations. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">The FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may disagree with our and/or our clinical trial investigators&#8217; interpretation of data from clinical trials in determining if serious adverse or unacceptable side effects are drug-related. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We, and our clinical trial investigators, currently determine if serious adverse or unacceptable side effects are drug-related. The FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may disagree with our or our clinical trial investigators&#8217; interpretation of data from clinical trials and the conclusion by us or our clinical trial investigators that a serious adverse effect or unacceptable side effect was not drug-related. The FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may require more information, including additional preclinical or clinical data to support approval, which may cause us to incur additional expenses, delay or prevent the approval of one of our drug candidates, and/or delay or cause us to change our commercialization plans, or we may decide to abandon the development or commercialization of the drug candidate altogether.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially-viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPOVIO or any of our drug candidates that receives marketing approval may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPOVIO or any of our drug candidates that receive marketing approval may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Efforts to educate the medical community and third-party payors on the benefits of our drug candidates will require significant resources and may not be successful. For example, current cancer treatments like chemotherapy and radiation therapy are well-established in the medical community, and doctors may continue to rely on these treatments. If XPOVIO or our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from sales of drugs and we may not become profitable. The degree of market acceptance of XPOVIO and our drug candidates, if approved for commercial sale, will depend on a number of factors, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">efficacy and potential advantages compared to alternative treatments;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the ability to offer our drugs for sale at competitive prices;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">convenience and ease of administration compared to alternative treatments;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the strength of marketing and distribution support;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the timing of market introduction of competitive products;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">sufficient third-party coverage or reimbursement;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">effectiveness of our sales and marketing efforts;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">adverse publicity about our drugs or favorable publicity about competitive products;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the prevalence and severity of any side effects;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">any restrictions on the use of our drugs together with other medications; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">inability of certain types of patients to take our drugs.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our estimates of the potential market opportunities for XPOVIO and our drug candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for XPOVIO, selinexor or any other drug candidates may be smaller than we expect, and as a result our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to establish and maintain sales, marketing and distribution capabilities or maintain current agreements or enter into additional sales, marketing and distribution agreements with third parties, we may not be successful in commercializing XPOVIO or any of our drug candidates that we may develop if and when they are approved. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are in the process of continuing to build and maintain a sales and marketing infrastructure for XPOVIO, our first product, and our company does not have any prior experience in the sales, marketing or distribution of pharmaceutical drugs. To achieve commercial success for any approved drug for which sales and marketing is not the responsibility of any strategic collaborator that we have or may have in the future, we must either develop a sales, marketing and distribution organization or outsource these functions to other third parties. In the future, </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">we may choose to build a sales, marketing and distribution infrastructure to market or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promote</div> one or more of our drug candidates, if and when they are approved, or enter into additional collaborations with respect to the sale, marketing and distribution of our drug candidates. We intend to work with existing and potential partners to establish the commercial infrastructure to support a potential launch of selinexor outside the United States.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are risks involved with both establishing and maintaining our own sales, marketing and distribution capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any commercial launch of a drug candidate. Further, we may underestimate the size of the sales force required for a successful product launch and may need to expand our sales force earlier and at a higher cost than we anticipated. If the commercial launch of any of our drug candidates for which we establish a commercial infrastructure is delayed or does not occur for any reason, including if we do not receive marketing approval on the timeframe we expect, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors that may inhibit our efforts to commercialize XPOVIO or any drug candidates for which we receive marketing approval on our own include: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive drug lines;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">unforeseen costs and expenses associated with creating an independent sales, marketing and distribution organization; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Entering into arrangements with third parties to perform sales and marketing services may result in lower revenues from the sale of drug or the profitability of these revenues to us than if we were to market and sell any drugs that we develop ourselves. In addition, we may not be successful in maintaining current arrangements or entering into additional arrangements with third parties to sell, market and distribute XPOVIO or any of our drug candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drugs effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing XPOVIO or any of our drug candidates for which we obtain marketing approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a limited number of engagements with specialty pharmacies and specialty distributors. The specialty pharmacies sell XPOVIO directly to patients. The specialty distributors sell XPOVIO to healthcare entities who then resell XPOVIO to patients. While we have entered into agreements with each of these pharmacies and distributors to distribute XPOVIO in the United States, they may not perform as agreed or they may terminate their agreements with us. Also, we may need to enter into agreements with additional pharmacies or distributors, and there is no guarantee that we will be able to do so on commercially reasonable terms or at all. If we are unable to maintain and, if needed, expand, our network of specialty pharmacies and specialty distributors, we would be exposed to substantial distribution risk. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not receive royalty or milestone revenue under our partnership agreements for several years, or at all. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our partnership agreements provide for payments on achievement of development and/or commercialization milestones and for royalties on product sales. However, because drug development entails a </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">high risk of failure, we may never realize any material portion of the milestone revenue provided in our partnership agreements and we do not expect to receive any royalty revenue for several years, if at all. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The discovery, development and commercialization of new drugs is highly competitive. We face competition with respect to XPOVIO and our drug candidates and will face competition with respect to any drug candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of major pharmaceutical, specialty pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drugs for the treatment of cancer and the other disease indications for which we are developing our drug candidates, although we believe that to date, none of these competitive drugs and therapies currently in development are based on scientific approaches that are the same as our approach. Potential competitors also include academic institutions and governmental agencies and public and private research institutions. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are initially focused on developing our current drug candidates for the treatment of cancer. There are a variety of available therapies marketed for cancer. In many cases, cancer drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic drugs. We expect that any of our drug candidates that are approved will be priced at a significant premium over competitive generic drugs. This may make it difficult for us to achieve our business strategy of using our drug candidates in combination with existing therapies or replacing existing therapies with our drug candidates. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are more effective, safer, more convenient or less costly than any that we are developing or that would render our drug candidates obsolete or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive.</div> Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or preventing us from entering into a particular indication at all.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we are able to effectively commercialize XPOVIO or any drug candidate that we may develop, the drugs may not receive coverage or may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, all of which would harm our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The legislation and regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or drug licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">governmental control even after initial approval is granted.&#160;In the United States, approval and reimbursement decisions are not linked directly, but there is increasing scrutiny from the Congress and regulatory authorities of the pricing of pharmaceutical products.&#160;As a result, we might obtain marketing approval for a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain marketing approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to effectively commercialize XPOVIO or any of our product candidates that we may develop successfully will depend, in part, on the extent to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Obtaining and maintaining adequate reimbursement for XPOVIO and any of our product candidates, if approved, may be difficult. Moreover, the process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for our products by third-party payors. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek, with respect to an approved product, additional clinical evidence that goes beyond the data required to obtain marketing approval.&#160;They may require such evidence to demonstrate clinical benefits and value in specific patient populations or they may call for costly pharmaceutical studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies before covering our products.&#160;Accordingly, we cannot be sure that reimbursement will be available for XPOVIO and any drug candidate that we commercialize and, if reimbursement is available, we cannot be sure as to the level of reimbursement and whether it will be adequate. Coverage and reimbursement may impact the demand for, or the price of, XPOVIO or any drug candidate for which we obtain marketing approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize XPOVIO or any drug candidate for which we obtain marketing approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There may be significant delays in obtaining reimbursement for newly-approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable regulatory authorities outside of the United States. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and to limit commercialization of XPOVIO and any other drugs that we may develop. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face an inherent risk of product liability exposure related to the testing of our drug candidates in human clinical trials. We face an even greater risk as we commercialize XPOVIO or any other drugs that we may develop. For example, we may be sued if any drug we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against claims that our drug candidates or drugs caused injuries, we will incur substantial liabilities or be required to limit commercialization of our drug candidates. Regardless of merit or eventual outcome, liability claims may result in: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">decreased demand for XPOVIO and any other drugs that we may develop;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">injury to our reputation and significant negative media attention;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">withdrawal of clinical trial participants;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">initiation of investigations by regulators;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">significant costs to defend the related litigation;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">substantial monetary awards to trial participants or patients;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">loss of revenue;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reduced resources of our management to pursue our business strategy; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the inability to successfully commercialize XPOVIO and any other drugs that we may develop.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently hold clinical trial and general product liability insurance coverage, but that coverage may not be adequate to cover any and all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The business that we conduct outside the United States may be adversely affected by international risk and uncertainties. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although our operations are based in the United States, we conduct business outside the United States and expect to continue to do so in the future. For instance, many of the sites at which our clinical trials are being conducted are located outside the United States. In addition, we plan to seek approvals to sell our products in foreign countries. Any business that we conduct outside the United States will be subject to additional risks that may materially adversely affect our ability to conduct business in international markets, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">potentially reduced protection for intellectual property rights;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the potential for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">economic weakness, including inflation, volatility in currency exchange rates or political instability in particular foreign economies and markets;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">business interruptions resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">geo-political</div> actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and fires; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act, or FCPA.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Financial Position, Convertible Senior Notes, Revenue Interest Financing Agreement and Need for Additional Capital </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred significant losses since inception. We expect to continue to incur losses in the future and may never achieve or maintain profitability. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Since inception, we have incurred significant operating losses. Our net losses were $199.6&#160;million, $178.4&#160;million, and $129.0&#160;million&#160;for the years ended December&#160;31, 2019, December&#160;31, 2018 and December&#160;31, 2017, respectively. As of December&#160;31, 2019 and December&#160;31, 2018, we had an accumulated deficit of $873.3&#160;million and $673.7&#160;million, respectively. As we only recently launched our first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved </div> product, XPOVIO, in July 2019, we have had limited revenues to date from product sales and have financed our operations to date principally through private placements of our preferred stock, proceeds from our initial public offering and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offerings of common stock, issuance of convertible debt, proceeds from a revenue interest financing and cash generated from our business development activities. We have devoted substantially all of our efforts to research and development, including preclinical studies and clinical trials, pursuing regulatory approvals and engaging in activities to commercially launch XPOVIO for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Other than the FDA&#8217;s accelerated approval of XPOVIO, our lead drug candidate, oral selinexor (for indications not yet approved), as well as eltanexor, verdinexor, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> are in clinical development. Although we expect to continue to generate revenue from sales of XPOVIO, there can be no assurance as to the amount or timing of any such revenue, and we expect to continue to incur significant expenses and operating losses. The net losses we incur may fluctuate significantly from quarter to quarter.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our expenses will continue to increase substantially as compared to prior periods as we continue to commercialize XPOVIO in the United States and engage in activities to prepare for the potential commercialization of additional indications for selinexor and the potential approval of our other drug candidates, including due to the impact of increased headcount, to support our clinical and commercialization activities, expanded infrastructure and increased insurance premiums. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our expenses will increase substantially if and as we: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">continue to commercialize XPOVIO in the United States and seek regulatory approval for XPOVIO outside of the United States;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">continue to grow our sales, marketing and distribution infrastructure during the commercialization of XPOVIO and any drug candidates for which we may obtain marketing approval, prior to or upon receiving marketing approval in the United States or outside the United States;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">continue our research and preclinical and clinical development of our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">initiate additional clinical trials for our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">seek marketing approvals for any of our drug candidates that successfully complete clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">maintain, expand and protect our intellectual property portfolio;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">manufacture our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">hire additional clinical, quality control, scientific, commercial and management personnel;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identify additional drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> other drugs and technologies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">add operational, financial and management information systems and personnel, including personnel to support our drug development, any commercialization efforts and our other operations as a public company; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">increase our product liability insurance coverage as we initiate and expand our commercialization efforts.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to become and remain profitable depends on our ability to commercialize a drug or drugs with significant market potential, either on our own or with a collaborator. While we began to generate revenue from the sales of XPOVIO in July 2019, there can be no assurance as to the amount or timing of any such revenue, and we may not achieve profitability for several years, if at all. This will require us to be successful in a range of challenging activities, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">successful launching of XPOVIO, including by further developing our sales force, marketing and distribution capabilities;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">achieving an adequate level of market acceptance and obtaining and maintaining coverage and adequate reimbursement from third-party payors for XPOVIO and any other drugs we commercialize;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">completing preclinical studies and clinical trials of our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtaining marketing approval for these drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">manufacturing at commercial scale, marketing, selling and distributing XPOVIO or any drug candidates for which we may obtain marketing approval;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">maintaining regulatory and marketing approvals for XPOVIO and for any drug candidates for which we obtain marketing approval;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establishing and managing any collaborations for the development, marketing and/or commercialization of our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">hiring and building a full commercial organization required for the marketing, selling and distribution for those drugs for which we obtain marketing approval; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtaining, maintaining and protecting our intellectual property rights.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase if we are required by the FDA or other regulatory authorities to perform clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies in addition to those that have been conducted or are currently expected, or if there are any delays in the development of any of our drug candidates or the manufacture of any of our drug candidates.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPOVIO is our only product that has been approved for sale and it has only been approved in the United States for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Our ability to become and remain profitable will depend, in part, on the timing and success of commercial sales of XPOVIO, which we commercially launched in the United States in July 2019. However, the successful commercialization of XPOVIO in the United States is subject to many risks. We are currently undertaking our first commercial launch with XPOVIO, and we may not be able to do so successfully. There are numerous examples of unsuccessful product launches and failures to meet expectations of market </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential, including by pharmaceutical companies with more experience and resources than us. We do not anticipate our revenue from sales of XPOVIO alone, in the currently approved indication, will be sufficient for us to become profitable for several years, if at all. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may never succeed in these activities and may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The nature and length of our operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We were incorporated in 2008 and commenced operations in 2009. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our platform, identifying potential drug candidates, conducting preclinical studies and early-phase and later-phase clinical trials of our drug candidates and establishing a commercial infrastructure to launch XPOVIO. We only recently launched XPOVIO and are still in the process of executing our commercial launch plan and, to date, have not generated significant revenue from the sale of XPOVIO. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, as a business with a short operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any particular quarterly or annual periods as indications of future operating performance. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and drug development programs or commercialization efforts. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect our expenses to increase in connection with our ongoing activities, particularly as we commercialize XPOVIO (selinexor) and continue the clinical trials of, and seek marketing approval and prepare for commercialization of, selinexor in additional indications and our other drug candidates. Our expenses have increased as we have begun commercializing XPOVIO, including costs associated with our sales force and increased marketing and distribution capabilities. If we obtain marketing approval for any drug candidates that we develop, we expect to incur significant additional commercialization expenses for such drug candidate to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any such drug candidate. Furthermore, we will continue to incur additional costs associated with operating as a public company, hiring additional personnel and expanding our facilities. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and drug development programs or any current or future commercialization efforts. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that our existing cash, cash equivalents and investments will enable us to fund our current operating and capital expenditure plans for at least twelve months from the date of issuance of the financial </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">statements contained in this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K.</div> Our future capital requirements will depend on many factors, including:</div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our ability to successfully commercialize and sell XPOVIO in the United States;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the cost of, and our ability to expand and maintain, the commercial infrastructure required to support the commercialization of XPOVIO and any other drug for which we receive marketing approval, including product sales, medical affairs, marketing and distribution;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the progress and results of our current and planned clinical trials of selinexor;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs, timing and outcome of regulatory review of our drug candidates, including whether any additional clinical trials or other activities are required for approval or label expansion;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our ability to establish and maintain collaborations on favorable terms;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the success of any collaborations that we have entered into and may enter into with third parties;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the extent to which we acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> other drugs and technologies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs of commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our drug candidates for which we receive marketing approval, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercialization</div> costs for our drug candidates incurred prior to receiving any such marketing approval, including the costs and timing of establishing product sales, marketing, manufacturing and distribution capabilities that are not the responsibility of any collaborator that we may have at such time;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the amount of revenue, if any, received from commercial sales of our drug candidates, assuming receipt of marketing approval;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the terms and timing of any future collaborations, partnerships, licensing, marketing, distribution or other arrangements that we may establish; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifying potential drug candidates, conducting preclinical studies and clinical trials, seeking marketing approvals and commercializing products are time-consuming, expensive and uncertain processes that take years to complete. Although we commercially launched XPOVIO in July 2019, we do not anticipate that our revenue from product sales of XPOVIO will be sufficient for us to become profitable for several years, if at all. In addition, we may never generate the necessary data or results required to obtain marketing approval of our drug candidates. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. Adequate additional financing may not be available to us on acceptable terms, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate development activities for one or more of our drug candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize XPOVIO or our drug candidates for which we obtain marketing approval. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Global credit and financial markets have experienced extreme disruptions over some of the past several years. Such disruptions have resulted, and could in the future result, in diminished liquidity and credit </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that any deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be compromised by economic downturns, a volatile business environment and unpredictable and unstable market conditions. If the equity and credit markets deteriorate, it may make any necessary equity or debt financing more difficult to secure, more costly or more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could harm our growth strategy, financial performance and stock price and could require us to delay or abandon plans with respect to our business, including clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers or other third parties with which we conduct business may not survive difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our indebtedness could limit cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the Convertible Senior Notes due 2025, or Notes. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We incurred $172.5&#160;million of indebtedness as a result of the sale of the Notes and $75.0&#160;million as a result of the initial closing pursuant to the Revenue Interest Financing Agreement, or Revenue Interest Agreement, that we entered into with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P., or HCR, on September&#160;14, 2019. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">increasing our vulnerability to adverse economic and industry conditions;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">limiting our ability to obtain additional financing;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">limiting our flexibility to plan for, or react to, changes in our business;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the Notes; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under our indebtedness, including the Notes, and our cash needs may increase in the future. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Servicing the Notes will require a significant amount of cash, and we may not have sufficient cash flow from our business to make payments on our indebtedness. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to pay the principal of or interest and additional interest, if any, on the Notes or to make cash payments in connection with any conversion of the Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service the Notes or other future indebtedness and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness or obtaining additional debt financing or equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the Notes or other future indebtedness will depend on the capital markets, our financial condition at such time and our obligations under any other existing indebtedness in effect at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the Notes. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash, to repurchase the Notes for cash upon a fundamental change, to pay the redemption price for any Notes we redeem or to refinance the Notes, and any future debt we incur may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders may require us to repurchase their Notes following a fundamental change at a cash repurchase price generally equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest and additional interest, if any.&#160;In addition, upon conversion, unless we elect to deliver solely shares of our common stock to settle conversions (other than paying cash in lieu of delivering any fractional share), we must satisfy the conversion in cash.&#160;We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the Notes, pay cash amounts due upon conversion or redemption of the Notes or refinance the Notes.&#160;In addition, our ability to repurchase the Notes, to pay cash upon conversion or redemption of the Notes or to refinance the Notes may be limited by law, regulatory authority or agreements governing any future indebtedness that we may incur. Our failure to repurchase notes at a time when the repurchase is required by the indenture governing the Notes or to pay cash upon conversion of the Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness, if any. Moreover, the occurrence of a fundamental change under the indenture could constitute an event of default under any such agreements. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or to pay cash upon conversion of the Notes. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event the conditional conversion feature of the Notes is triggered, holders of Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal amount of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In May 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. APB <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14-1,</div> Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement), which has subsequently been codified as Accounting Standards Codification <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20, </div> Debt with Conversion and Other Options, or ASC<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;470-20.</div> Under ASC<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;470-20,</div> an entity must separately account for the liability and equity components of the convertible debt instruments (such as the Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The effect of ASC<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;470-20</div> on the accounting for the Notes is that the equity component is required to be included in the additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital section of stockholders&#8217; equity at the issuance date, and the value of the equity component would be treated as debt discount for purposes of accounting for the debt component of the Notes. As a result, we will be required to record a greater amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> interest expense as a result of the amortization of the discounted carrying value of the Notes to their face amount over the term of the Notes. We will report a larger net loss in our financial results because ASC<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;470-20</div> will require interest to include both the amortization of the value of the debt discount and the instrument&#8217;s coupon interest rate, which could adversely affect our future financial results, the market price of our common stock and the trading price of the Notes.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, under certain circumstances, convertible debt instruments (such as the Notes) that may be settled entirely or partly in cash are currently eligible to be accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the future will continue to permit the use of the treasury stock method. If we are unable to use the treasury stock method in accounting for the shares issuable upon conversion of the Notes, then our diluted earnings per share would be adversely affected. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if any of the conditions to the convertibility of the Notes is satisfied, then we may be required under applicable accounting standards to reclassify the liability carrying value of the Notes as a current, rather than a long-term, liability. This reclassification could be required even if no holders convert their Notes and could materially reduce our reported working capital. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Revenue Interest Agreement with HCR contains various covenants and other provisions, which, if violated, could result in the acceleration of payments due under such agreement. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On September&#160;14, 2019, we entered into the Revenue Interest Agreement with HCR. Pursuant to the Revenue Interest Agreement, we are required to comply with various covenants relating to the conduct of our business and the commercialization of XPOVIO, including obligations to use commercially reasonable efforts to commercialize our products and limits on our ability to incur or prepay indebtedness, create or incur liens, pay dividends on or repurchase outstanding shares of our capital stock or dispose of assets. In addition, the Revenue Interest Agreement includes customary events of default upon the occurrence of enumerated events, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of revenue interests, failure to perform certain covenants and the occurrence of insolvency proceedings, specified judgments, specified cross-defaults or specified revocations, withdrawals or cancellations of regulatory approval for XPOVIO. Upon the occurrence of an event of default and in the event of a change of control, HCR may accelerate payments due under the Revenue Interest Agreement up to $138.8&#160;million, less the aggregate of all of the payments previously paid to HCR. Upon the occurrence of specified material adverse events or the material breach of specified representations and warranties, which will not be considered events of default, HCR may elect to terminate the Revenue Interest Agreement and require us to make payments necessary for HCR to receive $75&#160;million, less the aggregate of all of the payments made to date, plus a specified annual rate of return. In the event that we are unable to make such payment, then HCR may be able to foreclose on the collateral that was pledged to HCR, which consists of all of our present and future assets relating to XPOVIO. Any such foreclosure remedy would significantly and adversely affect us and could result in us losing our interest in such assets.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until such time, if ever, as we can generate substantial revenues from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For example, during the term of the Revenue Interest Agreement, we cannot make any voluntary or optional cash payment or prepayment on our existing convertible debt and cannot enter into any new debt without the consent of HCR. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we raise funds through further collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our research and drug development or current or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Dependence on Third Parties </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We depend on third parties for certain aspects of the development, marketing and/or commercialization of our drug candidates and plan to enter into additional collaborations. If those collaborations are not successful, we may not be able to capitalize on the market potential of these drug candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We intend to maintain our existing collaborations and will continue to seek additional third-party collaborators for certain aspects of the development, marketing and/or commercialization of our drug candidates. For example, we have entered into license arrangements with Ono Pharmaceutical Co., Ltd. and Antengene Therapeutics Limited, and plan to continue to seek to enter into additional license relationships, for marketing and commercialization of selinexor for other geographies outside the United States. In addition, we intend to seek one or more collaborators to aid in the further development, marketing and/or commercialization of our other SINE compounds for indications outside of oncology. Our likely collaborators for any collaboration arrangements include large and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-size</div> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In connection with any such arrangements with third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development, marketing and/or commercialization of our drug candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborations involving our drug candidates pose the following risks to us: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators may not perform their obligations as expected or in compliance with applicable regulatory requirements;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators may not pursue development, marketing and/or commercialization of our drug candidates or may elect not to continue or renew development, marketing or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drugs or drug candidates if the collaborators believe that competitive drugs are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and distribution of such drug or drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our drugs or drug candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources of our company;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">collaborators may learn about our discoveries and use this knowledge to compete with us in the future; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the number and type of our collaborations could adversely affect our attractiveness to collaborators or acquirers.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Collaboration agreements may not lead to development or commercialization of drug candidates in the most efficient manner, or at all. If our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> also apply to the activities of our collaborators.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to establish and maintain our agreements with third parties to distribute XPOVIO to patients, our results of operations and business could be adversely affected. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on third parties to commercially distribute XPOVIO to patients. For example, we have contracted with a limited number of specialty pharmacies and specialty distributors to sell and distribute XPOVIO. The use of specialty pharmacies and specialty distributors involves certain risks, including, but not limited to, risks that these organizations will: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">not provide us accurate or timely information regarding their inventories, the number of patients who are using XPOVIO or serious adverse reactions, events and/or product complaints regarding XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">not effectively sell or support XPOVIO or communicate publicly concerning XPOVIO in a manner that is contrary to FDA rules and regulations;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">not devote the resources necessary to sell XPOVIO in the volumes and within the time frames that we expect;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">be unable to satisfy financial obligations to us or others; or</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">cease operations.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any such events may result in decreased product sales and lower product revenue, which would harm our results of operations and business. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not able to maintain our existing collaborations or establish additional collaborations as we currently plan, we may have to alter our development and commercialization plans and our business could be adversely affected. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our drug development programs and the commercialization of our drug candidates for which we receive marketing approval will require substantial additional cash to fund expenses. As noted above, we expect to maintain our existing collaborations and collaborate with additional pharmaceutical and biotechnology companies for the development of our drug candidates and the commercialization of our drugs or the potential commercialization of our drug candidates. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside of the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also be restricted under then-existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such drug candidate, reduce or delay its development program or one or more of our other development programs, delay the commercialization of a drug or a drug candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate revenue from sales of drugs. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on some third parties as we conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on some third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, as we conduct our clinical trials. We currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our drug development activities. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The European Medicines Agency, or EMA, also requires us to comply with comparable standards. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and trial sites. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or any of the third parties that we rely on in connection with our clinical trials fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with such requirements.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div>We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. In such an event, our financial results and the commercial prospects for our drug candidates could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of such third parties could delay clinical development or marketing approval of our drug candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue from sales of drugs. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on third parties to conduct investigator-sponsored clinical trials of selinexor and our other drug candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our drug candidates may delay or impair our ability to obtain regulatory approval for selinexor and our other drug candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We rely on academic and private <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-academic</div> institutions to conduct and sponsor clinical trials relating to selinexor and our other drug candidates. We do not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we do not have control over the timing and reporting of the data from investigator-sponsored trials, nor do we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our drug candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our drug candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additionally, the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We contract with third parties for the manufacture of our drug candidates for preclinical studies and clinical trials and expect to continue to do so in connection with the commercialization of XPOVIO and for clinical trials and commercialization of any drug candidates that we develop and commercialize. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have any manufacturing facilities or personnel. We do not currently have nor do we plan to build internal infrastructure or capability to manufacture XPOVIO or our drug candidates for use in the conduct of our clinical trials or for commercial supply. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our drug candidates for preclinical studies and clinical trials under the guidance of members of our organization. We have engaged third-party manufacturers for drug substance and drug product services. We do not have a long term supply agreement with any of these third-party manufacturers, and we purchase our required drug supplies on a purchase order basis. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have engaged a third-party contract manufacturer for the commercial production of XPOVIO and intend to do the same for any drug candidate that is approved by any regulatory agency. Reliance on third-party manufacturers entails risks, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reliance on the third party for regulatory compliance and quality assurance;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the possible breach of the manufacturing agreement by the third party;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the possible failure of the third party to manufacture our drugs or drug candidates according to our schedule, or at all, including if the third-party manufacturer gives greater priority to the supply of other drugs over our drugs and drug candidates, or otherwise does not satisfactorily perform according to the terms of the manufacturing agreement;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">equipment malfunctions, power outages or other general disruptions experienced by our third-party manufacturers to their respective operations and other general problems with a multi-step manufacturing process;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the possible misappropriation or disclosure by the third party or others of our proprietary information, including our trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how;</div> and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This process is difficult and time consuming and we may face competition for access to manufacturing facilities, as there are a limited number of contract manufacturers operating under current Good Manufacturing Practices, or cGMPs, that are capable of manufacturing our drug candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Facilities used by our third-party manufacturers must be inspected by the FDA after we submit an NDA and before potential approval of the drug candidate. Similar regulations apply to manufacturers of our drug candidates for use or sale in foreign countries. We do not control the manufacturing </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our drug candidates. If our manufacturers cannot successfully manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable drug candidate as alternative qualified manufacturing facilities may not be available on a timely basis or at all. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us or the contract manufacturer, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our drug candidates and have a material adverse impact on our business, financial condition and results of operations. Any drugs that we may develop may compete with other drug candidates and drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any performance failure on the part of our existing or future manufacturers could delay clinical development, marketing approval or commercialization. If our current contract manufacturers cannot perform as agreed, we may be required to replace those manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our drug candidates or drugs, we may incur added costs and delays in identifying and qualifying any such replacement. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current and anticipated future dependence upon others for the manufacture of XPOVIO or any drug candidates that we develop may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal Compliance Matters </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. As a result, we cannot predict when or if we or any of our collaborators will obtain marketing approval to commercialize a drug candidate. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drugs are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, whose laws and regulations may differ from country to country. We are not permitted to market our drug candidates in the United States or in other countries until we or any of our collaborators receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside of the United States. In July 2019, the FDA approved XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;"> </div>(selinexor) in combination with dexamethasone for the treatment of adult patients with RRMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing, randomized Phase 3 BOSTON study evaluating selinexor in combination with Velcade<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (bortezomib) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose </div> dexamethasone may, if successful, serve as the confirmatory trial. In addition, we submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, in January 2019 with a request for conditional approval of selinexor as a treatment for patients with heavily pretreated multiple myeloma based on the results of the STORM study. During March 2019, the EMA had inspectors conduct a Good Clinical Practices, or GCP, inspection at our headquarters, which was also attended by the FDA, as well as inspections of two clinical sites that participated in Part 2 of the STORM study. While we did not receive any findings from the</div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">FDA, in May 2019, the EMA inspectors provided us a written inspection report seeking our responses to various questions and findings. We promptly addressed the questions and findings in the inspection report and submitted proposals to the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP. In September 2019, we received the Day 180 List of Outstanding Issues from CHMP, which identified two issues requiring resolution. First, CHMP requested that we reconfirm the IRC adjudicated response rate to justify a positive benefit-risk assessment and, second, CHMP requested that we address the findings from the GCP inspection and our corrective measures taken to justify that the clinical trial data are of sufficient quality to support a benefit-risk assessment. In January 2020, we were granted a three-month extension from CHMP to provide additional time to respond to the outstanding questions. We are currently working with CHMP to address the outstanding questions and expect to receive a decision on the application in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2020.</div> With the exception of our Supplemental New Drug Application, or sNDA, submission to the FDA requesting approval of selinexor to treat relapsed or refractory diffuse large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma, or DLBCL, we have not submitted any other application for, or received any marketing approval of, any of our drug candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA. The process of obtaining marketing approvals, both in the United States and abroad, is a lengthy, expensive and uncertain process. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other studies and testing. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval we or any of our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any of our collaborators to generate revenue from the particular drug candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since XPOVIO received accelerated approval by the FDA, we must still comply with post-approval development and regulatory requirements to maintain that approval and, if we fail to do so, FDA could withdraw its approval of XPOVIO, which would lead to substantially lower revenues. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">For drugs granted accelerated approval, the FDA typically requires post-marketing confirmatory trials to evaluate the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence. As a condition of the accelerated approval of XPOVIO, we are required to (i)&#160;complete and submit a final report with full datasets from the BOSTON study following completion of the study, (ii)&#160;conduct a randomized phase 2 clinical trial of selinexor plus dexamethasone with three doses of selinexor including the approved dose of 80 mg on days 1 and 3 of each week and two doses that are lower than the approved dose, in a similar patient population for which XPOVIO is indicated (which we plan to conduct outside the United States), (iii) conduct a trial with selinexor in patients who have mild, moderate or severe hepatic impairment, and (iv)&#160;conduct a drug interaction trial with selinexor in patients to evaluate the effect of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-administration</div> of a strong CYP3A4 inhibitor on the pharmacokinetics of selinexor.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that our product candidate is not shown to be </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate. Similar risks to those described above are also applicable to any application that we have submitted or may submit to the EMA to support conditional approval of selinexor to treat heavily pretreated multiple myeloma, relapsed/refractory DLBCL, or any other cancer indication. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There can be no assurance that the BOSTON study conducted as part of our post-marketing obligations will confirm that the surrogate marker used for accelerated approval of XPOVIO will eventually show an adequate correlation with clinical outcomes. If the BOSTON study fails to show such adequate correlation, we may not be able to maintain our previously granted marketing approval of XPOVIO. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in foreign jurisdictions. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to market and sell our drugs in the European Union and many other jurisdictions, we and our current or future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. We and our collaborators may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on June&#160;23, 2016, the electorate in the United Kingdom, or UK, voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the UK left the European Union on January&#160;31, 2020. Under the withdrawal agreement, there is a transitional period until December&#160;31, 2020 (extendable up to two years). Under the withdrawal agreement, there is a transitional period until December&#160;31, 2020 (extendable up to two years). Discussions between the UK and the European Union have so far mainly focused on finalizing withdrawal issues and transition agreements but have been extremely difficult to date. To date, only an outline of a trade agreement has been reached.&#160;Much remains open but the Prime Minister has indicated that the UK will not seek to extend the transitional period beyond the end of 2020.&#160;If no trade agreement has been reached before the end of the transitional period, there may be significant market and economic disruption. The Prime Minister has also indicated that the UK will not accept high regulatory alignment with the EU. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the regulatory framework for pharmaceutical products in the UK covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the UK. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the UK and/or European Union for our product candidates, which could significantly and materially harm our business. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">We may seek approval from the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities to use accelerated development pathways for our product candidates, including for selinexor in diffuse large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma. If we are not able to use such pathways, we may be required to conduct additional clinical trials beyond those that we contemplate and that would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we receive them at all. In addition, even if we are able to use an accelerated approval pathway, it may not lead to expedited approval of our product candidates, or approval at all. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Prior to seeking such accelerated approval, we will continue to seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the positive results of the SADAL study, we submitted a sNDA to the FDA in December 2019, with a request for accelerated approval for selinexor as a new treatment for adult patients with relapsed and/or refractory DLBCL, not otherwise specified, who have received at least two prior therapies. The FDA accepted the application for filing on February&#160;18, 2020 and granted Priority Review with a target decision date of June&#160;23, 2020 under the Prescription Drug User Fee Act, or PDUFA. In November 2018, the FDA granted fast track designation to selinexor for this indication. While the FDA agreed that the trial design and indication appear appropriate for accelerated approval, they reiterated to us in their feedback that the availability of accelerated approval will depend on the trial results and available therapies at the time of regulatory action. The FDA also has reiterated to us that it recommends, in general, a randomized trial with a progression-free survival endpoint as an initial registration approach and, for DLBCL, recommended two randomized trials that isolate the treatment effect of selinexor for a DLBCL indication. During a pre-sNDA meeting with the FDA in November 2019, the FDA noted that the sufficiency of efficacy, tolerability and dose optimization data would be a review issue. Although we believe that our SADAL study presents an opportunity for us to request that the FDA grant accelerated approval for selinexor in relapsed and/or refractory DLBCL, there can be no assurance that the FDA will grant such approval, whether on an accelerated basis, or at all. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There can also be no assurance that the FDA will agree with our surrogate endpoints or intermediate clinical endpoints, or that we will decide to pursue or submit any additional NDAs for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </div></div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A fast track designation or breakthrough therapy status by the FDA is not assured and, in any event, may not actually lead to a faster development or regulatory review or approval process and, moreover, would not assure FDA approval of our product candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be eligible for fast track designation or breakthrough therapy status for product candidates that we develop. If a product is intended for the treatment of a serious or life-threatening disease or condition and the product demonstrates the potential to address unmet medical needs for this disease or condition, the product sponsor may apply for FDA fast track designation. Additionally, a product candidate may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for such designation or status, the FDA could decide not to grant it. Moreover, even if we do receive such a designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that our product candidate will be approved by the FDA. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2018, the FDA granted fast track designation to selinexor for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy that include regimens comprised of an alkylating agent, a glucocorticoid, Velcade<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (bortezomib), Kyprolis<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (carfilzomib), Revlimid<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (lenalidomide), Pomalyst<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (pomalidomide) and Darzalex<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (daratumumab) and whose disease is refractory to at least one proteasome inhibitor (Velcade or Kyprolis), one immunomodulatory agent (Revlimid or Pomalyst), glucocorticoids and to Darzalex, as well as to the most recent therapy. In addition, in November 2018, the FDA granted fast track designation to selinexor for the treatment of patients that have relapsed and/or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. However, even with these fast track designations, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that selinexor will be approved by the FDA for additional indications. For example, in connection with our NDA for XPOVIO, in March 2019, the FDA extended the PDUFA action date by three months following our submission of additional, existing clinical information as an amendment to the NDA, which resulted in a nine-month review cycle despite the fast track designation. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidate. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the FDA&#8217;s goal to review an application is six months, rather than the standard review period of ten months. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. For example, in connection with our NDA for XPOVIO, in March 2019, the FDA extended the PDUFA action date by three months following our submission of additional, existing clinical information as an amendment to the NDA, which resulted in a nine-month review cycle. Receiving priority review from the FDA does not guarantee approval within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> review cycle or thereafter.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to obtain orphan drug exclusivity for our product candidates. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we obtain orphan drug exclusivity from the FDA for a product, as we have for XPOVIO as a treatment for patients with heavily pretreated multiple myeloma and selinexor in acute myeloid leukemia and DLBCL, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On August&#160;3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we or any of our collaborators obtain marketing approvals for our drug candidates, the terms of approvals and ongoing regulation of our drugs may limit how we, or they, manufacture and market our drugs, which could materially impair our ability to generate revenue. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once marketing approval has been granted, an approved drug and its manufacturer and marketer are subject to ongoing review and extensive regulation. We and our collaborators must therefore comply with requirements concerning advertising and promotion for XPOVIO or for any of our drug candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug&#8217;s approved labeling. Thus, we and our collaborators may not be able to promote any drugs we develop for indications or uses for which they are not approved. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, manufacturers of approved drugs and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, assuming we or our current or future collaborators receive marketing approval for one or more of our drug candidates, we, and our collaborators, and our and their contract manufacturers will continue to </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we and our collaborators are not able to comply with post-approval regulatory requirements, we and our collaborators could have the marketing approvals for our drugs withdrawn by regulatory authorities, and our or our collaborators&#8217; ability to market any future drugs could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPOVIO and any of our drug candidates for which we or our collaborators obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market, and we and our collaborators may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our drugs following approval. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XPOVIO and any of our drug candidates for which we or our collaborators obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such drug, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy, which could include requirements for a restricted distribution system. </div></div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; line-height: 12pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a drug. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use, and if we or our collaborators do not market any of our drug candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. In addition, later discovery of previously unknown AEs or other problems with our drugs or their manufacturers or manufacturing processes, data integrity issues with regulatory filings, or failure to comply with regulatory requirements, may yield various results, including:</div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">litigation involving patients taking our drug;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">restrictions on such drugs, manufacturers or manufacturing processes;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">restrictions on the labeling or marketing of a drug;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">restrictions on drug distribution or use;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">requirements to conduct post-marketing studies or clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">warning letters or untitled letters;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">withdrawal of the drugs from the market;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">refusal to approve pending applications or supplements to approved applications that we submit;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">recall of drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">fines, restitution or disgorgement of profits or revenues;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">suspension or withdrawal of marketing approvals;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">damage to relationships with any potential collaborators;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">unfavorable press coverage and damage to our reputation;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">refusal to permit the import or export of drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">drug seizure; or</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">injunctions or the imposition of civil or criminal penalties.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Cures Act and the Trump Administration&#8217;s regulatory reform initiatives, the FDA&#8217;s policies, regulations and guidance may be revised or revoked and that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump Administration may impact our business and industry. Namely, the Trump Administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-resourced FDA could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. In January 2017, President Trump issued an executive order, applicable to all executive agencies including the FDA, which requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;two-for-one&#8221; </div> provisions. This executive order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the executive order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB in February 2017, the administration indicates that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;two-for-one&#8221;</div> provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February&#160;24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a &#8220;Regulatory Reform Officer&#8221; and establish a &#8220;Regulatory Reform Task Force&#8221; to implement the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-for-one</div> provisions and other previously issued executive orders relating to the review of federal regulations. It is difficult to predict how these various requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With the recent passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved drug products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;20, 2019, President Trump signed legislation intended to facilitate the development of generic and biosimilar products. The bill, previously known as the CREATES Act, authorizes sponsors of ANDAs and 505(b)(2) applications to file lawsuits against companies holding NDAs that decline to provide sufficient quantities of an approved reference drug on commercially reasonable, market-based terms. Drug products on FDA&#8217;s drug shortage list are exempt from these new provisions unless the product has been on the list for more than six continuous months or the FDA determines that the supply of the product will help alleviate or prevent a shortage. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To bring an action under the statute, an ANDA or 505(b)(2) applicant must take certain steps to request the reference product, which, in the case of products covered by a REMS with ETASU include obtaining authorization from the FDA for the acquisition of the reference product. If the applicant does bring an action for failure to provide a reference product, there are certain affirmative defenses available to the NDA holder, which must be shown by a preponderance of evidence. If the applicant prevails in litigation, it is entitled to a court order directing the NDA holder to provide, without delay, sufficient quantities of the applicable product on commercially reasonable, market-based terms, plus reasonable attorney fees and costs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the new statutory provisions authorize a federal court to award the product developer an amount &#8220;sufficient to deter&#8221; the NDA holder from refusing to provide sufficient product quantities on commercially reasonable, market-based terms if the court finds, by a preponderance of the evidence, that the NDA holder did not have a legitimate business justification to delay providing the product or failed to comply with the court&#8217;s order. For the purposes of the statute, the term &#8220;commercially reasonable, market-based terms&#8221; is defined as (1)&#160;the nondiscriminatory price at or below the most recent wholesale acquisition cost for the product, (2)&#160;a delivery schedule that meets the statutorily defined timetable, and (3)&#160;no additional conditions on the sale. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we intend to comply fully with the terms of these new statutory provisions, we are still exposed to potential litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved drug products on commercially reasonable, market-based terms for testing in support of ANDAs and 505(b)(2) applications. Such litigation would subject us to additional litigation costs, damages and reputational harm, which could lead to lower revenues. The CREATES Act may enable generic competition with XPOVIO and any of our other drug candidates, if approved, which could impact our ability to maximize product revenue. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our drug candidates and affect the prices we, or they, may obtain. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell or commercialize XPOVIO or any drug candidate for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved drugs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Among the provisions of the Patient Protection and Affordable Care Act, or ACA, of potential importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any of our drug candidates that are approved for sale, are the following: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an annual, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% starting January&#160;1, 2019) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div> discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">extension of manufacturers&#8217; Medicaid rebate liability;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expansion of eligibility criteria for Medicaid programs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">new requirements to report certain financial arrangements with physicians and teaching hospitals;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent legislative amendments, will stay in effect through 2029 unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for XPOVIO and for any of our product candidates for which we may obtain regulatory approval or the frequency with which XPOVIO or any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for XPOVIO or any other approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump Administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, includes a provision repealing, effective January&#160;1, 2019, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-based</div> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate. Additionally, the 2020 federal spending package permanently eliminated, effective January&#160;1, 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACA-mandated</div> &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January&#160;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In July 2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, on December&#160;14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The Trump administration and CMS have both stated that the ruling will have no immediate effect, and on December&#160;30, 2018 the same judge issued an order staying the judgment pending appeal. The Trump Administration recently represented to the Court of Appeals considering this judgment that it does not oppose the lower court&#8217;s ruling. On July&#160;10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. On December&#160;18, 2019, that court affirmed the lower court&#8217;s ruling that the individual mandate portion of the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. On January&#160;21, 2020, the U.S. Supreme Court declined to review this decision on an expedited basis. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Trump Administration has also taken executive actions to undermine or delay implementation of the ACA. In January 2017, President Trump signed an executive order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a second executive order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the ACA exchanges. At the same time, the Trump Administration announced that it will discontinue the payment of cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is uncertain. Further, in July 2018 following a federal district court decision from New Mexico, the Administration announced that it would be freezing payments to insurers under the ACA to cover sicker patients until it or Congress can address the appropriate methodology for calculating and making such payments. It remains to be seen how this action will affect the implementation of the ACA. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business. It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to repeal and replace ACA provisions is uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion provisions. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from XPOVIO or from product candidates that we may successfully develop and for which we may obtain </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Further, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Specifically, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, on May&#160;11, 2018, the current administration issued a plan to lower drug prices. Under this blueprint for action, the current administration indicated that the Department of Health and Human Services, or HHS, will take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies, advance biosimilars and generics to boost price competition, evaluate the inclusion of prices in drug makers&#8217; ads to enhance price competition, speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers, avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid, work to give Medicare Part D plan sponsors more negotiation power with drug makers, examine which Medicare Part B drug prices could be negotiated by Medicare Part D plans, improve the design of the Medicare Part B Competitive Acquisition Program, update Medicare&#8217;s drug-pricing dashboard to increase transparency, prohibit Medicare Part D contracts that include &#8220;gag rules&#8221; that prevent pharmacists from informing patients when they could pay less <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div> by not using insurance, and require that Medicare Part D plan members be provided with an annual statement of plan payments, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div> spending, and drug price increases.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition, on December&#160;23, 2019, the Trump Administration published a proposed rulemaking that, if finalized, would allow states or certain other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-federal</div> government entities to submit importation program proposals to the FDA for review and approval. Applicants would be required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. At the same time, the FDA issued draft guidance that would allow manufacturers to import their own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> drugs that are authorized for sale in other countries (multi-market approved products).</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical drugs. We cannot be sure whether additional </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any collaborators to more stringent drug labeling and post-marketing testing and other requirements. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare providers, physicians and third party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anti-Kickback Statute</div></div>&#8212;the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">False Claims Act</div></div>&#8212;the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-claim</div> penalties, currently set at a minimum of $11,181 and a maximum of $22,363 per false claim; ;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIPAA</div></div>&#8212;the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transparency Requirements</div></div>&#8212;federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Analogous State and Foreign Laws</div></div>&#8212;analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services and are generally broad and are enforced by many different federal and state agencies as well as through private actions.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-empted</div> by HIPAA, thus complicating compliance efforts.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20&#160;million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#8217;s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act&#8212;which went into effect on January&#160;1, 2020&#8212;is creating similar risks and obligations as those created by GDPR, though the Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> jurisdictions, including the GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain drug candidates outside of the United States and require us to develop and implement costly compliance programs. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The Securities and Exchange Commission, or SEC, is involved with enforcement of the books and records provisions of the FCPA. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States, has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues from the sales of drugs, if any. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some countries, including the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we or our existing and future collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including in recent months, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain and maintain patent protection for our drug candidates and other discoveries, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drugs and other discoveries similar or identical to ours, and our ability to successfully commercialize our drug candidates and other discoveries may be adversely affected. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary drug candidates and other discoveries. We seek to protect our </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">proprietary position by filing patent applications in the United States and abroad related to our novel drug candidates and other discoveries that are important to our business. As of February&#160;10, 2020, 73 patents have issued that relate to XPO1 inhibitors, including composition of matter patents for selinexor, verdinexor and eltanexor in the United&#160;States, and their use in targeted therapeutics. In addition, 13 patents have issued that relate to our PAK4/NAMPT inhibitors, including two composition of matter patents for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in the United States and its use in targeted therapeutics. We cannot be certain that any other patents will issue with claims that cover any of our key drug candidates or other discoveries or drug candidates.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our drug candidates or other discoveries, or which effectively prevent others from commercializing competitive drugs and discoveries. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, in some foreign jurisdictions, our ability to secure patents based on our filings in the United States may depend, in part, on our ability to timely obtain assignment of rights to the invention from the employees and consultants who invented the technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Assuming the other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside of the United States, the first to file&#160;a patent application is entitled to the patent. In March 2013, the United States transitioned to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-inventor-to-file </div> system in which, assuming the other requirements for patentability are met, the first inventor to file&#160;a patent application is entitled to the patent. We may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, revocation, reexamination, or post-grant or <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our discoveries or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative discoveries or drugs in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> manner.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical discoveries and drugs, or limit the duration of the patent protection of our discoveries and drug candidates. Given the amount of time required </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competitors or commercial supply companies or others may infringe our patents and other intellectual property rights. For example, we are aware of third parties selling a version of our lead product candidate for research purposes, which may infringe our intellectual property rights. To counter such infringement, we may advise such companies of our intellectual property rights, including, in some cases, intellectual property rights that provide protection for our lead product candidates, and demand that they stop infringing those rights. Such demand may provide such companies the opportunity to challenge the validity of certain of our intellectual property rights, or the opportunity to seek a finding that their activities do not infringe our intellectual property rights. We may also be required to file infringement actions, which can be expensive and time-consuming. In an infringement proceeding, a defendant may assert and a court may agree with a defendant that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the intellectual property at issue. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Our commercial success depends upon our ability and the ability of any current and future collaborators to develop, manufacture, market and sell XPOVIO and our drug candidates and use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates and technology, including interference proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. No litigation asserting such infringement claims is currently pending against us, and we have not been found by a court of competent jurisdiction to have infringed a third party&#8217;s intellectual property rights. If we are found to infringe or think there is a risk we may be found to infringe, a third party&#8217;s intellectual property rights, we could be required or choose to obtain a license from such third party to continue developing, marketing and selling our drugs, drug candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive, </div> thereby giving our competitors access to the same intellectual property licensed to us. We could be forced, including by court order, to cease commercializing the infringing intellectual property or drug or to cease using the infringing technology. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information, of any such employee&#8217;s former employer. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the United States Patent and Trademark Office, or USPTO, and various foreign patent offices at various points over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with such provisions, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not successfully extend the term of patents covering our drug candidates under the Hatch-Waxman Amendments and similar foreign legislation, our business may be materially harmed. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending upon the timing, duration and conditions of FDA marketing approval, if any, of our drug candidates, one or more of our U.S. patents may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for one patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. The total patent term, including the extension period, may not exceed 14 years following FDA approval. Accordingly, the length of the extension, or the ability to even obtain an extension, depends on many factors. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, only a single patent can be extended for each qualifying FDA approval, and any patent can be extended only once and only for a single product. Laws governing analogous patent term extensions in </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Because both selinexor and verdinexor are protected by a single family of patents and applications, we may not be able to secure patent term extensions for both of these drug candidates in all jurisdictions where these drug candidates are approved, if ever. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain a patent term extension for a drug candidate or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that drug candidate, if any, in that jurisdiction will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue could be materially reduced. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In addition to seeking patents for our drugs, drug candidates and other discoveries, we also rely on trade secrets, including unpatented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who have access to them, such as our employees, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. To the extent that we are unable to timely enter into confidentiality and invention or patent assignment agreements with our employees and consultants, our ability to protect our business through trade secrets and patents may be harmed. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. To the extent inventions are made by a third party under an agreement that does not grant us an assignment of their rights in inventions, we may choose or be required to obtain a license.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not all of our trademarks are registered. Failure to secure those registrations could adversely affect our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;10, 2020, we have trademark registrations in the United States for our name and logo, and a combination of the two, XPOVIO, and PORE for our online portal. We also have pending applications in the United States to register two additional drug names (examination is currently suspended), and KARYFORWARD and a KARYFORWARD logo for our financial aid and charitable services. Outside the United States, XPOVIO is registered or pending in thirty additional jurisdictions, and is registered or pending in Katakana in Japan, Hangul in South Korea, and Chinese characters in Taiwan. We also have registrations or applications for eight additional possible drug names in numerous foreign jurisdictions. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would, which could adversely affect our business. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any proprietary name we propose to use with our key drug candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA typically conducts a review of proposed drug names, including an evaluation of potential for confusion with other drug names. If the FDA objects to any of our proposed proprietary drug names for any of our drug candidates, if approved, we may be required to expend significant additional resources in an effort to identify a suitable proprietary drug name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Employee Matters and Managing Growth </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future success depends on our ability to retain our Chief Executive Officer, our President and Chief Scientific Officer and other key executives and to attract, retain and motivate qualified personnel. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are highly dependent on Michael Kauffman, M.D., Ph.D., our Chief Executive Officer, and Sharon Shacham, Ph.D., M.B.A., our President and Chief Scientific Officer, as well as the other principal members of our management and scientific teams. Although we have entered into formal employment agreements with Drs.&#160;Kauffman and Shacham, these agreements do not prevent them from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of our key employees could impede the achievement of our research, development, commercialization and other business objectives. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drs. Kauffman and Shacham are married to each other. The separation or divorce of the couple in the future could adversely affect our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Kauffman, our Chief Executive Officer and member of our board of directors, and Dr.&#160;Shacham, our President and Chief Scientific Officer, are married to each other. They are two of our executive officers and are a vital part of our operations. If they were to become separated or divorced or could otherwise not amicably work with each other, one or both of them may decide to cease his or her employment with us or it could negatively impact our working environment. Alternatively, their work performance may not be satisfactory if they become preoccupied with issues relating to their personal situation. In these cases, our business could be materially harmed. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have expanded and expect to continue to expand our development, regulatory and sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have experienced and expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs, sales, marketing and distribution. To manage our current and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing such growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business and operations may be materially adversely affected in the event of computer system failures or security breaches, and the costs and consequences of implementing data protection measures could be significant. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite the implementation of security measures, our internal computer systems, and those of our contract research organizations and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber attacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our reputation or competitive position could be damaged, and the further development and commercialization of our drug candidates could be delayed or halted. We may also be vulnerable to cyber attacks by hackers, or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or result in legal proceedings. In addition, the cost and operational consequences of implementing further data protection measures could be significant. Moreover, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate security measures. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Common Stock </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our executive officers, directors and principal stockholders maintain the ability to control all matters submitted to stockholders for approval. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019, our executive officers, directors and a small number of stockholders own more than a majority of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establish a classified board of directors such that not all members of the board are elected at one time;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">limit the manner in which stockholders can remove directors from the board;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">limit who may call stockholder meetings;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An active trading market for our common stock may not be sustained. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although our common stock is listed on The Nasdaq Global Select Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for you to sell shares of our common stock without depressing the market price for the shares, or at all. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If securities analysts do not continue to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that analysts will provide favorable coverage or continue to cover us. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The price of our common stock has been and may be volatile in the future and fluctuate substantially. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our stock price has been and is likely to be volatile and may fluctuate substantially. For example, since January&#160;1, 2015, our common stock has traded at prices per share as high as $38.47 and as low as $3.92. On February&#160;20, 2020, the closing sale price of our common stock on The Nasdaq Global Select Market was $16.41 per share. The stock market in general and the market for pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our success in launching and commercializing XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the success of competitive drugs or technologies;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">results of clinical trials of our drug candidates or those of our competitors;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our success in commercializing our drug candidates, if and when approved;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">regulatory or legal developments in the United States and other countries;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the recruitment or departure of key personnel;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the level of expenses related to the commercial launch of XPOVIO and clinical development programs for any of our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the results of our efforts to discover, develop, acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional drug candidates or drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">variations in our financial results or those of companies that are perceived to be similar to us;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">changes in the structure of healthcare payment systems;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">market conditions in the pharmaceutical and biotechnology sectors;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">general economic, industry and market conditions; and</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the other factors described in this &#8220;Risk Factors&#8221; section.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities litigation or other litigation could result in substantial damages and may divert management&#8217;s time and attention from our business. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. We are a target of this type of litigation. See Part I, Item 3, &#8220;Legal Proceedings&#8221; in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for information concerning securities litigation recently initiated against us and certain of our executive officers and directors and certain other defendants. We may become the target of additional securities litigation in the future. For example, we may face additional securities class action litigation or other litigation if we fail to successfully launch and commercialize XPOVIO, or if we cannot obtain regulatory approvals for, or if we otherwise fail to successfully commercialize and launch, our drug candidates. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of such suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, we may incur substantial legal fees and costs in connection with any such litigation. We have not established any reserves for any potential liability relating to any such potential lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. We currently maintain insurance coverage for some of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be enough to cover damages awarded. In addition, certain types of damages may not be covered by insurance, and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. A decision adverse to our interests on one or more legal matters or litigation could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our reputation, financial condition and results of operations.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our drug candidates. Pending their use to fund our operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly especially since we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, and are no longer able to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are &#8220;emerging growth companies&#8221; and that were applicable to us prior to January&#160;1, 2019. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires us, on an annual basis, to review and evaluate our internal controls. To maintain compliance with Section&#160;404, we are required to document and evaluate our internal control over financial reporting, which has been both costly and challenging. We will need to continue to dedicate internal resources, continue to engage outside consultants and follow a detailed work plan to continue to assess and document the adequacy of internal control over financial reporting, continue to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. A portion of the outstanding shares of our common stock are eligible for sale in the public market under Rule 144 of the Securities Act of 1933, as amended, or the Securities Act, subject to the volume limitations and other conditions of Rule 144. The holders of these shares may at any time decide to sell their shares in the public market. We have also registered all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, to the extent applicable. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the provisions of the Internal Revenue Code of 1986, as amended, or the Code, our net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (and </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">state tax authorities under relevant state tax rules). In addition, as a result of the Tax Act, for U.S. federal income tax purposes, the use of net operating loss carryforwards arising in taxable years beginning after December&#160;31, 2017 is limited to 80% of our taxable income in any future taxable year, although such losses may be carried forward indefinitely. It is uncertain how various states will respond to the Tax Act. Furthermore, the use of net operating loss and tax credit carryforwards may become subject to an annual limitation under Sections 382 and 383 of the Code, respectively, and similar state provisions in the event of certain cumulative changes in the ownership interest of significant shareholders in excess of 50&#160;percent over a three-year period. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of a company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Our company has completed several financings since its inception which resulted in an ownership change under Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, some of which are outside of our control, could result in ownership changes in the future. For these reasons, we may not be able to use some or all of our net operating loss and tax credit carryforwards, even if we attain profitability. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The comprehensive tax reform bill could adversely affect our business and financial condition. </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Tax Act significantly revises the Internal Revenue Code of 1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 34% to a flat rate of 21%, limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely), one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain how various states will respond to the Tax Act. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;1B. </div></td>
<td id="tx853399_4" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Unresolved Staff Comments</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;2. </div></td>
<td id="tx853399_5" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Properties</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our headquarters are located in Newton, Massachusetts, where we lease 98,502 square feet of office and laboratory space. We also lease approximately 3,681 square feet of office space in Munich, Germany and 4,736 square feet of office space in Tel Aviv-Yafo, Israel. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;3. </div></td>
<td id="tx853399_6" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Legal Proceedings</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have been named as a defendant in securities class action litigation in the U.S. District Court for the District of Massachusetts. A complaint was filed on July&#160;23, 2019, by the Allegheny County Employees&#8217; Retirement System, against us and certain of our current and former executive officers and directors as well as the underwriters of our public offerings of common stock conducted in April 2017 and May 2018. A second complaint was filed by Heather Mehdi on September&#160;17, 2019, against the same defendants with the exception of the underwriters. The two complaints are related and we expect them to be consolidated by the court. Both complaints allege violations of federal securities laws based on our disclosures related to the results from the Phase 2 SOPRA study and Part 2 of the Phase 2b STORM study, and seek unspecified compensatory damages, including interest; reasonable costs and expenses, including attorneys&#8217; and expert fees; unspecified recessionary damages; and such equitable/injunctive relief or other relief as the court may deem just and proper. We have </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed the allegations and believe they are without merit. We intend to defend vigorously against this litigation. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;4. </div></td>
<td id="tx853399_7" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Mine Safety Disclosures</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;5. </div></td>
<td id="tx853399_9" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Information </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock, $0.0001 par value per share, began trading on the Nasdaq Global Select Market on November&#160;6, 2013, where its prices are quoted under the symbol &#8220;KPTI.&#8221; </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of February&#160;14, 2020, there were 6 holders of record of our common stock. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have never paid cash dividends on our common stock, and we do not expect to pay any cash dividends in the foreseeable future.&#160;</div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Sales of Unregistered Securities </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;6. </div></td>
<td id="tx853399_10" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Selected Financial Data</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable.&#160;</div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;7. </div></td>
<td id="tx853399_11" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. Some of the information contained in this discussion and analysis and set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in Part&#160;I&#8212;Item&#160;1A of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Overview </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We are an innovation-driven pharmaceutical company focused on the discovery, development and commercialization of novel, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div>elective <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">I</div>nhibitor of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">N</div>uclear <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">E</div>xport</div></div> (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SINE</div></div>) compounds that inhibit the nuclear export protein exportin 1, or XPO1. These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of high unmet medical need diseases. Our SINE compounds were the first oral XPO1 inhibitors in clinical development. Our lead asset, XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (selinexor) tablets, was the first SINE compound to receive marketing approval by the U.S. Food and Drug Administration, or FDA, on July&#160;3, 2019 and is currently indicated for use in adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, or PIs, at least two immunomodulatory agents, or IMiDs, and an anti-CD38 monoclonal antibody. We refer to myeloma that is refractory to these five agents as penta-refractory myeloma. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The ongoing, randomized Phase 3 BOSTON (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Bo</div></div></div>rtezomib, <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor and Dexame<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">t</div></div></div>has<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">on</div></div></div>e) study evaluating selinexor in combination with Velcade<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;</div> (bortezomib) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> dexamethasone in patients with myeloma treatment with between one and three prior therapies is expected to serve as the confirmatory trial.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our focus is on marketing XPOVIO in its currently approved indication as well as seeking the regulatory approval and potential commercialization of selinexor as an oral agent in additional cancer indications with significant unmet medical need. We plan to conduct additional clinical trials and seek additional approvals for the use of selinexor in combination with other oncology therapies to expand the patient populations that are eligible for selinexor. Thus, we are currently advancing the clinical development of selinexor in multiple hematological malignancies and solid tumor indications. Studies that support submitted applications for regulatory approval include STORM (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div></div>reatment of <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">R</div></div></div>efractory <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">M</div></div></div>yeloma) and SADAL (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>gainst <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">D</div></div></div>iffuse <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>ggressive <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">L</div></div></div>ymphoma). Ongoing clinical trials evaluating selinexor include the pivotal, randomized Phase 3 BOSTON study in multiple myeloma, the Phase 1b/2 STOMP (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor and Backbone <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">T</div></div></div>reatments <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">o</div></div></div>f <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">M</div></div></div>ultiple Myeloma <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">P</div></div></div>atients) study in combination with standard therapies in multiple myeloma, the Phase 2/3 SEAL (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Se</div></div></div>linexor in <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">A</div></div></div>dvanced <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">L</div></div></div>iposarcoma) study in liposarcoma, and the Phase 3 SIENDO (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">S</div></div></div>elinexor/Placebo After Combination Chemotherapy <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">I</div></div></div>n Patients with Advanced or Recurrent <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ENDO</div></div></div>metrial Cancer) study evaluating selinexor as maintenance therapy in endometrial cancer. During 2019, final data from the Phase 2b STORM study were published in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New England Journal of Medicine</div></div> (Chari, A. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">et al</div></div>. August 2019). In addition, we reported updated, positive data from the SADAL study as well as updated interim data for the STOMP study at various medical conferences. As a result of the positive results from STORM, in addition to the FDA approval of our first New Drug Application, or NDA, we also filed a Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA, in January 2019 and expect to receive a decision on our application in the middle of 2020.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Based on the positive results of the SADAL study, we submitted a Supplemental New Drug Application, or sNDA, to the FDA in December 2019, with a request for accelerated approval for selinexor as a new treatment for adult patients with relapsed and/or refractory diffuse large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma, or DLBCL, not otherwise specified, who have received at least two prior therapies. The FDA filed the application on February&#160;18, 2020 and granted Priority Review with a target decision date of June&#160;23, 2020 under the Prescription Drug User Fee Act, or PDUFA. Selinexor has received both Orphan Drug and Fast Track designations from the FDA for this same indication. Provided&#160;that marketing approval is granted by the FDA, we expect to be prepared to commercialize selinexor in the&#160;United States&#160;as a treatment for patients with relapsed and/or refractory DLBCL as early as the middle of 2020.&#160;We also plan to submit a MAA to the EMA in 2020 with a request for conditional approval.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition to selinexor, we are also advancing a pipeline of novel drug candidates including our other oral SINE compounds eltanexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-8602)</div> and verdinexor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(KPT-335),</div> as well as our oral dual PAK4/NAMPT inhibitor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274.</div> We began clinical testing of eltanexor, a second-generation SINE compound, in late 2015. Our clinical development program for eltanexor includes myelodysplastic syndrome, or MDS, colorectal cancer, or CRC, and metastatic castration-resistant prostate cancer, or CRPC. Based on clinical results to date and resource prioritization, we plan to focus on the development of eltanexor in MDS in 2020. We began clinical testing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in patients with hematologic or solid tumors during 2016 and we plan to study its combination with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-PD1</div> monoclonal antibody in a phase 1 clinical study in the near future. Finally, verdinexor is our lead compound that is being evaluated as a potential therapy for viral, rare disease and autoimmune indications in humans and by a collaborator as a potential therapy for cancers in companion animals.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As of December&#160;31, 2019, we had an accumulated deficit of $873.3&#160;million. We had net losses of $199.6&#160;million, $178.4&#160;million and $129.0&#160;million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. Net product sales for XPOVIO, which was approved by the FDA in July 2019, were $30.5&#160;million through December&#160;31, 2019. As we only recently launched XPOVIO, we have had limited revenues to date from product sales and have financed our operations to date principally through private placements of our preferred stock (prior to our initial public offering), proceeds from our initial public offering and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offerings of common stock, issuance of convertible debt, proceeds from a Revenue Interest Financing Agreement (deferred royalty obligation) and cash generated from our business development activities.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our expenses will continue to increase substantially as compared to prior periods as we continue to commercialize XPOVIO in the United States and engage in activities to prepare for the potential commercialization of additional indications for selinexor and the potential approval of our other drug candidates, including due to the impact of increased headcount, to support our clinical and commercialization activities, expanded infrastructure and increased insurance premiums. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our expenses will increase substantially if and as we: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">continue to commercialize XPOVIO in the United States and seek regulatory approval for XPOVIO outside of the United States;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">continue to grow our sales, marketing and distribution infrastructure during the commercialization of XPOVIO and any drug candidates for which we may obtain marketing approval, prior to or upon receiving marketing approval in the United States or outside the United States;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">continue our research and preclinical and clinical development of our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">initiate additional clinical trials for our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">seek marketing approvals for any of our drug candidates that successfully complete clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">maintain, expand and protect our intellectual property portfolio;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">manufacture our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">hire additional clinical, quality control, scientific, commercial and management personnel;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identify additional drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> other drugs and technologies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">add operational, financial and management information systems and personnel, including personnel to support our drug development, any commercialization efforts and our other operations as a public company; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">increase our product liability insurance coverage as we initiate and expand our commercialization efforts.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Overview </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We began generating product revenue from the sale of XPOVIO in the United States during the third quarter of 2019. Our ability to continue to generate product revenues will depend on our successful commercialization of XPOVIO and our obtaining additional marketing approvals for, and successfully commercializing, selinexor for additional indications. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the third quarter of 2019, our revenue was primarily from license arrangements as well as foundation and government grants and contracts. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Sales </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales includes the cost of producing and distributing inventories that are related to&#160;XPOVIO&#160;product revenue in the United States (including salary-related and stock-based compensation expenses for employees involved with&#160;XPOVIO&#160;production and distribution) and third-party royalties payable on our net product revenue for&#160;XPOVIO.&#160;We began capitalizing XPOVIO inventory costs during the third quarter of 2019 subsequent to FDA approval, as our expectation is that such costs will be recoverable through commercialization of XPOVIO. Prior to the capitalization of XPOVIO inventory costs, such costs were recorded as research and development expenses in the period incurred. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our drug candidates, which include: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">expenses incurred under agreements with third parties, including contract research organizations, contract manufacturing organizations and consultants that help conduct clinical trials and preclinical studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the cost of acquiring, developing and manufacturing clinical trial materials, including comparator drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other operating costs; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">costs associated with preclinical activities and regulatory operations.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected as prepaid expenses or accrued research and development expenses. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our research and development has been focused primarily on using our drug discovery and optimization platform to identify drug candidates, we have not historically tracked research and development costs by project. In addition, we use our employee and infrastructure resources across multiple research and development projects. The majority of our research and development expenses to date have been related to selinexor. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The successful development of our drug candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of these drug candidates. We are also unable to predict when, if ever, material net cash inflows will commence from any drug candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establishing an appropriate safety profile with Investigational New Drug-enabling toxicology studies, and ongoing clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">successful enrollment in, and completion of, clinical trials;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">receipt of marketing approvals from applicable regulatory authorities;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">establishing commercial sales and marketing capabilities and launching commercial sales of the drugs, if and when approved, whether alone or in collaboration with others; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">maintaining a continued acceptable safety profile of the drugs following approval.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change the costs and timing associated with the development of that drug candidate. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development activities are central to our business model. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as our drug candidates progress in clinical trials. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our drug candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, General and Administrative Expenses </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expenses consist primarily of salaries, benefits, travel, and other related costs, including stock-based compensation, for personnel in executive, finance, commercial and administrative functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our selling, general and administrative expenses will increase in the future to support continued research and development activities and our commercial operations, especially as it relates to the sales and marketing of XPOVIO. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Expense </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Interest expense consists of interest expense related to the aggregate $172.5&#160;million principal amount of 3.0% Convertible Senior Notes due 2025 that we issued in a private offering to qualified institutional buyers in October 2018 (the Notes) as well as interest expense related to the aggregate $75.0&#160;million principal amount of the deferred royalty obligation entered into in September 2019 with HealthCare Royalty Partners. A portion of the interest expense on both the Notes and the deferred royalty obligation is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> expense relating to the accretion of the value of the debt discount and amortization of issuance costs.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income (Expense) </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income consists primarily of interest income earned on our cash and cash equivalents and investments. Other expense consists primarily of foreign currency transaction losses associated with our German and Israeli subsidiaries whose functional currency is the Euro and Israeli Shekel, respectively. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Estimates </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with United States generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our financial condition and results of operations.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We adopted Accounting Standards Update&#160;(ASU)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2014-09,</div>&#160;Revenue from Contracts with Customers, as well as subsequent amendments, which were codified in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, on January&#160;1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder&#8217;s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following are the components of variable&#160;consideration related to product revenue: </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash discounts and distributor fees</div></div>: We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns: </div></div>Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product&#8217;s expiration date and ending twelve months after the product&#8217;s expiration date).&#160;We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&#160;Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chargebacks: </div></div>Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us.&#160;Our customers charge us for the discount provided to the healthcare entities.&#160;Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government rebates</div></div>: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (VA), the Department of Defense (DOD), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other incentives:</div></div>&#160;Other incentives offered by us include<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;co-payment</div>&#160;assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;co-payments</div> by the patient. We calculate the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on estimates of claims and the average<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;co-payment</div> assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue reserves and allowances:</div></div>&#160;As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable, and distributor fees, government rebates, and other incentives are recorded as a component of accrued expenses. As of December&#160;31, 2019, we have determined a material reversal of revenue would not occur in a future period&#160;for the estimates detailed above,</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and, therefore, the transaction price was not reduced further during the year ended December&#160;31, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and Asset Purchase Agreements </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We generate revenue from license, asset purchase or similar agreements with pharmaceutical companies for the development and commercialization of certain of our product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by such pharmaceutical companies may include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize the transaction price allocated to the license as revenue upon transfer of control of the license. We evaluate all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We utilize judgment to determine the transaction price. In connection therewith, we evaluate contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate </div> the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We then determine whether the performance obligations or combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. We evaluate the measure of progress, as applicable, for each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded within deferred revenue. Contract liabilities within deferred revenue are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Research and Development Expenses </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include fees paid to contract research organizations (CROs), and contract manufacturing organizations (CMOs), in connection with research and development activities for which we have not yet been invoiced. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We base our expenses related to CROs and CMOs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs and CMOs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepayment accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. Our estimates have not been materially different than amounts actually incurred to date. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our results of operations for the years ended December&#160;31, 2019 and 2018: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 60%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product revenue, net </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30,540 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">License and other revenue </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10,353 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30,336 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,605 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,407 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122,340 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161,372 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107,273 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105,421 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48,847 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24,870 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(189,275</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(179,883</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(130,538</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (expense) income, net </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(10,275</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,502 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,617 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(199,550</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(178,381</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(128,921</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(40</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(26</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(63</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(199,590</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(178,407</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(128,984</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of Years Ended December&#160;31, 2019 and 2018 </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Revenue, net.</div></div> We began to record product revenue, net in the third quarter of 2019 following the approval of XPOVIO by the FDA in July 2019 and its subsequent commercial launch in the United States. Product revenue, net for the year ended December&#160;31, 2019 was $30.5&#160;million.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License and Other Revenue.</div></div> License and other revenue for the year ended December&#160;31, 2019 was $10.4&#160;million compared to $30.3&#160;million for the year ended December&#160;31, 2018. We recognized $9.4&#160;million in revenue pursuant to a license arrangement with Antengene Therapeutics Limited, $0.3&#160;million in revenue for clinical supply provided to various partners, as well as $0.7&#160;million in revenue pursuant to a government grant arrangement during the year ended December&#160;31, 2019. In comparison, we recognized revenue pursuant to an Asset Purchase Agreement (APA) with Biogen MA Inc. (Biogen) for $10.0&#160;million and a license arrangement with Ono Pharmaceutical Co., Ltd. (Ono) for $19.7&#160;million, and $0.6&#160;million pursuant to a government grant arrangement during the year ended December&#160;31, 2018.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of Sales.</div></div>&#160;Cost of sales includes the cost of producing and distributing inventories that are related to&#160;XPOVIO&#160;product revenue in the United States during the respective period (including salary-related and stock-based compensation expenses for employees involved with&#160;XPOVIO&#160;production and distribution) and third-party royalties payable on our net product revenue for&#160;XPOVIO.&#160;We began capitalizing XPOVIO inventory costs during the third quarter of 2019 subsequent to FDA approval as it is our expectation that such costs will be recoverable through commercialization of XPOVIO. Prior to the capitalization of XPOVIO inventory costs, such costs were recorded as research and development expenses in the period incurred. During the year ended December&#160;31, 2019, we recorded $2.4&#160;million of cost of sales, including $1.6&#160;million related to royalties. The cost of sales during the year ended December&#160;31, 2019 only reflects a portion of the costs related to the manufacturing of XPOVIO and related materials, since, prior to FDA approval, these costs were expensed.&#160;The manufacturing costs of XPOVIO<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;on-hand</div>&#160;upon approval were approximately $2.8&#160;million. At December&#160;31, 2019, we have $2.7&#160;million of this previously expensed XPOVIO and related material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense.</div></div> Research and development expense decreased by approximately $39.1&#160;million to $122.3&#160;million for the year ended December&#160;31, 2019 from $161.4&#160;million for the year ended December&#160;31, 2018. The decrease was primarily related to:</div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a decrease of $17.5&#160;million in clinical trial costs, primarily related to the selinexor program;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a decrease of $11.7&#160;million in consulting and professional costs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a decrease of $9.6&#160;million in personnel costs; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a decrease of $0.9&#160;million in travel costs; offset by</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an increase of $0.6&#160;million in facility costs and information technology infrastructure costs.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect our research and development expenses to increase in 2020 as compared with 2019 as we continue clinical development of selinexor in our lead indications with a focus on regulatory submissions for selinexor. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition, based on the positive results of the SADAL study, we submitted an NDA to the FDA with a request for accelerated approval for selinexor as a new treatment for adult patients with relapsed or refractory diffuse large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma, or DLBCL, not otherwise specified, who have received at least two prior therapies. The FDA accepted the application for filing on February&#160;18, 2020 and granted Priority Review with a target decision date of June&#160;23, 2020 under the Prescription Drug User Fee Act, or PDUFA.&#160;We also plan to submit a MAA to the EMA in 2020 with a request for conditional approval.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selling, General and Administrative Expense.</div></div> Selling, general and administrative expense increased by approximately $56.6&#160;million to $105.4&#160;million for the year ended December&#160;31, 2019 from $48.8&#160;million for the year ended December&#160;31, 2018. The increase was primarily related to:</div> </div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an increase of $35.9&#160;million in personnel costs, primarily due to increased headcount and related onboarding costs associated with building our commercial team in preparation for and in connection with the U.S. commercial launch of XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an increase of $9.4&#160;million in commercial related activities;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an increase of $7.3&#160;million in costs related to corporate training, travel and corporate events; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an increase of $4.3&#160;million in facility costs and information technology infrastructure costs.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect our selling, general and administrative expenses to increase in 2020 to support of our expanding operating and commercial activities related to sales and marketing of XPOVIO and any of our drug candidates for which we obtain marketing approval. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income (Expense), Net</div></div>. Other income (expense), net decreased by approximately $11.8&#160;million to $10.3&#160;million in net expense for the year ended December&#160;31, 2019 from $1.5&#160;million in other income for the year ended December&#160;31, 2018. The net decrease is primarily due to a $13.2&#160;million increase of interest expense related to the Notes and the deferred royalty obligation offset by a $1.4&#160;million increase in interest income due to increased returns resulting from a general increase in interest rates and higher investment balances in 2019. We expect interest expense to increase in 2020 and beyond, related to the imputed interest on the deferred royalty obligation.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of Years Ended December&#160;31, 2018 and 2017 </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Discussion and analysis of the year ended December&#160;31, 2018 compared to the year ended December&#160;31, 2017 is included under the heading &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2018 as filed with the SEC on February&#160;28, 2019 (2018 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K). </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">During the third quarter of 2019, we began generating revenues from drug sales, as XPOVIO first became commercially available in the United States in July 2019. We have had limited revenues to date from product sales and have financed our operations principally through private placements of our preferred stock, proceeds from our initial public offering and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offerings of common stock, proceeds from the issuance of convertible debt, proceeds pursuant to the deferred royalty obligation, and cash generated from our business development activities.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As of December&#160;31, 2019, our principal source of liquidity was $264.0&#160;million of cash, cash equivalents and investments. We have had recurring losses and incurred a loss of $199.6&#160;million for the year ended December&#160;31, 2019. Net cash used in operations for the year ended December&#160;31, 2019 was $190.8&#160;million. We expect that cash, cash equivalents and investments at December&#160;31, 2019 will be sufficient to fund our current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of the financial statements contained in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On September&#160;14, 2019, we entered into a Revenue Interest Financing Agreement (deferred royalty obligation) with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P. (HCR). Pursuant to the Revenue Interest Agreement, HCR paid us $75.0&#160;million (First Investment Amount), less certain transaction expenses, at the initial closing, which occurred on September&#160;27, 2019, as disclosed in Note 15 to the Consolidated Financial Statements included under Part II, Item 8 of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;16, 2018, we completed an offering of $150.0&#160;million aggregate principal amount of the Notes. In addition, on October&#160;26, 2018, we issued an additional $22.5&#160;million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule&#160;144A under the Securities Act of 1933, as amended. The net proceeds from the sale of the Notes was $166.9&#160;million, after deducting the initial purchasers&#8217; discounts and commissions and actual offering expenses payable by us. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, we entered into an open market sale agreement (Open Market Sale Agreement) with Jefferies LLC, as agent, relating to an &#8220;at the market offering,&#8221; pursuant to which we may issue and sell shares of our common stock, having an aggregate offering price of up to $75.0&#160;million (Open Market Shares). As of February&#160;20, 2020, we had sold an aggregate of 3,712,359 shares under the Open Market Sale Agreement, for net proceeds of approximately $46.2&#160;million, all of which were sold during the year ended December&#160;31, 2019. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On May&#160;7, 2018, we completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offering under our shelf registration statement on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;S-3 </div> (File No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-222726)</div> pursuant to which we issued an aggregate of 10,525,424&#160;shares of common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $14.75 per share. We received aggregate net proceeds of approximately $145.7&#160;million from the offering after deducting the underwriting discounts and commissions and other offering expenses.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended December&#160;31, 2018 and 2017 combined, we received $44.6&#160;million in upfront payments under our arrangements with Anivive Lifesciences, Inc., Ono Pharmaceutical Co., Ltd., Biogen MA Inc., and Antengene Therapeutics Limited pursuant to which we are also entitled to receive milestone payments, if certain development goals and sales milestones are achieved, as well as royalties on future net sales of the licensed and sold products in the territories under such arrangements. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information regarding our cash flows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 62%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(190,822</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(159,117</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(73,717</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78,450 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(107,664</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17,108 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124,305 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">316,109 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75,743 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(78</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">211 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash, cash equivalents and restricted cash </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,952 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49,250 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19,345 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Cash Used in Operating Activities </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Net cash used in operating activities was $190.8&#160;million during the year ended December&#160;31, 2019 compared to $159.1&#160;million during the year ended December&#160;31, 2018. Net cash used in operating activities in both periods resulted primarily from our net losses adjusted for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges and changes in the components of working capital. The increase in cash used in operating activities during the year ended December&#160;31, 2019 compared to the year ended December&#160;31, 2018 was driven primarily by a $21.2&#160;million increase in our net loss due to an increase in our operating expenses and changes in the components of working capital.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Cash Provided by (Used in) Investing Activities </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by investing activities was $78.5&#160;million during the year ended December&#160;31, 2019, and increased by approximately $186.1&#160;million compared to $107.7&#160;million in net cash used in investing activities during the year ended December&#160;31, 2018. The increase was primarily related to an increase of $119.6&#160;million in the proceeds from maturities of investments, as well as&#160;a decrease of $64.3&#160;million in purchases of investments. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Cash Provided by Financing Activities </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities was $124.3&#160;million during the year ended December&#160;31, 2019 compared to $316.1&#160;million during the year ended December&#160;31, 2018. The $191.8&#160;million decrease is primarily </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">related to the net proceeds of $166.9&#160;million from the issuance of the Notes and $145.7&#160;million from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offering in May 2018, in comparison to net proceeds of $73.6&#160;million from the deferred royalty obligation executed with HCR in September 2019 and the net proceeds of $46.2&#160;million from the sale of Open Market Shares under the Open Market Sale Agreement during the year ended December&#160;31, 2019.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">A discussion of changes in our cash flow from the year ended December&#160;31, 2017 to the year ended December&#160;31, 2018 can be found in Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the 2018 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Funding requirements </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to commercialize XPOVIO and continue the clinical trials of, and as we seek marketing approval for, our drug candidates. In addition, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution of any of our drug candidates for which we obtain marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any such drug candidate. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We expect that cash, cash equivalents and short- and long-term investments at December&#160;31, 2019 will be sufficient to fund our current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of the financial statements contained in this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> while we continue to commercialize XPOVIO in the United States and continue the clinical trials of our drug candidates. Our future capital requirements will depend on many factors, including:</div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">revenue generated from commercial sales of XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">costs related to the sales and marketing of XPOVIO;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs, timing and outcome of regulatory review of our drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our drug candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the amount of revenue received from commercial sales of our drug candidates for which we receive marketing approval;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the progress and results of our current and planned clinical trials of selinexor;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our other drug candidates;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our ability to establish and maintain collaborations on favorable terms, if at all;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the success of any collaborations that we may enter into with third parties;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the extent to which we acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> other drugs and technologies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs associated with legal activities, including litigation, arising in the course of business activities and our ability to prevail in any such legal disputes; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;">&#160;</td>
<td style="width: 3%; vertical-align: top;">&#8226;</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifying potential drug candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. In addition, our drug candidates for which we receive marketing approval may not achieve commercial success. Our ability to become and remain profitable depends on our ability to generate revenue. While we began to generate revenue from the sales of XPOVIO in July 2019, there can be no assurance as to the amount or timing of any such revenue, and we may not achieve profitability for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. We may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.&#160;</div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Arrangements </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We did not have, during the periods presented, and we do not currently have, any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements, as defined under applicable Securities and Exchange Commission rules.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inflation </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not believe that inflation has had a significant impact on our revenues or results of operations since inception. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Recent accounting pronouncements which may be applicable to us are described in Note 2 to our Consolidated Financial Statements included under Part II,&#160;Item 8 of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;7A. </div></td>
<td id="tx853399_12" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Quantitative and Qualitative Disclosures about Market Risk</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;8. </div></td>
<td id="tx853399_13" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Financial Statements and Supplementary Data</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Our consolidated financial statements, together with the report of our independent registered public accounting firm, appears on pages&#160;133 through 138 of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div> <div id="tx853399_14" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9A. Controls and Procedures </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms prescribed by the Securities and Exchange Commission and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Senior Vice President, Chief Financial Officer and Treasurer), to allow timely decisions regarding required disclosure. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our management, under the supervision and with the participation of our Chief Executive Officer and Senior Vice President, Chief Financial Officer and Treasurer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Exchange Act) as of the end of the period covered by this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K.</div> Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on such evaluation, our Chief Executive Officer and Senior Vice President, Chief Financial Officer and Treasurer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2019.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> of the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control &#8211;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under that framework, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2019. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our independent registered public accounting firm that audited the financial statements included in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> has issued an attestation report on our internal control over financial reporting, which is included below.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control over Financial Reporting </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;13a-15(d)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(d)</div> of the Exchange Act that occurred during the quarter ended December&#160;31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and the Board of Directors of Karyopharm Therapeutics Inc. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on Internal Control over Financial Reporting </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We have audited Karyopharm Therapeutics Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2019, based on criteria established in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> (</div></div>2013 framework)<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> (</div></div>the COSO criteria). In our opinion, Karyopharm Therapeutics Inc. (the &#8220;Company&#8221;) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2019, based on the COSO criteria.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 consolidated financial statements of the Company and our report dated February&#160;26, 2020 expressed an unqualified opinion thereon. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definition and Limitations of Internal Control Over Financial Reporting </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Boston, Massachusetts </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_15" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;9B. Other Information </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Certain information required by Part&#160;III is omitted from this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> and is incorporated by reference from our definitive proxy statement relating to our 2020 annual meeting of stockholders, pursuant to Regulation&#160;14A of the Exchange Act, which we refer to as our 2020 Proxy Statement. We expect to file our 2020 Proxy Statement with the SEC within 120 days of December&#160;31, 2019.</div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;10. </div></td>
<td id="tx853399_17" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Directors, Executive Officers and Corporate Governance</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding our directors, including the audit committee and audit committee financial experts, and executive officers and compliance with Section&#160;16(a) of the Exchange Act, if applicable, will be included in our 2020 Proxy Statement and is incorporated herein by reference. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have adopted a Code of Business Conduct and Ethics for all of our directors, officers and employees as required by Nasdaq governance rules and as defined by applicable SEC rules. Stockholders may locate a copy of our Code of Business Conduct and Ethics on our website at www.karyopharm.com or request a copy without charge from: </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Investor Relations </div></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 Wells Avenue, 2<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">nd</div> Floor </div></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Newton, MA 02459 </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will post to our website any amendments to the Code of Business Conduct and Ethics and any waivers that are required to be disclosed by the rules of either the SEC or Nasdaq. </div></div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;11. </div></td>
<td id="tx853399_18" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Executive Compensation</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The information required by this Item&#160;11 of Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> regarding executive compensation will be included in our 2020 Proxy Statement and is incorporated herein by reference.</div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;12. </div></td>
<td id="tx853399_19" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The information required by this Item&#160;12 of Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> regarding security ownership of certain beneficial owners and management will be included in our 2020 Proxy Statement and is incorporated herein by reference.</div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;13. </div></td>
<td id="tx853399_20" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Certain Relationships and Related Transactions, and Director Independence</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The information required by this Item&#160;13 of Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> regarding certain relationships and related transactions and director independence will be included in our 2020 Proxy Statement and is incorporated herein by reference.</div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;14. </div></td>
<td id="tx853399_21" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Principal Accountant Fees and Services</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The information required by this Item&#160;14 of Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K</div> regarding principal accountant fees and services will be included in our 2020 Proxy Statement and is incorporated herein by reference.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART IV </div></div></div> <div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;15. </div></td>
<td id="tx853399_23" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Exhibits and Financial Statement Schedules</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)(1) Financial Statements </div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The financial statements listed below are filed as a part of this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K. </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Page<br/> number </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_1">Report of Independent Registered Public Accounting Firm</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_2">Consolidated Balance Sheets as of December&#160;31, 2019 and 2018</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_3">Consolidated Statements of Operations for the years ended December&#160;31, 2019, 2018 and 2017</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_4">Consolidated Statements of Comprehensive Loss for the years ended December&#160;31, 2019, 2018 and 2017</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_5">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2019, 2018 and 2017</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_6">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2019, 2018 and 2017</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin853399_7">Notes to Consolidated Financial Statements</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)(2) Financial Statement Schedules </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All financial schedules have been omitted because the required information is either presented in the consolidated financial statements or the notes thereto or is not applicable or required. </div></div> </div> </div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)(3) Exhibits </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The exhibits required by Item&#160;601 of Regulation<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;S-K</div> and Item&#160;15(b) of this Annual Report on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;10-K </div> are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and are incorporated herein.</div> <div style="margin-top: 18pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Item&#160;16. </div></td>
<td id="tx853399_24" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> Summary</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Board of Directors of Karyopharm Therapeutics Inc. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Karyopharm Therapeutics Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December&#160;31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2019, in conformity with U.S. generally accepted accounting principles. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>framework<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div>and our report dated February&#160;26, 2020 expressed an unqualified opinion thereon.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">Adoption of ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02 </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting Standards Update (ASU) No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>, and related amendments.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2014. </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Boston, Massachusetts </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_102" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div></div></div> </div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%; padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,<br/> 2019 </div></div></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: middle;;width:;"><div style="text-align: left;;font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,<br/> 2018 </div></div></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASSETS </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: middle;"><div style="text-align: left;;font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Current assets: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,858</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">118,021</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">133,098</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">210,178</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,862</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,289</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,413</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total current assets </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">278,570</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">334,612</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,046</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,863</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,617</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term investments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,016</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,001</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">714</ix:nonFraction></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">716</ix:nonFraction></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total assets </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294,963</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">341,192</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: middle;"><div style="text-align: left;;font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">985</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,332</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,878</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,493</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,341</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,362</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,646</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRentCreditCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">390</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">327</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,350</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,904</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior notes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,857</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,664</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty obligation </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredRoyaltyObligationNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73,588</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, net of current portion </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,202</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue, net of current portion </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,192</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,532</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent, net of current portion </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,922</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">245,189</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158,022</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; padding: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; equity: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></div> par value; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></div> shares authorized;<div style="letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div> issued and outstanding </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></div> par value; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></div> shares authorized; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">65,370,448</ix:nonFraction></ix:nonFraction></div> and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">60,829,308</ix:nonFraction></ix:nonFraction></div> shares issued and outstanding at December&#160;31, 2019 and 2018, respectively </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">923,142</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">857,156</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">244</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">873,338</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">673,748</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,774</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">183,170</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 78%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; equity </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294,963</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">341,192</ix:nonFraction> </div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;; vertical-align: middle;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_103" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div> </div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 1.5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenues: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Product revenue, net </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,540</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px 0px 0.375pt; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">License and other revenue </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_LicenseAndOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,353</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_LicenseAndOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,336</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2017To12_31_2017_LicenseAndOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,605</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px 0px 0.375pt; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total revenues </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,893</ix:nonFraction></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,336</ix:nonFraction></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; border-bottom: 0.75pt solid black;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,605</ix:nonFraction></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,407</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">122,340</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">161,372</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,273</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">105,421</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,847</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,870</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">230,168</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">210,219</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132,143</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">189,275</ix:nonFraction></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">179,883</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130,538</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other income (expense): </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Interest income </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,422</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,028</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,698</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,647</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,493</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Total other (expense) income, net </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,275</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,502</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,617</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,550</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,381</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,921</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,590</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,407</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,984</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share&#8212;basic and diluted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.22</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.14</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.81</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 64%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average number of common shares outstanding used in net loss per share&#8212;basic and diluted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">61,955,420</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">56,799,699</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">45,899,784</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1.5%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_104" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Comprehensive Loss </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> </div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 100%;font-size: 10pt;border-collapse: separate;border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 70%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px; width: 1%;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 70%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,590</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1%;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,407</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,984</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 70%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss): </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 70%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on investments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">97</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 70%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 16px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: right; width: 1%;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 70%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,383</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 1%;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,434</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,927</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_105" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div></div> </div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px; width: 0.2%;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px; width: 0.5%;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div><br/> Capital </div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Loss </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated<br/> Deficit </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2016 </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,887,829</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">528,617</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">274</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.2%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">366,104</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.5%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2016" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">162,243</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cumulative effect adjustment for adoption of new accounting guidance </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">253</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">253</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.5%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Vesting of restricted stock </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">182,496</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options and shares issued under the employee stock purchase plan </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">154,623</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">858</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">858</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,405</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,405</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock, net of issuance costs of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:StockIssuanceCosts" contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></div></div><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,308,202</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,884</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,885</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on investments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2017To12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">97</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.2%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">97</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2017To12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,984</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.5%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,984</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 5%;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2017 </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">49,533,150</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">625,017</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">217</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.2%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">495,341</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.5%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">129,464</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Vesting of restricted stock </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">113,800</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options and shares issued under the employee stock purchase plan </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">656,934</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,519</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,519</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,275</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,275</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock, net of issuance costs of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:StockIssuanceCosts" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:numdotdecimal">0.2</ix:nonFraction></div></div><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,525,424</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,704</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,705</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity component of 2025 Notes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,850</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,850</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity component of deferred financing costs for 2025 notes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="kpti:EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,209</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="kpti:EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,209</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on investments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.2%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,407</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.5%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,407</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 5%;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018 </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">60,829,308</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">857,156</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">244</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.2%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">673,748</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; width: 0.5%;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">183,170</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Vesting of restricted stock </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">17,500 </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; white-space: nowrap;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; text-align: right; white-space: nowrap;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; white-space: nowrap;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; text-align: right; white-space: nowrap;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; white-space: nowrap;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; white-space: nowrap; width: 5%;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; text-align: right; white-space: nowrap;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; white-space: nowrap;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; text-align: right; white-space: nowrap;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; white-space: nowrap;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt 4pt 0pt 0pt; height: 10px; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; text-align: right; white-space: nowrap;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; white-space: nowrap;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options and shares issued under the employee stock purchase plan </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">811,281</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,505</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,505</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,291</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,291</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock, net of issuance costs of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:StockIssuanceCosts" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></div></div><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,712,359</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; white-space: nowrap; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,190</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,191</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on investments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; white-space: nowrap; width: 5%; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding: 0pt 4pt 0pt 0pt; white-space: nowrap; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,590</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%; white-space: nowrap;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; white-space: nowrap;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,590</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 4pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 4pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 4pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 4pt 0pt 0pt; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 0.2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 4pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 4pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019 </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">65,370,448</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">923,142</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt; height: 10px; width: 5%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.2%;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">873,338</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 0.5%;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt; height: 10px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,774</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 0.2%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_106" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div></div> </div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%; padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 2%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-size: 9pt; padding: 0pt; line-height: 9pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">For the Year Ended December&#160;31, </div></div></div></div></div> </td>
<td style="padding: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 9pt; line-height: 9pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div></div> </td>
<td style="padding: 0pt 0pt 0.5pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 9pt; line-height: 9pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div></div> </td>
<td style="padding: 0pt 0pt 0.5pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 9pt; line-height: 9pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div></div> </td>
<td style="padding: 0pt 0pt 0.5pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating activities </div></div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,590</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,407</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,984</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities: </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">974</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">735</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">713</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net amortization of premiums and discounts on investments </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,382</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,187</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,291</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,275</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,405</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of the value of debt discount and issuance costs </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,193</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,420</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in operating assets and liabilities: </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,862</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">868</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,663</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">342</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets</div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,094</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,301</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,380</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">909</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other liabilities </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,512</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,255</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,070</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,175</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,362</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,027</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,921</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidRent" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,646</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidRent" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">280</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">190,822</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">159,117</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">73,717</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investing activities </div></div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">206</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,363</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from maturities of investments </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">257,145</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">137,510</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">115,544</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178,489</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">242,811</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">98,374</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,450</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">107,664</ix:nonFraction></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,108</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financing activities </div></div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of convertible senior notes, net of issuance costs </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,885</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of common stock, net of issuance costs </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:ProceedsFromPaymentsForCommonStockIssuanceNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,191</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:ProceedsFromPaymentsForCommonStockIssuanceNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,705</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:ProceedsFromPaymentsForCommonStockIssuanceNet" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,885</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from the exercise of stock options and shares issued under employee stock purchase plan </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,505</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,519</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">858</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from deferred royalty obligation, net </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:ProceedsFromDeferredRoyaltyObligation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73,609</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; text-align: right; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">124,305</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">316,109</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75,743</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px 0px 0.375pt; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate on cash, cash equivalents and restricted cash </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt; padding-bottom: 0.375pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt; border-bottom: 0.75pt solid black;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt; border-bottom: 0.75pt solid black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt 0pt 0.375pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt; padding-bottom: 0.375pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; line-height: 9pt; border-bottom: 0.75pt solid black;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt; border-bottom: 0.75pt solid black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; padding: 0pt 0pt 0.375pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt; padding-bottom: 0.375pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt; border-bottom: 0.75pt solid black;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt; border-bottom: 0.75pt solid black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">211</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt 0pt 0.375pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash, cash equivalents and restricted cash </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,952</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,250</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,345</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of period </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">118,737</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,487</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2016" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,142</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash end of period </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">130,689</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">118,737</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,487</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0pt 0pt 1.5px; font-family: &quot;Times New Roman&quot;; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets </div></div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; line-height: 9pt;;font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,858</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">118,021</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68,997</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term restricted cash </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term restricted cash </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">714</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">716</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">290</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total cash, cash equivalents and restricted cash </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">130,689</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">118,737</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,487</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures:</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; background: none;"></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for interest on convertible debt</div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,175</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets obtained in exchange for operating lease liabilities</div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,711</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,889</ix:nonFraction></div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 6%; line-height: 9pt; font-size: 9pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></div> </td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">138</div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div id="tx853399_107" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Karyopharm Therapeutics&#160;Inc. </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div id="fin853399_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> </div> </div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and Operations </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are an innovation-driven pharmaceutical company focused on the discovery, development and commercialization of novel, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Our <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">S</div></div>elective <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">I</div></div>nhibitor of <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">N</div></div>uclear <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">E</div></div>xport</div></div> (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SINE</div></div>) compounds function by binding with and inhibiting the nuclear export protein exportin 1 (XPO1). Our initial focus has been on seeking the regulatory approval and commercialization of our lead SINE compound, selinexor, as an oral agent in cancer indications with significant unmet clinical need. We were incorporated in Delaware on December&#160;22, 2008 and have a principal place of business in Newton, Massachusetts. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2019, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;<div style="font-size: 5.476pt; line-height: 4.05224pt;;display:inline;vertical-align: top;"> </div></div>(selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (&#8220;RRMM&#8221;) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Following accelerated approval by the FDA, XPOVIO became commercially available in the United States in July 2019.&#160;</div></div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019, we had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">873.3</ix:nonFraction>&#160;million. </div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have had limited revenues to date from product sales and have financed our operations principally through private placements of our preferred stock, proceeds from our initial public offering and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on </div> offerings of common stock, proceeds from the issuance of convertible debt, proceeds pursuant to the Revenue Interest Financing Agreement (deferred royalty obligation), and cash generated from our business development activities. We expect to continue to incur significant expenses and operating losses for at least the foreseeable future. We expect that our cash, cash equivalents and investments at December&#160;31, 2019 will be sufficient to fund current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. </div></div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11047426"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Segment Information </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_Segments" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment, which is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. All of our revenue to date has been derived in the United States. All of our material long-lived assets reside in the United States. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10142464"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">139</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelection_11047426" continuedAt="TextSelectionAppend_11047426_1"><ix:continuation id="TextSelection_10142464"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On an ongoing basis, we evaluate our estimates, including estimates related to our net product revenue, clinical trial accruals, stock-based compensation expense, interest expense on our deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div>&#160;other reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Although we regularly assess these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. </div>&#160;</div> </ix:continuation><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Principles of Consolidation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements at December&#160;31, 2019 include the accounts of (i)&#160;Karyopharm Therapeutics Inc., (ii)&#160;Karyopharm Securities Corp. (&#8220;KPSC&#8221;, our wholly-owned Massachusetts corporation incorporated in December&#160;2013), (iii) Karyopharm Europe GmbH (our wholly-owned German Limited Liability Company, incorporated in September 2014), (iv) Karyopharm Therapeutics (Bermuda) Ltd. (our limited liability company, registered in Bermuda in March 2015), and (vi)&#160;Karyopharm Israel Ltd. (our wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div>owned Israeli subsidiary formed in June 2018). All intercompany balances and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist primarily of demand deposit accounts and deposits in short-term money market funds. Cash equivalents are stated at cost, which approximates fair value. We consider all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. We do not hold any money market funds with significant liquidity restrictions that would be required to be excluded from cash equivalents. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We determine the appropriate classification of our investments in debt securities at the time of purchase. All of our securities are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div> investments are recorded at fair value, with unrealized gains or losses included in Accumulated Other Comprehensive Loss, exclusive of other-than-temporary impairment losses, if any. Short-term and long-term investments are composed of corporate debt securities, commercial paper, U.S. government agency securities and certificates of deposit.</div></ix:nonNumeric><ix:nonNumeric name="kpti:ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Risk </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents and investments. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10142521"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses, are presented at amounts that approximate fair value at December&#160;31, 2019 and 2018. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes </div></div></ix:nonNumeric></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">140</div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelection_10142521" continuedAt="TextSelectionAppend_10142521_1"><ix:continuation id="TextSelectionAppend_11047426_1" continuedAt="TextSelectionAppend_11047426_2"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">valuation</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 86%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our cash equivalents are composed of money market funds. We measure these investments at fair value.&#160;The fair value of cash equivalents is determined based on &#8220;Level&#160;1&#8221; inputs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Items classified as Level&#160;2 within the valuation hierarchy consist of commercial paper, corporate debt securities, U.S. government agency securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level&#160;3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations&#8221;, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1)&#160;our estimates of the probability and timing of related events; (2)&#160;the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3)&#160;our risk-adjusted discount rate that includes a company specific risk premium; (4)&#160;our cost of debt; (5)&#160;volatility; and (6)&#160;the probability of a change in control occurring during the term of the instrument.&#160;Our embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations.&#8221; </div></div> </ix:continuation></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">141</div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_10142521_1" continuedAt="TextSelectionAppend_10142521_2"><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><ix:continuation id="TextSelectionAppend_11047426_2" continuedAt="TextSelectionAppend_11047426_3"> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and liability </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%; padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,380</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,380</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,079</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,079</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,022</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,022</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,997</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,997</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,016</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,016</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-right: 5pt;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">206,494</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,380</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">135,114</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;&#8212;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial liability </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivative liability </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,300</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,300</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2018_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,881</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,881</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">143,079</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">143,079</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,978</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,978</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,124</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,124</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificate of deposit </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,997</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,997</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,001</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,001</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">289,060</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,881</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">212,179</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> </ix:continuation></ix:nonNumeric> </ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">142</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11047426_3" continuedAt="TextSelectionAppend_11047426_4"><ix:continuation id="TextSelectionAppend_10142521_2"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded<br/> Derivative<br/> Liability </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2018_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Addition of derivative related to deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 11%;">&#160;</td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2019To12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,300</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative since issuanc<div style="display:inline;">e</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2019To12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,300</ix:nonFraction></div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our <div style="letter-spacing: 0px; top: 0px;;display:inline;">L</div>evel 3 embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations&#8221;. </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, net </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:hidden10173497">three</span> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful economic lives of the related assets. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and any related gains or losses are reflected in the consolidated statements of operations. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell. We have not recorded an impairment in any period since inception. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred Rent </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from landlords related to our operating leases under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 840. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense. Tenant improvement allowances and other incentives were also recorded as deferred rent under ASC 840 through December&#160;31, 2018. Deferred rent and lease incentives are recorded as a reduction to our operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets as of December&#160;31, 2019.</div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11047454"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We adopted Accounting Standards Update (&#8220;ASU&#8221;)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2014-09,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Revenue from Contracts with Customers</div></div>, as well as subsequent amendments, which were codified in ASC 606, on January&#160;1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder&#8217;s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects </div></div></div> </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11047426_4" continuedAt="TextSelectionAppend_11047426_5"><ix:continuation id="TextSelection_11047454"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the consideration which we expect to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div></div>&#160;</div> </div> </ix:continuation><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10142554"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Product Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following are the components of variable&#160;consideration related to product revenue: </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash discounts and distributor fees:</div></div>&#160;We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).</div></ix:nonNumeric></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelection_10142554" continuedAt="TextSelectionAppend_10142554_1"><ix:continuation id="TextSelectionAppend_11047426_5" continuedAt="TextSelectionAppend_11047426_6"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns:</div></div>&#160;Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product&#8217;s expiration date and ending twelve months after the product&#8217;s expiration date).&#160;We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&#160;Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chargebacks:</div></div>&#160;Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us.&#160;Our customers charge us for the discount provided to the healthcare entities.&#160;Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government rebates</div></div>: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (&#8220;VA&#8221;), the Department of Defense (&#8220;DOD&#8221;), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other incentives:</div></div>&#160;Other incentives offered by us include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> by the patient. We calculate the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on estimates of claims and the average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue reserves and allowances: </div></div>As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recorded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of December&#160;31, 2019 and, </div></div> </div> </ix:continuation></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">45</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_10142554_1"><ix:continuation id="TextSelectionAppend_11047426_6" continuedAt="TextSelectionAppend_11047426_7"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">therefore, the transaction price was not reduced further during the year ended December&#160;31, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known. </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-style: normal; margin-top: 18pt; margin-bottom: 0px; font-size: 10pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">License and Asset Purchase Agreements </div></div></div></div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We generate revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain of our product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize the transaction price allocated to the license as revenue upon transfer of control of the license. We evaluate all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We utilize judgment to determine the transaction price. In connection therewith, we evaluate contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate </div> the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We then determine whether the performance obligations or combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. We evaluate the measure of progress, as applicable, for each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded within deferred revenue. Contract liabilities within deferred revenue are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </div></div> </ix:continuation></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">46</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11047426_7" continuedAt="TextSelectionAppend_11047426_8"> <div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customers</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of December&#160;31, 2019, we determined an allowance for doubtful accounts was not required based upon our review of contractual payment terms and individual customer circumstances.</div></div></ix:nonNumeric></div> <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Such costs are generally recorded as costs of sales upon shipment. In connection therewith, we value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales requirements as cost of sales.&#160;The determination of whether inventory costs will be realizable is based on our estimates.&#160;If actual market conditions are less favorable than projected by us, additional write-downs of inventory may be required, which would be recorded as cost of sales. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of Sales </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. </div></div></ix:nonNumeric><ix:nonNumeric name="kpti:DeferredRoyaltyObligationPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10142563"><div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Royalty Obligation </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We treat the liability related to net revenues, as discussed further in Note 15, as a deferred royalty obligation, amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense thereon using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty obligation, and record interest expense using the imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than </div></div></div> </div></ix:nonNumeric></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11047426_8" continuedAt="TextSelectionAppend_11047426_9"><ix:continuation id="TextSelection_10142563"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized. </div></div></div> </ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are charged to expense as incurred and include, but are not limited to: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that help conduct clinical trials and preclinical studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">the cost of acquiring, developing and manufacturing clinical trial materials, including comparator drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">facility, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">costs associated with preclinical activities and regulatory operations.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are accordingly reflected in the financial statements as prepaid or accrued research and development. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources, and currently consists of net loss, unrealized gains and losses on investments and foreign currency translation adjustments.</div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Transactions </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The functional currency of our subsidiaries in Germany and Israel are the Euro and Shekel, respectively. Foreign currency transaction gains and losses are recorded in the consolidated statement of operations. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange losses of less than $<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million were recorded in other income for the years ended December&#160;31, 2019, 2018 and 2017.</div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. We have evaluated available evidence and concluded that we may not realize the benefit of our deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets. We recognize interest and/or penalties related to income tax matters in income tax expense. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost plus profit margin basis. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) resulted in significant changes to the U.S. corporate income tax system.&#160;For additional details regarding this act, see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div>, &#8220;Income Taxes&#8221;. </div></div></ix:nonNumeric></ix:continuation></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> <div></div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11047426_9" continuedAt="TextSelectionAppend_11047426_10"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounting for Stock-Based Compensation </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We account for our stock-based compensation awards in accordance with FASB ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> including grants of employee stock options, restricted stock and restricted stock units, as<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">well</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> as modifications to existing stock options and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;), to be recognized in the consolidated statements of operations based on their fair values. We use the Black-Scholes option pricing model to determine the fair value of options granted. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense related to awards to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. Forfeitures are recognized as they occur. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Share </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Our potential dilutive shares, stock options, unvested restricted stock and restricted stock units are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%; padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></div> </td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,843,094</ix:nonFraction> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,917,084</ix:nonFraction> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2017To12_31_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,019,083</ix:nonFraction> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock units </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">787,320</ix:nonFraction> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2017To12_31_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">253,100</ix:nonFraction> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We have the option to settle the conversion obligation for our 3.00% convertible senior notes due 2025 (the &#8220;Notes&#8221;) in cash, shares or any combination of the two. As the Notes are not convertible as of December&#160;31, 2019, they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on our net loss position, there is no impact on the calculation of dilutive loss per share during the year ended December&#160;31, 2019.</div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10175318"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Standards </div></div></div></div>&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In February 2016, the FASB issued ASU&#160;No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Leases (Topic&#160;842)</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02&#8221;),</div> which supersedes the lease guidance under FASB ASC Topic 840, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>, resulting in the creation of FASB ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;).<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>The FASB also issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> including ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-10, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Codification Improvements to Topic 842, Leases </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-10&#8221;)</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic&#160;842) Targeted</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Improvements </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11&#8221;),</div> which we collectively refer to as the new leasing standard. In summary, the new leasing standard requires that all lessees (i)&#160;recognize, on the balance sheet, liabilities to remit lease payments and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii)&#160;disclose qualitative and quantitative information about its leasing arrangements. We adopted the standard effective January&#160;1, 2019 using the optional transition method under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11</div> and, therefore, prior period financial information has not been retrospectively adjusted.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pursuant to the guidance under ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02,</div> we elected the optional package of practical expedients to leases that commenced prior to the effective date, which allowed us to not reassess: (i)&#160;whether expired or existing contracts contain leases; (ii)&#160;lease classification for any expired or existing leases; and (iii)&#160;initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of</div></ix:nonNumeric></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">49</div></div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelection_10175318" continuedAt="TextSelectionAppend_10175318_1"><ix:continuation id="TextSelectionAppend_11047426_10" continuedAt="TextSelectionAppend_11047426_11"> <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">which we elected, including: (i)&#160;a policy to not record <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and leases on the balance sheet for short-term leases that qualify and (ii)&#160;a policy to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for certain classes of underlying assets on contracts entered into or modified after the effective date. We did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As summarized in the table below, the standard had a material impact on our condensed consolidated balance sheet as of December&#160;31, 2019, specifically through recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn01_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction>&#160;million for our existing operating lease for office space in Newton, MA on the effective date. The difference between the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and operating lease liabilities is due to the change in classification of deferred rent and lease incentives through December&#160;31, 2018 from liabilities to a reduction in our operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets. However, the standard did not have a material impact on our consolidated statement of operations and comprehensive loss for the twelve months ended December&#160;31, 2019, as expense for our existing operating leases continues to be recognized consistent with the recognition pattern before adoption of the new standard. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please refer to Note 9, &#8220;Commitments and Contingencies&#8221; for further information</div></div>.</div> <ix:nonNumeric name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 8%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> Prior to ASC<br/> 842 Adoption </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 842<br/> Adjustment</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> as Adjusted </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated balance sheet data (in thousands): </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div><br/> assets(1) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522752">11,711</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn01_01_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522753">11,711</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRentCreditCurrent" contextRef="PAsOn01_01_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522754">390</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredRentCreditCurrent" contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_10522755">390</ix:nonFraction></div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn01_01_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522756">3,922</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_10522757">3,922</ix:nonFraction></div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities(3) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522758">1,175</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn01_01_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522759">1,175</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease<br/> liabilities(3) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522760">14,848</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn01_01_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_10522761">14,848</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> </div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(1)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents capitalization of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, offset by reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(2)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(3)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents recognition of operating lease liabilities.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We implemented internal controls to enable the preparation of financial information upon adoption. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In June 2018, the FASB issued ASU&#160;No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation-Stock Compensation (Topic&#160;718): Improvements to Nonemployee Share-Based Payment Accounting</div></div> (&#8220;ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07&#8221;).</div> ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07</div> largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic&#160;718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance was adopted on January&#160;1, 2019 and it did not have a material impact on our consolidated financial statements.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In November 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-18, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and Topic 606</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> should be applied retrospectively to the date of initial application of ASC 606. We adopted this guidance effective January&#160;1, 2019 using the modified retrospective approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div>, &#8220;License and Asset Purchase Agreements,&#8221; were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.</div> </ix:continuation></ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div> <div></div> </div> </div> </div> <div style="break-after: page; margin-top: 1em; margin-bottom: 0em;"></div> <div> <div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11047426_11"><ix:continuation id="TextSelectionAppend_10175318_1"><div style="width: 100%; font-size: 10pt;"><div style="text-align: left;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;text-indent: 4%;">In December 2019, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2019-12, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Simplifying the Accounting for Income Taxes</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12&#8221;).</div> The ASU removes the exception to the incremental approach for intraperiod allocation of tax expense when a company has a loss from continuing operations and income from other items that are not included in continuing operations, such as income recorded in Other Comprehensive Income. The general rule under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-20-45-7</div> is that the tax effect of pretax income or loss from continuing operations should be determined by a computation that does not consider the tax effects of items that are not included in continuing<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">operations</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> incremental approach). Previously, companies could consider the impact on a loss from continuing operations of items in discontinued operations or other comprehensive income. However, under the amended guidance, companies should not consider the effect of items outside of continuing operations in calculating the tax effect on continuing operations. The new guidance is effective for public business entities with fiscal years, and the related interim periods, beginning after December&#160;15, 2020. For other entities, the ASU is effective for fiscal years beginning after December&#160;15, 2021, and interim periods within fiscal years beginning after December&#160;15, 2022. The guidance in the ASU may be adopted prior to the effective date. We adopted this guidance effective January&#160;1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-13, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#8217;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019. We do not expect the adoption of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> to have a material impact on our consolidated financial statements. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">In August 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-13, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement&#8212;Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> modify the disclosure requirements on fair value measurements in ASC&#160;820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> to have a material impact on our consolidated financial statements</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In August 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-15, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40)</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15&#8221;).</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> to have a material impact on our consolidated financial statements.</div></ix:continuation></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3. Property and Equipment, net </div></div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; padding: 0px;"></td>
<td style="width: 3%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 3%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 3%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful<br/>Life Years </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2019To12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">4</ix:nonNumeric> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">593</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2018_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">593</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2019To12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">654</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2018_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">607</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Office and computer equipment </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2019To12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">598</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2018_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">559</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2019To12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term</ix:nonNumeric> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,443</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2018_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,397</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,288</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,156</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,242</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,293</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,046</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,863</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense recorded for the years ended December&#160;31, 2019, 2018, and 2017 was $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;$<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction>&#160;million, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11047546"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4. Investments </div></div></div><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10175713"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The following table summarizes our investments in debt securities, classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> as of December&#160;31, 2019 (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; padding: 0px;"></td>
<td style="width: 7%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 7%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 7%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 7%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized&#160;Cost </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Gains </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Loss </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,110</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,079</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,004</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,022</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,990</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,997</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,017</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,016</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">135,121</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">135,114</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> </ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div></div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelection_11047546" continuedAt="TextSelectionAppend_11047546_1"><ix:continuation id="TextSelection_10175713"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table summarizes our investments in debt securities, classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> as of December&#160;31, 2018 (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized&#160;Cost </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Gains </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Loss </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">143,254</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">143,079</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,001</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,978</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,131</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,124</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,997</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,007</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,001</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">212,393</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">227</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">212,179</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> </ix:continuation></ix:continuation><div style="width: 100%; font-size: 10pt;"><div>&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11047546_1"><div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2019 and December&#160;31, 2018, we held <ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" contextRef="PAsOn12_31_2019" unitRef="Unit_Securities" decimals="INF" scale="0" format="ixt:numdotdecimal">27</ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" contextRef="PAsOn12_31_2018" unitRef="Unit_Securities" decimals="INF" scale="0" format="ixt:numdotdecimal">79</ix:nonFraction> debt securities, respectively, that were in an unrealized loss position. The aggregate fair value of debt securities in an unrealized loss position at December&#160;31, 2019 and 2018 was $<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">63.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">180.6</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2019 we did <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" contextRef="PAsOn12_31_2019_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_Securities" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></div>t have any securities in a continuous unrealized loss position for more than 12&#160;months.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2018, <ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" contextRef="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_Securities" decimals="0" scale="0" format="ixt:numdotdecimal">8</ix:nonFraction> corporate debt securities with a fair value of $<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">14.9</ix:nonFraction>&#160;million had been in a continuous unrealized loss position for more than 12&#160;months. The unrealized losses of less than $<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million related to these corporate debt securities were included in accumulated other comprehensive loss as of December&#160;31, 2018. At December&#160;31, 2018, we did not intend to sell the securities with an unrealized loss position in accumulated other comprehensive income, and it was not likely that we would be required to sell these securities before recovery of their amortized cost basis.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have experienced a credit loss and have the intent to sell the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>investment or if it is more likely than not that we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The unrealized losses at December&#160;31, 2019 and 2018 are attributable to changes in interest rates, and we do <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="kpti:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></div>t believe any unrealized losses represent other-than-temporary impairments. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5. Inventory </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our inventory of XPOVIO&#160;at December&#160;31, 2019 and 2018 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%; padding: 0px;"></td>
<td style="width: 20%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 20%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December&#160;31, 2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December&#160;31, 2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and work in process </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">273</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Finished goods </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total inventory </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2019, all of our inventory was related to&#160;XPOVIO, which was approved by the FDA in July 2019, at which time we began to capitalize costs to manufacture XPOVIO. Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO and related material were charged to research and development expense in the period incurred. At December&#160;31, 2019, we have determined that a reserve related to XPOVIO inventory is not required. </div></div></ix:nonNumeric> </div></div> <div><div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="kpti:AccruedExpensesDisclosureTextTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6. Accrued Expenses </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:AccruedResearchAndDevelopmentCostsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,122</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:AccruedResearchAndDevelopmentCostsCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,903</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Payroll and employee-related costs </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,630</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,103</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Professional fees </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,172</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,931</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">I</div>nterest</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,371</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="text-align: right; padding-left: 0px; background-color: rgb(255, 255, 255); padding-right: 5pt;">&#8212;</td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,583</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,556</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,878</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;&#160;&#160;&#160;&#160;<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,493</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> </ix:nonNumeric> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%; font-size: 10pt;"><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"></div></div><div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Related Party Transactions </div></div></div></div><div><div style="width: 100%; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We paid consulting expenses of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2018To12_31_2018_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2019To12_31_2019_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></ix:nonFraction>&#160;million for the years ended December&#160;31, 2019 and 2018, for consulting services with certain related parties, including a family member of management and a board member. At December&#160;31, 2019 and 2018, there was </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">less<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; font-family: &quot;Times New Roman&quot;, serif; top: 0px;;display:inline;">than</div><div style="font-size: 10pt; letter-spacing: 0px; font-family: &quot;Times New Roman&quot;, serif; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2019_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; font-family: &quot;Times New Roman&quot;, serif; top: 0px;;display:inline;">&#160;million</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2018_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction>, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively, included in accounts payable and accrued expenses due to related parties.&#160;</div></div></div></div></div></div></ix:nonNumeric></div><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11050304"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8. Stockholders&#8217; Equity </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Underwritten Offerings </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On May&#160;7, 2018, we completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offering under our shelf registration statement on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;S-3 </div> (File No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-222726)</div> pursuant to which we issued an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,525,424</ix:nonFraction>&#160;shares of common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">14.75</ix:nonFraction> per share. We received aggregate net proceeds of approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">145.7</ix:nonFraction>&#160;million from the offering after deducting the underwriting discounts and commissions and other offering expenses.</div></ix:nonNumeric></div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelection_11050304" continuedAt="TextSelectionAppend_11050304_1"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On April&#160;28, 2017, we completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offering under our shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3 </div> (File No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-214489)</div> pursuant to which we issued an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_28_2017To04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,902,439</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">10.25</ix:nonFraction> per share. We received net proceeds of approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P04_28_2017To04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:numdotdecimal">37.9</ix:nonFraction> <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>from the offering after deducting the underwriting discount and commissions and offering expenses.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Controlled Equity Offering Sales Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On December&#160;7, 2015, we entered into a Controlled Equity Offering Sales Agreement (as amended on November&#160;7, 2016 and December&#160;1, 2017, the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co., as sales agent (&#8220;Cantor&#8221;), pursuant to which we issued and sold through Cantor an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P12_07_2015To12_07_2015_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,172,159</ix:nonFraction>&#160;shares of our common stock, for net proceeds of approximately $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P12_07_2015To12_07_2015_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">89.1</ix:nonFraction>&#160;million. The Sales Agreement was terminated effective <span style="-sec-ix-hidden:hidden10182875">August&#160;12, 2018</span>. Under the Sales Agreement, Cantor sold shares of our common stock by methods deemed to be an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div> offering as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). We paid Cantor a commission of up to <ix:nonFraction name="kpti:CommissionPercentageOnGrossProceedsFromSaleOfShares" contextRef="P01_01_2018To12_31_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>% of the gross proceeds from the sale of the shares of our common stock pursuant to the Sales Agreement and provided Cantor with customary indemnification and contribution rights.</div></ix:continuation><ix:continuation id="TextSelectionAppend_11050304_1" continuedAt="TextSelectionAppend_11050304_2"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2018, we did not sell any shares under the Sales Agreement. During the year ended December&#160;31, 2017, we sold an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2017To12_31_2017_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,405,763</ix:nonFraction> shares under the Sales Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2017To12_31_2017_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction>&#160;million. </div>&#160;</div></ix:continuation><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div></div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050304_2" continuedAt="TextSelectionAppend_11050304_3"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Open Market Sale Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;17, 2018, we entered into an Open Market Sale Agreement (the &#8220;Open Market Sale Agreement&#8221;) with Jefferies LLC, as agent (&#8220;Jefferies&#8221;), pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $<ix:nonFraction name="kpti:AggregateOfferingPrice" contextRef="PAsOn08_07_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million (the &#8220;Open Market Shares&#8221;) from time to time through Jefferies (the &#8220;Open Market Offering&#8221;). </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under the Open Market Sale Agreement, Jefferies may sell the Open Market Shares by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act. We may sell the Open Market Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Open Market Sale Agreement, but we have no obligation to sell any of the Open Market Shares in the Open Market Offering. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We or Jefferies may suspend or terminate the offering of Open Market Shares upon notice to the other party and subject to other conditions. We have agreed to pay Jefferies commissions for its services in acting as agent in </div></div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11050304_3"><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">the sale of the Open Market Shares in the amount of up to <ix:nonFraction name="kpti:CommissionPercentageOnGrossProceedsFromSaleOfShares" contextRef="P01_01_2018To12_31_2018_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>% of gross proceeds from the sale of the Open Market Shares pursuant to the Open Market Sale Agreement. We have also agreed to provide Jefferies with customary indemnification and contribution rights. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, we sold an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_JefferiesLLCMembersrtCounterpartyNameAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,712,359</ix:nonFraction> Open Market Shares under the Open Market Sale Agreement, for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_JefferiesLLCMembersrtCounterpartyNameAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">46.2</ix:nonFraction>&#160;million. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11060110"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9. </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are party to an operating lease of <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" contextRef="PAsOn12_31_2019_OfficeAndResearchSpaceLeaseMemberusgaapLeaseArrangementTypeAxis" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:numdotdecimal">98,502</ix:nonFraction> square feet of office and research space in Newton, Massachusetts with a term through September&#160;30, 2025 (the &#8220;Newton, MA Lease&#8221;). Pursuant to the Newton, MA Lease, we have provided a security deposit in the form of a cash-collateralized letter of credit in the amount of $<ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn12_31_2019_OfficeAndResearchSpaceLeaseMemberusgaapLeaseArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million. The amount is classified within long-term restricted cash. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Upon the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> we recorded an operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> asset of $<ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million and corresponding lease liability of $<ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction>&#160;million related only to the Newton, MA Lease. As of December&#160;31, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>, there was a balance of $<ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="PAsOn12_31_2018_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn12_31_2018_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>&#160;million related to unamortized deferred rent and tenant incentive allowances, respectively, for the Newton, MA Lease, both accounted for as liabilities. These balances were deducted from the lease liability on the Newton, MA Lease in arriving at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> asset upon adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> on January&#160;1, 2019.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Newton, MA Lease provides for increases in future minimum annual rental payments, as defined in the lease agreement. The Newton, MA Lease also includes real estate taxes and common area maintenance (&#8220;CAM&#8221;) charges in the annual rental payments. As these charges were included in minimum annual rental payments as part of our accounting for the Newton, MA Lease under ASC 840 through December&#160;31, 2018, we have included such amounts in the calculation of the operating lease liability, consistent with ASC 842 and our accounting policy elections thereunder, as specified in Note 2, &#8220;Recent Accounting Pronouncements.&#8221; The operating lease cost for the Newton, MA Lease for the year ended December&#160;31, 2019 was $<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>&#160;million, of which approximately $<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2019To12_31_2019_CommonAreaMaintenanceMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction>&#160;million was charges for CAM. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition, we are party to short-term leases having a term of twelve months or less at the commencement date. We recognize short-term lease expense on a straight-line basis and do not record a related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of</div> use asset or lease liability for such leases. These costs were insignificant for the year ended December&#160;31, 2019.</div></ix:nonNumeric></div></div> <div> <div style="width: 100%;font-size: 10pt;"><ix:continuation id="TextSelection_11060110" continuedAt="TextSelectionAppend_11060110_1"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease Commitments </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">As of December&#160;31, 2019, future minimum lease payments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> operating lease agreements for which we have recognized operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and liabilities are as follows (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 83%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="width: 9%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Years ending December&#160;31, </div></div></div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-left: 0px; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future<br/> Minimum<br/> Payments </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,200</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,277</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,447</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,718</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024 and thereafter </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,735</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,377</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px 0px 0px 5em; background: none; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,529</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Present value of minimum lease payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,848</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric></ix:continuation> <div style="width: 100%; font-size: 10pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelectionAppend_11060110_1"> <div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;">As of December&#160;31, 2019, the remaining lease term on the Newton, MA Lease was <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2019" format="ixt-sec:duryear">5.8</ix:nonNumeric> years. The lease has a renewal option for an additional five years, although there is no economic penalty for failure to exercise the option. However, because we did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard, and the renewal option was not previously considered in our assessment of the lease term for the Newton, MA Lease before adoption of ASC 842, the renewal option was not considered as part of the lease term in calculating the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and liabilities as of January&#160;1, 2019.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As a discount rate was not directly observable for our Newton, MA Lease, the discount rate used to calculate the net present value of future payments was our incremental borrowing rate calculated at transition based on the remaining lease term. Upon adoption and through December&#160;31, 2019, the discount rate used to calculate the operating lease liability was <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">11.0</ix:nonFraction>%. The incremental borrowing rate is the rate of interest that we would expect to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. In determining the incremental borrowing rate, we considered<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;">(i)&#160;our estimated public credit rating, (ii)&#160;our observable debt yields, as well as other bonds in the market issued by other companies with similar credit ratings as us, and (iii)&#160;adjustments necessary for collateral, lease term, and inflation or foreign currency.</div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Litigation </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time we may face legal claims or actions in the normal course of business. We have been named as a defendant in securities class action litigation in the U.S. District Court for the District of Massachusetts. A complaint was filed on July&#160;23, 2019, by the Allegheny County Employees&#8217; Retirement System, against us and certain of our current and former executive officers and directors as well as the underwriters of our public offerings of common stock conducted in April 2017 and May 2018. A second complaint was filed by Heather Mehdi on September&#160;17, 2019, against the same defendants with the exception of the underwriters. The two complaints are related and we expect them to be consolidated by the court. Both complaints allege violations of federal securities laws based on our disclosures related to the results from the Phase 2 SOPRA study and Part 2 of the Phase 2b STORM study, and seek unspecified compensatory damages, including interest; reasonable costs and expenses, including attorneys&#8217; and expert fees; unspecified recessionary damages; and such equitable/injunctive relief or other relief as the court may deem just and proper. We have reviewed the allegations and believe they are without merit. We intend to defend vigorously against this litigation.</div></div></div> </div> </ix:continuation></div> <div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10. Product Revenue </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">To date, our only source of product revenue has been from the U.S. sales of XPOVIO, which we began shipping to our customers in July 2019. <ix:nonNumeric name="kpti:ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" contextRef="P01_01_2019To12_31_2019_XpovioMembersrtProductOrServiceAxis" escape="true" continuedAt="TextSelection_10181484">The following table summarizes activity in each of the product revenue allowance and reserve categories from the date of approval by the FDA through December&#160;31, 2019&#160;(in thousands):</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_10181484">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Discounts&#160;and<br/> Chargebacks </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees,&#160;Rebates,<br/> and Other<br/> Incentives </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr>
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance at July&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionDiscountsAndChargeBacks" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision related to sales in the current year </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionProvisionForDiscountsAndChargeBacks" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,657</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,318</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionSaleReturnsReserveForSaleReturns" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,209</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Credit and payments made </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:RevenueRecognitionPaymentsForChargeBacks" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,655</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">499</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,154</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-left: 0.26in; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Ending balance at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionDiscountsAndChargeBacks" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,002</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionFeesRebatesAndOtherIncentives" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,819</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionSalesReturn" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,055</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> </ix:continuation> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Discounts, chargebacks, and returns are recorded as reductions of accounts receivable, and fees, rebates, and other incentives are recorded as a component of accrued expenses. </div></div></ix:nonNumeric> <div style="width: 100%; font-size: 10pt;"> <div>&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2019To12_31_2019_LicenseAndAssetPurchaseAgreementsMembersrtProductOrServiceAxis" escape="true" continuedAt="TextSelection_11050344"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11. License and Asset Purchase Agreements </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Antengene License Agreement </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Effective May&#160;23, 2018 (the &#8220;Antengene Effective Date&#8221;), we entered into a License Agreement (&#8220;Antengene License Agreement&#8221;) with Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong (&#8220;Antengene&#8221;) and a subsidiary of Antengene Corporation Co. Ltd., a corporation organized and existing under the laws of the People&#8217;s Republic of China, pursuant to which we granted Antengene exclusive rights to develop and commercialize, at its own cost, (i)&#160;selinexor, our lead, novel, oral Selective Inhibitor of Nuclear Export (&#8220;SINE&#8221;) compound, (ii)&#160;eltanexor, our second-generation oral SINE compound, and (iii)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;KPT-9274,</div> our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> orally bioavailable small molecule that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive </div> dual modulator of PAK4 and NAMPT, each for the diagnosis, treatment and/or prevention of all human oncology indications (the &#8220;Oncology Field&#8221;), as well as (iv)&#160;verdinexor, our lead compound in development for the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>treatment of viral indications for the diagnosis, treatment and/or prevention of certain human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-oncology </div> indications (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-Oncology</div> Field&#8221;) (the &#8220;Antengene Licensed Compounds&#8221;). We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the Oncology Field in mainland China and Macau and licensed the development and commercial rights to Antengene for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in the Oncology Field and verdinexor in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Oncology</div> Field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam (the &#8220;Antengene Territory&#8221;).</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pursuant to the terms of the Antengene License Agreement, we received an upfront payment of $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million, and could receive up to $<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">105.0</ix:nonFraction>&#160;million in milestone payments if certain development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>goals are achieved and up to $<ix:nonFraction name="kpti:RevenueRecognitionPotentialFutureMilestonePayments" contextRef="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction>&#160;million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty based on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, upon Antengene&#8217;s election and the parties&#8217; full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the &#8220;Antengene Manufacturing Election&#8221;), we will grant to Antengene <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> rights to manufacture the Antengene Licensed Compounds and products containing such compounds in or outside of the Antengene Territory solely for development and commercialization in the fields in the Antengene Territory.</div></ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> </div> </div> <ix:continuation id="TextSelection_11050344" continuedAt="TextSelectionAppend_11050344_1"><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As part of the Antengene License Agreement, Antengene will also have the right to participate in global clinical studies of the Antengene Licensed Compounds and will bear the cost and expense for patients enrolled in clinical studies in the Antengene Territory. Antengene is responsible for seeking regulatory and marketing approvals for the Antengene Licensed Compounds in the Antengene Territory, as well as any development of the products specifically necessary to obtain such approvals. Antengene is also responsible for the commercialization of the Antengene Licensed Compounds in the Oncology Field and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Oncology</div> Field, as applicable, in the Antengene Territory at its own cost and expense. Until such time as Antengene elects to manufacture its own drug substance, we will furnish clinical supplies of drug substance to Antengene for use in Antengene&#8217;s development efforts pursuant to a clinical supply agreement between us and Antengene, and Antengene may elect to have us provide commercial supplies of drug product to Antengene pursuant to a commercial supply agreement between us and Antengene, in each case the costs of which will be borne by Antengene. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Antengene License Agreement will continue in effect on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country </div> basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Antengene <ix:nonNumeric name="kpti:LicenseAgreementTerminationDescription" contextRef="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">License Agreement may be terminated earlier by (i)&#160;either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii)&#160;Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with <ix:nonNumeric name="kpti:LicenseAgreementTerminationNoticePeriod" contextRef="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" format="ixt-sec:durday">180</ix:nonNumeric> days&#8217; prior notice or (iii)&#160;us in the event Antengene challenges or assists with a challenge to certain of our patent rights.</ix:nonNumeric></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We assessed the Antengene arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Antengene, is a customer. We identified the following material promises under the contract: </div></div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">57</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11050344_1" continuedAt="TextSelectionAppend_11050344_2"><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;exclusive licenses for each Antengene Licensed Compound, (ii)&#160;initial data transfers for each Antengene Licensed Compound, which consisted of regulatory data compiled by us for the Antengene Licensed Compounds as of the Antengene Effective Date, and (iii)&#160;obligations to stand-ready to provide an initial clinical supply for each Antengene Licensed Compound. We also identified immaterial promises under the contract relating to information exchanges and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Antengene, including (i)&#160;additional data transfers for each Antengene Licensed Compound, which would consist of the transfer of additional regulatory data compiled by us for each Antengene Licensed Compound after the Antengene Effective Date, (ii)&#160;obligations to provide additional clinical supply and related substance supply for each Antengene Licensed Compound upon request by Antengene, (iii)&#160;manufacturing technology transfers and licenses for each Antengene Licensed Compound under the Antengene Manufacturing Election, as detailed above, and (iv)&#160;options for a backup compound, which represents Antengene&#8217;s option to select a replacement compound in the event it elects to discontinue the development of the Antengene Licensed Compounds (the &#8220;Antengene Transfer Options&#8221;). The Antengene Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Antengene License Agreement. Finally, we also identified certain other customer options that would create a manufacturing obligation for us if exercised by Antengene, including for commercial supply. These options do not represent a material right, as they are not offered at a significant and incremental discount. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In further evaluating the promises detailed above, we determined that the exclusive licenses, initial data transfers, and stand-ready obligation to provide initial clinical supply for each Antengene Licensed Compound were not distinct from one another, and must be combined as four separate performance obligations (the &#8220;Antengene Combined License Obligation for selinexor<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div>&#8221;&#160;&#8220;Antengene Combined License Obligation for eltanexor<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div>&#8221;&#160;&#8220;Antengene Combined License Obligation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274&#8221;</div> and &#8220;Antengene Combined License Obligation for verdinexor&#8221;). This is because, for each Antengene Licensed Compound, Antengene requires the initial data transfer and initial clinical supply to derive benefit from the exclusive licenses, since we did not grant manufacturing licenses to any of the Antengene Licensed Compounds at contract inception. We also determined that each of the Antengene Transfer Options represents a distinct performance obligation. Based on these determinations, we identified eight performance obligations at the inception of the Antengene License Agreement, including (i)&#160;the Antengene Combined License Obligation for selinexor, (ii)&#160;the Antengene Combined License Obligation for eltanexor, (iii)&#160;the Antengene Combined License Obligation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> (iv)&#160;the Antengene Combined License Obligation for verdinexor, and the four components of the Antengene Transfer Options, including (v)&#160;the material right for additional data transfer, (vi)&#160;the material right for additional clinical supply and related substance supply, (vii)&#160;the material right for manufacturing technology transfer and license, and (viii)&#160;the material right for the option for a backup compound.</div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We further determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the four Antengene Combined License Obligations for selinexor, eltanexor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> and verdinexor. In connection therewith, we also estimated the standalone selling price for each of the material rights within the Antengene Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million transaction price amongst the Antengene Combined License Obligations as follows: $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction>&#160;million for selinexor, $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;million for eltanexor, $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_KPT9274MemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> and $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_VerdinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million for verdinexor. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Upon execution of the Antengene License Agreement, the only fixed component of the transaction price included the $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment owed to us. As referenced above, we are eligible to receive additional payments of up to $<ix:nonFraction name="kpti:RevenueRecognitionPotentialFutureMilestonePayments" contextRef="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">105.0</ix:nonFraction>&#160;million in milestone payments if certain development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>goals</div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">58</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11050344_2" continuedAt="TextSelectionAppend_11050344_3"><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">are achieved and up to $<ix:nonFraction name="kpti:PotentialCommercialMilestonePayments" contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction>&#160;million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, we would receive cost reimbursement in connection with Antengene&#8217;s election to receive additional clinical supply for the Antengene Licensed Compounds in the future. We <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">expect to receive </div> the next milestone <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">payment </div>under this agreement, which is $<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million, upon the first NDA filing in the Antengene Territory in Multiple Myeloma.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The future <div style="letter-spacing: 0px; top: 0px;;display:inline;">development a<div style="letter-spacing: 0px; top: 0px;;display:inline;">nd </div></div>regulatory milestones and cost reimbursement for providing additional clinical supply of the Antengene Licensed Compounds, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price at contract inception and/or through December&#160;31, 2019, because the amounts were fully constrained as of December&#160;31, 2019. As part of our<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside of our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Antengene, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property licenses granted to Antengene and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Through the year ended December&#160;31, 2019, we recognized $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction>&#160;million in revenue under the Antengene License Agreement, as the Antengene Combined License Obligation for selinexor was satisfied when the initial clinical supply of selinexor was delivered during the second quarter of 2019. Revenue will be recognized for the Antengene Combined License Obligation for eltanexor,&#160;the Antengene Combined License Obligation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> and the Antengene Combined License Obligation for verdinexor once our promise to provide initial clinical supply of each of the Antengene Licensed Compounds in the future is fulfilled. We currently expect the initial clinical supplies of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div>, eltanexor and verdinexor&#160;to be delivered within twelve months of the balance sheet date of December&#160;31, 2019. Accordingly, and as of December&#160;31, 2019, the remaining $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction>&#160;million of the upfront payment represents a contract liability, all of which was included in deferred revenue and is classified as a current liability.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Biogen Asset Purchase Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;24, 2018, we entered into an Asset Purchase Agreement (the &#8220;APA&#8221;) and Letter Agreement with Biogen MA Inc., a Massachusetts corporation and subsidiary of Biogen, Inc. (&#8220;Biogen&#8221;). </div></div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">Under the terms of the APA and Letter Agreement, we sold to Biogen exclusive worldwide rights to develop and commercialize our oral SINE compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> and certain related assets with an initial focus in amyotrophic lateral sclerosis (&#8220;ALS&#8221;) (the &#8220;Transfer of IP&#8221;), and also granted Biogen: (i)&#160;an exclusive worldwide license under certain of our intellectual property to manufacture or have manufactured <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Manufacturing License&#8221;), (ii)&#160;a technology transfer package, consisting of information and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how </div> regarding the manufacture of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Manufacturing Technology Transfer&#8221;), (iii)&#160;a right, at Biogen&#8217;s request, to have us provide transition assistance regarding manufacturing and other matters (the &#8220;Transition Assistance&#8221;), (iv)&#160;existing inventory of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Inventory&#8221;), (v)&#160;an initial supply of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Initial Supply&#8221;), and (vi)&#160;a right, at Biogen&#8217;s request, to have us manufacture and supply the active pharmaceutical ingredient for an additional supply of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Additional Supply&#8221;). In consideration for these rights, we received an upfront payment of $<ix:nonFraction name="kpti:UpfrontPaymentReceived" contextRef="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>&#160;million, and we are eligible to receive additional payments of up to $<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis_MaximumMembersrtRangeAxis_SalesMilestoneMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">142.0</ix:nonFraction>&#160;million based on the achievement by Biogen of future specified development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>milestones, and up to $<ix:nonFraction name="kpti:PotentialCommercialMilestonePayments" contextRef="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction>&#160;million based on the achievement by Biogen of future specified commercial milestones. We will also be eligible to receive tiered royalty payments that reach low double-digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product and the expiration of specified patent protection for the applicable product, determined on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div> basis.</div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="display:inline;">59</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11050344_3" continuedAt="TextSelectionAppend_11050344_4"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We and Biogen have made customary representations and warranties and agreed to customary covenants in the APA, including covenants requiring Biogen to use commercially reasonable efforts to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> in specified neurological indications, including ALS, in any of the United States, United Kingdom, France, Spain, Germany or Italy. The APA will continue in effect until the expiration of all royalty obligations, provided that the APA may be terminated earlier by Biogen, subject to the requirements that Biogen (i)&#160;negotiate in good faith with us regarding an assignment or license back to us of the purchased assets and (ii)&#160;not transfer or license the purchased assets to a third party unless such third party assumes Biogen&#8217;s obligations to us under the APA.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Biogen, is a customer. We identified the following material promises in the arrangement: the Transfer of IP and the Manufacturing License. We also identified immaterial promises under the contract that were not deemed performance obligations. We further determined that other promises for Additional Supply and Transition<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Assistance represented customer options, which would create an obligation for us if exercised by Biogen. Since no additional or material consideration is owed to us by Biogen upon exercise of the customer options for Additional Supply and Transition Assistance, we determined that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement. We then determined that the Transfer of IP and the Manufacturing License were not distinct from one another and must be combined as a performance obligation (the &#8220;Combined Performance Obligation&#8221;). This is because Biogen requires the Manufacturing License to derive benefit from the Transfer of IP. Based on these determinations, as well as the considerations noted above with respect to the material rights for Additional Supply and Transition Assistance, we identified three distinct performance obligations at the inception of the contract: (i)&#160;the Combined Performance Obligation, (ii)&#160;the material right for Additional Supply, and (iii)&#160;the material right for Transition Assistance. We further determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:UpfrontPaymentReceived" contextRef="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> </div>million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, we estimated the stand-alone selling price of the (i)&#160;Combined Performance Obligation, (ii)&#160;material right for Additional Supply, and (iii)&#160;material right for Transition Assistance, and determined that the stand-alone selling price of the material rights for Additional Supply and Transition Assistance were insignificant based on various quantitative and qualitative considerations. Accordingly, we further determined that the allocation of the transaction price to the material rights for Additional Supply and Transition Assistance was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, we determined that substantially all of the $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> </div>million transaction price should be allocated to the Combined Performance Obligation. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.</div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">Upon execution of the APA, the transaction price included only the $<ix:nonFraction name="kpti:UpfrontPaymentReceived" contextRef="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment owed to us. We may receive further payments upon the achievement of certain regulatory and sales milestones, as detailed above, as well as tiered royalty payments that reach low double-digits based on future net sales. <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">We expect to receive the next milestone payment under this agreement, which is $<ix:nonFraction name="kpti:UpfrontPaymentReceived" contextRef="P01_01_2019To12_31_2019_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;million, when the fifth patient in a Phase 1 Multiple Ascending Dose Trial in the United States of a Product in amyotrophic lateral sclerosis is dosed.</div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The future development and regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of December&#160;31, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such milestones is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Biogen, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur. </div></div></div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="display:inline;">0</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11050344_4" continuedAt="TextSelectionAppend_11050344_5"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We recognized $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2018To03_31_2018_BiogenMAIncMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>&#160;million of revenue during the first quarter of 2018, which was when we had satisfied our promises under the Combined Performance Obligation by transferring the underlying promised goods. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Ono License Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Effective October&#160;11, 2017 (the &#8220;Ono Effective Date&#8221;), we entered into a license agreement (the &#8220;Ono License Agreement&#8221;) with Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan (&#8220;Ono&#8221;), pursuant to which we granted Ono exclusive rights to develop and commercialize, at its own cost, selinexor and eltanexor, for the diagnosis, treatment and/or prevention of all human oncology indications (the &#8220;Ono Field&#8221;) in Japan, Republic of Korea, Republic of China (Taiwan) and Hong Kong, as well as in the ten Southeast Asian countries currently comprising the Association of Southeast Asian Nations (the &#8220;Ono Territory&#8221;)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(the &#8220;Ono Exclusive License&#8221;). Pursuant to the terms of the Ono License Agreement, we received an upfront payment of &#165;<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;billion (US$<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">21.9</ix:nonFraction>&#160;million on the date received), and could receive up to &#165;<ix:nonFraction name="kpti:RevenueRecognitionPotentialFutureMilestonePayments" contextRef="P10_11_2017To10_11_2017_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_JPY" decimals="INF" scale="9" format="ixt:numdotdecimal">10.15</ix:nonFraction>&#160;billion (approximately US$<ix:nonFraction name="kpti:RevenueRecognitionPotentialFutureMilestonePayments" contextRef="P10_11_2017To10_11_2017_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">90.5</ix:nonFraction>&#160;million at the exchange rate as of the Ono Effective Date) in milestone payments if certain development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>goals are achieved and up to &#165;<ix:nonFraction name="kpti:RevenueRecognitionPotentialFutureMilestonePayments" contextRef="P10_11_2017To10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis" unitRef="Unit_JPY" decimals="INF" scale="9" format="ixt:numdotdecimal">9.0</ix:nonFraction>&#160;billion (approximately US$<ix:nonFraction name="kpti:RevenueRecognitionPotentialFutureMilestonePayments" contextRef="P10_11_2017To10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">80.2</ix:nonFraction>&#160;million at the exchange rate as of the Ono Effective Date) in milestone payments if certain sales milestones are achieved, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, upon Ono&#8217;s election and the parties&#8217; full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the &#8220;Ono Manufacturing Election&#8221;), we will grant to Ono <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> rights to manufacture selinexor, eltanexor and products containing such compounds in or outside of the Ono Territory solely for development and commercialization in the Ono Field in the Ono Territory.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As part of the Ono License Agreement, Ono will also have the right to participate in global clinical studies of selinexor and eltanexor and will bear the cost and expense for patients enrolled in clinical studies in the Ono Territory. Ono is responsible for seeking regulatory and marketing approvals for selinexor and eltanexor in the Ono Territory, as well as any development of the products specifically necessary to obtain such approvals. Ono is also responsible for the commercialization of products containing selinexor or eltanexor in the Ono Field in the Ono Territory at its own cost and expense. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Subject to the Ono Manufacturing Election, we will furnish clinical supplies of drug substance to Ono for use in Ono&#8217;s development efforts pursuant to a clinical supply agreement between us and Ono, and Ono may elect to have us provide commercial supplies of drug product to Ono pursuant to a commercial supply agreement between us and Ono, in each case the costs of which will be borne by Ono. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Ono License Agreement will continue in effect on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div> basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, <span style="-sec-ix-hidden:hidden10185021">the Ono License Agreement may be terminated earlier by (i)&#160;either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party,</span><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(ii)&#160;Ono on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div> basis for certain safety reasons or on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country </div> basis for any reason with <ix:nonNumeric name="kpti:LicenseAgreementTerminationNoticePeriod" contextRef="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" format="ixt-sec:durday">180</ix:nonNumeric>&#160;days&#8217; prior notice or (iii)&#160;us in the event Ono challenges or assists with a challenge to certain of our patent rights.</div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Ono, is a customer. We identified the following material promises under the contract: (i)&#160;the Ono Exclusive License for selinexor and eltanexor, (ii)&#160;initial data transfer for selinexor and eltanexor, which consisted of regulatory data compiled by us for the licensed compounds and products as of the Ono Effective Date, (iii)&#160;initial clinical supply for selinexor, which consisted of units of clinical supply for Ono to conduct its Phase&#160;I Trial, and (iv)&#160;an obligation to stand-ready to provide initial clinical supply for eltanexor. We also identified immaterial promises under the contract relating to information exchanges, and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Ono, including the (i)&#160;additional data transfer for selinexor and eltanexor, which would consist </div></div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="display:inline;">1</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11050344_5" continuedAt="TextSelectionAppend_11050344_6"><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the transfer of additional regulatory data compiled by us for the licensed compounds and products after the Ono Effective Date, (ii)&#160;additional clinical supply and related substance supply for selinexor and eltanexor, which would consist of supplying Ono with units and substance of selinexor and eltanexor incremental to the initial clinical supply for selinexor and the obligation to stand-ready to provide initial clinical supply for eltanexor, as noted above, (iii)&#160;manufacturing technology transfer and license for selinexor and eltanexor under the Ono Manufacturing Election, as detailed above, and (iv)&#160;options for a backup compound, which represents Ono&#8217;s option to select a replacement compound in the event it elects to discontinue the development of either of the licensed compounds (the &#8220;Ono Transfer Options&#8221;). The Ono Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Ono License Agreement. We also identified certain other customer options that would create a manufacturing obligation for us if exercised by Ono, including commercial supply. This </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">option is referred to herein as the &#8220;Ono Manufacturing Option.&#8221; The Ono Manufacturing Option does not represent a material right, as it is not offered at a significant and incremental discount. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In further evaluating the promises detailed above, we determined that the (i)&#160;Ono Exclusive License, initial data transfer, and initial clinical supply for selinexor and (ii)&#160;Ono Exclusive License, initial data transfer, and obligation to stand-ready to provide initial clinical supply of eltanexor were not distinct from one another, and must be combined as two separate performance obligations (the &#8220;Ono Combined License Obligation for selinexor&#8221; and the &#8220;Ono Combined License Obligation for eltanexor&#8221;). This is because, for both selinexor and eltanexor, Ono requires the initial data transfer and clinical supply to derive benefit from the Ono Exclusive License since we did not grant manufacturing licenses for selinexor and eltanexor at contract inception. We also determined that each of the Ono Transfer Options represents a distinct performance obligation. Based on these determinations, we identified six distinct performance obligations at the inception of the Ono License Agreement, including (i)&#160;the Ono Combined License Obligation for selinexor, (ii)&#160;the Ono Combined License Obligation for eltanexor, and the four components of the Ono Transfer Options, including (iii)&#160;the material right for additional data transfer, (iv)&#160;the material right for additional clinical supply and related substance supply, (iv)&#160;the material right for manufacturing technology transfer and license, and (vi)&#160;the material right for the option for a backup compound. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We further determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of &#165;<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;billion (US$<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">21.9</ix:nonFraction>&#160;million on the date received) constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on our best estimate of their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the Ono Combined License Obligation for selinexor and the Ono Combined License Obligation for eltanexor. In connection therewith, we estimated the standalone selling price for each of the material rights within the Ono Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the &#165;<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;billion (US$<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">21.9</ix:nonFraction>&#160;million on the date received) upfront transaction price between the Ono Combined License Obligations as follows: $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction>&#160;million for selinexor and $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn09_30_2019_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction>&#160;million for eltanexor. We believe that a change in the assumptions used to determine our best estimate of the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations. </div></div></div></ix:continuation><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"></div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050344_6" continuedAt="TextSelectionAppend_11050344_7"> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0px; line-height: 12pt;">Upon execution of the Ono License Agreement, the transaction price included only the &#165;<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;billion (US$<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">21.9</ix:nonFraction>&#160;million on the date received) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment owed to us. As referenced above, we are eligible to receive additional payments of up to &#165;<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn09_30_2019_ClinicalDevelopmentAndRegulatoryMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_ScenarioPlanMembersrtStatementScenarioAxis" unitRef="Unit_JPY" decimals="-7" scale="9" format="ixt:numdotdecimal">10.15</ix:nonFraction>&#160;billion (approximately US$<ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn09_30_2019_ClinicalDevelopmentAndRegulatoryMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_ScenarioPlanMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">90.5</ix:nonFraction>&#160;million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>milestones and up to &#165;<ix:nonFraction name="kpti:PotentialCommercialMilestonePayments" contextRef="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:numdotdecimal">9.0</ix:nonFraction>&#160;billion (approximately US$<ix:nonFraction name="kpti:PotentialCommercialMilestonePayments" contextRef="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">80.2</ix:nonFraction>&#160;million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified commercial milestones, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, we could receive cost reimbursement in connection with our promise to stand-ready to provide initial clinical supply for eltanexor in the future. We <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">expect to receive </div>the next <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">milestone payment under this agreement upon the first licensed<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product in Multiple </div>Myelomna<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of &#165;</div><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion (approximately US$</div><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="PAsOn12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million), in Japan.</div></div> </ix:continuation> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 12pt;">&#160;</div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelectionAppend_11050344_7"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The future development and regulatory milestones and cost reimbursement for providing initial clinical supply of eltanexor, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of December 31, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Ono, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Ono and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As the initial clinical supply of selinexor was delivered in April 2018, the Ono Combined License Obligation for selinexor was determined to be fulfilled and revenue of $<ix:nonFraction name="us-gaap:Revenues" contextRef="P04_01_2019To06_30_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction>&#160;million was recognized during the quarter ended June&#160;30, 2018. The transaction price allocated to the Ono Combined License Obligation for eltanexor will be recognized as revenue once our stand-ready promise to provide initial clinical supply of eltanexor in the future is fulfilled, which is the last remaining undelivered promise associated with the Ono Combined License Obligation for eltanexor. As of December&#160;31, 2019, $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction>&#160;million of the Ono License Agreement upfront payment is included in deferred revenue and is classified as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liability.</div> </ix:continuation></div> <div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11050372"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12. Stock-based Compensation </div></div></div> <div style="width: 100%;"> <div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During 2010, we established the 2010 Stock Incentive Plan (the &#8220;Plan&#8221; or the &#8220;2010 Plan&#8221;). Under the terms of the Plan, we granted options to our employees, officers, directors, consultants and advisors. The exercise price of each stock option is the fair market value as determined in good faith by the Board of Directors (the Board) at the time each option is granted. We granted service-based options under the Plan, which generally vest as follows: <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodonememberMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of the shares vest one calendar year from the vesting start date, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodtwomemberMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">2.083</ix:nonFraction>% of the shares vest on the first day of each month for the three years thereafter. The options granted under the Plan generally expire in <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years from the date of grant. We will grant no further stock options or other awards under the 2010 Plan. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2013, </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Board </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> adopted and our stockholders approved the 2013 Stock Incentive Plan (the &#8220;2013 Plan&#8221;). The 2013 Plan became effective immediately prior to the closing of the IPO and provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Plan is equal to the sum of (1)&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">969,696</ix:nonFraction> shares plus (2)&#160;the number of shares (up to <ix:nonFraction name="kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" contextRef="PAsOn10_31_2013_MaximumMembersrtRangeAxis_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,126,377</ix:nonFraction> shares) equal to the sum of the number of shares of common stock then available for issuance under the 2010 Plan and the number of shares of common stock subject to outstanding awards under the 2010 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&#160;31, 2014 and continuing until, and including, the fiscal year ending December&#160;31, 2023, equal to the lesser of (A)&#160;<ix:nonFraction name="kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" contextRef="P10_01_2013To10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,939,393</ix:nonFraction> shares of common stock, (B)&#160;<ix:nonFraction name="kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" contextRef="P10_01_2013To10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>% of the number of shares of common stock outstanding on the first day of such fiscal year, or (C)&#160;an amount determined by the Board. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In January 2019, 2018 and 2017, the number of shares available for issuance under the 2013 Plan was increased by <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,939,393</ix:nonFraction>, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2018_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,939,393</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2017_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,675,513</ix:nonFraction> shares of common stock, respectively. As of December&#160;31, 2019, we had <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P01_01_2019To12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,373,779</ix:nonFraction>&#160;shares available for issuance under the 2013 Plan. </div></div></ix:nonNumeric> <div style="width: 100%; font-size: 10pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelection_11050372" continuedAt="TextSelectionAppend_11050372_1"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with all share-based payment awards, total stock-based compensation expense recognized was as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,457</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,686</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,208</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,834</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,589</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2017To12_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,197</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,291</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,275</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,405</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_11050372_1" continuedAt="TextSelectionAppend_11050372_2"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock Options </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">The total stock-based compensation </div> expense related to employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options for the years ended December&#160;31, 2019, 2018 and 2017 was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">12.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.7</ix:nonFraction>&#160;million, respectively.&#160;</div> </ix:continuation></div> </div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050372_2" continuedAt="TextSelectionAppend_11050372_3"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes stock option activity for employees and nonemployees: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px;width: 92%;font-size: 10pt;border-spacing: 0px;">
<tr>
<td style="width: 53%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 5%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Options </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(year) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/> &#160;Intrinsic<br/> &#160;Value </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in<br/> thousands) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,917,084</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.78</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">7.4</ix:nonNumeric></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,197</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Granted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,325,390</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.67</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercised </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">394,358</ix:nonFraction></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.18</ix:nonFraction> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Forfeited </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,005,022</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.36</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden11073498">9, 843,094</span> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">12.40</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">7.0</ix:nonNumeric></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">82,134</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,391,153</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.65</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">5.6</ix:nonNumeric></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,879</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The total intrinsic value of stock options exercised for the years ended December&#160;31, 2019, 2018 and 2017 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million, respectively. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The fair value of each stock option granted to employees is estimated on the date of grant and for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> on each reporting date and upon vesting using the Black-Scholes option-pricing model. The following table summarizes the assumptions used in calculating the fair value of the awards:</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Volatility </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">79</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">81</ix:nonFraction>%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">79</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">81</ix:nonFraction>% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">79</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">6.0</ix:nonNumeric> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">9.8</ix:nonNumeric> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">9.6</ix:nonNumeric> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.42</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.58</ix:nonFraction>%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.50</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.05</ix:nonFraction>% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.76</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.29</ix:nonFraction>% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dividend </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We use the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment</div></div>, to calculate the expected term as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees and utilize the contractual term for options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. The expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to us, including early stage of product development and therapeutic focus. For these analyses, we select companies with comparable characteristics to</div> </ix:continuation> <div style="width: 100%; font-size: 10pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelectionAppend_11050372_3" continuedAt="TextSelectionAppend_11050372_4"> <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">ours including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the options. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. We account for forfeitures as they occur.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Using the Black-Scholes option-pricing model, the weighted-average grant date fair values of options granted during the years ended December&#160;31, 2019, 2018 and 2017 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.01</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.91</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.22</ix:nonFraction> per share, respectively. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">At December&#160;31, 2019, the total unrecognized compensation related to unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option awards granted under the 2013 Plan was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">26.7</ix:nonFraction>&#160;million, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.66</ix:nonNumeric>&#160;years.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Units </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one share of our common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of our common stock on the date of grant.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;">We grant RSUs with service conditions that vest in </div><ix:nonFraction name="kpti:RightsReceivedForEachRestrictedShareUnit" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_Installment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"> or </div><ix:nonFraction name="kpti:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_Installment" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"> equal annual installments provided that the employee remains employed with us.</div></div> </ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> </div> </div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050372_4" continuedAt="TextSelectionAppend_11050372_5"><ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, we granted <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,065,970</ix:nonFraction></div> shares of RSUs under the 2013 Plan. The following is a summary of RSU activity for the 2013 Plan for the years ended December&#160;31, 2019 and 2018, respectively: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 15%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of<br/> Shares<br/> Underlying&#160;RSUs </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/> Grant&#160;Date<br/> Fair&#160;Value </div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.87</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Granted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,065,970</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.25</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Forfeited </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">286,150</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.24</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Vested </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,500</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.96</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">787,320</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.28</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The total stock-based compensation expense related to RSUs for the years ended December&#160;31, 2019, 2018 and 2017 was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million and <div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2017To12_31_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction>&#160;million, respectively. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.8</ix:nonFraction>&#160;million of unrecognized compensation costs related to unvested RSUs, which are expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">3.12</ix:nonNumeric>&#160;years. </div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_11050372_5" continuedAt="TextSelectionAppend_11050372_6"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We have an Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that permits eligible employees to enroll in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden10168480">six-month</span> </div> offering periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of the fair market value of the common stock on the first or last day of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month </div> offering period, whichever is lower. Purchase dates under the ESPP occur on or about May&#160;1 and November&#160;1 each year. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">In 2013, our shareholders approved an increase in the number of shares of common stock authorized for issuance pursuant to the ESPP to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">242,424</ix:nonFraction> shares of common stock, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2019_MinimumMembersrtRangeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">484,848</ix:nonFraction> shares of our common stock, <ix:nonFraction name="kpti:PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% of the number of outstanding shares on such date, or an amount determined by the Board.</ix:nonNumeric></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">During the years ended December&#160;31, 2019, 2018 and 2017, $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million, respectively, was withheld from employees, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> basis, in order to purchase <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">415,257</ix:nonFraction>, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">98,770</ix:nonFraction> and</div> </ix:continuation> <div style="width: 100%; font-size: 10pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelectionAppend_11050372_6" continuedAt="TextSelectionAppend_11050372_7"> <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,582</ix:nonFraction> shares of our common stock, respectively. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded stock-based compensation expense <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">related to the ESPP<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2019, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">404,332</ix:nonFraction> shares of <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">our</div> common stock remained available for issuance under the ESPP. As of December&#160;31, 2019, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million of total unrecognized stock-based compensation expense related to the ESPP.&#160;The expense is expected to be recognized over a period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four months</ix:nonNumeric>.</div> </ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" escape="true"><div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_11050372_7" continuedAt="TextSelectionAppend_11050372_8">The fair value of the option component of the shares purchased under the ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:</ix:continuation> </div></div></div> <ix:continuation id="TextSelectionAppend_11050372_8">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%; padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended<br/> December&#160;31, </div></div></div></div> </td>
<td style="padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">61</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">104</ix:nonFraction>% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">61</ix:nonFraction>% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">78</ix:nonFraction>% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years) </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.5</ix:nonNumeric> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.5</ix:nonNumeric> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">0.5</ix:nonNumeric> </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction>% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.3</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.1</ix:nonFraction>% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.3</ix:nonFraction>% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> </ix:continuation></div></ix:nonNumeric></div> </div> <div><div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13. 401(k) Plan </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have a 401(k)&#160;retirement and profit-sharing plan (the &#8220;401(k)&#160;Plan&#8221;) covering all qualified employees. The 401(k)&#160;Plan allows each participant to contribute a portion of their base wages up to an amount not to exceed an annual statutory maximum. Effective January&#160;1, 2011, we adopted a Safe Harbor Plan that provides a Company match up to <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>% of salary. We contributed a match of $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million to the&#160;401(k)&#160;Plan for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_11074520"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14. Income Taxes </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">New Tax Legislation </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;). This legislation reduced the U.S. corporate tax rate from the current rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>% to <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>% for tax years beginning after December&#160;31, 2017. As a result of the enacted law, we were required to revalue deferred tax assets and liabilities existing as of December&#160;31, 2017 from the <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>% federal rate in effect through the end of 2017, to the new 21% rate.&#160;We have recognized the impact of the TCJA in these consolidated financial statements and related disclosures. In the year ended December&#160;31, 2018, we recorded an impact of $<ix:nonFraction name="kpti:ProvisionForIncomeTaxesForFederalTaxRateChanges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million related to the return to provision items for federal rate change, which is offset by a full valuation allowance. The impact of the remeasurement of our U.S. deferred tax assets and liabilities to <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>% resulted in the reduction of deferred tax assets of approximately $<ix:nonFraction name="kpti:TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">42.7</ix:nonFraction>&#160;million, which is offset by a full valuation allowance.&#160;There was no impact to our income statement due to the reduction in the U.S. corporate tax rate. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2019, 2018 and 2017, we recorded an income tax expense of less than $</div></div><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_DEsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million for our operations in Germany. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost-plus profit margin. </div></div></div></ix:nonNumeric> <div style="width: 100%; font-size: 10pt;"><div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0;margin-bottom: 0px;">&#160;</div><div style="width: 100%; font-size: 10pt;"><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div><ix:nonNumeric name="kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><ix:continuation id="TextSelection_11074520" continuedAt="TextSelectionAppend_11074520_1"><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of loss before income taxes were as follows (in thousands): </div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt; text-align: right;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt;page-break-inside: avoid;background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,350</ix:nonFraction> </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,689</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,680</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,200</ix:nonFraction> </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">149,692</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">93,241</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Totals </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">199,550</ix:nonFraction> </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">178,381</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128,921</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table></ix:continuation><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div></div></div><div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11074520_1" continuedAt="TextSelectionAppend_11074520_2"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true" continuedAt="TextSelection_10524448">The significant components of our deferred tax assets are comprised of the following (in thousands):</ix:nonNumeric> </div></div></div><ix:continuation id="TextSelection_10524448">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and state net operating loss carryforwards </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,909</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">116,236</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,914</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,228</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Accruals and other temporary differences </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,212</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,605</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,374</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,307</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Capitalized research and development </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,021</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,388</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets and intangibles </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsFixedAssetsAndIntangibles" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,893</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsFixedAssetsAndIntangibles" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,422</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,051</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Foreign net operating loss carryforwards </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr>
<td style="padding: 0in; width: 69%;;vertical-align:top;"><div style="margin: 0in 0in 0in 0in;text-indent: -1em;margin-left: 3em;line-height: normal;font-family: Calibri, sans-serif;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Lease liability </div></div></td>
<td style="padding: 0in; width: 6%;;vertical-align:top;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsLeaseLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,443</ix:nonFraction></div></div></td>
<td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; width: 5%;;vertical-align:top;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin: 0in 0in 0in 3em; text-indent: -1em; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty embedded derivative</div>&#160;</div></td>
<td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="kpti:DeferredTaxAssetsRoyaltyEmbadedDerivatives" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">533</ix:nonFraction></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; margin-top: 0px; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt;;text-align:right;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">224,943</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173,247</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,538</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Convertible debt amortization </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:DeferredTaxLiabilitiesConvertibleDebtAmortization" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,431</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:DeferredTaxLiabilitiesConvertibleDebtAmortization" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,538</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 69%;;vertical-align:top;"><div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 0in;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;margin-left: 3em;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use asset </div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 6%;;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:DeferredTaxAssetsRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,462</ix:nonFraction></div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">) </div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 5%;;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in 2pt 0in 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 3em;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty obligation </div></div></td>
<td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:DeferredTaxAssetsDeferredRoyaltyObligation" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">518</ix:nonFraction></div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">) </div></div></td>
<td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,538</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_11074520_2" continuedAt="TextSelectionAppend_11074520_3"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December&#160;31, 2019 and 2018. The valuation allowance increased </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">51.7</ix:nonFraction> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million during the year ended December&#160;31, 2019 to $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">224.9</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, from $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">173.2</ix:nonFraction>&#160;million during the year ended December&#160;31, 2018, primarily due to the generation of net operating losses. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 12pt;">&#160;</div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2019To12_31_2019" escape="true"><ix:continuation id="TextSelectionAppend_11074520_3" continuedAt="TextSelectionAppend_11074520_4"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%; padding: 0px;"></td>
<td style="width: 6%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 5%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 5%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Federal income tax expense at statutory rate </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">34.0</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">State income tax, net of federal benefit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">5.9</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development credit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">6.0</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">7.8</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">8.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.5</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">3.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">9.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">25.9</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">28.2</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustments </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Federal rate change </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">33.2</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 15px; vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table></ix:continuation><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric></div></div> <div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11074520_4" continuedAt="TextSelectionAppend_11074520_5"><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2018, we had U.S. federal net operating loss carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">576.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">427.0</ix:nonFraction>&#160;million, respectively, which may be able to offset future income tax liabilities. Of the $</div></div><ix:nonFraction name="kpti:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" contextRef="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">576.5</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million carryforward as of December&#160;31, 2019, $</div></div><ix:nonFraction name="kpti:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" contextRef="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">283.6</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of the carryforward has an indefinite life and</div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div><ix:nonFraction name="kpti:NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" contextRef="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">292.9</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million will expire at various dates through 2037. As of December&#160;31, 2019 and 2018, we had U.S. state net operating loss carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">502.3</ix:nonFraction>&#160;million and </div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2018_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">414.8</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, which may be available to offset future state income tax liabilities and expire at various dates through 203<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. Also as of December&#160;31, 2019, we had foreign net operating loss carryforwards of less than</div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="PAsOn12_31_2019_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, which <div style="letter-spacing: 0px; top: 0px;;display:inline;">have an indefinite li<div style="letter-spacing: 0px; top: 0px;;display:inline;">fe and </div></div>may be able to offset future foreign income tax liabilities.</div></div></div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2018, we had federal research and development tax credit carryforwards of approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">58.5</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">46.9</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, available to reduce future tax liabilities, which expire at various dates through 203<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. As of December&#160;31, 2019 and 2018, we had state research and development tax credit carryforwards of approximately $</div></div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2019_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2018_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, available to reduce future tax liabilities, which expire at various dates through 203<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. We completed a study of R&amp;D tax credits through December&#160;31, 2018 and adjusted our deferred tax asset for the result of that study.&#160;For the year ending December&#160;31, 2019, we generated research credits but have not conducted a study to document the qualified activities. This study may result in an adjustment to our research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against our research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a <span style="-sec-ix-hidden:hidden10534998">three</span>-year period in excess of <ix:nonFraction name="kpti:OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:numdotdecimal">50</ix:nonFraction>&#160;percent, as defined under Sections&#160;382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of us immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Previously, we have completed several financings since our inception, which resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code. We completed a Section&#160;382 analysis through July&#160;31, 2015 and subsequently reduced our deferred tax assets for tax attributes we believe will expire unused. We updated our Section&#160;382 analysis through December&#160;31, 2019 and confirmed there were no ownership changes since July&#160;31, 2015. In the future, we may complete financings that could result in a change in control, </div></div></ix:continuation><div style="width: 100%; font-size: 10pt;"><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="display:inline;">8</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><ix:continuation id="TextSelectionAppend_11074520_5"><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">which will reduce our deferred tax assets for tax attributes we believe will expire unused due to the change in control limitations. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In October 2016 the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-16.</div> This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this standard on January&#160;1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional deferred tax assets of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn01_01_2018_AccountingStandardsUpdate201616MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.2</ix:nonFraction>&#160;million which were offset by a corresponding valuation allowance.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2019 and 2018, we had <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We or one of our subsidiaries file income tax returns in the United States, and various state and foreign jurisdictions. The federal, state and foreign income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2019. To the extent we have tax attribute<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">carryforwards</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</div></div></ix:continuation></div></div><div><div style="width: 100%; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" escape="true" continuedAt="TextSelection_11050493"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Long-term obligations </div></div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.00% Convertible Senior Notes due 2025 </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On October&#160;16, 2018, we completed an offering of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction>&#160;million aggregate principal amount of our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.00</ix:nonFraction>% convertible senior notes due 2025 (the &#8220;Notes&#8221;). In addition, on October&#160;26, 2018, we issued an additional $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_26_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">22.5</ix:nonFraction>&#160;million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule&#160;144A under the Securities Act. In accordance with accounting guidance for debt with conversion and other options, we separately accounted for the liability component (&#8220;Liability Component&#8221;) and the embedded conversion option (&#8220;Equity Component&#8221;) of the Notes by allocating the proceeds between the Liability Component and the Equity Component, due to our ability to settle the Notes in cash, shares of our common stock or a combination of cash and shares of our common stock, at our option. In connection with the issuance of the Notes, we incurred approximately $<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction>&#160;million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs between the Liability Component and the Equity Component based on the allocation of the proceeds. Of the total debt issuance costs, $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction>&#160;million was allocated to the Equity Component and recorded as a reduction to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and $<ix:nonFraction name="kpti:DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction>&#160;million was allocated to the Liability Component and recorded as a reduction of the Notes. The portion allocated to the Liability Component is amortized to interest expense using the effective interest method over <ix:nonNumeric name="kpti:DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Notes are our senior unsecured obligations and bear interest at a rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.00</ix:nonFraction>% per year payable semiannually in arrears on April&#160;15 and October&#160;15 of each year, beginning on April&#160;15, 2019. Upon conversion, the Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>The Notes will be subject to redemption at our option, on or after October 15, 2022, in whole or in part, if the conditions described below are satisfied. The Notes will mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P10_16_2018To10_16_2018" format="ixt:datemonthdayyearen"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" format="ixt:datemonthdayyearen">October&#160;15, 2025</ix:nonNumeric></ix:nonNumeric>, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to satisfaction of certain conditions and during the periods described below, the Notes may be converted at an initial conversion rate of <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P10_16_2018To10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">63.0731</ix:nonFraction>&#160;shares of common stock per $<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P10_16_2018To10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction> principal amount of the Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">15.85</ix:nonFraction> per share of common stock).</div></ix:nonNumeric><div style="width: 100%; font-size: 10pt;"><div>&#160;</div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">169</div></div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_11050493" continuedAt="TextSelectionAppend_11050493_1">Holders of the Notes may convert all or any portion of their Notes, in multiples of $<ix:nonFraction name="kpti:PrincipalAmountPerNoteUsedInConversionRate" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction> principal amount, at their option at any time prior to the close of business on the business day immediately preceding <ix:nonNumeric name="us-gaap:DebtInstrumentConvertibleLatestDate1" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" format="ixt:datemonthdayyearen">June&#160;15, 2025</ix:nonNumeric> only under the following circumstances:</ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_11050493_1" continuedAt="TextSelectionAppend_11050493_2"><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(1)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">during any calendar quarter commencing after the calendar quarter ending on December&#160;31, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_D" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> trading days (whether or not consecutive) during the period of <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_D" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>% of the conversion price for the Notes on each applicable trading day;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(2)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"><ix:nonNumeric name="kpti:DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" contextRef="P01_01_2019To12_31_2019">during the five business day period immediately after any <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_D" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> consecutive trading day</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>period (the &#8220;Measurement Period&#8221;) in which the trading price per $<ix:nonFraction name="kpti:PrincipalAmountOfNotesUsedInConversionRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:numdotdecimal">1,000</ix:nonFraction> principal amount of Notes for each trading day of the Measurement Period was less than <ix:nonFraction name="kpti:DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(3)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">if we call the Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(4)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">upon the occurrence of specified corporate events as described within the indenture governing the Notes.</td></tr></table><div style="clear: both; max-height: 0px;"></div></ix:continuation><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div></div></div><div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_11050493_2" continuedAt="TextSelectionAppend_11050493_3">As of December&#160;31, 2019, none of the above circumstances had occurred and as such, the Notes could not have been converted.</ix:continuation> </div></div></div></div></div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050493_3" continuedAt="TextSelectionAppend_11050493_4"> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We may not redeem the Notes prior to October&#160;15, 2022. On or after October&#160;15, 2022, we may redeem for cash all or part of the Notes at our option if the last reported sale price of our common stock equals or exceeds <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_D" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_D" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction> consecutive trading day period ending within five trading days prior to the date on which we send any notice of redemption. The redemption price will be <ix:nonFraction name="kpti:DebtInstrumentRepurchasePricePercentage" contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any convertible note for redemption will constitute a make-whole fundamental change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that convertible note, if it is converted in connection with the redemption, will be increased in certain circumstances. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The initial carrying amount of the Liability Component of $<ix:nonFraction name="kpti:DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">101.2</ix:nonFraction>&#160;million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> borrowing rate for similar debt. The Equity Component of the Notes of $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">67.9</ix:nonFraction>&#160;million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Notes of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">172.5</ix:nonFraction>&#160;million and the fair value of the liability of the Notes of approximately $<ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">104.7</ix:nonFraction>&#160;million on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount is amortized to interest expense using the effective interest method over <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P01_01_2019To12_31_2019" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification.</div> <ix:nonNumeric name="us-gaap:ConvertibleDebtTableTextBlock" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The outstanding balances of the Notes as of December&#160;31, 2019 consisted of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Liability component: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Principal </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">172,500</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: debt discount and issuance costs, net </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="kpti:DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62,643</ix:nonFraction></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,857</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity component: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,641</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We determined the expected life of the Notes was equal to its seven-year term. The effective interest rate on the Liability Component of the Notes was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">11.85</ix:nonFraction>%. As of December&#160;31, 2019, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted</div> value&#8221; did not</div> </ix:continuation> <div style="width: 100%; font-size: 10pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelectionAppend_11050493_4" continuedAt="TextSelectionAppend_11050493_5"> <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">exceed the remaining principal amount of the Notes. The fair value of the Notes was determined based on data points other than quoted prices that are observable, either directly or indirectly, and has been classified as Level&#160;2 within the fair value hierarchy. The fair value of the Notes, which differs from their carrying value, is influenced by market interest rates, our stock price and stock price volatility. The estimated fair value of the Notes as of December&#160;31, 2019 was approximately $<ix:nonFraction name="kpti:DebtInstrumentEstimatedFairValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">251.0</ix:nonFraction>&#160;million.</div> <ix:nonNumeric name="kpti:ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth total interest expense recognized related to the Notes during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 74%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 18%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/> December&#160;31,&#160;2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Contractual interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,175</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,849</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">344</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,368</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric></ix:continuation></div> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> </div> <div> <div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050493_5" continuedAt="TextSelectionAppend_11050493_6"><ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" escape="true"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments on the Notes as of&#160;December&#160;31, 2019 were as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 74%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended December&#160;31, </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Future&#160;Minimum&#160;Payments </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,175</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,175</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,175</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,175</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024 and thereafter </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">182,850</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total minimum payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">203,550</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: interest </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,050</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized discount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,643</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 9%; height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior notes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,857</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-size: 10pt;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred Royalty Obligation</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In September&#160;2019, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we entered into a Revenue Interest Financing Agreement (&#8221;deferred royalty obligation&#8221;) with HealthCare Royalty Partners </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">III, L.P. and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) whereby HCR will receive payments from us at a tiered percentage (the &#8220;Applicable Tiered Percentage&#8221;) of future net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties. We received $<ix:nonFraction name="kpti:ProceedsFromFirstInvestmentAmount" contextRef="P01_01_2019To09_30_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million upon closing (the &#8220;First Investment Amount&#8221;) and have the right to receive an additional $<ix:nonFraction name="kpti:SecondInvestmentAmount" contextRef="P01_01_2019To09_30_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million (the &#8220;Second Investment Amount&#8221; and together with the First Investment Amount, the &#8220;Investment Amount&#8221;) upon the achievement of future regulatory and commercial milestones and subject to the approval of both parties and customary closing conditions. </div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In exchange for the First Investment Amount, HCR will receive a tiered royalty in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits based on worldwide net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties. The Applicable Tiered Percentages are subject to reduction in the future if a target based on cumulative U.S. net sales is met. Total royalty payments are capped </div>at <ix:nonFraction name="kpti:RoyaltyPaymentsApplicableTieredPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">185</ix:nonFraction>% of the Investment Amount.</div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If HCR has not received <ix:nonFraction name="kpti:RoyaltyGuaranteesCommitmentsPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMemberKPTIRoyaltyPaymentDueDateAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction>% of the Investment Amount by December&#160;31, 2022 or <ix:nonFraction name="kpti:RoyaltyGuaranteesCommitmentsPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMemberKPTIRoyaltyPaymentDueDateAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of the Investment Amount by December&#160;31, 2024, we must make a cash payment sufficient to gross HCR up to such minimum amounts. </div></div> </ix:continuation> <div style="width: 100%; font-size: 10pt;"> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="width: 100%;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <ix:continuation id="TextSelectionAppend_11050493_6" continuedAt="TextSelectionAppend_11050493_7"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As the repayment of the&#160;funded amount is contingent upon worldwide net product sales and upfront payments, milestones, and royalties, the repayment term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period commenced on October&#160;1, 2019 and expires on the earlier of (i)&#160;the date in which HCR has received cash payments totaling an aggregate of <ix:nonFraction name="kpti:RoyaltyPaymentsApplicableTieredPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">185</ix:nonFraction>% of the Investment Amount or (ii)&#160;the legal maturity date of October&#160;1, 2031. If HCR has not received payments equal to <ix:nonFraction name="kpti:RoyaltyPaymentsApplicableTieredPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">185</ix:nonFraction>% </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Investment Amount by the twelve-year anniversary of the initial closing date, we shall pay an amount equal to the Investment Amount plus a specific annual rate of return less payments previously received by HCR. In the event of a change of control, we are obligated to pay HCR an amount equal to <ix:nonFraction name="kpti:RoyaltyPaymentsApplicableTieredPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">185</ix:nonFraction>% of the Investment Amount less payments previously received by HCR. In addition, upon the occurrence of an event of default, including, among others, our failure to pay any amounts due to HCR under the deferred royalty obligation, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the United States or our breach of any covenant contained in the Revenue Interest Financing Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay HCR an amount equal to <ix:nonFraction name="kpti:RoyaltyPaymentsApplicableTieredPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">185</ix:nonFraction>% of the Investment Amount less payments previously received by HCR. In addition, upon an event of default, HCR may exercise all other rights and remedies available under the Revenue Interest Financing Agreement, including foreclosing on the collateral that was pledged to HCR, which consists of all of our present and future assets relating to XPOVIO.</div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have evaluated the terms of the deferred royalty obligation and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, we have accounted for the transaction as long-term debt. We have further evaluated the terms of the debt and determined that the repayment </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">of <ix:nonFraction name="kpti:RoyaltyPaymentsApplicableTieredPercentage" contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">185</ix:nonFraction>% </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Investment Amount, less any payments made to date, upon&#160;a change of control is an embedded derivative that requires bifurcation&#160;from the debt instrument and fair value recognition. We determined the fair value of the derivative using an option pricing Monte Carlo simulation model taking into account the probability of change of control occurring and potential repayment amounts and timing of such payments that would result under various scenarios, as further described in Note 2. The aggregate fair value of the embedded derivative at issuance date is included in deferred royalty obligation. We will remeasure the embedded derivative to fair value each reporting period until the time the features lapse and/or termination of the deferred royalty obligation. </div></div></div> </div> </ix:continuation> <div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div> </div> </div> <div><div style="width: 100%; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_11050493_7"><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effective interest rate as of December&#160;31, 2019 was </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">18.4</ix:nonFraction><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the deferred royalty obligation, we incurred debt issuance costs </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">totaling $</div></div><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. Debt issuance costs have been netted against the debt as of December&#160;31, 2019 and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short and long-term classification of these costs, as well as the period over which these costs will be amortized. </div></div></div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of&#160;the deferred royalty obligation at December&#160;31, 2019 was $</div></div><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2019_DeferredRoyaltyObligationMemberusgaapBalanceSheetLocationAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">71.3</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million based on </div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> $</div><ix:nonFraction name="kpti:ProceedsFromFirstInvestmentAmount" contextRef="P01_01_2019To12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of proceeds, net of fair value of the bifurcated embedded derivative liability and debt issuance costs incurred. The carrying value of the deferred royalty obligation approximates fair value at December&#160;31, 2019 and was measured using Level&#160;3 inputs. The estimated fair market value was calculated using an option pricing Monte Carlo simulation model with inputs consistent with those used in determining the embedded&#160;derivative values as described in Note&#160;2. </div></div></div></div></ix:continuation><div style="margin-top: 1em; margin-bottom: 0em; background: none;"></div><div style="width: 100%;"><div style="width: 100%; font-size: 10pt;"><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">172</div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;"><div style="width: 100%; font-size: 10pt;"><div style="width: 100%; font-size: 10pt;"><div style="width: 100%; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXHIBIT INDEX </div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 15%; padding: 0px;"></td>
<td style="width: 82%; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;Number&#160;&#160;&#160;&#160;</div></div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit </div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;3.1 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519215344/d760010dex31.htm">Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on August&#160;7, 2019) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;3.2 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000110465913085435/a13-19023_12ex3d2.htm">Amended and Restated By-Laws of the Registrant (incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on November&#160;18, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;4.1 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009972/a2216956zex-4_1.htm">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Amendment No.&#160;1 to Registration Statement on Form S-1 (File&#160;No.&#160;333-191584) filed with the Commission on October&#160;28, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;4.2 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009519/a2216876zex-4_2.htm">Third Amended and Restated Investors&#8217; Rights Agreement dated as of July&#160;26, 2013 (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191584) filed with the Commission on October&#160;4, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;4.3 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518300266/d637251dex41.htm">Indenture (including form of Note) with respect to the Registrant&#8217;s 3.00% convertible senior notes due 2025, dated as of October&#160;16, 2018, between the Registrant and Wilmington Trust, National Association, as trustee (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on October&#160;16, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;4.4** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d853399dex44.htm">Description of Securities Registered under Section&#160;12 of the Exchange Act</a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.1* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009519/a2216876zex-10_1.htm">2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191584) filed with the Commission on October&#160;4, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.2* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009519/a2216876zex-10_2.htm">Forms of Non-Qualified Stock Option Agreement under 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191584) filed with the Commission on October&#160;4, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.3* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009972/a2216956zex-10_3.htm">2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Amendment No.&#160;1 to Registration Statement on Form S-1 (File No.&#160;333-191584) filed with the Commission on October&#160;28, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.4* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009972/a2216956zex-10_4.htm">Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Amendment No.&#160;1 to Registration Statement on Form S-1 (File&#160;No.&#160;333-191584) filed with the Commission on October&#160;28, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.5* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009972/a2216956zex-10_5.htm">Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Amendment No.&#160;1 to Registration Statement on Form&#160;S-1 (File No.&#160;333-191584) filed with the Commission on October&#160;28, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.6* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515370974/d60961dex101.htm">Form of Restricted Stock Unit Agreement under the 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36167) filed with the Commission on November&#160;9, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.7* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518159200/d575436dex103.htm">Form of Nonstatutory Stock Option Agreement for Inducement Grants (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36167) filed with the Commission on May&#160;10, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.8* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009972/a2216956zex-10_6.htm">2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Amendment No.&#160;1 to Registration Statement on Form S-1 (File&#160;No.&#160;333-191584) filed with the Commission on October&#160;28, 2013) </a> </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173</div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-right: auto; margin-left: auto; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 13%; padding: 0px;"></td>
<td style="width: 82%; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;Number&#160;&#160;&#160;&#160;</div></div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit </div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.9* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009519/a2216876zex-10_12.htm">Form of Indemnification Agreement between the Registrant and each of its Directors (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 (File&#160;No.&#160;333-191584) filed with the Commission on October&#160;4, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.10* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515091264/d824483dex1016.htm">Managing Director Agreement, dated October&#160;15, 2014, by and between Karyopharm Europe GmbH and Ran Frenkel (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No.&#160;001-36167) filed with the Commission on March&#160;13, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.11* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515091264/d824483dex1017.htm">Letter Agreement, dated October&#160;15, 2014, by and between the Registrant and Ran Frenkel (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Annual Report on Form&#160;10-K (File&#160;No.&#160;001-36167) filed with the Commission on March&#160;13, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.12* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515018888/d857880dex101.htm">Amended and Restated Letter Agreement, dated as of January&#160;23, 2015, between the Registrant and Michael Kauffman, M.D., Ph.D. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on January&#160;23,&#160;2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.13* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515018888/d857880dex102.htm">Amended and Restated Letter Agreement, dated as of January&#160;23, 2015, between the Registrant and Sharon Shacham, Ph.D., M.B.A. (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on January&#160;23,&#160;2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.14* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515091264/d824483dex1022.htm">Amendment to Managing Director Agreement, dated February&#160;15, 2015, by and between Karyopharm Europe GmbH and Ran Frenkel (incorporated by reference to Exhibit 10.22 to the Registrant&#8217;s Annual Report on Form 10-K (File No.&#160;001-36167) filed with the Commission on March&#160;13, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.15* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515219303/d941191dex101.htm">Offer Letter, dated June&#160;7, 2015, between the Registrant and Ran Frenkel (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on June&#160;10, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.16* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312517084396/d282276dex1016.htm">First Amendment to Letter Agreement, dated October&#160;4, 2016, between the Registrant and Ran Frenkel (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No.&#160;001-36167) filed with the Commission on March&#160;16, 2017) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.17* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515370974/d60961dex102.htm">Amended and Restated Letter Agreement, dated as of September&#160;18, 2015, between the Registrant and Christopher B. Primiano (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on November&#160;9,&#160;2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.18* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515370974/d60961dex103.htm">Amendment to Managing Director Agreement, dated October&#160;16, 2015, between Karyopharm Europe GmbH and Ran Frenkel (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on November&#160;9,&#160;2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.19* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312517282755/d406161dex101.htm">Offer Letter, dated September&#160;9, 2017, between the Registrant and Michael Falvey (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36167) filed with the Commission on September&#160;12, 2017) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.20* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518241301/d498055dex104.htm">Offer Letter, dated June&#160;7, 2018, between the Registrant and Anand Varadan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on August&#160;7, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.21* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519012897/d684265dex101.htm">Separation Agreement dated as of January&#160;17, 2019, between the Registrant and Michael Falvey (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on January&#160;18, 2019) </a> </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174</div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-right: auto; margin-left: auto; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 11%; padding: 0px;"></td>
<td style="width: 82%; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;Number&#160;&#160;&#160;&#160;</div></div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit </div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.22* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519012897/d684265dex102.htm">Consulting Agreement, dated as of January&#160;18, 2019, between the Registrant and Michael Falvey (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on January&#160;18, 2019) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.23* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312517282755/d406161dex102.htm">Nonstatutory Stock Option Agreement, dated September&#160;9, 2017, between the Registrant and Michael Falvey (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on September&#160;12, 2017) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.24 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000110465914024882/a14-9393_1ex10d1.htm">Office Lease Agreement between NS Wells Acquisition LLC and the Registrant, dated March&#160;27, 2014 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on April&#160;1, 2014) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.25 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515001785/d845399dex101.htm">First Amendment to Lease, dated December&#160;31, 2014, by and between the Registrant and NS Wells Acquisition LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on January&#160;5, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.26 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312515370974/d60961dex105.htm">Second Amendment to Lease, dated October&#160;22, 2015, by and between the Registrant and NS Wells Acquisition LLC (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36167) filed with the Commission on November&#160;9, 2015) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.27 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518159200/d575436dex102.htm">Third Amendment to Lease, dated February&#160;28, 2018, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36167) filed with the Commission on May&#160;10, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.28 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518241301/d498055dex103.htm">Fourth Amendment to Lease, dated June&#160;6, 2018, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36167) filed with the Commission on August&#160;7, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.29&#8224;</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000104746913009519/a2216876zex-10_14.htm">Research Agreement, dated as of July&#160;18, 2011, between the Registrant and the Multiple Myeloma Research Foundation, Inc. (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-191584) filed with the Commission on October&#160;4, 2013) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.30 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518251656/d545412dex101.htm">Open Market Sale Agreement<span style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">SM</span>, dated August&#160;17, 2018, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on August&#160;17, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.31&#8224;</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518084024/d529132dex1030.htm">License Agreement, dated October&#160;11, 2017, by and between the Registrant and Ono Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Annual Report on Form 10-K (File No.&#160;001-36167) filed with the Commission on March&#160;15, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.32&#8224;</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518159200/d575436dex101.htm">Asset Purchase Agreement, dated January&#160;24, 2018, by and between the Registrant and Biogen MA Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on May&#160;10, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.33&#8224;</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518241301/d498055dex101.htm">License Agreement, dated May&#160;23, 2018, by and between the Registrant and Antengene Therapeutics Limited (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on August&#160;7, 2018) </a> </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175</div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-right: auto; margin-left: auto; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 11%; padding: 0px;"></td>
<td style="width: 83%; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;Number&#160;&#160;&#160;&#160;</div></div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit </div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.34 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312518241301/d498055dex102.htm">Parent Company Guarantee, dated May&#160;23, 2018, by and between the Registrant and Antengene Therapeutics Limited (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No.&#160;001-36167) filed with the Commission on August&#160;7, 2018) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.35* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519050016/d712162dex101.htm">Offer Letter, dated February&#160;3, 2019, between the Registrant and Michael Mason (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36167) filed with the Commission on February&#160;25, 2019) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.36* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519050016/d712162dex102.htm">Nonstatutory Stock Option Agreement, dated February&#160;25, 2019, between the Registrant and Michael Mason (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on February&#160;25, 2019) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.37* </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519214061/d786800dex101.htm">Karyopharm Therapeutics Inc. Annual Bonus Plan (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No.&#160;001-36167) filed with the Commission on August&#160;6, 2019) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;10.38*** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="http://www.sec.gov/Archives/edgar/data/1503802/000119312519282510/d810264dex102.htm">Revenue Interest Financing Agreement, dated September&#160;14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36167) filed with the Commission on November&#160;4, 2019) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;21.1** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d853399dex211.htm">Subsidiaries of the Registrant </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;23.1** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d853399dex231.htm">Consent of Ernst&#160;&amp; Young LLP (Independent registered public accounting firm for the Registrant) </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;31.1** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d853399dex311.htm">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;31.2** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d853399dex312.htm">Certification of Senior Vice President, Chief Financial Officer and Treasurer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;32.1** </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d853399dex321.htm">Certifications pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of The Sarbanes-Oxley Act of 2002, by Michael G. Kauffman, M.D., Ph.D., Chief Executive Officer of the Registrant, and Michael Mason, Senior Vice President, Chief Financial Officer and Treasurer of the Registrant </a> </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.INS</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.SCH</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inline XBRL Schema Document </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.CAL </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inline XBRL Calculation Linkbase Document </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.LAB</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inline XBRL Labels Linkbase Document </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.PRE</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inline XBRL Presentation Linkbase Document </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.DEF</div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inline XBRL Definition Linkbase Document </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; white-space: nowrap; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="display:inline;">&#8224; </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Confidential treatment has been granted as to portions of the exhibit.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176</div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; vertical-align: top; white-space: nowrap;"><div style="display:inline;">* </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Indicates a management contract or compensatory plan or arrangement.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="display:inline;">** </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Filed with this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="display:inline;">*** </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Certain portions of this exhibit (indicated by &#8220;***&#8221;) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177</div></div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 100%; font-size: 10pt;"><div id="tx853399_25" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 45%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 5%; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 3%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 44%; padding: 0px;"></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">KARYOPHARM THERAPEUTICS INC. </div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 16px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date: February&#160;26, 2020 </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By: </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Michael G. Kauffman </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Kauffman, M.D., Ph.D. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer and Director </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Executive Officer) </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 38%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 44%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 16%; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signature </div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title </div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date </div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Michael G. Kauffman </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief&#160;Executive&#160;Officer&#160;and&#160;Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26,&#160;2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael G. Kauffman, M.D., Ph.D. </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Executive Officer) </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td rowspan="2" style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Michael Mason </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael Mason </div></div></div></td>
<td rowspan="2" style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior Vice President, Chief Financial Officer and Treasurer </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Financial and Accounting Officer) </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Garen G. Bohlin </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Garen G. Bohlin </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Mikael Dolsten </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mikael Dolsten, M.D., Ph.D. </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ J. Scott Garland </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J. Scott Garland </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Barry E. Greene </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Barry E. Greene </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Deepika R. Pakianathan </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deepika R. Pakianathan, Ph.D. </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Mansoor Raza Mirza </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;26, 2020 </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mansoor Raza Mirza, M.D. </div></div></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: top;"><div style="display:inline;">&#160;</div></td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div style="width: 100%;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178</div></div></div></div></div></div></div></div></div></div></div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>d853399dex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;4.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of the common stock, $0.0001 par value per share (the &#147;Common Stock&#148;), of Karyopharm Therapeutics Inc.
(&#147;us,&#148; &#147;our&#148; or &#147;we&#148;), which is the only security of the Company registered under Section&nbsp;12 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), summarizes certain information
regarding the Common Stock in our certificate of incorporation, our <FONT STYLE="white-space:nowrap">by-laws</FONT> and applicable provisions of the Delaware General Corporation Law (the &#147;DGCL&#148;), and is qualified by reference to our
certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> which are incorporated by reference as Exhibit 3.1 and Exhibit 3.2, respectively, to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of which
this Exhibit 4.4 is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 200,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, $0.0001&nbsp;par value per
share (the &#147;Preferred Stock&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Annual Meeting. </I>Annual meetings of our stockholders are held on the date designated in accordance with our <FONT
STYLE="white-space:nowrap">by-laws.</FONT> Written notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The presence in person or by proxy of the holders of record of a
majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders may be called for any purpose by the board of
directors, the chairman of the board or the chief executive officer. Except as may be otherwise provided by applicable law, our certificate of incorporation or our <FONT STYLE="white-space:nowrap">by-laws,</FONT> all elections shall be decided by a
plurality, and all other questions shall be decided by a majority, of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Each holder of Common Stock is entitled to one vote for each share held of record on all matters to be voted upon by
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Subject to the rights, powers and preferences of any outstanding Preferred Stock, and except as provided
by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the Common Stock out of legally available assets or funds when and as declared by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation and Dissolution</I>. Subject to the rights, powers and preferences of any outstanding Preferred Stock, in the event of our
liquidation or dissolution, our net assets will be distributed pro rata to the holders of our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Rights</I>. Holders
of the Common Stock have no right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the stock into any other security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the stock redeemed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase additional stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain their proportionate ownership interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock does not have cumulative voting rights. The rights, preferences and privileges of the holders of Common Stock are subject to,
and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that we may designate and issue. Holders of shares of the Common Stock are not required to make additional capital contributions. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions of Our Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> and the
DGCL That May Have Anti-Takeover Effects </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Board of Directors</I>. Our certificate of incorporation and <FONT
STYLE="white-space:nowrap">by-laws</FONT> provide for a board of directors divided as nearly equally as possible into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third year following the
year of such election. The number of directors comprising our board of directors is fixed from time to time by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors by Stockholders</I>. Our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> provide
that, subject to the rights of holders of any series of Preferred Stock, a member of our board of directors may only be removed for cause and only by an affirmative vote of the holders of at least 75% of the outstanding shares entitled to vote on
the election of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Super-Majority Voting</I>. The DGCL provides generally that the affirmative vote of a majority of the
shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> unless a corporation&#146;s certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws,</FONT> as the case may be, requires a greater percentage. Subject to the rights of holders of any series of Preferred Stock, our <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended or repealed by a
majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of
at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal, or to adopt any provisions inconsistent with, any of the provisions of our certificate of incorporation
described under the prior two paragraphs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder Nomination of Directors</I>. Our <FONT STYLE="white-space:nowrap">by-laws</FONT>
provide that a stockholder must notify us in writing of any stockholder nomination of a director not earlier than 120 days but not later than 90 days prior to the first anniversary of the preceding year&#146;s annual meeting; provided, that if the
date of the annual meeting is advanced by more than 20 days, or delayed by more than 60 days, from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the 120<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to the date of such annual meeting and not later than close of business on the later of (x)&nbsp;the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day prior to the date of such
meeting and (y)&nbsp;the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the day on which notice of the date of such annual meeting was mailed or public announcement of the date of such annual meeting is first made by us,
whichever occurs first. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>No Action By Written Consent</I>. Our certificate of incorporation and our
<FONT STYLE="white-space:nowrap">by-laws</FONT> provide that our stockholders may not act by written consent and may only act at duly called meetings of stockholders. Our certificate of incorporation and our
<FONT STYLE="white-space:nowrap">by-laws</FONT> also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our board of directors, chairman of the board or chief executive officer. In addition,
our <FONT STYLE="white-space:nowrap">by-laws</FONT> establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Business Combination Statute</I>. We are subject to Section&nbsp;203 of the DGCL. Subject to certain exceptions,
Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for three years following the date that the person became an interested stockholder,
unless the interested stockholder attained such status with the approval of the corporation&#146;s board of directors or unless the business combination is approved in a prescribed manner or the interested stockholder acquired at least 85% of the
corporation&#146;s outstanding voting stock in the transaction in which it became an interested stockholder. A &#147;business combination&#148; includes, among other things, a merger or consolidation involving us and the &#147;interested
stockholder&#148; and the sale of more than 10% of our assets. In general, an &#147;interested stockholder&#148; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or
controlling or controlled by such entity or person. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d853399dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries of Karyopharm Therapeutics Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jurisdiction of Incorporation or Organization</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karyopharm Securities Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Massachusetts</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karyopharm Europe GmbH</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karyopharm Therapeutics (Bermuda) Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Bermuda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karyopharm Israel Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Israel</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d853399dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the following Registration Statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8,</FONT> File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-194746)</FONT> pertaining to the 2010 Stock Incentive Plan of Karyopharm Therapeutics Inc., 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc., and 2013 Employee Stock Purchase Plan of Karyopharm
Therapeutics Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statements (Form <FONT STYLE="white-space:nowrap">S-8,</FONT> File Nos. <FONT
STYLE="white-space:nowrap">333-202742,</FONT> <FONT STYLE="white-space:nowrap">333-216732,</FONT> and <FONT STYLE="white-space:nowrap">333-223675)</FONT> pertaining to the 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statements (Form <FONT STYLE="white-space:nowrap">S-8,</FONT> File Nos. <FONT
STYLE="white-space:nowrap">333-210221</FONT> and <FONT STYLE="white-space:nowrap">333-229971)</FONT> pertaining to the 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc. and 2013 Employee Stock Purchase Plan of Karyopharm Therapeutics Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement (Form <FONT STYLE="white-space:nowrap">S-3,</FONT> File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-226038)</FONT> and related Prospectuses of Karyopharm Therapeutics Inc. for the registration of debt securities, common stock, preferred stock, warrants, and units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8,</FONT> File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-226639)</FONT> pertaining to Inducement Stock Option Awards (September 2017 - July 2018) of Karyopharm Therapeutics Inc.; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement (Form <FONT STYLE="white-space:nowrap">S-8,</FONT> File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-233094)</FONT> pertaining to Inducement Stock Option Awards (August 2018 - July 2019) of Karyopharm Therapeutics Inc.; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">of our reports dated February&nbsp;26, 2020, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc. and the
effectiveness of internal control over financial reporting of Karyopharm Therapeutics Inc., included in this Annual Report <FONT STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;26, 2020 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d853399dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Michael G. Kauffman, M.D., Ph.D., certify that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Karyopharm Therapeutics Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to
be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;26, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael G. Kauffman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael G. Kauffman, M.D., Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Chief
Executive Officer</I></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d853399dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Michael Mason, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have
reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Karyopharm Therapeutics Inc.; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my
knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to
be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;26, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Mason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael Mason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior&nbsp;Vice&nbsp;President,&nbsp;Chief&nbsp;Financial&nbsp;Officer&nbsp;and&nbsp;Treasurer</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial and Accounting Officer)</I></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d853399dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Karyopharm Therapeutics Inc. (the
&#147;Company&#148;) for the year ended December&nbsp;31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C.
(section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results
of operations of the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: February&nbsp;26, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael G. Kauffman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael G. Kauffman, M.D., Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Chief Executive Officer</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Michael Mason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Mason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President, Chief Financial Officer and Treasurer</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial and Accounting Officer)</I></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>kpti-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-February-2020 [12:33:30] {PM}-->
<schema targetNamespace="http://www.karyopharm.com/20191231" elementFormDefault="qualified" xmlns:kpti="http://www.karyopharm.com/20191231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.karyopharm.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" id="CondensedConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity" id="CondensedConsolidatedStatementOfStockholdersEquity">
<link:definition>1006 - Statement - Condensed Consolidated Statement of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" id="CondensedConsolidatedStatementOfStockholdersEquityParenthetical">
<link:definition>1007 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/OrganizationAndOperations" id="OrganizationAndOperations">
<link:definition>1009 - Disclosure - Organization and Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1011 - Disclosure - Property and Equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/Investments" id="Investments">
<link:definition>1012 - Disclosure - Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/Inventory" id="Inventory">
<link:definition>1013 - Disclosure - Inventory</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1014 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1015 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1016 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/ProductRevenue" id="ProductRevenue">
<link:definition>1018 - Disclosure - Product Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements" id="LicenseAndAssetPurchaseAgreements">
<link:definition>1019 - Disclosure - License and Asset Purchase Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1020 - Disclosure - Stock-based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/KPlan" id="KPlan">
<link:definition>1021 - Disclosure - 401(k) Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1022 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LongTermObligations" id="LongTermObligations">
<link:definition>1023 - Disclosure - Long-Term Obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1026 - Disclosure - Property and Equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/InvestmentsTables" id="InvestmentsTables">
<link:definition>1027 - Disclosure - Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/InventoryTables" id="InventoryTables">
<link:definition>1028 - Disclosure - Inventory (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1029 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1030 - Disclosure - Commitments and Contingencies  (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/ProductRevenueTables" id="ProductRevenueTables">
<link:definition>1031 - Disclosure - Product Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1032 - Disclosure - Stock-based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/IncomeTaxesTable" id="IncomeTaxesTable">
<link:definition>1033 - Disclosure - Income Taxes (Table)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LongTermObligationsTables" id="LongTermObligationsTables">
<link:definition>1034 - Disclosure - Long-Term Obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail" id="OrganizationAndOperationsAdditionalInformationDetail">
<link:definition>1035 - Disclosure - Organization and Operations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails">
<link:definition>1037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Financial Assets That Have Been Measured at Fair Value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails" id="SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails">
<link:definition>1038 - Disclosure - Summary of Significant Accounting Policies - The Changes in the Estimated Fair Value of Our Embedded Derivative Liability - (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail">
<link:definition>1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail" id="SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail">
<link:definition>1040 - Disclosure -  Summary of Significant Accounting Policies- Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842 (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
<link:definition>1041 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Property and Equipment, net - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" id="InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail">
<link:definition>1043 - Disclosure - Investments - Summary of Investments, Classified as Available-for-Sale (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail" id="InvestmentsAdditionalInformationDetail">
<link:definition>1044 - Disclosure - Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail" id="InventoryScheduleOfInventoryCurrentDetail">
<link:definition>1045 - Disclosure - Inventory - Schedule of Inventory Current (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" id="AccruedExpensesScheduleOfAccruedExpensesDetail">
<link:definition>1046 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail" id="StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail">
<link:definition>1048 - Disclosure - Stockholders' Equity - Controlled Equity Offering Sales Agreement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1049 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" id="CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail">
<link:definition>1050 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Rent Payments Under Lease Agreement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail" id="ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail">
<link:definition>1051 - Disclosure - Product Revenue -  Schedule of Product Discounts Returns Allowances Reconciliation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail" id="LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail">
<link:definition>1052 - Disclosure - License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail" id="LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail">
<link:definition>1053 - Disclosure - License and Asset Purchase Agreements - Additional Information - Biogen Asset Purchase Agreement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail" id="LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail">
<link:definition>1054 - Disclosure - License and Asset Purchase Agreements - Additional Information - Ono License Agreement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail" id="NetLossPerShareAdditionalInformationDetail">
<link:definition>1055 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Stock-based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail" id="StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail">
<link:definition>1057 - Disclosure - Stock-based Compensation - Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail" id="StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail">
<link:definition>1058 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity for Employees and Nonemployees (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail" id="StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail">
<link:definition>1059 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Each Employee and Non-employee Stock Award on Grant Date Using Black Scholes Option Pricing Model (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail" id="StockBasedCompensationSummaryOfRsuActivityDetail">
<link:definition>1060 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail" id="StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail">
<link:definition>1061 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/KPlanAdditionalInformationDetail" id="KPlanAdditionalInformationDetail">
<link:definition>1062 - Disclosure - 401(k) Plan - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1063 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" id="IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail">
<link:definition>1064 - Disclosure - Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" id="IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail">
<link:definition>1065 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" id="IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail">
<link:definition>1066 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail" id="LongTermObligationsAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Long-Term Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail" id="LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail">
<link:definition>1068 - Disclosure - Long-Term Obligations - Summary of Outstanding Balances of Convertible Notes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" id="LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail">
<link:definition>1069 - Disclosure - Long-Term Obligations - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" id="LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail">
<link:definition>1070 - Disclosure - Long-Term Obligations - Summary of Future Minimum Payments on Convertible Notes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="kpti-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
<element name="DeferredRoyaltyObligationNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredRoyaltyObligationNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LicenseAndOtherMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_LicenseAndOtherMember" substitutionGroup="xbrli:item" />
<element name="EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_StockIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ControlledEquityOfferingSalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_ControlledEquityOfferingSalesAgreementMember" substitutionGroup="xbrli:item" />
<element name="ProceedsFromPaymentsForCommonStockIssuanceNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromDeferredRoyaltyObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ProceedsFromDeferredRoyaltyObligation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_IncreaseDecreaseInOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedExpensesDisclosureTextTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_AccruedExpensesDisclosureTextTextBlock" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsDisclosureTextblockTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" substitutionGroup="xbrli:item" />
<element name="LicenseAndAssetPurchaseAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_LicenseAndAssetPurchaseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="DeferredRoyaltyObligationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_DeferredRoyaltyObligationPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="XpovioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_XpovioMember" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_EmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="EmployeeAndNonEmployeeStockOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_EmployeeAndNonEmployeeStockOptionMember" substitutionGroup="xbrli:item" />
<element name="ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="RegulatoryAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_RegulatoryAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesAndGeneralInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_AccountingPoliciesAndGeneralInformationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccountingPoliciesAndGeneralInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_AccountingPoliciesAndGeneralInformationLineItems" substitutionGroup="xbrli:item" />
<element name="LongTermInvestmentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_LongTermInvestmentsMember" substitutionGroup="xbrli:item" />
<element name="AdjustmentsForChangeInAccountingPrincipleTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_AdjustmentsForChangeInAccountingPrincipleTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AdjustmentsForChangeInAccountingPrincipleLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" substitutionGroup="xbrli:item" />
<element name="AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_AccruedResearchAndDevelopmentCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConsultingAndHistopathologyServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_ConsultingAndHistopathologyServicesMember" substitutionGroup="xbrli:item" />
<element name="ConsultingAndContractResearchServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_ConsultingAndContractResearchServicesMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="JefferiesLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_JefferiesLLCMember" substitutionGroup="xbrli:item" />
<element name="CantorFitzgeraldAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_CantorFitzgeraldAndCoMember" substitutionGroup="xbrli:item" />
<element name="EquityOfferingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_EquityOfferingLineItems" substitutionGroup="xbrli:item" />
<element name="AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_AggregateOfferingPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommissionPercentageOnGrossProceedsFromSaleOfShares" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" substitutionGroup="xbrli:item" />
<element name="SaleAgreementTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_SaleAgreementTerminationDate" substitutionGroup="xbrli:item" />
<element name="OpenMarketSaleAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_OpenMarketSaleAgreementMember" substitutionGroup="xbrli:item" />
<element name="LeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_LeasesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="OfficeAndResearchSpaceLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_OfficeAndResearchSpaceLeaseMember" substitutionGroup="xbrli:item" />
<element name="LeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_LeasesLineItems" substitutionGroup="xbrli:item" />
<element name="CommonAreaMaintenanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_CommonAreaMaintenanceMember" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionDiscountsAndChargeBacks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_RevenueRecognitionDiscountsAndChargeBacks" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionProvisionForDiscountsAndChargeBacks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionPaymentsForChargeBacks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionPaymentsForChargeBacks" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionSalesReturn" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_RevenueRecognitionSalesReturn" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionFeesRebatesAndOtherIncentives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueRecognitionSaleReturnsReserveForSaleReturns" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EltanexorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_EltanexorMember" substitutionGroup="xbrli:item" />
<element name="KPT9274Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_KPT9274Member" substitutionGroup="xbrli:item" />
<element name="SelinexorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_SelinexorMember" substitutionGroup="xbrli:item" />
<element name="VerdinexorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_VerdinexorMember" substitutionGroup="xbrli:item" />
<element name="AntengeneTherapeuticsLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_AntengeneTherapeuticsLimitedMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentGoalsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_DevelopmentGoalsMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_DevelopmentMilestoneMember" substitutionGroup="xbrli:item" />
<element name="SalesEventsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_SalesEventsMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_LicenseAgreementTerminationDescription" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_LicenseAgreementTerminationNoticePeriod" substitutionGroup="xbrli:item" />
<element name="PotentialCommercialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_PotentialCommercialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueRecognitionPotentialFutureMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RevenueRecognitionPotentialFutureMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BiogenMAIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_BiogenMAIncMember" substitutionGroup="xbrli:item" />
<element name="SalesMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_SalesMilestoneMember" substitutionGroup="xbrli:item" />
<element name="AssetPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_AssetPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_UpfrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OnoPharmaceuticalCompanyLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_OnoPharmaceuticalCompanyLimitedMember" substitutionGroup="xbrli:item" />
<element name="ClinicalDevelopmentAndRegulatoryMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandThirteenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_TwoThousandThirteenStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="TwothousandtenstockoptionplanmemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_TwothousandtenstockoptionplanmemberMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" substitutionGroup="xbrli:item" />
<element name="RightsReceivedForEachRestrictedShareUnit" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_RightsReceivedForEachRestrictedShareUnit" substitutionGroup="xbrli:item" />
<element name="VestingperiodonememberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_VestingperiodonememberMember" substitutionGroup="xbrli:item" />
<element name="VestingperiodtwomemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_VestingperiodtwomemberMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_IncomeTaxDisclosureTableTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="ProvisionForIncomeTaxesForFederalTaxRateChanges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" substitutionGroup="xbrli:item" />
<element name="OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsFixedAssetsAndIntangibles" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsRoyaltyEmbadedDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxLiabilitiesConvertibleDebtAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsDeferredRoyaltyObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DeferredTaxAssetsDeferredRoyaltyObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentEstimatedFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DebtInstrumentEstimatedFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentRepurchasePricePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_DebtInstrumentRepurchasePricePercentage" substitutionGroup="xbrli:item" />
<element name="DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" substitutionGroup="xbrli:item" />
<element name="DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrincipalAmountOfNotesUsedInConversionRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_PrincipalAmountOfNotesUsedInConversionRate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrincipalAmountPerNoteUsedInConversionRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_PrincipalAmountPerNoteUsedInConversionRate" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromFirstInvestmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_ProceedsFromFirstInvestmentAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SecondInvestmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="kpti_SecondInvestmentAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RoyaltyPaymentsApplicableTieredPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_RoyaltyPaymentsApplicableTieredPercentage" substitutionGroup="xbrli:item" />
<element name="RoyaltyGuaranteesCommitmentsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_RoyaltyGuaranteesCommitmentsPercentage" substitutionGroup="xbrli:item" />
<element name="HealthcareRoyaltyPartnersIvLpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_HealthcareRoyaltyPartnersIvLpMember" substitutionGroup="xbrli:item" />
<element name="RoyaltyPaymentDueDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_RoyaltyPaymentDueDateAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RoyaltyPaymentDueDateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_RoyaltyPaymentDueDateDomain" substitutionGroup="xbrli:item" />
<element name="RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" substitutionGroup="xbrli:item" />
<element name="DeferredRoyaltyObligationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_DeferredRoyaltyObligationMember" substitutionGroup="xbrli:item" />
<element name="RevenueInterestFinancingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_RevenueInterestFinancingAgreementMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentLiabilityComponentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="kpti_DebtInstrumentLiabilityComponentAbstract" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>kpti-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-February-2020 [12:33:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" roleURI="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InventoryScheduleOfInventoryCurrentDetail" roleURI="http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpensesScheduleOfAccruedExpensesDetail" roleURI="http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRentCreditCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationNoncurrent" xlink:label="loc_KPTI_DeferredRoyaltyObligationNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_KPTI_DeferredRoyaltyObligationNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" use="optional" order="19" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ReceivablesNetCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" use="optional" order="30" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xlink:label="loc_KPTI_ProceedsFromPaymentsForCommonStockIssuanceNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_KPTI_ProceedsFromPaymentsForCommonStockIssuanceNet" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromDeferredRoyaltyObligation" xlink:label="loc_KPTI_ProceedsFromDeferredRoyaltyObligation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_KPTI_ProceedsFromDeferredRoyaltyObligation" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xlink:label="loc_KPTI_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_KPTI_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="25" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_KPTI_AccruedResearchAndDevelopmentCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_KPTI_AccruedResearchAndDevelopmentCostsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xlink:label="loc_KPTI_DeferredTaxLiabilitiesConvertibleDebtAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_KPTI_DeferredTaxLiabilitiesConvertibleDebtAmortization" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xlink:label="loc_KPTI_DeferredTaxAssetsDeferredRoyaltyObligation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_KPTI_DeferredTaxAssetsDeferredRoyaltyObligation" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_KPTI_DeferredTaxAssetsRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_KPTI_DeferredTaxAssetsRightOfUseAsset" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xlink:label="loc_KPTI_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_KPTI_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xlink:label="loc_KPTI_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_KPTI_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="loc_KPTI_DeferredTaxAssetsFixedAssetsAndIntangibles" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_KPTI_DeferredTaxAssetsFixedAssetsAndIntangibles" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsLeaseLiability" xlink:label="loc_KPTI_DeferredTaxAssetsLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_KPTI_DeferredTaxAssetsLeaseLiability" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xlink:label="loc_KPTI_DeferredTaxAssetsRoyaltyEmbadedDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_KPTI_DeferredTaxAssetsRoyaltyEmbadedDerivatives" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoods" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="5" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>kpti-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-February-2020 [12:33:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#ProductRevenue" roleURI="http://www.karyopharm.com/role/ProductRevenue" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreements" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligations" roleURI="http://www.karyopharm.com/role/LongTermObligations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#ProductRevenueTables" roleURI="http://www.karyopharm.com/role/ProductRevenueTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationTables" roleURI="http://www.karyopharm.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsTables" roleURI="http://www.karyopharm.com/role/LongTermObligationsTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" roleURI="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#NetLossPerShareAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationSummaryOfRsuActivityDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CoverPage" roleURI="http://www.karyopharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#Investments" roleURI="http://www.karyopharm.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsTables" roleURI="http://www.karyopharm.com/role/InvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensation" roleURI="http://www.karyopharm.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingencies" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#Inventory" roleURI="http://www.karyopharm.com/role/Inventory" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InventoryTables" roleURI="http://www.karyopharm.com/role/InventoryTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InventoryScheduleOfInventoryCurrentDetail" roleURI="http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxes" roleURI="http://www.karyopharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesTable" roleURI="http://www.karyopharm.com/role/IncomeTaxesTable" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#OrganizationAndOperations" roleURI="http://www.karyopharm.com/role/OrganizationAndOperations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#OrganizationAndOperationsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNet" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail" roleURI="http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#RelatedPartyTransactions" roleURI="http://www.karyopharm.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpenses" roleURI="http://www.karyopharm.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpensesTables" roleURI="http://www.karyopharm.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpensesScheduleOfAccruedExpensesDetail" roleURI="http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#KPlan" roleURI="http://www.karyopharm.com/role/KPlan" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#KPlanAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/KPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockholdersEquity" roleURI="http://www.karyopharm.com/role/StockholdersEquity" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_500699" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_70" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_NetIncomeLoss_69" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_OperatingIncomeLoss_66" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_71" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_StatementTable_500696" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_500768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_500696" xlink:to="loc_srt_ProductOrServiceAxis_500768" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_500768" xlink:to="loc_srt_ProductsAndServicesDomain_500769" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500769_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_500768" xlink:to="loc_srt_ProductsAndServicesDomain_500769_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_500770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_500769" xlink:to="loc_us-gaap_ProductMember_500770" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAndOtherMember" xlink:label="loc_kpti_LicenseAndOtherMember_500771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_500769" xlink:to="loc_kpti_LicenseAndOtherMember_500771" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_500700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_OperatingExpensesAbstract_500700" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_77" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_OperatingExpenses_78" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_500707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_500707" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_InterestExpense_73" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_InvestmentIncomeInterest_72" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_74" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500702" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500702" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_125" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_137" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_NetIncomeLoss_140" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_138" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_SharesIssued_132" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StatementTable_126" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_124" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_124" xlink:to="loc_us-gaap_EquityComponentDomain_123" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_123_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_124" xlink:to="loc_us-gaap_EquityComponentDomain_123_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_129" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_128" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_CommonStockMember_127" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_RetainedEarningsMember_130" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockholdersEquity_131" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_136" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_134" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_135" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_467967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_467967" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_467968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_467968" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome_576316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome_576316" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_576324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_576324" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xlink:label="loc_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt_576327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt_576327" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_508927" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_StockIssuanceCosts" xlink:label="loc_kpti_StockIssuanceCosts_508922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_508927" xlink:to="loc_kpti_StockIssuanceCosts_508922" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_508924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_508927" xlink:to="loc_us-gaap_StatementTable_508924" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_508966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_508924" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_508966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_508967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_508966" xlink:to="loc_us-gaap_EquityComponentDomain_508967" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_508967_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_508966" xlink:to="loc_us-gaap_EquityComponentDomain_508967_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_508968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_508967" xlink:to="loc_us-gaap_CommonStockMember_508968" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_508925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_508924" xlink:to="loc_us-gaap_TypeOfArrangementAxis_508925" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_508925" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_508925" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_kpti_ControlledEquityOfferingSalesAgreementMember_508945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942" xlink:to="loc_kpti_ControlledEquityOfferingSalesAgreementMember_508945" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/ProductRevenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_501551" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_500792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_501551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_500792" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_501548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_501551" xlink:to="loc_us-gaap_StatementTable_501548" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_501552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_501548" xlink:to="loc_srt_ProductOrServiceAxis_501552" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_501553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_501552" xlink:to="loc_srt_ProductsAndServicesDomain_501553" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_501553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_501552" xlink:to="loc_srt_ProductsAndServicesDomain_501553_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_501554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_501553" xlink:to="loc_us-gaap_ProductMember_501554" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_500885" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500885" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_594" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_500885" xlink:to="loc_us-gaap_StatementTable_500882" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_500883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_500882" xlink:to="loc_srt_ProductOrServiceAxis_500883" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_500883" xlink:to="loc_srt_ProductsAndServicesDomain_500884" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500884_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_500883" xlink:to="loc_srt_ProductsAndServicesDomain_500884_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAndAssetPurchaseAgreementsMember" xlink:label="loc_kpti_LicenseAndAssetPurchaseAgreementsMember_500946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_500884" xlink:to="loc_kpti_LicenseAndAssetPurchaseAgreementsMember_500946" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_633" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_633" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_636" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_633" xlink:to="loc_us-gaap_StatementTable_634" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_634" xlink:to="loc_us-gaap_DebtInstrumentAxis_631" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_631" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_632" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_632_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_631" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_632_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_632" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_635" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/ProductRevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_500805" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_500805" xlink:to="loc_us-gaap_StatementTable_500802" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_500808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_500802" xlink:to="loc_srt_ProductOrServiceAxis_500808" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_500808" xlink:to="loc_srt_ProductsAndServicesDomain_500809" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500809_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_500808" xlink:to="loc_srt_ProductsAndServicesDomain_500809_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_XpovioMember" xlink:label="loc_kpti_XpovioMember_500810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_500809" xlink:to="loc_kpti_XpovioMember_500810" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xlink:label="loc_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock_500806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_500805" xlink:to="loc_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock_500806" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_577039" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_619" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_618" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_575943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_575943" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_575945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_575945" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_575947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_StatementTable_575947" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_575948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_575947" xlink:to="loc_us-gaap_PlanNameAxis_575948" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_575949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_575948" xlink:to="loc_us-gaap_PlanNameDomain_575949" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_575949_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_575948" xlink:to="loc_us-gaap_PlanNameDomain_575949_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember_575957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_575949" xlink:to="loc_kpti_EmployeeStockPurchasePlanMember_575957" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_577040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_575947" xlink:to="loc_us-gaap_AwardTypeAxis_577040" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_577040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_577040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577043" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_641" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_644" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xlink:label="loc_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock_645" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_646" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_us-gaap_StatementTable_642" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_642" xlink:to="loc_us-gaap_DebtInstrumentAxis_639" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_639" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_640" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_640_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_639" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_640_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_640" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_643" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccountingPoliciesAndGeneralInformationLineItems" xlink:label="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_576339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_576339" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_576839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_576839" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_576840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_OperatingLeaseLiability_576840" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_576847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_NumberOfOperatingSegments_576847" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_576863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_576863" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccountingPoliciesAndGeneralInformationTable" xlink:label="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_576876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" xlink:to="loc_srt_RangeAxis_576876" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_576878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_576876" xlink:to="loc_srt_RangeMember_576878" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_576878_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_576876" xlink:to="loc_srt_RangeMember_576878_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_576879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_576878" xlink:to="loc_srt_MaximumMember_576879" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_576880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_576878" xlink:to="loc_srt_MinimumMember_576880" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_607424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" xlink:to="loc_us-gaap_TypeOfAdoptionMember_607424" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_607424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" xlink:to="loc_us-gaap_TypeOfAdoptionMember_607424_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_607427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_607424" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_607427" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_296" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_296" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_296" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" xlink:to="loc_us-gaap_CertificatesOfDepositMember_315" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" xlink:to="loc_us-gaap_MoneyMarketFundsMember_314" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_307" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_308" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_460495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_460495" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_FinancialInstrumentAxis_301" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_301" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_301" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" xlink:to="loc_us-gaap_CommercialPaperMember_317" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_316" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_318" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_InvestmentTypeAxis_303" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_303" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_304" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_304_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_303" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_304_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LongTermInvestmentsMember" xlink:label="loc_kpti_LongTermInvestmentsMember_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_304" xlink:to="loc_kpti_LongTermInvestmentsMember_313" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_304" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_312" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_311" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" xlink:to="loc_us-gaap_AvailableForSaleSecurities_310" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_309" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_500964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_500964" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_500965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_500964" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_500965" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_575199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_575199" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_575199_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_575199_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_575200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_575199" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_575200" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_575203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_575203" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_575204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_575204" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_575205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_575205" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_355" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_355" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_358" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_355" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" xlink:to="loc_us-gaap_AwardTypeAxis_354" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_360" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_501732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_501732" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_501732_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_501732_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityContractMember" xlink:label="loc_us-gaap_EquityContractMember_501733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_501732" xlink:to="loc_us-gaap_EquityContractMember_501733" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_501734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityContractMember_501733" xlink:to="loc_us-gaap_StockOptionMember_501734" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail">
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xlink:label="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AdjustmentsForChangeInAccountingPrincipleTable" xlink:label="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" xlink:to="loc_srt_RestatementAxis_161" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_161" xlink:to="loc_srt_RestatementDomain_162" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_162_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_161" xlink:to="loc_srt_RestatementDomain_162_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_162" xlink:to="loc_srt_RestatementAdjustmentMember_169" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_162" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_168" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_164" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_165" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_OperatingLeaseLiability_166" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_167" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_575251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_EquipmentMember_575251" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_575252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_575252" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_575253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_OfficeEquipmentMember_575253" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_575254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_575254" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_575256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_575256" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_575259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_575259" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_575261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_575261" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_575263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_575263" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_575265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_575265" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_333" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_334" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_332" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_335" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_321" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_321" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_321" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326" xlink:to="loc_us-gaap_CertificatesOfDepositMember_331" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_FinancialInstrumentAxis_323" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_337" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_336" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_338" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_InvestmentTypeAxis_324" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_324" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_325" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_324" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_325_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LongTermInvestmentsMember" xlink:label="loc_kpti_LongTermInvestmentsMember_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_325" xlink:to="loc_kpti_LongTermInvestmentsMember_330" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_325" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_329" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_349" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xlink:label="loc_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments_350" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_346" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_348" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_347" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_345" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" xlink:to="loc_us-gaap_FinancialInstrumentAxis_341" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_341" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_341" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_351" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_575754" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_575754" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_575752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_575752" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_575753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_575752" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_575753" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_575753_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_575752" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_575753_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConsultingAndHistopathologyServicesMember" xlink:label="loc_kpti_ConsultingAndHistopathologyServicesMember_575755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_575753" xlink:to="loc_kpti_ConsultingAndHistopathologyServicesMember_575755" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConsultingAndContractResearchServicesMember" xlink:label="loc_kpti_ConsultingAndContractResearchServicesMember_575756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_575753" xlink:to="loc_kpti_ConsultingAndContractResearchServicesMember_575756" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_575757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_575754" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_575757" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_575758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_575754" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_575758" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EquityOfferingLineItems" xlink:label="loc_kpti_EquityOfferingLineItems_483" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AggregateOfferingPrice" xlink:label="loc_kpti_AggregateOfferingPrice_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_AggregateOfferingPrice_495" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xlink:label="loc_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares_496" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_494" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xlink:label="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_srt_CounterpartyNameAxis_481" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_481" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_481" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_JefferiesLLCMember" xlink:label="loc_kpti_JefferiesLLCMember_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" xlink:to="loc_kpti_JefferiesLLCMember_498" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CantorFitzgeraldAndCoMember" xlink:label="loc_kpti_CantorFitzgeraldAndCoMember_575668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" xlink:to="loc_kpti_CantorFitzgeraldAndCoMember_575668" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_srt_RangeAxis_484" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_484" xlink:to="loc_srt_RangeMember_485" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_485_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_484" xlink:to="loc_srt_RangeMember_485_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_485" xlink:to="loc_srt_MaximumMember_497" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_488" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_488" xlink:to="loc_us-gaap_EquityComponentDomain_482" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_482_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_488" xlink:to="loc_us-gaap_EquityComponentDomain_482_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_482" xlink:to="loc_us-gaap_CommonStockMember_491" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_468835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_468835" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_468836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_468835" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_468836" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_468836_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_468835" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_468836_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_us-gaap_TypeOfArrangementAxis_489" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_489" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_489" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OpenMarketSaleAgreementMember" xlink:label="loc_kpti_OpenMarketSaleAgreementMember_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" xlink:to="loc_kpti_OpenMarketSaleAgreementMember_490" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_kpti_ControlledEquityOfferingSalesAgreementMember_575666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" xlink:to="loc_kpti_ControlledEquityOfferingSalesAgreementMember_575666" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_SharePrice_493" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_468834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_468834" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_500947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_500947" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SaleAgreementTerminationDate" xlink:label="loc_kpti_SaleAgreementTerminationDate_577298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_SaleAgreementTerminationDate_577298" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LeasesLineItems" xlink:label="loc_kpti_LeasesLineItems_444" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_452" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_457" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_456" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LeasesTable" xlink:label="loc_kpti_LeasesTable_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_kpti_LeasesTable_445" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" xlink:to="loc_us-gaap_TypeOfAdoptionMember_450" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" xlink:to="loc_us-gaap_TypeOfAdoptionMember_450_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_450" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_466" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_442" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_442" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_443" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_443_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_442" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_443_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OfficeAndResearchSpaceLeaseMember" xlink:label="loc_kpti_OfficeAndResearchSpaceLeaseMember_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_443" xlink:to="loc_kpti_OfficeAndResearchSpaceLeaseMember_451" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CommonAreaMaintenanceMember" xlink:label="loc_kpti_CommonAreaMaintenanceMember_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447" xlink:to="loc_kpti_CommonAreaMaintenanceMember_463" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_srt_StatementGeographicalAxis_449" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_449" xlink:to="loc_srt_SegmentGeographicalDomain_448" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_449" xlink:to="loc_srt_SegmentGeographicalDomain_448_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_462" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_461" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_OperatingLeaseCost_458" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_SecurityDeposit_453" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_AccountsReceivableNet_203" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_ContractWithCustomerLiability_198" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationDescription" xlink:label="loc_kpti_LicenseAgreementTerminationDescription_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_LicenseAgreementTerminationDescription_201" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationNoticePeriod" xlink:label="loc_kpti_LicenseAgreementTerminationNoticePeriod_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_LicenseAgreementTerminationNoticePeriod_200" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_PotentialCommercialMilestonePayments_204" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPotentialFutureMilestonePayments" xlink:label="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_199" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_202" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_Revenues_205" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" xlink:to="loc_us-gaap_ProjectMember_179" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" xlink:to="loc_us-gaap_ProjectMember_179_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EltanexorMember" xlink:label="loc_kpti_EltanexorMember_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_EltanexorMember_194" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_KPT9274Member" xlink:label="loc_kpti_KPT9274Member_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_KPT9274Member_195" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SelinexorMember" xlink:label="loc_kpti_SelinexorMember_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_SelinexorMember_193" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VerdinexorMember" xlink:label="loc_kpti_VerdinexorMember_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_VerdinexorMember_196" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174" xlink:to="loc_us-gaap_UpFrontPaymentArrangementMember_188" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_MajorCustomersAxis_175" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_175" xlink:to="loc_srt_NameOfMajorCustomerDomain_176" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_175" xlink:to="loc_srt_NameOfMajorCustomerDomain_176_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AntengeneTherapeuticsLimitedMember" xlink:label="loc_kpti_AntengeneTherapeuticsLimitedMember_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_176" xlink:to="loc_kpti_AntengeneTherapeuticsLimitedMember_189" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_ProductOrServiceAxis_177" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_177" xlink:to="loc_srt_ProductsAndServicesDomain_178" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_178_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_177" xlink:to="loc_srt_ProductsAndServicesDomain_178_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentGoalsMember" xlink:label="loc_kpti_DevelopmentGoalsMember_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_178" xlink:to="loc_kpti_DevelopmentGoalsMember_192" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentMilestoneMember" xlink:label="loc_kpti_DevelopmentMilestoneMember_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_178" xlink:to="loc_kpti_DevelopmentMilestoneMember_190" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesEventsMember" xlink:label="loc_kpti_SalesEventsMember_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_178" xlink:to="loc_kpti_SalesEventsMember_191" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_RangeAxis_180" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_180" xlink:to="loc_srt_RangeMember_181" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_180" xlink:to="loc_srt_RangeMember_181_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_181" xlink:to="loc_srt_MaximumMember_197" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_208" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_StatementScenarioAxis_187" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_187" xlink:to="loc_srt_ScenarioUnspecifiedDomain_185" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_185_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_187" xlink:to="loc_srt_ScenarioUnspecifiedDomain_185_default" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_AccountsReceivableNet_229" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_231" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_kpti_PotentialCommercialMilestonePayments_230" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_MajorCustomersAxis_212" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_212" xlink:to="loc_srt_NameOfMajorCustomerDomain_213" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_212" xlink:to="loc_srt_NameOfMajorCustomerDomain_213_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_BiogenMAIncMember" xlink:label="loc_kpti_BiogenMAIncMember_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_213" xlink:to="loc_kpti_BiogenMAIncMember_224" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_ProductOrServiceAxis_214" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_214" xlink:to="loc_srt_ProductsAndServicesDomain_215" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_215_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_214" xlink:to="loc_srt_ProductsAndServicesDomain_215_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesMilestoneMember" xlink:label="loc_kpti_SalesMilestoneMember_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_215" xlink:to="loc_kpti_SalesMilestoneMember_225" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AssetPurchaseAgreementMember" xlink:label="loc_kpti_AssetPurchaseAgreementMember_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217" xlink:to="loc_kpti_AssetPurchaseAgreementMember_226" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_RangeAxis_218" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_218" xlink:to="loc_srt_RangeMember_219" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_218" xlink:to="loc_srt_RangeMember_219_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_219" xlink:to="loc_srt_MaximumMember_227" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_StatementScenarioAxis_223" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_223" xlink:to="loc_srt_ScenarioUnspecifiedDomain_221" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_221_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_223" xlink:to="loc_srt_ScenarioUnspecifiedDomain_221_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_221" xlink:to="loc_us-gaap_ScenarioPlanMember_232" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_UpfrontPaymentReceived" xlink:label="loc_kpti_UpfrontPaymentReceived_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_kpti_UpfrontPaymentReceived_228" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_501613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_501613" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_AccountsReceivableNet_264" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_ContractWithCustomerLiability_259" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_267" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationDescription" xlink:label="loc_kpti_LicenseAgreementTerminationDescription_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_LicenseAgreementTerminationDescription_262" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationNoticePeriod" xlink:label="loc_kpti_LicenseAgreementTerminationNoticePeriod_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_LicenseAgreementTerminationNoticePeriod_261" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_PotentialCommercialMilestonePayments_265" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPotentialFutureMilestonePayments" xlink:label="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_260" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_263" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_Revenues_266" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" xlink:to="loc_us-gaap_ProjectMember_242" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" xlink:to="loc_us-gaap_ProjectMember_242_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EltanexorMember" xlink:label="loc_kpti_EltanexorMember_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_242" xlink:to="loc_kpti_EltanexorMember_257" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SelinexorMember" xlink:label="loc_kpti_SelinexorMember_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_242" xlink:to="loc_kpti_SelinexorMember_256" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237" xlink:to="loc_us-gaap_UpFrontPaymentArrangementMember_251" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_MajorCustomersAxis_238" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_238" xlink:to="loc_srt_NameOfMajorCustomerDomain_239" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_239_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_238" xlink:to="loc_srt_NameOfMajorCustomerDomain_239_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OnoPharmaceuticalCompanyLimitedMember" xlink:label="loc_kpti_OnoPharmaceuticalCompanyLimitedMember_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_239" xlink:to="loc_kpti_OnoPharmaceuticalCompanyLimitedMember_252" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_ProductOrServiceAxis_240" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_240" xlink:to="loc_srt_ProductsAndServicesDomain_241" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_241_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_240" xlink:to="loc_srt_ProductsAndServicesDomain_241_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_241" xlink:to="loc_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember_255" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentGoalsMember" xlink:label="loc_kpti_DevelopmentGoalsMember_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_241" xlink:to="loc_kpti_DevelopmentGoalsMember_253" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesEventsMember" xlink:label="loc_kpti_SalesEventsMember_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_241" xlink:to="loc_kpti_SalesEventsMember_254" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_RangeAxis_243" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_243" xlink:to="loc_srt_RangeMember_244" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_243" xlink:to="loc_srt_RangeMember_244_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_244" xlink:to="loc_srt_MaximumMember_258" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_268" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_StatementScenarioAxis_250" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_250" xlink:to="loc_srt_ScenarioUnspecifiedDomain_248" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_250" xlink:to="loc_srt_ScenarioUnspecifiedDomain_248_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_248" xlink:to="loc_us-gaap_ScenarioPlanMember_269" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_365" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_368" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_StatementTable_366" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_366" xlink:to="loc_us-gaap_DebtInstrumentAxis_363" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_363" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_364" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_363" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_364_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_364" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_367" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_407" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_416" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_409" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_411" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_408" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xlink:label="loc_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance_417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_AwardTypeAxis_395" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_395" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_395" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_420" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_575964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_575964" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_575975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_us-gaap_RestrictedStockMember_575975" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_PlanNameAxis_396" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_396" xlink:to="loc_us-gaap_PlanNameDomain_397" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_397_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_396" xlink:to="loc_us-gaap_PlanNameDomain_397_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_397" xlink:to="loc_kpti_EmployeeStockPurchasePlanMember_404" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TwoThousandThirteenStockOptionPlanMember" xlink:label="loc_kpti_TwoThousandThirteenStockOptionPlanMember_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_397" xlink:to="loc_kpti_TwoThousandThirteenStockOptionPlanMember_403" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TwothousandtenstockoptionplanmemberMember" xlink:label="loc_kpti_TwothousandtenstockoptionplanmemberMember_575963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_397" xlink:to="loc_kpti_TwothousandtenstockoptionplanmemberMember_575963" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_srt_RangeAxis_398" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_398" xlink:to="loc_srt_RangeMember_399" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_399_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_398" xlink:to="loc_srt_RangeMember_399_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_399" xlink:to="loc_srt_MaximumMember_406" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_399" xlink:to="loc_srt_MinimumMember_405" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_575980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_VestingAxis_575980" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_575981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_575980" xlink:to="loc_us-gaap_VestingDomain_575981" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_575981_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_575980" xlink:to="loc_us-gaap_VestingDomain_575981_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VestingperiodonememberMember" xlink:label="loc_kpti_VestingperiodonememberMember_575983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_575981" xlink:to="loc_kpti_VestingperiodonememberMember_575983" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VestingperiodtwomemberMember" xlink:label="loc_kpti_VestingperiodtwomemberMember_575985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_575981" xlink:to="loc_kpti_VestingperiodtwomemberMember_575985" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_418" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_415" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:label="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_410" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_413" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_414" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_575961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_575961" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_575962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_575962" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan_576002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan_576002" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual_576004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual_576004" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual_576005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual_576005" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_576007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_576007" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_576008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_576008" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_576012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_576012" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_576039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_576039" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_576043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_576043" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_576522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_576522" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RightsReceivedForEachRestrictedShareUnit" xlink:label="loc_kpti_RightsReceivedForEachRestrictedShareUnit_576933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_RightsReceivedForEachRestrictedShareUnit_576933" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_576967" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_576967" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_575855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_575855" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_575857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_575855" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_575857" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_575857_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_575855" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_575857_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_575858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_575857" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_575858" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_575860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_575857" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_575860" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_576968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_576967" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_576968" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" xlink:to="loc_us-gaap_AwardTypeAxis_372" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_372" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_372" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_392" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_391" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_381" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_387" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_379" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_377" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_390" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_376" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_382" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_388" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_389" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_384" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_385" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_383" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_378" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_576072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_576072" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_576074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_576074" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_576076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_576076" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_576078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_576078" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_576080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" xlink:to="loc_srt_RangeAxis_576080" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_576081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_576080" xlink:to="loc_srt_RangeMember_576081" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_576081_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_576080" xlink:to="loc_srt_RangeMember_576081_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_576082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_576081" xlink:to="loc_srt_MinimumMember_576082" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_576083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_576081" xlink:to="loc_srt_MaximumMember_576083" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_577055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" xlink:to="loc_us-gaap_AwardTypeAxis_577055" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_577055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_577055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577063" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" xlink:to="loc_us-gaap_AwardTypeAxis_424" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_424" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_424" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_438" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_430" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_429" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_434" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_428" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_433" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_431" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_436" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_575897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_575897" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_575898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_575898" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_575902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_575902" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_575909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" xlink:to="loc_srt_RangeAxis_575909" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_575910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_575909" xlink:to="loc_srt_RangeMember_575910" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_575910_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_575909" xlink:to="loc_srt_RangeMember_575910_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_575911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_575910" xlink:to="loc_srt_MaximumMember_575911" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_575912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_575910" xlink:to="loc_srt_MinimumMember_575912" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" xlink:to="loc_us-gaap_PlanNameAxis_576126" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_576127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_576126" xlink:to="loc_us-gaap_PlanNameDomain_576127" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_576127_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_576126" xlink:to="loc_us-gaap_PlanNameDomain_576127_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember_576129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_576127" xlink:to="loc_kpti_EmployeeStockPurchasePlanMember_576129" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_575920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_575920" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncomeTaxDisclosureLineItems" xlink:label="loc_kpti_IncomeTaxDisclosureLineItems_575118" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncomeTaxDisclosureTableTable" xlink:label="loc_kpti_IncomeTaxDisclosureTableTable_575088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_IncomeTaxDisclosureTableTable_575088" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_575089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_575089" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_575090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_575089" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_575090" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_575090_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_575089" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_575090_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_575094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_575090" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_575094" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_575106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_575106" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_575108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" xlink:to="loc_us-gaap_TypeOfAdoptionMember_575108" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_575108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" xlink:to="loc_us-gaap_TypeOfAdoptionMember_575108_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_575109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_575108" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_575109" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_575111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_575111" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_575111" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_575111" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_575113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112" xlink:to="loc_us-gaap_ResearchMember_575113" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_575114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_srt_StatementGeographicalAxis_575114" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_575115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_575114" xlink:to="loc_srt_SegmentGeographicalDomain_575115" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_575115_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_575114" xlink:to="loc_srt_SegmentGeographicalDomain_575115_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_575117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_575115" xlink:to="loc_country_DE_575117" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_590705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_srt_RangeAxis_590705" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_590707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_590705" xlink:to="loc_srt_RangeMember_590707" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_590707_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_590705" xlink:to="loc_srt_RangeMember_590707_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_590709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_590707" xlink:to="loc_srt_MaximumMember_590709" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575119" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xlink:label="loc_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges_575120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges_575120" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xlink:label="loc_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets_575122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets_575122" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_575123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_575123" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_575126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_575126" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_575130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_OperatingLossCarryforwards_575130" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:label="loc_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_575135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_575135" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xlink:label="loc_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation_575139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation_575139" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_575141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_575141" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_575146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_575146" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:label="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575162" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:label="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575167" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_575168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_575168" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_575173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_575173" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_606331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_606331" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_507" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_514" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_534" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_520" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_519" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_532" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_521" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleLatestDate1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleLatestDate1_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleLatestDate1_523" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_526" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xlink:label="loc_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock_529" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xlink:label="loc_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription_527" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentEstimatedFairValue" xlink:label="loc_kpti_DebtInstrumentEstimatedFairValue_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentEstimatedFairValue_535" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_512" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_517" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_518" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xlink:label="loc_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent_531" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_524" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentRepurchasePricePercentage" xlink:label="loc_kpti_DebtInstrumentRepurchasePricePercentage_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentRepurchasePricePercentage_530" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentTerm_536" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xlink:label="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod_516" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xlink:label="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes_515" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_513" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PrincipalAmountOfNotesUsedInConversionRate" xlink:label="loc_kpti_PrincipalAmountOfNotesUsedInConversionRate_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_PrincipalAmountOfNotesUsedInConversionRate_528" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PrincipalAmountPerNoteUsedInConversionRate" xlink:label="loc_kpti_PrincipalAmountPerNoteUsedInConversionRate_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_PrincipalAmountPerNoteUsedInConversionRate_522" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_533" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_SubsequentEventTable_508" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_DebtInstrumentAxis_501" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_501" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_502" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_502_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_501" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_502_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_502" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_509" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_504" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_504" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_505" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_504" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_505_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_505" xlink:to="loc_us-gaap_ConvertibleDebtMember_511" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_468948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_srt_StatementScenarioAxis_468948" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_468949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_468948" xlink:to="loc_srt_ScenarioUnspecifiedDomain_468949" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_468949_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_468948" xlink:to="loc_srt_ScenarioUnspecifiedDomain_468949_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_468950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_468949" xlink:to="loc_srt_ScenarioForecastMember_468950" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_dei_LegalEntityAxis_500896" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_500897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_500896" xlink:to="loc_dei_EntityDomain_500897" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_500897_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_500896" xlink:to="loc_dei_EntityDomain_500897_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_HealthcareRoyaltyPartnersIvLpMember" xlink:label="loc_kpti_HealthcareRoyaltyPartnersIvLpMember_500898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_500897" xlink:to="loc_kpti_HealthcareRoyaltyPartnersIvLpMember_500898" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateAxis" xlink:label="loc_kpti_RoyaltyPaymentDueDateAxis_500903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_kpti_RoyaltyPaymentDueDateAxis_500903" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateDomain" xlink:label="loc_kpti_RoyaltyPaymentDueDateDomain_500905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_kpti_RoyaltyPaymentDueDateAxis_500903" xlink:to="loc_kpti_RoyaltyPaymentDueDateDomain_500905" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateDomain" xlink:label="loc_kpti_RoyaltyPaymentDueDateDomain_500905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_kpti_RoyaltyPaymentDueDateAxis_500903" xlink:to="loc_kpti_RoyaltyPaymentDueDateDomain_500905_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" xlink:label="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember_500906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_RoyaltyPaymentDueDateDomain_500905" xlink:to="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember_500906" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" xlink:label="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember_500908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_RoyaltyPaymentDueDateDomain_500905" xlink:to="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember_500908" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_500912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_500912" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_500913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_500912" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_500913" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_500913_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_500912" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_500913_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationMember" xlink:label="loc_kpti_DeferredRoyaltyObligationMember_500914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_500913" xlink:to="loc_kpti_DeferredRoyaltyObligationMember_500914" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_500923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_500923" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_500891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_TypeOfArrangementAxis_500891" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_500891" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_500891" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueInterestFinancingAgreementMember" xlink:label="loc_kpti_RevenueInterestFinancingAgreementMember_500893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892" xlink:to="loc_kpti_RevenueInterestFinancingAgreementMember_500893" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromFirstInvestmentAmount" xlink:label="loc_kpti_ProceedsFromFirstInvestmentAmount_500889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_ProceedsFromFirstInvestmentAmount_500889" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SecondInvestmentAmount" xlink:label="loc_kpti_SecondInvestmentAmount_500890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_SecondInvestmentAmount_500890" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentsApplicableTieredPercentage" xlink:label="loc_kpti_RoyaltyPaymentsApplicableTieredPercentage_500894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_RoyaltyPaymentsApplicableTieredPercentage_500894" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_kpti_RoyaltyGuaranteesCommitmentsPercentage_500900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_RoyaltyGuaranteesCommitmentsPercentage_500900" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_500917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_500917" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_500920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_500920" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_501009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_501009" use="optional" order="65" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_542" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_542" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_548" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentLiabilityComponentAbstract" xlink:label="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_542" xlink:to="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" xlink:to="loc_us-gaap_ConvertibleDebt_547" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_545" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xlink:label="loc_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" xlink:to="loc_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance_546" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_542" xlink:to="loc_us-gaap_DebtInstrumentTable_544" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_544" xlink:to="loc_us-gaap_DebtInstrumentAxis_540" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_540" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_543" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_543_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_540" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_543_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_543" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_549" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_553" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_557" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_558" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_DebtInstrumentTable_555" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_555" xlink:to="loc_us-gaap_DebtInstrumentAxis_552" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_552" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_554" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_554_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_552" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_554_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_554" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_560" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_InterestExpenseDebt_559" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_556" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_564" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_572" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_DebtInstrumentTable_566" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_566" xlink:to="loc_us-gaap_DebtInstrumentAxis_563" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_563" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_565" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_565_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_563" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_565_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_565" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_577" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_574" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_573" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebt_576" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtCurrent_575" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_571" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_567" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_570" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_569" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_568" use="optional" order="15" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>kpti-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-February-2020 [12:33:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">EntityInteractiveDataCurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Short-term restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Long-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease and right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US">Long-term restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent non-current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred revenue, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US">Deferred Rent Credit, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Non-current operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized; 65,370,448 and 60,829,308 shares issued and outstanding at December 31, 2019 and 2018, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationNoncurrent" xlink:label="loc_kpti_DeferredRoyaltyObligationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredRoyaltyObligationNoncurrent" xml:lang="en-US">Deferred Royalty Obligation Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DeferredRoyaltyObligationNoncurrent" xml:lang="en-US">Deferred royalty obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredRoyaltyObligationNoncurrent" xlink:to="lab_kpti_DeferredRoyaltyObligationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredRoyaltyObligationNoncurrent" xml:lang="en-US">Deferred Royalty Obligation Noncurrent</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 9)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted-average number of common shares outstanding used in net loss per share&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (expense) income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenues:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product Revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAndOtherMember" xlink:label="loc_kpti_LicenseAndOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LicenseAndOtherMember" xml:lang="en-US">License And Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LicenseAndOtherMember" xml:lang="en-US">License and other revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LicenseAndOtherMember" xlink:to="lab_kpti_LicenseAndOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LicenseAndOtherMember" xml:lang="en-US">License And Other Revenue.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) on investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) on investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income (loss) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Beginning balance,Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Ending balance,Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Exercise of stock options and shares issued under the employee stock purchase plan, (shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Common stock available for payment related to tax withholding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Vesting of restricted stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options and shares issued under the employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" xml:lang="en-US">Cumulative effect adjustment for adoption of new accounting guidance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Equity component of 2025 Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Debt issuance costs allocated to equity component and recorded as a reduction to additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xlink:label="loc_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xml:lang="en-US">Equity Component Of Deferred Financing Costs Related To Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xml:lang="en-US">Equity component of deferred financing costs for 2025 notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xlink:to="lab_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xml:lang="en-US">Equity Component Of Deferred Financing Costs Related To Convertible Debt</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_StockIssuanceCosts" xlink:label="loc_kpti_StockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_StockIssuanceCosts" xml:lang="en-US">Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_StockIssuanceCosts" xml:lang="en-US">Issuance of stock, issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_StockIssuanceCosts" xlink:to="lab_kpti_StockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_StockIssuanceCosts" xml:lang="en-US">Represents the aggregate cost incurred directly with the issuance of an equity security.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_kpti_ControlledEquityOfferingSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ControlledEquityOfferingSalesAgreementMember" xml:lang="en-US">Controlled Equity Offering Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ControlledEquityOfferingSalesAgreementMember" xml:lang="en-US">Controlled Equity Offering Sales Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ControlledEquityOfferingSalesAgreementMember" xlink:to="lab_kpti_ControlledEquityOfferingSalesAgreementMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from the exercise of stock options and shares issued under employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xlink:label="loc_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xml:lang="en-US">Proceeds From Payments For Common Stock Issuance Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xlink:to="lab_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xml:lang="en-US">Proceeds from payments for common stock issuance net.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromDeferredRoyaltyObligation" xlink:label="loc_kpti_ProceedsFromDeferredRoyaltyObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ProceedsFromDeferredRoyaltyObligation" xml:lang="en-US">Proceeds From Deferred Royalty Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ProceedsFromDeferredRoyaltyObligation" xml:lang="en-US">Proceeds from deferred royalty obligation, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ProceedsFromDeferredRoyaltyObligation" xlink:to="lab_kpti_ProceedsFromDeferredRoyaltyObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ProceedsFromDeferredRoyaltyObligation" xml:lang="en-US">Proceeds From Deferred Royalty Obligation.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xlink:label="loc_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xml:lang="en-US">Proceeds From Issuance Of Convertible Senior Notes Net Of Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xml:lang="en-US">Proceeds from issuance of convertible senior notes, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xlink:to="lab_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xml:lang="en-US">Proceeds from issuance of convertible senior notes, net of issuance costs.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from maturities of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Net amortization of premiums and discounts on investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of the value of debt discount and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase Decrease in Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase decrease in operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xml:lang="en-US">Increase decrease in operating lease right of use asset.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xml:lang="en-US">Increase (Decrease) in Prepaid Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidRent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:label="loc_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:to="lab_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xml:lang="en-US">Cash paid for amounts included in measurement of operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Cash paid for interest on convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccruedExpensesDisclosureTextTextBlock" xlink:label="loc_kpti_AccruedExpensesDisclosureTextTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AccruedExpensesDisclosureTextTextBlock" xml:lang="en-US">Accrued Expenses Disclosure Text [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AccruedExpensesDisclosureTextTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AccruedExpensesDisclosureTextTextBlock" xlink:to="lab_kpti_AccruedExpensesDisclosureTextTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AccruedExpensesDisclosureTextTextBlock" xml:lang="en-US">Accrued expenses disclosure text block.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" xlink:label="loc_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" xml:lang="en-US">Related party transactions disclosure textBlock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" xlink:to="lab_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" xml:lang="en-US">Related party transactions disclosure textBlock.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Product Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">License and Asset Purchase Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAndAssetPurchaseAgreementsMember" xlink:label="loc_kpti_LicenseAndAssetPurchaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LicenseAndAssetPurchaseAgreementsMember" xml:lang="en-US">License and Asset Purchase Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LicenseAndAssetPurchaseAgreementsMember" xml:lang="en-US">License and Asset Purchase Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LicenseAndAssetPurchaseAgreementsMember" xlink:to="lab_kpti_LicenseAndAssetPurchaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LicenseAndAssetPurchaseAgreementsMember" xml:lang="en-US">License and Asset Purchase Agreements.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xml:lang="en-US">Three Percentage Convertible Senior Notes Due Two Thousand Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xml:lang="en-US">3% Convertible Senior Notes Due 2025 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:to="lab_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xml:lang="en-US">3% Convertible senior notes due two thousand twenty five.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Long-Term Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Product Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US">Cost of Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationPolicyTextBlock" xlink:label="loc_kpti_DeferredRoyaltyObligationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredRoyaltyObligationPolicyTextBlock" xml:lang="en-US">Deferred Royalty Obligation [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DeferredRoyaltyObligationPolicyTextBlock" xml:lang="en-US">Deferred Royalty Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredRoyaltyObligationPolicyTextBlock" xlink:to="lab_kpti_DeferredRoyaltyObligationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredRoyaltyObligationPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for deferred royalty obligation.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" xlink:label="loc_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Concentrations Of Credit Risk And Of Balance Sheet Risk Policy Text Block [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" xlink:to="lab_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Concentrations Of Credit Risk And Of Balance Sheet Risk Policy Text Block</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Accounting for Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xml:lang="en-US">Schedule of Financial Assets That Have Been Measured at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Our Embedded Derivative Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Summary of Investments, Classified as Available-for-Sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Minimum Future Rent Payments Under Lease Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xlink:label="loc_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xml:lang="en-US">Schedule Of Product Discounts Returns Allowances Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xml:lang="en-US">Schedule of Product Discounts Returns Allowances Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xlink:to="lab_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xml:lang="en-US">Tabular disclosure of reconciliation of product discounts returns allowances.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_XpovioMember" xlink:label="loc_kpti_XpovioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_XpovioMember" xml:lang="en-US">XPOVIO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_XpovioMember" xlink:to="lab_kpti_XpovioMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_EmployeeStockPurchasePlanMember" xml:lang="en-US">ESPP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_EmployeeStockPurchasePlanMember" xlink:to="lab_kpti_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of RSU Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity for Employees and Nonemployees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_EmployeeAndNonEmployeeStockOptionMember" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_EmployeeAndNonEmployeeStockOptionMember" xml:lang="en-US">Employee and Nonemployee Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:to="lab_kpti_EmployeeAndNonEmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_EmployeeAndNonEmployeeStockOptionMember" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Significant Components of Company's Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" xlink:label="loc_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" xml:lang="en-US">Components Of Income Loss Before Income Taxes [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" xml:lang="en-US">Schedule of Components of Income (Loss) Before Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" xlink:to="lab_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" xml:lang="en-US">Components Of Income Loss Before Income Taxes Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Summary of Outstanding Balances of Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xlink:label="loc_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xml:lang="en-US">Scheduleof Interest Expense Recognized Relatedto Convertible Notes Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xml:lang="en-US">Schedule of Interest Expense Recognized Related to Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xlink:to="lab_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xml:lang="en-US">Scheduleof Interest Expense Recognized Relatedto Convertible Notes Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Summary of Future Minimum Payments on Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RegulatoryAssetsAbstract" xlink:label="loc_kpti_RegulatoryAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RegulatoryAssetsAbstract" xml:lang="en-US">Regulatory Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RegulatoryAssetsAbstract" xlink:to="lab_kpti_RegulatoryAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RegulatoryAssetsAbstract" xml:lang="en-US">Regulatory Assets [Abstract]</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccountingPoliciesAndGeneralInformationTable" xlink:label="loc_kpti_AccountingPoliciesAndGeneralInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AccountingPoliciesAndGeneralInformationTable" xml:lang="en-US">Accounting Policies And General Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationTable" xlink:to="lab_kpti_AccountingPoliciesAndGeneralInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AccountingPoliciesAndGeneralInformationTable" xml:lang="en-US">Accounting policies and general information [Table].</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccountingPoliciesAndGeneralInformationLineItems" xlink:label="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AccountingPoliciesAndGeneralInformationLineItems" xml:lang="en-US">Accounting Policies And General Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems" xlink:to="lab_kpti_AccountingPoliciesAndGeneralInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AccountingPoliciesAndGeneralInformationLineItems" xml:lang="en-US">Accounting Policies And General Information [Line item].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xml:lang="en-US">Financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xml:lang="en-US">Financial liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xml:lang="en-US">Embedded derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xml:lang="en-US">Debt Security, Corporate, US [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government and Agency Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LongTermInvestmentsMember" xlink:label="loc_kpti_LongTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LongTermInvestmentsMember" xml:lang="en-US">Long Term Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LongTermInvestmentsMember" xml:lang="en-US">Long-term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LongTermInvestmentsMember" xlink:to="lab_kpti_LongTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LongTermInvestmentsMember" xml:lang="en-US">Long Term Investments [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-term Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" xml:lang="en-US">Financial Asset that have been measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Addition of derivative related to deferred royalty obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Change in fair value of derivative since issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Unvested Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Dilutive securities excluded from the calculation of diluted net loss per share due to anti-dilutive effect (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityContractMember" xlink:label="loc_us-gaap_EquityContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityContractMember" xml:lang="en-US">Equity Contract [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityContractMember" xlink:to="lab_us-gaap_EquityContractMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Outstanding Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AdjustmentsForChangeInAccountingPrincipleTable" xlink:label="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AdjustmentsForChangeInAccountingPrincipleTable" xml:lang="en-US">Adjustments For Change In Accounting Principle [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AdjustmentsForChangeInAccountingPrincipleTable" xml:lang="en-US">Adjustments For Change In Accounting Principle [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable" xlink:to="lab_kpti_AdjustmentsForChangeInAccountingPrincipleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AdjustmentsForChangeInAccountingPrincipleTable" xml:lang="en-US">Adjustments For Change In Accounting Principle [Table]</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xlink:label="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xml:lang="en-US">Adjustments For Change In Accounting Principle [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xml:lang="en-US">Adjustments For Change In Accounting Principle [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xlink:to="lab_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xml:lang="en-US">Adjustments For Change In Accounting Principle [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Restatement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Restatement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Restatement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Restatement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Restatement Adjustment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Restatement Adjustment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xml:lang="en-US">Commercial Paper [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Gross Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Gross Unrealized Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Unrealized losses , included in accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xml:lang="en-US">Amortized Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Debt Securities, Available-for-sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xlink:label="loc_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xml:lang="en-US">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xml:lang="en-US">Unrealized losses, other-than-temporary impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xlink:to="lab_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xml:lang="en-US">Available for sale securities accumulated gross unrealized loss before tax other than temporary impairments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xml:lang="en-US">Aggregate fair value of debt securities with unrealized loss position for less than one year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xml:lang="en-US">Aggregate fair value of corporate debt securities with continuous unrealized loss position for more than 12 months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xml:lang="en-US">Number of corporate debt securities with continuous unrealized loss position for more than 12 months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xml:lang="en-US">Number of debt securities with unrealized loss position for less than one year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Work in Process and Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" xml:lang="en-US">Raw materials and work in process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_kpti_AccruedResearchAndDevelopmentCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US">Accrued Research And Development Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US">Research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_kpti_AccruedResearchAndDevelopmentCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US">Accrued research and development costs current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Payroll and employee-related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConsultingAndHistopathologyServicesMember" xlink:label="loc_kpti_ConsultingAndHistopathologyServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ConsultingAndHistopathologyServicesMember" xml:lang="en-US">Consulting And Histopathology Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ConsultingAndHistopathologyServicesMember" xml:lang="en-US">Consulting and Histopathology Services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ConsultingAndHistopathologyServicesMember" xlink:to="lab_kpti_ConsultingAndHistopathologyServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ConsultingAndHistopathologyServicesMember" xml:lang="en-US">Consulting and histopathology services</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConsultingAndContractResearchServicesMember" xlink:label="loc_kpti_ConsultingAndContractResearchServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ConsultingAndContractResearchServicesMember" xml:lang="en-US">Consulting And Contract Research Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ConsultingAndContractResearchServicesMember" xml:lang="en-US">Consulting and Contract Research Services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ConsultingAndContractResearchServicesMember" xlink:to="lab_kpti_ConsultingAndContractResearchServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ConsultingAndContractResearchServicesMember" xml:lang="en-US">Consulting And Contract Research Services [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Expenses for consulting and histopathology services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Accounts payable or accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xlink:label="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xlink:to="lab_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Table]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_JefferiesLLCMember" xlink:label="loc_kpti_JefferiesLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_JefferiesLLCMember" xml:lang="en-US">Jefferies LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_JefferiesLLCMember" xml:lang="en-US">Jefferies LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_JefferiesLLCMember" xlink:to="lab_kpti_JefferiesLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_JefferiesLLCMember" xml:lang="en-US">Jefferies LLC.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CantorFitzgeraldAndCoMember" xlink:label="loc_kpti_CantorFitzgeraldAndCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_CantorFitzgeraldAndCoMember" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_CantorFitzgeraldAndCoMember" xml:lang="en-US">Cantor Fitzgerald &amp; Co. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_CantorFitzgeraldAndCoMember" xlink:to="lab_kpti_CantorFitzgeraldAndCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_CantorFitzgeraldAndCoMember" xml:lang="en-US">Cantor Fitzgerald And Co</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EquityOfferingLineItems" xlink:label="loc_kpti_EquityOfferingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_EquityOfferingLineItems" xml:lang="en-US">Equity Offering [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_EquityOfferingLineItems" xml:lang="en-US">Equity Offering [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_EquityOfferingLineItems" xlink:to="lab_kpti_EquityOfferingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_EquityOfferingLineItems" xml:lang="en-US">Equity offering.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AggregateOfferingPrice" xlink:label="loc_kpti_AggregateOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AggregateOfferingPrice" xml:lang="en-US">Aggregate Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AggregateOfferingPrice" xml:lang="en-US">Aggregate offering price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AggregateOfferingPrice" xlink:to="lab_kpti_AggregateOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AggregateOfferingPrice" xml:lang="en-US">Aggregate offering price.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xlink:label="loc_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xml:lang="en-US">Commission Percentage On Gross Proceeds From Sale Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xml:lang="en-US">Percentage of commission of gross proceeds from the sale of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xlink:to="lab_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xml:lang="en-US">Commission percentage on gross proceeds from sale of shares.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Net proceeds after deducting underwriting discounts, commissions and offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Public offering price of common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net proceeds from sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SaleAgreementTerminationDate" xlink:label="loc_kpti_SaleAgreementTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_SaleAgreementTerminationDate" xml:lang="en-US">Sale Agreement Termination Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_SaleAgreementTerminationDate" xml:lang="en-US">Sales agreement term date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_SaleAgreementTerminationDate" xlink:to="lab_kpti_SaleAgreementTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_SaleAgreementTerminationDate" xml:lang="en-US">Sale Agreement Termination Date</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OpenMarketSaleAgreementMember" xlink:label="loc_kpti_OpenMarketSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_OpenMarketSaleAgreementMember" xml:lang="en-US">Open Market Sale Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_OpenMarketSaleAgreementMember" xml:lang="en-US">Open Market Sale Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_OpenMarketSaleAgreementMember" xlink:to="lab_kpti_OpenMarketSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_OpenMarketSaleAgreementMember" xml:lang="en-US">Open market sale agreement.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LeasesTable" xlink:label="loc_kpti_LeasesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LeasesTable" xml:lang="en-US">Leases [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LeasesTable" xml:lang="en-US">Leases [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LeasesTable" xlink:to="lab_kpti_LeasesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LeasesTable" xml:lang="en-US">Leases [Table]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OfficeAndResearchSpaceLeaseMember" xlink:label="loc_kpti_OfficeAndResearchSpaceLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_OfficeAndResearchSpaceLeaseMember" xml:lang="en-US">Office And Research Space Lease [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_OfficeAndResearchSpaceLeaseMember" xml:lang="en-US">Office and Research Space Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_OfficeAndResearchSpaceLeaseMember" xlink:to="lab_kpti_OfficeAndResearchSpaceLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_OfficeAndResearchSpaceLeaseMember" xml:lang="en-US">Office and research space lease.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LeasesLineItems" xlink:label="loc_kpti_LeasesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LeasesLineItems" xml:lang="en-US">Leases [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LeasesLineItems" xml:lang="en-US">Leases [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LeasesLineItems" xlink:to="lab_kpti_LeasesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LeasesLineItems" xml:lang="en-US">Leases [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of Real Estate Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Office and laboratory space leased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">Leasehold Improvements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">Allowance for improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating lease discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit in the form of a letter of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CommonAreaMaintenanceMember" xlink:label="loc_kpti_CommonAreaMaintenanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_CommonAreaMaintenanceMember" xml:lang="en-US">Common Area Maintenance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_CommonAreaMaintenanceMember" xml:lang="en-US">Common Area Maintenance [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_CommonAreaMaintenanceMember" xlink:to="lab_kpti_CommonAreaMaintenanceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_CommonAreaMaintenanceMember" xml:lang="en-US">Common Area Maintenance [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US">2024 and thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US">Lessee operating lease liability payments due after year four.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: present value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionDiscountsAndChargeBacks" xlink:label="loc_kpti_RevenueRecognitionDiscountsAndChargeBacks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionDiscountsAndChargeBacks" xml:lang="en-US">Revenue Recognition Discounts And Charge Backs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_kpti_RevenueRecognitionDiscountsAndChargeBacks" xml:lang="en-US">Beginning balance at July&#160;3, 2019</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_kpti_RevenueRecognitionDiscountsAndChargeBacks" xml:lang="en-US">Ending balance at December&#160;31, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionDiscountsAndChargeBacks" xlink:to="lab_kpti_RevenueRecognitionDiscountsAndChargeBacks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionDiscountsAndChargeBacks" xml:lang="en-US">Revenue recognition discounts and charge backs.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" xlink:label="loc_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" xml:lang="en-US">Revenue Recognition Provision For Discounts And Charge Backs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" xml:lang="en-US">Provision related to sales in the current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" xlink:to="lab_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" xml:lang="en-US">Revenue recognition provision for discounts and charge backs.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPaymentsForChargeBacks" xlink:label="loc_kpti_RevenueRecognitionPaymentsForChargeBacks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionPaymentsForChargeBacks" xml:lang="en-US">Revenue Recognition Payments For Charge Backs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionPaymentsForChargeBacks" xml:lang="en-US">Credit and payments made</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionPaymentsForChargeBacks" xlink:to="lab_kpti_RevenueRecognitionPaymentsForChargeBacks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionPaymentsForChargeBacks" xml:lang="en-US">Revenue recognition payments for charge backs.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" xlink:label="loc_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" xml:lang="en-US">Revenue Recognition Provision For Fees Rebates And Other Incentives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" xml:lang="en-US">Provision related to sales in the current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" xlink:to="lab_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" xml:lang="en-US">revenue recognition provision for discounts and charge backs.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" xlink:label="loc_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" xml:lang="en-US">Revenue Recognition Payments For Fees Rebates And Other Incentives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" xml:lang="en-US">Credit and payments made</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" xlink:to="lab_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" xml:lang="en-US">Revenue recognition payments for fees rebates and other incentives</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionSalesReturn" xlink:label="loc_kpti_RevenueRecognitionSalesReturn" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionSalesReturn" xml:lang="en-US">Revenue Recognition Sales Return</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_kpti_RevenueRecognitionSalesReturn" xml:lang="en-US">Ending balance at December&#160;31, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionSalesReturn" xlink:to="lab_kpti_RevenueRecognitionSalesReturn" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionSalesReturn" xml:lang="en-US">Revenue recognition sales return.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:label="loc_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Revenue Recognition Provision For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Provision related to sales in the current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:to="lab_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Revenue recognition provision for discounts charge backs fees rebates other incentives and sales returns.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:label="loc_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Revenue Recognition Payments For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Credit and payments made</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:to="lab_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Revenue recognition payments for discounts charge backs fees rebates other incentives and sales returns.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:label="loc_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Revenue Recognition Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Ending balance at December&#160;31, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:to="lab_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xml:lang="en-US">Revenue recognition discounts charge backs fees rebates other incentives and sales returns.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" xlink:label="loc_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" xml:lang="en-US">Revenue Recognition Fees Rebates And Other Incentives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" xml:lang="en-US">Ending balance at December&#160;31, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" xlink:to="lab_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" xml:lang="en-US">Revenue recognition fees rebates and other incentives</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" xlink:label="loc_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" xml:lang="en-US">Revenue Recognition Sale Returns Reserve for Sale Returns</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" xml:lang="en-US">Provision related to sales in the current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" xlink:to="lab_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" xml:lang="en-US">Revenue recognition, sales returns, reserve for sales returns.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xml:lang="en-US">Project [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xml:lang="en-US">Project [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProjectMember" xml:lang="en-US">Project [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProjectMember" xml:lang="en-US">Project [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EltanexorMember" xlink:label="loc_kpti_EltanexorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_EltanexorMember" xml:lang="en-US">Eltanexor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_EltanexorMember" xml:lang="en-US">Eltanexor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_EltanexorMember" xlink:to="lab_kpti_EltanexorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_EltanexorMember" xml:lang="en-US">Eltanexor.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_KPT9274Member" xlink:label="loc_kpti_KPT9274Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_KPT9274Member" xml:lang="en-US">KPT-9274 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_KPT9274Member" xml:lang="en-US">KPT-9274 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_KPT9274Member" xlink:to="lab_kpti_KPT9274Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_KPT9274Member" xml:lang="en-US">KPT-9274.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SelinexorMember" xlink:label="loc_kpti_SelinexorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_SelinexorMember" xml:lang="en-US">Selinexor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_SelinexorMember" xml:lang="en-US">Selinexor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_SelinexorMember" xlink:to="lab_kpti_SelinexorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_SelinexorMember" xml:lang="en-US">Selinexor.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VerdinexorMember" xlink:label="loc_kpti_VerdinexorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_VerdinexorMember" xml:lang="en-US">Verdinexor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_VerdinexorMember" xml:lang="en-US">Verdinexor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_VerdinexorMember" xlink:to="lab_kpti_VerdinexorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_VerdinexorMember" xml:lang="en-US">Verdinexor.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xml:lang="en-US">Deferred Revenue [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xml:lang="en-US">Deferred Revenue [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UpFrontPaymentArrangementMember" xml:lang="en-US">Up-front Payment Arrangement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UpFrontPaymentArrangementMember" xml:lang="en-US">Up-front Payment Arrangement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UpFrontPaymentArrangementMember" xlink:to="lab_us-gaap_UpFrontPaymentArrangementMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AntengeneTherapeuticsLimitedMember" xlink:label="loc_kpti_AntengeneTherapeuticsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AntengeneTherapeuticsLimitedMember" xml:lang="en-US">Antengene Therapeutics Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AntengeneTherapeuticsLimitedMember" xml:lang="en-US">Antengene Therapeutics Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AntengeneTherapeuticsLimitedMember" xlink:to="lab_kpti_AntengeneTherapeuticsLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AntengeneTherapeuticsLimitedMember" xml:lang="en-US">Antengene Therapeutics Limited.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentGoalsMember" xlink:label="loc_kpti_DevelopmentGoalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DevelopmentGoalsMember" xml:lang="en-US">Development Goals [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DevelopmentGoalsMember" xml:lang="en-US">Development Goals [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DevelopmentGoalsMember" xlink:to="lab_kpti_DevelopmentGoalsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DevelopmentGoalsMember" xml:lang="en-US">Development goals.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentMilestoneMember" xlink:label="loc_kpti_DevelopmentMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DevelopmentMilestoneMember" xml:lang="en-US">Development Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DevelopmentMilestoneMember" xml:lang="en-US">Development Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DevelopmentMilestoneMember" xlink:to="lab_kpti_DevelopmentMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DevelopmentMilestoneMember" xml:lang="en-US">Development milestone.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesEventsMember" xlink:label="loc_kpti_SalesEventsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_SalesEventsMember" xml:lang="en-US">Sales Events [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_SalesEventsMember" xml:lang="en-US">Sales Milestone Events [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_SalesEventsMember" xlink:to="lab_kpti_SalesEventsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_SalesEventsMember" xml:lang="en-US">Sales events.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xml:lang="en-US">License Agreement Terms [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xml:lang="en-US">Government Research Grant Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts Receivable, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNet" xml:lang="en-US">Milestone payments receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Upfront payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationDescription" xlink:label="loc_kpti_LicenseAgreementTerminationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LicenseAgreementTerminationDescription" xml:lang="en-US">License Agreement, Termination Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LicenseAgreementTerminationDescription" xml:lang="en-US">License agreement termination description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LicenseAgreementTerminationDescription" xlink:to="lab_kpti_LicenseAgreementTerminationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LicenseAgreementTerminationDescription" xml:lang="en-US">License agreement, termination description.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationNoticePeriod" xlink:label="loc_kpti_LicenseAgreementTerminationNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_LicenseAgreementTerminationNoticePeriod" xml:lang="en-US">License Agreement Termination Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_LicenseAgreementTerminationNoticePeriod" xml:lang="en-US">License agreement termination prior notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_LicenseAgreementTerminationNoticePeriod" xlink:to="lab_kpti_LicenseAgreementTerminationNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_LicenseAgreementTerminationNoticePeriod" xml:lang="en-US">License agreement termination notice period.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_PotentialCommercialMilestonePayments" xml:lang="en-US">Potential Commercial Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_PotentialCommercialMilestonePayments" xml:lang="en-US">Commercial milestone payments receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_PotentialCommercialMilestonePayments" xlink:to="lab_kpti_PotentialCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_PotentialCommercialMilestonePayments" xml:lang="en-US">Potential commercial milestone payments.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPotentialFutureMilestonePayments" xlink:label="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueRecognitionPotentialFutureMilestonePayments" xml:lang="en-US">Revenue Recognition Potential Future Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueRecognitionPotentialFutureMilestonePayments" xml:lang="en-US">Milestone payments receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments" xlink:to="lab_kpti_RevenueRecognitionPotentialFutureMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RevenueRecognitionPotentialFutureMilestonePayments" xml:lang="en-US">Revenue recognition potential future milestone payments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Performance obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_BiogenMAIncMember" xlink:label="loc_kpti_BiogenMAIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_BiogenMAIncMember" xml:lang="en-US">Biogen MA Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_BiogenMAIncMember" xml:lang="en-US">Biogen MA Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_BiogenMAIncMember" xlink:to="lab_kpti_BiogenMAIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_BiogenMAIncMember" xml:lang="en-US">Biogen MA Inc.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesMilestoneMember" xlink:label="loc_kpti_SalesMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_SalesMilestoneMember" xml:lang="en-US">Sales Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_SalesMilestoneMember" xml:lang="en-US">Sales Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_SalesMilestoneMember" xlink:to="lab_kpti_SalesMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_SalesMilestoneMember" xml:lang="en-US">Sales milestone.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AssetPurchaseAgreementMember" xlink:label="loc_kpti_AssetPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_AssetPurchaseAgreementMember" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_AssetPurchaseAgreementMember" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_AssetPurchaseAgreementMember" xlink:to="lab_kpti_AssetPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_AssetPurchaseAgreementMember" xml:lang="en-US">Asset purchase agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_UpfrontPaymentReceived" xlink:label="loc_kpti_UpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_UpfrontPaymentReceived" xml:lang="en-US">Upfront Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_UpfrontPaymentReceived" xml:lang="en-US">Upfront payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_UpfrontPaymentReceived" xlink:to="lab_kpti_UpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_UpfrontPaymentReceived" xml:lang="en-US">Represents the amount of upfront payment received under research agreements.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioPlanMember" xml:lang="en-US">Scenario, Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScenarioPlanMember" xml:lang="en-US">Scenario, Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPlanMember" xlink:to="lab_us-gaap_ScenarioPlanMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OnoPharmaceuticalCompanyLimitedMember" xlink:label="loc_kpti_OnoPharmaceuticalCompanyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_OnoPharmaceuticalCompanyLimitedMember" xml:lang="en-US">Ono Pharmaceutical Company Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_OnoPharmaceuticalCompanyLimitedMember" xml:lang="en-US">Ono Pharmaceutical Co Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_OnoPharmaceuticalCompanyLimitedMember" xlink:to="lab_kpti_OnoPharmaceuticalCompanyLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_OnoPharmaceuticalCompanyLimitedMember" xml:lang="en-US">Ono Pharmaceutical Company Limited.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xml:lang="en-US">Clinical Development And Regulatory Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xml:lang="en-US">Clinical Development and Regulatory Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xml:lang="en-US">Clinical development and regulatory milestone.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Deferred Revenue, non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Notes, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Unvested Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TwoThousandThirteenStockOptionPlanMember" xlink:label="loc_kpti_TwoThousandThirteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_TwoThousandThirteenStockOptionPlanMember" xml:lang="en-US">Two Thousand Thirteen Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_TwoThousandThirteenStockOptionPlanMember" xml:lang="en-US">2013 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_TwoThousandThirteenStockOptionPlanMember" xlink:to="lab_kpti_TwoThousandThirteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_TwoThousandThirteenStockOptionPlanMember" xml:lang="en-US">Two Thousand Thirteen Stock Option Plan [Member]</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TwothousandtenstockoptionplanmemberMember" xlink:label="loc_kpti_TwothousandtenstockoptionplanmemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_TwothousandtenstockoptionplanmemberMember" xml:lang="en-US">TwoThousandTenStockOptionPlanMember [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_TwothousandtenstockoptionplanmemberMember" xml:lang="en-US">2010 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_TwothousandtenstockoptionplanmemberMember" xlink:to="lab_kpti_TwothousandtenstockoptionplanmemberMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Aggregate Intrinsic Value,Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock shares available for issuance under ESPP</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Period for recognition of unrecognized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Total unrecognized stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Total unrecognized stock-based compensation expense related to unvested stock options including estimated forfeitures | $</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xlink:label="loc_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xml:lang="en-US">Percentage Of Outstanding Shares Of Common Stock Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xml:lang="en-US">Percentage of shares of common stock available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xlink:to="lab_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xml:lang="en-US">Percentage of outstanding shares of common stock reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Employee stock purchase plan, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of shares of common stock authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:label="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xml:lang="en-US">Service condition that vest in equal annual installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:to="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installments</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xml:lang="en-US">Offering period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Purchase price of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedFromPriorStockIncentivePlan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xml:lang="en-US">Number of additional shares authorized under the 2010 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xlink:to="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedFromPriorStockIncentivePlan</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xml:lang="en-US">Annual increase in number of additional shares authorized under the Plan through December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xlink:to="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnual</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedInPercentageAnnual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xml:lang="en-US">Percentage applied to the outstanding shares as annual increase in the number of shares authorized for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xlink:to="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedInPercentageAnnual</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Number of additional shares available under the 2013 plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value of stock options exercised | $</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair values of options granted (in dollars per share) | $ / shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Employee stock purchase plan, amount withheld from employees | $</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Shares Underlying RSUs, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RightsReceivedForEachRestrictedShareUnit" xlink:label="loc_kpti_RightsReceivedForEachRestrictedShareUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RightsReceivedForEachRestrictedShareUnit" xml:lang="en-US">Rights Received For Each Restricted Share Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RightsReceivedForEachRestrictedShareUnit" xlink:to="lab_kpti_RightsReceivedForEachRestrictedShareUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RightsReceivedForEachRestrictedShareUnit" xml:lang="en-US">Rights received for each restricted share unit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VestingperiodonememberMember" xlink:label="loc_kpti_VestingperiodonememberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_VestingperiodonememberMember" xml:lang="en-US">VestingPeriodOneMember [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_VestingperiodonememberMember" xml:lang="en-US">Percent Vesting One Calendar Year from Vesting Start Date [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_VestingperiodonememberMember" xlink:to="lab_kpti_VestingperiodonememberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_VestingperiodonememberMember" xml:lang="en-US">Vesting period one member</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VestingperiodtwomemberMember" xlink:label="loc_kpti_VestingperiodtwomemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_VestingperiodtwomemberMember" xml:lang="en-US">VestingPeriodTwoMember [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_VestingperiodtwomemberMember" xml:lang="en-US">Percentage Vesting on the First Day of each Month after One Calendar Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_VestingperiodtwomemberMember" xlink:to="lab_kpti_VestingperiodtwomemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_VestingperiodtwomemberMember" xml:lang="en-US">Vesting period two member</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementCompensationItemsAbstract" xlink:label="loc_us-gaap_IncomeStatementCompensationItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementCompensationItemsAbstract" xml:lang="en-US">Compensation Items [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementCompensationItemsAbstract" xlink:to="lab_us-gaap_IncomeStatementCompensationItemsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling,General and Administrative Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Shares, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Shares, Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Shares, Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years), Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Shares, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Shares Underlying RSUs, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Shares Underlying RSUs, Unvested beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Shares Underlying RSUs, Unvested ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Unvested beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Unvested ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of Shares Underlying RSUs, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined contribution plan, matching percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined contribution plan, matching amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncomeTaxDisclosureTableTable" xlink:label="loc_kpti_IncomeTaxDisclosureTableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_IncomeTaxDisclosureTableTable" xml:lang="en-US">Income Tax Disclosure Table [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_IncomeTaxDisclosureTableTable" xml:lang="en-US">Income Tax Disclosure Table [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable" xlink:to="lab_kpti_IncomeTaxDisclosureTableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_IncomeTaxDisclosureTableTable" xml:lang="en-US">Income Tax Disclosure Table</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_DE" xml:lang="en-US">GERMANY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_DE" xml:lang="en-US">Germany [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncomeTaxDisclosureLineItems" xlink:label="loc_kpti_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems" xlink:to="lab_kpti_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal statutory rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal income tax expense at statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xlink:label="loc_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xml:lang="en-US">Provision For Income Taxes For Federal Tax Rate Changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xml:lang="en-US">Impact related to provision items for federal rate change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xlink:to="lab_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xml:lang="en-US">Provision For Income Taxes For Federal Tax Rate Changes.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xlink:label="loc_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017 Change In Tax Rate Reduction In Deferred Tax Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xml:lang="en-US">Reduction in deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xlink:to="lab_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017 Change In Tax Rate Reduction In Deferred Tax Assets.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Increase in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:label="loc_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xml:lang="en-US">Deferred Tax Asset Net Operating Loss Carry forwards Indefinite Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xml:lang="en-US">Net operating loss carryforwards indefinite life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:to="lab_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xml:lang="en-US">Deferred Tax Asset Net Operating Loss Carry forwards Indefinite Life</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xlink:label="loc_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xml:lang="en-US">Net Operating Loss Carryforwards Have Indefinite Expiration Date Respect To Foreign Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xml:lang="en-US">Net operating loss carryforwards indefinite life remaining</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xlink:to="lab_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xml:lang="en-US">Net Operating Loss Carryforwards Have Indefinite Expiration Date Respect To Foreign Operation.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xml:lang="en-US">Net operating loss carryforwards foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xml:lang="en-US">Foreign net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:label="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xml:lang="en-US">Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xml:lang="en-US">Period over which certain cumulative changes in the ownership interest of significant shareholders will be considered, subject to an annual limitation of net operating loss and tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:to="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xml:lang="en-US">Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:label="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xml:lang="en-US">Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xml:lang="en-US">Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:to="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xml:lang="en-US">Percentage of cumulative changes in the ownership interest of significant shareholders that will be considered, subject to an annual limitation of net operating loss and tax credit carryforwards</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Interest or penalties related to uncertain tax positions recognized in statements of operations and comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">U.S.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Totals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xlink:label="loc_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xml:lang="en-US">Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xml:lang="en-US">U.S. and state net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xlink:to="lab_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic and state and local operating loss carryforwards.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xlink:label="loc_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xml:lang="en-US">Accruals and other temporary differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xlink:to="lab_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and other temporary differences.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Capitalized research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="loc_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xml:lang="en-US">Deferred Tax Assets Fixed Assets And Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xml:lang="en-US">Fixed Assets and Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:to="lab_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xml:lang="en-US">Deferred Tax Assets Fixed Assets And Intangibles.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsLeaseLiability" xlink:label="loc_kpti_DeferredTaxAssetsLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsLeaseLiability" xml:lang="en-US">Deferred Tax Assets Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DeferredTaxAssetsLeaseLiability" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsLeaseLiability" xlink:to="lab_kpti_DeferredTaxAssetsLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsLeaseLiability" xml:lang="en-US">Deferred tax assets lease liability.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xlink:label="loc_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xml:lang="en-US">Deferred Tax Assets Royalty Embaded Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xml:lang="en-US">Deferred Tax Assets Royalty Embaded Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xlink:to="lab_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xml:lang="en-US">Deferred tax assets royalty embaded derivatives.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xlink:label="loc_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xml:lang="en-US">Deferred Tax Liabilities Convertible Debt Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xml:lang="en-US">Convertible debt amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xlink:to="lab_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xml:lang="en-US">Deferred Tax Liabilities, Convertible Debt Amortization.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_kpti_DeferredTaxAssetsRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsRightOfUseAsset" xml:lang="en-US">Deferred Tax Assets Right of use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_kpti_DeferredTaxAssetsRightOfUseAsset" xml:lang="en-US">Right-of-use&#160;asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsRightOfUseAsset" xlink:to="lab_kpti_DeferredTaxAssetsRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsRightOfUseAsset" xml:lang="en-US">Deferred tax assets right of use asset.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xlink:label="loc_kpti_DeferredTaxAssetsDeferredRoyaltyObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xml:lang="en-US">Deferred Tax Assets Deferred Royalty Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xml:lang="en-US">Deferred royalty obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xlink:to="lab_kpti_DeferredTaxAssetsDeferredRoyaltyObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xml:lang="en-US">Deferred tax assets deferred royalty obligation.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income tax, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Research and development credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Provision to return adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Federal rate change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Note Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Fair value of liability of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Notes converted in to common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Notes converted in to common stock, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xml:lang="en-US">Equity component of convertible notes recognized as debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xml:lang="en-US">Equity component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Notes, conversion price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleLatestDate1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleLatestDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleLatestDate1" xml:lang="en-US">Debt Instrument, Convertible, Latest Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleLatestDate1" xml:lang="en-US">Debt instrument, convertible latest date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleLatestDate1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleLatestDate1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xml:lang="en-US">Debt instrument convertible threshold consecutive trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xlink:label="loc_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xml:lang="en-US">Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xml:lang="en-US">Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xlink:to="lab_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xml:lang="en-US">Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xlink:label="loc_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xml:lang="en-US">Debt Instrument Convertible Threshold Measurement Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xml:lang="en-US">Description of debt instrument convertible period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xlink:to="lab_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xml:lang="en-US">Debt instrument convertible threshold measurement period description.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentEstimatedFairValue" xlink:label="loc_kpti_DebtInstrumentEstimatedFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentEstimatedFairValue" xml:lang="en-US">Debt Instrument Estimated Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtInstrumentEstimatedFairValue" xml:lang="en-US">Estimated fair value of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentEstimatedFairValue" xlink:to="lab_kpti_DebtInstrumentEstimatedFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentEstimatedFairValue" xml:lang="en-US">Debt Instrument Estimated Fair Value</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Notes, maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xlink:label="loc_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xml:lang="en-US">Debt Instrument Non Convertible Initial Amount Of Liability Component</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xml:lang="en-US">Initial amount of liability component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xlink:to="lab_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xml:lang="en-US">Debt instrument non convertible initial amount of liability component.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Notes conversion price, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentRepurchasePricePercentage" xlink:label="loc_kpti_DebtInstrumentRepurchasePricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentRepurchasePricePercentage" xml:lang="en-US">Debt Instrument Repurchase Price Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtInstrumentRepurchasePricePercentage" xml:lang="en-US">Notes, repurchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentRepurchasePricePercentage" xlink:to="lab_kpti_DebtInstrumentRepurchasePricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentRepurchasePricePercentage" xml:lang="en-US">Debt instrument repurchase price percentage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Expected life of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xlink:label="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xml:lang="en-US">Debt Issuance Costs Allocated To Liability Component Amortized To Interest Expense Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xml:lang="en-US">Debt discount and issuance costs amortized to interest expense, amortization period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xlink:to="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xml:lang="en-US">Debt issuance costs allocated to liability component amortized to interest expense amortization period.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xlink:label="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xml:lang="en-US">Debt Issuance Costs Allocated To Liability Component Recorded As Reduction Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xml:lang="en-US">Debt issuance costs allocated to liability component and recorded as a reduction of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xlink:to="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xml:lang="en-US">Debt issuance costs allocated to liability component recorded as reduction of convertible notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PrincipalAmountOfNotesUsedInConversionRate" xlink:label="loc_kpti_PrincipalAmountOfNotesUsedInConversionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_PrincipalAmountOfNotesUsedInConversionRate" xml:lang="en-US">Principal Amount Of Notes Used In Conversion Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_PrincipalAmountOfNotesUsedInConversionRate" xml:lang="en-US">Principal amount of notes used in conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_PrincipalAmountOfNotesUsedInConversionRate" xlink:to="lab_kpti_PrincipalAmountOfNotesUsedInConversionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_PrincipalAmountOfNotesUsedInConversionRate" xml:lang="en-US">Principal amount of notes used in conversion rate.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PrincipalAmountPerNoteUsedInConversionRate" xlink:label="loc_kpti_PrincipalAmountPerNoteUsedInConversionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_PrincipalAmountPerNoteUsedInConversionRate" xml:lang="en-US">Principal Amount Per Note Used In Conversion Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_PrincipalAmountPerNoteUsedInConversionRate" xml:lang="en-US">Principal amount of notes used in conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_PrincipalAmountPerNoteUsedInConversionRate" xlink:to="lab_kpti_PrincipalAmountPerNoteUsedInConversionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_PrincipalAmountPerNoteUsedInConversionRate" xml:lang="en-US">Principal Amount Per Note Used In Conversion Rate</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromFirstInvestmentAmount" xlink:label="loc_kpti_ProceedsFromFirstInvestmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_ProceedsFromFirstInvestmentAmount" xml:lang="en-US">Proceeds From First Investment Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_ProceedsFromFirstInvestmentAmount" xml:lang="en-US">First investment amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_ProceedsFromFirstInvestmentAmount" xlink:to="lab_kpti_ProceedsFromFirstInvestmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_ProceedsFromFirstInvestmentAmount" xml:lang="en-US">First investment amount.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SecondInvestmentAmount" xlink:label="loc_kpti_SecondInvestmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_SecondInvestmentAmount" xml:lang="en-US">Second Investment Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_SecondInvestmentAmount" xml:lang="en-US">Second investment amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_SecondInvestmentAmount" xlink:to="lab_kpti_SecondInvestmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_SecondInvestmentAmount" xml:lang="en-US">Second investment amount.</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentsApplicableTieredPercentage" xlink:label="loc_kpti_RoyaltyPaymentsApplicableTieredPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RoyaltyPaymentsApplicableTieredPercentage" xml:lang="en-US">Royalty Payments Applicable Tiered Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RoyaltyPaymentsApplicableTieredPercentage" xml:lang="en-US">Aggregate Royalties Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RoyaltyPaymentsApplicableTieredPercentage" xlink:to="lab_kpti_RoyaltyPaymentsApplicableTieredPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RoyaltyPaymentsApplicableTieredPercentage" xml:lang="en-US">Royalty Payments Applicable Tiered Percentage</label>
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_kpti_RoyaltyGuaranteesCommitmentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RoyaltyGuaranteesCommitmentsPercentage" xml:lang="en-US">Royalty Guarantees Commitments Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RoyaltyGuaranteesCommitmentsPercentage" xml:lang="en-US">Royalty Payable Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RoyaltyGuaranteesCommitmentsPercentage" xlink:to="lab_kpti_RoyaltyGuaranteesCommitmentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_RoyaltyGuaranteesCommitmentsPercentage" xml:lang="en-US">Investment percentage receiveable on future date.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Deferred royalty obligation at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xml:lang="en-US">Notes instrument, trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Scenario, Forecast [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_HealthcareRoyaltyPartnersIvLpMember" xlink:label="loc_kpti_HealthcareRoyaltyPartnersIvLpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_HealthcareRoyaltyPartnersIvLpMember" xml:lang="en-US">HealthCare Royalty Partners IV LP [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_HealthcareRoyaltyPartnersIvLpMember" xml:lang="en-US">HealthCare Royalty Partners IV LP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_HealthcareRoyaltyPartnersIvLpMember" xlink:to="lab_kpti_HealthcareRoyaltyPartnersIvLpMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateAxis" xlink:label="loc_kpti_RoyaltyPaymentDueDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RoyaltyPaymentDueDateAxis" xml:lang="en-US">Royalty Payment Due Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RoyaltyPaymentDueDateAxis" xlink:to="lab_kpti_RoyaltyPaymentDueDateAxis" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateDomain" xlink:label="loc_kpti_RoyaltyPaymentDueDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RoyaltyPaymentDueDateDomain" xml:lang="en-US">Royalty Payment Due Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RoyaltyPaymentDueDateDomain" xlink:to="lab_kpti_RoyaltyPaymentDueDateDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" xlink:label="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" xml:lang="en-US">Royalty Due On December Thirty One Two Thousand Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" xml:lang="en-US">Royalty Due On December 31, 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" xlink:to="lab_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" xlink:label="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" xml:lang="en-US">Royalty Due On December Thirty One Two Thousand Twenty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" xml:lang="en-US">Royalty Due On December 31, 2024 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" xlink:to="lab_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationMember" xlink:label="loc_kpti_DeferredRoyaltyObligationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DeferredRoyaltyObligationMember" xml:lang="en-US">Deferred Royalty Obligation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DeferredRoyaltyObligationMember" xml:lang="en-US">Deferred Royalty Obligation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DeferredRoyaltyObligationMember" xlink:to="lab_kpti_DeferredRoyaltyObligationMember" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueInterestFinancingAgreementMember" xlink:label="loc_kpti_RevenueInterestFinancingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_RevenueInterestFinancingAgreementMember" xml:lang="en-US">Revenue Interest Financing Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_RevenueInterestFinancingAgreementMember" xml:lang="en-US">Revenue Interest Financing Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_RevenueInterestFinancingAgreementMember" xlink:to="lab_kpti_RevenueInterestFinancingAgreementMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentLiabilityComponentAbstract" xlink:label="loc_kpti_DebtInstrumentLiabilityComponentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentLiabilityComponentAbstract" xml:lang="en-US">Debt Instrument Liability Component [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_kpti_DebtInstrumentLiabilityComponentAbstract" xml:lang="en-US">Liability component:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract" xlink:to="lab_kpti_DebtInstrumentLiabilityComponentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentLiabilityComponentAbstract" xml:lang="en-US">Debt Instrument Liability Component [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Net carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xlink:label="loc_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xml:lang="en-US">Debt Instrument Unamortized Discount Premiumand Debt Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xml:lang="en-US">Less: debt discount and issuance costs, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xlink:to="lab_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xml:lang="en-US">Debt Instrument Unamortized Discount Premiumand Debt Issuance</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Total interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US">Contractual interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Total minimum payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: unamortized discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Interest Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Less: interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Convertible senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less: current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">2024 and thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>kpti-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 26-February-2020 [12:33:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CoverPage" roleURI="http://www.karyopharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#OrganizationAndOperations" roleURI="http://www.karyopharm.com/role/OrganizationAndOperations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNet" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#Investments" roleURI="http://www.karyopharm.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#Inventory" roleURI="http://www.karyopharm.com/role/Inventory" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpenses" roleURI="http://www.karyopharm.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#RelatedPartyTransactions" roleURI="http://www.karyopharm.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockholdersEquity" roleURI="http://www.karyopharm.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingencies" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#ProductRevenue" roleURI="http://www.karyopharm.com/role/ProductRevenue" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreements" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensation" roleURI="http://www.karyopharm.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#KPlan" roleURI="http://www.karyopharm.com/role/KPlan" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxes" roleURI="http://www.karyopharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligations" roleURI="http://www.karyopharm.com/role/LongTermObligations" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsTables" roleURI="http://www.karyopharm.com/role/InvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InventoryTables" roleURI="http://www.karyopharm.com/role/InventoryTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpensesTables" roleURI="http://www.karyopharm.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#ProductRevenueTables" roleURI="http://www.karyopharm.com/role/ProductRevenueTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationTables" roleURI="http://www.karyopharm.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesTable" roleURI="http://www.karyopharm.com/role/IncomeTaxesTable" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsTables" roleURI="http://www.karyopharm.com/role/LongTermObligationsTables" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#OrganizationAndOperationsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail" roleURI="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" roleURI="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InvestmentsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#InventoryScheduleOfInventoryCurrentDetail" roleURI="http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#AccruedExpensesScheduleOfAccruedExpensesDetail" roleURI="http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" roleURI="http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail" roleURI="http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail" roleURI="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#NetLossPerShareAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationSummaryOfRsuActivityDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#KPlanAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/KPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" roleURI="http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsAdditionalInformationDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail" />
<roleRef xlink:type="simple" xlink:href="kpti-20191231.xsd#LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" roleURI="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187796" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_468877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentType_468877" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_501013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_AmendmentFlag_501013" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_468878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentPeriodEndDate_468878" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_501014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalYearFocus_501014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_501015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalPeriodFocus_501015" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_501017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CurrentFiscalYearEndDate_501017" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_468880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityRegistrantName_468880" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_468879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_TradingSymbol_468879" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_501016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCentralIndexKey_501016" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_468881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFilerCategory_468881" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_468882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntitySmallBusiness_468882" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_468883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityEmergingGrowthCompany_468883" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_468884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_468884" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_574767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityPublicFloat_574767" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_574766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_574766" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_468885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCurrentReportingStatus_468885" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_575012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityInteractiveDataCurrent_575012" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_574997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFileNumber_574997" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_574998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityIncorporationStateCountryCode_574998" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_574999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityTaxIdentificationNumber_574999" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_575000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressAddressLine1_575000" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_575001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCityOrTown_575001" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_575003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressPostalZipCode_575003" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_575005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CityAreaCode_575005" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_575007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_LocalPhoneNumber_575007" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_574996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentTransitionReport_574996" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_574995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentAnnualReport_574995" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_468905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityShellCompany_468905" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_574768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityVoluntaryFilers_574768" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_575002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressStateOrProvince_575002" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_575010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_Security12bTitle_575010" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_575011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_SecurityExchangeName_575011" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17" xlink:to="loc_us-gaap_AssetsAbstract_18" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18" xlink:to="loc_us-gaap_AssetsCurrentAbstract_19" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_29" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_500600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_ReceivablesNetCurrent_500600" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_500602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_InventoryNet_500602" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_576520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_576520" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_19" xlink:to="loc_us-gaap_AssetsCurrent_31" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_23" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_24" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_25" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_26" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_18" xlink:to="loc_us-gaap_Assets_27" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_21" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccountsPayableCurrent_38" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_39" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_DeferredRevenueCurrent_40" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_41" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_42" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_43" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesCurrent_44" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_32" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationNoncurrent" xlink:label="loc_kpti_DeferredRoyaltyObligationNoncurrent_500606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_kpti_DeferredRoyaltyObligationNoncurrent_500606" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_33" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_34" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_35" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_Liabilities_36" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_577001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_577001" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_PreferredStockValue_45" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_46" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_47" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_49" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_50" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_53" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_54" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_PreferredStockSharesIssued_55" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_56" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_57" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_58" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_CommonStockSharesIssued_59" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_60" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_62" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62" xlink:to="loc_us-gaap_StatementTable_500696" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_500768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500696" xlink:to="loc_srt_ProductOrServiceAxis_500768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_500768" xlink:to="loc_srt_ProductsAndServicesDomain_500769" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_500770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_500769" xlink:to="loc_us-gaap_ProductMember_500770" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAndOtherMember" xlink:label="loc_kpti_LicenseAndOtherMember_500771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_500769" xlink:to="loc_kpti_LicenseAndOtherMember_500771" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_500699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500696" xlink:to="loc_us-gaap_StatementLineItems_500699" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500702" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500702" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_500700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_OperatingExpensesAbstract_500700" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_500707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_500707" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_77" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_500700" xlink:to="loc_us-gaap_OperatingExpenses_78" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_OperatingIncomeLoss_66" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_InvestmentIncomeInterest_72" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_InterestExpense_73" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_74" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_500701" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_NetIncomeLoss_69" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_70" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500699" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_71" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_80" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_80" xlink:to="loc_us-gaap_NetIncomeLoss_85" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_80" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_82" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_83" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_84" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_122" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_122" xlink:to="loc_us-gaap_StatementTable_126" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_124" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_124" xlink:to="loc_us-gaap_EquityComponentDomain_123" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_CommonStockMember_127" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_128" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_129" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_123" xlink:to="loc_us-gaap_RetainedEarningsMember_130" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126" xlink:to="loc_us-gaap_StatementLineItems_125" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockholdersEquity_131" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_SharesIssued_132" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome_576316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome_576316" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_134" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_136" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_137" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_467967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_467967" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_467968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_467968" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_576324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_576324" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt" xlink:label="loc_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt_576327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt_576327" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_138" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_139" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_NetIncomeLoss_140" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_StockholdersEquity_141" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_125" xlink:to="loc_us-gaap_SharesIssued_142" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_508920" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_508924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_508920" xlink:to="loc_us-gaap_StatementTable_508924" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_508966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_508924" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_508966" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_508967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_508966" xlink:to="loc_us-gaap_EquityComponentDomain_508967" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_508968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_508967" xlink:to="loc_us-gaap_CommonStockMember_508968" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_508925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_508924" xlink:to="loc_us-gaap_TypeOfArrangementAxis_508925" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_508925" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_kpti_ControlledEquityOfferingSalesAgreementMember_508945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508942" xlink:to="loc_kpti_ControlledEquityOfferingSalesAgreementMember_508945" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_508927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_508924" xlink:to="loc_us-gaap_StatementLineItems_508927" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_StockIssuanceCosts" xlink:label="loc_kpti_StockIssuanceCosts_508922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_508927" xlink:to="loc_kpti_StockIssuanceCosts_508922" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_87" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92" xlink:to="loc_us-gaap_ProfitLoss_111" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88" xlink:to="loc_us-gaap_DepreciationAndAmortization_95" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_96" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88" xlink:to="loc_us-gaap_ShareBasedCompensation_98" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_97" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_500714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_500714" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_500715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_500715" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_100" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_101" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_102" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_kpti_IncreaseDecreaseInOperatingLeaseLiabilities_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_kpti_IncreaseDecreaseInOperatingLeaseLiabilities_103" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_460322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_460322" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent_104" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_112" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_107" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_108" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_109" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_110" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts" xlink:label="loc_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts_576619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" xlink:to="loc_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts_576619" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromPaymentsForCommonStockIssuanceNet" xlink:label="loc_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet_460333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" xlink:to="loc_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet_460333" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_105" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromDeferredRoyaltyObligation" xlink:label="loc_kpti_ProceedsFromDeferredRoyaltyObligation_500716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" xlink:to="loc_kpti_ProceedsFromDeferredRoyaltyObligation_500716" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_106" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_116" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_117" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_460337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_460337" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_118" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_93" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_93" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_113" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_460759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_93" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_460759" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_93" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_114" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_115" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_87" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_94" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_500719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_94" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_500719" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_94" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_119" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:label="loc_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_94" xlink:to="loc_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_120" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/OrganizationAndOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_575036" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_575038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_575036" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_575038" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_579" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_579" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575229" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_575230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575229" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_575230" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/Investments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_602" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_602" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_603" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/Inventory">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_500949" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_500950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_500949" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_500950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_575771" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccruedExpensesDisclosureTextTextBlock" xlink:label="loc_kpti_AccruedExpensesDisclosureTextTextBlock_575780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_575771" xlink:to="loc_kpti_AccruedExpensesDisclosureTextTextBlock_575780" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_575725" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock" xlink:label="loc_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock_575726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_575725" xlink:to="loc_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock_575726" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_577163" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_577166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_577163" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_577166" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_621" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_621" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_622" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/ProductRevenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500791" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_501548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500791" xlink:to="loc_us-gaap_StatementTable_501548" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_501552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501548" xlink:to="loc_srt_ProductOrServiceAxis_501552" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_501553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_501552" xlink:to="loc_srt_ProductsAndServicesDomain_501553" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_501554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_501553" xlink:to="loc_us-gaap_ProductMember_501554" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_501551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501548" xlink:to="loc_us-gaap_StatementLineItems_501551" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_500792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_501551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_500792" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_593" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_593" xlink:to="loc_us-gaap_StatementTable_500882" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_500883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500882" xlink:to="loc_srt_ProductOrServiceAxis_500883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_500883" xlink:to="loc_srt_ProductsAndServicesDomain_500884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAndAssetPurchaseAgreementsMember" xlink:label="loc_kpti_LicenseAndAssetPurchaseAgreementsMember_500946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_500884" xlink:to="loc_kpti_LicenseAndAssetPurchaseAgreementsMember_500946" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_500885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500882" xlink:to="loc_us-gaap_StatementLineItems_500885" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500885" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_594" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_614" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_614" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_615" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/KPlan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_576155" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_576156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_576155" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_576156" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_575008" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_575009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_575008" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_575009" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_630" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_630" xlink:to="loc_us-gaap_StatementTable_634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_634" xlink:to="loc_us-gaap_DebtInstrumentAxis_631" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_631" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_632" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_632" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_635" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_634" xlink:to="loc_us-gaap_StatementLineItems_633" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_633" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_636" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_582" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_583" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_575056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_575056" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_575058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_UseOfEstimates_575058" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_575061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_575061" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_575063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_575063" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_575064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_575064" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock" xlink:label="loc_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock_575066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock_575066" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_575067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_575067" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_575069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_575069" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_575070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_575070" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_575071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_575071" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_575072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_575072" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_500756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_500756" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_500757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_500757" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_500758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_500758" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_500759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_500759" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationPolicyTextBlock" xlink:label="loc_kpti_DeferredRoyaltyObligationPolicyTextBlock_500760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_kpti_DeferredRoyaltyObligationPolicyTextBlock_500760" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_575073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_575073" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_575074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_575074" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_575075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_575075" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_575076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_575076" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_575077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_575077" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_575078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_575078" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_575079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_575079" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_575081" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_575082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575081" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_575082" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_575084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575081" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_575084" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_576755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575081" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_576755" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_575100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575081" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_575100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575235" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_575238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575235" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_575238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InvestmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_605" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_605" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_606" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InventoryTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_500952" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_500953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_500952" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_500953" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_575785" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_575786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_575785" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_575786" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_624" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_624" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_625" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/ProductRevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500800" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_500802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_500800" xlink:to="loc_us-gaap_StatementTable_500802" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_500808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500802" xlink:to="loc_srt_ProductOrServiceAxis_500808" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_500809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_500808" xlink:to="loc_srt_ProductsAndServicesDomain_500809" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_XpovioMember" xlink:label="loc_kpti_XpovioMember_500810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_500809" xlink:to="loc_kpti_XpovioMember_500810" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_500805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_500802" xlink:to="loc_us-gaap_StatementLineItems_500805" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock" xlink:label="loc_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock_500806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_500805" xlink:to="loc_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock_500806" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_617" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_575947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_617" xlink:to="loc_us-gaap_StatementTable_575947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_577040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_575947" xlink:to="loc_us-gaap_AwardTypeAxis_577040" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_577040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577042" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577043" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_575948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_575947" xlink:to="loc_us-gaap_PlanNameAxis_575948" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_575949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_575948" xlink:to="loc_us-gaap_PlanNameDomain_575949" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember_575957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_575949" xlink:to="loc_kpti_EmployeeStockPurchasePlanMember_575957" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_577039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_575947" xlink:to="loc_us-gaap_StatementLineItems_577039" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_575943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_575943" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_618" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_575945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_575945" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577039" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_619" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesTable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_575014" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock" xlink:label="loc_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock_577156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_575014" xlink:to="loc_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock_577156" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_575016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_575014" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_575016" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_575017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_575014" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_575017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_638" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_638" xlink:to="loc_us-gaap_StatementTable_642" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_642" xlink:to="loc_us-gaap_DebtInstrumentAxis_639" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_639" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_640" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_640" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_643" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_642" xlink:to="loc_us-gaap_StatementLineItems_641" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_644" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock" xlink:label="loc_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock_645" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_641" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_646" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_575045" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_575047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_575045" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_575047" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RegulatoryAssetsAbstract" xlink:label="loc_kpti_RegulatoryAssetsAbstract_144" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccountingPoliciesAndGeneralInformationTable" xlink:label="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_RegulatoryAssetsAbstract_144" xlink:to="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_576876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" xlink:to="loc_srt_RangeAxis_576876" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_576878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_576876" xlink:to="loc_srt_RangeMember_576878" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_576880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_576878" xlink:to="loc_srt_MinimumMember_576880" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_576879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_576878" xlink:to="loc_srt_MaximumMember_576879" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_607424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_607423" xlink:to="loc_us-gaap_TypeOfAdoptionMember_607424" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_607427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_607424" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_607427" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccountingPoliciesAndGeneralInformationLineItems" xlink:label="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationTable_576872" xlink:to="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_576847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_NumberOfOperatingSegments_576847" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_576339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_576339" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_576839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_576839" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_576840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_OperatingLeaseLiability_576840" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_576863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AccountingPoliciesAndGeneralInformationLineItems_576874" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_576863" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_295" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_295" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_307" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_308" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_460495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_300" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_460495" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_296" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_296" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" xlink:to="loc_us-gaap_MoneyMarketFundsMember_314" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_305" xlink:to="loc_us-gaap_CertificatesOfDepositMember_315" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_InvestmentTypeAxis_303" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_303" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_304" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_304" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_312" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LongTermInvestmentsMember" xlink:label="loc_kpti_LongTermInvestmentsMember_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_304" xlink:to="loc_kpti_LongTermInvestmentsMember_313" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_FinancialInstrumentAxis_301" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_301" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_316" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" xlink:to="loc_us-gaap_CommercialPaperMember_317" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_306" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_318" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_298" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_309" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" xlink:to="loc_us-gaap_AvailableForSaleSecurities_310" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_302" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_311" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_500964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_297" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_500964" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_500965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_500964" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_500965" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract_575195" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract_575195" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_575199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_575198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_575199" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_575200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_575199" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_575200" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_575197" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_575207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_575207" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_575203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_575203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_575204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_575204" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_575205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_575202" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_575205" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_353" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_353" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" xlink:to="loc_us-gaap_AwardTypeAxis_354" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_356" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_360" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_501732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_501731" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_501732" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityContractMember" xlink:label="loc_us-gaap_EquityContractMember_501733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_501732" xlink:to="loc_us-gaap_EquityContractMember_501733" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_501734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityContractMember_501733" xlink:to="loc_us-gaap_StockOptionMember_501734" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_357" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_355" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_355" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_358" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_158" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AdjustmentsForChangeInAccountingPrincipleTable" xlink:label="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_158" xlink:to="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" xlink:to="loc_srt_RestatementAxis_161" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_161" xlink:to="loc_srt_RestatementDomain_162" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_162" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_168" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_162" xlink:to="loc_srt_RestatementAdjustmentMember_169" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AdjustmentsForChangeInAccountingPrincipleLineItems" xlink:label="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleTable_160" xlink:to="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_164" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_165" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_OperatingLeaseLiability_166" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems_159" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_167" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575241" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575241" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_575249" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_575251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_EquipmentMember_575251" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_575252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_575252" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_575253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_OfficeEquipmentMember_575253" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_575254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_575250" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_575254" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_575248" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_575256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_575256" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_575259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_575259" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_575261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_575261" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_575263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_575263" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_575265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_575255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_575265" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575325" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_575326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_575325" xlink:to="loc_us-gaap_DepreciationAndAmortization_575326" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_320" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_320" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_InvestmentTypeAxis_324" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_324" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_325" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_325" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_329" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LongTermInvestmentsMember" xlink:label="loc_kpti_LongTermInvestmentsMember_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_325" xlink:to="loc_kpti_LongTermInvestmentsMember_330" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_FinancialInstrumentAxis_323" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_336" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_328" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_338" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_321" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_321" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_326" xlink:to="loc_us-gaap_CertificatesOfDepositMember_331" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_322" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_332" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_333" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_334" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_327" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_335" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_340" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_340" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" xlink:to="loc_us-gaap_FinancialInstrumentAxis_341" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_341" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_344" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_343" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear_345" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_346" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear_347" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_348" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_349" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments" xlink:label="loc_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_342" xlink:to="loc_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments_350" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_500955" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves_501580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_500955" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves_501580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_500961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_500955" xlink:to="loc_us-gaap_InventoryFinishedGoods_500961" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_500962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_500955" xlink:to="loc_us-gaap_InventoryNet_500962" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_kpti_AccruedResearchAndDevelopmentCostsCurrent_575790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" xlink:to="loc_kpti_AccruedResearchAndDevelopmentCostsCurrent_575790" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_575791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_575791" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_575792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_575792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_589112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" xlink:to="loc_us-gaap_InterestPayableCurrent_589112" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_575793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_575793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_575794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_575789" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_575794" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_575749" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_575749" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_575752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_575752" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_575753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_575752" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_575753" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConsultingAndHistopathologyServicesMember" xlink:label="loc_kpti_ConsultingAndHistopathologyServicesMember_575755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_575753" xlink:to="loc_kpti_ConsultingAndHistopathologyServicesMember_575755" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ConsultingAndContractResearchServicesMember" xlink:label="loc_kpti_ConsultingAndContractResearchServicesMember_575756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_575753" xlink:to="loc_kpti_ConsultingAndContractResearchServicesMember_575756" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_575754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_575751" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_575754" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_575757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_575754" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_575757" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_575758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_575754" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_575758" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_479" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable" xlink:label="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_479" xlink:to="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_srt_RangeAxis_484" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_484" xlink:to="loc_srt_RangeMember_485" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_485" xlink:to="loc_srt_MaximumMember_497" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_srt_CounterpartyNameAxis_481" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_481" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_JefferiesLLCMember" xlink:label="loc_kpti_JefferiesLLCMember_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" xlink:to="loc_kpti_JefferiesLLCMember_498" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CantorFitzgeraldAndCoMember" xlink:label="loc_kpti_CantorFitzgeraldAndCoMember_575668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_486" xlink:to="loc_kpti_CantorFitzgeraldAndCoMember_575668" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_us-gaap_TypeOfArrangementAxis_489" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_489" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OpenMarketSaleAgreementMember" xlink:label="loc_kpti_OpenMarketSaleAgreementMember_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" xlink:to="loc_kpti_OpenMarketSaleAgreementMember_490" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_kpti_ControlledEquityOfferingSalesAgreementMember_575666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_480" xlink:to="loc_kpti_ControlledEquityOfferingSalesAgreementMember_575666" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_488" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_488" xlink:to="loc_us-gaap_EquityComponentDomain_482" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_482" xlink:to="loc_us-gaap_CommonStockMember_491" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_468835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_468835" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_468836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_468835" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_468836" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EquityOfferingLineItems" xlink:label="loc_kpti_EquityOfferingLineItems_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable_487" xlink:to="loc_kpti_EquityOfferingLineItems_483" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_SharePrice_493" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_494" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AggregateOfferingPrice" xlink:label="loc_kpti_AggregateOfferingPrice_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_AggregateOfferingPrice_495" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares" xlink:label="loc_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares_496" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_468834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_468834" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_500947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_500947" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SaleAgreementTerminationDate" xlink:label="loc_kpti_SaleAgreementTerminationDate_577298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_EquityOfferingLineItems_483" xlink:to="loc_kpti_SaleAgreementTerminationDate_577298" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_440" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LeasesTable" xlink:label="loc_kpti_LeasesTable_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_440" xlink:to="loc_kpti_LeasesTable_445" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_442" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_442" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_443" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OfficeAndResearchSpaceLeaseMember" xlink:label="loc_kpti_OfficeAndResearchSpaceLeaseMember_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_443" xlink:to="loc_kpti_OfficeAndResearchSpaceLeaseMember_451" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_441" xlink:to="loc_us-gaap_TypeOfAdoptionMember_450" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_450" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_466" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_srt_StatementGeographicalAxis_449" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_449" xlink:to="loc_srt_SegmentGeographicalDomain_448" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_CommonAreaMaintenanceMember" xlink:label="loc_kpti_CommonAreaMaintenanceMember_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_447" xlink:to="loc_kpti_CommonAreaMaintenanceMember_463" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LeasesLineItems" xlink:label="loc_kpti_LeasesLineItems_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesTable_445" xlink:to="loc_kpti_LeasesLineItems_444" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_452" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_SecurityDeposit_453" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_456" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_457" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_OperatingLeaseCost_458" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_461" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_LeasesLineItems_444" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_462" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_471" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_472" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_469" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_473" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_474" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_476" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_468" xlink:to="loc_us-gaap_OperatingLeaseLiability_477" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionDiscountsAndChargeBacks" xlink:label="loc_kpti_RevenueRecognitionDiscountsAndChargeBacks_575370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionDiscountsAndChargeBacks_575370" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks" xlink:label="loc_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks_575380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks_575380" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPaymentsForChargeBacks" xlink:label="loc_kpti_RevenueRecognitionPaymentsForChargeBacks_575382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionPaymentsForChargeBacks_575382" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionDiscountsAndChargeBacks" xlink:label="loc_kpti_RevenueRecognitionDiscountsAndChargeBacks_575400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionDiscountsAndChargeBacks_575400" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives" xlink:label="loc_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives_575408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives_575408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives" xlink:label="loc_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives_575409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives_575409" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionFeesRebatesAndOtherIncentives" xlink:label="loc_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives_577417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives_577417" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns" xlink:label="loc_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns_577498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns_577498" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionSalesReturn" xlink:label="loc_kpti_RevenueRecognitionSalesReturn_575472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionSalesReturn_575472" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:label="loc_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns_575481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns_575481" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:label="loc_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns_575482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns_575482" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns" xlink:label="loc_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns_575483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575321" xlink:to="loc_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns_575483" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_171" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_171" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_173" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_174" xlink:to="loc_us-gaap_UpFrontPaymentArrangementMember_188" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_172" xlink:to="loc_us-gaap_ProjectMember_179" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SelinexorMember" xlink:label="loc_kpti_SelinexorMember_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_SelinexorMember_193" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EltanexorMember" xlink:label="loc_kpti_EltanexorMember_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_EltanexorMember_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_KPT9274Member" xlink:label="loc_kpti_KPT9274Member_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_KPT9274Member_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VerdinexorMember" xlink:label="loc_kpti_VerdinexorMember_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_179" xlink:to="loc_kpti_VerdinexorMember_196" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_182" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_208" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_MajorCustomersAxis_175" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_175" xlink:to="loc_srt_NameOfMajorCustomerDomain_176" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AntengeneTherapeuticsLimitedMember" xlink:label="loc_kpti_AntengeneTherapeuticsLimitedMember_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_176" xlink:to="loc_kpti_AntengeneTherapeuticsLimitedMember_189" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_ProductOrServiceAxis_177" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_177" xlink:to="loc_srt_ProductsAndServicesDomain_178" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentMilestoneMember" xlink:label="loc_kpti_DevelopmentMilestoneMember_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_178" xlink:to="loc_kpti_DevelopmentMilestoneMember_190" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesEventsMember" xlink:label="loc_kpti_SalesEventsMember_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_178" xlink:to="loc_kpti_SalesEventsMember_191" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentGoalsMember" xlink:label="loc_kpti_DevelopmentGoalsMember_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_178" xlink:to="loc_kpti_DevelopmentGoalsMember_192" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_RangeAxis_180" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_180" xlink:to="loc_srt_RangeMember_181" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_181" xlink:to="loc_srt_MaximumMember_197" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_srt_StatementScenarioAxis_187" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_187" xlink:to="loc_srt_ScenarioUnspecifiedDomain_185" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_186" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_ContractWithCustomerLiability_198" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPotentialFutureMilestonePayments" xlink:label="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_199" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationNoticePeriod" xlink:label="loc_kpti_LicenseAgreementTerminationNoticePeriod_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_LicenseAgreementTerminationNoticePeriod_200" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationDescription" xlink:label="loc_kpti_LicenseAgreementTerminationDescription_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_LicenseAgreementTerminationDescription_201" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_202" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_AccountsReceivableNet_203" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_kpti_PotentialCommercialMilestonePayments_204" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_183" xlink:to="loc_us-gaap_Revenues_205" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_211" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_211" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_MajorCustomersAxis_212" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_212" xlink:to="loc_srt_NameOfMajorCustomerDomain_213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_BiogenMAIncMember" xlink:label="loc_kpti_BiogenMAIncMember_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_213" xlink:to="loc_kpti_BiogenMAIncMember_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_216" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_AssetPurchaseAgreementMember" xlink:label="loc_kpti_AssetPurchaseAgreementMember_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_217" xlink:to="loc_kpti_AssetPurchaseAgreementMember_226" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_StatementScenarioAxis_223" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_223" xlink:to="loc_srt_ScenarioUnspecifiedDomain_221" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_221" xlink:to="loc_us-gaap_ScenarioPlanMember_232" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_RangeAxis_218" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_218" xlink:to="loc_srt_RangeMember_219" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_219" xlink:to="loc_srt_MaximumMember_227" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_srt_ProductOrServiceAxis_214" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_214" xlink:to="loc_srt_ProductsAndServicesDomain_215" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesMilestoneMember" xlink:label="loc_kpti_SalesMilestoneMember_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_215" xlink:to="loc_kpti_SalesMilestoneMember_225" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_222" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_UpfrontPaymentReceived" xlink:label="loc_kpti_UpfrontPaymentReceived_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_kpti_UpfrontPaymentReceived_228" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_AccountsReceivableNet_229" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_kpti_PotentialCommercialMilestonePayments_230" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_501613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_501613" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_220" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_231" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_234" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_234" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_236" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="loc_us-gaap_UpFrontPaymentArrangementMember_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_237" xlink:to="loc_us-gaap_UpFrontPaymentArrangementMember_251" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_235" xlink:to="loc_us-gaap_ProjectMember_242" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SelinexorMember" xlink:label="loc_kpti_SelinexorMember_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_242" xlink:to="loc_kpti_SelinexorMember_256" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EltanexorMember" xlink:label="loc_kpti_EltanexorMember_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_242" xlink:to="loc_kpti_EltanexorMember_257" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_245" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_247" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_268" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_MajorCustomersAxis_238" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_238" xlink:to="loc_srt_NameOfMajorCustomerDomain_239" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OnoPharmaceuticalCompanyLimitedMember" xlink:label="loc_kpti_OnoPharmaceuticalCompanyLimitedMember_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_239" xlink:to="loc_kpti_OnoPharmaceuticalCompanyLimitedMember_252" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_StatementScenarioAxis_250" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_250" xlink:to="loc_srt_ScenarioUnspecifiedDomain_248" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_248" xlink:to="loc_us-gaap_ScenarioPlanMember_269" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_ProductOrServiceAxis_240" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_240" xlink:to="loc_srt_ProductsAndServicesDomain_241" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DevelopmentGoalsMember" xlink:label="loc_kpti_DevelopmentGoalsMember_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_241" xlink:to="loc_kpti_DevelopmentGoalsMember_253" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SalesEventsMember" xlink:label="loc_kpti_SalesEventsMember_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_241" xlink:to="loc_kpti_SalesEventsMember_254" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="loc_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_241" xlink:to="loc_kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember_255" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_srt_RangeAxis_243" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_243" xlink:to="loc_srt_RangeMember_244" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_244" xlink:to="loc_srt_MaximumMember_258" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_249" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_ContractWithCustomerLiability_259" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueRecognitionPotentialFutureMilestonePayments" xlink:label="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_RevenueRecognitionPotentialFutureMilestonePayments_260" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationNoticePeriod" xlink:label="loc_kpti_LicenseAgreementTerminationNoticePeriod_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_LicenseAgreementTerminationNoticePeriod_261" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_LicenseAgreementTerminationDescription" xlink:label="loc_kpti_LicenseAgreementTerminationDescription_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_LicenseAgreementTerminationDescription_262" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_263" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_AccountsReceivableNet_264" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PotentialCommercialMilestonePayments" xlink:label="loc_kpti_PotentialCommercialMilestonePayments_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_kpti_PotentialCommercialMilestonePayments_265" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_Revenues_266" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_246" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_267" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_362" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_362" xlink:to="loc_us-gaap_StatementTable_366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_366" xlink:to="loc_us-gaap_DebtInstrumentAxis_363" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_363" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_364" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_364" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_367" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_366" xlink:to="loc_us-gaap_StatementLineItems_365" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_365" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_368" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_394" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_PlanNameAxis_396" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_396" xlink:to="loc_us-gaap_PlanNameDomain_397" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TwothousandtenstockoptionplanmemberMember" xlink:label="loc_kpti_TwothousandtenstockoptionplanmemberMember_575963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_397" xlink:to="loc_kpti_TwothousandtenstockoptionplanmemberMember_575963" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TwoThousandThirteenStockOptionPlanMember" xlink:label="loc_kpti_TwoThousandThirteenStockOptionPlanMember_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_397" xlink:to="loc_kpti_TwoThousandThirteenStockOptionPlanMember_403" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_397" xlink:to="loc_kpti_EmployeeStockPurchasePlanMember_404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_srt_RangeAxis_398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_398" xlink:to="loc_srt_RangeMember_399" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_399" xlink:to="loc_srt_MaximumMember_406" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_399" xlink:to="loc_srt_MinimumMember_405" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_AwardTypeAxis_395" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_395" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_575964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_575964" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_575975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_us-gaap_RestrictedStockMember_575975" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_402" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_420" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_575980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_VestingAxis_575980" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_575981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_575980" xlink:to="loc_us-gaap_VestingDomain_575981" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VestingperiodonememberMember" xlink:label="loc_kpti_VestingperiodonememberMember_575983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_575981" xlink:to="loc_kpti_VestingperiodonememberMember_575983" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_VestingperiodtwomemberMember" xlink:label="loc_kpti_VestingperiodtwomemberMember_575985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_575981" xlink:to="loc_kpti_VestingperiodtwomemberMember_575985" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_400" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_575962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_575962" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_575961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_575961" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_415" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual_576004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual_576004" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual_576005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual_576005" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan" xlink:label="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan_576002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan_576002" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_576007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_576007" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_407" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_576008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_576008" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_576012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_576012" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_409" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_408" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RightsReceivedForEachRestrictedShareUnit" xlink:label="loc_kpti_RightsReceivedForEachRestrictedShareUnit_576933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_RightsReceivedForEachRestrictedShareUnit_576933" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:label="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_410" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_413" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_414" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_416" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance" xlink:label="loc_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance_417" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_411" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_418" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_576039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_576039" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_576043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_576043" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_576522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_576522" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementCompensationItemsAbstract" xlink:label="loc_us-gaap_IncomeStatementCompensationItemsAbstract_575852" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementCompensationItemsAbstract_575852" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_575855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_575855" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_575857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_575855" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_575857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_575858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_575857" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_575858" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_575860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_575857" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_575860" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_576967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_575854" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_576967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_576968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_576967" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_576968" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_371" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_371" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" xlink:to="loc_us-gaap_AwardTypeAxis_372" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_372" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_375" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_373" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_376" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_377" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_378" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_379" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_380" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_381" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_382" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_383" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_384" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_385" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_386" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_387" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_388" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_389" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_390" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_391" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_576071" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_576071" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_576080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" xlink:to="loc_srt_RangeAxis_576080" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_576081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_576080" xlink:to="loc_srt_RangeMember_576081" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_576082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_576081" xlink:to="loc_srt_MinimumMember_576082" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_576083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_576081" xlink:to="loc_srt_MaximumMember_576083" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_577055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" xlink:to="loc_us-gaap_AwardTypeAxis_577055" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_577055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeAndNonEmployeeStockOptionMember" xlink:label="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577056" xlink:to="loc_kpti_EmployeeAndNonEmployeeStockOptionMember_577063" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_576074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_576074" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_576076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_576076" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_576078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_576078" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_576072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_576984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_576072" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_423" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_423" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" xlink:to="loc_us-gaap_AwardTypeAxis_424" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_424" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_427" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_438" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_428" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_429" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_430" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_431" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_432" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_433" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_434" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_435" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_436" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_437" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_575895" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_575895" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" xlink:to="loc_us-gaap_PlanNameAxis_576126" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_576127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_576126" xlink:to="loc_us-gaap_PlanNameDomain_576127" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_EmployeeStockPurchasePlanMember" xlink:label="loc_kpti_EmployeeStockPurchasePlanMember_576129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_576127" xlink:to="loc_kpti_EmployeeStockPurchasePlanMember_576129" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_575909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" xlink:to="loc_srt_RangeAxis_575909" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_575910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_575909" xlink:to="loc_srt_RangeMember_575910" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_575912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_575910" xlink:to="loc_srt_MinimumMember_575912" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_575911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_575910" xlink:to="loc_srt_MaximumMember_575911" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575908" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_575920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_575920" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_575897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_575897" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_575902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_575902" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_575898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_575916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_575898" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/KPlanAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_576161" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_576162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_576161" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_576162" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_576163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_576161" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_576163" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_575085" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncomeTaxDisclosureTableTable" xlink:label="loc_kpti_IncomeTaxDisclosureTableTable_575088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_575085" xlink:to="loc_kpti_IncomeTaxDisclosureTableTable_575088" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_575089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_575089" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_575090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_575089" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_575090" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_575094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_575090" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_575094" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_575102" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_575106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_575103" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_575106" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_575108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_575107" xlink:to="loc_us-gaap_TypeOfAdoptionMember_575108" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_575109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_575108" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_575109" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_575111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_575111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_575111" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_575113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575112" xlink:to="loc_us-gaap_ResearchMember_575113" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_575114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_srt_StatementGeographicalAxis_575114" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_575115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_575114" xlink:to="loc_srt_SegmentGeographicalDomain_575115" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_575117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_575115" xlink:to="loc_country_DE_575117" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_590705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_srt_RangeAxis_590705" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_590707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_590705" xlink:to="loc_srt_RangeMember_590707" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_590709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_590707" xlink:to="loc_srt_MaximumMember_590709" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_IncomeTaxDisclosureLineItems" xlink:label="loc_kpti_IncomeTaxDisclosureLineItems_575118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureTableTable_575088" xlink:to="loc_kpti_IncomeTaxDisclosureLineItems_575118" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575119" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges" xlink:label="loc_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges_575120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges_575120" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets" xlink:label="loc_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets_575122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets_575122" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_575123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_575123" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_575126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_575126" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_575130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_OperatingLossCarryforwards_575130" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife" xlink:label="loc_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_575135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife_575135" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation" xlink:label="loc_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation_575139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation_575139" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_575141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_575141" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_575146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_575146" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:label="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575162" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered" xlink:label="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered_575167" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_575168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_575168" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_575173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_575173" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_606331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_IncomeTaxDisclosureLineItems_575118" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_606331" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_575019" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_575020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_575019" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_575020" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_575021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_575019" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_575021" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_575022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_575019" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_575022" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_577408" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_577408" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal" xlink:label="loc_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal_575025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal_575025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_575027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_575027" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences" xlink:label="loc_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences_575028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences_575028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_575029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_575029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_575030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_575030" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:label="loc_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles_575032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles_575032" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_575033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_575033" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_575034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_575034" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsLeaseLiability" xlink:label="loc_kpti_DeferredTaxAssetsLeaseLiability_589561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_kpti_DeferredTaxAssetsLeaseLiability_589561" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives" xlink:label="loc_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives_606010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives_606010" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_575037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_575037" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_575039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_577409" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_575039" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_577410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_577408" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_577410" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization" xlink:label="loc_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization_575041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_577410" xlink:to="loc_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization_575041" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_kpti_DeferredTaxAssetsRightOfUseAsset_589562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_577410" xlink:to="loc_kpti_DeferredTaxAssetsRightOfUseAsset_589562" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredTaxAssetsDeferredRoyaltyObligation" xlink:label="loc_kpti_DeferredTaxAssetsDeferredRoyaltyObligation_589563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_577410" xlink:to="loc_kpti_DeferredTaxAssetsDeferredRoyaltyObligation_589563" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_575042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_577410" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_575042" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_575043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_577408" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_575043" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_575050" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_575051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_575051" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_575052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_575052" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_575053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_575053" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_575054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_575054" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_575055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_575055" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_575057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_575057" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_575059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_575059" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_575060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_575060" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_575062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_575049" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_575062" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_500" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_500" xlink:to="loc_us-gaap_SubsequentEventTable_508" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_DebtInstrumentAxis_501" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_501" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_502" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_502" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_509" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_504" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_504" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_505" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_505" xlink:to="loc_us-gaap_ConvertibleDebtMember_511" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_468948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_srt_StatementScenarioAxis_468948" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_468949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_468948" xlink:to="loc_srt_ScenarioUnspecifiedDomain_468949" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_468950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_468949" xlink:to="loc_srt_ScenarioForecastMember_468950" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_500891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_TypeOfArrangementAxis_500891" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_500891" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RevenueInterestFinancingAgreementMember" xlink:label="loc_kpti_RevenueInterestFinancingAgreementMember_500893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_500892" xlink:to="loc_kpti_RevenueInterestFinancingAgreementMember_500893" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_dei_LegalEntityAxis_500896" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_500897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_500896" xlink:to="loc_dei_EntityDomain_500897" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_HealthcareRoyaltyPartnersIvLpMember" xlink:label="loc_kpti_HealthcareRoyaltyPartnersIvLpMember_500898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_500897" xlink:to="loc_kpti_HealthcareRoyaltyPartnersIvLpMember_500898" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateAxis" xlink:label="loc_kpti_RoyaltyPaymentDueDateAxis_500903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_kpti_RoyaltyPaymentDueDateAxis_500903" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentDueDateDomain" xlink:label="loc_kpti_RoyaltyPaymentDueDateDomain_500905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_RoyaltyPaymentDueDateAxis_500903" xlink:to="loc_kpti_RoyaltyPaymentDueDateDomain_500905" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember" xlink:label="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember_500906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_RoyaltyPaymentDueDateDomain_500905" xlink:to="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember_500906" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember" xlink:label="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember_500908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_RoyaltyPaymentDueDateDomain_500905" xlink:to="loc_kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember_500908" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_500912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_500912" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_500913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_500912" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_500913" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DeferredRoyaltyObligationMember" xlink:label="loc_kpti_DeferredRoyaltyObligationMember_500914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_500913" xlink:to="loc_kpti_DeferredRoyaltyObligationMember_500914" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_500921" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_500923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_500922" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_500923" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_508" xlink:to="loc_us-gaap_SubsequentEventLineItems_507" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_512" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_513" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_514" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes" xlink:label="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes_515" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod" xlink:label="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod_516" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_517" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_518" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_519" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_520" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_521" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PrincipalAmountPerNoteUsedInConversionRate" xlink:label="loc_kpti_PrincipalAmountPerNoteUsedInConversionRate_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_PrincipalAmountPerNoteUsedInConversionRate_522" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleLatestDate1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleLatestDate1_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleLatestDate1_523" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_524" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_501009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_501009" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_526" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription" xlink:label="loc_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription_527" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_PrincipalAmountOfNotesUsedInConversionRate" xlink:label="loc_kpti_PrincipalAmountOfNotesUsedInConversionRate_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_PrincipalAmountOfNotesUsedInConversionRate_528" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock" xlink:label="loc_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock_529" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentRepurchasePricePercentage" xlink:label="loc_kpti_DebtInstrumentRepurchasePricePercentage_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentRepurchasePricePercentage_530" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent" xlink:label="loc_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent_531" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_532" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_533" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_534" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentEstimatedFairValue" xlink:label="loc_kpti_DebtInstrumentEstimatedFairValue_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_DebtInstrumentEstimatedFairValue_535" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentTerm_536" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ProceedsFromFirstInvestmentAmount" xlink:label="loc_kpti_ProceedsFromFirstInvestmentAmount_500889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_ProceedsFromFirstInvestmentAmount_500889" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_SecondInvestmentAmount" xlink:label="loc_kpti_SecondInvestmentAmount_500890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_SecondInvestmentAmount_500890" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyPaymentsApplicableTieredPercentage" xlink:label="loc_kpti_RoyaltyPaymentsApplicableTieredPercentage_500894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_RoyaltyPaymentsApplicableTieredPercentage_500894" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_kpti_RoyaltyGuaranteesCommitmentsPercentage_500900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_kpti_RoyaltyGuaranteesCommitmentsPercentage_500900" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_500917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_500917" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_500920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_507" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_500920" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_539" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_539" xlink:to="loc_us-gaap_DebtInstrumentTable_544" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_544" xlink:to="loc_us-gaap_DebtInstrumentAxis_540" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_540" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_543" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_543" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_549" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_544" xlink:to="loc_us-gaap_DebtInstrumentLineItems_542" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentLiabilityComponentAbstract" xlink:label="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_542" xlink:to="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_545" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance" xlink:label="loc_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" xlink:to="loc_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance_546" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kpti_DebtInstrumentLiabilityComponentAbstract_541" xlink:to="loc_us-gaap_ConvertibleDebt_547" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_542" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_548" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_551" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_551" xlink:to="loc_us-gaap_DebtInstrumentTable_555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_555" xlink:to="loc_us-gaap_DebtInstrumentAxis_552" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_552" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_554" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_554" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_560" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_555" xlink:to="loc_us-gaap_DebtInstrumentLineItems_553" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_556" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_557" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_558" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_553" xlink:to="loc_us-gaap_InterestExpenseDebt_559" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_562" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_562" xlink:to="loc_us-gaap_DebtInstrumentTable_566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_566" xlink:to="loc_us-gaap_DebtInstrumentAxis_563" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_563" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_565" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="kpti-20191231.xsd#kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember" xlink:label="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_565" xlink:to="loc_kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember_577" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_566" xlink:to="loc_us-gaap_DebtInstrumentLineItems_564" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_567" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_568" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_569" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_570" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_571" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_572" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_573" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_574" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebtCurrent_575" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_564" xlink:to="loc_us-gaap_LongTermDebt_576" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g853399g23c59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g853399g23c59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1TB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0:^=# X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $6P
M!T           0                         !              =    $
M6P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
M6P    !29VAT;&]N9P  !T     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !%L     4F=H=&QO;F<
M  =      W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M<36.?H6NK8YSO["9E%XY#P4T_0_[K8G^?_L2]#_N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( 64"4@,!$0 "$0$#$0'_Q  >  $  00# 0$
M            !@$$!0<" P@)"O_$ 'H0  $$ 0(" P@+" L("@P)#04" P0&
M 0 '"!$2$Q4)%!<A5)25U18Q05%55Y*3T=+4&!E35F%QE]8B(R52@9&6H;'3
M\!HD)C(T-D;!)S,U-T1%1UAE\0I"0V-G='6#I*7&X2A(9&9S=H2%AH?$UW*"
MIK7#8J.SPL7_Q  = 0$!  (# 0$!             0(% P0&!P@)_\0 ;!$
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M4ZFIGQ,.2;D\DS,LAIO4MRE$G576E]SP]37Y$!-K%:7TZ0"$*<E[^GT '_\
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M3%@+ Y"XO>-[;:\?VWUXJ'$_>20ET, X?5&[."7'E/SI>Y^TC2#T&EWVO19
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M5+)4E0!S *DC.U_""%7(!(&2]A-\K&Q-A#=H^Z8;<;B"1+YVD6:L'3M\(A8
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M<5W@SVONM#X;3D&R7JI;W1+'2CU/NUBG4.\!BH&K[,'C:1C(,HS42ILBX<M
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MO/Y>N);I/RE>N'L2$?B53OFV?U?][W/?_CTMT#;V.S;?UQ?.>'YQZ.GH$7T
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M(I$<5L\&39IR$;FW!%<8 VXEA>VLX;' W??:"2A6F<::LS-;VF=VJ"LGQ\H
M>K$AJFS(-PJ,Y5?<%3C@F80MBG)89R43?DC$(T]8-L.Z.I[TJ<'?9FP,6&F'
M\DK1,\'->A@K"Q=HL1<&5/JNR86QL1R^V)->*T_6<CS0^\0IIB0?A#A<2*60
M],2HQM=W0[#9</7N((&B,U&L,:O6DE'VZ<,.0TV-F;3W"XS.PDB"NU8$HG"[
M08:SBO/ Y(J*-K";3$(W"8A&4&T7C[')WP9/[JUJUAI6T&\P'9I,5=6@6;&X
MDF<T[LM:BDH-MC2XXDLP'<(C+7'3/G (Y%@,7'M2._IL4"A$,L^T_=$B3!Y5
M0WTKT<*\&65H8,WD0!+@3D?=B59*P,,6$?MD0*26Q6VS(.K$V[%&MXTSU1&%
M;!MGF29IPBA&-"TSNG\EL]$F;LU.// 6@="AD2;>WD<1< $>L[?SXTH-'@;(
MS9HA$TQ(O ^[DR3T]UN<J.NG@40@6(=D0C(#]F>Z''5;<0MRM\ZZ1@#SS+E]
MD4DQ#HF)E?,5B]56[-)BU[;.$6,$XKUF"G-LW&K+7AH98-HC8!4NUCPQ.*A%
MK&V&[HL6)T_%OXHX2QU<N-"-2I];9IP$M)&)V[L5=W"P]&'[01J[8U8L9Y)D
M$!M(";7'2HL*<S"@Y%QQ^D(OPFVG=*94%R-<]Y*:Z\S;*B9$/UTS5A.6@@DM
M3SMH!VC,38*)*LK1*8./ @> 4VB,S*M+G>REM<@M%$A4(D42J\<@635<V_<>
M;:Q!RP" 5L @HE GO!=NQ\"WVF]V1RR!-KMMR"]PCT@77=O:4L(H2&AC;0RZ
MX!Q90DJY2T(RFYVU7%!N#LA8:0+MIT!N@2VHX88LNR!]SC6W#+]WJUE,EMYF
M@UPK 0^2%.G(3$> 84+#BU6@9-C@\'J^U)P:#NW;9#M_AV^J_F%[A@[I5.)Q
MREKWDJ5AK1,#L17[%M=3-_=_]M,0&]G']MWK%-K.ZT2(5O$:5NP]X:'[><<Z
MJX%XANAC;0?L2:\V_!0B^H?#GW4&EV>OVJU[^4K=:!'A['CSU'<W+W"J4>1G
M91JCP"I".=33RL"2YO/EW=BP[B9>JD605E%*6)-+-1 <9X8A'V,@.3'8,-TC
M%8A$'8D=R=#C2U3XT28ME"I46/.7%A+F,,/Y6TU+5#B*D-H2\J+'RO+2$(NM
M(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1\S
M^(C9;<\]NO9+'7:G-L @XD1(BR1C\3.6>\P8P6\S+1,?B9;>Q(@NK2EK+Z%,
MJ;7EQ*U*;3^#.63V,?*%R@\I6)<7T6I83EZ76%4HRK53J-58G4B1H=+IKVN:
ME:'.LHTIB3=4WHS"RIHH4K142E/<9?;0VE*M*XOL2",U$^^&ZT:1\ F]?Q:6
M#YX/ZT_M^?7S'W&/*MG_ )7P+EQJU=\GZ,V]-K1R\Y9XK^2/WHIX!=Z_%_L:
M6'Q_]]#\\?E_W3_IT]QCRK9_Y8P)E_TM7?1_P9ASEGBOY(_>AX!=Z_BTL'SH
MCV_2?/E^7E_!X]/<8<JU[=V,";=O=:N;./\ Y->CU0YRU_M[/>C;P_.],5\
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M9K#*Z-,S<U+IE7:72))"'5SDA3W$OAV0>44):6@-J;(<*E*2CJ/N)<4"F]@
M+G+,%5\@2-XZMEXA_$/LGN;<MS")ZLUI945)@#FVI3<Z SS=9;4EU&6Y#[3B
M<ISG&/\ %SC/CSC/M:^-<N/L;<><I./IS%% J.%9>G3$A(RJ&JK4*I+3B7)9
M+@<*FY6BSK.@2L:!YP5'.Z4V$<C+Z&T:*M*^D3DFXL1^&[?&CON:M[?Q(?\
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M%MB<L_3)B0Y3WS.LLKISAFFVC,51@TRG3<ZF<G)R2E6^<7EI@.-STQ-R4HR
MA2-:E"4ECFZD<=T7OX1TBE0!.6>D!>_2?)LRMLPTJ!O"Q8(%-O906!?KM5*E
MPP^RQFBP>!7% U[=G165B8I6(#"R@H>3".N3W8$/"0^2:)#A1\:Z0Z2F\=IJ
MTO1J[.R-/F*72IBI2$M4F#.RC-/5(]PYN4'-FYE$G)/2LJM$Z9A;+15+<Y2X
MM];"GLK(ML-LT[;"QLDG?NOPC-$MQ-W(5KJ 1%T D,62 5-@2X"N3'VG?94]
M,KYA@>.'!FB[18K(K$FMYA0(422R0>?P5[(L+IV1!V$SBC'$K6J)2.[5+=34
MI9Z?I\W*4F86VLU-3TO,MM2S4JF:YV^Y)/4\M,M-J2ZXX)DRTVN;6UCHH(4K
M:03L(V6L<@,B;   7N-QO$@#+WBJSQIH/NE4%O2C5JMY(A$@3)L&<8E!A1MR
M=VZ@!@=%%644?#SHI%$F%%>GO#0LCIO9'0G>_(M8ZI"YMB3Q11E.N3E7JK[J
M9.9>;>G9B48FU$3HD=2B6J$O.L/L/!QIHS)EY5PESF[)$@WMOVFXL=&V9-K#
M(C/(;!GE$!LIC<7;9J8>3<Z:7792H"%+BQ80Z5/GNT!KO(,=F R@]F;#BCSX
M!U$:4["CH)E@>)TAIR)(CXF^8K,]B?"8<J7=FB3JJI,24LZTU+,K?F.XS"9>
M6GGI*::0^TAF<D%)2XIE*9B<DP^L*:<0':+*%KG;F;W-TD6SMLOF.F\;[[GL
M:(6+B5)&RK^))(E6R\F8_AMMK#KJLQDY7AMI*&TXRE.,<D)PGQ>+&OLOL7)^
M9J>)\<S\XM*YF:IU+<>6E*4)4KG,PFX0D!*19(%@(+RMY_JC[TZ_:D<<-(0T
MA#2$6+\5YQ:G$DYL5'+&>J92/RTC"4\LYQF1 ?<\?+*E=)W.,9SGET4\L80B
MP5AM+:7E662EE>,Y0ZIT'AM6,8<5G*5Y&]%6,):=SG.,YQC#;F<^)"N2$77>
M$GX9)_-B?5>D(IB#(SG.,&R6<IY85C"!&<ISG'/&,X[+YXYXSC..?MXSSTA%
M>\)/PR3^;$^J](1UXBN*=4RD]/R\A*5K:QV-EU"%?XJE-X&=-*5?]JK.,8S[
MF=(1R7#>;3E3APBA./;4M(A*<>[X\J%XQ[6,Y_@TA%<09"NEC!LEG*<]%6,(
M$9Z*N6,]%7(7XL\LXSRSX^6<9]K.-(0S!D)QE2C9)*4XSE6<H$8QC&,<\YSG
M(OEC&,>/.?%RY>]I"*]X2<X\1DG[_/H"?'_ZKTA#O"3\,D_FQ/JO2$43"?6E
M*T&R2T*3A25)2(4E258YI4E6!><93G&<9QG&<XSC//'BTA%,PWD\\*.$4YQC
M&<XRD/CEA6>BG.>8OQ84K&4XSGQ9SCECQZ0BN8$C&,YR:)8QCQYSE C&,8]_
M.<B_%I"*X@2<XQG!HGG&<<\9P@1G&<9]K.,]E^/&=(1Q5"?1_CG"*/%E7-20
MZ?V*?&K/C%^UC'^-GVL8\><XTA%<P9"<<U&R2<<\8YY0(QCFK.,8QSR+]O.<
MXQC'MYSG&,>/2$,P9"<<U&B6,<\8YY0(QCFK.$IQSR+]O.<XQC'NYSC&/'G2
M$,P9"<94HT2PG&,YSG*!&,8QC'/.<YR+Y8QC'CSG/BQC2$5[PDY]HT3^0)]5
MZ0AWA)^&2?S8GU7I"..(3ZLJPDV1SE&>BK&$B,Y2KEA7)6,"^>,]%25<L\L\
ME8S[6<:0@F&\K_%.$5?L4K_8I$9_8+Y]!?B%Y_8KZ*NBKVE='/+.>6=(17,&
M1C'/)HEC'/&.>4",8YJSA*<>,7[>59QC&/;SG.,8\>=(17O"3\,D_FQ/JO2$
M.\)/PR3^;$^J](13$)]65=$V2SE.>BK&$",]%7+"NCGD+SG&>BI.>6?'RSC/
MM9YY0BO>$GX9)_-B?5>D(=X2?ADG\V)]5Z0CCF&]A*EY.$<(3TNDK*0_13T,
MYPOI*[+Y8Z.<9PKGG'1SC.,\N6=(1R[PD_#)/YL3ZKTA'!R(ZRC+CQT@TVG_
M !EN8#H1C\ZE#,)Q_#G2$<,L9PTE_-@FX87U>$/<PW5+RZI*&^BYD9T%9<6I
M*4<E9Z:E82GGG.,:0CAE"<8SG-CE8PE[O=6<K"8QB1^ SG(WQ/?]ZS^S_P#Z
M=(1V)CJ4GI)/SE)Z2$=).0V4]-SH]6GG@9G'2<Z:.@GGS5TT]'&>ECFA'#+6
M$Y0G-CEX4M6$HQE83&5JRI:,)3CLW'25E;;B,83C.<K0M.,<TJQA""FL)SG"
MK%+3E+N&%84L+C*7\IPO#.>8WQ.Y1G"\-Y_9Y3G"NCRSC.D(IA"<I<7BQRLH
M9SC#R\+"92UE6>BG#BNS>2,J5^QQA6<9SGQ8\>D(YK84VC+CE@FH0E24Y6O(
M9*,*4E*TIRI0S&,*4E25)QG//*5)SC&<9QG2$5[V7UF6NWYW6)Z&<M_N-T\8
M=Z75<T=F=+&'.@OH9SC]GT%='.>CGDA')41U&<X6=((RE.%JPK =.<(SGHX5
MG&1F.2<J_8X5GQ9SXN?/2$="TMMR&(CEEDHER<O)C15N TR)"HS:'I"6&5#<
M..Y8:<;=>PVE66FUH6OHI5C.4(NN\)/PR3^;$^J](1K(_NKMW5BQ$%8-R%BR
MPIN.[.@R8T?#S2)2(KK&&\MU]:)2W&IL=WJXJWW$M*<<6E+<>0IKYM7^5_DU
MPO59^B8@Q=3*55J8U+O3LC-)FTOMHFDRRV"V$RRDS*G&YMAS5RRGG$ME;BTI
M0R\IO-+:U"X2H@WS R\GFC"JWWVA2A*\[K8Y94ZGHXA84ZC+/0ZSK64UO+S2
M<96G"5.H0ES.%X;RK+;F$Z97L@.1M*$K./:391>3HAJHJ=06"D.ZUE,D760"
ML:*G4(2OPM65:"]&ZEWWBMWI[>;?'9G?/:/#SC'A89RMO#^5+PPPIC/>[*GW
M4MR4U[,9U?5I_:T-NK6^XIMEA+CSK;:\SR^<CH=6R<?T/2;#Y4L*FRP>;LE]
MU+<R)4R[JPV/ ;:=6MY:D-,I6ZXA"FJ=]XKJC@G?;:)367<;K8RE*VF^CWFG
M#RLO-K=;4B/[&\/K:RVWE67D-*91E3:5K2IUK"\1R_\ (X6RZ,>TBVL;:T-7
M4 \I3K:W6RF7,EKUMJ;05:Y+9922A*EA3C84U3GO%;\[</1VZ#%<;Z;1+=99
M3NPWTG\L)0KO9K#2,R,XPUA]]5=ZB-X\_MO?+C6&,87E_J\(7E-3R_<CBG&6
MAC^B:3Y8"%'GB64F9MJ@\^J5#$L<_P H)AQK4:*]=J]!>BU3F?@*W[N'#CZ=
MN6Z."=^-H5(<7C=?&$MMX=STX6$96C+Z8_-E*ZVE3ZL.JY*0QAQ:4H=<4G#3
M+RT8I]D#R-J0XOO^HX2VV'3IMS[96V7Q+A3"5R:53!UQT2E@.*2$.+4 VTZI
M#5.>\5U0SOQM"E*5YW6QG"LN8Z.(6%.)RUE.%Y<:36\NM8QE6.674(2O//H9
M5T5<HKV0/(VE"5G'M(LHNC1#514XC4J2ES6M)DBZR 5 )+R$!>905!)(:EWW
MBN.0OT_1MX=$=BM]-HDNN,YW7;Z;??'25B.TIE68S2GG4MR4UW,=Y75HSU2&
M75J?6IMIC#CKK2%\BN7WD=2ZXR<?T32:U^DL&;4PHRS1>>2U,IE3+O*"!X"&
M77%/+4AID..N-H4U3OO%;+[,['9EM\F5XX8WVVB4WES&ZV,X2XTWT.\DX>RI
MYMQUM2(_L;P^MO+;:LY>0VII'2;2XM*GF<+P'L@.1PH+@Q[2+!QIO0U=0#Q4
M\VMYM29<R6O6VIM!5KD-EI.DV%+"G6@MJG/>*ZNWGX1.:I;JO>6I#U3O*SB(
MF6TRL1,#,.,9=;0ZCKF7@[3R.:'$>-3>,85S0KDXE2<>\POC'#&-9%ZI85K,
MG6Y%B8$J_,R16IMF9,NS-<W<UC;:D/)8F&'%MJ 6V'4A82KP1@I*DD!0*21<
M BV78'J/"(2?WPVNK!6>$-[BD8A09+?@SH:0<B4Y'DQFF7WDKS#J[Z,MI:?;
M4E]*E1W.3J6G5KCR$M>&K_+SR487JL[1*YBQN3JM.F792=DTTJN3;LN^PRQ,
M.A?,Z;,)U:69AM8?"BPNSJ6W%+EYA+6:6G% $))!S!) &9MO(\EML8S'$3LY
MES#7A/G=+*<*PO(*7U/)3/7XQF1[%>]TKZO/C:4[AQ+G-A2,/XRWC6>Z2Y%=
M;J>_>7TM$*T^Y-?U'A,\X"3,]RN;!S5;6B[K0X"P4!\%L74.VOH'K3?JO?M?
M9'!/$9LTI&5XW-)\L+:;Z.:X0PZI3Z5K:RVQFI8>=0I+>>DXVVIM&5-I<4E3
MS.'.-/LEN112"L8U0=%;#>@:%B5+RU3"5K9U4N:.'WDK2VJZVFUMH);2M22\
MR'&H=]YQ_I)MEMN;V'GBN>(O9K&&<^$\AG#[>'$92 FJPE"GUQ\9?RFIY[U5
MUK:OV$GJ5]6IM_*>H>9<73[)7D3_ ")[]V2'T!Q!31L0J"$%]<N#,%-)(E5%
MUM0T)HLKU9;>T=2\TXMJ'<_ .72GA?+//S7BOW16S?-_'A/GX[W0I;F<@9F$
MK2EY#&>]U9JF$R\]8M.<)BY>4IO"WTXRRTZXB^Z5Y$[O@XW8'-T*6M1H^( E
M:4OHEU<V6:2$S9UBTV3*EY2FPMY(++3KB&H=R\ ]:=_$7N//:V^.*N(S9I*$
MKSN<2Y9<>:Z&*Z0R\E;"&UN]8QBI9?:1A+J<H<<;0V[E+J6EK4P^EO%7LEN1
M-* LXU;L7'VR@4/$I?0J70TMXNRXHY?:0E+J=%QUM#;A2\EM:U2[X;NH=]YP
M_I)W[+&^?FCGGB(V<PZIKPGSLJ2E2LKP"E98SA#.7U)3)Q5<QU+ZO&<):2[E
MQ;O)A"%/YPWGD/LDN14/*8[]Y8J2%DK%*KQESH,&84E,V*7S5;FJ'@M)>+BW
M2&$(4^I+9FH=M?0/6+[;;+W]'3LC@GB,V;4C+F-S26<86RWT?8Z0P\I4A#BV
MLML9J6'W6U);5E3K3:VF\J92XM"GV,.8)]DKR**05C&K9LXRUJ^X>) ^M4PA
MQQDMRQHXF'4*2VHEUII;2"II+BTJ?8#C4.^\_P#$FW7>T5QQ%[-YRSC&Y\_/
M7I0I"L )F4)PMQ32>O7BJ="+GIH5S3)4RI*.BZK&&EH6J^Z4Y%-)E(QNP2^E
MM:"*/B H2EUPM(U[@I)1*G32=),RIE2$:+BPEI25JNH=S\ Y=*?1GGYMNZ-B
MTNZ5?<*)+FT^Z33$>#(S%EY1#BQ'67>CA6.DQ/!17\MKQG]K?2VIEW*5I;<5
ME"\)^F81QIAK'=*76\*5--6I:)V8IZIM,M.2J>=RJ6EOM)1/2\LZL(2^T=:A
MM3*].R'%%*@.-25(.BH6-KVN-GF,:=XAANRM]KT[:C=F]2QN7^\SL9M6$QI,
M"7%;E.0"+$F&&3'<<PUB6TF(Z^M,A+JF<L+<<:3GP/*?BCD@?;=P1RC8@DI!
M;C;-4$F^]/R;S6K0^Y+S34W+M:D.Z#;X:96ZO7$ZK4.+6VA52APC20DG=<"^
M9W;[7[91\_X7"9PQP)<<F,XB#T&; FPI,"5$ARXI*+,PI<J!*A+8%M3$/,N1
ML/-S(G+O9[$=76-./1^L^#2U,]BE+.-3LICZ?8F):8E3+K:JU0:FVYEP*?E7
M9="*0F:5;5:27V4%+:BT%.(6\P%YZ+QVMY;]O';L%K>7;Z)2[L)LR\S'8=XN
MMPWHZY>2S3:RQYUEH@X<[95/<0IA;42<JQ1DFE/OX:DY)(9+J5URV9*MVN?]
MCDXAAM7*S7EI><YVW?%-96AMYVH:\//'F"FY9XS[(F"9K5.)<#<TJVDVZ<=6
M\/\ 1&PZ#;>;Y#;O%L[W.W;UM\/VRB)DXDCBUOR"#H=(><0P3.-RYH%F:RI(
MA<K+&'B U$WJI"1J')$?#K:IN&.3#KR,$SGL;4OSDV.56N(?-/$I,/JQ-5TK
MF)!J8;:3+(>53DJG&43)2X)9A3Z;I7,!K0:<<12V\=C1L"=A).S.YML-\]E^
M.^.Q[8399V2.*O\ %E>W28N7-6-*+DEUG1[^1S$"9EDCWCDS$86.<3%PGKVX
MBVU3FV,96HCC/([4?8W+7+3CO*A6E34I,36HF#7JRJI2[S4JRQ,Z2^YIGF&1
M+.!L%6K86.<!HJ4B:"9JWMNKV[\SMZ;'<;;=_&)^)X-JN>$IG!^)C<XB&*QR
M<7KHQTBN'.BS"+KAB,XGK,(>8F%&772#+B,HD3&U.R$N.IZ6O>4GD_Y+Z[2V
MJC1L98MJ5)J#4VRU-2N*IYV5F6E3;J9U"2F7T%I,ZT\F80H%*GFSI@N)TABK
M3!LI !SN"I0R(X6W[3QC'ENYX;?GYSI0[O)=31-_#27R);.",YY+#2&&$NRY
MC3S[B66&T,M84YG"&D)0C"4IQC&$]R&<E-3F%SE0J6)YV:<2VE<Q-UM^8>4E
MM"6T)4X])N.$)0D)2"NR0 !8; 6L"UDV\I\V[=&W]A>$/;G8>VOW$-?K 2)N
M#WAS;;\<>B.VR^I*G%92L8^M2E83C'B4G'NXY>UCVN!L#\GW)XJ><PV9A$Q4
M4M-S<S.S<U-O+:84M3;*4E#;"&TK6I=T,)<4HV6XM*4!,*E*VV &Z]_J&_/?
MOCV/VA _&>?\P.]3Z^A=V:9\;1\AW]R)'=%D19LC,6-9YCLG#.7^]\)$I>ZA
M*\-J>PVL4E:F\+4E"EXQE.%9PG.<9SKM2\W+S84J7=#H00%$!0L3>WYR4[;'
M9PA&=CLN,)4ER7(EY4KI87(3&2I&.6,=!/>L:,CH\\=+]DE2N><_LN7+&.S"
M+C2$1JYU]5LI]KJJ9>("K-6CM?3.RSF1B$HR+E#L2\L8=9R_B/F3UV6</-9<
MZ'0PZWE73PA'S.7W-9PT8&EK'N%5AL&)>MN;PJF;=44Y1Z7 ET49 KY!L0)A
M7]_")UM##L/&"DO+W,P5,RDPE,S%LK0C.F>"[BB/-DG9''%N %G$J:$K;F*J
MS;A@]@B%M <LHY C$-P##XV>6#C'AIB=$DIGRW)CZ&WV!TDA#FNW;\(1L_>;
MADWROD+<$1MSQ#JVJ1?6*?,>NH<#96MR1MCJE.;J*)[!L#>:\)?&SW(\0].&
M2 KB9+\=T<T]"<D1#(EGVR]<(TM:N#;BK.V1T("XL=PJA3TU22X[>(=ZW%(V
MDG;"1FJ3GA3=:GW%\(*K\!X59C429$2W8(+AQBKCK!BD.JJP1"-UR^#ZPO<2
M%SW\$[O3*;-M0AL<V1J]4!R;Y%1FG;7U24/=*7%NV4AT1,>VU:*R,IH"2^.V
M9,(>3&+C,SU(1IFW\ .\E_'2Q%MXK;.2 R]MIE,74YD6[6*J(L,B:3<]FJHE
MVW*M)R89?BD%*D2)UBD2(SKTD4(=&UEH>&AH1N6_</6^Q.Z&'J)NS#I],O&^
M8[<NQR*\U80%M'UAG:T+4CM5(S(]C='6:&;-TRNNPG1XZM%@[<U]YLKEJ),C
MET(U-8^!S?(AB+61O%)?GZ>8I9X+;I-IN.[5IE9,O7=@Q%?C S&YLL<8AV*C
M2Y^WAR$;D/B8(B-(GQQ4LL68DB$(E9G@NWAFX,#!'%CN<#KTEBQ,!&V+3NTL
M^%A$S[1< $P:3NTSWV.JK<;HQ2KL;V6D4DR(.;8<4Y@=6X[M;M_A"+Z%PC;W
MC%;XM+XGK?9@6X>S^\VVU$JEDG78C!IA._D\SZ)8YA0[=;/-FEMOH2YE=P9A
ML0YA0+-C81'@$!LZ=8D(QAOA W\/QR;</BCME)8+*NN8D>OE-V&9]:C6B/.2
M,9'*A;R1*LQ.#LSXX/H!ZN*JP2!7QA3;6LT.Q2B!=Y"(UG@(W;;L$DQ'XJ[L
M\F4P$AN23<W<ZQFL"@821&;K[DPSNU+@$PDFSSYMP0R>&%W@A7DNNN"Y<T@0
M>0BY/\"V]1N0%B/<6U]FU4,/K+.:V?F[@V!DJ3KVY8W<G!8Q,*;E29I&>J8+
MCC8$Z0^N3#'+4-D9(!XPX;"0C:&W'"INQ3[)6SM@XE;U:(U7(IDQ@W:^X440
M9;4?K<R=+L(69N,4 39A:LBS%86%8$1J'7DDV2M,J%;G((J)H1J/<?N?^Z6X
MT6^C#G%=>#8*S/R<U@#96+23@4V"[9H"HT)I;%^AOE4L4&K48'(7)4UVA;X-
MSNTI*G-P#0EI"-Q;K\(EFW,VT5MOC>ZZCH30;=8+$E3#M]+*<CWS<H1:ZLL^
MI=]C3[6_0*2/F[?B)5B(D)J8Y)PJ.E"749CN4&VZ_8]'DZHQ()W[O3U\+CS[
MXB1#A'X@C)(!)*<59IP97[5@HD2S W PR9 QIE?EB8)U#VZS@XB:$.A)4A@G
M)%/CGI!R:ZZ%3,A"R$6Z0]Z-G1MXYB_FO:,0E6]72!F0;<8CEKX&-Z#86%71
M7%[N9 $O.L9LS)HSN/;E6")BRG9I 7+38]S2$=P(:IQ9FF%A"V<)E]XQ#69B
M,-SQ)>Z0]Z.C9EZ//%*5>^\NWUGMQC)VWA>XFV0.TU?I7$?;%I#VOI6YUZQV
M,0)JM=<W&"V[!2JKR5([AW,F-I\ Q0HH+=O<3<2FS6"S32JJ-&NY="8',\.W
M;9;.,@+ "][=O\. RCI$\$N^,0 -AS^-#>2791H+LJ/9LV._*RQ,5>';-VJ\
M#1N#& G)4<'+F5=E1X;.6]#S!3,<>@C8(]A:+$=(\"6^;MD-6ZO<5!NEF[%8
MZB9G/5[.ZLER*(I\!]B!4\$+)O$?)V -.ER5/&<VB237,:8CL0&P\1F%#@.W
M:\(K0> ?>6EP(,%CBYO,!L-2=LZA7(]<5?H4"NKVZ(5EM4YB*8W1.+-CC@,;
M;N=5LSY>O!BVX!=(^)D,+$CF4(FKG!IO1+V^VWIQ?B[W+L<ZGV$><+$+(TJ<
MQ(EB=T!>XP8\.?%3P5F,V0)%$LU4;$W,LE^H+41])-NC,21\2,I#L(@4_@8X
MGGZ4FM0>.W="(7S3)M8S99#]ZE%HI>1;"=DB7"%*C;DC6W"T*+-@UYQDK")9
ME 16!\6<)5,9EC';MV,(SUGX'M^"\;*@'&SO-52LRP'C!J?#L-^(LD(A6*!;
M%B80TSN&1&5V#7"D(P=B,UZ&,[[5.C L+@"6W^L0B-M=SXW=KM>F"=M^+*Z[
M?D"EJR>+DPCVX"6)\871Z13:HGL=>YRA+!$>JH2"AQ_$-QBP,FEB76HN P$B
M-0B=5O@TWS@K 1;/Q=[D6(0.-B9QA+!_=4.<-@8%H-&B]4<+P=V4-,0K1 +Q
M(,DTR/;LX>-5J\,C&9\6199)Y".Z#PG\1X"L6V+CB\W+O!JPW#;0I&@'2,L'
M745\%=!Q&XB99(2^[N$'@S*JY.&18FW]XI9(TH7!:M!TO$*SX;#MV]$(@I/@
M WC)#' <CBPLTP,NKG![PR4+M38LE=#N[&-R']QBPJ+N&W&E6AB-(,"%R>GA
M)/)7"RB)#$1]HF@>W:QC8CW"+ORTPH8,XMKXP)*(<585SB&Y1 _WVY08=:??
MJYYS=1$JLMSK3VG<'HL1+D0:M^'# 1Q,J-VKE"+*W<%U^LVT<7:4WO*9OT&;
MN"4.%3-[G6>R$!=:.;!E]JI<0<Y:;)9"!-<.XD7[O%&2S$,:RDP3;CH3.B1G
MI;MV\_DA'0=X"BR]L8^V];W:@NC!!_<R?6@VX.UM'O%)!1]S2-TG%+'%JKD$
M8A_<>/BYR&5F2DXK2^]&BPVMT"GP;-,;A/3"(@CN:(NQ%82MQKQ72=<CV^Y&
MC@RG;;":P4W$%6]>^C[Z]P"A(A989"V1%[TNCQMF#AP\T$)'%T 7!T^P1IP!
MV[=OIA&ZZ;P[7JO*M&5+ PQQ7<7;"Q"0K).;*3#"U'BFW(WLG.R)#\=?,E$H
MMU U6*A*W>^"59>BXDH"H"*C(1Y@L'<FJQN%N%:K'N?N' .TN][MV/=FRTVO
MT2" GCE'(&\8A-#I5GF%#DFHTWJMS(UPFO"(,6UHW=([N;G5ZQUPSN@U'J2$
M:\N?<:HE\!/5PUO%6X,"*TN'$D@-GXD(C<GH5,XBJ^+O>\;T^XE&KYNN8*[]
M-R+Y?!;51+G!56?;KK]0.FAYVL(1Z*-]SJ8<JFZ@2GW.DU%.Y^^] WN/TMK9
MRFDMI[A[ R.QIP;2]S LMK-]LU?B'=J;00'-5_<:G-.N;EGE66+958>[]=O1
M;S^?U0C2V>Y87YG9ZU;$HWJVS+[>63=K;?>I,0WL[:4R(-GHNUFV.UKE3B-#
M-X(L2'MH@7MZI52KL9M):K#Y 8*NPEXP5;Q!")'1>YFW[;"71S%3W=V<*V[;
MPO1K$+W%MO#U/=W(MQ.LUZJ@IP?<*W@-V@\HQ1XJ*UEND505'#MU42Z'#KGD
MFZXW)*(1G=[>YKVK>BU[G6ZR[Y KD2W,V6F[42U[H;1"CSX?M.]!K8B.->H%
MBVO813J3'$(=VR#N0G+* N:8MXL=PMY5N:@DA&Z>&G@7&;"[B7#<LO?';C8S
M-SO=D"R!==8J.'(E^-V0\6<O.6R)E^VV3*[*R"63BR 0:37Z3MVQ(KRYE2%2
MHJ$>^M(1X.WUX<=P[SN$6M56? 21YJ&.:=:,3'(\B$Y"CQ(^6X?3AS^]TN*A
MH>4[#5$6K#TEI>%(E2L/_DKE2]C ]RD8TJ^+48V32$U:7I\LJGO8=36#+)D6
M)-K2E)I^L2AD2ZN4"U<R986=9,)6ZM$Y-(=[+4P&TA)056)(.D$[?^RJ]KG,
M\>C/42N$K>A3DA66JEA+V92D\K#*P_C,I2<JQ(EI#XDSDIPA/["2M:5*RM:<
M-J==Z?A5^PL=6Y,J/*19#YG2FV%2F9O.+0HB9G$XC$S/(0$#P)IQ:%*+BTI;
M4ZYIY\Z&5FSEM\/: +9#1LGRB_D.R**X2MZ58\;-,Z>793BL8+JQ%Y2X[4=?
M50$@\0X[J4-Y4F0RRAY#G4.LJ:>B1W$8J]A9,+; /*.QK2[-K4!@N7$H$S<L
MU++U-/%?$G+/)0VI:9B790\A>H<94T]*LNI<Z'P9ME;\IGD23<Z%S?T=,<L<
M)>]&'$*PU4NBG$3.<^R&5WUTXD5,7&&Y_8W?C#*\=)6(S3J8[:<,-Y;7WK'4
MCD'L+G@\VOVR+MH$II7PK_*]*5DDR8#50.(E3C#! 4H2K3J9="-2WJU\W94B
M<Z&]O;_M=-]FC8D1UHX2-Z$<LX:IF5)7%6C';"^HSWKE>4XD1,@\QIO2Z6,+
MS+;>Z:<.)=PZE]W&>%OV%<PV@ <H[!<2Y)N-CO+9YL>9ZW1$U)'$"I6>4O6#
M37-M/E8#B7=:'W ;SH?!GY?';8Z-QNL!EOX05PC[SY::;PU4/V$=4=67#TA[
MQ9G.S<*C8>#*S STG$H5B(IO+G]\J6O*9TIM9?L*7BVPTGE(39N5,LX7<))?
ML#/NSP5)ZW$2E4X:3B4+3)%HK/.%*643LRTMSH?!F][BR[#9;/P<^.?U QR5
MPD;SJ4_G+52QA[OC..5AE8>QF0M"\XD2DATR)F$]#&.C(<4G*LY7C"5*5TLU
M>PK=4N:)Y2/ ?$UH:.%2E\&9=0X><S*<1A^>2C0'@33BTE1*P$E2@7.AE^3.
M1%_#&[@-"P\T%<).]*D^-FF=++LMQ6,&%XC8Q+8;85AF"D'B'&<0E&5-OL,M
MNMKZAQG+3L.,XC%?L*YA:+'E'8#A>G7% 8+8$IHSLNU+K#%/%?$G*NH2VI2)
MB79;=0LL.-%EV48<0YT/@S;AIV(S/]+1).WHCDGA+WH2ZA?55/*4XB9SG%BD
MXD]*)%Q%3AJ?V-WY':5CI*Q&:=3'0G##>4+Q$CJ;Y$>PM=0^TY[9%VT<S*O^
M"Q$V52DF)1.JJ'?$9N785X2DRS3J6$(#+1;6)674B<Z%K:LY[](6S-SX.@03
MT[3MCTAPT[)W?:TO:"=N6$2@N,&#X; B1U_+,%^2\MU_.(</"EK2_A*G%I<=
M7E&,N.KSRY?H[D7Y*E\D>&ZAA]=<:KYG:T[5DS;5(;HP;2Y3J;(!A;#<Y.Z]
MP=SRZN:<=#KI=T5@E&FK@><UJPH)*0$VL5!5\U';8$;>&[;NC6F[7#'N19MP
M;)9:V_7I@L[+ED$8FSG1,V.[/AHBNQ75L0Y;LJ.SU2%(;<?3'6E3Z$QV<2Y2
MG?C6.O8HNXTQGB'%??TBF-UR<G9Q$BWAH//RRIV09D5-NU%NM2;\VR@,(<##
MB QHJ?;0TCG4RMWE1,!" G0)L+7TK#(D[-$\;7R/EL(UO]R3O3T,XZFF]/II
M5C]V%][<D,9CXYP>Q.\U/*1GI=\J:Z[+G2>4O+ZU.Z\G[BM\-%/MCL:S6H6
M,&,\TT42IE1I2'=\2BG]"RC-%HOES2=*R\I3D9\Z%_YLVM;\_,9WO?0N;<-_
M1'-OA+WG;?8=PS4^BTY!<SRL<K$CG!;PWA,>=V-F7"2O]DI*(RTMMYPQS0YF
M)&RWFW["QUN9EGO;()0PY3G% 864F;4:>VEL"6GSB-4U)(<\(I0PXEMK\A^3
M6926*'.Q\&;V.>GEGT:.[+,GCLO'6GA'WI2WEO+5.\3+;*,H-/-)SA$G$K.9
M3;87"2&<KRI.,S.N4E&&487EJ+':1PH]A2^AI39Y2&B0RVRV6\'--((;G.>
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MVEI9!)=<;4\KPG%1UG%I6M2O"&RP(O:P .=\[VW>F)GEK<_W-MV/Y9C/5_\
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MPDHC!+WZ?>D1:B.G"+*_32<.6?>+(&LRX5MBR*S(CKD8>0>96*RCOW'4Z0B
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M;M&)L86PS]R=V;,JO;@0KN'BV!K:-^:-%"8]8@!-M1=TA;3P=QPNW8H13:\
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M?Y!#\U8^II"*=FCO((7FK']7I"*]G#_(8?FK'U-(0[.'^00_-6/J:0AV</\
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MFK9?G"MM@> MP&Z4+6XI804,H;2I3SRFVD J6(RJ$^U3Y*9G5H6\B51IK;9
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MJ>F1<$]SJFMTQEN0G%U%<H[-NOLI>"D*<=D)1U*95R7::6PDM-H!6%><13:
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M30I#1.>B$NC/6FW,S(X?86TMN9LIE3*D7?N 6!.!%QHYC^7S%^-T^]$0.O\
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MI(/<7)49<O(RYJ)")$*U9"T:2RN98F5%=T&_Y1A('!)5?2590]U?=5\/7QI
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M"VLH1^N>3+"_)Y4,$4.=KDCA]ZJ/)J)FG)V8:1-*T*I.M,ZU#DP@C18;9"/
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MX;QG.4HPXZ^M>$XSG.<)Y\L9SGEC4L#M /E ,6Y&PD>0GMVZ!&.]A51\7^
M;T:#\7M_]]\?T?Q:?]E/'8-VS=;9?HOUPN>*OE'UPS2ZC\7X;Q_]&@_?\?\
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MV^-U7;EQBC/SJ9=K(#,[D9-UT>P?3*GPJO#L59F19ILI#JU>.2#$4,-5BP%
MQ-QK&$.W:\0IC?GC@DV!;I/:<U5Q[[-DA$Z]&VPL%Q=IT$7N;=0Y6XPC(Z-"
M WWLFCA!12BP 5QS;=P'Y AN/LQ-&V]BWU]"-C#-[-]7PMK!31>Z3;L3<X+
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MWIC8QUZ0U+BUV1'#&:J1S8$([#/%EQDSI98*#X0+'7^M1N$U7[/.A7$RS):
MA<3:L5S 9JC$6!**$52!R@5BE"^TWA:\AB$IHR)<<=NW;R0CU'5]U[B6K?#N
M3F*AN9W%W0N=0-E(PM;+%HI]?H&^!VL7,)#4Y(6-CWA-!J-R'MMJDI0+-=XM
M=8T^E6D(\!T+>7NI-VL8.)#VX#!F!IN\F2#>Z&V!#;8):]JZX_L*YMZ^^5CE
M+8L;N?NI4[1NN3GTWM*JO4+<,8FKFXD8#1"<VWH1B<;_ /=+YI"FKKFWY,I4
M(\D82O5GM/#W9Z ;;;DD>'>#=@D?;R9+-V(\/H3][W;?KN0$@,8O(*G3'ZZ7
MN+U+DD[V[=NQA&Q]T=WNZ [>[%/SJO2[!N!N4O=_<R%FUYVCC3(43;FHWK<N
MI44/%V[H\DS?'3%]"U&C7=JVN4<A2YT&[NAW[1M^-(QKW2W;MG",W(LO='I=
M]R%I[E>D"E;LGF$2MRMN6:M6H>V0*I[+V5OOXQ6TG72,TN4O6Y%3'9%D8V"A
M*@M8A6&/B";?F.W;M:$0V\\2O'XSN5=!(O9:ST.IYW!V<#4MN=L+8]V6PX>P
M")$NY>RVY;6W ^**UYG#,HE8+92(%D35R,,1M^X@9.M"[?7D(]E\-CO$X63$
MLV]1Z'*KA@/;^\*_+I4*AVL3*C[B$XM(E'PK.2,ALD4VZC#B1R)@K$AB"\]P
M<S")9;[1;0CUQI"&D(:0AI"&D(:0AI"&D(:0AI"/Q_\ =6N##B\W8XV=Y[_0
M-G[W:Z,=K>W\:CG&[+5C(Z4H6#I+)=%3@/&A!';N.P2AGTRXI",5>(E6[ 69
M4B)<(S8S]5\FG*'@;#^#J+3*Q6)>4GV9FH.3K":95%*0EUV=+)FW9>2FF:@5
M(4QHA"V=6VIE!!5**4[\<Q9AC$%3KD_-R,DX]+*9E1+N*FY, K0EC6!A+K[+
MDJ0H.$J4E>DH+(.B\D)^?,K@"X\''S<U&PF[F9AMZX=]N^S*JI.RV33\%]C%
MJL_:?*Z1Y*D2%DHN!(#M"4EZ;EZ'B;AAGW*.5GDS 90<026@PF2* :%6RPDL
MI<2KFDMS#^1*3=(:7K9C039%EZ%SYU6"\6'34*:]I.F8"_\ *-/#I#A04F8>
MYP><A5B5)T&KJNJZ2JPK*[GSQR.J>@IV W#R-;G7&=%840JWL:0^6K$,?">&
MTSV3_N*9D3(,=F0?[=G8Z+(-[(Q/L;5@KBCE;Y-@E#G? R'BB1;612ZWSDI:
MFEN.:V=[E$3#*6UJ4EC4-WN\C6GG'Y*G!.*BI2!3E:L*F%IO.2&HNXR$HU<M
MSN[3A6D NZU5O 5HC5?E.YC@&X[T28Q-6PV[N",1RILLR,7&K8M+40/45 WD
M#+MVI^XXJ,MF-%& ,@)V1H5 P-VE,[$40(17*OR9D*:[O21:6F:41W"K1E"X
M[.A].LD>86==4"M:YCG"--XN.AM&N#:,A@S%@LX:<_K$K9 /=*0YP$IERVHI
MFN<> V#HI#.J40C11I*T--5G [GMQS,*AQ%\/^X:(#TVG2"331&K( N=D*F=
M^.':OBSK]E4J,B8[B/)P6$9PVZ39PTOM?K(5<Y6^34ZQP8@8+B6YY#152ZWS
MFSQ3JPQ.&ECF:%Z"=)&H> 4&CI)U/AXIP5BM);1W.6&RJ64YHSE/#-VP0LO2
MXFR9A2=(C3UB+@KLDZSP>A?<^>.YX9"C/; [GK=$UK(P<@C8ZL5;B.JO<RP*
M8JB$G87L(A][$)<QZ)E=@Q)+/V$GB0SFUIA!<QRM<F:77%)K\KHO3*G'=71*
MVSI T]$N%3:33G.?KTFT(TKRX#081H_R4K>@P5BPI3>G.A3324MZ=0I[B@H3
M)=M+*$TGF@"5%0'Y4%6L5I7="47$G@ X\5+-2F]A-VLRC6+,B6ZBX59LO,:*
M$(4MK%I/=JKQ<H[ZF779\;LT#F;-3W_UL?IIC)B.5CDR&I2JOR00P90H"J%6
ME,H+32T*YG+F0',5)ND(5K)C11=!"OSH'!>+;.*%.?TG0^%VJ-/#B@XM*DA]
MWG)YRDVNI)0U=6=TY"*S.Y\<<SV782.'_<10UDA=IT1A1.K>QM#IBN0X$!X9
M3LV?I RTF5 C-/G,G2/-# ->1Z<5E>"\1RM\FP2E9Q R'2W(-N'N56Q-$,S+
MBW [.BEGG#*$.*4&1+MW)>3K3SD:JKP3BHJ4@4Y>K"IE:?Y9(:FZV0ELHEN=
M#5.%20-9K%:)U9T4AF[EQ%X!>/!F9%*9V&W>P1AN5!EF2W=*LBTM1 M2<"OI
M$W;M-> HN*MF)%%@^P)^1@=(H/@A-R"5/(1?*OR9E*F>[TCJ5HFU%)H-:YH5
MO3B7T:V0,@-<ZH%:W'^<-Z;Q<=U: \&VZG!F++APT^8#B5L@'NE(:_11+J;4
M437."4(20E(9U2K(*4:2]65G](_<0=FMZ=C-D]RZ9O%3S5(ES-P46$6'*M04
M(=1+J%1%2I[:QQ0M'?D.R@S\=^0I]A]_O5+JX;#:F<K_ #AROXCHN)\4R]1H
M,YSV211V)53P:FF@'T5"IO*0E$W+2K@ 9?84 EM2$A00'%*2JWU/!-+GZ11U
M2M19U$P9QUY+>DTLZI4O*(!*F'7D$EQMRY*@I1NK1 (O\=>Z"<._'"3XRM_+
M!1J/OC)J%CNM\+5:?4K!, #YU<)4P2/@/1BB"LF-)#/RXY-AVKI&09A*/@F*
MBS&I%GCRA_V7 N,.3NGX1H<G6*C0VJ@Q*2:)EN=DES;B743\RXL%")6Z'0TM
MHIF2\XELEMQ;9$J4.>'Q)1,4S-;GWZ?+U%R5<==4TJ6F4L)T3*L(!TB]X22X
ME?Y'5H*P%!"KNZ2?'F.'+C\[WQC- XAN\<3(KBFNUR^0V9**LJ(M:Z/DWF:\
M1[^YHS9L&$1>LRXZJ!ULE+2/5=_?)5<_Y5P]IE"@#S%8>T3-A8'/A): 1J\^
M;:C3M9(=LDDZ48>QF"#S2JZ&DDG\N- *$OHDF6YSIE04-'7:P"_A:.8 [1W#
MGW0=LN#>71.)=,Q@EMX[&>;OLV*;98&CLM2<B+\Y+4.I#<9Q41(]B>&*^QA*
M1S9%V8NL2,D3F/.2C5/A-5PUHENH@@TAY3)4XZDMZZ0$MK)XJ 65J;?9$Q^4
M+80)E.KQ&'<:!2"9.KZ07*D'GR0L)0A6GH31=*)< D )4VO5W3I%6J.G81>&
M_N@"1S+:-O\ B'3T L!@DB,:+B8ZWVKB_.R@T+>,R7KQC$)<1UEN'("NPN4%
M;G38K[RYV:L><E6L6>ZN';%]Q3>E(N.J*3)H;!9=$DA,B=8% Z:7PNR[$*?
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MU^/NFY+7N#"WQVS,R^HDTT',1M\%L5,)6]$E^EE$@"0GK(ULR/BX3&+DJVJ
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M8"?QFW)_25=?76G/W/@)'YC*?PH=[<KXQQ#^T59^V17P8"?QFW(_25=?=_\
MOK_J]S3G[GP$C\QE/X4.]N5\8XA_:*L_;(IX,!/XS;D_I*NOKK3G[GP$C\QE
M/X4.]N5\8XA_:*L_;(># 3^,VY/B_P#"5=?77C_ATY^Y\!(_,93^%#O;E?&.
M(?VBK/VR'@P$_C-N3^DJZ^NM.?N? 2/S&4_A0[VY7QCB']HJS]LBN=L!.?\
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MY_YW6>/15NB'W??"+G_2OB,]-7/_ %6_^WNZ=YF)OBU$_4ROV6'MZ\E'C3E
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M2&UN .'31*)<5I7LM:@#H@ :$^]%6+Q_[*XKVO%^Y4G^/_%\?\VME[9E0O\
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MS=A2SD"MIM!;*W$&TR(^1*D)RDBE]G,/+V'494L.';;].<(L(>^?#F0-1J]
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MTI4V\N9F5>%4"H*??<6XX0H%2U$DQYQE=?EJ[+XFE^5K##%>E$4UN7J;-2Q
MW,--T>2EZ=2VQH8;#9;D9*5EY9A"D%*&FDBQ-R=C-[JDVFVVFMDMX6FFD(;;
M;0*HR$-MH3A*$(1B^XPE"$XPE*<8QA.,8QC&.7+6T%5=2 E-#K 2   &I
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M>$.\V2_3S _SNO\ ]W(>%DO\2N\?HRC_ *_:=UGO$E9_52/WA#O-DOT\P/\
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M//.<Y]30L.43#,J[)4&G,4R5>?5-.L2Y<*%S"FVVE.DNN.*TBVTT@V4!9";
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MSB3^T9+[JA[N;EFS_P E\GV^W^0ZYYK_ /"CK'IA]Y0VL^-F]_- ?4VGN=<
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MK%ON7A:K4BLT +;K%<RL L!)-5T%0IQX5<2A-@?'E2F8=>*5>Q#2+N(ZL-D
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M>&WUC.W3'\\>>8?^%IGR6/W<X>% )[?LQS^?O^9]/\/\^AEZI[R<ZW=UC?\
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M@Y6VC> 8]?)3E"3)RB'':<'$RLN'0I+.F' RE*PHE-RH*"@JYOI7OG>([X4
MF?;N.<^Y_E\SG_'SYZXN;U2_\W. 6R 4YEL_VM]OPRCM<\P_>^MIE_\ JL?N
MP\* 3\<<X_\ M\S'/'M^_P"/VM.;U2_\W.6O[YW][?OVP$YA\;':9\EC]V'A
M0"?CCGQ__+YF?S>+G[WM>Y[VG-ZIN1.#SN=.?YVTCTF]P!$YYA_X6F;/>R_[
MNWT^B'A0">+/LQS^3^_YGT_DTYO5+_F3A'_6<^C2W>7/HASS#_PM,^2QN_[,
M/"@$_''Q>W_E\S^/V].;U3WDYL]\YF;_ /6V6\GU0YYA_P"%IGR6/W8KX4 F
M?],<Y_)W_,S_ #<_Y_\ W:<WJ?P<YLM?2<\UAI;MMK[R.$.>X?R_*TSH\%CZ
M='CL'5OAC= )S\5QSS]_O^9S]KW^?O8_IU!+U07_ "<YLM:[EO/X5[6)L!O\
MD#.X?%[NTL#?X,O^[VRX"&=T G/E[,<\_P D^9S_ (\9]S^;5YO5-R)SY3EO
M_P!6RUQU<; )S#VT.TSY+'UIC=&Q-F)65%Z=?(/D@T*QCX]>DN]8MK,-=9"R
M)R8[SF,+>;28=(87G*E80]AQK&<81A./44Y+J)-E+P6'0%Z8<)*[EU9%RJYV
M$6Z+6RCY_6UR[M4FG)53:F%:@(+(2&SHR[25:(2 /SPH$C:JYS.9W[KNQJH:
M0AI"&D(:0AI"&D(:0AI"&D(:0AI",45B-$X<\3/%,DQ9*'(@3XLE;*HTV%-8
M7'EQ)##N,X<8?9=<8>;7C*7&UJQGGC/+2$:'^Y;X?,@YM<7L3070Q+,;).&^
M*@/Y)YAQYT&/DG*>PN80RV-)D1']^2'^F$F2 CG2$NJA:=N,(;<<,^T>UP&U
MUNMT1I\3=BKQ:RQC4]!1HBM<( +B0E1G<(A-#A@FJUP; C,Q6\X9$,2)3DHB
M_-FRD(GT+:Z@#@ERK<#;>LPP&X2CRKN&CPA[(VTYM.2"K'VU$0WAF;@UDL3R
M02ZC*9.9TGK,9ZY?-",7?=D]J]T7E2-P]JZM;WUC) =3IN)#EK4.E+<4]'SG
M.,>-6'Y32'_\H:C3R45IUN,2GM24(N8FT&VD* V,8VPJRX39ZM6E+<N% GN8
MLM.@U0;5C_?$YN3)48!0*+3H@\BI[,MEFM!TX=SWFUE*$;-Z^9Y#GSEG2$.O
MF>09\Z9^C2$.OF>09Y_^,L_T\O\ 5I"'7S/(,^<LZ0AU\SR#/G+.D(=?,\@S
MYRS]&D(=?,\ASYRSI"'7S/(,^<L_1I"'7S/(<^<LZ0AU\SR#/G+.D(=?,\@S
MYRSI"'7S/<@9\Y9Q_JSI"'7S/(,^<L_1I"'7S/(,^<L_1I"'7S/(<^<LZ0AU
M\SR#/G+.D(=?,\@SYRS]&D(=?,\ASYRSI"'7S/(<^<LZ0AU\SR#/Y/[Y9^CQ
M?SZ0AU\SR'/G+.D(=?,\@SYRSI"'7S/(,^<LZ0AU\SR#/G+/T?G_ +9\2$.O
MF>09\Y9TA#KYGD&?.6?HTA#KYGD&?.6=(0Z^9Y!GSEG2$.OF>09\Y9TA#KYG
MD&?.6=(0Z^9Y!GSEGZ-(0Z^9Y!GSEG2$.OF>09\Y9TA#KYGD.?.6=(0Z^9Y!
MGSEGZ-(0Z^9Y!GSEG2$.OF>09\Y9^C2$=+F''LX4\):=5C'+"G'(SF<8YYSC
M&,J3G.,>/GR]KGG.D(Z^HQ\"QOXXGU-(0ZC'P+&_CB?4TA#J,>Z%C<__ -:)
M_3T-(=C#J,? L;^.)]32$.HQ\"QOXXGU-(0ZC'P)&^5$^II"'48^!8W\<3ZF
MD(=1CX%C<O\ ]:)]3W](1VMY>9Z6&1;;6,^/.&WH[?2SC]]A*<>U[_CTA'%:
M%.*RMP0PM:N724M<5:L\O?4I.<YY>YSTA'#J,? L;Y43VOD:0[>>'48^!8W\
M<3ZFD(=1CX%C?QQ/J:0AU&/@6-_'$^II"'48^!8W\<3ZFD(=1CX%C?D_91/J
M?G_MG2$.HQ\"QOXXGU-(0ZC'P+&_CB?4TA'<VI]E/1:&(:3G//*6WHZ$YSGV
M\\DXQCGXL>/ES\6D([.OF>09\Z9^C2$.OF>09\Z9^C2$.OF>09\Y9TA#KYGD
M.?.6=(0Z^9Y!GG_XRS_3R_U:0AU\SR#/G+.D(=?,\@SYRSI"'7S/(<^<LZ0A
MU\SR#/G+/T:0AU\SR#/G+/T:0AA^9S\<'.,>+Q]\LY_/[GN?SZ0B]TA$9M\2
M'-!.,SS\JL1FR0"6HQ#)=E/-.#SXR?'A*F9<:3WL7DQF@\V(XK+1*'/?'.M/
M-RELN('I]4>.+#M7Q:1QY$93-Z:EABSVZS68R6/'[6DK714NVSB=6 U=Z4&M
M*<04UW \3/9'+J0F&J%+9A"YZ93\QW(%.\'8!NX9\/7T[HP(5N(S)VWRSN+9
M'R$9"V[BW"J._P 'N5[L52XF:;49QYPN3K%)MTU,L$-IH':X9"?(RXEABGXP
MZ0*W&BMFY\ZL  \.#73!"78YEHF/0!<,+6%P3NN.-]G5^%ML"#<^$ =P)RMY
M.V_.*0*]QL1\,R;?O7M'&K[3@R<;-@\#QSH\+$35EV]^-%+[5$8DI'>(VUO
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MS9.#D(UM[ BMTVUS#8WC8;P,Q.S#J:A3W))Q#"6):9EJ[,NR[B4E<P\7E4A
M=2HJ=DFF"A"0RMF?6LS<JAM>2^ZJVDI*'0\DK*UMKED)4DFS:-#7JT2 $N+7
M<DJ"VD_DG"1B(IKBP[0CP*?6][K%,%KL1"#-F[I\.[O6N5R1;HLF@EJ8[Q*V
MQ4ZO!=TY51AV>[D;:5O<0 %);=2&T,2G,S+K,(NI67INB-ATH;<99D*P5(!7
M+-N3S4VB@RI1,<R1-H;D6Y1J2$V\W.DZQ "*$5!)2$IF5:(*@I3S-B0'"&BV
MJ:<);UI:475.K=U:%,V"57,:J6]_$'7K."L!Z!=[@)<36B<%!3?GA< 1BD;
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MHH/4F1'=0T,GH#(DQ^FS$CQ"$UY<DL?2E^?9")@U/)%)C3.6S*_I[;K<-D-
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:;3R*L[@,E<_5NR\G#S0L/\"1UVC>NI%C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g853399g25t47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g853399g25t47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '9"^=6@X0DE-! 0      $$< 5H  QLE1QP"   "9O\< E  !41E;'1A
M' (% "--:6-R;W-O9G0@5V]R9" M(#(P,3D@,3 M2R!$<F%F=%\R-@ X0DE-
M!"4      ! T;'$+>TX6J5F]3A8:49<9.$))300Z      #W    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    * $$ 4 !. "  +0 @ #0 ,P X       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%FV9          *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/T
M       2 #4    ! "T    &       !.$))30/W       <  #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MDP   B           0                         !              (@
M   !DP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !DP    !29VAT;&]N9P   B     &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   9,     4F=H=&QO
M;F<   (@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    !.$))300,     !.K     0   *    !W   !X   WR   !./ !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !W * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#JJFBNIE=?L8QK6L8W
MVM   :UK&PUK6J1+_P!YWWE.T>UOP'Y$[BUHEQ@>)24C)>/SG?>5!S[!^<[[
MRIM]6]VW'87>+CPK-/3&SNN<;'=VMT:/B])33K==8=M>][O(F%;KPKR?TMA;
M_(822C7Y6#@C9=:RLQ(I;](_V?I_YWIK)ROK#DO!9ALKH9^^]S'/_P R?29_
MX*DIV-E&,PV/<*V#FRQW_?G'8J.1]8L*K2@/R7?O26M_S[/^^5+G[G7WO]2^
MWU7_ +SW@D?U?=[?[*G712YLV7MK=.C1M=(T_P"$:DIM9'7NIW$[;/0:>U?T
MO^W7[G_YFQ43;>X[G6V$GDE[B3_TD<XN+K&6TZZ2T<?]O(+VM8]S6N#V@Z/&
M@(\>7)*6WV_Z1_\ G._O3[[?](__ #G?WIDH24OOM_TC_P#.=_>EOM_??_G.
M_O3PEH$E+;[?](__ #G?WI;K?WW_ .<[^].DDI6ZW]]_^<[^]*;?](__ #W?
MWIX*4)*8[K?](_\ SG?WIG.MVN_2/X/Y[O[U. F>WVN^!24__]#K3ZSKG48]
M>Y[#M<?S1"L4],;NWY#C?9^Z-&C^U_Y%$R^H=/P:P;K6G>-S*:0"7@_GAK/S
M'?OOV5+!SOK!G94UT_JE'&UA_2$?R[OS?ZM*2G;S.I=/Z>/3N?NL'&-4)/\
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M0ZIIF6D&-6_S
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>= &W_6CK@YC_P"G1OQX?:.]HB<<^><Y&\CFCKB3F-OSY@>??]^P]HSVB/\
M;QSG/_[4M;_\=XP^T;[0XC_EYYSD$3(YHZX([_\ RYCZ_/@-7M&^T0=N?7.<
M>G\J.N(WW_Y]_=VXU_G&^T3_ +>^<_\ O2US_P <XT/M'^T0#GGUSHG_ .M'
M7'_'?3C/YR'M$?[>N='^]+7'_'>-A[1WM%*GIY\\Z2/_ *TM<?\ '>-_YQ7M
M%_[>N<_^]/7'_'>W&?SBO:+_ -O7.?\ WIZX_P".\:J]HWVBD"3SZYT9,?\
M6EK@_P#_ '>-/YR'M$?[>N='^]+7'_'>,_G(>T1_MZYT?[TM<?\ '>,_G(>T
M1_MZYT?[TM<?\=XS^<A[1'^WKG1_O2UQ_P =XS^<A[1'^WKG1_O2UQ_QWC/Y
MR'M$?[>N='^]+7'_ !WC/YR'M$?[>N='^]+7'_'>,_G(>T1_MZYT?[TM<?\
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M!,=MS\SZDQ../"A4?9)&Y.X$9R<[QZGCSP(,E*1(S,"=^QWF,[]B>YX\\)0
M^$0/(@SD',1L(_LQ''O2=X^UMYD#^_[QQ] 7Y*?J_F\ZRB(_EGU%O/\ ZD<N
M_P .$N^H3^?;RH9/YVN.X A)K'NG?&P'?/"24!6X\I &\3C]YV)D^7&="0""
M ($8\S!@G/;Y;8VXSH02 !C:8SWR=NQWWQ)[<9X85@"(G,S$[?./K/;@%:(
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M750(27*AQQ:A,GBMXT'I4J*W.:FDW%J^)2UL7PB3@JDVV3@?%)5D<;C0VEA
M'-/2&^PIKY$1L/\ -TDP/)(QOQGZ!Z5ZB3S1TD3O)I[\1\^DVX_*0!QM^@VE
MX_ZTM)?_ +M?/O\ ^;MOKZ\;?H+I7'_*MHX8&#3WV9/_ .&X_C,\>?H+I?\
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MD8,2)CZ8.?QX\/E\I@=AZ>1V.\2)P>/%H2L09 ^9])G;&/H/3CQ*$B(2!B#
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M3'I/X<""G0).22">T8![??D>?GP6#/V@4G ^1![@^@VSWG/EJ65%4(!([DX
M_C_">-UM(:1)E2E'YB!N!/E,]OIP&72-D])&!DB/K,_@)D\>H?=D)$JF!M)_
M>?G\_N/H*B!U)@_3.T8&Q/<>?&_2K^J?N/!ALJ5D)SZB1$9/H.WRD<& UW,X
M@PF3F"?I';M@]N!N@Q*4&-NH=OE_2)'D/EP$XGJ!"@4D;*(/W1B)]3C@,M$8
MR?*!B8SYSMZ;=N U-RL@@DR-I(.V8\C,P._IP(EF921Y# F#\NXV\X\AP.FC
M"AD=,8RF1OV[_/Z[&>,51I/V4JB>DJ*2$@Q,=1Z1/H)/[QS;#X8=Z4^&I:D
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M(GT]8X3^CL=S& F3@008\Y]=L\;--MA9ZT82"1)*<C8;"2>T@Y(W[ZN(2XX
M@0DQ$#$Q\L_3A3IZ)*.GJ *ATDR/,YP2-@([;\'H $0=@=IS/>).>_:!CA/N
M=YLUD92_>;I;;2PL]*'KE74M TI9,!#;E2ZTE2R>D=*5$SY8X>5ATM?]3,L5
M5CME3<**IZ%,7"G;+M ZE2@ MNL1++K8!ZB6UKE(,!6 %G7?+R]Z$=M[5U\-
MQNY4J:FG=;!3U"5(6E25$D%*DJ 4%'K )@8!CM+:D+4HK]2)CL3WR3) $;P/
M3@TF ,$D9B?3!S@>O;CW$[$D3^,F8[QOMVQMC(( ,8.)[ QVG)_&,SQKVC8S
M$8QL 1G F#WB<=CQN)!$$@R ""09[09F?+,\2;8;3?=4)%$NH:15:J\&WVJX
M5,J8J*NUJ:0JWUJP/U3SB%H0VM1*BGP75_"J> ;+0ZCT-K>DL]VH*FV5;=P8
MH[C;ZUM3+=0PX\EM2'$.)Z':=YM:NE8!0M"B4DSQ9;G9[.M5RVU!I;7&@FWK
ME8=0UU'5LV*C;<JKC8:M:TNNLGP^LKH"2I;#JP"TA7AK*@D*XM1J/EARPO\
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M5;6VD)6&VFE%;E.X@&>E'2V0 OIA*DIR2>*.QN.V\1L-SZ1^P?3CPIQ)'VI
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M!/+GE2D)V[!(&,<<C=9T@.L]7GI)/Z47\3) '^=JN2#$$B(/SX(4MO"H4K[
MQ()DQ_5$8R=SCRF.%E" D!"!B(D',B<1G/[OEP:0W) @=1^X$X_9@G@XA@D$
MI*<;$SO(GYXVC;SR>!TM?UNV,1D3,9G&W:3WX%"0-AQMQN$$@DX\@0?3TV_O
M^N_A@]SB-SGZ8[<#ML_"/*3@R#)\_H!$>8X4Z>GA(44@J)@3@#ML>Q!DF-L\
M'0D B!L()[ []X.Q/H!$8''H!.T';'VHSV,]L8B-@./>E?V8(,P 9$]H/?\
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M1F8CA#;0IQ02&G25 !"0"LJDR! DD^@&1P=IZ-"WFFGG2VEQ102G!0J"$2#
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M8DQ!X0.XD$1@$R?EVSM@ ]\<;0<  D[8$S, F>T1,G$;^@@3TGJ(DG;,^8G
M.2#WV&!/!QE!ZNJ,#;&)]/7U[??)Y*>DB?+)\L]R>\;Y._ @QWGY@?V1P,TA
M2OB)A)D&<SYR,S'SW\^#@$D))@$@$Q(CN?,P#M]\<*C4RD@8P)^*#$?38;XG
M<;<*32P!"@8@$1('F?3T),9[;\# R,&?42!])G]_RXP$D@ 'Z]^T 9[_ -G
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MK%R^UIJ>T?G2R62NNMI9N2;>IVG!6TS7/FD:5UMR?"$U-(ERH4E*4A386N
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M]*PPQ3A*6:5A"0PVE*3 4A/^N7"<+<*4 CXP9)#V:>2(0 5B,-H/2A,#'6X
MD=._P-)0D;$JP.!+WJ?3VDK/47[5=[MNGK+1-%Q^NN54U24R #)"5/*277)@
M)0@%2Y@!6XYJ\Y?RE-$@ZBTCR H*>HO=I;Z'M;:J:/YIZ%86[8K<A:/>%I!Z
MVJJL<+&Q13N2#QP_Y^<PKYS>U<J_W_4=UU%=E-A%=55M0XXP'1E;-*V50VPV
MLK#:4PD)@ ]($1%2:=6M(2A!)@?UB 2/ECUP<]]SQ;+EY[.FH=2Z07?[%6VB
MFKV*AM9IJY134N-0"4M@$0(,D_$3B!&_0'0@T[:>2MUY8:PIZ)ZY5]0NN76)
M<"C3/!L!*J4X4%)*3NH""3$\0\39K';*:S4255#)>6ANH>47% E1CX>GI02)
MD Q/U'$.:KI4-W%X%(A2NL3M!SY]\]/EW\N--$,4Z]8Z7;>IV7V'+]:FWF'D
M)<:>:76,H<;=0M*DJ0I*BE23(4"9F..KEITAIG3RW19K%:[:5.K63243#)DG
M,%" 1D=CO\A#B@D2-AOM_!_;MQ6[VI*'WCEO0OR)I]5V\I$9ARAN"%P9B<R3
M!Q (V(Y[EB 8!)D#.!OF((R!N#DQP,W2@B1&_F /NSCYR>!TTJ1N9 V$?V_V
M'^T84R3 '7!\MOP'WQP<:H@()P")G<_C_9_>H,TB3]G)&Q/UQV_&1Z]N%IBA
M'2%J(S$&#MW*8,R03V@F<'!X4D-(;CH2#V& 8&85@;]\=SOP82VJ/B(G^/XW
M_L @1&P/S(GY\"^$Y,!)W]?OVX-LTZADF9 F(!'<C(($QO)^7!WPU$"! [8[
M?,#/!>MHFJRBK*2L:0_35-,\P\TO*%MK;4E22((@I) /8Y&<CC[:J-%.BMIV
MR4L4]YO3++9!44H1=*E" I9)*ND  21)'<\*W3F 0-\QL,D@S,&=\D#RW'$I
MZ*YQZ_Y=VNKLNEKTW0VNX/O/U]$[;Z"L8K?']S+S=2*MAU3K"S;Z-?@E71XM
M.AP!*D@\-[6^NM0\PKNB^:FJ:6IKFJ1N@:]THJ6@IVJ5IZH?2TBGI&VT8>J7
MUJ6>I2E.'XND!(0[3=Q:%5RDVM%<Y6V]VCIJA;B4HH%/DMO/^&?B6XIHAM"P
MXD(2I7P$D$$K?;'*VJ%/0TOBU3Z5K#;24];@:2I:I[_"E)/IZ$< E*4DR!()
M!V[;I,[]A$Y],SY"<@)CY?N^8G/8 8SQ@2 0(,_6!/<#!&=_(2)X\"0< 9WG
MJ)(!W ]<^G[#Q9;V3:=3VI^9$ *Z:#3F3Y%=>,;C:#VR<<78<M\JCH /I,'U
M(\\^?G\^ #;1CTV@2/E^ W)X[Q?DN:<,\@-8).2><.H%3MOHKE\-@3Y>?''+
M5R1^EVJ"1DZCOD)C(BZ568V$YD??,&$&"8">Y$;1G$?+OOY0?(^RUT@ ]\J\
MAZ?VQ].#S2.I0_JI_@ <'9$1$#T^7W1.?3MP.RA,A:R.F3 G,CO!C'[> W?U
MZT@J(3.$XZ8S$@=_G$>4GA08;0T),$Q.T$;3C8 1B=ONX')2I*B# ]-P=R?G
M!^X;^1.H5T @*)*M@#@$;@Y.TXQGSWXRF0XM96<%20 )[=SL8$ B,$SZ@\*R
M$0($D[ SMO,3D0<;SC/H9!C$C$#.^PCT)GR/!QEE9/Q)4 4$ID0"#_2$[B?+
MOZ\=1K&FI=TW8G:9[H%1I:Q%ATCQ33N_FJE*5!E92%M*5E24J&0>YDMU6CJ"
M^+IKMJ-ANFU7:WVW$7VQ/.VYYQ3(<;I*OI5*'!T%;*FJA#W0.IDGH4)BF[:^
MOMXN>MN3>H+=15%\J;:FLTE=62VPF]T:U>+1NO,NK#5/<0ME^G<+1#:G6I2E
M/BIFM5^TQ>]+*0-1VVMMCBUAOJJ65(9*U 2AAZ"TZX1W2M6X(XUH7V$!(ZP.
MOI2VA)ZU+6<!,_TE'R$Y( '#GMM)<ZZM3;K!3-U=W2Y_EEQ?07[;9!D%IEN.
MBNN(!)5/53L* "@I6!/&E.75-:7/>[D^[<+HX9?JJE0=?6HY4"8"6T[="$A*
M4X $<2DA;+ \-M($".E/VI @ F 8P/7M&>!U5;5)2OU]QJJ:VT%&VI^JJZU]
MNDI*=EL$K=??=6AME'2#U+=4!MYQQS9]H?\ *C\J^5OYPTURBIT<S-:L^+3K
MNB2XWI&VU">I'4:H*;7<_#7\732_JU$072..)7-SVE>=OM 7X7GF'J^NKFFW
ME.V^QT2C0V*UH63#5';F2EB4I 3XK_B/*W*R>&O;J^\.,> JJ<"'$A+BDF%J
M0 0$*6,]/:#@;8VX<ULM'B$=0ZE%6\Y43$SCTR3'?SS+6G]-,!;:WD 01@P=
MR"9,9B?P^^=[->:BT4XIZ)]3+83TE*5$#  &00-A_$P#*]1U+BE^(Z2I<A+A
M.4[#$[@YWG!R>_ %LO5&ZNI8J_%?:0H.-J:)/AOH(41U21!.^>_KPUKO>'KW
M7/N*I0PRA0;9$Y*08E4DG.#]^T<.WE?;#<>8NB*-,E51J>S(*9QTBN:6HX\D
MI)_?QV"J+>SXSY&P>4).PA1Z?+8?>,=@.-54;93TX$[QC.P.WF>\Q^(K'[53
M9HN6E#,D5&KJ!M( RHMT%Q>7 !S\*4S.=_6.="GG%'X04YD #OYGZ?2<\&&
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M:M-M)*I2JNI*=P*O52A,=-3=UUBFE))IT,=1'%?[?1]1!6"1(^U)SN9QWF1
MB3'#]M= !TE*9,09';8[9E0.!,B"0<#B0K91I2!(^&! @?L,Q VW(C,YXDFS
M4J04$X$@&0#@'X>PSW.Y)Z< $\/^C?0A,' [$8QY@3 'XB/EPL(JW"/A68 ]
M?Q@[_P >G&JGW%'<Q'EF1F8/W ^<>G'K"U,I<2RHMI=/4L)44]1(@J$G!@#
MC&(X$'F#ZE7GOW\QN3PM:>N-TMMXMMSM"G4W.VUC%?1.,%7B(>HUA]!'3"L>
M&>K.4SN#''9'2NHZ?6.E[!JRDZ? OUN9JUI3LS7('@7*F('V54U<V\VI),B
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MT=H/E364^JK+6T_,BNJJ6JLMY->^NF73@A3U(W2-O"C+#K*R5J=84^'$I*7
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M@8TF*N] Q!U'J,>< 7FL!WV'KOMOMQCC/4928A(,3Z=IB2<3ZXX""EHCI4M
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MAYUI.QM^C28';KNI^D_NV''4ZI92"IL@E,&#N?/$@9'E]^_#?J:#XIR 9D@
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M@Y,# B) )R.$.MMY 4H  IP)$ P<'S(\\?ACCI)[$R.CE7J(&2?Y0[J>P_\
M)O28.(/<'./EW/$S53!_2;4:N@0;]=\D'?\ .-2#&<R?/SS'"(BD6?LH@SL
M2.YP(QW&Y_9P,*1XF((.^8Q.^2#O\]YF<\'6;>4E*E"3Y0(! .2.^=HC<3@<
M'/=4B3 !5!$B1V,Y'[//A$U!<;=I^UUEVN;Z6*2D;+BW%$!2U9#;2"<K<=,)
M0C))( !B>*^:<HKAS*O[FJKX545CH"I-LIEQX5-3@B%A)D+JGS)<5$PH 8 X
M7-(GF'[.=SU_S"9L]75<G&%O:G7<FEI=>MM&\MOWZCJJ5)\="6WUJ#2T(Z%,
ME'4.HDBG=7?JS\I1SA1?=0W6MT/RNT?0W>SV-Q-<JGK*RE?!55*>J%0W3JJ2
MTPPGQ$+\%DA ^-148NUAHO5WLQBZHL%.;IR\=JE6^T:MMM4W5/VMM+JD!-Z-
M*.EQ3_66E5-4RAM]!Z3'3Q%FO= Z*YJZ9I]3W!BR4^I*9)J EP,(:NS*DGQG
MJ52H2V_\/Q-!25=<'I4".*GU.@=#VRN34TGOM./#,T[%:XPV^5 %:>A$]3:@
M"EY ('03 F 69<:RZ55^4NZ4K+5.&$4U/2TJ/\B<M+82VPBC5*AT-(2 D@EP
M/)4M9\23P9?MK3 #C"PY3.0I"@05#MTK ^RH]Q$2#GMP EKJ/P>N  8$]SV@
MG:?7T!QID2!,G,;00-QB-^Q.\_+A9HZ8+(4H$)G [9CY#<>7W\+[;0$08CR_
M"/+,YWW\Y JWO !Z4%:R"$H2 I1(W &^>Y_@N*R66Y70%UWK90(/@(*0\01\
M,@Y3( [#![<*;>F[TQ4A2/$73E>QDE($8)!B8)SVV[\/ V(7&WU-KKT+=I:I
M!;>9*BE$@RA< @)6TJ%H)RE0!&1Q$FH^2-SU(*2T-T=N;\"KI>G5;#J:6J5:
MV70MQFNMW0H/7)E*0FGK:5;*7DSX[95"N/J#Y6>WCR9TOIC3E6[;KTG6%OTK
M8M*5E;4V]JKN7N]IMM+;UK3<"VI24OEA3[I:<2I:UDDS!XCGVJ>=O+CF38K#
M?-.ZB5>KFNN14L6II"V7:-MUA354*U#B2&NA"D^&2>I2D#LI7%)$ZB0XE(30
MKZND %;PQL8@(P/*#CRWXW\9ZM?9J&V4TU33K2MFH94XE]!0>ILAU/3_ *M4
M*0H *08Z2.+ U/M'<_*VTT]C5S.U#26ZFI44?3:W&+=65#+:0E(K+C1,-5]0
MOHA!6NIE21\4G)A*ZO5E8XY7W*MK*^J=45.U-;4/5-0XI7VE*>>4XXM2U945
M*),B(X9-95/,O);2B$N@]+BA V.Q/RSC;SGA6TA:M3WFIK:M[3]SI;!:SXE7
M?JI#;%N;80YT%U;[B@&6U*!"5N )/3(D0#)=5S(M-51'3'+JTC4.H@VI;%GH
MW?&%R0S4L,5-R<JWTI+=-3J<2Z\JD0E*FTP%E/4>';RZJ[S?+=</TALALMUM
M=S?MU4P@N*IWE-(0H/TRW$A2FOC*%$R I!@Q@2@U1)3'2C81(!$YG?<R,3/?
MRXKMS3I[9;M16K4>LF+A=-,TU=44IHJ=ARJI:1JGIVUI!I6Y"G:BH4'*IY0\
M1#*4H3TH)EQ<N[WIVYZPKJ3EQ3TS6FZW3[%?<BNGJ:6FI;JU6+2CW=+WQ,(<
M9J@TXPR$4QJ2MQ"2YXRC/-6DM)6VDI#B&4NJ5'P2LJ3ONH @D=R))XCFX.5-
MQ?2TRXHI*@DH; 3TQ ,D#M$>N>#3ND7&_!?;(6XX %0# D9ZO48!V/$LZ+T^
MX"A*D$%!$],@*.\^<;Q,_OXL9:;6I+:?A(("1 F$@=8 Q'Q'IG;?Z0]Z&WP
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ML*WW4>\VIQYMP(*W%I6E*U-!I84.(3=1X+[C86E7@NK;#K:A"^A105MKQ\)
M!!!^(*G;@\;M<RP_3FOJ5,58:#[;CJUI=\-M+;?45=1^!M*6Q! Z$A,0G*:)
MC'S&1(R  >_EZ;;9XZK_ )*%).I^>X__ $#1.V\==XDY$S]/+OMVN9;&) )
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M<&.XS\IB=N.LOY)1(5JGGR#M^;]%1'HY=Y.">\_/CMTE/2(&($=_60=_G&<
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M;*2"1D1)),YF,8\M^)RU=S0<51J914*Z CI!*R(^'8)G>1B9S.>*WK>K-3W
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M(DQ^PC(P?V^?'BE](GY@SOZ'S_#(\N"#[ZC@F4R8 '<=ICM.<G)VQPD5"X!
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M\PK2H@S!@@')[\37:_8N]K=E+87[*_M'(!@$JY(<S!$@QOI<>>?/TR.'B?9
M]K1M '\USVBX   ')+F63GX1MIC'3WF8(VQ'!FW^QM[6225.^R_[1 48)*N2
MG,H>>\Z:Q']^T<+R?9!]JU*<>S%[0Q _^9;F1/\ _;4DQM])X]5[(GM7DP/9
MA]H61D_\BW,GOY?Z-'Y^F,\#L>R#[5O5GV8_:%'?I/);F0.TR3^C0P,F<3Y<
M.6A]DCVJ4)ZOYLWM! X&>3',;N/_ ';W,QL,[SPXZ7V5/:I;(!]FGV@$Q$$\
MFN8P@C<&=.;'MZD]P.%YCV6O:D,$>S9S^! )(_D<YB;XV_T=&?N.PWGA<IO9
M=]J$$3[-_/L$"5 \G^80!$^NG1!WV^[?A;9]E[VFD&5>SGSXB,#^2'F#(G>?
M]'NV^._KQE7[-7M.,(/A>SAS[6H#'3R?YA* G/;3T02,_P!HX3F/9C]JBH)6
M/9RY\M[JA?*+F"G ,1G3X@'O\B .'K:_9>]I]"FE+]GGGBA*R/A5RGUZ"">G
M*NK3\CSG;?._%@]->S7[0[#3?C<B.<K:DH (<Y8:V21B0/BL8(F1/E,XVXD^
MW>S_ ,_4HZ%<D>;Z2,I!Y::S'?(S9?O'KCA>8Y"\]T&3R4YNC P>6^LB,[#_
M )FS/E&V<<**.0O/:>K^13FT)@P>6^L0"/3_ #-MN/W<'F.17/4*ZCR6YL@C
M.>7.L(( ^S!L\>4'TCA71R+YX+3GDUS7![A7+O5X,^@-GQ$@^D#;,*]%R0YW
M2D*Y-\U04DS/+W5T 1B?\T8[8WGY\.^CY*\Z E(7RBYH)('?0&K!F>Y-H!!^
MS\\SP[Z'DSSB#:9Y3\RY!&#H35 B2.YM6._^'#QI.4?-Q(;4>5G,@3 (5HC4
MP5/:?\V""#D=_2#PZZ;E/S8*.E7+'F$" (G1>I!OVS;)W^?[N-5\JN;(<*1R
MPYA=/G^A6I(WC<6PD2,SGL1WX.TG*+FL'$3RUY@"%B5*T;J, ;!.]M $B#Y^
M?;B4;#RMYCL-!3G+[6J"01"]*7Y*@5?:A)MZ3![SWVC8R1;N7?,!ML!S0VL$
M&(^+3-Z!@1&#1")WSOY>3BH="Z[0HI5HG5P&P)TY>2,C>/<A&?GL#PN-:+UP
MG[6CM5&<1^CUWD^IFD\XB/,G8<'$:,UMB=&ZK,@8_1Z\$9_^YX\O\.# T7K8
M?^1VJ@1M&G[L?_\ $_C[H'3HS7 R-(:I/K^C]V_::2,=\1C@4:,UJHYTEJ<*
M[?Z/W7<8B320#^W>?,NO1.M5*)_1#5'I&G[M'K_X)]2?3OOPGU.AM;_%&CM5
M&4R(T_=O4C_P3RC;&V>&A4Z UX7UDZ*U<L')_P!&[P1G)"8HCCTP02<;<(%5
MRYU^I7P:%UDH&)C3%[,8V,44Y[8X27>6W,2#_H'K/!!_Z+7P[?*A)@;[ 9X+
MIY<<Q#*?T!UGL<C2U\SCUH?G_8!P"OEES"(D:"UGD[?HM?1(& <4..^/,GZ$
M7>5G,)<G] =9GSC2U][;S- ,SO!SY9X(GE1S'G&@-:$'>=*WTXDQO;^\^>_W
M<8GE/S&"I_0#6H__ %4ONX@QB@GU.?P/"I3\K^8C<$Z!UH,?^JU\$'&?^X 1
M._D/.9'"HQRTYAE0'Z!ZRCO.E[X!V@S[C P<8]=H/#GI>7.O$!*?T(U@E1,=
M1TU>4Q,?:FB]<&/K/#SH.7NMFDI!T;J@ P9.G[L#F9F:3[_,\+:=":T$#]$-
M3@;R;!=1(QYTD>7IV].#;>AM8_\ JEJ8 =C8KJ($9F:2)WW\LQ/!T:)U<D?]
M$]2&<_\ ,5T[#M-+M^$;\#(T-J]8Z_T5U*#N9L5S(R<?^"XF-Y^4S@!WE_JX
ME75I'49D3U"Q7,'O./=1).3MN,3'"+5\N=7+'_1'4BYV(L-T)[$8%&3W.<?2
M>&S5\KM9J7*-':J[DC]'KL4YS.*.)R<C(P8X0E\MM<MJ*3HC59C:--W@@#/E
M1&=YS ]28XU3R\UVD8T/JT21,:;O..TC_(OXW,[<;?R?Z].^B-7'!$_HU>1.
MT_\ @6).Q\I@=SX>7^OMOT)U=OO^C=YVQ$_Y$/68S]#Q>OV8]/7^TZ"N]/<[
J'=[;4+U?7OH8K[96T;RV56:P(2\EJH9;6IM3C;B$N!/05-K2#*% ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g853399g76b11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g853399g76b11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2FV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *9J^$&4#A"24T$!       01P!6@ #&R5'' (   )F_QP"4  %1&5L=&
M$< @4 (TUI8W)O<V]F="!7;W)D("T@,C Q.2 Q,"U+($1R869T7S(V #A"24
MT$)0      $#1L<0M[3A:I6;U.%AI1EQDX0DE-!#H      /<    0     0
M      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6
MT     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W
M!R:6YT97).86UE5$585     H 00!0 $X (  M "  -  S #@       ]P<F
MEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M    IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V
M8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G
M1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M   %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'
M-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M    !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M           $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M    !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M        !2<VQT56YT1B-0>&Q 77S@P         IV96-T;W)$871A8F]O;
M$     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M               %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U
M!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F
M5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6
M-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #
MA"24T#[0      $ !U\X,  0 " '7S@P !  (X0DE-!"8       X
M      /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30
M/S       )           ! #A"24TG$       "@ !          (X0DE- _
M0      !( -0    $ +0    8       $X0DE- _<      !P  /________
M____________________\#Z   .$))300(       0     0   D    )
M   #A"24T$'@      !      X0DE-!!H      S4    &
M&3   "(          !                          $              B
M    &3                      $                         $
M$       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F
M<   &3     %)G:'1L;VYG   "(     9S;&EC97-6;$QS     4]B:F,
M !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$
ME$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -87
M5T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M          3&5F=&QO;F<          $)T;VUL;VYG   !DP    !29VAT;&
M]N9P   B     #=7)L5$585     $       !N=6QL5$585     $
M!-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q497
MAT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&
MEG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$
M%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T
M-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
MET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F
M]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0D
ME-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M  !     (X0DE-! P     '[8    !    H    '<   '@  #?(   'YH &
M !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B
M 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M  ]M8  0    #3+4A0("
M                       !%C<')T   !4    #-D97-C   !A    &QW='
M!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !
M1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M   (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97
MAT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&
M%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !
M)S4D="($E%0S8Q.38V+3(N,0
M                              6%E:(        /-1  $    !%LQ865
MH@                     %A96B        !OH@  ./4   .06%E:(
M   &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %D
ME%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:
M            !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,B
MXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M              9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&
MET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:6
M5W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M               '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M   5A96B       $P)5@!0    5Q_G;65A<P         !
M           H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M\ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ?
M"! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
M  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!?
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MP'_)C]*?VZ_DO^W/]M____[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@
M'_VP"$  P(" @)" P)"0P1"PH+$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              #_X3G5:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#(P+3 R+3(Q5# Y.C4X.C R*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#(M,C%4
M,3 Z,3DZ,S K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP
M.DUE=&%D871A1&%T93XR,#(P+3 R+3(Q5#$P.C$Y.C,P*S U.C,P/"]X;7 Z
M365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G0Z(%!R:6YT(%1O(%!$1CPO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/D1E;'1A/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \
M<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@
M,C Q.2 Q,"U+($1R869T7S(V/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA
M=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CDS0T0S-44Y-C0U-$5!,3%!
M-D9#1$5",38P,3<R-C<P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 R+3(Q5#$P.C$Y.C,P*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B+SX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP
M+F1I9#HY,T-$,S5%.38T-31%03$Q039&0T1%0C$V,#$W,C8W,#PO>&UP34TZ
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HY,T-$,S5%.38T-31%03$Q039&0T1%0C$V,#$W,C8W,#PO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX
M;7 N9&ED.CDS0T0S-44Y-C0U-$5!,3%!-D9#1$5",38P,3<R-C<P/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XQ
M/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_   L( 4@!NP$!$0#_Q  >   !! ,! 0$
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M!;HB-W3D'/%#^8WZ2+VC-:>\1-.:@=T#2GBI*6:%)D.U!+2K@!54DJ4^%A)
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MD&E^@N#N;?/]]O[N/0PL]T_*Y_#;C(1U&UC<G< ''[OSMQG[JKN%W]$_Q?\
MLXS3$40+(6KR(%L?A\S\KVXR]Q6H8;5D=R!:_H=\9_#SQE]G*&>FP-S;J'87
M)L 3V]2>PXQ5"*2 H=(-\E1S87-L'S'[N,3%%L'UL"?S)3CUMWX\,?M8V%_Z
M5[>1 [_EQA[OW'5;Y>8\[;?0XQZ\8^!MD]KX%OIF_P L'MQU"]G5D_R-Z/\
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MCY^=\6]#:U$D)5;U!&-[=ACOD6[=N/? <L#TFQ\B"?/(W(P!;.?PXTD"]LI
MN+9O][:W;&/+?.;\96V.,$"ZK=[6P>WD<[=K#CIQ[/)!Y/Z0^Z/\_P#^MVU1
M6Q_'GQ9^:W>7+!)(]Z?Z2-A^T4/6]\ V.X].$I;&PN,W-_(;>>=[$8-Q],@T
M -KFQ_?OG![C VMYWX^+=K_!T@]S?;;&,7O<@6\K"W&);! (W[VV^HQTV/XY
M/KPG<3L+9 -SWQ>P^1[ 6MWOPT37$H2HK*$H0D%:E$)"4Y-[D@6WQ<=_/B/*
MWJRFL_LHJO?7$GI4&A^S21:X4Z<$CX>HIZKYWO@%?GU:KK#?4M+2U60PPE24
MJN?A22D>(Z2<6N1>Y &>)+T;R7U9JA;?A4]Z,RX4J+K[2_$*22%*0S8+2-QU
MO%"+@?%L.+CZ&]FVC4-MF760B1+!"BI80XZDXNEI*@J,S_T_"=<%P0I) (G>
M/'H5 2(U/B--N6 #;#?CRG/(E9*W5$Y-U+ !WMP[LTZO5-'6&T4B*0+OS+%T
MI.Y0DDI! L38+MM;<<.$:E4.FK2ZXA57FB_5(D+46^H6%TINGX0;V2@-IR,6
MX9-8\P=/:-I3]6U?J6C:3HC"%*4]49L:G1^D GI:;44O/N$X2VTAQQ1MT@FU
MN<?-C]);RRTNN53^6M&F:_J2$N);JDDNTN@)= (2M!< FS&DJ *O#2T% &RP
M;D<ON;/M>\]^<#TAJOZRETBA.*4&=,Z9 HU(::420VY[J$S)A (2IR;*>6JV
M]N*S*4M:E+6I2U*45*6M14I2E;DJ42HD_,]SQ\!B^<]K6SY7.-O*YOBW<>A)
MQ@#?._X]N_EZ\;.@X*@HA7W;@@*MOTD6"K=[;'?/&SPEY'0I-@#]U1L#@&UC
MB^!?<XO?C,(Z2000I-KW!21GR/Y6\K^HR((M>^1<7%K@8N,"XOOZXQQ]M_&/
MPVXR'4=C^=OR']0XS"3W))OBQ/\ CGT_PSX^X^_P_C^W<=N/0;>1^8!_>.-Z
M'$'X5) WS86VS\KF^VV!Z\;T]) L+BV+6 L!;( S^';.<\;TH!&$X![[VN,>
MEQ< 6))S?RV(05$!*;V(.PMYV)(QL,WS8]@;JQ&O]Y6QV O?%KWP1G?S[^?&
MT,-C^C?YDVQ@7%[''F-\BW&P )P$@;["P[^5P =[?+%^/3]?S_J_JX^[8WMB
M_P"5[YXPZ5$$+(M8BR4D7%K6))/Y6OZB_'J4A(Q<;;V\MO3UL!G-[\9\??Q_
M'\>?'F!<]CW-K>G[\?+UN?OX[^OX_P 'RX^]?0X-Q\KW%_J?PSQ]:VWG_:>]
M_K]=N/B;?3?';^,_+MQ]^[?;/>^/X._'V3MCR_ON,#\^/O/MO\\=^]^WY<?"
M_GD6VQY?G\M@?D>,"VA5BI*23W[[=CO\OJ>/0A M9(%L;#;M<CL/7OZ[]-O9
M]%N46DA__'_+_E/6O+^///%E)B")DS8#WJ1O<;N*QO<W.3;;!/"<H4#;X?/?
MTR#MYG&!OBU^,PVD$F]R#F]M\]KV_=BXWO;UP? <"^VWKBQ_=Y^0S9(MQ#2%
M+6I+:4))6M:@A"4I!*E*4H@)%MR=@+BV+1O7>8E,B*4Q2TBJ2 ""ZE9$-"ML
MNV_:@>35P=NON(QFU&O:D>2A]UQ3:E61%CI4VQ>^P;1=;RNUE%9VM;B6M"\B
M-3ZJ=:483\:.HI4I;S2DE*56)46R ENX(4"^M)(-PA5QQ=30_LZ:7TOX$NII
M$R6V HE:@I256-_B4E(0+]F4MVL!U$Y,S)E4FDI$"B04K?N1X$)H+7U7MU.N
M 60"-U+5U6R!M9Q8H58J"0]5I2*/%4;AELWEN).Y2575?U2D)!N.KAXA0:53
M5I:I, /RE_")3X#[KB^Q3U'H3<DFZBK:XMOP <Q.9>G- PY$O5U=@M26$E2*
M%&JE)>KK]DDI0Q2E5!J0 K[H<=2VU<Y5?CE_S@]N3G74#,I/)SE@W08A*VF]
M3:AF46?5E()(\6-3Q6$PHJE#*?&3)4@[&XQS4US3_:#YEU-RL:Y5J+4LUU2E
M#[0KU)=88!L>F/$351'C-BP"4--I ';OP#_R2<QKV&E96W_E"B_N^T\8SW'K
MQZ.47,DWMI278;D3Z+87_P#2=_RXR_DAYE6QI.4;[?Y0HM_Q^U/[?KQG_))S
M* %])RO4FH40#T_XS_J['TX60.2O-*I24Q(VENAU86I*I==TS3V $"ZNJ5/K
M4>,@VOTI4ZE2E6"0HX-Z*53)JZ9IR!JOD-3-2QZ)IR#2FJ&]S,Y31-.4RJT^
M##A.UBE)AUF-6'I%>]WD3:L:E59'@3IS\F(E*VF2V3TRL5V+K>N:AJ'L]Z9J
MFGZYR]H>B'].O\P>5*$M.TRN.UAZJQI+=?ZF93@]W91(; DD,J2\XMIQ:>--
M>9INH:M*U'-]E+1+E8J<^I3ZJ\YS)Y<^Z.O3Y+;JDQX+&KX\=AI#(+49I#81
M!+2/=B Z^%-M5I=,J%!@P#[,NE/?8%.$&$\YS$Y8HC4YR5+?FU63&2UJM+S_
M +V_*D>YQIZY#5+"&/ Z@DMC-.G]&&IMO?[%+2\BD!I"G&%\TN7#,LU)LQ6V
M9:7&-6I:$0,HE.2*5X7NLB0\A3A"4&_/CF%27J)K/4,)ZBQ-/ U27)C4.#58
M%:C4F%+>7(B0&ZE39M0B2!&CK;:ZD2W5 I 6>K' ;Q]Q]Q]QM2RXH7M8>:L
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MR<,N)7M5(U%J1E*RG3FFE-U2H%Y)(2U)>0Y[I!!6+*+SQ6D7/ADBW'(CG/\
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M@9-Q\L\8F,W:WX[YMV)O>WIQ\6+FPL1BP(R-AWOC?OC\N-:F0 >L#U( M?\
M#JOZV'&DQFU&X5F^$[8VO?:PSD6[[\8JB*2">PN;Y._Y8\KC%L[VT%E?TW]/
MQ!^=AF^?+C$H(*B3YGO^';U]>->_I_&_^/U'&002+CN3O;_'&?[^V8;)))R
M-P-M^Y%L@;;XX]*$GSVMV_K!_L].%$5QZ+(8E1G'&9$9YI]B0T2EQE]E:7&G
M6UIL4+;6E*TJ!ND@&^.#+5\%,F5$U+$9;9AZG9747&6  S%JP5T5B,TA("6F
M_?O$DL,I^!EB2TVFR4#@2$8G>X]3TV_ $D?AO^)VB,FP!M<=QN?G_&>-B8Z
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M$J6HWN2I1))))))-S<[\9<-U4EOQ(W5$8$B6\XW'C-+5X;1>=-DK?<L?#8:
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MJS(38FQ=@:5I9CA8N.ILU&UP$A5OBX9'.:OM&RON:AY2:823<(I&@ZC5W4
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ME*9"+7,>NT"3-FR94M3K[SSZUN//N+==<5>W6I:RM:EFPRM1N#N>'6/II*;
MI&,$!( /I<7(L?3;)MP]QZ T $AOJ.QNF]S<*R<XN+=N'R-0%$ !JU[7-NQ[
M^M@/6P Q?AZCZ=-P2FWW00$]C\@!?T-@/4</K&G4]VR?*X%NV1:Y^=LFV_?@
M@C4,IM9( P,) O8XML3\K?+O9\CTGIN"@W[7%B2/47.V?XMP\,07$+0I(^X4
MVZ1L0, FUK[6(V\]^+7\IM+0:Q K3\UF-.D5%@IIT)U3:$O+@H1[XE<EQB0&
M7#XZ7FF_#)DIB*8PIY +OS$Y)52%1(TN@RX-;>CAN!.$%U,=T17&F9$!Y]F6
M\A*9)4Z\TXU%6Z@LIC.D(4X6Q!].I$&DO)CZBI]0:ELO*06W0MAL,JL2^1X2
MW7%LE2BE";-N)Z1UC=3[4*;I>/&F"#+A_MU)3'+;E1DNE/5]]U#\)@,(0V5=
M: MU16I*4J("E< \R.R'/"C.*<CH2$H<<;\-;G2FQ44 JZ$E1)L3>Q!.;V1"
M,!W)/H?2^^-MC;UWX["^RS'MR'T)^S)QJ?-U9_VXZA\A;\.(GGPRFKU-2@.I
M51FD')L1)=..Y.1L3W[6NWU-FHHITU=+9;D5%,5Y4%E]7ALN2DH46D.KN.E"
ME=/5D$;$C)$%4?17,C3U'F:TU3J^M5+5:IJ:DQ16I*31&J4VDO2J4F&R\J.A
M"D>(@(6PE32FT/)<)!X:.<NL.=#4J@R.5<N@4S3S^EA7I4NITZ/4Y=3J2I!0
MFD0P^\ANS413<AUMA/O"B5]*P$$<.7LSZ\YP:RHNK9'-ZE0H/V35DQJ+6(M/
M%';J$5+!7-;7%+BT*;A*2D^] -I/B*0NZFR>+,:1U/IZMSV)U'K,*JQ:?.CB
M8]2YC$M4=2'$KZ5EI3@0HI!*00;V)3?I-I$JG*Z,U0$-NTJ#"I3]<=U53XTQ
M9>;AR(X2XVNERGEN.Q$/F4MY<5M7A/%EM10E(((RSX*@2RXV\D+4E2VEI6FZ
M38IN@E-QW!^+L0.R@(L.M1(0D=1)-DA(S<WV  OWM;.#P#TW4_+?6U?-%@ZB
MIE9JE-CU-J12X4P^,ME]CW:2I*B@MNF,KH<*FRZ$*1\5MQ*$6$B.RRR@.+2T
MVVV%*)6M0;2$)*EJ!)587*CN;G'#DVP+77O@A)O8 ?+>UKG^ZW'K@N E+>;D
M V  /H+[6&YMGSXT> Z2+I.0;9%[F^001CRO@VR#Q;/E)/@Z8Y8SZY69"(%+
MAS]0UN?->!\*+3:9"AB7)=Z05!MEN*^M02DW#1 !..*'5/\ 3'\@Z3J)$2!H
M+F%JG3C$QY#M3@I@P)%2@1%K]XF4N$]X\@L^ TY(:]Y,4EH64II5^G]#&A*[
M0=1Z/TMJ'345V'0-2T"D:AI3$F(N!+%/K5/CU.()L9Y(D,S0Q);]Y9D NM/%
M:%Y!)/&R+ $BXN#>YWN!V&/0Y%NU^'!A[I<!(  (38$ 6('86Q?M:UM^URE;
M[+$=4N0\Q&C)1U+DR7FX[*$@$DJ=?6AL#<D]0M8&_?CF)[6O/2-K*J)Y8Z4J
MR5Z0I#[;VI:G$>_FU?JS-G$PV%HQ)I].6$H0H=33TT+>25(;;4:?/&CRXDB!
M(6TJ'*CN17F5-N*;<8=0II;9LV1T*0H@@7-S?L..;_M8>S>)ZJ!S&Y?4^:G4
M- C^[5:K:0E&EZD08(0:1JB"$>$ZFL1XH$"LMM(>8J[46),6&97CJ7SRUOS&
M]JWF3$:Y5U+G1KRO:;J"OLV=36J*['J4N&JS2XU<-!IKE:JB"D=+D4F1[RH]
M*FR3QTV]@3V(YO+"O1.<&O8U3AU:!2WX&BZ-6@VU64)J$,0)6HJQ";?DJHZU
MTXN0*+0GI"YE/AONNU!+4M:6&>CXG5MS6$C2$22Z\8]0TU,HSTA5W$IJ#%7E
MR8+DC"Y#:HM*G1G&W5+(:DL+!2MD7L>]RZJ[D6-4JA!-,@-5.GQTU*;TLAAZ
M3*;C-O(2H^*MM*UCK6E/AJ;NDJ(5F</]C7H*;28?,F@Q851D5!AA]Q+BV336
MI:".LM0NE+3#[BT$MR%];2ED(4E#@4HUJY<1:[7&:IJ"%IO]8X^CN;M7;FL,
M!,>H4FBA,NGSR_%/2[(;:_FRU.0R7FF0IQ2%-]*D2ES1B(7/H[6@JTS4V*TV
MIR32Y$EN--H;R CQ6YANDNL)4X$M+-EN6N4D7LED*T_RM@PUU!#.M>8=3:4]
M3M*4I]'1':0$EZH5VJN)<9I5*C*4@.ND&1(4M+,9MQ9)1[3=*\P.9SHGZPD!
MZGK*3$TY&1)I>B("$CX FCAP3=1R4VNJ=77G&5N?$W&2VE*1.6GN5M"I2&!.
M*9RV DM1FFFFXD>P%D,1VD)AQT)*;=" HX/4#@"8J7377/#C4F"EE*?A CM]
M3AL, N #HOM8=">X[\>ZUU!RUY/T-S5'.+7- T32D,N.I-7J#*)LPM)*UHA0
MKKF2G; 61&8=420+;7_/M[;OZ6R+S 8JO*;V=6%431C*76ZY7ZK'D-5S6<1"
M>CW6 TVXD4RDO*5XKR7_ .=RF@$$,MJ4E7YV:G2J;79%;U */!9\>1*DOLL1
M4,1FY+R5*6MIA)+:%E;F%6)O< B^45$I46=&=HB/YO(4%.4]X+4@J="3>(\N
MXNR\/@0HF[2^E7W YPO%'$G3RHS[9]_T_,7X"E)ZGE0)*TB9$<4;_P"]97AR
MF<FPERB#N ECTCQ(D17ABR)K[2R$V(0LL.I&P)OU._*^PP.'44-2WW; (1XS
MI"0D"Z2XHI'>Q M:^=Q?AYC:>!_[V5$VN23G8;=B/7RV&.""+IZ]OV0 ^0R=
MQMY[=OEMPY.TV)3HRID]UF'$9MXLB0M+;2+FR0I9-@5$A(&Y-K65?C4S7=&)
ML#J*D#(R9*,>N0;]\?A;AS:U%H@"RM24=.>\IO&!VV -N]LGAR1J70]P?UEI
M%A;_ (6@ ^N^<$W^O?A:UJC0@%SJBAI'8&6@8P",8'[L^>0O;U9H('&JZ(,F
M]YC0MY[X/TR-O(<'.FN<] T@P^W0==4>"])6DJ?3.9<\-*0DVCM.-E+3SB@/
M$>!ZBE*4BQ!/#M6^?E#K3[3R]94"*0"Y*;8EMEJ?*4AEMV5.:=2I$A3B&6TA
MI2"R@ ]*!U$E$US;T#-4_P#;FJZ!4BDQ'H<=R86VDKBE#:XK"HS:?=FGXP*%
MH"VT.=";GK2D\-LWF9H?5&H_LVC-Z;HSKR>F%#HLYZ1&FJ2VDJZ/?)4A:9*B
M%$M)("^E9;2   ZJB(M<6-\7(M<]]@#8'-CN<_)(Y!2<=-[=T]QV-QBVPP?0
MB^W77V76$HY%:&38X_6;\]8:@/\ K#S[CBLO,F/J;4&KH'+W2<I=,F:AGU61
M4ZNRD^]0Z1$E=#J8CH!\%Y]Q92X\ '$-I*6R%.=23F/IV3I-)H3]7>K@IX2P
MS4Y?AF8^VEM 4F2M!(<<:<ZVPX?C6E*2HJ/Q'*3$CU!A<64@N,NCI<0%K;*D
MD=)Z5MD+22DE)Z3=0)!N#;C13J#3*;2X='8C)<@4]E#,9N4$R%-MH*E(!*P>
MI2;V"B ; 7OW2:EAS9.FJ[$I#;(FRJ9.C1$.I4EH.R67&E*4EJRU'I<4L(3;
MK6$I)%[\5YAZ*B<NN6]%USRQ29];@28M-U7(@O+D4]*&I+B)5+U!3$*)2Z\E
M*DQI#_NLL$>+%60A9%M^?&KH53Y;4.")%5@3Y2XHBQF6IC#\Z%5DJ2Q1GG8C
M9?IZH[4) >DQUJ7)CK0T"VM04H&Y;<NHNB6:B(,RH/Q:J(,GHFNN=*'TQ_VR
MV(;Q6N(E?6EI27EK?=6V77U%:CPP\[-7U.B4@Z/TM3WI^J]6TZH1H,Q:@U H
MT52 Q*J<MY1-W&4.J$5A">I;X0"KI !AG1]&IG*5[2&J:K$]Z,&<NFU>=%:2
M9+;=8@>Y/20D!"WV8[W@%SJM=/6L N;WW0D%MM:/C;=0E:%('4DH4+I4DB^X
M(/R.1>W"E$8*WO;88(5?._SN+7&0#D6SM$-!SU*!L<>M\?$<>A'GY6(XT2&&
MV&GGUNAIF.VX\XMPV"&VD%;BR; !*4I)O?8>O'//FA[;NK*EI[7VAZ-'6YH:
MI:?F:(TG1:493%:JM2K,]R&_6Y3\&+,E3_MMZ5)ALT='@LKB*AI0LO\ B%WE
MWJ;D7SJY6<V-'\K=8\FM?#5>I(E&EZ,HR=.5.>NK-5A#3\&J49Z#&7]JF&AY
MYB932YX;,MM3-5CH<:Z4]P/9G_2"<Q.6NMZ0YS%558^EXC%,T[S$TU6XU4C5
M$QHLLTN7JUN!5GW7J7J+3[C854X4-$&)+@MR&7(#4AMHH_2X[K+3].I'V]4J
MS38E"]W:EIJLB4A$)V/(:#L9QE\JL_[RVI*XX9ZU/)4DH"N*F<PO;"\!3].Y
M:4MAQ:>MK]8ZXQXS=T_"':?2PL(7W6V[-*TD6/N]\<4]U7S(U_K=Y3NJ-65J
MJAPDB,Y+<:@M [(9@1O!B,H /2E#;*4@8 %N 9+&03<BY/58WZK^9N.HDY!S
M<]L<;"A)N+=K;DY_'!R#ZXMMQK+1*>E02H6L0;$;>6,=NQ_?PCBT:#&F)E0(
M$5BH+( D1HC2)2U$X >::#I).  JY)P-K6<Y>Z'Y@U53+U783#HZ@%%^J-J9
MJ!9WZV$)"75W20I(E)(/]$IN#Q*,_2^A]/ZWH;U(J+;E?C49VJK<JQC@.2V6
MJA1T]3)"4)2F)5YJX:4K6KWAM*4K*U \6JUYJ'2=,Y8M*UD[&I]0D4M-,E-R
M ##K#KT<-1Y=-0M*?%?#Q0OPF#XQ6D*0D*SP$2!6T\D&&]%ZECT-$>C_ &A4
MXZXB:AXM/;;+TDTJ.[*80)J'VW5(B.N!EQP@J6$W0>>U']M#07L[1M2F=71J
M2;K&6BOZ1DF-3(<[52ZLV6%PY]'A.LQJ;4H\L28=5@W+<5QI#CBU(4''*1ZM
M]I/F!R_UW4M4\TM..4:)K&9&J- H\"HN%4%J84SHSC<A2VFYT&3!>+<A#*$-
MQW#'5%4H-*\3M'[-F@-/<T])L\XJ+*56U51B+'FT\.A_W92 ),'Q %+6AH-.
M!:FU$(+O4XI*UMBUKH^FZPZH1HM/6TTU]]QY"XT1JV22I73UA(W4XI6" $@)
MMQ$G,[VD/9EY -NIYK\X]*(K[#+KZ-&4.K0*IJ-XM K+ I<*0Y(;62+!,@L
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M7Q)(X!=8T'W:NN)6IEYTMM%[P5I=0ESI%T%;=P5)L+@FX5@^?#.Q2[V"4=(
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M<420 AL;9MT@CY]QPKCZ/DJ@)U/S"KT/16FK]2)M9<Z9LZXZBU3J?<R)3IN
ME#32E74 $FW"^'S2>B TGD=HM%,"P6WN8^N8?OE6F?T0]I_2B0"PWNXW,K$E
ME)NG_)]C<X1N4-2UC4F:_P RJ]5]8U)2O$#^HYBJ@AE:L]$"FJ(I-,;!)\-J
M)$NA-DI((%Y)U/H327+[1U3URW%CT3]5X+U1?JG6F&EF*PT3(#J[(NRXV"AQ
MM2&VW$JZ""% '\7?,W5]/<Y\:XUOR^C>Y:9EZNJM6I,-1!< ?FJ><#0;2EOW
M1]WQE--WNVRM";J(OPKH^KI,O54&IR(SD9"TV9@/+08,]F6/"G0):EI#?N<U
MA;L5"PXE<=:T.+)4FPM=R^Y0HIVM=(U)V4^QIK4RU14R6*M+>>HS]1A/"F1%
MI=A1 VTY(*H,B1=;S/2ZR@H*PM5C];:4CT&)I%QB&S"%*UQ1675); =95+:J
M%*#JW+%SJ]YF,I4M:B57-SL>(WYMP*@]R9T)JNFL,HF4R*UI6MSVVRF4]3)1
M?3##J@02B)4(CT6ZQ=!E,I24[<4G11%.74M)4M1*B5 7*KC/4223YFUSL=N'
M!JC!%OA4<C^C?/?_ !MGR[<.;%/N0 @Y)^]N+W&+6OYB^Q%[CA\C4M6>K[U@
M2+?*^W8>0\\;9?XD! 4+)SMG.;6VV)WV\[G !X,(*W(R4*3\)"1M@$=\BQN;
M ; >1[\$3->EL]!0IRZ""+*L+@WMY9MW!S?!%KE%+KQEPT39$8J4PJ2UT*>
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M9 QNHV!Q;L=B!C\?J!QJZK6WVWO_ %[&_H?RSQU.]G%2OY&=&_&1_I#BZO\
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M"QL<FULXW-]CV7-1K&R&RFUB21:PS<A6V/( ?3/"]N&#_NF3>XOC?/:U[WN
M <W%[<+VXZ4CI P/E^5_0;?GPN;BK404).;#M>W<WP +XO8#;AQ:IZB1<7)
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M)+K;T&NMN-J0E:'$&DRU$*0H*!%TIP1\@..I4:)TH2$HZ$H%DMI2 E(& $I
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MH\J)6GZDHAI14MN8PU$06Y2HO6GW<-KBH9:?*5K>]X*% (0FU>D1R/A L!L
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M@B$IAQQ^+4G_ +1JBY=2IZXFGJ>Y3VV*K.@HJ50CKGQ"Q3))44\'C_L::O\
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MJU$K-1KTU^31*^TTZRQ6X$+Q8]*C+;#KC9BM1&(KD9Q3"QTV X%:NE:ET-S
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M $!+:UE64I4H('WU #(2#;J5V"1<GMC/&2/_ #DJ25)2KI6 % $7LH7(N+Y
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MI;KR*C#\")\*^I;;J9+A7TWZ3^C?D!S]H=58%-UC!8T]5GH!C(J,1*U41\A
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M/JW,*J4V5R\E-A4ZMU;2529H,*2H$J+TNG/19E-<ER7%]/7'A)DRG5(2.M1
MXY_3-,:3AU5,;22]1O42G$M0)&H:F9<Z0$JZ?>G(\9F'#B=:;>&RS'"TH-G7
M%J4 @YHT!""V.CJ)("1;S[$#:U_K].)HT](>IWAK:04J2D WVWN, [CUOZ[#
MAPK^GJ?JTMOU%A)?204N);'B8-@"H"]L"WI<@@;"D"ABEUL0EP^I#?2IF04[
MHVML0",I/<FYL=N)>TI#>,F3XC13&20638B_GYXR<6NK.=^).50X%5@38%0B
M1)D2?$=@R(\N.F3'=9> ^!UE2@%H0OI<""M-UI&UN'SEMHF)H+2M/TS#F29L
M:$J2MIZ2.CPTR9#L@,QF0MP1XC'B^''CI<6&FDA(6>)2CQ@NP 'Q7-R"+_.X
M(O;-QBWX\.[4=*+$Y(_"_P OJ<8'IQFZ2$$@VR/+SV_CO^'##-7=(O8YL1L
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MA1LX=^I*M48M#^SM(HU#0-.UM+L*L:9<>4\T\JFRPXW(6MMM$E]E]P)6OWA
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MDB3)+[DY@+B,MR&BAI]227$H*4*<^8G-[3FM-$! 99I>J<P4PJ528<!M,,^
MRLR7VH++C+:HC;[$B-&EJC3'72\[&2XHJ%6^/OX_C'Y<3;[,PO[2'(86/_NI
M:8P?_P!^[DG.?+/?SX_6@VD$[>0%NWG^'\8QPX(1<V%K8M<$FU[7['-MK_/'
M%KN6[*OU+HMT@_YQV'G5IWD"/S/%%9-+<7.FD@)O+DX^\;>.JQ^63\K;X-MR
M::&V[^&JP\P>H@7]+^>>GR\[\-TA@-MN.+Z6T('6MQ:NE+:$#J4I:E$)0E*0
M5+)LE(!)(3GCEMSEYDJYT:^5IK3TA;O+O1\HH<FQ[J;U#5F5%,J8T!AV*TZ5
M0Z< #XRDN2472ZT$RS2EQ>5D&FRW*2U6N9U9B-_J5H]Q/B1]-0G 6XNI-1-H
MNIA"' 78D-Q2'IKJ+I3X8\03GRLT;,HC4BOZIF/535=?<,VJU:;9<E17<EP)
MOTLM@'PX,9%FVD!/AH2 .HTU3J"DT*%-J52D1*93J;#>ES9TUU#$2G0H[:W'
M793RU)0CI0A3C[A6+=)%K$ _DV]MGVF&>>W.:L5ZC/\ 5H;22Y-!T5T]2$U-
MM#G3.K_A'(55Y"5*BW'B(@ICH)NHC@.]DEZDN\W8*]>:>>J^GIT2H1:PW(B/
M+C,0)4)]+3J7NBS;C;I;6'$JNE0PKRLES3A<NN6[E7I^AZH)$"O];CR5/IEL
M0&3U>''2]M<)-EDY P3@VI[*?@U?QZ4F,TTN,ER2W*0CI;4V!U>*ET62%)O<
MD*%P.^_#8[&F"(DF8D4\%,B[(4A]YQ"1T>(Y<A038]"K!0N<WSP9<LM.KU15
M4IBEARK/+6S$:F64RX BX1\5NEUX@I2L8M@XR9XI^@VG*94X];H*J).HKQ<$
MM:EM>\J:5;PFT]00NRA]Y."@@BXX"*BQXKX78J23T@C:P%L@>>?EZV/#I1RN
M"ZAUA70XDI*56M8I/4,^6QOCB5XVKJNZPEAR0M:"FW3<D'M95\&Y&,"Q4;=^
M,8D-<B8F42>E22E;9!*5W/WNP[D8QO;-^#2GT_I(_9I!N#TVQD7NH')/;?%S
M87QP=TVEJ7TGI[ VMMCN3@ VV )-S8\2!3*>>I*0D@ VO;!.>JVUQO<=K8\N
M)'I5-^XGIR;$XO@9N<; # O<Y-^)(I5*22D!-SFZK9OY7[)[Y%C;M;B5J!0T
M*6@K;/2DIN2-][WN!@'L;7..QM9#2 :A(; 2 " ">X^$' %OO9WO8V L;<2#
M)<:DQELN$+0XDI*;&_Q7%SY9)-]P1BPXCEZ@,M]3/B796LJZ=S8JZK7)P,]_
MJ>W&+L!"0$-I "4@)S;O>XN";GO<D8%N_";[.6K< G%S88L>V3?U]?GG:W3,
MW("2=[ ;7&.P_.Y-]^'>) "2.E([#JMMZ7N22?W[D\&$-OPVRFP %AV.<G<?
M,7OD;</#<Q]M/2V2 !YG SO:VU\7-OIC@=J=1?+ACM76ZH94JYM@6L,# R<6
MQ;OP+>#4S(05%:VU7)ZATFUQ<>1[9';. 3>7=)TQ]]""X%&UKJ((L /6X)N0
M-L #'$D.P"AJP!PE5]A<_.P&,BQ[6N.(PKSRF"XVW=10%&UKG).-A?>Q/ID;
M\1^M^8I2B0NW8*2KUM; )OM?('IOQ\LK<:*K$$B]B,8W],@ &]SW)MGAM6,
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M@YWM@6)M^'YCC88#@[B_U/G_ .:,X\^]^$2T*;44J%OZ^,4.A#J;*'4#>V^
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M97X]OI?\. BN4IZ./NW)/PE()N,[&P(]-KV%P-^!)FAR79(<2'"L))S@'.Q
MOVW^5S;B5-'TN0E?Q)&X! &;DX[ DC!N1B_IQ,46 66P.DDE.2D>8&!VQDY
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MI\!@(C1(C"4-M-H "2HJ)?H$1#+0-K'I'I88Q;8#N3W\^W&;UU60D7)N2/Q
MSV[\.M.@](/P@8!)';U^6<;W]."6,A+9! VO\R;?WX ]=B<K'I"UI#+:E&X
M OM86[?C^^]\FVB^7Z:WXCDEWPE.*%G#<* .^01:YMF_]UCJ'IY>DZ=[LQ)1
M.:)*BVYTJLKL+'M;UWX:YM96_+2RMHM*.Z>FS:NV GZ;[;7M<<$5"0MDK>6H
MGJ/4!Y ^6^;$''J;W&#J,I<I20"K.XM@VV/>UR;7! P>UKS+IG0<6LQ+/N^$
MZX!T.#/02?.^/+!3O:W;B<].Z&5IRG*:4\U4F@OKZ%$7.!A))VMZ][XVX4O5
M)R:78R6G([3!\-N.;@(MBZ0;@W![Y\L6L\QUJ:8:0OXU  &]MS\[[V['UX5L
M/*Z@4@WO@ FVQN"!@7-A;M>^#P11 %. $VR+]NXR.QW_ "].":%]]/?)N.V0
M1^_?SQP21T!3J #<"^1>P)( N-S;>^< 6) %C*%"0X.DVL0<  _@<Y-AC%A@
M=^%+VCY#SJ7XJ4E*E)*D$@_"<[]@KN"-^#FBT!R XUUM@!P#J2I/H+W(N,6/
M;&!@@6F:B!,8!LVZ!L0!@$7 W-B"0"3Z8.>)&ICJ;IM8 $*%MSL#] 0#;Z\2
M)#7UAD@;'&0"1]-\G.^_;@RA&[5[B^-M[7S<;7QY7VWQP_4]I"E7(OFP-MMQ
M];D7/GGMC@ICM)VP<[VP+@]MLC86N!@<*BRTJUTBX&]M\WS_ '?AQDEM*,@"
MY'IC\/06SQZI72DJ-L>9X8*C) 2JQ^(I*1L,G<Y[_,6!'X@516D(Z38D '-[
MC.;XWQ_8;<"DA8 <.US?O^ZQODC?Y@\",YP*ZKFQN0 "02,E5C;L,#8WS?OP
M*2LH.=PJWGL+W)QVL2+6^IX&'$]04.]R1\P;B_8B^_\ A9E>8R=[[$':]MB,
M; W&=O//&M$?X@+ VMZ7N1?Y['%@?G;AWCL] !(^(]CB^;]AC\K 7W/#TU C
MRF%QY<=B2P^ AUB0TV\RZ@BY0XTZE3;B=E%*TF]AN1P_4O0NDU=*CI;3A%KD
M&ATLVN3YQ<7VWO;;-K%S.A='D63I/37W1O0Z786[7$4 X\CYWX5_J)H^V-*:
M;L!WH=+L3BP)]T_=C-K[CA*[H/2%K_JEILC)N*%2[ ?_ -*+@GR\K<!=:Y?:
M6%U(TKITI/5?IHE-R+7OB-N","UB?RBZJ:+TT M*=-4!*DD[46G VW38^ZX_
M&UNQ/ D=*:<2JQTY01<WS2*>+D_..$B]OK;@BIFEM-E)"],T X!S1::03?\
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M>UD#8>R][1%]C;DGS*W%]S^K7Q'\/(<;V?8]]K)(!/LO>T1DFW_<4YDY[?\
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M '$<'=-Y,<Y$ !7*3F:E0()ZM!:J3<'-[_90[XV/[K'$7E!S>"$%7*OF0%)
MP=#:G '2!W^R\; [$WMPXKY3\X"GI'*WF,!8)-M$:FO8?*E_C]0+8''D;DWS
M;6\E1Y6\Q$V)-U:)U*-O,*IF;YSVN.)1T_RCYHMEOQ>6^O&^FQ(7H_4*+7-A
M<FG@7 )L+=L^0F2G<M>8;;:;Z#UFE024D+TO7 ; WV]QO<DFXV.V."J)H+F
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1VY&"T]25)4+C*2"+@@\?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g853399g91m71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g853399g91m71.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ',"^<V X0DE-! 0      $$< 5H  QLE1QP"   "9O\< E  !41E;'1A
M' (% "--:6-R;W-O9G0@5V]R9" M(#(P,3D@,3 M2R!$<F%F=%\R-@ X0DE-
M!"4      ! T;'$+>TX6J5F]3A8:49<9.$))300Z      #W    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    * $$ 4 !. "  +0 @ #0 ,P X       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%AB(H         *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/T
M       2 #4    ! "T    &       !.$))30/W       <  #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MD@   B           0                         !              (@
M   !D@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !D@    !29VAT;&]N9P   B     &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   9(     4F=H=&QO
M;F<   (@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    !.$))300,     !+<     0   *    !V   !X   W4   !+  !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !V * # 2(
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MUXV5]+K=8PV.=MLL]/Z=C'SZ53&.;_-O_P '_A?41FOINK&5BN]3$M)--H!
M+9@?3A[/[:'5T.NPW,I-PHO<774,L+:I/TOY#=W[JV<7%Q,>I]8<U@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MFZ_[QJ_^-QD7R^&8O%V/G%PK#^/Z[CWVW?/]KW;_ /?ZS_B\=T[RV4W6Z%(
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M1D82F)&"9'! U]QKI#CBPDP"VT"TV 1]U:L$C$[^0CR=%CT3>;PI(IJ):62
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M$MKZ=LYFB&O>;_,WF?5+JM=:VO\ J$J6I2*6KKWA0,A1GI9H&E(I&D#8)2T
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M&>-@@G(G;,[8\N^QSB,<"H:G[V)R/D(G]_KZ<"]"!^R"())/;>?[HVXV 3
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M+<3VWX],9&XP>F.Q&\=LYGR^?&"F23$J[]X_H^0_?QE6,'<;2< F/[Q]?QP
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M]SP#'X1DP<'>,P)[>7UXPI3;:2IQ00E()*U$)2 !)DJ@    @D1)G XC>_\
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MTO&'7TRDQN4-]9V!@CB%KQJB_P"HUE-34.MTJU$>Y4DI: .P4$F5[_M$CO\
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MNCI)!S@\ )8<4GQ"D]*3TJ4$DI22>E/4H83U; *(F1!G'&Z4*3/>1,03!QM
MC,')[>D<9/?>1\)@ $;;&?S'UWXW#:R" E1.\Q @=B2,>O8G83'!AIEU*@J4
M@=1)R"8, ], C8 B8S((@D<&^_3&! G>1&VWJ/I/&03&=^^#^6\_3CQB)B<=
MNX,=N/;_ "_C\Y^D<>[_ .,1^Z?\>W&>,';)^>-\?4[>7E\^,Y.P/S D=OGY
M_O\ *>-PV5;X/:,Y@YQ'G_AP,FGSF)B03!SL0.W;SC'UX,^Z+0A"UMK2TZ5!
MMSH(;6I(E:4J(Z5*3^T 21WX#\+X@#T)&,K6AM C_66LI;0-I*B!YD3QL_3/
MTZUMOM.,N(A2VW6RVI*2.H**5P0GIA041TE)"@2D@DU7VFNMSC+=6VTE513,
M5K"FJBGJ67::I0%LNMOTSCK*TK2=DN$I(*5 *! WMUDN%V54BA90ZJDITU#X
M4\TT4LJJ&:8%(=6CQ#XS[:2EOJ6 2LCH2I2>V%WDW6Z"9/VC6XC_ /6G3Z@P
M-H!&T GIX3B2 9D8)R3&1A1G.P.3@ 3WX8FH.86G[!UL>,JXW!(/^144.*0O
M_P#3OR6F8Q*>LN&,),<0A?M9W[42G4N.KH:%6$T-(HI*P=@ZL0MU1W^(@&3C
M@736A[Y?5(31T#C;:U %Y8A)DQ(4H?$<[)!.^0=[C\N/9=N5::>KNS)IZ>$+
M6[5)* ML$$^$P0'%8W6[X:, P1GBYFF>7&E-',H53TK+M0R!_E#R40V4P"I!
M(2AN/-$'U._"Q5:F;6M5)9Z=VZU< )13@BG;)@!3M00&T $R<R #YY$:TE=K
MGT5&IZ]-'2&%IH*=12"DCJ",#Q72 >D_=1($JG/#MHV+=;&@S9Z!+02!-0XA
M,S$%0$=(VGJ5)!P% C+4UIKC2FA[6_?];ZJM5AMK""MRMNU:W3,@(!44,A9#
MC[A PU3M.+6<)2J8XY;\\/TH6C[%[Y9.2]E<U7< '&AJ>ZM*I+.TY"DI<HJ-
M914U0'WTN/(0@[>'&>.1W-'GSS9YS7!ZNUSJNYU[#JU*:MJ*AQBUTJ%*)\)F
MB;4EH)2, =!VGOQ$;: V"!Z$G8;=O/\ K,[[%Q _:'T,\>#B#^T!\R!_'C/4
MG_6 ^9C]_&W'N/<>X]Q[CW'N/<>X]QLE)/H(W[?U_+@=M!5  )2 94 2 >Q[
M[_W#MP<2VA&1)('>3^0'8CR]=MA4I*B $J,]H@_21^&/3UX&"(G]4H[3/;S^
M7U_'RR L$?JB!$_",_/(S_"=^W @*R2 VL0!@B8B?428\LXXV $)224JD I@
MSY^4B=@.Y/<<#"BZE=?2OI$?LE/Q;DP<P._;L"8C@84?4?\ 1I!'3*E%,').
M D=220>F('D>!DTI(,]*0/NA$R9/4"3\.TXW&Y@'' [;"$$$@*(3&0F 223(
MDR3Y^OD!P.8&,1'T[[X@3^? 2F6E _ A2X)S@3O),@ GZ?/'#IT=RVUCS"=K
MV-(VVAN#EN2@U;=5J#3-A\-+W6A'AG4=ZM*:@$@@BE4^4X+G1(F[BM.\R+E;
M*&@U3R<LUV31?8;5/6HYH<J&JAVW:?MM/1T-$[XNJ74.);<0^@/=(=]Q?32=
M<,H5P)3Z>UI3^]TZ^1&F:JBJ'W:QBB?YD<H33VUQ=/4,(IZ-"=3MH-.TT^FG
M2]5I?KO=RN*@.!!0AZET3S"NJ=)-:;Y+:;T^JPWJW76YU#7,7E"[5W.FME75
M5-+1"H9U2VXTAI-2AE2RI:GFZ5A3_B+2>#]QTOS!KZ^KJ*GDY8KG3W"XU5;6
M)NG,?D^[5J34J:**5FJ;U4EUEJF2'PR4D?K'U+()2.%#^S^L%6Y-"GD+I6AE
M+8<>HN8O)\+EFH<=0$>/J9X+#K*FVJA3Y<<E*ELJ1*0-K_I+4-4Q?:.U\C-,
MN)N-#[O;[C4Z]Y/L/VHN4;+2J:E9:U2 *1BH#CC;KJU5JB KQX44BA^HM,7C
M2-WK+#J"V&VW6C4@5-&I^DJTI#@ZVU-5=#45=#4LN(/6T_25+S#B3*'",\(N
M0/7 &1^[ G? \HG;CQ&(VD0(_':8 Q!SGT '&!.X[R23L!/;;??M.9],@G)Q
M\P)^GKWB">^VW'AV!B8/[_X]]L_EGN8F<2 /7&?\9V[1QF#.)[]B0#Z^7RD>
MG&X;/?';?MWSY^1WX'0R3!"=QN?YY^O;'RX'2QD9G<XV(WW)[DX[<&$L]X !
M[',1Y;CUW\MN%N\W2Q59M%KM_@LW2FM2:BOHVD_$V/&73>\.DDDFJ*4N1L%!
M1&\<:T[Z:JSU=$JE#3UHK6'D59"IK&Z]"DJ:E4IZZ=:0HI3LDDG;"+64BGV5
M-!,]:V^L&9*0XE2P B23 ^& "3 X7.8ENU!>+<R:A[WFX7:U4[#3[#"_>7[>
MTM%.M(0VCQ77U4B7&T*2"XLQTR8' 3MK;L]LL-BIT.+;M5GIF ^XLN>.'NJH
M!:ZB>BF0ET-LMP.A"((ZIXDOEVBEMR;]?:QE+U):]/L)\$('6_67+4-LID(Z
MCDAIENH=V '3 DF>.D6MM96/35TN@KJQ*JLW"M4U0TP#U4X14N* "!\+:""9
M<<+: 1][ FOFH.8]]OQ6Q3*5:*!1(+-,L^\.H,B':@03U #J2V$I^]E0'"=I
MW15^U"ZCW"B6&G%]*JMV4MR=R%E*E**C,A(*_.!D7,Y9>RQ7UON];<Z9:63T
MK-36H4V@]R:>E)"W0.SCI2V=Y,QQ=O3'+72&C66E-TS=75M)$OOI00V0!E,)
M\)D2,! *ADE4YX6*K5#;KON%GIW+E53TAJE0?=VCL"\_'2 F1U?%])X,LZ1N
MEQ"*K5%>FFHY"A;Z=10"DC8Q#KTD *GPT&/O8D.BD:HJ!GP;-0-L-H@&H<2@
MK\^N(Z4G<]205&<S@<,S77,30G+FTOZBU]JNU6*W,)6X]67:M0PA91)Z*>G2
M5U-6\2(2U3-N+5@!([\FN>_Z5"WTYK;#R*L!KW/UC"=7W]E3-(@Y'C6VTP%K
M&.IMRL4 <'PP<<<D>8O-OF3S<NSEXU]JJZ7]]3BEMLU50X*&E"S/334@*6&4
M#8);;C'SXCL!I DGK.T#8?+^?[N-5/DG8#ZDCTD1'XG\>-2M2L$D"=@8'X [
M>A_#C2?I'GL<''TW/'N_?'Y_E^[Z\;05'N2(\^^T_/M/TX,-A8W229_:V [D
M'>3C G;@?CW'N/0?(YV]>,]*CV/[OW\;AOS/X<;!N=NH_+_#C(:DP HF)CT\
M]N-Q3F=H]9(CT&W\_7@5-/G)WDPD$_4DC'X?+@XW;W%G#2R,3U#X>XF< [&9
M.\P,<*35K7CK6 !,(2)) C<[ 9@3/F.#[= RB%%"E* ,]0)DG8J'H9Z8@0/0
M'@PEM '2E  Q@)&>^Q&P^<X/<9%\+8] ]-NWD.W&.DB.D?AL8D=MLG?C(0HC
M[A(F-B,' ,DYSW!F1MYX\/R0 1)D],$G,[2(QD'/TX\4J&XQM(R <>L"(D C
MM@R8XUZ2#U%) P"<[[R/,?#OO,SG''H)@G (GN)[;C<2#W,><'CQC\X_A S@
MG>1VW'&3Y#&1]/Q(Q\I$]CD<>V\M\?U.?,^?&OA-DDE"9R<@&3]0<Q]/RX 7
M2M'9M$D$XF.J,=6.H^1@]R1!B0!2 J)*$I2 (!/4?4GR.1@P0$B)!XW%*T"
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M$GI2>K>0!^!!]/Z' B*=Q1$B ?Q\OE)\N#2:5 (D*4=L;3!P1W],8WX%+0&
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M(^\/7O'<[3P(FD*H*@H@"!,G'X;_ $X-(ID@S 'TWV[3^/\ CP82VD#8?(8
M[8V.,1OZ\;=*09[1W]((F(S@ QC@,(4<P! ]!WC8?/RX]X*3DS)WC _K\.-D
MTW4H%(( G?UVDG?\.#0I1C\P$S^9S\L<&VZ!9(^$QM\4 ;3@ 3@?GCSA0;H6
MD$R.K&\ "2"-LS$SVV]<C*ID**<D 9Z1]TPF /,2>XF,]\\:BG1U$J)(!P
M ,)GSW.>TY](.,H2%# @'LF2)SM^.?Q'?A7:1L<=!)@Y[8B(['U_?P/$?U_7
MX<>X]QLE)4<8R!GUXV\/U_+?CWA[00?IGY1W/RXU*5#M/RSQX C)&P)&W;SR
M(C'%P>5]JYM6O1])0T'*ZIU3IJO^TJ^D<<>82T7[JEMKWVGE2RA26$*:6E2>
MAY/2%@= X=S5DYI4+]"NW\A:EEFCI5T:J1VHH5TU<RMMQ#CM?#*'GJI87X:E
M(<2R64-I+2E J)B^V[FI<;-<J"B]GQ%MK[@TXEFZ(3:UKI'7*2NH5U+3)IT
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MA&1MV,G;M!VV/TX'2PLY"8C';\OY<"-TSBE'! 2=U#?Z9QZS_$<'6Z4)R$Y
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M:20I"MTD&"DIP93,$^>8@\"TML?N%6S14C174U*PVR@*2"MPF$I'40)4<"2
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M1TAN000!)CBK>KOTHOZ-'E^7$5O/O3U_J&)FGTS1U]]6M2<$(6RTVRHG8D.
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MYK#;5.THGI;124Z4-.0A01XM0I\N $]")@2B]=K+8:=-.R*=E#:8;IZ5"$)
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M7ZC/]I=1K4<&^WB "<GW^J.5 X@@?ZTP1&9)0-8$Q':02F!\H_+TX,-LDA,
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M![ $1OY$]QC\D>HJ?$$)0M:<1TH4LDX),C(&T"0,3GM>S4D_VDOX R+W=2,
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M>H)Z@!Q=%ZG6KJB(SD'/: 2<0.XW/G/!=>FJZN1XR&%5#2(ZD(!$';J40,
M@YWS)X6],6Q]ZN70FE#CC;92TP&PHD)25K5D28@R=^+5:C;5_:._E,F;W=/S
MKJD1]?+^?":&U)@8429).^ <?S[=AP*H['(!&\#?<3WQG\A,;:?>E$'J*@0<
M#/K\M^#24I:'FYD[=\@9]-X^G&A2N"J"))R8F3Z#;M'G^/'D-*61U2G/Q';
M(DQY@1V[?7A6802I*4[$]1,3D$0#Z3@D]B1VGA60V)B)GR$9^7T$F=OS5V:8
M1\4# ^(C.<XVQO@^F=N#B6$$STR<""9R#'R&.W?@REL 3$03@"2?6?R\OGCC
M<) )B4G8#? V^F_IVGC)ZL[8&V^#(B=Y,#YF.,$DP!D$ $$'>3F=XQD_RX]X
M02-B8!$$0#G('?$1WF1PLZEY3N:\Y+\TK(I ]\UCHC4>GK0%#+:J^W5%.7T@
MS"W'"&4$9">KI^]Q\LO)?FIJ_P!G;F;H^HN=%4-U/*7F(FZW.RU#:F77*JWH
M?M-SHY6!T*?I%K6V% =1"% 9''T=-?I+?96N.DV=2G6CU/6.4J'G-,KH'W+V
MS4E'4JC#*$E*UA?PI="NE6\CMS;YM\X]7^V;KZVUU%INZT?+;1;C[NC])!MU
MVNNUR=/1_:*_AL%BE:;0D+2'>DM(Z6T9*B;P<AN2J.6MOJ+M<%MU.IM1T](;
MBMM(\.C92DK;H&3&4-=7Q' +DGMQ9I#*$1TI!,@=A)[;"3.!_?PY/[,7%=+3
M5=,E%4U4AP.!I4NTM0VA;JJ5]LPI#RF4+<:!PXD'H)((X>5B30:DL%PI+JSX
MUVLK:!05#:3[[[@\AQE<H0.JH1;:E-*]TD*4AE;^( A%L-6[9:Q-NNB%+M-Q
M44=8^-#+A4$)K:8J^#Q&MEI@=224+&1%@*OD+>]36ZGJ6:BB22WUVV\H 30U
M["QU)8J2D=5.\"925$A*NI,@#AOZ6]G>^5EP<;U%4,VZBIGBVXFG4'G*@(,%
M3:YZ$H6!A9DD' VXM5I_36D-"4H9L]NID/I"4JJ.A#E4ZH")6\H%9!.\$ 2-
M\<8NVHU%LJ??%*Q,@%8"BGIVB94<JQ WR-N&,J]UES>]RLM.HE2@DU*P295,
MP?O$R1@2#V$CB>M">SU9-7T-4WKJW)U!05K"O>Z"L2I;3S93U] $RA0(3TK0
M4J28@@@<?,;S)]I+7NDN:/,FQ\OM2G0%K3S0NVE&-)6=":7[ ME/65%NIZ85
M-8M=6A0;H2]5NPI ??4I)'6.+!WRV\JJG3>G[]4ZIO6I=>> FJU-3ZIKZFZT
M+E:%A3)9:\4,/4Y2 X ZV4P8 @@\0/IKF=;+3J77%"XBGM>HU/N76VUE$QTT
M]<E32134;3!@4]*AD%KP6QT$_/CG#SGT[JNZZTNVM44=77T]2I-=6O--+6:1
M"93+G2"4,R#T'81$XXG3DOJ.S7;2SE-<EH546Q*U>$LCJ=HJB4/(^(SU-.]*
MPD#[JB>W$>WR@OMV5J.V434VETU-5;G%$!%=3T!"JCP6B9<+/6$^( 05-N)!
ME*H:[5HIKEHE]2DD5-$RJC<$ J)IJA3S>PW*77$__<QVXBMFS,I49"B9D&#]
M.QQ]XF//TX5J:V)204-P9GR[[^NQF//AP,,UP;\%M]Y+1,EM*UI229V$Y/<=
MI^?!QFSD_$M)4<F3YXQ)@XG\>%%JT@Q")DYQ,>LC&Y(/YS/"JU35:$>$EQY+
M4?<2I03&Y$3'I$9QCSV3IZX5(4IEAPH!'4KH42,'J.VX2003ZXD8F#E=IUNW
M:ML]-647P5I8'CU#)4#XR@@K"E)(3!DC'E/;CH#[27)D:#J-)O:9=^T=.:LL
M5&Y44U$H+-+<E,-E])2C[GB*5U=LS$\,[1G*^UV*I-ZN)J$4+=K"4T%>05>\
M.H^($* E"=T@B<[<0WK*EM"KI5+H*=IMGQ5P&T@ PHCX8C&.V(@9XCWW)VM=
M]WITR22$CRVB(R/H1G,[\.>EY97]-*+B:9TE#S2T);0I2WFP>HE,# /[7:)F
M(CB[UNT2U5\B*NM=0U3ZD9?376YH@)JW*=I?2ZPJ(7\23@;02?7BG?/K2].[
M[.FJ[RY1OT=UI1;'*E:E=*'V7=16A'0IL@&0I4SC,;\4>6$@GI ! R(!\N_>
M!^_M,$N8E4]P3 F"(C\1^XB9XLIR^Y%V74>G;/JC4&LJ*U4EX8N8IK;+;%6:
MFD4&F)??<2V62ZH.52DIZFV$J6)4 .&9S+T'8-()TV;%=G+@[<Z6J<N3+U11
M5"J9^FJ%,H>:<HG'$>ZU:1XK 60KH*9 )/# L-F>OEQ]R:6V@,L/UE4ZM00E
MJDI$^(\N3WZ)"1N5$ 9(XL5>7_9ZU3R^=M-DMEQTUS!T[;DU5)=PE1H=0FF2
M!6,UR5K,..+5++B0DX'PXXJL6XF#,0.P!WG'KVWF<<:]&YF 1MD;1MC<1G^7
M& A4X.8@_O.9'?/GY]^,E*I $2)F>^/J?/Y^L\'+ V5ZXT "F K55,DF>PI:
MHSYG;CH Q0)6HGI$ S)VSZ1F/F-N)+TLRQ1A86E*D.@!25 0000(Q$Y/K\MR
M][.S9;=<U7!BD::J2VIOK2A,@*!! [)D$SW/"QJ( :AOZ=IO-TB!D'WY\@_G
M.=B)X2"$@9R1GN3CS]#^&>-.DE<X"8D 8!^NX[3W_+@XPV0GXA&<$;Y/D1@"
M<]\>G&Q;R"DXV5,D^L _*(W^O P1)V!@#N!G,3VS.1YXX&2F 8 ))(SW,P!\
ML?7N>#]*RH**U2"1TI3\XDY/F,8&YGA292>H&, $Y&\SD>L\+34J2DGMB#Y>
MGF/F>QG:.%%E@""3!,F()C'8G!_=@CYFB@1&PB#Y3^.)GMMP$I@R2"(Q(@S'
M?Z>F!N>-/!(\Y&/3'G,G[I/TV.!P*AG$D '<" 8R8$_O^?SX5+;;UW*NI:%D
M?'4O(1._2F96LS^RA 4M7H#Q9VG8:IZ=EAA(2RRTEII. "A @2G'Q*(43WSQ
MS<]I_P!@&P\V-27#F7RU78M.Z\NU,IC4=GOUL;N&D=7@(Z4U%;3CI<H+LW\/
MAW"G()(ET*(D\ZM/_HRN<]LU#UZDL]BIK*A\O5%;:;O0J9;IDJZE>[I?_6)1
M A 4@J (&8''2KEWRM1HRS4-A9I[-9;'0(9 M=BI4HK+Q4MB#7:CO#@-5<'2
MJ5IIFU(I&Y ""( F()2D)2  $QT@; "0($XP8'E@=N!$@XPK8P?(C:3MD]Y]
M>'C::VZWBH<MB7$T_71T[PN"3TE-3;W@ECW@(C=IY3?CI!(;Z@OX4R5(:=U?
MHU]K4%QIWV4L7)L(KFD%3+B'PIU'4ZWU-.H=2EU!DP2$I4.H\6SUAH/1.O\
MEY9KY:7&;)JEYYFK<8I4#W:I\5GHJ5.-)CP2I02Y\(2GK )'D]](FY6/2]#I
MQZM544U&V 5JE)<4-S@G & /09X.55V2PV1X@2D E1Z_VA,1.9CUW^8/#!NF
MK&FBI-/^N>S*E3"29_CQC3FDM4:]K4-T=)4U39(EP)4EI,Q^T83ODGR!($[6
M%I+5RIY/M,U',755&;N "SINTI5<[NM83]SW.B2\\E2LCJ=#8D=A/#_LWM;Z
M;IJEBEM'*K5[=D"@@W>K11TQ\/"4O>XJ*JE0CXE)44F,0<CCY@_TQW(?3^@_
M:$LW/WELE36B.?5/67:Y4K:"RU:>8-E4P+VPIN &%7*F?I[DEI0!54(KBF4B
M>*P\O[_6Z@TE3W=;ZG*FVE%KKDE4GHZ :=Q0F5" 4%1P" #Y<,JH=>3K"IU0
MV\*I.GTT'VC2@@K<HG7_  W'0@$J\-D?>4 8!!, \3%;=6:3NFM&J2U-4[EK
MO"'*.KI'U(6GW>I8+CR7D*'Q,M+"E)69".H@YX;-[Y$Z'LANVKM/7G4;-O94
M[4UECM%,VXUT!0\9%-75/0AMI:E&##@0)Z1 X<NKN4[U(W2ZTT?2NN4FB+=H
MZWWJTI>-0'[1JBEKKG4W E9!ZF*BOIZ2I)&<K7]Q1XBZ_P"C=/:(9O[-9=T5
M O24UEJH:9LJ4R:A)<"'U'X1TR4*Z3!(QZ5[;LY*U$(^&3!VD$R =R,&3'?;
M'"M3V;:$$F3.P /R/:(&?/Z<+=/:HB4A,1"=^T'SF?PGYQPJM6CJ(/08@@8V
M&W?&?Z]%>GLDP.F, 8&>Q@1&>QC.9^3MMFE&WG$^((&%&0"2#&_:._T[=YTT
MO9;10MMH<IVW4*D.)4$D*@C>0>XV.\^N)STZG2+3K2E6ZB4\VV33J6VD+;6G
MJ5"3$_>$B"0/E'$@7S7IKK9;K<XVVX4.]%,MT^(6B@B$-E1/3!3TB-L >7$$
MZWUG<:I#M-\;:D.J97&)",)&P@@ ?S.3Q"RZ6HK7%*6I7Q$DDS@S)DQWQ.<]
M\\..QVENE>0\I )!&2,GO@CR]-MN\<61L&HZ=B@;84VA00$A 4$X@1GN8F/E
MMGAY)U6[X?N;81X8:/2E()24JDJ2!$$1,GBKOM1UM3_R%ZX94DM-.TEJ5 PE
M4ZFLV -A! .^X''/!741'3MN 9)\OG^XF3VX# ZCW !&Y'G/U_")VQPIL+K*
MD-4K2JNH\,*\!AGQGBA*I+@;:;ZBD* E90F#N2<\:%:VE%*TK"P("7 92 8@
MI5L 9 $#\0>#EIMEZNMP:HM/,5=3=:I+C+-+1H4Z[4H=3TN-EE!!6A0Z3TSN
M!OPH:BTIJ71]6U0:HLU?9*]ZF34(8KV54[KC2_A\1M)W0L@^8)P=N&T3\7F#
M!(($[ 9'S@F<_@3QKB,XF)C,Q!S\AN9[DQM/@0#,8,[?09S$"?E)\@"<C()!
M,QN3V^0\LQ ^NX"CIH!S7W+U,F/[54\;Q/NE5G^O[CT4:9@S! $>A)[8Q@]Y
M,<.&B=\-(09G*DJF!/J2=Y]#D\;L7M9KW*9*"4I!)4LE,JZ020?I@]P<[\2O
MJ0$:AOJ@1_Z9NI.<_P#/ZG?;L.W"2$IZ3W4H8 D G/Y>0$3/IP.TT0>I>X!P
M=@?G\QWG]_!@3F=NP&^WF8C\C/Y[I;V.1'[))CO,[P<^?]YAMLK'PQC!,S'?
MRR>XQ$XQPH-,AN.YW((D$R#N?43V_#@PD2<F  23Y0,?G ^O!UH&)(,)5TG,
MC$F!MB)^?K/"HE:%%)3@0!'EV\\ Y\C,R.Q4F%RD*)V/EF/KY[;_ "VX-B"?
M/>?0[?3OVSY^?I],[8_'<@#UCC GY08CL<8S^>P\HXS.?,^A\I[?/'S^7$B:
M H?U]5<E#_0MBFISW#CJ?UJXSE+<M[_MJF#Q,3!26X"I($Y[$;B.X^F.XVG#
MRRD!(P#O*I,'<@8'?!_?N(TUQ=@U3(MC1(<J"':A0.S PAL "1UJ'48QTXXB
MD())&0 /([&8/KMF<C\N-@T"1.?+MMG^ [[C/!A">G<"<CS $&(Q^9C/YB>+
M=*9#U19677KBTVM=.VT"HK6KX0E0!CI,PJ3 &?*;EZ/U#=;CH)O2-ZME)4FI
M2E=6X\CQ0Q'2M*6BH84E0("@8 ) Q/#VME'36JB;:^%IMA(2A*L)2D#$#8 9
MQPG775C5,@MTY2OIV65=*<>HR?4#.(G,\,ZG<U%JZN316>D?K'G% =+*5%M
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M 24M,*>;Z4 "0I"001/"9RG6:ZY:HMK3H%'JG0FC''T.)0L>ZU]GJK8IU"'
MK--4L)6.H'I<:&Q.>?>K[-=F-3WFUWQ;M17VBYUMM=+H(Z31/+8  4/A2J)
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M/4' (7!^*2"9ZHV@Q"C@GB=]1,I&H]0 DJ/VS=)!B/\ G]0<").\[Y(D>J8
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M,D#J@_VFM%BU<T7[DRR44VJ[+:]1!03 56J\:S70I&P*KA:G:A4#"JGJ[CB
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M%,TTA;BR  &T)0.I0GNDP))5(@; :6W4=)<*Q=($J9F!2NND!-3 R""?U:R
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M*$P"&"2%"3=,<NF6JM=WNCM;=[S5GKJ]07U:J^[5*S]X,>-**%@?]&TRAIE
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M3'?MP9"<&2 ).!OMZ$8_'RX%"D)$#8#L#N?3>3YGY3P(VXG),)F!G!GUQ,;
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MV,G;!CSS'E'G' @0D9SWDJW$[$ =MAZ_3C)*0")C!F1WVW'G)R9'EC@-#B$
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MD=L_P\N'=;K0AI)J:T]* DJ(40$I3TDR3,[08B=SN.&Y?-5W'3NNN6>J=/\
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M@H4^XLN8,Y>RMRFK:H5'-#4#*S=-1.5#&FVWD2:>V*<+=9=D%8@&M="Z2D(
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M]W&4I*C"1/\ #Y\'FF0D8 4O<DC[I]-S^4'SX,):!S)'5VP-N^" <;1/XF.
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M]KTK4:^K*VEUB:9[QM24+;E5_:)%-E=754:Z_K^TW6AU**%.)=<(^&3/$/\
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M9#5.ARK?4G+:5+*%$MI))4G"3NH?".)LT]>;YRY4BY7ARDO=N34%FYV^U/4
M=HU5E,MEP590RBH:JE26FX/A]2%H<*DRA3!YD\T-3\SKP]<+Y5>%0-K<%KL=
M*5,6RV4H64T[#-*V0TIQFG2VT7E(ZR$) Z4PD1[34+]6IQ%(RXZIBG>J70D8
M:891UNNK_P!5"$@E1/; F!P4Z"-CU [@2)\AQ,GLU)ZO:5Y"""">8=))/<_9
MMQSG.-_W9X^H!VEZ@93N")\Q/X'YX.3CA-?M\I5"0KJW\]^Q@9_ >N.&M74:
MFE0 8G,C(.!!/XP2=C&_%?[Y3K%[O9Z2/\[7('!P?>WQ(VP1 \ISPF(IE*)(
M!)Q! (@[Q!W&^.VV\\">YNGZQ,[QYD1@P( 'UR.#;5OA0),@;2!'K@029Q/]
M_!_W= (]!$1@>8SMO'&CE.CI))A(!)F $@ DJ),  ;G8 "3M/%7]8ZBJ>8.H
M!HK314JRL5 ;NM<RHD5[R%_K*9"Q(-(A0A9F%D&?A$%4U=R6OM^I-+?\FB:=
M[6NC;FW<&P\\*:CK63T>]6L/ 0V\L(!:690A<]<!<\1%[3WMI\R="!7LNTEE
MJ;=S3O33%JN]QJ5'W:V6J[T\!=(XAP)J7*BE<4IA4)0V?C(ZA BC_P 1C1=B
MY8Z<OVD=5T!YKU-.A;:+K7I9IVNL*6]2%A04E*'FRN'P9*E=87U CB U:SU?
M;M6.:"UW9V[574+**.MLM:H^X7%H? *ZWO.*4RZ*A \1M]I<+P%P1'$,<T>5
MO+BDNIN=!]FU]!=$K4JF0&45M'6@=3E.^D +/0?NKRE485B.(#%FM5@9JE:2
M89:O2DO,TSK[Q=##CZ2E;-.%GH9K%MDMLNG(GH!"BD\,>S(6MQZFNK:VDN+4
M'/%2H+HJ@?#U+! 4$+RET$''2XG[N5-^@%*LIE+B(/AK!!2I(&TC<R!)QF//
MC1#77)$@ R3&(DG&,B!GT.)X-H:2G$ G?$XSCZF?3;UX7*.EDA:AB,2,R3WC
MR\]N%Q#6!ZCMO_AZ?QXW+R6=AU+V2@"5$DQ@0<^FYG'"Y8[+<;JLJ?)IT@A2
M62>E:QB!!B,0?D/IPNU&C[HV]XE&' D$!;14'.G(S([[Q^?J[+;::EA* \E0
M7 !B9,;F)D3$$0 !PUKURS?J$UC=FI[756^ZK4NLM=V0M":.L4DA-QM-6Q#U
M,\"1X[*RMAU @I! /'5G]';SQT7[*W*!_E=K6S7"^K=U=<=:MW&B#3U,+E74
M](P&44CP/AI8%(@MN &5*4I0F..CUQ]N/E3S7L%ZI+]6W;3K[;+R:>GKF2][
M\UX10AMIQ@= <(PEHA*4[R3CCEY7ZIIWKC7JH**:)574*HU/+4%EA3JBVI:1
MLHI(5T]IB3W#3>:MTPFF9 5(4GI4L$''203! \C$X^7#NT3J?5NA+D]>=(WR
MMT_75#*Z9YRA<4V'F%D'H<:(+;B4'XFRH%3:A*""HR=O^J-8:M=+NJ-3WR_$
M*Z@W<;A4U#(*B3\%.ISP$R?]5H;1M'#&KF@U^K:2I14F.D Y)G$YW[1D*DGA
MH/U%U=14)I:-^JJ6P? HZ=(+[R\=*4=1 !43)4H](!D[<23IBW732UJ8U;S&
MM!TQ:G"LT*;O4(6BZ.-02S2IINI=0Z52@M(!4()40""5:X\PM2:\2\URKL;%
MP3:3-X=J_#%):4>!XK8;HVWS4$O($)\122# ""3Q+&AWJV]::M-UNU JVW"I
MIPJKH2A: TZ%%*RE"QU!*R.M()D)(WX?35&A)^Z3L1/_ &C'EGN /EC<\5DY
MCMVW3.KK7K;4]GN&H+2JKN[+Z*-CWQ-.U0.NT5NI665A3:6J5Y@55>$#K4Y4
M2Y@( =7+_4MFU)KNH/+ZD^S]/W#3**J^^/;S14XNU/6I\&I0RH)"' W5B@+G
MPLO.EXH!\):S8&I3X8;;D*<53+=4M((1^K* 2F,0H+3T;R1,QQ'%T?>JU*8;
M<*RCX5($B1,=1CO!SZ=N#J-*!VA0^"#4)SX<&4F)S()@DYG$<//26GW6WFD*
M3EP]1(3DC,B8WWSCBRUALRVT(3TF$Q ,29P"?(1()C^'$B45MR"1)P"H@P!!
M^[C;'S\^W#4YA\TN7/*2WT]?KS4-+:$UG4**D"'*NYUWAA)<516^G2NH>;;.
M%NE"&43!<!QQKR\YJ<N^;5JJ+IH#45+>F:1P,UM.A+E-7T+BQA-;0OA+[(6)
M\-?2IM4&%R.GA5N]9;*&!67"CI75 +0W4U+++BD@QU);6L.*$@)*DI*001/;
MAD7#4MC*U-IKJ=QIM!6_7(?971,*,]#3KR5D>,L)40T)6 F5)\T&IU+9:9RB
M:76I<5<$M.4Q8;<?0IE\A++SBVTJ2TRZ2 A;A2%$B >%!Y !P/A4)!\B?+OZ
MQY#@-#74H) ))()V/:,[  8^??@^VA* $@>DXDGS/UXK5[;RRGV1^<J4X_S+
M8@3,[ZUTU((B.V/D8\^.$/221!V&XV'G!Q,F?ZP!$I(DF8F.V1Y[;^I\^+":
M(UOH.GL=@T[J>CJD4C-<ZU?6&:2B52W"BJ:AMQ=P=JRTJX(K:2G2MNF;9>#1
M6I)*8ZI>U'S7Y&6^GN5*SRW<<8JZ5QAJG7X*DAZF+J:1YRH<ZGUHJ%)IWWVT
M*002XV"1'#4MW,_05OHM;,TNG':5J^.5#UKM"*:AJ*'KJ[*NA2S4/U#3E2PQ
M17!:;@PFG6E16TE*B03Q&]ZU@FOUX=662V-T/4NUNHME(PEAHN4EOHZ:K0VQ
M3@!+52\P^X4H22.N5 F9*WVY6-5;>7J2FNR?MM_WIYBMZ6%T86[[PIM)Z0JH
M4VI10AQQ(!;3/2"K@>SV#1EP32/U.KU6U:JME%3;ZZW.*=#9<2%J;JFE>% 0
M5**E(/3&0>)BU%IVS4-17M6*ILZJJKMJ6:TGQ/<ZNU-AI(%&\@AD^)"&W74=
M2EN]22D3'%87TH2^\A*5);0ZZE(6(<2D.*2E*NQ4D#/J#VP9B]FH)/M+\@8!
M(_Y1:49Q$VNY$^6T#S\MN/J-"5;0-C'S)G8]A'R''BPH@2,G'IDC;'R.W;MO
MPG5%M2[,I )/E@P1M@X[C/;BM-\I2J^WD],C[6N4;!)_RQX$2-L'>8Q/!-%$
MKL (\A!^1_"3WWGT--6M:E G:))Q^&V?,[B.%!%M:09,=0V\OF=L^6/RQQAR
MC2GJ)"",Y @R?/;>!D @$'RXJQSLYBN,U!T#I1XKN]>$L7>JIE%2Z-AX]*J5
MM:,IJ'D$APB%-MDY!)X#T'I_[!IJ2S6IDU%]N/0BH=91XCK7B@#PFB 3XJ^Y
MD= )ZR8GCHIRSTOI/E99$:LYB76WVMM" \?>U]2E.!((8HZ5(75W&K6J$ENG
M;<45J/40F3QS*_2'<C^67M9ZILW-SDU5ZGT/SLTS;&[?2UM]L3MNTGKJW4#B
MG*&CKWV'G*JU5[8*FZ"YK9*0%H;J$%N2GE/I3G!K"GU17:'Y@)KM,:]TZM5M
MKK/?'5TRT/4XZ9:4M7AEM] #M'44ZE4U4E:%MK(5@I[0^OZ/4UHTRP]7!N]6
MVMZ$71) K&:=24EQIQT_K5,B 0A2BA)GIB8XJ?3T^KK_ %;E=2UR[G3VYU3C
M"B5(:4O8N/D2MQ*4F0C )\^SK3II574-5Q":=U]M**UE"^JCJ'DC+K;D LO
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M\LA*%^4CI $?O!!@_P M\\,FK&%".Q).8QM)WSW,_+A!."?F>,<&6$@E)/\
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MJ[*9*'*9""I74V'#U+<PF#T)QL^KCI^SWMRG=N=MHZYRD433*J:=I_PPK+B
M'$JE"_VD'X2>V."EOT'IBVWA=[H;33T]>IA;%.XE)#5(AR"XFE:^XR' /B*
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M(X/TNDM,D@#3EAR,#['MP\_.G!. 8),D# X<[.C]+@)*M.6 X _]#6_/J?\
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M!5&1$SOY_(_C)FK52UX27&TRF%!1[1$$F,D;]^W&S3K3 (; 5B HR2/D1O\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6818055808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail) - Antengene Therapeutics Limited [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 23, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination prior notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LicenseAgreementTerminationDescription', window );">License agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">License Agreement may be terminated earlier by (i)&#160;either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii)&#160;Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days&#8217; prior notice or (iii)&#160;us in the event Antengene challenges or assists with a challenge to certain of our patent rights.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Development Milestone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Milestone payments receivable</a></td>
<td class="nump">$ 105.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Sales Milestone Events [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPotentialFutureMilestonePayments', window );">Milestone payments receivable</a></td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_PotentialCommercialMilestonePayments', window );">Commercial milestone payments receivable</a></td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Development Goals [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPotentialFutureMilestonePayments', window );">Milestone payments receivable</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_SelinexorMember', window );">Selinexor [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_EltanexorMember', window );">Eltanexor [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_KPT9274Member', window );">KPT-9274 [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_VerdinexorMember', window );">Verdinexor [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember', window );">Up-front Payment Arrangement [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payments</a></td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_LicenseAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_LicenseAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_PotentialCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_PotentialCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition potential future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kpti_AntengeneTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kpti_AntengeneTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_DevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_DevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_SalesEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_SalesEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_DevelopmentGoalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_DevelopmentGoalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_SelinexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_SelinexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_EltanexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_EltanexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_KPT9274Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_KPT9274Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_VerdinexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_VerdinexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821798944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,291<span></span>
</td>
<td class="nump">$ 17,275<span></span>
</td>
<td class="nump">$ 20,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember', window );">Employee And Non Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised | $ | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair values of options granted (in dollars per share) | $ / shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.01<span></span>
</td>
<td class="nump">$ 8.91<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense related to unvested stock options including estimated forfeitures | $ | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares Underlying RSUs, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense related to unvested stock options including estimated forfeitures | $ | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RightsReceivedForEachRestrictedShareUnit', window );">Rights Received For Each Restricted Share Unit | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments', window );">Service condition that vest in equal annual installment | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares Underlying RSUs, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_TwothousandtenstockoptionplanmemberMember', window );">2010 Plan [Member] | Employee And Non Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_TwothousandtenstockoptionplanmemberMember', window );">2010 Plan [Member] | Employee And Non Employee Stock Option [Member] | Percent Vesting One Calendar Year from Vesting Start Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_TwothousandtenstockoptionplanmemberMember', window );">2010 Plan [Member] | Employee And Non Employee Stock Option [Member] | Percentage Vesting on the First Day of each Month after One Calendar Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.083%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_TwothousandtenstockoptionplanmemberMember', window );">2010 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_TwoThousandThirteenStockOptionPlanMember', window );">2013 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="nump">969,696<span></span>
</td>
<td class="nump">1,939,393<span></span>
</td>
<td class="nump">1,939,393<span></span>
</td>
<td class="nump">1,675,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual', window );">Annual increase in number of additional shares authorized under the Plan through December 31, 2023</a></td>
<td class="nump">1,939,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual', window );">Percentage applied to the outstanding shares as annual increase in the number of shares authorized for issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available under the 2013 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,373,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_TwoThousandThirteenStockOptionPlanMember', window );">2013 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan', window );">Number of additional shares authorized under the 2010 Plan</a></td>
<td class="nump">2,126,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance', window );">Percentage of shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Employee stock purchase plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2013, our shareholders approved an increase in the number of shares of common stock authorized for issuance pursuant to the ESPP to 242,424 shares of common stock, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of 484,848 shares of our common stock, 1% of the number of outstanding shares on such date, or an amount determined by the Board.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan, amount withheld from employees | $ | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock available for payment related to tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,257<span></span>
</td>
<td class="nump">98,770<span></span>
</td>
<td class="nump">57,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RightsReceivedForEachRestrictedShareUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rights received for each restricted share unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RightsReceivedForEachRestrictedShareUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedFromPriorStockIncentivePlan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedInPercentageAnnual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kpti_TwothousandtenstockoptionplanmemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kpti_TwothousandtenstockoptionplanmemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=kpti_VestingperiodonememberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=kpti_VestingperiodonememberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=kpti_VestingperiodtwomemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=kpti_VestingperiodtwomemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kpti_TwoThousandThirteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kpti_TwoThousandThirteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643415248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10. Product Revenue </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">To date, our only source of product revenue has been from the U.S. sales of XPOVIO, which we began shipping to our customers in July 2019. The following table summarizes activity in each of the product revenue allowance and reserve categories from the date of approval by the FDA through December&#160;31, 2019&#160;(in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Discounts&#160;and<br/> Chargebacks </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees,&#160;Rebates,<br/> and Other<br/> Incentives </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr>
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance at July&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision related to sales in the current year </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,657 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,318 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,209 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Credit and payments made </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,655</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(499</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,154</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-left: 0.26in; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Ending balance at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,002 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,819 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,055 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div>  <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Discounts, chargebacks, and returns are recorded as reductions of accounts receivable, and fees, rebates, and other incentives are recorded as a component of accrued expenses. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808205728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Segment Information </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. All of our revenue to date has been derived in the United States. All of our material long-lived assets reside in the United States. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On an ongoing basis, we evaluate our estimates, including estimates related to our net product revenue, clinical trial accruals, stock-based compensation expense, interest expense on our deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div>&#160;other reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Although we regularly assess these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. </div>&#160;</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Principles of Consolidation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements at December&#160;31, 2019 include the accounts of (i)&#160;Karyopharm Therapeutics Inc., (ii)&#160;Karyopharm Securities Corp. (&#8220;KPSC&#8221;, our wholly-owned Massachusetts corporation incorporated in December&#160;2013), (iii) Karyopharm Europe GmbH (our wholly-owned German Limited Liability Company, incorporated in September 2014), (iv) Karyopharm Therapeutics (Bermuda) Ltd. (our limited liability company, registered in Bermuda in March 2015), and (vi)&#160;Karyopharm Israel Ltd. (our wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div>owned Israeli subsidiary formed in June 2018). All intercompany balances and transactions have been eliminated in consolidation. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist primarily of demand deposit accounts and deposits in short-term money market funds. Cash equivalents are stated at cost, which approximates fair value. We consider all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. We do not hold any money market funds with significant liquidity restrictions that would be required to be excluded from cash equivalents. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We determine the appropriate classification of our investments in debt securities at the time of purchase. All of our securities are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div> investments are recorded at fair value, with unrealized gains or losses included in Accumulated Other Comprehensive Loss, exclusive of other-than-temporary impairment losses, if any. Short-term and long-term investments are composed of corporate debt securities, commercial paper, U.S. government agency securities and certificates of deposit.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Risk </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents and investments. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses, are presented at amounts that approximate fair value at December&#160;31, 2019 and 2018. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">valuation</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 86%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our cash equivalents are composed of money market funds. We measure these investments at fair value.&#160;The fair value of cash equivalents is determined based on &#8220;Level&#160;1&#8221; inputs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Items classified as Level&#160;2 within the valuation hierarchy consist of commercial paper, corporate debt securities, U.S. government agency securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level&#160;3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations&#8221;, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1)&#160;our estimates of the probability and timing of related events; (2)&#160;the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3)&#160;our risk-adjusted discount rate that includes a company specific risk premium; (4)&#160;our cost of debt; (5)&#160;volatility; and (6)&#160;the probability of a change in control occurring during the term of the instrument.&#160;Our embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations.&#8221; </div></div>  <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and liability </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%; padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-right: 5pt;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">206,494 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,114 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;&#8212;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial liability </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivative liability </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificate of deposit </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">289,060 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,179 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded<br/> Derivative<br/> Liability </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Addition of derivative related to deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 11%;">&#160;</td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative since issuanc<div style="display:inline;">e</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;">&#8212;</td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our <div style="letter-spacing: 0px; top: 0px;;display:inline;">L</div>evel 3 embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations&#8221;. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, net </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:hidden10173497">three</span> to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful economic lives of the related assets. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and any related gains or losses are reflected in the consolidated statements of operations. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell. We have not recorded an impairment in any period since inception. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred Rent </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from landlords related to our operating leases under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 840. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense. Tenant improvement allowances and other incentives were also recorded as deferred rent under ASC 840 through December&#160;31, 2018. Deferred rent and lease incentives are recorded as a reduction to our operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets as of December&#160;31, 2019.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We adopted Accounting Standards Update (&#8220;ASU&#8221;)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2014-09,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Revenue from Contracts with Customers</div></div>, as well as subsequent amendments, which were codified in ASC 606, on January&#160;1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder&#8217;s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects </div></div></div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the consideration which we expect to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div></div>&#160;</div> </div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Product Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following are the components of variable&#160;consideration related to product revenue: </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash discounts and distributor fees:</div></div>&#160;We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns:</div></div>&#160;Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product&#8217;s expiration date and ending twelve months after the product&#8217;s expiration date).&#160;We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&#160;Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chargebacks:</div></div>&#160;Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us.&#160;Our customers charge us for the discount provided to the healthcare entities.&#160;Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government rebates</div></div>: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (&#8220;VA&#8221;), the Department of Defense (&#8220;DOD&#8221;), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other incentives:</div></div>&#160;Other incentives offered by us include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> by the patient. We calculate the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on estimates of claims and the average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue reserves and allowances: </div></div>As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recorded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of December&#160;31, 2019 and, </div></div> </div>  <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">therefore, the transaction price was not reduced further during the year ended December&#160;31, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known. </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-style: normal; margin-top: 18pt; margin-bottom: 0px; font-size: 10pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">License and Asset Purchase Agreements </div></div></div></div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We generate revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain of our product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize the transaction price allocated to the license as revenue upon transfer of control of the license. We evaluate all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We utilize judgment to determine the transaction price. In connection therewith, we evaluate contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate </div> the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We then determine whether the performance obligations or combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. We evaluate the measure of progress, as applicable, for each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded within deferred revenue. Contract liabilities within deferred revenue are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </div></div>  <div style="width: 100%; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customers</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of December&#160;31, 2019, we determined an allowance for doubtful accounts was not required based upon our review of contractual payment terms and individual customer circumstances.</div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Such costs are generally recorded as costs of sales upon shipment. In connection therewith, we value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales requirements as cost of sales.&#160;The determination of whether inventory costs will be realizable is based on our estimates.&#160;If actual market conditions are less favorable than projected by us, additional write-downs of inventory may be required, which would be recorded as cost of sales. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of Sales </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. </div></div><div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Royalty Obligation </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We treat the liability related to net revenues, as discussed further in Note 15, as a deferred royalty obligation, amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense thereon using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty obligation, and record interest expense using the imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than </div></div></div> </div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized. </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are charged to expense as incurred and include, but are not limited to: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that help conduct clinical trials and preclinical studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">the cost of acquiring, developing and manufacturing clinical trial materials, including comparator drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">facility, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">costs associated with preclinical activities and regulatory operations.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are accordingly reflected in the financial statements as prepaid or accrued research and development. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources, and currently consists of net loss, unrealized gains and losses on investments and foreign currency translation adjustments.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Transactions </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The functional currency of our subsidiaries in Germany and Israel are the Euro and Shekel, respectively. Foreign currency transaction gains and losses are recorded in the consolidated statement of operations. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange losses of less than $0.1&#160;million were recorded in other income for the years ended December&#160;31, 2019, 2018 and 2017.</div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. We have evaluated available evidence and concluded that we may not realize the benefit of our deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets. We recognize interest and/or penalties related to income tax matters in income tax expense. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost plus profit margin basis. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) resulted in significant changes to the U.S. corporate income tax system.&#160;For additional details regarding this act, see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div>, &#8220;Income Taxes&#8221;. </div></div><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounting for Stock-Based Compensation </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We account for our stock-based compensation awards in accordance with FASB ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> including grants of employee stock options, restricted stock and restricted stock units, as<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">well</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> as modifications to existing stock options and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;), to be recognized in the consolidated statements of operations based on their fair values. We use the Black-Scholes option pricing model to determine the fair value of options granted. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense related to awards to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. Forfeitures are recognized as they occur. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Share </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Our potential dilutive shares, stock options, unvested restricted stock and restricted stock units are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%; padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></div> </td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,843,094 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,917,084 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,019,083 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock units </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">787,320 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25,000 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">253,100 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We have the option to settle the conversion obligation for our 3.00% convertible senior notes due 2025 (the &#8220;Notes&#8221;) in cash, shares or any combination of the two. As the Notes are not convertible as of December&#160;31, 2019, they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on our net loss position, there is no impact on the calculation of dilutive loss per share during the year ended December&#160;31, 2019.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Standards </div></div></div></div>&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In February 2016, the FASB issued ASU&#160;No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Leases (Topic&#160;842)</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02&#8221;),</div> which supersedes the lease guidance under FASB ASC Topic 840, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>, resulting in the creation of FASB ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;).<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>The FASB also issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> including ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-10, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Codification Improvements to Topic 842, Leases </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-10&#8221;)</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic&#160;842) Targeted</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Improvements </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11&#8221;),</div> which we collectively refer to as the new leasing standard. In summary, the new leasing standard requires that all lessees (i)&#160;recognize, on the balance sheet, liabilities to remit lease payments and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii)&#160;disclose qualitative and quantitative information about its leasing arrangements. We adopted the standard effective January&#160;1, 2019 using the optional transition method under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11</div> and, therefore, prior period financial information has not been retrospectively adjusted.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pursuant to the guidance under ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02,</div> we elected the optional package of practical expedients to leases that commenced prior to the effective date, which allowed us to not reassess: (i)&#160;whether expired or existing contracts contain leases; (ii)&#160;lease classification for any expired or existing leases; and (iii)&#160;initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of</div> <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">which we elected, including: (i)&#160;a policy to not record <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and leases on the balance sheet for short-term leases that qualify and (ii)&#160;a policy to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for certain classes of underlying assets on contracts entered into or modified after the effective date. We did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As summarized in the table below, the standard had a material impact on our condensed consolidated balance sheet as of December&#160;31, 2019, specifically through recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets of $11.7&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and lease liabilities of $16.0&#160;million for our existing operating lease for office space in Newton, MA on the effective date. The difference between the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and operating lease liabilities is due to the change in classification of deferred rent and lease incentives through December&#160;31, 2018 from liabilities to a reduction in our operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets. However, the standard did not have a material impact on our consolidated statement of operations and comprehensive loss for the twelve months ended December&#160;31, 2019, as expense for our existing operating leases continues to be recognized consistent with the recognition pattern before adoption of the new standard. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please refer to Note 9, &#8220;Commitments and Contingencies&#8221; for further information</div></div>.</div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 8%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> Prior to ASC<br/> 842 Adoption </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 842<br/> Adjustment</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> as Adjusted </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated balance sheet data (in thousands): </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div><br/> assets(1) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,711</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,711</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">390</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(390</div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3,922</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(3,922</div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities(3) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,175</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,175</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease<br/> liabilities(3) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,848</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,848</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> </div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 12pt; margin-bottom: 0px;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(1)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents capitalization of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, offset by reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(2)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(3)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents recognition of operating lease liabilities.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We implemented internal controls to enable the preparation of financial information upon adoption. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In June 2018, the FASB issued ASU&#160;No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation-Stock Compensation (Topic&#160;718): Improvements to Nonemployee Share-Based Payment Accounting</div></div> (&#8220;ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07&#8221;).</div> ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07</div> largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic&#160;718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance was adopted on January&#160;1, 2019 and it did not have a material impact on our consolidated financial statements.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In November 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-18, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and Topic 606</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> should be applied retrospectively to the date of initial application of ASC 606. We adopted this guidance effective January&#160;1, 2019 using the modified retrospective approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div>, &#8220;License and Asset Purchase Agreements,&#8221; were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.</div> <div style="width: 100%; font-size: 10pt;"><div style="text-align: left;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;text-indent: 4%;">In December 2019, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2019-12, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Simplifying the Accounting for Income Taxes</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12&#8221;).</div> The ASU removes the exception to the incremental approach for intraperiod allocation of tax expense when a company has a loss from continuing operations and income from other items that are not included in continuing operations, such as income recorded in Other Comprehensive Income. The general rule under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-20-45-7</div> is that the tax effect of pretax income or loss from continuing operations should be determined by a computation that does not consider the tax effects of items that are not included in continuing<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">operations</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> incremental approach). Previously, companies could consider the impact on a loss from continuing operations of items in discontinued operations or other comprehensive income. However, under the amended guidance, companies should not consider the effect of items outside of continuing operations in calculating the tax effect on continuing operations. The new guidance is effective for public business entities with fiscal years, and the related interim periods, beginning after December&#160;15, 2020. For other entities, the ASU is effective for fiscal years beginning after December&#160;15, 2021, and interim periods within fiscal years beginning after December&#160;15, 2022. The guidance in the ASU may be adopted prior to the effective date. We adopted this guidance effective January&#160;1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-13, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#8217;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019. We do not expect the adoption of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> to have a material impact on our consolidated financial statements. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">In August 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-13, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement&#8212;Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> modify the disclosure requirements on fair value measurements in ASC&#160;820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> to have a material impact on our consolidated financial statements</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In August 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-15, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40)</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15&#8221;).</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> to have a material impact on our consolidated financial statements.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808223632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AccruedExpensesDisclosureTextTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6. Accrued Expenses </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,122 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,903</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Payroll and employee-related costs </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,630 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,103</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Professional fees </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,172 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,931</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">I</div>nterest</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,371</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="text-align: right; padding-left: 0px; background-color: rgb(255, 255, 255); padding-right: 5pt;">&#8212;</td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,583 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,556 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,878 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;&#160;&#160;&#160;&#160;<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;32,493</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_AccruedExpensesDisclosureTextTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_AccruedExpensesDisclosureTextTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822196800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Financial Assets That Have Been Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 206,494<span></span>
</td>
<td class="nump">$ 289,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">89,079<span></span>
</td>
<td class="nump">143,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">43,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | US Government and Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">19,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=kpti_LongTermInvestmentsMember', window );">Long-term [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">71,380<span></span>
</td>
<td class="nump">76,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Short-term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Long-term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">2,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">71,380<span></span>
</td>
<td class="nump">76,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">71,380<span></span>
</td>
<td class="nump">76,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">135,114<span></span>
</td>
<td class="nump">212,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">89,079<span></span>
</td>
<td class="nump">143,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">43,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term [Member] | US Government and Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">19,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Long-term [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Certificates of Deposit [Member] | Short-term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Certificates of Deposit [Member] | Long-term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">2,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=kpti_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=kpti_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6646538752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock', window );">Schedule of Components of Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of loss before income taxes were as follows (in thousands): </div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt; text-align: right;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt;page-break-inside: avoid;background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(23,350 </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28,689</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(35,680</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(176,200 </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(149,692</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(93,241</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Totals </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(199,550 </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(178,381</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(128,921</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Company's Deferred Tax Assets</a></td>
<td class="text">The significant components of our deferred tax assets are comprised of the following (in thousands):
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and state net operating loss carryforwards </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">150,909 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">116,236 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,914 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,228 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Accruals and other temporary differences </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,212 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,605 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">62,374 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">49,307 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Capitalized research and development </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,021 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,388 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets and intangibles </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,893 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,422 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,051 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">527 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Foreign net operating loss carryforwards </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr>
<td style="padding: 0in; width: 69%;;vertical-align:top;"><div style="margin: 0in 0in 0in 0in;text-indent: -1em;margin-left: 3em;line-height: normal;font-family: Calibri, sans-serif;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Lease liability </div></div></td>
<td style="padding: 0in; width: 6%;;vertical-align:top;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">3,443</div></div></td>
<td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; width: 5%;;vertical-align:top;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin: 0in 0in 0in 3em; text-indent: -1em; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty embedded derivative</div>&#160;</div></td>
<td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">533</div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; margin-top: 0px; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt;;text-align:right;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(224,943 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(173,247</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,411 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,538 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Convertible debt amortization </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(13,431 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,538</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 69%;;vertical-align:top;"><div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 0in;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;margin-left: 3em;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use asset </div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 6%;;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(2,462</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">) </div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 5%;;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in 2pt 0in 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 3em;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty obligation </div></div></td>
<td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(518</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">) </div></div></td>
<td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,411 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,538</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%; padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 5%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 5%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Federal income tax expense at statutory rate </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">State income tax, net of federal benefit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.7</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.7</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.9</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.5</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3.9</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development credit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7.8</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2.5</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(9.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(25.9</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28.2</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustments </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.6</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.6</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Federal rate change </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.3</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(33.2</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 15px; vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components Of Income Loss Before Income Taxes Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6645281136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14. Income Taxes </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">New Tax Legislation </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;). This legislation reduced the U.S. corporate tax rate from the current rate of 34% to 21% for tax years beginning after December&#160;31, 2017. As a result of the enacted law, we were required to revalue deferred tax assets and liabilities existing as of December&#160;31, 2017 from the 34% federal rate in effect through the end of 2017, to the new 21% rate.&#160;We have recognized the impact of the TCJA in these consolidated financial statements and related disclosures. In the year ended December&#160;31, 2018, we recorded an impact of $0.5&#160;million related to the return to provision items for federal rate change, which is offset by a full valuation allowance. The impact of the remeasurement of our U.S. deferred tax assets and liabilities to 21% resulted in the reduction of deferred tax assets of approximately $42.7&#160;million, which is offset by a full valuation allowance.&#160;There was no impact to our income statement due to the reduction in the U.S. corporate tax rate. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2019, 2018 and 2017, we recorded an income tax expense of less than $</div></div>0.1<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million for our operations in Germany. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost-plus profit margin. </div></div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of loss before income taxes were as follows (in thousands): </div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt; text-align: right;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt;page-break-inside: avoid;background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(23,350 </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28,689</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(35,680</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(176,200 </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(149,692</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(93,241</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding: 0pt 0pt 0.5px; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 54%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Totals </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(199,550 </div></div></td>
<td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(178,381</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(128,921</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 54%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The significant components of our deferred tax assets are comprised of the following (in thousands): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and state net operating loss carryforwards </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">150,909 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">116,236 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,914 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,228 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Accruals and other temporary differences </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,212 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,605 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">62,374 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">49,307 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Capitalized research and development </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,021 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,388 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets and intangibles </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,893 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,422 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,051 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">527 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 69%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Foreign net operating loss carryforwards </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr>
<td style="padding: 0in; width: 69%;;vertical-align:top;"><div style="margin: 0in 0in 0in 0in;text-indent: -1em;margin-left: 3em;line-height: normal;font-family: Calibri, sans-serif;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Lease liability </div></div></td>
<td style="padding: 0in; width: 6%;;vertical-align:top;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">3,443</div></div></td>
<td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; width: 5%;;vertical-align:top;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin: 0in 0in 0in 3em; text-indent: -1em; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty embedded derivative</div>&#160;</div></td>
<td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">533</div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; margin-top: 0px; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt;;text-align:right;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-bottom: 0px; line-height: normal; font-family: &quot;Times New Roman&quot;, serif; font-size: 10pt; margin-top: 0px;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(224,943 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(173,247</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,411 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,538 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Convertible debt amortization </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(13,431 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,538</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 69%;;vertical-align:top;"><div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 0in;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;margin-left: 3em;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use asset </div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 6%;;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(2,462</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">) </div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 5%;;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="background: rgba(255, 255, 255, 0); padding: 0in 2pt 0in 0in;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 3em;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Deferred royalty obligation </div></div></td>
<td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(518</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">) </div></div></td>
<td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,411 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(15,538</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax assets </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 69%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December&#160;31, 2019 and 2018. The valuation allowance increased </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately $51.7 </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million during the year ended December&#160;31, 2019 to $224.9&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, from $173.2&#160;million during the year ended December&#160;31, 2018, primarily due to the generation of net operating losses. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 12pt;">&#160;</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%; padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 5%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 5%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/>December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Federal income tax expense at statutory rate </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">34.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">State income tax, net of federal benefit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.7</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.7</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.9</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Permanent differences </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.5</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3.9</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development credit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7.8</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2.5</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(9.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(25.9</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28.2</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustments </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.6</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.0</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(0.6</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1.4</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Federal rate change </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.3</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(33.2</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 72%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt; height: 15px; vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 72%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2018, we had U.S. federal net operating loss carryforwards of approximately $576.5&#160;million and $427.0&#160;million, respectively, which may be able to offset future income tax liabilities. Of the $</div></div>576.5<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million carryforward as of December&#160;31, 2019, $</div></div>283.6<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of the carryforward has an indefinite life and</div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div>292.9<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million will expire at various dates through 2037. As of December&#160;31, 2019 and 2018, we had U.S. state net operating loss carryforwards of approximately $502.3&#160;million and </div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">$</div>414.8<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, which may be available to offset future state income tax liabilities and expire at various dates through 203<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. Also as of December&#160;31, 2019, we had foreign net operating loss carryforwards of less than</div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div>0.1<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, which <div style="letter-spacing: 0px; top: 0px;;display:inline;">have an indefinite li<div style="letter-spacing: 0px; top: 0px;;display:inline;">fe and </div></div>may be able to offset future foreign income tax liabilities.</div></div></div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019 and 2018, we had federal research and development tax credit carryforwards of approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">58.5&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div>46.9<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, available to reduce future tax liabilities, which expire at various dates through 203<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. As of December&#160;31, 2019 and 2018, we had state research and development tax credit carryforwards of approximately $</div></div>4.9<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div>3.0<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, available to reduce future tax liabilities, which expire at various dates through 203<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div>. We completed a study of R&amp;D tax credits through December&#160;31, 2018 and adjusted our deferred tax asset for the result of that study.&#160;For the year ending December&#160;31, 2019, we generated research credits but have not conducted a study to document the qualified activities. This study may result in an adjustment to our research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against our research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a <span style="-sec-ix-hidden:hidden10534998">three</span>-year period in excess of 50&#160;percent, as defined under Sections&#160;382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of us immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Previously, we have completed several financings since our inception, which resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code. We completed a Section&#160;382 analysis through July&#160;31, 2015 and subsequently reduced our deferred tax assets for tax attributes we believe will expire unused. We updated our Section&#160;382 analysis through December&#160;31, 2019 and confirmed there were no ownership changes since July&#160;31, 2015. In the future, we may complete financings that could result in a change in control, </div></div><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">which will reduce our deferred tax assets for tax attributes we believe will expire unused due to the change in control limitations. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In October 2016 the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-16.</div> This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this standard on January&#160;1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional deferred tax assets of approximately $19.2&#160;million which were offset by a corresponding valuation allowance.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2019 and 2018, we had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We or one of our subsidiaries file income tax returns in the United States, and various state and foreign jurisdictions. The federal, state and foreign income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2019. To the extent we have tax attribute<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">carryforwards</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622181760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; padding: 0px;"/>
<td style="width: 3%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 3%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 3%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful<br/>Life Years </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">593 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">593 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">654 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">607 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Office and computer equipment </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">598 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">559 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,443 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,397 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,288 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,156 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,242</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,293</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,046 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,863 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808208896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=kpti_ConsultingAndHistopathologyServicesMember', window );">Consulting and Histopathology Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses for consulting and histopathology services</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=kpti_ConsultingAndContractResearchServicesMember', window );">Consulting and Contract Research Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable or accrued expenses</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=kpti_ConsultingAndHistopathologyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=kpti_ConsultingAndHistopathologyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=kpti_ConsultingAndContractResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=kpti_ConsultingAndContractResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822566224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments, Classified as Available-for-Sale (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 135,121<span></span>
</td>
<td class="nump">$ 212,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">135,114<span></span>
</td>
<td class="nump">212,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">89,110<span></span>
</td>
<td class="nump">143,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">89,079<span></span>
</td>
<td class="nump">143,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">39,004<span></span>
</td>
<td class="nump">44,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">43,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term [Member] | US Government and Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">4,990<span></span>
</td>
<td class="nump">19,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">19,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=kpti_LongTermInvestmentsMember', window );">Long-term [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">2,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 2,016<span></span>
</td>
<td class="nump">$ 2,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=kpti_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=kpti_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6975206624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">65,370,448<span></span>
</td>
<td class="nump">60,829,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">65,370,448<span></span>
</td>
<td class="nump">60,829,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6642909632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Controlled Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_StockIssuanceCosts', window );">Issuance of stock, issuance costs</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kpti_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kpti_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6975247952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations - Summary of Outstanding Balances of Convertible Notes (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component</a></td>
<td class="nump">$ 67,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember', window );">3% Convertible Senior Notes Due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal</a></td>
<td class="nump">172,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance', window );">Less: debt discount and issuance costs, net</a></td>
<td class="num">(62,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Net carrying amount</a></td>
<td class="nump">109,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component</a></td>
<td class="nump">$ 65,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentLiabilityComponentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Liability Component [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentLiabilityComponentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Unamortized Discount Premiumand Debt Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643074800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of RSU Activity (Detail) - Unvested Restricted Stock Units [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Underlying RSUs, Unvested beginning balance | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares Underlying RSUs, Granted | shares</a></td>
<td class="nump">1,065,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares Underlying RSUs, Forfeited | shares</a></td>
<td class="num">(286,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares Underlying RSUs, Vested | shares</a></td>
<td class="num">(17,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Underlying RSUs, Unvested ending balance | shares</a></td>
<td class="nump">787,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested beginning balance | $ / shares</a></td>
<td class="nump">$ 9.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">9.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">8.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested ending balance | $ / shares</a></td>
<td class="nump">$ 9.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6644241344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">$ (23,350)<span></span>
</td>
<td class="num">$ (28,689)<span></span>
</td>
<td class="num">$ (35,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">(176,200)<span></span>
</td>
<td class="num">(149,692)<span></span>
</td>
<td class="num">(93,241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Totals</a></td>
<td class="num">$ (199,550)<span></span>
</td>
<td class="num">$ (178,381)<span></span>
</td>
<td class="num">$ (128,921)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>33
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d853399d10k.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 222,
   "dts": {
    "calculationLink": {
     "local": [
      "kpti-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kpti-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d853399d10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kpti-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kpti-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "kpti-20191231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 637,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 2,
    "http://www.karyopharm.com/20191231": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 12
   },
   "keyCustom": 73,
   "keyStandard": 390,
   "memberCustom": 37,
   "memberStandard": 41,
   "nsprefix": "kpti",
   "nsuri": "http://www.karyopharm.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.karyopharm.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Property and Equipment, net",
     "role": "http://www.karyopharm.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Investments",
     "role": "http://www.karyopharm.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Inventory",
     "role": "http://www.karyopharm.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:AccruedExpensesDisclosureTextTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Accrued Expenses",
     "role": "http://www.karyopharm.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:AccruedExpensesDisclosureTextTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Related Party Transactions",
     "role": "http://www.karyopharm.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Stockholders' Equity",
     "role": "http://www.karyopharm.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "role": "http://www.karyopharm.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Product Revenue",
     "role": "http://www.karyopharm.com/role/ProductRevenue",
     "shortName": "Product Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_LicenseAndAssetPurchaseAgreementsMembersrtProductOrServiceAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - License and Asset Purchase Agreements",
     "role": "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements",
     "shortName": "License and Asset Purchase Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_LicenseAndAssetPurchaseAgreementsMembersrtProductOrServiceAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Stock-based Compensation",
     "role": "http://www.karyopharm.com/role/StockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - 401(k) Plan",
     "role": "http://www.karyopharm.com/role/KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Income Taxes",
     "role": "http://www.karyopharm.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Long-Term Obligations",
     "role": "http://www.karyopharm.com/role/LongTermObligations",
     "shortName": "Long-Term Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.karyopharm.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Investments (Tables)",
     "role": "http://www.karyopharm.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Inventory (Tables)",
     "role": "http://www.karyopharm.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "kpti:AccruedExpensesDisclosureTextTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.karyopharm.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "kpti:AccruedExpensesDisclosureTextTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Commitments and Contingencies  (Tables)",
     "role": "http://www.karyopharm.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies  (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_XpovioMembersrtProductOrServiceAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Product Revenue (Tables)",
     "role": "http://www.karyopharm.com/role/ProductRevenueTables",
     "shortName": "Product Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_XpovioMembersrtProductOrServiceAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Income Taxes (Table)",
     "role": "http://www.karyopharm.com/role/IncomeTaxesTable",
     "shortName": "Income Taxes (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Long-Term Obligations (Tables)",
     "role": "http://www.karyopharm.com/role/LongTermObligationsTables",
     "shortName": "Long-Term Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Organization and Operations - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail",
     "shortName": "Organization and Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segments",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Financial Assets That Have Been Measured at Fair Value (Details)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Financial Assets That Have Been Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Summary of Significant Accounting Policies - The Changes in the Estimated Fair Value of Our Embedded Derivative Liability - (Details)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails",
     "shortName": "Summary of Significant Accounting Policies - The Changes in the Estimated Fair Value of Our Embedded Derivative Liability - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect (Detail)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure -  Summary of Significant Accounting Policies- Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842 (Detail)",
     "role": "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail",
     "shortName": "Summary of Significant Accounting Policies- Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn01_01_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
     "shortName": "Property and Equipment, net - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Property and Equipment, net - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Investments - Summary of Investments, Classified as Available-for-Sale (Detail)",
     "role": "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
     "shortName": "Investments - Summary of Investments, Classified as Available-for-Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Securities",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Investments - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail",
     "shortName": "Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Securities",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Inventory - Schedule of Inventory Current (Detail)",
     "role": "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail",
     "shortName": "Inventory - Schedule of Inventory Current (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "kpti:AccruedExpensesDisclosureTextTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kpti:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "role": "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "kpti:AccruedExpensesDisclosureTextTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kpti:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Stockholders' Equity - Controlled Equity Offering Sales Agreement - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Controlled Equity Offering Sales Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRentCreditNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Rent Payments Under Lease Agreement (Detail)",
     "role": "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail",
     "shortName": "Commitments and Contingencies - Schedule of Minimum Future Rent Payments Under Lease Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "kpti:RevenueRecognitionDiscountsAndChargeBacks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Product Revenue -  Schedule of Product Discounts Returns Allowances Reconciliation (Detail)",
     "role": "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail",
     "shortName": "Product Revenue -  Schedule of Product Discounts Returns Allowances Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "kpti:RevenueRecognitionDiscountsAndChargeBacks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail)",
     "role": "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
     "shortName": "License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2018To03_31_2018_BiogenMAIncMembersrtMajorCustomersAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - License and Asset Purchase Agreements - Additional Information - Biogen Asset Purchase Agreement (Detail)",
     "role": "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
     "shortName": "License and Asset Purchase Agreements - Additional Information - Biogen Asset Purchase Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2018To03_31_2018_BiogenMAIncMembersrtMajorCustomersAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P04_01_2019To06_30_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - License and Asset Purchase Agreements - Additional Information - Ono License Agreement (Detail)",
     "role": "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
     "shortName": "License and Asset Purchase Agreements - Additional Information - Ono License Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P04_01_2019To06_30_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Net Loss Per Share - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail",
     "shortName": "Net Loss Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Stock-based Compensation - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Stock-based Compensation - Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards (Detail)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail",
     "shortName": "Stock-based Compensation - Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity for Employees and Nonemployees (Detail)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail",
     "shortName": "Stock-based Compensation - Summary of Stock Option Activity for Employees and Nonemployees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Each Employee and Non-employee Stock Award on Grant Date Using Black Scholes Option Pricing Model (Detail)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Each Employee and Non-employee Stock Award on Grant Date Using Black Scholes Option Pricing Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2016",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Condensed Consolidated Statement of Stockholders' Equity",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statement of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2016",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Detail)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail",
     "shortName": "Stock-based Compensation - Summary of RSU Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model (Detail)",
     "role": "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - 401(k) Plan - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/KPlanAdditionalInformationDetail",
     "shortName": "401(k) Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "-5",
      "lang": null,
      "name": "kpti:ProvisionForIncomeTaxesForFederalTaxRateChanges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail)",
     "role": "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets (Detail)",
     "role": "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes (Detail)",
     "role": "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Long-Term Obligations - Additional Information (Detail)",
     "role": "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
     "shortName": "Long-Term Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P10_16_2018To10_16_2018",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Long-Term Obligations - Summary of Outstanding Balances of Convertible Notes (Detail)",
     "role": "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail",
     "shortName": "Long-Term Obligations - Summary of Outstanding Balances of Convertible Notes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentAnnualPrincipalPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "kpti:ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Long-Term Obligations - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail)",
     "role": "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail",
     "shortName": "Long-Term Obligations - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "kpti:ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "kpti:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "kpti:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Long-Term Obligations - Summary of Future Minimum Payments on Convertible Notes (Detail)",
     "role": "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail",
     "shortName": "Long-Term Obligations - Summary of Future Minimum Payments on Convertible Notes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Organization and Operations",
     "role": "http://www.karyopharm.com/role/OrganizationAndOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d853399d10k.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "GERMANY",
        "verboseLabel": "Germany [Member]"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "EntityInteractiveDataCurrent"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "kpti_AccountingPoliciesAndGeneralInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Policies And General Information [Line item].",
        "label": "Accounting Policies And General Information [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesAndGeneralInformationLineItems",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_AccountingPoliciesAndGeneralInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting policies and general information [Table].",
        "label": "Accounting Policies And General Information [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesAndGeneralInformationTable",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_AccruedExpensesDisclosureTextTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued expenses disclosure text block.",
        "label": "Accrued Expenses Disclosure Text [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesDisclosureTextTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_AdjustmentsForChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments For Change In Accounting Principle [Line Items]",
        "label": "Adjustments For Change In Accounting Principle [Line Items]",
        "terseLabel": "Adjustments For Change In Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "AdjustmentsForChangeInAccountingPrincipleLineItems",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_AdjustmentsForChangeInAccountingPrincipleTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments For Change In Accounting Principle [Table]",
        "label": "Adjustments For Change In Accounting Principle [Table]",
        "terseLabel": "Adjustments For Change In Accounting Principle [Table]"
       }
      }
     },
     "localname": "AdjustmentsForChangeInAccountingPrincipleTable",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_AggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate offering price.",
        "label": "Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "AggregateOfferingPrice",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_AntengeneTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Antengene Therapeutics Limited.",
        "label": "Antengene Therapeutics Limited [Member]",
        "terseLabel": "Antengene Therapeutics Limited [Member]"
       }
      }
     },
     "localname": "AntengeneTherapeuticsLimitedMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset purchase agreement.",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available for sale securities accumulated gross unrealized loss before tax other than temporary impairments.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments",
        "terseLabel": "Unrealized losses, other-than-temporary impairments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen MA Inc.",
        "label": "Biogen MA Inc [Member]",
        "terseLabel": "Biogen MA Inc [Member]"
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cantor Fitzgerald And Co",
        "label": "Cantor Fitzgerald And Co [Member]",
        "terseLabel": "Cantor Fitzgerald &amp; Co. [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash paid for amounts included in measurement of operating lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical development and regulatory milestone.",
        "label": "Clinical Development And Regulatory Milestone [Member]",
        "terseLabel": "Clinical Development and Regulatory Milestone [Member]"
       }
      }
     },
     "localname": "ClinicalDevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission percentage on gross proceeds from sale of shares.",
        "label": "Commission Percentage On Gross Proceeds From Sale Of Shares",
        "terseLabel": "Percentage of commission of gross proceeds from the sale of Shares"
       }
      }
     },
     "localname": "CommissionPercentageOnGrossProceedsFromSaleOfShares",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_CommonAreaMaintenanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Area Maintenance [Member]",
        "label": "Common Area Maintenance [Member]",
        "terseLabel": "Common Area Maintenance [Member]"
       }
      }
     },
     "localname": "CommonAreaMaintenanceMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components Of Income Loss Before Income Taxes Table [Text Block]",
        "label": "Components Of Income Loss Before Income Taxes [Table Text Block]",
        "verboseLabel": "Schedule of Components of Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentrations Of Credit Risk And Of Balance Sheet Risk Policy Text Block",
        "label": "Concentrations Of Credit Risk And Of Balance Sheet Risk Policy Text Block [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_ConsultingAndContractResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting And Contract Research Services [Member]",
        "label": "Consulting And Contract Research Services [Member]",
        "terseLabel": "Consulting and Contract Research Services [Member]"
       }
      }
     },
     "localname": "ConsultingAndContractResearchServicesMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_ConsultingAndHistopathologyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting and histopathology services",
        "label": "Consulting And Histopathology Services [Member]",
        "terseLabel": "Consulting and Histopathology Services [Member]"
       }
      }
     },
     "localname": "ConsultingAndHistopathologyServicesMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_ControlledEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Controlled Equity Offering Sales Agreement [Member]",
        "terseLabel": "Controlled Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock.",
        "label": "Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock",
        "terseLabel": "Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument convertible threshold measurement period description.",
        "label": "Debt Instrument Convertible Threshold Measurement Period Description",
        "terseLabel": "Description of debt instrument convertible period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdMeasurementPeriodDescription",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_DebtInstrumentEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Estimated Fair Value",
        "label": "Debt Instrument Estimated Fair Value",
        "terseLabel": "Estimated fair value of convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentEstimatedFairValue",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DebtInstrumentLiabilityComponentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Liability Component [Abstract]",
        "label": "Debt Instrument Liability Component [Abstract]",
        "terseLabel": "Liability component:"
       }
      }
     },
     "localname": "DebtInstrumentLiabilityComponentAbstract",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument non convertible initial amount of liability component.",
        "label": "Debt Instrument Non Convertible Initial Amount Of Liability Component",
        "terseLabel": "Initial amount of liability component"
       }
      }
     },
     "localname": "DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DebtInstrumentRepurchasePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument repurchase price percentage.",
        "label": "Debt Instrument Repurchase Price Percentage",
        "terseLabel": "Notes, repurchase price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePricePercentage",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Unamortized Discount Premiumand Debt Issuance",
        "label": "Debt Instrument Unamortized Discount Premiumand Debt Issuance",
        "verboseLabel": "Less: debt discount and issuance costs, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt issuance costs allocated to liability component amortized to interest expense amortization period.",
        "label": "Debt Issuance Costs Allocated To Liability Component Amortized To Interest Expense Amortization Period",
        "terseLabel": "Debt discount and issuance costs amortized to interest expense, amortization period"
       }
      }
     },
     "localname": "DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt issuance costs allocated to liability component recorded as reduction of convertible notes.",
        "label": "Debt Issuance Costs Allocated To Liability Component Recorded As Reduction Of Convertible Notes",
        "terseLabel": "Debt issuance costs allocated to liability component and recorded as a reduction of convertible notes"
       }
      }
     },
     "localname": "DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredRoyaltyObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Royalty Obligation [Member]",
        "terseLabel": "Deferred Royalty Obligation [Member]"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_DeferredRoyaltyObligationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Royalty Obligation Noncurrent",
        "label": "Deferred Royalty Obligation Noncurrent",
        "terseLabel": "Deferred royalty obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationNoncurrent",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredRoyaltyObligationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred royalty obligation.",
        "label": "Deferred Royalty Obligation [Policy Text Block]",
        "terseLabel": "Deferred Royalty Obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationPolicyTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Asset Net Operating Loss Carry forwards Indefinite Life",
        "label": "Deferred Tax Asset Net Operating Loss Carry forwards Indefinite Life",
        "verboseLabel": "Net operating loss carryforwards indefinite life"
       }
      }
     },
     "localname": "DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsDeferredRoyaltyObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets deferred royalty obligation.",
        "label": "Deferred Tax Assets Deferred Royalty Obligation",
        "negatedLabel": "Deferred royalty obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredRoyaltyObligation",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsFixedAssetsAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets Fixed Assets And Intangibles.",
        "label": "Deferred Tax Assets Fixed Assets And Intangibles",
        "verboseLabel": "Fixed Assets and Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibles",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 15.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic and state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local",
        "verboseLabel": "U.S. and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets right of use asset.",
        "label": "Deferred Tax Assets Right of use Asset",
        "negatedLabel": "Right-of-use\u00a0asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseAsset",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 16.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets royalty embaded derivatives.",
        "label": "Deferred Tax Assets Royalty Embaded Derivatives",
        "terseLabel": "Deferred Tax Assets Royalty Embaded Derivatives"
       }
      }
     },
     "localname": "DeferredTaxAssetsRoyaltyEmbadedDerivatives",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and other temporary differences.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other Temporary Differences",
        "verboseLabel": "Accruals and other temporary differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Convertible Debt Amortization.",
        "label": "Deferred Tax Liabilities Convertible Debt Amortization",
        "negatedLabel": "Convertible debt amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleDebtAmortization",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_DevelopmentGoalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development goals.",
        "label": "Development Goals [Member]",
        "terseLabel": "Development Goals [Member]"
       }
      }
     },
     "localname": "DevelopmentGoalsMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_DevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development milestone.",
        "label": "Development Milestone [Member]",
        "terseLabel": "Development Milestone [Member]"
       }
      }
     },
     "localname": "DevelopmentMilestoneMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_EltanexorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eltanexor.",
        "label": "Eltanexor [Member]",
        "terseLabel": "Eltanexor [Member]"
       }
      }
     },
     "localname": "EltanexorMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_EmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee And Non Employee Stock Option [Member]",
        "label": "Employee And Non Employee Stock Option [Member]",
        "terseLabel": "Employee and Nonemployee Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Component Of Deferred Financing Costs Related To Convertible Debt",
        "label": "Equity Component Of Deferred Financing Costs Related To Convertible Debt",
        "terseLabel": "Equity component of deferred financing costs for 2025 notes"
       }
      }
     },
     "localname": "EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_EquityOfferingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity offering.",
        "label": "Equity Offering [Line Items]",
        "terseLabel": "Equity Offering [Line Items]"
       }
      }
     },
     "localname": "EquityOfferingLineItems",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_HealthcareRoyaltyPartnersIvLpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "HealthCare Royalty Partners IV LP [Member]",
        "terseLabel": "HealthCare Royalty Partners IV LP [Member]"
       }
      }
     },
     "localname": "HealthcareRoyaltyPartnersIvLpMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Disclosure.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_IncomeTaxDisclosureTableTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Disclosure Table",
        "label": "Income Tax Disclosure Table [Table]",
        "verboseLabel": "Income Tax Disclosure Table [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTableTable",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Jefferies LLC.",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC [Member]"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_KPT9274Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "KPT-9274.",
        "label": "KPT-9274 [Member]",
        "terseLabel": "KPT-9274 [Member]"
       }
      }
     },
     "localname": "KPT9274Member",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leases [Line Items]",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leases [Table]",
        "label": "Leases [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_LicenseAgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement, termination description.",
        "label": "License Agreement, Termination Description",
        "terseLabel": "License agreement termination description"
       }
      }
     },
     "localname": "LicenseAgreementTerminationDescription",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_LicenseAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement termination notice period.",
        "label": "License Agreement Termination Notice Period",
        "terseLabel": "License agreement termination prior notice period"
       }
      }
     },
     "localname": "LicenseAgreementTerminationNoticePeriod",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "kpti_LicenseAndAssetPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and Asset Purchase Agreements.",
        "label": "License and Asset Purchase Agreements [Member]",
        "terseLabel": "License and Asset Purchase Agreements [Member]"
       }
      }
     },
     "localname": "LicenseAndAssetPurchaseAgreementsMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_LicenseAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License And Other Revenue.",
        "label": "License And Other [Member]",
        "terseLabel": "License and other revenue"
       }
      }
     },
     "localname": "LicenseAndOtherMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Investments [Member]",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term [Member]"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Operating Loss Carryforwards Have Indefinite Expiration Date Respect To Foreign Operation.",
        "label": "Net Operating Loss Carryforwards Have Indefinite Expiration Date Respect To Foreign Operation",
        "verboseLabel": "Net operating loss carryforwards indefinite life remaining"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_OfficeAndResearchSpaceLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office and research space lease.",
        "label": "Office And Research Space Lease [Member]",
        "terseLabel": "Office and Research Space Lease [Member]"
       }
      }
     },
     "localname": "OfficeAndResearchSpaceLeaseMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_OnoPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ono Pharmaceutical Company Limited.",
        "label": "Ono Pharmaceutical Company Limited [Member]",
        "terseLabel": "Ono Pharmaceutical Co Ltd [Member]"
       }
      }
     },
     "localname": "OnoPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Open market sale agreement.",
        "label": "Open Market Sale Agreement [Member]",
        "terseLabel": "Open Market Sale Agreement [Member]"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered.",
        "label": "Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered",
        "verboseLabel": "Period over which certain cumulative changes in the ownership interest of significant shareholders will be considered, subject to an annual limitation of net operating loss and tax credit carryforwards"
       }
      }
     },
     "localname": "OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of cumulative changes in the ownership interest of significant shareholders that will be considered, subject to an annual limitation of net operating loss and tax credit carryforwards",
        "label": "Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered",
        "verboseLabel": "Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered"
       }
      }
     },
     "localname": "OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "kpti_PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of outstanding shares of common stock reserved for future issuance.",
        "label": "Percentage Of Outstanding Shares Of Common Stock Reserved For Future Issuance",
        "terseLabel": "Percentage of shares of common stock available for issuance"
       }
      }
     },
     "localname": "PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_PotentialCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential commercial milestone payments.",
        "label": "Potential Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments receivable"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePayments",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_PrincipalAmountOfNotesUsedInConversionRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Principal amount of notes used in conversion rate.",
        "label": "Principal Amount Of Notes Used In Conversion Rate",
        "terseLabel": "Principal amount of notes used in conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOfNotesUsedInConversionRate",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_PrincipalAmountPerNoteUsedInConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Principal Amount Per Note Used In Conversion Rate",
        "label": "Principal Amount Per Note Used In Conversion Rate",
        "terseLabel": "Principal amount of notes used in conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountPerNoteUsedInConversionRate",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ProceedsFromDeferredRoyaltyObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Deferred Royalty Obligation.",
        "label": "Proceeds From Deferred Royalty Obligation",
        "terseLabel": "Proceeds from deferred royalty obligation, net"
       }
      }
     },
     "localname": "ProceedsFromDeferredRoyaltyObligation",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ProceedsFromFirstInvestmentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First investment amount.",
        "label": "Proceeds From First Investment Amount",
        "terseLabel": "First investment amount"
       }
      }
     },
     "localname": "ProceedsFromFirstInvestmentAmount",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from issuance of convertible senior notes, net of issuance costs.",
        "label": "Proceeds From Issuance Of Convertible Senior Notes Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of convertible senior notes, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ProceedsFromPaymentsForCommonStockIssuanceNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from payments for common stock issuance net.",
        "label": "Proceeds From Payments For Common Stock Issuance Net",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForCommonStockIssuanceNet",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provision For Income Taxes For Federal Tax Rate Changes.",
        "label": "Provision For Income Taxes For Federal Tax Rate Changes",
        "verboseLabel": "Impact related to provision items for federal rate change"
       }
      }
     },
     "localname": "ProvisionForIncomeTaxesForFederalTaxRateChanges",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RegulatoryAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Assets [Abstract]",
        "label": "Regulatory Assets [Abstract]"
       }
      }
     },
     "localname": "RegulatoryAssetsAbstract",
     "nsuri": "http://www.karyopharm.com/20191231",
     "xbrltype": "stringItemType"
    },
    "kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related party transactions disclosure textBlock.",
        "label": "Related party transactions disclosure textBlock [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextblockTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_RevenueInterestFinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Revenue Interest Financing Agreement [Member]"
       }
      }
     },
     "localname": "RevenueInterestFinancingAgreementMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_RevenueRecognitionDiscountsAndChargeBacks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition discounts and charge backs.",
        "label": "Revenue Recognition Discounts And Charge Backs",
        "periodEndLabel": "Ending balance at December\u00a031, 2019",
        "periodStartLabel": "Beginning balance at July\u00a03, 2019"
       }
      }
     },
     "localname": "RevenueRecognitionDiscountsAndChargeBacks",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition discounts charge backs fees rebates other incentives and sales returns.",
        "label": "Revenue Recognition Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns",
        "periodEndLabel": "Ending balance at December\u00a031, 2019"
       }
      }
     },
     "localname": "RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionFeesRebatesAndOtherIncentives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition fees rebates and other incentives",
        "label": "Revenue Recognition Fees Rebates And Other Incentives",
        "periodEndLabel": "Ending balance at December\u00a031, 2019"
       }
      }
     },
     "localname": "RevenueRecognitionFeesRebatesAndOtherIncentives",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionPaymentsForChargeBacks": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition payments for charge backs.",
        "label": "Revenue Recognition Payments For Charge Backs",
        "terseLabel": "Credit and payments made"
       }
      }
     },
     "localname": "RevenueRecognitionPaymentsForChargeBacks",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition payments for discounts charge backs fees rebates other incentives and sales returns.",
        "label": "Revenue Recognition Payments For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns",
        "terseLabel": "Credit and payments made"
       }
      }
     },
     "localname": "RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition payments for fees rebates and other incentives",
        "label": "Revenue Recognition Payments For Fees Rebates And Other Incentives",
        "terseLabel": "Credit and payments made"
       }
      }
     },
     "localname": "RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionPotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition potential future milestone payments.",
        "label": "Revenue Recognition Potential Future Milestone Payments",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialFutureMilestonePayments",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition provision for discounts and charge backs.",
        "label": "Revenue Recognition Provision For Discounts And Charge Backs",
        "terseLabel": "Provision related to sales in the current year"
       }
      }
     },
     "localname": "RevenueRecognitionProvisionForDiscountsAndChargeBacks",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition provision for discounts charge backs fees rebates other incentives and sales returns.",
        "label": "Revenue Recognition Provision For Discounts Charge Backs Fees Rebates Other Incentives And Sales Returns",
        "terseLabel": "Provision related to sales in the current year"
       }
      }
     },
     "localname": "RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "revenue recognition provision for discounts and charge backs.",
        "label": "Revenue Recognition Provision For Fees Rebates And Other Incentives",
        "terseLabel": "Provision related to sales in the current year"
       }
      }
     },
     "localname": "RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition, sales returns, reserve for sales returns.",
        "label": "Revenue Recognition Sale Returns Reserve for Sale Returns",
        "terseLabel": "Provision related to sales in the current year"
       }
      }
     },
     "localname": "RevenueRecognitionSaleReturnsReserveForSaleReturns",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RevenueRecognitionSalesReturn": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition sales return.",
        "label": "Revenue Recognition Sales Return",
        "periodEndLabel": "Ending balance at December\u00a031, 2019"
       }
      }
     },
     "localname": "RevenueRecognitionSalesReturn",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_RightsReceivedForEachRestrictedShareUnit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights received for each restricted share unit.",
        "label": "Rights Received For Each Restricted Share Unit"
       }
      }
     },
     "localname": "RightsReceivedForEachRestrictedShareUnit",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Royalty Due On December Thirty One Two Thousand Twenty Four [Member]",
        "terseLabel": "Royalty Due On December 31, 2024 [Member]"
       }
      }
     },
     "localname": "RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Royalty Due On December Thirty One Two Thousand Twenty Two [Member]",
        "terseLabel": "Royalty Due On December 31, 2022 [Member]"
       }
      }
     },
     "localname": "RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_RoyaltyGuaranteesCommitmentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment percentage receiveable on future date.",
        "label": "Royalty Guarantees Commitments Percentage",
        "terseLabel": "Royalty Payable Percentage"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentage",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_RoyaltyPaymentDueDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Royalty Payment Due Date [Axis]"
       }
      }
     },
     "localname": "RoyaltyPaymentDueDateAxis",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_RoyaltyPaymentDueDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Royalty Payment Due Date [Domain]"
       }
      }
     },
     "localname": "RoyaltyPaymentDueDateDomain",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_RoyaltyPaymentsApplicableTieredPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Payments Applicable Tiered Percentage",
        "label": "Royalty Payments Applicable Tiered Percentage",
        "terseLabel": "Aggregate Royalties Percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentsApplicableTieredPercentage",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_SaleAgreementTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Agreement Termination Date",
        "label": "Sale Agreement Termination Date",
        "terseLabel": "Sales agreement term date"
       }
      }
     },
     "localname": "SaleAgreementTerminationDate",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "kpti_SalesEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales events.",
        "label": "Sales Events [Member]",
        "terseLabel": "Sales Milestone Events [Member]"
       }
      }
     },
     "localname": "SalesEventsMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales milestone.",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone [Member]"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of reconciliation of product discounts returns allowances.",
        "label": "Schedule Of Product Discounts Returns Allowances Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Product Discounts Returns Allowances Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Table]",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsTable",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Scheduleof Interest Expense Recognized Relatedto Convertible Notes Table [Text Block]",
        "label": "Scheduleof Interest Expense Recognized Relatedto Convertible Notes Table [Text Block]",
        "terseLabel": "Schedule of Interest Expense Recognized Related to Convertible Notes"
       }
      }
     },
     "localname": "ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "kpti_SecondInvestmentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second investment amount.",
        "label": "Second Investment Amount",
        "terseLabel": "Second investment amount"
       }
      }
     },
     "localname": "SecondInvestmentAmount",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_SelinexorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selinexor.",
        "label": "Selinexor [Member]",
        "terseLabel": "Selinexor [Member]"
       }
      }
     },
     "localname": "SelinexorMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installments",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installments",
        "terseLabel": "Service condition that vest in equal annual installment"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "kpti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnual",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedAnnual",
        "terseLabel": "Annual increase in number of additional shares authorized under the Plan through December 31, 2023"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedFromPriorStockIncentivePlan",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedFromPriorStockIncentivePlan",
        "terseLabel": "Number of additional shares authorized under the 2010 Plan"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "kpti_Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedInPercentageAnnual",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedInPercentageAnnual",
        "terseLabel": "Percentage applied to the outstanding shares as annual increase in the number of shares authorized for issuance"
       }
      }
     },
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "kpti_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the aggregate cost incurred directly with the issuance of an equity security.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Issuance of stock, issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017 Change In Tax Rate Reduction In Deferred Tax Assets.",
        "label": "Tax Cuts And Jobs Act Of 2017 Change In Tax Rate Reduction In Deferred Tax Assets",
        "verboseLabel": "Reduction in deferred tax asset"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "3% Convertible senior notes due two thousand twenty five.",
        "label": "Three Percentage Convertible Senior Notes Due Two Thousand Twenty Five [Member]",
        "terseLabel": "3% Convertible Senior Notes Due 2025 [Member]"
       }
      }
     },
     "localname": "ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligations",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsTables",
      "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_TwoThousandThirteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Thirteen Stock Option Plan [Member]",
        "label": "Two Thousand Thirteen Stock Option Plan [Member]",
        "terseLabel": "2013 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandThirteenStockOptionPlanMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_TwothousandtenstockoptionplanmemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandTenStockOptionPlanMember [Member]",
        "terseLabel": "2010 Plan [Member]"
       }
      }
     },
     "localname": "TwothousandtenstockoptionplanmemberMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of upfront payment received under research agreements.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "kpti_VerdinexorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Verdinexor.",
        "label": "Verdinexor [Member]",
        "terseLabel": "Verdinexor [Member]"
       }
      }
     },
     "localname": "VerdinexorMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_VestingperiodonememberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting period one member",
        "label": "VestingPeriodOneMember [Member]",
        "terseLabel": "Percent Vesting One Calendar Year from Vesting Start Date [Member]"
       }
      }
     },
     "localname": "VestingperiodonememberMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_VestingperiodtwomemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting period two member",
        "label": "VestingPeriodTwoMember [Member]",
        "terseLabel": "Percentage Vesting on the First Day of each Month after One Calendar Year [Member]"
       }
      }
     },
     "localname": "VestingperiodtwomemberMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "kpti_XpovioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "XPOVIO [Member]"
       }
      }
     },
     "localname": "XpovioMember",
     "nsuri": "http://www.karyopharm.com/20191231",
     "presentation": [
      "http://www.karyopharm.com/role/ProductRevenueTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r63",
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r148",
      "r219",
      "r224",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r146",
      "r219",
      "r222",
      "r409",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/ProductRevenue",
      "http://www.karyopharm.com/role/ProductRevenueTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/ProductRevenue",
      "http://www.karyopharm.com/role/ProductRevenueTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r121",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Restatement Adjustment [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "verboseLabel": "Scenario, Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r147",
      "r219",
      "r223",
      "r411",
      "r420",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r195",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]",
        "verboseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201616Member": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.",
        "label": "Accounting Standards Update 2016-16 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201616Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r25",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, Net",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r49"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43",
      "r188"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Less accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]",
        "verboseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Debt issuance costs allocated to equity component and recorded as a reduction to additional paid-in capital",
        "verboseLabel": "Equity component of 2025 Notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r232",
      "r234",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r234",
      "r264",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r85",
      "r99",
      "r342"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r81",
      "r99",
      "r344"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r99",
      "r344"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of the value of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities excluded from the calculation of diluted net loss per share due to anti-dilutive effect (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Office and laboratory space leased"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r143",
      "r377",
      "r398"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r62"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Loss",
        "terseLabel": "Unrealized losses , included in accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value",
        "terseLabel": "Aggregate fair value of debt securities with unrealized loss position for less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value",
        "terseLabel": "Aggregate fair value of corporate debt securities with continuous unrealized loss position for more than 12 months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r154",
      "r158",
      "r173"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r156",
      "r173"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r156",
      "r173"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year",
        "terseLabel": "Number of debt securities with unrealized loss position for less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investment positions in available-for-sale investments that have been in a continuous unrealized loss position for greater than or equal to a year for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year",
        "terseLabel": "Number of corporate debt securities with continuous unrealized loss position for more than 12 months"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r235",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationTables",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r316",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r40",
      "r101"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r102",
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r101",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r338"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r227",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r54",
      "r194",
      "r385",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares available for issuance under ESPP"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 65,370,448 and 60,829,308 shares issued and outstanding at December 31, 2019 and 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r72",
      "r74",
      "r75"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r307",
      "r313",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r215",
      "r216",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r215",
      "r216",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred Revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r19",
      "r380",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "verboseLabel": "Net carrying amount"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of liability of convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Note Offering [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of Outstanding Balances of Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r227",
      "r230",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notes converted in to common stock, shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Notes converted in to common stock, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Long-Term Obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r378",
      "r380",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligations",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsTables",
      "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r202",
      "r380",
      "r396"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component",
        "verboseLabel": "Equity component of convertible notes recognized as debt discount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Notes, conversion price per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleLatestDate1": {
     "auth_ref": [
      "r53",
      "r209",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Latest date when the debt instrument can be converted into equity, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Convertible, Latest Date",
        "terseLabel": "Debt instrument, convertible latest date"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleLatestDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument convertible threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Notes instrument, trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r343",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r51",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Notes, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r51",
      "r205",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt Instrument Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r52",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Notes, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligations",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsTables",
      "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Notes conversion price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r53",
      "r113",
      "r209",
      "r210",
      "r211",
      "r212",
      "r342",
      "r343",
      "r345",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail",
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Expected life of convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r342",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "verboseLabel": "Cash paid for interest on convertible debt"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Investments, Classified as Available-for-Sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Rent"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r44",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r287",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r49",
      "r346"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r55",
      "r346"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "positiveLabel": "Deferred rent, net of current portion",
        "terseLabel": "Deferred rent",
        "verboseLabel": "Deferred rent non-current"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "terseLabel": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]",
        "terseLabel": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r277",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r277",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "verboseLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r276",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 13.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Net operating loss carryforwards foreign",
        "verboseLabel": "Foreign net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r293",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r276",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail": {
       "order": 14.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, matching amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, matching percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r99",
      "r186"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r317",
      "r319",
      "r321",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r157",
      "r227",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security issued by corporation domiciled in United States of America (US).",
        "label": "Debt Security, Corporate, US [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "DomesticCorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r45",
      "r116",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Accounts payable or accrued expenses"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share\u2014basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r115",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate",
        "verboseLabel": "Federal income tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "verboseLabel": "Federal rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "verboseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "verboseLabel": "Provision to return adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r281",
      "r282",
      "r299"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "verboseLabel": "Research and development credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "verboseLabel": "Embedded derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument embedded in host contract.",
        "label": "Embedded Derivative Financial Instruments [Member]",
        "terseLabel": "Embedded Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee-related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Total unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Total unrecognized stock-based compensation expense related to unvested stock options including estimated forfeitures | $"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityContractMember": {
     "auth_ref": [
      "r227",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to share prices.",
        "label": "Equity Contract [Member]"
       }
      }
     },
     "localname": "EquityContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.",
        "label": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets That Have Been Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r227",
      "r228",
      "r230",
      "r325",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r230",
      "r325",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r230",
      "r325",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r230",
      "r325",
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r329",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r329",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Our Embedded Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value of derivative since issuance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Addition of derivative related to deferred royalty obligation"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements) [Abstract]",
        "terseLabel": "Financial Asset that have been measured at fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r107",
      "r333",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial liability"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Deferred royalty obligation at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r335",
      "r336",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r337",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r184",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r121",
      "r375",
      "r386",
      "r408"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Totals"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementCompensationItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Compensation Items [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementCompensationItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "verboseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "verboseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "verboseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "verboseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r142",
      "r300"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r107",
      "r279",
      "r280",
      "r285",
      "r286",
      "r292",
      "r301",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidRent": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Rent",
        "negatedLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r141",
      "r341",
      "r344",
      "r388"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r85",
      "r206"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r49"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r384",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "verboseLabel": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r59",
      "r179"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r60",
      "r107",
      "r130",
      "r180",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r34",
      "r182"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r83",
      "r140"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r376",
      "r391",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r6",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Allowance for improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r382",
      "r402"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Government Research Grant Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r203",
      "r380",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less: current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r117",
      "r198"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r117",
      "r198"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r117",
      "r198"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r117",
      "r198"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r117",
      "r198"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r97",
      "r100"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r71",
      "r73",
      "r80",
      "r100",
      "r128",
      "r387",
      "r407"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome": {
     "auth_ref": [
      "r119",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the effect of a change in accounting principle on net income.",
        "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income",
        "terseLabel": "Cumulative effect adjustment for adoption of new accounting guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r353",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "positiveTerseLabel": "Present value of minimum lease payments",
        "terseLabel": "Lease liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "positiveLabel": "Operating lease right-of-use assets",
        "terseLabel": "Operating lease and right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/OrganizationAndOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r49"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r64",
      "r339"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "presentationGuidance": "Unrealized gain (loss) on investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r49"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r89",
      "r91",
      "r155"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefits Disclosure [Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r235",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r93",
      "r267"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from the exercise of stock options and shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r89",
      "r90",
      "r155"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue",
        "verboseLabel": "Product Revenue [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.karyopharm.com/role/ProductRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r71",
      "r73",
      "r95",
      "r143",
      "r145",
      "r306",
      "r308",
      "r309",
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r43",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r107",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r42",
      "r187"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r189",
      "r404"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r107",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r20",
      "r381",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r20",
      "r381",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r25",
      "r31",
      "r403",
      "r414"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r149",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r229",
      "r359",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses for consulting and histopathology services"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r273",
      "r424"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r107",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "verboseLabel": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r13",
      "r101",
      "r106"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Short-term restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r5",
      "r16",
      "r101",
      "r106",
      "r421"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Long-term restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r213",
      "r401"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenues:",
        "verboseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Product Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "License and Asset Purchase Agreements",
        "verboseLabel": "Product Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements",
      "http://www.karyopharm.com/role/ProductRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r78",
      "r138",
      "r139",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r354",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan [Member]",
        "terseLabel": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r389",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Significant Components of Company's Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r234",
      "r263",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Minimum Future Rent Payments Under Lease Agreement"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Payments on Convertible Notes"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r43",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r111",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r235",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r242",
      "r253",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity for Employees and Nonemployees"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit in the form of a letter of credit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82",
      "r178"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling,General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r233",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description",
        "terseLabel": "Employee stock purchase plan, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares Underlying RSUs, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares Underlying RSUs, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares Underlying RSUs, Unvested ending balance",
        "periodStartLabel": "Number of Shares Underlying RSUs, Unvested beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Unvested ending balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Unvested beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares Underlying RSUs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend",
        "verboseLabel": "Dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Aggregate Intrinsic Value,Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available under the 2013 plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares of common stock authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised | $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair values of options granted (in dollars per share) | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r244",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending balance",
        "periodStartLabel": "Shares, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding, Ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r233",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationTables",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r107",
      "r235",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Public offering price of common shares"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r259",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail",
      "http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance,Shares",
        "periodStartLabel": "Beginning balance,Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r57",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements",
      "http://www.karyopharm.com/role/LongTermObligations",
      "http://www.karyopharm.com/role/LongTermObligationsTables",
      "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail",
      "http://www.karyopharm.com/role/ProductRevenue",
      "http://www.karyopharm.com/role/ProductRevenueTables",
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements",
      "http://www.karyopharm.com/role/LongTermObligations",
      "http://www.karyopharm.com/role/LongTermObligationsTables",
      "http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail",
      "http://www.karyopharm.com/role/ProductRevenue",
      "http://www.karyopharm.com/role/ProductRevenueTables",
      "http://www.karyopharm.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r208",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Exercise of stock options and shares issued under the employee stock purchase plan, (shares)",
        "verboseLabel": "Common stock available for payment related to tax withholding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r208",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Issuance of common stock, net of issuance costs",
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r23",
      "r24",
      "r208",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r208",
      "r213",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r208",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan, amount withheld from employees | $"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r208",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r57",
      "r208",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options and shares issued under the employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "verboseLabel": "Outstanding Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r150"
     ],
     "calculation": {
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "verboseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "verboseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]",
        "verboseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical",
      "http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail",
      "http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r227",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government and Agency Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail",
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "verboseLabel": "Interest or penalties related to uncertain tax positions recognized in statements of operations and comprehensive loss"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UpFrontPaymentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein all amount due is received from customer before delivery of goods or services, and revenue will be recognized upon customer acceptance of delivered goods or services.",
        "label": "Up-front Payment Arrangement [Member]",
        "terseLabel": "Up-front Payment Arrangement [Member]"
       }
      }
     },
     "localname": "UpFrontPaymentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail",
      "http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of common shares outstanding used in net loss per share\u2014basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r426": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r427": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r428": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r429": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>d853399d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:kpti="http://www.karyopharm.com/20191231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kpti-20191231.xsd" xlink:type="simple"/>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="P10_16_2018To10_16_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <startDate>2018-10-16</startDate>
            <endDate>2018-10-16</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn02_14_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2020-02-14</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="P10_02_2018To10_02_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <startDate>2018-10-02</startDate>
            <endDate>2018-10-02</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OfficeAndResearchSpaceLeaseMemberusgaapLeaseArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">kpti:OfficeAndResearchSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">kpti:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kpti:SelinexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kpti:EltanexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_KPT9274MemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kpti:KPT9274Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_VerdinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kpti:VerdinexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:SalesEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">kpti:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">kpti:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">kpti:HealthcareRoyaltyPartnersIvLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMemberKPTIRoyaltyPaymentDueDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kpti:RoyaltyPaymentDueDateAxis">kpti:RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">kpti:HealthcareRoyaltyPartnersIvLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMemberKPTIRoyaltyPaymentDueDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="kpti:RoyaltyPaymentDueDateAxis">kpti:RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">kpti:HealthcareRoyaltyPartnersIvLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DeferredRoyaltyObligationMemberusgaapBalanceSheetLocationAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">kpti:DeferredRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kpti:ConsultingAndContractResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MinimumMembersrtRangeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">kpti:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">kpti:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kpti:ConsultingAndContractResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_JefferiesLLCMembersrtCounterpartyNameAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kpti:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseAndAssetPurchaseAgreementsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:LicenseAndAssetPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodonememberMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">kpti:VestingperiodonememberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodtwomemberMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwothousandtenstockoptionplanmemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">kpti:VestingperiodtwomemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonAreaMaintenanceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kpti:CommonAreaMaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseAndOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:LicenseAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_XpovioMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:XpovioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DEsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kpti:ConsultingAndHistopathologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kpti:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kpti:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicenseAndOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:LicenseAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">kpti:ConsultingAndHistopathologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kpti:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_LicenseAndOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:LicenseAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kpti:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2017_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:DevelopmentGoalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-05-23</endDate>
        </period>
    </context>
    <context id="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:SalesEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-05-23</endDate>
        </period>
    </context>
    <context id="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-23</instant>
        </period>
    </context>
    <context id="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:DevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-23</instant>
        </period>
    </context>
    <context id="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:AntengeneTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:SalesEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-23</instant>
        </period>
    </context>
    <context id="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-24</startDate>
            <endDate>2018-01-24</endDate>
        </period>
    </context>
    <context id="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis_MaximumMembersrtRangeAxis_SalesMilestoneMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-24</instant>
        </period>
    </context>
    <context id="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">kpti:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-24</instant>
        </period>
    </context>
    <context id="P01_01_2018To03_31_2018_BiogenMAIncMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="P10_11_2017To10_11_2017_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:DevelopmentGoalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-11</startDate>
            <endDate>2017-10-11</endDate>
        </period>
    </context>
    <context id="P10_11_2017To10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:SalesEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-11</startDate>
            <endDate>2017-10-11</endDate>
        </period>
    </context>
    <context id="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-11</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kpti:SelinexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">kpti:EltanexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_ClinicalDevelopmentAndRegulatoryMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_ScenarioPlanMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kpti:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kpti:OnoPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_28_2017To04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-28</startDate>
            <endDate>2017-04-28</endDate>
        </period>
    </context>
    <context id="PAsOn04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-28</instant>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-16</startDate>
            <endDate>2018-10-16</endDate>
        </period>
    </context>
    <context id="P10_16_2018To10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-16</startDate>
            <endDate>2018-10-16</endDate>
        </period>
    </context>
    <context id="PAsOn10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-16</instant>
        </period>
    </context>
    <context id="PAsOn10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-16</instant>
        </period>
    </context>
    <context id="PAsOn10_26_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-26</instant>
        </period>
    </context>
    <context id="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kpti:ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-15</startDate>
            <endDate>2022-10-15</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2018_AccountingStandardsUpdate201616MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-07</startDate>
            <endDate>2018-05-07</endDate>
        </period>
    </context>
    <context id="PAsOn05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="P12_07_2015To12_07_2015_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kpti:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-07</startDate>
            <endDate>2015-12-07</endDate>
        </period>
    </context>
    <context id="PAsOn08_07_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kpti:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">kpti:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-07</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2013_MaximumMembersrtRangeAxis_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="P10_01_2013To10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kpti:TwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-10-01</startDate>
            <endDate>2013-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503802</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_JPY">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="Unit_Securities">
        <measure>kpti:Securities</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Segments">
        <measure>kpti:Segments</measure>
    </unit>
    <unit id="Unit_D">
        <measure>utr:D</measure>
    </unit>
    <unit id="Unit_Installment">
        <measure>kpti:Installment</measure>
    </unit>
    <kpti:LicenseAgreementTerminationDescription
      contextRef="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      id="hidden10185021">the Ono License Agreement may be terminated earlier by (i) either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Ono on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days' prior notice or (iii) us in the event Ono challenges or assists with a challenge to certain of our patent rights.</kpti:LicenseAgreementTerminationDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="hidden11073498"
      unitRef="Unit_shares">9843094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <dei:AmendmentFlag contextRef="P01_01_2019To12_31_2019">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2019To12_31_2019">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2019To12_31_2019">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2019To12_31_2019">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityRegistrantName contextRef="P01_01_2019To12_31_2019" id="hidden10168366">Karyopharm Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P01_01_2019To12_31_2019">0001503802</dei:EntityCentralIndexKey>
    <kpti:OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered contextRef="P01_01_2019To12_31_2019" id="hidden10534998">P3D</kpti:OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered>
    <kpti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      id="hidden10168480">P6M</kpti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis"
      id="hidden10173497">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <kpti:SaleAgreementTerminationDate contextRef="P10_02_2018To10_02_2018" id="hidden10182875">2018-08-12</kpti:SaleAgreementTerminationDate>
    <dei:DocumentType contextRef="P01_01_2019To12_31_2019">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P01_01_2019To12_31_2019">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2019To12_31_2019">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="P01_01_2019To12_31_2019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2019To12_31_2019">001-36167</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2019To12_31_2019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2019To12_31_2019">26-3931704</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2019To12_31_2019">85 Wells Avenue, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2019To12_31_2019">Newton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2019To12_31_2019">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2019To12_31_2019">02459</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2019To12_31_2019">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2019To12_31_2019">658-0600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2019To12_31_2019">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2019To12_31_2019">KPTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2019To12_31_2019">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2019To12_31_2019">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2019To12_31_2019">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2019To12_31_2019">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2019To12_31_2019">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2019To12_31_2019">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2019To12_31_2019">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2019To12_31_2019">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P01_01_2019To12_31_2019">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn06_30_2019"
      decimals="0"
      unitRef="Unit_USD">343517677</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn02_14_2020"
      decimals="INF"
      unitRef="Unit_shares">65548095</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">128858000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">118021000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">133098000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">210178000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7862000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">346000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7289000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">6413000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1117000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">278570000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">334612000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3046000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10617000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2016000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">2001000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">714000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">716000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">294963000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">341192000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">985000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">4332000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">40878000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">32493000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2341000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">9362000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1646000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">390000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">327000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46350000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">46904000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">109857000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">102664000</us-gaap:ConvertibleLongTermNotesPayable>
    <kpti:DeferredRoyaltyObligationNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">73588000</kpti:DeferredRoyaltyObligationNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13202000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2192000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">4532000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3922000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">245189000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">158022000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2018"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2018"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">65370448</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">65370448</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">60829308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_shares">60829308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">923142000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">857156000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-37000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-244000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-873338000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-673748000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">49774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">183170000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">294963000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">341192000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">30540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_LicenseAndOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">10353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_LicenseAndOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">30336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2017To12_31_2017_LicenseAndOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1605000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">40893000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">30336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">1605000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2407000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">122340000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">161372000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">107273000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">105421000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">48847000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">24870000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">230168000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">210219000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">132143000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-189275000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-179883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-130538000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5422000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">4028000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">1698000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15647000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">2493000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-50000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-33000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-81000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-10275000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1502000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">1617000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199550000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178381000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128921000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">26000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">63000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199590000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128984000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2017To12_31_2017"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">61955420</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="0"
      unitRef="Unit_shares">56799699</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2017To12_31_2017"
      decimals="0"
      unitRef="Unit_shares">45899784</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199590000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128984000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">207000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">39000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-97000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-66000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">154000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199383000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178434000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128927000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">41887829</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">528617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2016_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-366104000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2016"
      decimals="-3"
      unitRef="Unit_USD">162243000</us-gaap:StockholdersEquity>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome
      contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">253000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome
      contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-253000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">182496</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">154623</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">858000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">858000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">20405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <kpti:StockIssuanceCosts
      contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">1100</kpti:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">7308202</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">74884000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">74885000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2017To12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-97000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-97000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2017To12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">154000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">154000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-128984000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128984000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">49533150</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">625017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-495341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">129464000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">113800</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">656934</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3519000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3519000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">17275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">17275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <kpti:StockIssuanceCosts
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">200</kpti:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">10525424</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">145704000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">145705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">67850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">67850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <kpti:EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2209000</kpti:EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt>
    <kpti:EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-2209000</kpti:EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">39000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">39000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-66000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-66000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-178407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178407000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">60829308</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">857156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-244000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-673748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">183170000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">811281</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4505000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4505000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <kpti:StockIssuanceCosts
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">1000.0</kpti:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">3712359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">46190000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46191000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">207000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">207000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-199590000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199590000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">65370448</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">923142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-873338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">49774000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199590000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178407000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128984000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">974000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">735000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">713000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1382000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-1187000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15291000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">17275000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">20405000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7193000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1420000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7862000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">346000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">868000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">4663000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-342000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <kpti:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1094000</kpti:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-3301000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-1380000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">909000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">8512000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">11255000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">10070000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <kpti:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1175000</kpti:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-9362000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-8027000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">21921000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInPrepaidRent
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-2646000</us-gaap:IncreaseDecreaseInPrepaidRent>
    <us-gaap:IncreaseDecreaseInPrepaidRent
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">280000</us-gaap:IncreaseDecreaseInPrepaidRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-190822000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-159117000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-73717000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">2363000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">62000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">257145000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">137510000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">115544000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">178489000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">242811000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">98374000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78450000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-107664000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">17108000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <kpti:ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">166885000</kpti:ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts>
    <kpti:ProceedsFromPaymentsForCommonStockIssuanceNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46191000</kpti:ProceedsFromPaymentsForCommonStockIssuanceNet>
    <kpti:ProceedsFromPaymentsForCommonStockIssuanceNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">145705000</kpti:ProceedsFromPaymentsForCommonStockIssuanceNet>
    <kpti:ProceedsFromPaymentsForCommonStockIssuanceNet
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">74885000</kpti:ProceedsFromPaymentsForCommonStockIssuanceNet>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4505000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3519000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">858000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <kpti:ProceedsFromDeferredRoyaltyObligation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">73609000</kpti:ProceedsFromDeferredRoyaltyObligation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">124305000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">316109000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">75743000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-78000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">211000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11952000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">49250000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">19345000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">118737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">69487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2016"
      decimals="-3"
      unitRef="Unit_USD">50142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">130689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">118737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">69487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">128858000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">118021000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">68997000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1117000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">714000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">716000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">290000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">130689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">118737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">69487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5175000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11711000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <kpti:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2889000</kpti:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Organization and Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are an innovation-driven pharmaceutical company focused on the discovery, development and commercialization of novel, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in-class&lt;/div&gt; drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Our &lt;div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;S&lt;/div&gt;&lt;/div&gt;elective &lt;div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;I&lt;/div&gt;&lt;/div&gt;nhibitor of &lt;div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;N&lt;/div&gt;&lt;/div&gt;uclear &lt;div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;E&lt;/div&gt;&lt;/div&gt;xport&lt;/div&gt;&lt;/div&gt; (&lt;div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SINE&lt;/div&gt;&lt;/div&gt;) compounds function by binding with and inhibiting the nuclear export protein exportin 1 (XPO1). Our initial focus has been on seeking the regulatory approval and commercialization of our lead SINE compound, selinexor, as an oral agent in cancer indications with significant unmet clinical need. We were incorporated in Delaware on December&#160;22, 2008 and have a principal place of business in Newton, Massachusetts. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2019, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approved XPOVIO&lt;div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;"&gt;&#xae;&lt;div style="font-size: 5.476pt; line-height: 4.05224pt;;display:inline;vertical-align: top;"&gt; &lt;/div&gt;&lt;/div&gt;(selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (&#x201c;RRMM&#x201d;) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Following accelerated approval by the FDA, XPOVIO became commercially available in the United States in July 2019.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2019, we had an accumulated deficit of $873.3&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have had limited revenues to date from product sales and have financed our operations principally through private placements of our preferred stock, proceeds from our initial public offering and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follow-on &lt;/div&gt; offerings of common stock, proceeds from the issuance of convertible debt, proceeds pursuant to the Revenue Interest Financing Agreement (deferred royalty obligation), and cash generated from our business development activities. We expect to continue to incur significant expenses and operating losses for at least the foreseeable future. We expect that our cash, cash equivalents and investments at December&#160;31, 2019 will be sufficient to fund current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">-873300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. All of our revenue to date has been derived in the United States. All of our material long-lived assets reside in the United States. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On an ongoing basis, we evaluate our estimates, including estimates related to our net product revenue, clinical trial accruals, stock-based compensation expense, interest expense on our deferred royalty obligation&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt;&#160;other reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Although we regularly assess these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. &lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements at December&#160;31, 2019 include the accounts of (i)&#160;Karyopharm Therapeutics Inc., (ii)&#160;Karyopharm Securities Corp. (&#x201c;KPSC&#x201d;, our wholly-owned Massachusetts corporation incorporated in December&#160;2013), (iii) Karyopharm Europe GmbH (our wholly-owned German Limited Liability Company, incorporated in September 2014), (iv) Karyopharm Therapeutics (Bermuda) Ltd. (our limited liability company, registered in Bermuda in March 2015), and (vi)&#160;Karyopharm Israel Ltd. (our wholly&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;owned Israeli subsidiary formed in June 2018). All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist primarily of demand deposit accounts and deposits in short-term money market funds. Cash equivalents are stated at cost, which approximates fair value. We consider all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. We do not hold any money market funds with significant liquidity restrictions that would be required to be excluded from cash equivalents. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We determine the appropriate classification of our investments in debt securities at the time of purchase. All of our securities are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-for-sale&lt;/div&gt; investments are recorded at fair value, with unrealized gains or losses included in Accumulated Other Comprehensive Loss, exclusive of other-than-temporary impairment losses, if any. Short-term and long-term investments are composed of corporate debt securities, commercial paper, U.S. government agency securities and certificates of deposit.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentrations of Credit Risk and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Off-Balance&lt;/div&gt; Sheet Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents and investments. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-balance&lt;/div&gt; sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses, are presented at amounts that approximate fair value at December&#160;31, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;valuation&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 13%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 86%; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#160;inputs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#160;inputs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#160;inputs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our cash equivalents are composed of money market funds. We measure these investments at fair value.&#160;The fair value of cash equivalents is determined based on &#x201c;Level&#160;1&#x201d; inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Items classified as Level&#160;2 within the valuation hierarchy consist of commercial paper, corporate debt securities, U.S. government agency securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level&#160;3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;, &#x201c;Long-Term Obligations&#x201d;, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1)&#160;our estimates of the probability and timing of related events; (2)&#160;the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3)&#160;our risk-adjusted discount rate that includes a company specific risk premium; (4)&#160;our cost of debt; (5)&#160;volatility; and (6)&#160;the probability of a change in control occurring during the term of the instrument.&#160;Our embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;, &#x201c;Long-Term Obligations.&#x201d; &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about our financial assets &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and liability &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; padding-right: 5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;206,494 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,114 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&#x2014;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Embedded derivative liability &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificate of deposit &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;289,060 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,179 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Embedded&lt;br/&gt; Derivative&lt;br/&gt; Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Addition of derivative related to deferred royalty obligation&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of derivative since issuanc&lt;div style="display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;L&lt;/div&gt;evel 3 embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;, &#x201c;Long-Term Obligations&#x201d;. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, generally &lt;span style="-sec-ix-hidden:hidden10173497"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful economic lives of the related assets. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and any related gains or losses are reflected in the consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell. We have not recorded an impairment in any period since inception. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Rent &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from landlords related to our operating leases under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 840. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense. Tenant improvement allowances and other incentives were also recorded as deferred rent under ASC 840 through December&#160;31, 2018. Deferred rent and lease incentives are recorded as a reduction to our operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets as of December&#160;31, 2019.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We adopted Accounting Standards Update (&#x201c;ASU&#x201d;)&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2014-09,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, as well as subsequent amendments, which were codified in ASC 606, on January&#160;1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder&#x2019;s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the consideration which we expect to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following are the components of variable&#160;consideration related to product revenue: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash discounts and distributor fees:&lt;/div&gt;&lt;/div&gt;&#160;We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product returns:&lt;/div&gt;&lt;/div&gt;&#160;Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product&#x2019;s expiration date and ending twelve months after the product&#x2019;s expiration date).&#160;We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&#160;Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Chargebacks:&lt;/div&gt;&lt;/div&gt;&#160;Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us.&#160;Our customers charge us for the discount provided to the healthcare entities.&#160;Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Government rebates&lt;/div&gt;&lt;/div&gt;: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (&#x201c;VA&#x201d;), the Department of Defense (&#x201c;DOD&#x201d;), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other incentives:&lt;/div&gt;&lt;/div&gt;&#160;Other incentives offered by us include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payments&lt;/div&gt; by the patient. We calculate the accrual for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on estimates of claims and the average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product revenue reserves and allowances: &lt;/div&gt;&lt;/div&gt;As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recorded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of December&#160;31, 2019 and, &lt;/div&gt;&lt;/div&gt; &lt;/div&gt;  &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;therefore, the transaction price was not reduced further during the year ended December&#160;31, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-style: normal; margin-top: 18pt; margin-bottom: 0px; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License and Asset Purchase Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We generate revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain of our product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize the transaction price allocated to the license as revenue upon transfer of control of the license. We evaluate all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We utilize judgment to determine the transaction price. In connection therewith, we evaluate contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate &lt;/div&gt; the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We then determine whether the performance obligations or combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees. We evaluate the measure of progress, as applicable, for each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded within deferred revenue. Contract liabilities within deferred revenue are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/div&gt;&lt;/div&gt;  &lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;customers&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of December&#160;31, 2019, we determined an allowance for doubtful accounts was not required based upon our review of contractual payment terms and individual customer circumstances.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Such costs are generally recorded as costs of sales upon shipment. In connection therewith, we value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales requirements as cost of sales.&#160;The determination of whether inventory costs will be realizable is based on our estimates.&#160;If actual market conditions are less favorable than projected by us, additional write-downs of inventory may be required, which would be recorded as cost of sales. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of Sales &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. &lt;/div&gt;&lt;/div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Royalty Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We treat the liability related to net revenues, as discussed further in Note 15, as a deferred royalty obligation, amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense thereon using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty obligation, and record interest expense using the imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are charged to expense as incurred and include, but are not limited to: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that help conduct clinical trials and preclinical studies;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;the cost of acquiring, developing and manufacturing clinical trial materials, including comparator drugs;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;facility, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;costs associated with preclinical activities and regulatory operations.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are accordingly reflected in the financial statements as prepaid or accrued research and development. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources, and currently consists of net loss, unrealized gains and losses on investments and foreign currency translation adjustments.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign Currency Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The functional currency of our subsidiaries in Germany and Israel are the Euro and Shekel, respectively. Foreign currency transaction gains and losses are recorded in the consolidated statement of operations. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange losses of less than $0.1&#160;million were recorded in other income for the years ended December&#160;31, 2019, 2018 and 2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. We have evaluated available evidence and concluded that we may not realize the benefit of our deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets. We recognize interest and/or penalties related to income tax matters in income tax expense. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost plus profit margin basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) resulted in significant changes to the U.S. corporate income tax system.&#160;For additional details regarding this act, see Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;, &#x201c;Income Taxes&#x201d;. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting for Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We account for our stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees,&lt;/div&gt; including grants of employee stock options, restricted stock and restricted stock units, as&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;well&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; as modifications to existing stock options and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;), to be recognized in the consolidated statements of operations based on their fair values. We use the Black-Scholes option pricing model to determine the fair value of options granted. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation expense related to awards to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. Forfeitures are recognized as they occur. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Our potential dilutive shares, stock options, unvested restricted stock and restricted stock units are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,843,094 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,917,084 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,019,083 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested restricted stock units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;787,320 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,000 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;253,100 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We have the option to settle the conversion obligation for our 3.00% convertible senior notes due 2025 (the &#x201c;Notes&#x201d;) in cash, shares or any combination of the two. As the Notes are not convertible as of December&#160;31, 2019, they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on our net loss position, there is no impact on the calculation of dilutive loss per share during the year ended December&#160;31, 2019.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;In February 2016, the FASB issued ASU&#160;No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2016-02,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Leases (Topic&#160;842)&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02&#x201d;),&lt;/div&gt; which supersedes the lease guidance under FASB ASC Topic 840, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;, resulting in the creation of FASB ASC Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 842&#x201d;).&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;The FASB also issued amendments to ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; including ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-10, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Codification Improvements to Topic 842, Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-10&#x201d;)&lt;/div&gt; and ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic&#160;842) Targeted&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Improvements &lt;/div&gt;&lt;/div&gt;(&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11&#x201d;),&lt;/div&gt; which we collectively refer to as the new leasing standard. In summary, the new leasing standard requires that all lessees (i)&#160;recognize, on the balance sheet, liabilities to remit lease payments and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii)&#160;disclose qualitative and quantitative information about its leasing arrangements. We adopted the standard effective January&#160;1, 2019 using the optional transition method under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11&lt;/div&gt; and, therefore, prior period financial information has not been retrospectively adjusted.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;Pursuant to the guidance under ASU&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2016-02,&lt;/div&gt; we elected the optional package of practical expedients to leases that commenced prior to the effective date, which allowed us to not reassess: (i)&#160;whether expired or existing contracts contain leases; (ii)&#160;lease classification for any expired or existing leases; and (iii)&#160;initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of&lt;/div&gt; &lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;which we elected, including: (i)&#160;a policy to not record &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and leases on the balance sheet for short-term leases that qualify and (ii)&#160;a policy to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for certain classes of underlying assets on contracts entered into or modified after the effective date. We did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;As summarized in the table below, the standard had a material impact on our condensed consolidated balance sheet as of December&#160;31, 2019, specifically through recognition of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets of $11.7&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;and lease liabilities of $16.0&#160;million for our existing operating lease for office space in Newton, MA on the effective date. The difference between the operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and operating lease liabilities is due to the change in classification of deferred rent and lease incentives through December&#160;31, 2018 from liabilities to a reduction in our operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets. However, the standard did not have a material impact on our consolidated statement of operations and comprehensive loss for the twelve months ended December&#160;31, 2019, as expense for our existing operating leases continues to be recognized consistent with the recognition pattern before adoption of the new standard. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Please refer to Note 9, &#x201c;Commitments and Contingencies&#x201d; for further information&lt;/div&gt;&lt;/div&gt;.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1,&#160;2019&lt;br/&gt; Prior to ASC&lt;br/&gt; 842 Adoption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 842&lt;br/&gt; Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1,&#160;2019&lt;br/&gt; as Adjusted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated balance sheet data (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;br/&gt; assets(1) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,711&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,711&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,922&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,922&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities(3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,175&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,175&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease&lt;br/&gt; liabilities(3) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0px;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents capitalization of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets, offset by reclassification of deferred rent and tenant incentives to operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(2)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents reclassification of deferred rent and tenant incentives to operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents recognition of operating lease liabilities.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We implemented internal controls to enable the preparation of financial information upon adoption. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In June 2018, the FASB issued ASU&#160;No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-07, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation-Stock Compensation (Topic&#160;718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-07&#x201d;).&lt;/div&gt; ASU&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-07&lt;/div&gt; largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic&#160;718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance was adopted on January&#160;1, 2019 and it did not have a material impact on our consolidated financial statements.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In November 2018, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-18, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the Interaction between Topic 808 and Topic 606&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&#x201d;).&lt;/div&gt; The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; should be applied retrospectively to the date of initial application of ASC 606. We adopted this guidance effective January&#160;1, 2019 using the modified retrospective approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;, &#x201c;License and Asset Purchase Agreements,&#x201d; were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;text-indent: 4%;"&gt;In December 2019, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2019-12, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&#x201d;).&lt;/div&gt; The ASU removes the exception to the incremental approach for intraperiod allocation of tax expense when a company has a loss from continuing operations and income from other items that are not included in continuing operations, such as income recorded in Other Comprehensive Income. The general rule under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-20-45-7&lt;/div&gt; is that the tax effect of pretax income or loss from continuing operations should be determined by a computation that does not consider the tax effects of items that are not included in continuing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;operations&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;so-called&lt;/div&gt; incremental approach). Previously, companies could consider the impact on a loss from continuing operations of items in discontinued operations or other comprehensive income. However, under the amended guidance, companies should not consider the effect of items outside of continuing operations in calculating the tax effect on continuing operations. The new guidance is effective for public business entities with fiscal years, and the related interim periods, beginning after December&#160;15, 2020. For other entities, the ASU is effective for fiscal years beginning after December&#160;15, 2021, and interim periods within fiscal years beginning after December&#160;15, 2022. The guidance in the ASU may be adopted prior to the effective date. We adopted this guidance effective January&#160;1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Issued Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2016-13, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#x2019;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019. We do not expect the adoption of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; to have a material impact on our consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;In August 2018, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-13, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&#x2014;Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement &lt;/div&gt;&lt;/div&gt;(&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&#x201d;).&lt;/div&gt; The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; modify the disclosure requirements on fair value measurements in ASC&#160;820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; to have a material impact on our consolidated financial statements&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In August 2018, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-15, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40)&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&#x201d;).&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; to have a material impact on our consolidated financial statements.&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. All of our revenue to date has been derived in the United States. All of our material long-lived assets reside in the United States. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_Segments">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On an ongoing basis, we evaluate our estimates, including estimates related to our net product revenue, clinical trial accruals, stock-based compensation expense, interest expense on our deferred royalty obligation&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt;&#160;other reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Although we regularly assess these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. &lt;/div&gt;&#160;&lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements at December&#160;31, 2019 include the accounts of (i)&#160;Karyopharm Therapeutics Inc., (ii)&#160;Karyopharm Securities Corp. (&#x201c;KPSC&#x201d;, our wholly-owned Massachusetts corporation incorporated in December&#160;2013), (iii) Karyopharm Europe GmbH (our wholly-owned German Limited Liability Company, incorporated in September 2014), (iv) Karyopharm Therapeutics (Bermuda) Ltd. (our limited liability company, registered in Bermuda in March 2015), and (vi)&#160;Karyopharm Israel Ltd. (our wholly&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;owned Israeli subsidiary formed in June 2018). All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist primarily of demand deposit accounts and deposits in short-term money market funds. Cash equivalents are stated at cost, which approximates fair value. We consider all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. We do not hold any money market funds with significant liquidity restrictions that would be required to be excluded from cash equivalents. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We determine the appropriate classification of our investments in debt securities at the time of purchase. All of our securities are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-for-sale&lt;/div&gt; investments are recorded at fair value, with unrealized gains or losses included in Accumulated Other Comprehensive Loss, exclusive of other-than-temporary impairment losses, if any. Short-term and long-term investments are composed of corporate debt securities, commercial paper, U.S. government agency securities and certificates of deposit.&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <kpti:ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentrations of Credit Risk and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Off-Balance&lt;/div&gt; Sheet Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents and investments. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;off-balance&lt;/div&gt; sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.&lt;/div&gt;</kpti:ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses, are presented at amounts that approximate fair value at December&#160;31, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;valuation&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 13%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 86%; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#160;inputs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#160;inputs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 8px; padding-left: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#160;inputs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our cash equivalents are composed of money market funds. We measure these investments at fair value.&#160;The fair value of cash equivalents is determined based on &#x201c;Level&#160;1&#x201d; inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Items classified as Level&#160;2 within the valuation hierarchy consist of commercial paper, corporate debt securities, U.S. government agency securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level&#160;3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;, &#x201c;Long-Term Obligations&#x201d;, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1)&#160;our estimates of the probability and timing of related events; (2)&#160;the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3)&#160;our risk-adjusted discount rate that includes a company specific risk premium; (4)&#160;our cost of debt; (5)&#160;volatility; and (6)&#160;the probability of a change in control occurring during the term of the instrument.&#160;Our embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;, &#x201c;Long-Term Obligations.&#x201d; &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about our financial assets &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and liability &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; padding-right: 5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;206,494 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,114 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&#x2014;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Embedded derivative liability &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificate of deposit &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;289,060 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,179 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Embedded&lt;br/&gt; Derivative&lt;br/&gt; Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Addition of derivative related to deferred royalty obligation&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of derivative since issuanc&lt;div style="display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;L&lt;/div&gt;evel 3 embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;, &#x201c;Long-Term Obligations&#x201d;. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock contextRef="P01_01_2019To12_31_2019"> &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about our financial assets &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and liability &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 46%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt;&#160; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; padding-right: 5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;206,494 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;71,380 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,114 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&#x2014;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Embedded derivative liability &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; padding-right: 5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in&#160;Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&lt;br/&gt; (Level&#160;3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificate of deposit &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;289,060 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,881 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,179 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; </us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">71380000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">71380000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">89079000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">89079000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">39022000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">39022000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4997000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4997000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2016000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2016000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">206494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">71380000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">135114000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2300000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">2300000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2018_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">76881000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">76881000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">143079000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">143079000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">43978000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">43978000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">19124000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">19124000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3997000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3997000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2001000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2001000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">289060000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">76881000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">212179000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Embedded&lt;br/&gt; Derivative&lt;br/&gt; Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Addition of derivative related to deferred royalty obligation&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of derivative since issuanc&lt;div style="display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,300&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2018_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2019To12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">2300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2019To12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019_EmbeddedDerivativeFinancialInstrumentsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">2300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, generally &lt;span style="-sec-ix-hidden:hidden10173497"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful economic lives of the related assets. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and any related gains or losses are reflected in the consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell. We have not recorded an impairment in any period since inception. &lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Rent &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from landlords related to our operating leases under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 840. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense. Tenant improvement allowances and other incentives were also recorded as deferred rent under ASC 840 through December&#160;31, 2018. Deferred rent and lease incentives are recorded as a reduction to our operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets as of December&#160;31, 2019.&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We adopted Accounting Standards Update (&#x201c;ASU&#x201d;)&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2014-09,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, as well as subsequent amendments, which were codified in ASC 606, on January&#160;1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder&#x2019;s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the consideration which we expect to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt; &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following are the components of variable&#160;consideration related to product revenue: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash discounts and distributor fees:&lt;/div&gt;&lt;/div&gt;&#160;We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product returns:&lt;/div&gt;&lt;/div&gt;&#160;Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product&#x2019;s expiration date and ending twelve months after the product&#x2019;s expiration date).&#160;We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&#160;Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Chargebacks:&lt;/div&gt;&lt;/div&gt;&#160;Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us.&#160;Our customers charge us for the discount provided to the healthcare entities.&#160;Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Government rebates&lt;/div&gt;&lt;/div&gt;: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (&#x201c;VA&#x201d;), the Department of Defense (&#x201c;DOD&#x201d;), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other incentives:&lt;/div&gt;&lt;/div&gt;&#160;Other incentives offered by us include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payments&lt;/div&gt; by the patient. We calculate the accrual for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on estimates of claims and the average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product revenue reserves and allowances: &lt;/div&gt;&lt;/div&gt;As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recorded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of December&#160;31, 2019 and, &lt;/div&gt;&lt;/div&gt; &lt;/div&gt;  &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;therefore, the transaction price was not reduced further during the year ended December&#160;31, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-style: normal; margin-top: 18pt; margin-bottom: 0px; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License and Asset Purchase Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We generate revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain of our product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize the transaction price allocated to the license as revenue upon transfer of control of the license. We evaluate all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We utilize judgment to determine the transaction price. In connection therewith, we evaluate contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate &lt;/div&gt; the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We then determine whether the performance obligations or combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees. We evaluate the measure of progress, as applicable, for each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded within deferred revenue. Contract liabilities within deferred revenue are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;customers&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of December&#160;31, 2019, we determined an allowance for doubtful accounts was not required based upon our review of contractual payment terms and individual customer circumstances.&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Such costs are generally recorded as costs of sales upon shipment. In connection therewith, we value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales requirements as cost of sales.&#160;The determination of whether inventory costs will be realizable is based on our estimates.&#160;If actual market conditions are less favorable than projected by us, additional write-downs of inventory may be required, which would be recorded as cost of sales. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of Sales &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. &lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <kpti:DeferredRoyaltyObligationPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Royalty Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We treat the liability related to net revenues, as discussed further in Note 15, as a deferred royalty obligation, amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense thereon using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty obligation, and record interest expense using the imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </kpti:DeferredRoyaltyObligationPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are charged to expense as incurred and include, but are not limited to: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that help conduct clinical trials and preclinical studies;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;the cost of acquiring, developing and manufacturing clinical trial materials, including comparator drugs;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;facility, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top; padding-left: 0px;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;costs associated with preclinical activities and regulatory operations.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are accordingly reflected in the financial statements as prepaid or accrued research and development. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources, and currently consists of net loss, unrealized gains and losses on investments and foreign currency translation adjustments.&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign Currency Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The functional currency of our subsidiaries in Germany and Israel are the Euro and Shekel, respectively. Foreign currency transaction gains and losses are recorded in the consolidated statement of operations. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net foreign exchange losses of less than $0.1&#160;million were recorded in other income for the years ended December&#160;31, 2019, 2018 and 2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2017To12_31_2017"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. We have evaluated available evidence and concluded that we may not realize the benefit of our deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets. We recognize interest and/or penalties related to income tax matters in income tax expense. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost plus profit margin basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) resulted in significant changes to the U.S. corporate income tax system.&#160;For additional details regarding this act, see Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;, &#x201c;Income Taxes&#x201d;. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting for Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We account for our stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees,&lt;/div&gt; including grants of employee stock options, restricted stock and restricted stock units, as&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;well&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; as modifications to existing stock options and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;), to be recognized in the consolidated statements of operations based on their fair values. We use the Black-Scholes option pricing model to determine the fair value of options granted. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation expense related to awards to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. Forfeitures are recognized as they occur. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Our potential dilutive shares, stock options, unvested restricted stock and restricted stock units are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,843,094 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,917,084 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,019,083 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested restricted stock units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;787,320 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,000 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;253,100 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We have the option to settle the conversion obligation for our 3.00% convertible senior notes due 2025 (the &#x201c;Notes&#x201d;) in cash, shares or any combination of the two. As the Notes are not convertible as of December&#160;31, 2019, they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on our net loss position, there is no impact on the calculation of dilutive loss per share during the year ended December&#160;31, 2019.&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding stock options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,843,094 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,917,084 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,019,083 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested restricted stock units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;787,320 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,000 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;253,100 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_shares">9843094</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_shares">8917084</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2017To12_31_2017_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_shares">7019083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">787320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">25000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2017To12_31_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">253100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;In February 2016, the FASB issued ASU&#160;No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2016-02,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Leases (Topic&#160;842)&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02&#x201d;),&lt;/div&gt; which supersedes the lease guidance under FASB ASC Topic 840, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;, resulting in the creation of FASB ASC Topic 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 842&#x201d;).&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;The FASB also issued amendments to ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; including ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-10, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Codification Improvements to Topic 842, Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-10&#x201d;)&lt;/div&gt; and ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic&#160;842) Targeted&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Improvements &lt;/div&gt;&lt;/div&gt;(&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11&#x201d;),&lt;/div&gt; which we collectively refer to as the new leasing standard. In summary, the new leasing standard requires that all lessees (i)&#160;recognize, on the balance sheet, liabilities to remit lease payments and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii)&#160;disclose qualitative and quantitative information about its leasing arrangements. We adopted the standard effective January&#160;1, 2019 using the optional transition method under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11&lt;/div&gt; and, therefore, prior period financial information has not been retrospectively adjusted.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;Pursuant to the guidance under ASU&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2016-02,&lt;/div&gt; we elected the optional package of practical expedients to leases that commenced prior to the effective date, which allowed us to not reassess: (i)&#160;whether expired or existing contracts contain leases; (ii)&#160;lease classification for any expired or existing leases; and (iii)&#160;initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of&lt;/div&gt; &lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;which we elected, including: (i)&#160;a policy to not record &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and leases on the balance sheet for short-term leases that qualify and (ii)&#160;a policy to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for certain classes of underlying assets on contracts entered into or modified after the effective date. We did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;As summarized in the table below, the standard had a material impact on our condensed consolidated balance sheet as of December&#160;31, 2019, specifically through recognition of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets of $11.7&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;and lease liabilities of $16.0&#160;million for our existing operating lease for office space in Newton, MA on the effective date. The difference between the operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and operating lease liabilities is due to the change in classification of deferred rent and lease incentives through December&#160;31, 2018 from liabilities to a reduction in our operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets. However, the standard did not have a material impact on our consolidated statement of operations and comprehensive loss for the twelve months ended December&#160;31, 2019, as expense for our existing operating leases continues to be recognized consistent with the recognition pattern before adoption of the new standard. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Please refer to Note 9, &#x201c;Commitments and Contingencies&#x201d; for further information&lt;/div&gt;&lt;/div&gt;.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1,&#160;2019&lt;br/&gt; Prior to ASC&lt;br/&gt; 842 Adoption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 842&lt;br/&gt; Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1,&#160;2019&lt;br/&gt; as Adjusted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated balance sheet data (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;br/&gt; assets(1) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,711&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,711&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,922&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,922&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities(3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,175&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,175&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease&lt;br/&gt; liabilities(3) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0px;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents capitalization of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets, offset by reclassification of deferred rent and tenant incentives to operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(2)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents reclassification of deferred rent and tenant incentives to operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents recognition of operating lease liabilities.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We implemented internal controls to enable the preparation of financial information upon adoption. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In June 2018, the FASB issued ASU&#160;No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-07, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation-Stock Compensation (Topic&#160;718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-07&#x201d;).&lt;/div&gt; ASU&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-07&lt;/div&gt; largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic&#160;718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance was adopted on January&#160;1, 2019 and it did not have a material impact on our consolidated financial statements.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In November 2018, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-18, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the Interaction between Topic 808 and Topic 606&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&#x201d;).&lt;/div&gt; The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; should be applied retrospectively to the date of initial application of ASC 606. We adopted this guidance effective January&#160;1, 2019 using the modified retrospective approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;, &#x201c;License and Asset Purchase Agreements,&#x201d; were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;text-indent: 4%;"&gt;In December 2019, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2019-12, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&#x201d;).&lt;/div&gt; The ASU removes the exception to the incremental approach for intraperiod allocation of tax expense when a company has a loss from continuing operations and income from other items that are not included in continuing operations, such as income recorded in Other Comprehensive Income. The general rule under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-20-45-7&lt;/div&gt; is that the tax effect of pretax income or loss from continuing operations should be determined by a computation that does not consider the tax effects of items that are not included in continuing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;operations&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;so-called&lt;/div&gt; incremental approach). Previously, companies could consider the impact on a loss from continuing operations of items in discontinued operations or other comprehensive income. However, under the amended guidance, companies should not consider the effect of items outside of continuing operations in calculating the tax effect on continuing operations. The new guidance is effective for public business entities with fiscal years, and the related interim periods, beginning after December&#160;15, 2020. For other entities, the ASU is effective for fiscal years beginning after December&#160;15, 2021, and interim periods within fiscal years beginning after December&#160;15, 2022. The guidance in the ASU may be adopted prior to the effective date. We adopted this guidance effective January&#160;1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Issued Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2016-13, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#x2019;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019. We do not expect the adoption of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; to have a material impact on our consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;In August 2018, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-13, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&#x2014;Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement &lt;/div&gt;&lt;/div&gt;(&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&#x201d;).&lt;/div&gt; The amendments in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; modify the disclosure requirements on fair value measurements in ASC&#160;820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; to have a material impact on our consolidated financial statements&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In August 2018, the FASB issued ASU No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;2018-15, &lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40)&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&#x201d;).&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; to have a material impact on our consolidated financial statements.&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn01_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">11700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">16000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="width: 100%; font-size: 10pt;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1,&#160;2019&lt;br/&gt; Prior to ASC&lt;br/&gt; 842 Adoption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 842&lt;br/&gt; Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1,&#160;2019&lt;br/&gt; as Adjusted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated balance sheet data (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;br/&gt; assets(1) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,711&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,711&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(390&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred rent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current(2) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,922&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,922&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities(3) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,175&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,175&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 57%;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease&lt;br/&gt; liabilities(3) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0px;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents capitalization of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets, offset by reclassification of deferred rent and tenant incentives to operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(2)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents reclassification of deferred rent and tenant incentives to operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;Represents recognition of operating lease liabilities.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522752"
      unitRef="Unit_USD">11711000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn01_01_2019"
      decimals="-3"
      id="Fact_10522753"
      unitRef="Unit_USD">11711000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="PAsOn01_01_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522754"
      unitRef="Unit_USD">390000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522755"
      unitRef="Unit_USD">-390000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn01_01_2019_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522756"
      unitRef="Unit_USD">3922000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522757"
      unitRef="Unit_USD">-3922000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522758"
      unitRef="Unit_USD">1175000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn01_01_2019"
      decimals="-3"
      id="Fact_10522759"
      unitRef="Unit_USD">1175000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn01_01_2019_RestatementAdjustmentMembersrtRestatementAxis"
      decimals="-3"
      id="Fact_10522760"
      unitRef="Unit_USD">14848000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn01_01_2019"
      decimals="-3"
      id="Fact_10522761"
      unitRef="Unit_USD">14848000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Property and Equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 44%; padding: 0px;"/&gt;
&lt;td style="width: 3%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 3%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 3%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-left: 0px; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated&#160;Useful&lt;br/&gt;Life Years &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;593 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;593 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;654 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;607 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office and computer equipment &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;598 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;559 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,443 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,397 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,288 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,156 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated depreciation and amortization &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,242&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,293&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,046 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,863 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization expense recorded for the years ended December&#160;31, 2019, 2018, and 2017 was $1.0&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$0.7&#160;million and $0.7&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 44%; padding: 0px;"/&gt;
&lt;td style="width: 3%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 3%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 3%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-left: 0px; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated&#160;Useful&lt;br/&gt;Life Years &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Laboratory equipment &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;593 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;593 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;654 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;607 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Office and computer equipment &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;598 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;559 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,443 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,397 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,288 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,156 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated depreciation and amortization &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,242&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,293&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,046 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,863 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2019To12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">593000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2018_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">593000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2019To12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">654000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2018_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2019To12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2018_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">559000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2019To12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2018_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5397000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">7288000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">7156000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4242000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3293000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3046000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2017To12_31_2017"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;The following table summarizes our investments in debt securities, classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; as of December&#160;31, 2019 (in thousands):&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%; padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized&#160;Cost &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,110 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,004 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,990 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,017 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,121 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(44 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,114 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The following table summarizes our investments in debt securities, classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; as of December&#160;31, 2018 (in thousands):&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 50%; padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized&#160;Cost &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,254 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(178&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;44,001 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,131 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,000 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,007 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,393 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(227&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,179 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2019 and December&#160;31, 2018, we held 27&#160;and 79 debt securities, respectively, that were in an unrealized loss position. The aggregate fair value of debt securities in an unrealized loss position at December&#160;31, 2019 and 2018 was $63.8&#160;million and $180.6&#160;million, respectively. As of December&#160;31, 2019 we did &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;no&lt;/div&gt;t have any securities in a continuous unrealized loss position for more than 12&#160;months.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2018, 8 corporate debt securities with a fair value of $14.9&#160;million had been in a continuous unrealized loss position for more than 12&#160;months. The unrealized losses of less than $0.1&#160;million related to these corporate debt securities were included in accumulated other comprehensive loss as of December&#160;31, 2018. At December&#160;31, 2018, we did not intend to sell the securities with an unrealized loss position in accumulated other comprehensive income, and it was not likely that we would be required to sell these securities before recovery of their amortized cost basis.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have experienced a credit loss and have the intent to sell the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;investment or if it is more likely than not that we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The unrealized losses at December&#160;31, 2019 and 2018 are attributable to changes in interest rates, and we do &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;no&lt;/div&gt;t believe any unrealized losses represent other-than-temporary impairments. &lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;The following table summarizes our investments in debt securities, classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; as of December&#160;31, 2019 (in thousands):&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%; padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 7%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized&#160;Cost &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,110 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;89,079 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,004 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,022 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,990 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,997 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,017 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,016 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,121 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(44 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;135,114 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The following table summarizes our investments in debt securities, classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; as of December&#160;31, 2018 (in thousands):&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 50%; padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized&#160;Cost &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&#160;Unrealized&lt;br/&gt;Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,254 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(178&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;143,079 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;44,001 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,978 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government and agency securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,131 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,124 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,000 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,997 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt securities (one to two year maturity) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,007 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,393 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(227&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;212,179 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">89110000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">43000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">89079000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">39004000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2019_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">39022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4990000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2019_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2017000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2019_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2016000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">135121000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">37000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">135114000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">143254000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">143079000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">44001000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2018_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">43978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">19131000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">17000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2018_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">19124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2018_CertificatesOfDepositMemberusgaapCashAndCashEquivalentsAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2007000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2018_DomesticCorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_LongTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">212393000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">227000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">212179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_Securities">27</us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear>
    <us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_Securities">79</us-gaap:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">63800000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="PAsOn12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">180600000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
      contextRef="PAsOn12_31_2019_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_Securities">0</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
      contextRef="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      unitRef="Unit_Securities">8</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">14900000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2018_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <kpti:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
      contextRef="PAsOn12_31_2018"
      decimals="0"
      unitRef="Unit_USD">0</kpti:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments>
    <kpti:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</kpti:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents our inventory of XPOVIO&#160;at December&#160;31, 2019 and 2018 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%; padding: 0px;"/&gt;
&lt;td style="width: 20%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 20%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials and work in process &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;273&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total inventory &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2019, all of our inventory was related to&#160;XPOVIO, which was approved by the FDA in July 2019, at which time we began to capitalize costs to manufacture XPOVIO. Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO and related material were charged to research and development expense in the period incurred. At December&#160;31, 2019, we have determined that a reserve related to XPOVIO inventory is not required. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents our inventory of XPOVIO&#160;at December&#160;31, 2019 and 2018 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%; padding: 0px;"/&gt;
&lt;td style="width: 20%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 20%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials and work in process &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;273&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total inventory &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;346&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">273000</us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2018"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">346000</us-gaap:InventoryNet>
    <kpti:AccruedExpensesDisclosureTextTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%; padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,122 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,903&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll and employee-related costs &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,630 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional fees &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,172 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,931&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;I&lt;/div&gt;nterest&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,371&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; background-color: rgb(255, 255, 255); padding-right: 5pt;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,556 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,878 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;32,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; </kpti:AccruedExpensesDisclosureTextTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%; padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,122 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,903&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payroll and employee-related costs &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,630 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,103&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional fees &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,172 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,931&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;I&lt;/div&gt;nterest&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,371&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-left: 0px; background-color: rgb(255, 255, 255); padding-right: 5pt;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,556 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,878 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;32,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <kpti:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13122000</kpti:AccruedResearchAndDevelopmentCostsCurrent>
    <kpti:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">15903000</kpti:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13630000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">10103000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6172000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">4931000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4371000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3583000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1556000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">40878000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">32493000</us-gaap:AccruedLiabilitiesCurrent>
    <kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We paid consulting expenses of $0.2&#160;million for the years ended December&#160;31, 2019 and 2018, for consulting services with certain related parties, including a family member of management and a board member. At December&#160;31, 2019 and 2018, there was &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;less&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, serif; top: 0px;;display:inline;"&gt;than&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, serif; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $0.1&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, serif; top: 0px;;display:inline;"&gt;&#160;million&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and $0, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;respectively, included in accounts payable and accrued expenses due to related parties.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</kpti:RelatedPartyTransactionsDisclosureTextblockTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2018To12_31_2018_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2019To12_31_2019_ConsultingAndHistopathologyServicesMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2019_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2018_ConsultingAndContractResearchServicesMemberusgaapRelatedPartyTransactionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underwritten Offerings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;On May&#160;7, 2018, we completed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follow-on&lt;/div&gt; offering under our shelf registration statement on Form&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;S-3 &lt;/div&gt; (File No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;333-222726)&lt;/div&gt; pursuant to which we issued an aggregate of 10,525,424&#160;shares of common stock, which included the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $14.75 per share. We received aggregate net proceeds of approximately $145.7&#160;million from the offering after deducting the underwriting discounts and commissions and other offering expenses.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;On April&#160;28, 2017, we completed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follow-on&lt;/div&gt; offering under our shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3 &lt;/div&gt; (File No.&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;333-214489)&lt;/div&gt; pursuant to which we issued an aggregate of 3,902,439 shares of common stock at a public offering price of $10.25 per share. We received net proceeds of approximately $37.9 &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;from the offering after deducting the underwriting discount and commissions and offering expenses.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Controlled Equity Offering Sales Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;On December&#160;7, 2015, we entered into a Controlled Equity Offering Sales Agreement (as amended on November&#160;7, 2016 and December&#160;1, 2017, the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp; Co., as sales agent (&#x201c;Cantor&#x201d;), pursuant to which we issued and sold through Cantor an aggregate of 9,172,159&#160;shares of our common stock, for net proceeds of approximately $89.1&#160;million. The Sales Agreement was terminated effective &lt;span style="-sec-ix-hidden:hidden10182875"&gt;August&#160;12, 2018&lt;/span&gt;. Under the Sales Agreement, Cantor sold shares of our common stock by methods deemed to be an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;at-the-market&#x201d;&lt;/div&gt; offering as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). We paid Cantor a commission of up to 3.0% of the gross proceeds from the sale of the shares of our common stock pursuant to the Sales Agreement and provided Cantor with customary indemnification and contribution rights.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2018, we did not sell any shares under the Sales Agreement. During the year ended December&#160;31, 2017, we sold an aggregate of 3,405,763 shares under the Sales Agreement for net proceeds of approximately $37.0&#160;million. &lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Open Market Sale Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;17, 2018, we entered into an Open Market Sale Agreement (the &#x201c;Open Market Sale Agreement&#x201d;) with Jefferies LLC, as agent (&#x201c;Jefferies&#x201d;), pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $75.0&#160;million (the &#x201c;Open Market Shares&#x201d;) from time to time through Jefferies (the &#x201c;Open Market Offering&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Open Market Sale Agreement, Jefferies may sell the Open Market Shares by methods deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act. We may sell the Open Market Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Open Market Sale Agreement, but we have no obligation to sell any of the Open Market Shares in the Open Market Offering. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We or Jefferies may suspend or terminate the offering of Open Market Shares upon notice to the other party and subject to other conditions. We have agreed to pay Jefferies commissions for its services in acting as agent in &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the sale of the Open Market Shares in the amount of up to 3.0% of gross proceeds from the sale of the Open Market Shares pursuant to the Open Market Sale Agreement. We have also agreed to provide Jefferies with customary indemnification and contribution rights. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2019, we sold an aggregate of 3,712,359 Open Market Shares under the Open Market Sale Agreement, for net proceeds of approximately $46.2&#160;million. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">10525424</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">14.75</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P05_07_2018To05_07_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">145700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_28_2017To04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">3902439</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.25</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P04_28_2017To04_28_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-2"
      unitRef="Unit_USD">37900</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P12_07_2015To12_07_2015_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">9172159</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P12_07_2015To12_07_2015_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">89100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <kpti:CommissionPercentageOnGrossProceedsFromSaleOfShares
      contextRef="P01_01_2018To12_31_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      unitRef="Unit_pure">0.030</kpti:CommissionPercentageOnGrossProceedsFromSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2017To12_31_2017_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">3405763</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2017To12_31_2017_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">37000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <kpti:AggregateOfferingPrice
      contextRef="PAsOn08_07_2018_JefferiesLLCMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</kpti:AggregateOfferingPrice>
    <kpti:CommissionPercentageOnGrossProceedsFromSaleOfShares
      contextRef="P01_01_2018To12_31_2018_CantorFitzgeraldAndCoMembersrtCounterpartyNameAxis_ControlledEquityOfferingSalesAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.030</kpti:CommissionPercentageOnGrossProceedsFromSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_JefferiesLLCMembersrtCounterpartyNameAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">3712359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_JefferiesLLCMembersrtCounterpartyNameAxis_OpenMarketSaleAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">46200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are party to an operating lease of 98,502 square feet of office and research space in Newton, Massachusetts with a term through September&#160;30, 2025 (the &#x201c;Newton, MA Lease&#x201d;). Pursuant to the Newton, MA Lease, we have provided a security deposit in the form of a cash-collateralized letter of credit in the amount of $0.6&#160;million. The amount is classified within long-term restricted cash. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;Upon the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; we recorded an operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; asset of $11.7&#160;million and corresponding lease liability of $16.0&#160;million related only to the Newton, MA Lease. As of December&#160;31, 201&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;, there was a balance of $1.7&#160;million and $2.6&#160;million related to unamortized deferred rent and tenant incentive allowances, respectively, for the Newton, MA Lease, both accounted for as liabilities. These balances were deducted from the lease liability on the Newton, MA Lease in arriving at the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; asset upon adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02&lt;/div&gt; on January&#160;1, 2019.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Newton, MA Lease provides for increases in future minimum annual rental payments, as defined in the lease agreement. The Newton, MA Lease also includes real estate taxes and common area maintenance (&#x201c;CAM&#x201d;) charges in the annual rental payments. As these charges were included in minimum annual rental payments as part of our accounting for the Newton, MA Lease under ASC 840 through December&#160;31, 2018, we have included such amounts in the calculation of the operating lease liability, consistent with ASC 842 and our accounting policy elections thereunder, as specified in Note 2, &#x201c;Recent Accounting Pronouncements.&#x201d; The operating lease cost for the Newton, MA Lease for the year ended December&#160;31, 2019 was $2.8&#160;million, of which approximately $0.9&#160;million was charges for CAM. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In addition, we are party to short-term leases having a term of twelve months or less at the commencement date. We recognize short-term lease expense on a straight-line basis and do not record a related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of&lt;/div&gt; use asset or lease liability for such leases. These costs were insignificant for the year ended December&#160;31, 2019.&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;As of December&#160;31, 2019, future minimum lease payments under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; operating lease agreements for which we have recognized operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and liabilities are as follows (in thousands):&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 83%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years ending December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-left: 0px; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future&lt;br/&gt; Minimum&lt;br/&gt; Payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,200 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,277 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,447 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,718 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024 and thereafter &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,735 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum lease payments &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,377 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0px 0px 0px 5em; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: present value adjustment &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,529&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of minimum lease payments &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;"&gt;As of December&#160;31, 2019, the remaining lease term on the Newton, MA Lease was 5.8 years. The lease has a renewal option for an additional five years, although there is no economic penalty for failure to exercise the option. However, because we did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard, and the renewal option was not previously considered in our assessment of the lease term for the Newton, MA Lease before adoption of ASC 842, the renewal option was not considered as part of the lease term in calculating the operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and liabilities as of January&#160;1, 2019.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a discount rate was not directly observable for our Newton, MA Lease, the discount rate used to calculate the net present value of future payments was our incremental borrowing rate calculated at transition based on the remaining lease term. Upon adoption and through December&#160;31, 2019, the discount rate used to calculate the operating lease liability was 11.0%. The incremental borrowing rate is the rate of interest that we would expect to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. In determining the incremental borrowing rate, we considered&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"&gt;(i)&#160;our estimated public credit rating, (ii)&#160;our observable debt yields, as well as other bonds in the market issued by other companies with similar credit ratings as us, and (iii)&#160;adjustments necessary for collateral, lease term, and inflation or foreign currency.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time we may face legal claims or actions in the normal course of business. We have been named as a defendant in securities class action litigation in the U.S. District Court for the District of Massachusetts. A complaint was filed on July&#160;23, 2019, by the Allegheny County Employees&#x2019; Retirement System, against us and certain of our current and former executive officers and directors as well as the underwriters of our public offerings of common stock conducted in April 2017 and May 2018. A second complaint was filed by Heather Mehdi on September&#160;17, 2019, against the same defendants with the exception of the underwriters. The two complaints are related and we expect them to be consolidated by the court. Both complaints allege violations of federal securities laws based on our disclosures related to the results from the Phase 2 SOPRA study and Part 2 of the Phase 2b STORM study, and seek unspecified compensatory damages, including interest; reasonable costs and expenses, including attorneys&#x2019; and expert fees; unspecified recessionary damages; and such equitable/injunctive relief or other relief as the court may deem just and proper. We have reviewed the allegations and believe they are without merit. We intend to defend vigorously against this litigation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="PAsOn12_31_2019_OfficeAndResearchSpaceLeaseMemberusgaapLeaseArrangementTypeAxis"
      decimals="INF"
      unitRef="Unit_sqft">98502</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn12_31_2019_OfficeAndResearchSpaceLeaseMemberusgaapLeaseArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:SecurityDeposit>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">11700000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn12_31_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">16000000.0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="PAsOn12_31_2018_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn12_31_2018_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">2600000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2019To12_31_2019_CommonAreaMaintenanceMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;As of December&#160;31, 2019, future minimum lease payments under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; operating lease agreements for which we have recognized operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt; assets and liabilities are as follows (in thousands):&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 83%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 9%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 8pt;padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-left: 0px; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years ending December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-left: 0px; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future&lt;br/&gt; Minimum&lt;br/&gt; Payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,200 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,277 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,447 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,718 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024 and thereafter &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,735 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum lease payments &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,377 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0px 0px 0px 5em; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: present value adjustment &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,529&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of minimum lease payments &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,848 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3447000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3718000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <kpti:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6735000</kpti:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5529000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">14848000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn12_31_2019">P5Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.110</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Product Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;To date, our only source of product revenue has been from the U.S. sales of XPOVIO, which we began shipping to our customers in July 2019. The following table summarizes activity in each of the product revenue allowance and reserve categories from the date of approval by the FDA through December&#160;31, 2019&#160;(in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discounts&#160;and&lt;br/&gt; Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fees,&#160;Rebates,&lt;br/&gt; and Other&lt;br/&gt; Incentives &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning balance at July&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision related to sales in the current year &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,657 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,318 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;234 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,209 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit and payments made &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,655&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(499&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,154&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-left: 0.26in; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending balance at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,002 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,819 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;234 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,055 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discounts, chargebacks, and returns are recorded as reductions of accounts receivable, and fees, rebates, and other incentives are recorded as a component of accrued expenses. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <kpti:ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock contextRef="P01_01_2019To12_31_2019_XpovioMembersrtProductOrServiceAxis">The following table summarizes activity in each of the product revenue allowance and reserve categories from the date of approval by the FDA through December&#160;31, 2019&#160;(in thousands):
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discounts&#160;and&lt;br/&gt; Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fees,&#160;Rebates,&lt;br/&gt; and Other&lt;br/&gt; Incentives &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term: &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning balance at July&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision related to sales in the current year &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,657 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,318 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;234 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,209 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit and payments made &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,655&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(499&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,154&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-left: 0.26in; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending balance at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,002 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,819 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;234 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,055 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; </kpti:ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock>
    <kpti:RevenueRecognitionDiscountsAndChargeBacks
      contextRef="PAsOn12_31_2018"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <kpti:RevenueRecognitionProvisionForDiscountsAndChargeBacks
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2657000</kpti:RevenueRecognitionProvisionForDiscountsAndChargeBacks>
    <kpti:RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2318000</kpti:RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives>
    <kpti:RevenueRecognitionSaleReturnsReserveForSaleReturns
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">234000</kpti:RevenueRecognitionSaleReturnsReserveForSaleReturns>
    <kpti:RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5209000</kpti:RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns>
    <kpti:RevenueRecognitionPaymentsForChargeBacks
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-1655000</kpti:RevenueRecognitionPaymentsForChargeBacks>
    <kpti:RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-499000</kpti:RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives>
    <kpti:RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-2154000</kpti:RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns>
    <kpti:RevenueRecognitionDiscountsAndChargeBacks
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1002000</kpti:RevenueRecognitionDiscountsAndChargeBacks>
    <kpti:RevenueRecognitionFeesRebatesAndOtherIncentives
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1819000</kpti:RevenueRecognitionFeesRebatesAndOtherIncentives>
    <kpti:RevenueRecognitionSalesReturn
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">234000</kpti:RevenueRecognitionSalesReturn>
    <kpti:RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3055000</kpti:RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2019To12_31_2019_LicenseAndAssetPurchaseAgreementsMembersrtProductOrServiceAxis">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. License and Asset Purchase Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antengene License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Effective May&#160;23, 2018 (the &#x201c;Antengene Effective Date&#x201d;), we entered into a License Agreement (&#x201c;Antengene License Agreement&#x201d;) with Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong (&#x201c;Antengene&#x201d;) and a subsidiary of Antengene Corporation Co. Ltd., a corporation organized and existing under the laws of the People&#x2019;s Republic of China, pursuant to which we granted Antengene exclusive rights to develop and commercialize, at its own cost, (i)&#160;selinexor, our lead, novel, oral Selective Inhibitor of Nuclear Export (&#x201c;SINE&#x201d;) compound, (ii)&#160;eltanexor, our second-generation oral SINE compound, and (iii)&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;KPT-9274,&lt;/div&gt; our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in-class&lt;/div&gt; orally bioavailable small molecule that is a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-competitive &lt;/div&gt; dual modulator of PAK4 and NAMPT, each for the diagnosis, treatment and/or prevention of all human oncology indications (the &#x201c;Oncology Field&#x201d;), as well as (iv)&#160;verdinexor, our lead compound in development for the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;treatment of viral indications for the diagnosis, treatment and/or prevention of certain human &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-oncology &lt;/div&gt; indications (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Non-Oncology&lt;/div&gt; Field&#x201d;) (the &#x201c;Antengene Licensed Compounds&#x201d;). We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the Oncology Field in mainland China and Macau and licensed the development and commercial rights to Antengene for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274&lt;/div&gt; in the Oncology Field and verdinexor in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Oncology&lt;/div&gt; Field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam (the &#x201c;Antengene Territory&#x201d;).&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;Pursuant to the terms of the Antengene License Agreement, we received an upfront payment of $11.7&#160;million, and could receive up to $105.0&#160;million in milestone payments if certain development &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and regulatory &lt;/div&gt;goals are achieved and up to $45.0&#160;million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty based on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, upon Antengene&#x2019;s election and the parties&#x2019; full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the &#x201c;Antengene Manufacturing Election&#x201d;), we will grant to Antengene &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; rights to manufacture the Antengene Licensed Compounds and products containing such compounds in or outside of the Antengene Territory solely for development and commercialization in the fields in the Antengene Territory.&lt;/div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the Antengene License Agreement, Antengene will also have the right to participate in global clinical studies of the Antengene Licensed Compounds and will bear the cost and expense for patients enrolled in clinical studies in the Antengene Territory. Antengene is responsible for seeking regulatory and marketing approvals for the Antengene Licensed Compounds in the Antengene Territory, as well as any development of the products specifically necessary to obtain such approvals. Antengene is also responsible for the commercialization of the Antengene Licensed Compounds in the Oncology Field and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Oncology&lt;/div&gt; Field, as applicable, in the Antengene Territory at its own cost and expense. Until such time as Antengene elects to manufacture its own drug substance, we will furnish clinical supplies of drug substance to Antengene for use in Antengene&#x2019;s development efforts pursuant to a clinical supply agreement between us and Antengene, and Antengene may elect to have us provide commercial supplies of drug product to Antengene pursuant to a commercial supply agreement between us and Antengene, in each case the costs of which will be borne by Antengene. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The Antengene License Agreement will continue in effect on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-product,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country &lt;/div&gt; basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Antengene License Agreement may be terminated earlier by (i)&#160;either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii)&#160;Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days&#x2019; prior notice or (iii)&#160;us in the event Antengene challenges or assists with a challenge to certain of our patent rights.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We assessed the Antengene arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Antengene, is a customer. We identified the following material promises under the contract: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i)&#160;exclusive licenses for each Antengene Licensed Compound, (ii)&#160;initial data transfers for each Antengene Licensed Compound, which consisted of regulatory data compiled by us for the Antengene Licensed Compounds as of the Antengene Effective Date, and (iii)&#160;obligations to stand-ready to provide an initial clinical supply for each Antengene Licensed Compound. We also identified immaterial promises under the contract relating to information exchanges and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Antengene, including (i)&#160;additional data transfers for each Antengene Licensed Compound, which would consist of the transfer of additional regulatory data compiled by us for each Antengene Licensed Compound after the Antengene Effective Date, (ii)&#160;obligations to provide additional clinical supply and related substance supply for each Antengene Licensed Compound upon request by Antengene, (iii)&#160;manufacturing technology transfers and licenses for each Antengene Licensed Compound under the Antengene Manufacturing Election, as detailed above, and (iv)&#160;options for a backup compound, which represents Antengene&#x2019;s option to select a replacement compound in the event it elects to discontinue the development of the Antengene Licensed Compounds (the &#x201c;Antengene Transfer Options&#x201d;). The Antengene Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Antengene License Agreement. Finally, we also identified certain other customer options that would create a manufacturing obligation for us if exercised by Antengene, including for commercial supply. These options do not represent a material right, as they are not offered at a significant and incremental discount. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In further evaluating the promises detailed above, we determined that the exclusive licenses, initial data transfers, and stand-ready obligation to provide initial clinical supply for each Antengene Licensed Compound were not distinct from one another, and must be combined as four separate performance obligations (the &#x201c;Antengene Combined License Obligation for selinexor&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#x201d;&#160;&#x201c;Antengene Combined License Obligation for eltanexor&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#x201d;&#160;&#x201c;Antengene Combined License Obligation for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274&#x201d;&lt;/div&gt; and &#x201c;Antengene Combined License Obligation for verdinexor&#x201d;). This is because, for each Antengene Licensed Compound, Antengene requires the initial data transfer and initial clinical supply to derive benefit from the exclusive licenses, since we did not grant manufacturing licenses to any of the Antengene Licensed Compounds at contract inception. We also determined that each of the Antengene Transfer Options represents a distinct performance obligation. Based on these determinations, we identified eight performance obligations at the inception of the Antengene License Agreement, including (i)&#160;the Antengene Combined License Obligation for selinexor, (ii)&#160;the Antengene Combined License Obligation for eltanexor, (iii)&#160;the Antengene Combined License Obligation for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274,&lt;/div&gt; (iv)&#160;the Antengene Combined License Obligation for verdinexor, and the four components of the Antengene Transfer Options, including (v)&#160;the material right for additional data transfer, (vi)&#160;the material right for additional clinical supply and related substance supply, (vii)&#160;the material right for manufacturing technology transfer and license, and (viii)&#160;the material right for the option for a backup compound.&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 0em; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;We further determined that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment of $11.7&#160;million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the four Antengene Combined License Obligations for selinexor, eltanexor, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274&lt;/div&gt; and verdinexor. In connection therewith, we also estimated the standalone selling price for each of the material rights within the Antengene Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the $11.7&#160;million transaction price amongst the Antengene Combined License Obligations as follows: $9.4&#160;million for selinexor, $1.0&#160;million for eltanexor, $1.1&#160;million for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274,&lt;/div&gt; and $0.2&#160;million for verdinexor. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;Upon execution of the Antengene License Agreement, the only fixed component of the transaction price included the $11.7&#160;million &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment owed to us. As referenced above, we are eligible to receive additional payments of up to $105.0&#160;million in milestone payments if certain development &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and regulatory &lt;/div&gt;goals&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;are achieved and up to $45.0&#160;million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, we would receive cost reimbursement in connection with Antengene&#x2019;s election to receive additional clinical supply for the Antengene Licensed Compounds in the future. We &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expect to receive &lt;/div&gt; the next milestone &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;payment &lt;/div&gt;under this agreement, which is $5.0&#160;million, upon the first NDA filing in the Antengene Territory in Multiple Myeloma.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The future &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;development a&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;nd &lt;/div&gt;&lt;/div&gt;regulatory milestones and cost reimbursement for providing additional clinical supply of the Antengene Licensed Compounds, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price at contract inception and/or through December&#160;31, 2019, because the amounts were fully constrained as of December&#160;31, 2019. As part of our&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside of our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Antengene, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property licenses granted to Antengene and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;Through the year ended December&#160;31, 2019, we recognized $9.4&#160;million in revenue under the Antengene License Agreement, as the Antengene Combined License Obligation for selinexor was satisfied when the initial clinical supply of selinexor was delivered during the second quarter of 2019. Revenue will be recognized for the Antengene Combined License Obligation for eltanexor,&#160;the Antengene Combined License Obligation for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274,&lt;/div&gt; and the Antengene Combined License Obligation for verdinexor once our promise to provide initial clinical supply of each of the Antengene Licensed Compounds in the future is fulfilled. We currently expect the initial clinical supplies of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-9274&lt;/div&gt;, eltanexor and verdinexor&#160;to be delivered within twelve months of the balance sheet date of December&#160;31, 2019. Accordingly, and as of December&#160;31, 2019, the remaining $2.3&#160;million of the upfront payment represents a contract liability, all of which was included in deferred revenue and is classified as a current liability.&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Biogen Asset Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;24, 2018, we entered into an Asset Purchase Agreement (the &#x201c;APA&#x201d;) and Letter Agreement with Biogen MA Inc., a Massachusetts corporation and subsidiary of Biogen, Inc. (&#x201c;Biogen&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 0em; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;Under the terms of the APA and Letter Agreement, we sold to Biogen exclusive worldwide rights to develop and commercialize our oral SINE compound &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; and certain related assets with an initial focus in amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) (the &#x201c;Transfer of IP&#x201d;), and also granted Biogen: (i)&#160;an exclusive worldwide license under certain of our intellectual property to manufacture or have manufactured &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; (the &#x201c;Manufacturing License&#x201d;), (ii)&#160;a technology transfer package, consisting of information and our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how &lt;/div&gt; regarding the manufacture of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; (the &#x201c;Manufacturing Technology Transfer&#x201d;), (iii)&#160;a right, at Biogen&#x2019;s request, to have us provide transition assistance regarding manufacturing and other matters (the &#x201c;Transition Assistance&#x201d;), (iv)&#160;existing inventory of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; (the &#x201c;Inventory&#x201d;), (v)&#160;an initial supply of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; (the &#x201c;Initial Supply&#x201d;), and (vi)&#160;a right, at Biogen&#x2019;s request, to have us manufacture and supply the active pharmaceutical ingredient for an additional supply of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; (the &#x201c;Additional Supply&#x201d;). In consideration for these rights, we received an upfront payment of $10.0&#160;million, and we are eligible to receive additional payments of up to $142.0&#160;million based on the achievement by Biogen of future specified development &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and regulatory &lt;/div&gt;milestones, and up to $65.0&#160;million based on the achievement by Biogen of future specified commercial milestones. We will also be eligible to receive tiered royalty payments that reach low double-digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product and the expiration of specified patent protection for the applicable product, determined on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt; basis.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We and Biogen have made customary representations and warranties and agreed to customary covenants in the APA, including covenants requiring Biogen to use commercially reasonable efforts to develop &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KPT-350&lt;/div&gt; in specified neurological indications, including ALS, in any of the United States, United Kingdom, France, Spain, Germany or Italy. The APA will continue in effect until the expiration of all royalty obligations, provided that the APA may be terminated earlier by Biogen, subject to the requirements that Biogen (i)&#160;negotiate in good faith with us regarding an assignment or license back to us of the purchased assets and (ii)&#160;not transfer or license the purchased assets to a third party unless such third party assumes Biogen&#x2019;s obligations to us under the APA.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Biogen, is a customer. We identified the following material promises in the arrangement: the Transfer of IP and the Manufacturing License. We also identified immaterial promises under the contract that were not deemed performance obligations. We further determined that other promises for Additional Supply and Transition&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Assistance represented customer options, which would create an obligation for us if exercised by Biogen. Since no additional or material consideration is owed to us by Biogen upon exercise of the customer options for Additional Supply and Transition Assistance, we determined that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement. We then determined that the Transfer of IP and the Manufacturing License were not distinct from one another and must be combined as a performance obligation (the &#x201c;Combined Performance Obligation&#x201d;). This is because Biogen requires the Manufacturing License to derive benefit from the Transfer of IP. Based on these determinations, as well as the considerations noted above with respect to the material rights for Additional Supply and Transition Assistance, we identified three distinct performance obligations at the inception of the contract: (i)&#160;the Combined Performance Obligation, (ii)&#160;the material right for Additional Supply, and (iii)&#160;the material right for Transition Assistance. We further determined that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.0 &lt;/div&gt;million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, we estimated the stand-alone selling price of the (i)&#160;Combined Performance Obligation, (ii)&#160;material right for Additional Supply, and (iii)&#160;material right for Transition Assistance, and determined that the stand-alone selling price of the material rights for Additional Supply and Transition Assistance were insignificant based on various quantitative and qualitative considerations. Accordingly, we further determined that the allocation of the transaction price to the material rights for Additional Supply and Transition Assistance was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, we determined that substantially all of the $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.0 &lt;/div&gt;million transaction price should be allocated to the Combined Performance Obligation. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 0em; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;Upon execution of the APA, the transaction price included only the $10.0&#160;million &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment owed to us. We may receive further payments upon the achievement of certain regulatory and sales milestones, as detailed above, as well as tiered royalty payments that reach low double-digits based on future net sales. &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We expect to receive the next milestone payment under this agreement, which is $2.0&#160;million, when the fifth patient in a Phase 1 Multiple Ascending Dose Trial in the United States of a Product in amyotrophic lateral sclerosis is dosed.&lt;/div&gt;&lt;/div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The future development and regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of December&#160;31, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such milestones is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Biogen, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognized $10.0&#160;million of revenue during the first quarter of 2018, which was when we had satisfied our promises under the Combined Performance Obligation by transferring the underlying promised goods. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ono License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;Effective October&#160;11, 2017 (the &#x201c;Ono Effective Date&#x201d;), we entered into a license agreement (the &#x201c;Ono License Agreement&#x201d;) with Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan (&#x201c;Ono&#x201d;), pursuant to which we granted Ono exclusive rights to develop and commercialize, at its own cost, selinexor and eltanexor, for the diagnosis, treatment and/or prevention of all human oncology indications (the &#x201c;Ono Field&#x201d;) in Japan, Republic of Korea, Republic of China (Taiwan) and Hong Kong, as well as in the ten Southeast Asian countries currently comprising the Association of Southeast Asian Nations (the &#x201c;Ono Territory&#x201d;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(the &#x201c;Ono Exclusive License&#x201d;). Pursuant to the terms of the Ono License Agreement, we received an upfront payment of &#xa5;2.5&#160;billion (US$21.9&#160;million on the date received), and could receive up to &#xa5;10.15&#160;billion (approximately US$90.5&#160;million at the exchange rate as of the Ono Effective Date) in milestone payments if certain development &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and regulatory &lt;/div&gt;goals are achieved and up to &#xa5;9.0&#160;billion (approximately US$80.2&#160;million at the exchange rate as of the Ono Effective Date) in milestone payments if certain sales milestones are achieved, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, upon Ono&#x2019;s election and the parties&#x2019; full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the &#x201c;Ono Manufacturing Election&#x201d;), we will grant to Ono &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; rights to manufacture selinexor, eltanexor and products containing such compounds in or outside of the Ono Territory solely for development and commercialization in the Ono Field in the Ono Territory.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the Ono License Agreement, Ono will also have the right to participate in global clinical studies of selinexor and eltanexor and will bear the cost and expense for patients enrolled in clinical studies in the Ono Territory. Ono is responsible for seeking regulatory and marketing approvals for selinexor and eltanexor in the Ono Territory, as well as any development of the products specifically necessary to obtain such approvals. Ono is also responsible for the commercialization of products containing selinexor or eltanexor in the Ono Field in the Ono Territory at its own cost and expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subject to the Ono Manufacturing Election, we will furnish clinical supplies of drug substance to Ono for use in Ono&#x2019;s development efforts pursuant to a clinical supply agreement between us and Ono, and Ono may elect to have us provide commercial supplies of drug product to Ono pursuant to a commercial supply agreement between us and Ono, in each case the costs of which will be borne by Ono. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The Ono License Agreement will continue in effect on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-product,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country&lt;/div&gt; basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, &lt;span style="-sec-ix-hidden:hidden10185021"&gt;the Ono License Agreement may be terminated earlier by (i)&#160;either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party,&lt;/span&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(ii)&#160;Ono on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-product&lt;/div&gt; basis for certain safety reasons or on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product-by-product,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;country-by-country &lt;/div&gt; basis for any reason with 180&#160;days&#x2019; prior notice or (iii)&#160;us in the event Ono challenges or assists with a challenge to certain of our patent rights.&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 0em; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Ono, is a customer. We identified the following material promises under the contract: (i)&#160;the Ono Exclusive License for selinexor and eltanexor, (ii)&#160;initial data transfer for selinexor and eltanexor, which consisted of regulatory data compiled by us for the licensed compounds and products as of the Ono Effective Date, (iii)&#160;initial clinical supply for selinexor, which consisted of units of clinical supply for Ono to conduct its Phase&#160;I Trial, and (iv)&#160;an obligation to stand-ready to provide initial clinical supply for eltanexor. We also identified immaterial promises under the contract relating to information exchanges, and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Ono, including the (i)&#160;additional data transfer for selinexor and eltanexor, which would consist &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the transfer of additional regulatory data compiled by us for the licensed compounds and products after the Ono Effective Date, (ii)&#160;additional clinical supply and related substance supply for selinexor and eltanexor, which would consist of supplying Ono with units and substance of selinexor and eltanexor incremental to the initial clinical supply for selinexor and the obligation to stand-ready to provide initial clinical supply for eltanexor, as noted above, (iii)&#160;manufacturing technology transfer and license for selinexor and eltanexor under the Ono Manufacturing Election, as detailed above, and (iv)&#160;options for a backup compound, which represents Ono&#x2019;s option to select a replacement compound in the event it elects to discontinue the development of either of the licensed compounds (the &#x201c;Ono Transfer Options&#x201d;). The Ono Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Ono License Agreement. We also identified certain other customer options that would create a manufacturing obligation for us if exercised by Ono, including commercial supply. This &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;option is referred to herein as the &#x201c;Ono Manufacturing Option.&#x201d; The Ono Manufacturing Option does not represent a material right, as it is not offered at a significant and incremental discount. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In further evaluating the promises detailed above, we determined that the (i)&#160;Ono Exclusive License, initial data transfer, and initial clinical supply for selinexor and (ii)&#160;Ono Exclusive License, initial data transfer, and obligation to stand-ready to provide initial clinical supply of eltanexor were not distinct from one another, and must be combined as two separate performance obligations (the &#x201c;Ono Combined License Obligation for selinexor&#x201d; and the &#x201c;Ono Combined License Obligation for eltanexor&#x201d;). This is because, for both selinexor and eltanexor, Ono requires the initial data transfer and clinical supply to derive benefit from the Ono Exclusive License since we did not grant manufacturing licenses for selinexor and eltanexor at contract inception. We also determined that each of the Ono Transfer Options represents a distinct performance obligation. Based on these determinations, we identified six distinct performance obligations at the inception of the Ono License Agreement, including (i)&#160;the Ono Combined License Obligation for selinexor, (ii)&#160;the Ono Combined License Obligation for eltanexor, and the four components of the Ono Transfer Options, including (iii)&#160;the material right for additional data transfer, (iv)&#160;the material right for additional clinical supply and related substance supply, (iv)&#160;the material right for manufacturing technology transfer and license, and (vi)&#160;the material right for the option for a backup compound. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We further determined that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment of &#xa5;2.5&#160;billion (US$21.9&#160;million on the date received) constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on our best estimate of their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the Ono Combined License Obligation for selinexor and the Ono Combined License Obligation for eltanexor. In connection therewith, we estimated the standalone selling price for each of the material rights within the Ono Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the &#xa5;2.5&#160;billion (US$21.9&#160;million on the date received) upfront transaction price between the Ono Combined License Obligations as follows: $19.7&#160;million for selinexor and $2.2&#160;million for eltanexor. We believe that a change in the assumptions used to determine our best estimate of the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0px; line-height: 12pt;"&gt;Upon execution of the Ono License Agreement, the transaction price included only the &#xa5;2.5&#160;billion (US$21.9&#160;million on the date received) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment owed to us. As referenced above, we are eligible to receive additional payments of up to &#xa5;10.15&#160;billion (approximately US$90.5&#160;million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified development &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and regulatory &lt;/div&gt;milestones and up to &#xa5;9.0&#160;billion (approximately US$80.2&#160;million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified commercial milestones, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, we could receive cost reimbursement in connection with our promise to stand-ready to provide initial clinical supply for eltanexor in the future. We &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expect to receive &lt;/div&gt;the next &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;milestone payment under this agreement upon the first licensed&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product in Multiple &lt;/div&gt;Myelomna&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, of &#xa5;&lt;/div&gt;1.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;billion (approximately US$&lt;/div&gt;1.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; million), in Japan.&lt;/div&gt;&lt;/div&gt;  &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The future development and regulatory milestones and cost reimbursement for providing initial clinical supply of eltanexor, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of December 31, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Ono, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Ono and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur. &lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;As the initial clinical supply of selinexor was delivered in April 2018, the Ono Combined License Obligation for selinexor was determined to be fulfilled and revenue of $19.7&#160;million was recognized during the quarter ended June&#160;30, 2018. The transaction price allocated to the Ono Combined License Obligation for eltanexor will be recognized as revenue once our stand-ready promise to provide initial clinical supply of eltanexor in the future is fulfilled, which is the last remaining undelivered promise associated with the Ono Combined License Obligation for eltanexor. As of December&#160;31, 2019, $2.2&#160;million of the Ono License Agreement upfront payment is included in deferred revenue and is classified as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liability.&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">105000000.0</us-gaap:AccountsReceivableNet>
    <kpti:RevenueRecognitionPotentialFutureMilestonePayments
      contextRef="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000.0</kpti:RevenueRecognitionPotentialFutureMilestonePayments>
    <kpti:LicenseAgreementTerminationDescription contextRef="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">License Agreement may be terminated earlier by (i)&#160;either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii)&#160;Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days&#x2019; prior notice or (iii)&#160;us in the event Antengene challenges or assists with a challenge to certain of our patent rights.</kpti:LicenseAgreementTerminationDescription>
    <kpti:LicenseAgreementTerminationNoticePeriod contextRef="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">P180D</kpti:LicenseAgreementTerminationNoticePeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"
      decimals="-5"
      unitRef="Unit_USD">9400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_KPT9274MemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_VerdinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11700000</us-gaap:ContractWithCustomerLiability>
    <kpti:RevenueRecognitionPotentialFutureMilestonePayments
      contextRef="P05_23_2018To05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">105000000.0</kpti:RevenueRecognitionPotentialFutureMilestonePayments>
    <kpti:PotentialCommercialMilestonePayments
      contextRef="PAsOn05_23_2018_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_SalesEventsMembersrtProductOrServiceAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000.0</kpti:PotentialCommercialMilestonePayments>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000.0</us-gaap:AccountsReceivableNet>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">9400000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2019_AntengeneTherapeuticsLimitedMembersrtMajorCustomersAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2300000</us-gaap:ContractWithCustomerLiability>
    <kpti:UpfrontPaymentReceived
      contextRef="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000.0</kpti:UpfrontPaymentReceived>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis_MaximumMembersrtRangeAxis_SalesMilestoneMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">142000000.0</us-gaap:AccountsReceivableNet>
    <kpti:PotentialCommercialMilestonePayments
      contextRef="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">65000000.0</kpti:PotentialCommercialMilestonePayments>
    <kpti:UpfrontPaymentReceived
      contextRef="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000.0</kpti:UpfrontPaymentReceived>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <kpti:UpfrontPaymentReceived
      contextRef="P01_24_2018To01_24_2018_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000.0</kpti:UpfrontPaymentReceived>
    <kpti:UpfrontPaymentReceived
      contextRef="P01_01_2019To12_31_2019_AssetPurchaseAgreementMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000.0</kpti:UpfrontPaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2018To03_31_2018_BiogenMAIncMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-8"
      unitRef="Unit_JPY">2500000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">21900000</us-gaap:ContractWithCustomerLiability>
    <kpti:RevenueRecognitionPotentialFutureMilestonePayments
      contextRef="P10_11_2017To10_11_2017_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="INF"
      unitRef="Unit_JPY">10150000000</kpti:RevenueRecognitionPotentialFutureMilestonePayments>
    <kpti:RevenueRecognitionPotentialFutureMilestonePayments
      contextRef="P10_11_2017To10_11_2017_DevelopmentGoalsMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="INF"
      unitRef="Unit_USD">90500000</kpti:RevenueRecognitionPotentialFutureMilestonePayments>
    <kpti:RevenueRecognitionPotentialFutureMilestonePayments
      contextRef="P10_11_2017To10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_JPY">9000000000.0</kpti:RevenueRecognitionPotentialFutureMilestonePayments>
    <kpti:RevenueRecognitionPotentialFutureMilestonePayments
      contextRef="P10_11_2017To10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis"
      decimals="INF"
      unitRef="Unit_USD">80200000</kpti:RevenueRecognitionPotentialFutureMilestonePayments>
    <kpti:LicenseAgreementTerminationNoticePeriod contextRef="P01_01_2019To12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis">P180D</kpti:LicenseAgreementTerminationNoticePeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-8"
      unitRef="Unit_JPY">2500000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">21900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-8"
      unitRef="Unit_JPY">2500000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">21900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SelinexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"
      decimals="-5"
      unitRef="Unit_USD">19700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn09_30_2019_EltanexorMemberusgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-8"
      unitRef="Unit_JPY">2500000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn10_11_2017_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_UpFrontPaymentArrangementMemberusgaapDeferredRevenueArrangementTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">21900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn09_30_2019_ClinicalDevelopmentAndRegulatoryMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_ScenarioPlanMembersrtStatementScenarioAxis"
      decimals="-7"
      unitRef="Unit_JPY">10150000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn09_30_2019_ClinicalDevelopmentAndRegulatoryMilestoneMembersrtProductOrServiceAxis_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_ScenarioPlanMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">90500000</us-gaap:AccountsReceivableNet>
    <kpti:PotentialCommercialMilestonePayments
      contextRef="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="-8"
      unitRef="Unit_JPY">9000000000.0</kpti:PotentialCommercialMilestonePayments>
    <kpti:PotentialCommercialMilestonePayments
      contextRef="PAsOn09_30_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">80200000</kpti:PotentialCommercialMilestonePayments>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis"
      decimals="-8"
      unitRef="Unit_JPY">1500000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="PAsOn12_31_2019_LicenseAgreementTermsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis_SalesEventsMembersrtProductOrServiceAxis_ScenarioPlanMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">1500000</us-gaap:AccountsReceivableNet>
    <us-gaap:Revenues
      contextRef="P04_01_2019To06_30_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">19700000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2019_OnoPharmaceuticalCompanyLimitedMembersrtMajorCustomersAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Stock-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 100%;"&gt; &lt;div/&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During 2010, we established the 2010 Stock Incentive Plan (the &#x201c;Plan&#x201d; or the &#x201c;2010 Plan&#x201d;). Under the terms of the Plan, we granted options to our employees, officers, directors, consultants and advisors. The exercise price of each stock option is the fair market value as determined in good faith by the Board of Directors (the Board) at the time each option is granted. We granted service-based options under the Plan, which generally vest as follows: 25% of the shares vest one calendar year from the vesting start date, 2.083% of the shares vest on the first day of each month for the three years thereafter. The options granted under the Plan generally expire in 10&#160;years from the date of grant. We will grant no further stock options or other awards under the 2010 Plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2013, &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Board &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; adopted and our stockholders approved the 2013 Stock Incentive Plan (the &#x201c;2013 Plan&#x201d;). The 2013 Plan became effective immediately prior to the closing of the IPO and provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Plan is equal to the sum of (1)&#160;969,696 shares plus (2)&#160;the number of shares (up to 2,126,377 shares) equal to the sum of the number of shares of common stock then available for issuance under the 2010 Plan and the number of shares of common stock subject to outstanding awards under the 2010 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&#160;31, 2014 and continuing until, and including, the fiscal year ending December&#160;31, 2023, equal to the lesser of (A)&#160;1,939,393 shares of common stock, (B)&#160;4% of the number of shares of common stock outstanding on the first day of such fiscal year, or (C)&#160;an amount determined by the Board. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2019, 2018 and 2017, the number of shares available for issuance under the 2013 Plan was increased by 1,939,393, 1,939,393 and 1,675,513 shares of common stock, respectively. As of December&#160;31, 2019, we had 2,373,779&#160;shares available for issuance under the 2013 Plan. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with all share-based payment awards, total stock-based compensation expense recognized was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,457 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,686 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,208 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Selling, general and administrative &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,834 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,589 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,197 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,291 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,275 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,405 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total stock-based compensation &lt;/div&gt; expense related to employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock options for the years ended December&#160;31, 2019, 2018 and 2017 was $12.6&#160;million, $16.4&#160;million and $16.7&#160;million, respectively.&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes stock option activity for employees and nonemployees: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px;width: 92%;font-size: 10pt;border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(year) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;br/&gt; &#160;Intrinsic&lt;br/&gt; &#160;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(in&lt;br/&gt; thousands) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,917,084 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.78 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.4&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,197 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,325,390 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.67 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(394,358&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.18 &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,005,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.36 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden11073498"&gt;9, 843,094&lt;/span&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12.40 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.0&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;82,134 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options exercisable at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,391,153 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.65 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.6&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,879&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total intrinsic value of stock options exercised for the years ended December&#160;31, 2019, 2018 and 2017 was $2.2&#160;million, $6.0&#160;million and $0.4&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The fair value of each stock option granted to employees is estimated on the date of grant and for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; on each reporting date and upon vesting using the Black-Scholes option-pricing model. The following table summarizes the assumptions used in calculating the fair value of the awards:&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 49%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ended December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;79%-81%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;79%-81% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;79%-85% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.5-6.0 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.5-9.8 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.5-9.6 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.42%-2.58%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.50%-3.05% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.76%-2.29% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We use the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Payment&lt;/div&gt;&lt;/div&gt;, to calculate the expected term as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees and utilize the contractual term for options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees.&lt;/div&gt; The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. The expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to us, including early stage of product development and therapeutic focus. For these analyses, we select companies with comparable characteristics to&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;ours including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the options. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. We account for forfeitures as they occur.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Using the Black-Scholes option-pricing model, the weighted-average grant date fair values of options granted during the years ended December&#160;31, 2019, 2018 and 2017 was $6.01, $8.91 and $7.22 per share, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;At December&#160;31, 2019, the total unrecognized compensation related to unvested employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock option awards granted under the 2013 Plan was $26.7&#160;million, which we expect to recognize over a weighted-average period of approximately 2.66&#160;years.&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A restricted stock unit (&#x201c;RSU&#x201d;) represents the right to receive one share of our common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of our common stock on the date of grant.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"&gt;We grant RSUs with service conditions that vest in &lt;/div&gt;two&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"&gt; or &lt;/div&gt;four&lt;div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"&gt; equal annual installments provided that the employee remains employed with us.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2019, we granted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,065,970&lt;/div&gt; shares of RSUs under the 2013 Plan. The following is a summary of RSU activity for the 2013 Plan for the years ended December&#160;31, 2019 and 2018, respectively: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 15%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;br/&gt; Underlying&#160;RSUs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-Average&lt;/div&gt;&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested at December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,000 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.87 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,065,970 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.25 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(286,150 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.24 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17,500 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.96 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;787,320 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.28 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total stock-based compensation expense related to RSUs for the years ended December&#160;31, 2019, 2018 and 2017 was $1.6&#160;million, $0.4&#160;million and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;3.4&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2019, there was $5.8&#160;million of unrecognized compensation costs related to unvested RSUs, which are expected to be recognized over a weighted average period of 3.12&#160;years. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;We have an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) that permits eligible employees to enroll in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden10168480"&gt;six-month&lt;/span&gt; &lt;/div&gt; offering periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first or last day of the applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;six-month &lt;/div&gt; offering period, whichever is lower. Purchase dates under the ESPP occur on or about May&#160;1 and November&#160;1 each year. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2013, our shareholders approved an increase in the number of shares of common stock authorized for issuance pursuant to the ESPP to 242,424 shares of common stock, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of 484,848 shares of our common stock, 1% of the number of outstanding shares on such date, or an amount determined by the Board.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;During the years ended December&#160;31, 2019, 2018 and 2017, $1.7&#160;million, $0.9&#160;million and 0.4&#160;million, respectively, was withheld from employees, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;after-tax&lt;/div&gt; basis, in order to purchase 415,257, 98,770 and&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;57,582 shares of our common stock, respectively. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded stock-based compensation expense &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;related to the ESPP&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;of $1.1&#160;million, $0.4&#160;million and $0.2&#160;million, respectively. As of December&#160;31, 2019, 404,332 shares of &lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;our&lt;/div&gt; common stock remained available for issuance under the ESPP. As of December&#160;31, 2019, there was $0.4&#160;million of total unrecognized stock-based compensation expense related to the ESPP.&#160;The expense is expected to be recognized over a period of four months.&lt;/div&gt; The fair value of the option component of the shares purchased under the ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ended&lt;br/&gt; December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;61&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;-104% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;48%-61% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;48%-78% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.4&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;-2.5% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.3%-2.1% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5%-1.3% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodonememberMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis_VestingperiodtwomemberMemberusgaapVestingAxis"
      decimals="5"
      unitRef="Unit_pure">0.02083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">969696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan
      contextRef="PAsOn10_31_2013_MaximumMembersrtRangeAxis_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2126377</kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedfrompriorstockincentiveplan>
    <kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual
      contextRef="P10_01_2013To10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1939393</kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedannual>
    <kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual
      contextRef="P10_01_2013To10_31_2013_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</kpti:Sharebasedcompensationarrangementbysharebasedpaymentawardnumberofadditionalsharesauthorizedinpercentageannual>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1939393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2018_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1939393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2017_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1675513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P01_01_2019To12_31_2019_TwoThousandThirteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2373779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with all share-based payment awards, total stock-based compensation expense recognized was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,457 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,686 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,208 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Selling, general and administrative &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,834 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,589 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,197 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,291 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,275 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,405 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">6457000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">8686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">11208000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">8834000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">8589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2017To12_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">9197000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">17275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">20405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">16400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">16700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes stock option activity for employees and nonemployees: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px;width: 92%;font-size: 10pt;border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 6%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(year) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aggregate&lt;br/&gt; &#160;Intrinsic&lt;br/&gt; &#160;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(in&lt;br/&gt; thousands) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,917,084 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.78 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.4&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,197 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,325,390 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.67 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(394,358&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.18 &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,005,022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.36 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options outstanding at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden11073498"&gt;9, 843,094&lt;/span&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12.40 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.0&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;82,134 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options exercisable at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,391,153 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.65 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.6&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,879&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">8917084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">3325390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">394358</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">2005022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">82134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">5391153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">39879000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">6000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The fair value of each stock option granted to employees is estimated on the date of grant and for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; on each reporting date and upon vesting using the Black-Scholes option-pricing model. The following table summarizes the assumptions used in calculating the fair value of the awards:&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 49%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ended December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;79%-81%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;79%-81% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;79%-85% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years) &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.5-6.0 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.5-9.8 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.5-9.6 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.42%-2.58%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.50%-3.05% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.76%-2.29% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;%&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2018To12_31_2018_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2017To12_31_2017_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">26700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2019To12_31_2019_EmployeeAndNonEmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <kpti:RightsReceivedForEachRestrictedShareUnit
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_Installment">2</kpti:RightsReceivedForEachRestrictedShareUnit>
    <kpti:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_Installment">4</kpti:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2019, we granted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,065,970&lt;/div&gt; shares of RSUs under the 2013 Plan. The following is a summary of RSU activity for the 2013 Plan for the years ended December&#160;31, 2019 and 2018, respectively: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 15%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;br/&gt; Underlying&#160;RSUs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-Average&lt;/div&gt;&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested at December&#160;31, 2018 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,000 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.87 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,065,970 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.25 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(286,150 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.24 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17,500 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.96 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested at December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;787,320 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.28 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1065970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1065970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">286150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">787320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2017To12_31_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P3Y1M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">In 2013, our shareholders approved an increase in the number of shares of common stock authorized for issuance pursuant to the ESPP to 242,424 shares of common stock, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of 484,848 shares of our common stock, 1% of the number of outstanding shares on such date, or an amount determined by the Board.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">242424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2019_MinimumMembersrtRangeAxis_TwothousandtenstockoptionplanmemberMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">484848</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <kpti:PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</kpti:PercentageOfOutstandingSharesOfCommonStockReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">415257</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">98770</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">57582</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">404332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P4M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">&lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the option component of the shares purchased under the ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ended&lt;br/&gt; December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;61&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;-104% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;48%-61% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;48%-78% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.4&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;-2.5% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.3%-2.1% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.5%-1.3% &lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: center; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MinimumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis_MaximumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2019To12_31_2019_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2018To12_31_2018_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2017To12_31_2017_EmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13. 401(k) Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have a 401(k)&#160;retirement and profit-sharing plan (the &#x201c;401(k)&#160;Plan&#x201d;) covering all qualified employees. The 401(k)&#160;Plan allows each participant to contribute a portion of their base wages up to an amount not to exceed an annual statutory maximum. Effective January&#160;1, 2011, we adopted a Safe Harbor Plan that provides a Company match up to 4% of salary. We contributed a match of $1.7&#160;million, $1.1&#160;million and $0.6&#160;million to the&#160;401(k)&#160;Plan for the years ended December&#160;31, 2019, 2018 and 2017, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2017To12_31_2017"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Tax Legislation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;). This legislation reduced the U.S. corporate tax rate from the current rate of 34% to 21% for tax years beginning after December&#160;31, 2017. As a result of the enacted law, we were required to revalue deferred tax assets and liabilities existing as of December&#160;31, 2017 from the 34% federal rate in effect through the end of 2017, to the new 21% rate.&#160;We have recognized the impact of the TCJA in these consolidated financial statements and related disclosures. In the year ended December&#160;31, 2018, we recorded an impact of $0.5&#160;million related to the return to provision items for federal rate change, which is offset by a full valuation allowance. The impact of the remeasurement of our U.S. deferred tax assets and liabilities to 21% resulted in the reduction of deferred tax assets of approximately $42.7&#160;million, which is offset by a full valuation allowance.&#160;There was no impact to our income statement due to the reduction in the U.S. corporate tax rate. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December&#160;31, 2019, 2018 and 2017, we recorded an income tax expense of less than $&lt;/div&gt;&lt;/div&gt;0.1&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million for our operations in Germany. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost-plus profit margin. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of loss before income taxes were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 54%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt; text-align: right;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt;page-break-inside: avoid;background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 54%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23,350 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28,689&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(35,680&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 54%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(176,200 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(149,692&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(93,241&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 54%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 54%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Totals &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(199,550 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(178,381&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(128,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 54%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The significant components of our deferred tax assets are comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and state net operating loss carryforwards &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;150,909 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;116,236 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,914 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,228 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accruals and other temporary differences &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,212 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,605 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credits &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;62,374 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;49,307 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capitalized research and development &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,021 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,388 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets and intangibles &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,893 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,422 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,051 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;527 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign net operating loss carryforwards &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0in; width: 69%;;vertical-align:top;"&gt;&lt;div style="margin: 0in 0in 0in 0in;text-indent: -1em;margin-left: 3em;line-height: normal;font-family: Calibri, sans-serif;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liability &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 6%;;vertical-align:top;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 5%;;vertical-align:top;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin: 0in 0in 0in 3em; text-indent: -1em; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred royalty embedded derivative&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;533&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt;;text-align:right;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(224,943 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(173,247&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,411 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,538 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible debt amortization &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(13,431 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,538&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 69%;;vertical-align:top;"&gt;&lt;div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 0in;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;margin-left: 3em;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use asset &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 6%;;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,462&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 5%;;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in 2pt 0in 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 3em;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred royalty obligation &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(518&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,411 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,538&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December&#160;31, 2019 and 2018. The valuation allowance increased &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;approximately $51.7 &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million during the year ended December&#160;31, 2019 to $224.9&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, from $173.2&#160;million during the year ended December&#160;31, 2018, primarily due to the generation of net operating losses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 12pt;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%; padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 5%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 5%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal income tax expense at statutory rate &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income tax, net of federal benefit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent differences &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision to return adjustments &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal rate change &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(33.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective income tax rate &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt; height: 15px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2019 and 2018, we had U.S. federal net operating loss carryforwards of approximately $576.5&#160;million and $427.0&#160;million, respectively, which may be able to offset future income tax liabilities. Of the $&lt;/div&gt;&lt;/div&gt;576.5&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million carryforward as of December&#160;31, 2019, $&lt;/div&gt;&lt;/div&gt;283.6&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of the carryforward has an indefinite life and&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;292.9&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million will expire at various dates through 2037. As of December&#160;31, 2019 and 2018, we had U.S. state net operating loss carryforwards of approximately $502.3&#160;million and &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;$&lt;/div&gt;414.8&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively, which may be available to offset future state income tax liabilities and expire at various dates through 203&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;. Also as of December&#160;31, 2019, we had foreign net operating loss carryforwards of less than&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;0.1&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, which &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;have an indefinite li&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fe and &lt;/div&gt;&lt;/div&gt;may be able to offset future foreign income tax liabilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2019 and 2018, we had federal research and development tax credit carryforwards of approximately &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;58.5&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and $&lt;/div&gt;&lt;/div&gt;46.9&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively, available to reduce future tax liabilities, which expire at various dates through 203&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;. As of December&#160;31, 2019 and 2018, we had state research and development tax credit carryforwards of approximately $&lt;/div&gt;&lt;/div&gt;4.9&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and $&lt;/div&gt;&lt;/div&gt;3.0&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively, available to reduce future tax liabilities, which expire at various dates through 203&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;. We completed a study of R&amp;amp;D tax credits through December&#160;31, 2018 and adjusted our deferred tax asset for the result of that study.&#160;For the year ending December&#160;31, 2019, we generated research credits but have not conducted a study to document the qualified activities. This study may result in an adjustment to our research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against our research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a &lt;span style="-sec-ix-hidden:hidden10534998"&gt;three&lt;/span&gt;-year period in excess of 50&#160;percent, as defined under Sections&#160;382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of us immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Previously, we have completed several financings since our inception, which resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code. We completed a Section&#160;382 analysis through July&#160;31, 2015 and subsequently reduced our deferred tax assets for tax attributes we believe will expire unused. We updated our Section&#160;382 analysis through December&#160;31, 2019 and confirmed there were no ownership changes since July&#160;31, 2015. In the future, we may complete financings that could result in a change in control, &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;which will reduce our deferred tax assets for tax attributes we believe will expire unused due to the change in control limitations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;In October 2016 the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-16.&lt;/div&gt; This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this standard on January&#160;1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional deferred tax assets of approximately $19.2&#160;million which were offset by a corresponding valuation allowance.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2019 and 2018, we had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We or one of our subsidiaries file income tax returns in the United States, and various state and foreign jurisdictions. The federal, state and foreign income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2019. To the extent we have tax attribute&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;carryforwards&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2017To12_31_2017"
      decimals="2"
      unitRef="Unit_pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2017To12_31_2017"
      decimals="2"
      unitRef="Unit_pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <kpti:ProvisionForIncomeTaxesForFederalTaxRateChanges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">500000</kpti:ProvisionForIncomeTaxesForFederalTaxRateChanges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <kpti:TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">42700000</kpti:TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_DEsrtStatementGeographicalAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of loss before income taxes were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 54%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt; text-align: right;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt;page-break-inside: avoid;background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 54%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23,350 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28,689&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(35,680&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 54%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(176,200 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(149,692&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(93,241&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 54%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0pt 0pt 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 54%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Totals &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(199,550 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(178,381&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(128,921&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 54%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</kpti:ComponentsOfIncomeLossBeforeIncomeTaxesTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-23350000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-28689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-35680000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-176200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-149692000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-93241000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-199550000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-178381000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2017To12_31_2017"
      decimals="-3"
      unitRef="Unit_USD">-128921000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2019To12_31_2019">The significant components of our deferred tax assets are comprised of the following (in thousands):
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and state net operating loss carryforwards &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;150,909 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;116,236 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,914 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,228 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accruals and other temporary differences &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,212 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,605 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credits &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;62,374 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;49,307 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capitalized research and development &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,021 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,388 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets and intangibles &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,893 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,422 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,051 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;527 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign net operating loss carryforwards &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;72 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0in; width: 69%;;vertical-align:top;"&gt;&lt;div style="margin: 0in 0in 0in 0in;text-indent: -1em;margin-left: 3em;line-height: normal;font-family: Calibri, sans-serif;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liability &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 6%;;vertical-align:top;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 5%;;vertical-align:top;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 0in 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding:0in 2.0pt 0in 0in;vertical-align:bottom;"&gt;&lt;div style="margin-bottom:.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin: 0in 0in 0in 3em; text-indent: -1em; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred royalty embedded derivative&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;533&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; text-align: right; line-height: normal; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt;;text-align:right;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0px; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(224,943 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(173,247&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,411 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,538 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible debt amortization &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(13,431 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,538&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 69%;;vertical-align:top;"&gt;&lt;div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 0in;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;margin-left: 3em;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use asset &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 6%;;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,462&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in; width: 5%;;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background: rgba(255, 255, 255, 0); padding: 0in 2pt 0in 0in;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0in; width: 69%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin-top:0in;margin-right:0in;margin-bottom: 0in;margin-left: 3em;text-indent: -1em;line-height:normal;font-family:Calibri,sans-serif;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred royalty obligation &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 6%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(518&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding: 0in 2pt 0in 0in; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,411 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15,538&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 69%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax assets &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 69%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">150909000</kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal>
    <kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">116236000</kpti:DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11914000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">11228000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <kpti:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4212000</kpti:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences>
    <kpti:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3605000</kpti:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">62374000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">49307000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1021000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1388000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <kpti:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5893000</kpti:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <kpti:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">6422000</kpti:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1051000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">527000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">72000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <kpti:DeferredTaxAssetsLeaseLiability
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3443000</kpti:DeferredTaxAssetsLeaseLiability>
    <kpti:DeferredTaxAssetsRoyaltyEmbadedDerivatives
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">533000</kpti:DeferredTaxAssetsRoyaltyEmbadedDerivatives>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">224943000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">173247000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">15538000</us-gaap:DeferredTaxAssetsGross>
    <kpti:DeferredTaxLiabilitiesConvertibleDebtAmortization
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">13431000</kpti:DeferredTaxLiabilitiesConvertibleDebtAmortization>
    <kpti:DeferredTaxLiabilitiesConvertibleDebtAmortization
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">15538000</kpti:DeferredTaxLiabilitiesConvertibleDebtAmortization>
    <kpti:DeferredTaxAssetsRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2462000</kpti:DeferredTaxAssetsRightOfUseAsset>
    <kpti:DeferredTaxAssetsDeferredRoyaltyObligation
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">518000</kpti:DeferredTaxAssetsDeferredRoyaltyObligation>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">15538000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">51700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">224900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2018"
      decimals="-5"
      unitRef="Unit_USD">173200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2019To12_31_2019">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%; padding: 0px;"/&gt;
&lt;td style="width: 6%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 5%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 5%; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal income tax expense at statutory rate &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;34.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income tax, net of federal benefit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent differences &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7.8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2.5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(9.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25.9&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision to return adjustments &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(0.6&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1.4&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal rate change &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(33.2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 72%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective income tax rate &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt; height: 15px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.060</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.078</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">0.084</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">-0.094</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.259</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">-0.282</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2017To12_31_2017"
      decimals="3"
      unitRef="Unit_pure">-0.332</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2017To12_31_2017"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-5"
      unitRef="Unit_USD">576500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-5"
      unitRef="Unit_USD">427000000.0</us-gaap:OperatingLossCarryforwards>
    <kpti:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife
      contextRef="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="-5"
      unitRef="Unit_USD">576500000</kpti:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife>
    <kpti:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife
      contextRef="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">283600000</kpti:DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife>
    <kpti:NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation
      contextRef="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">292900000</kpti:NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2019_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">502300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2018_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">414800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="PAsOn12_31_2019_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2019_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">58500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2018_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">46900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2019_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">4900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2018_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <kpti:OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_pure">50</kpti:OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn01_01_2018_AccountingStandardsUpdate201616MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-5"
      unitRef="Unit_USD">19200000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15. Long-term obligations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.00% Convertible Senior Notes due 2025 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;On October&#160;16, 2018, we completed an offering of $150.0&#160;million aggregate principal amount of our 3.00% convertible senior notes due 2025 (the &#x201c;Notes&#x201d;). In addition, on October&#160;26, 2018, we issued an additional $22.5&#160;million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule&#160;144A under the Securities Act. In accordance with accounting guidance for debt with conversion and other options, we separately accounted for the liability component (&#x201c;Liability Component&#x201d;) and the embedded conversion option (&#x201c;Equity Component&#x201d;) of the Notes by allocating the proceeds between the Liability Component and the Equity Component, due to our ability to settle the Notes in cash, shares of our common stock or a combination of cash and shares of our common stock, at our option. In connection with the issuance of the Notes, we incurred approximately $5.6&#160;million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs between the Liability Component and the Equity Component based on the allocation of the proceeds. Of the total debt issuance costs, $2.2&#160;million was allocated to the Equity Component and recorded as a reduction to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and $3.4&#160;million was allocated to the Liability Component and recorded as a reduction of the Notes. The portion allocated to the Liability Component is amortized to interest expense using the effective interest method over seven years.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The Notes are our senior unsecured obligations and bear interest at a rate of 3.00% per year payable semiannually in arrears on April&#160;15 and October&#160;15 of each year, beginning on April&#160;15, 2019. Upon conversion, the Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.&lt;div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;The Notes will be subject to redemption at our option, on or after October 15, 2022, in whole or in part, if the conditions described below are satisfied. The Notes will mature on October&#160;15, 2025, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to satisfaction of certain conditions and during the periods described below, the Notes may be converted at an initial conversion rate of 63.0731&#160;shares of common stock per $1 principal amount of the Notes (equivalent to an initial conversion price of approximately $15.85 per share of common stock).&lt;/div&gt;Holders of the Notes may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time prior to the close of business on the business day immediately preceding June&#160;15, 2025 only under the following circumstances:&lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top; padding-left: 0px;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;during any calendar quarter commencing after the calendar quarter ending on December&#160;31, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top; padding-left: 0px;"&gt;(2)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;during the five business day period immediately after any five consecutive trading day&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;period (the &#x201c;Measurement Period&#x201d;) in which the trading price per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top; padding-left: 0px;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;if we call the Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; text-align: left; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top; padding-left: 0px;"&gt;(4)&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;"&gt;upon the occurrence of specified corporate events as described within the indenture governing the Notes.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;As of December&#160;31, 2019, none of the above circumstances had occurred and as such, the Notes could not have been converted. &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We may not redeem the Notes prior to October&#160;15, 2022. On or after October&#160;15, 2022, we may redeem for cash all or part of the Notes at our option if the last reported sale price of our common stock equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending within five trading days prior to the date on which we send any notice of redemption. The redemption price will be 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any convertible note for redemption will constitute a make-whole fundamental change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that convertible note, if it is converted in connection with the redemption, will be increased in certain circumstances. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;The initial carrying amount of the Liability Component of $101.2&#160;million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-convertible&lt;/div&gt; borrowing rate for similar debt. The Equity Component of the Notes of $67.9&#160;million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Notes of $172.5&#160;million and the fair value of the liability of the Notes of approximately $104.7&#160;million on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount is amortized to interest expense using the effective interest method over seven years. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The outstanding balances of the Notes as of December&#160;31, 2019 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability component: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;172,500 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: debt discount and issuance costs, net &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(62,643&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;109,857 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity component: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;65,641 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;We determined the expected life of the Notes was equal to its seven-year term. The effective interest rate on the Liability Component of the Notes was 11.85%. As of December&#160;31, 2019, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;if-converted&lt;/div&gt; value&#x201d; did not&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 0in; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;exceed the remaining principal amount of the Notes. The fair value of the Notes was determined based on data points other than quoted prices that are observable, either directly or indirectly, and has been classified as Level&#160;2 within the fair value hierarchy. The fair value of the Notes, which differs from their carrying value, is influenced by market interest rates, our stock price and stock price volatility. The estimated fair value of the Notes as of December&#160;31, 2019 was approximately $251.0&#160;million.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth total interest expense recognized related to the Notes during the year ended December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 18%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual interest expense &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of debt discount &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,849 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of debt issuance costs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;344 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total interest expense &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,368 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum payments on the Notes as of&#160;December&#160;31, 2019 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years ended December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future&#160;Minimum&#160;Payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024 and thereafter &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;182,850 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum payments &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;203,550 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: interest &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(31,050 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized discount &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(62,643 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 9%; height: 15px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible senior notes &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;109,857 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"&gt;&lt;div style="font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Royalty Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September&#160;2019, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;we entered into a Revenue Interest Financing Agreement (&#x201d;deferred royalty obligation&#x201d;) with HealthCare Royalty Partners &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;III, L.P. and HealthCare Royalty Partners IV, L.P. (&#x201c;HCR&#x201d;) whereby HCR will receive payments from us at a tiered percentage (the &#x201c;Applicable Tiered Percentage&#x201d;) of future net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties. We received $75.0&#160;million upon closing (the &#x201c;First Investment Amount&#x201d;) and have the right to receive an additional $75.0&#160;million (the &#x201c;Second Investment Amount&#x201d; and together with the First Investment Amount, the &#x201c;Investment Amount&#x201d;) upon the achievement of future regulatory and commercial milestones and subject to the approval of both parties and customary closing conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In exchange for the First Investment Amount, HCR will receive a tiered royalty in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single&lt;/div&gt; digits based on worldwide net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties. The Applicable Tiered Percentages are subject to reduction in the future if a target based on cumulative U.S. net sales is met. Total royalty payments are capped &lt;/div&gt;at 185% of the Investment Amount.&lt;/div&gt; &lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;If HCR has not received 65% of the Investment Amount by December&#160;31, 2022 or 100% of the Investment Amount by December&#160;31, 2024, we must make a cash payment sufficient to gross HCR up to such minimum amounts. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the repayment of the&#160;funded amount is contingent upon worldwide net product sales and upfront payments, milestones, and royalties, the repayment term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period commenced on October&#160;1, 2019 and expires on the earlier of (i)&#160;the date in which HCR has received cash payments totaling an aggregate of 185% of the Investment Amount or (ii)&#160;the legal maturity date of October&#160;1, 2031. If HCR has not received payments equal to 185% &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the Investment Amount by the twelve-year anniversary of the initial closing date, we shall pay an amount equal to the Investment Amount plus a specific annual rate of return less payments previously received by HCR. In the event of a change of control, we are obligated to pay HCR an amount equal to 185% of the Investment Amount less payments previously received by HCR. In addition, upon the occurrence of an event of default, including, among others, our failure to pay any amounts due to HCR under the deferred royalty obligation, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the United States or our breach of any covenant contained in the Revenue Interest Financing Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay HCR an amount equal to 185% of the Investment Amount less payments previously received by HCR. In addition, upon an event of default, HCR may exercise all other rights and remedies available under the Revenue Interest Financing Agreement, including foreclosing on the collateral that was pledged to HCR, which consists of all of our present and future assets relating to XPOVIO.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have evaluated the terms of the deferred royalty obligation and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, we have accounted for the transaction as long-term debt. We have further evaluated the terms of the debt and determined that the repayment &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of 185% &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the Investment Amount, less any payments made to date, upon&#160;a change of control is an embedded derivative that requires bifurcation&#160;from the debt instrument and fair value recognition. We determined the fair value of the derivative using an option pricing Monte Carlo simulation model taking into account the probability of change of control occurring and potential repayment amounts and timing of such payments that would result under various scenarios, as further described in Note 2. The aggregate fair value of the embedded derivative at issuance date is included in deferred royalty obligation. We will remeasure the embedded derivative to fair value each reporting period until the time the features lapse and/or termination of the deferred royalty obligation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The effective interest rate as of December&#160;31, 2019 was &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18.4&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the deferred royalty obligation, we incurred debt issuance costs &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;totaling $&lt;/div&gt;&lt;/div&gt;1.4&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. Debt issuance costs have been netted against the debt as of December&#160;31, 2019 and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short and long-term classification of these costs, as well as the period over which these costs will be amortized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="width: 100%; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value of&#160;the deferred royalty obligation at December&#160;31, 2019 was $&lt;/div&gt;&lt;/div&gt;71.3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million based on &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt; $&lt;/div&gt;75.0&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of proceeds, net of fair value of the bifurcated embedded derivative liability and debt issuance costs incurred. The carrying value of the deferred royalty obligation approximates fair value at December&#160;31, 2019 and was measured using Level&#160;3 inputs. The estimated fair market value was calculated using an option pricing Monte Carlo simulation model with inputs consistent with those used in determining the embedded&#160;derivative values as described in Note&#160;2. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0300</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_26_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">5600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <kpti:DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">3400000</kpti:DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes>
    <kpti:DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">P7Y</kpti:DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0300</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P10_16_2018To10_16_2018">2025-10-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P10_16_2018To10_16_2018_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">2025-10-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P10_16_2018To10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">63.0731</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P10_16_2018To10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">1</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_16_2018_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15.85</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <kpti:PrincipalAmountPerNoteUsedInConversionRate
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">1</kpti:PrincipalAmountPerNoteUsedInConversionRate>
    <us-gaap:DebtInstrumentConvertibleLatestDate1 contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">2025-06-15</us-gaap:DebtInstrumentConvertibleLatestDate1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_D">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_D">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1.30</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <kpti:DebtInstrumentConvertibleThresholdMeasurementPeriodDescription contextRef="P01_01_2019To12_31_2019">during the five business day period immediately after any five consecutive trading day</kpti:DebtInstrumentConvertibleThresholdMeasurementPeriodDescription>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_D">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <kpti:PrincipalAmountOfNotesUsedInConversionRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_USD">1000</kpti:PrincipalAmountOfNotesUsedInConversionRate>
    <kpti:DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0.98</kpti:DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_pure">1.30</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_D">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_D">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <kpti:DebtInstrumentRepurchasePricePercentage
      contextRef="P10_15_2022To10_15_2022_ScenarioForecastMembersrtStatementScenarioAxis_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_pure">1</kpti:DebtInstrumentRepurchasePricePercentage>
    <kpti:DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">101200000</kpti:DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">67900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">172500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD">104700000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentTerm contextRef="P01_01_2019To12_31_2019">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The outstanding balances of the Notes as of December&#160;31, 2019 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability component: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;172,500 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: debt discount and issuance costs, net &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(62,643&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;109,857 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity component: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;65,641 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">172500000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <kpti:DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">-62643000</kpti:DebtInstrumentUnamortizedDiscountPremiumandDebtIssuance>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">109857000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">65641000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.1185</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <kpti:DebtInstrumentEstimatedFairValue
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD">251000000.0</kpti:DebtInstrumentEstimatedFairValue>
    <kpti:ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth total interest expense recognized related to the Notes during the year ended December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 18%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual interest expense &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of debt discount &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,849 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of debt issuance costs &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;344 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total interest expense &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,368 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</kpti:ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5175000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">6849000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">344000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">12368000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="P01_01_2019To12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis">&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum payments on the Notes as of&#160;December&#160;31, 2019 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;font-size: 1pt;padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years ended December&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future&#160;Minimum&#160;Payments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,175 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024 and thereafter &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;182,850 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum payments &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;203,550 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: interest &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(31,050 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized discount &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(62,643 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 9%; height: 15px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible senior notes &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; padding-left: 0px;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;109,857 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5175000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5175000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5175000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5175000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">182850000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">203550000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">31050000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">62643000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2019_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">109857000</us-gaap:LongTermDebt>
    <kpti:ProceedsFromFirstInvestmentAmount
      contextRef="P01_01_2019To09_30_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</kpti:ProceedsFromFirstInvestmentAmount>
    <kpti:SecondInvestmentAmount
      contextRef="P01_01_2019To09_30_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</kpti:SecondInvestmentAmount>
    <kpti:RoyaltyPaymentsApplicableTieredPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">1.85</kpti:RoyaltyPaymentsApplicableTieredPercentage>
    <kpti:RoyaltyGuaranteesCommitmentsPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMemberKPTIRoyaltyPaymentDueDateAxis"
      decimals="INF"
      unitRef="Unit_pure">0.65</kpti:RoyaltyGuaranteesCommitmentsPercentage>
    <kpti:RoyaltyGuaranteesCommitmentsPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMemberKPTIRoyaltyPaymentDueDateAxis"
      decimals="INF"
      unitRef="Unit_pure">1</kpti:RoyaltyGuaranteesCommitmentsPercentage>
    <kpti:RoyaltyPaymentsApplicableTieredPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">1.85</kpti:RoyaltyPaymentsApplicableTieredPercentage>
    <kpti:RoyaltyPaymentsApplicableTieredPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">1.85</kpti:RoyaltyPaymentsApplicableTieredPercentage>
    <kpti:RoyaltyPaymentsApplicableTieredPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">1.85</kpti:RoyaltyPaymentsApplicableTieredPercentage>
    <kpti:RoyaltyPaymentsApplicableTieredPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">1.85</kpti:RoyaltyPaymentsApplicableTieredPercentage>
    <kpti:RoyaltyPaymentsApplicableTieredPercentage
      contextRef="PAsOn12_31_2019_HealthcareRoyaltyPartnersIvLpMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">1.85</kpti:RoyaltyPaymentsApplicableTieredPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      unitRef="Unit_pure">0.184</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2019_DeferredRoyaltyObligationMemberusgaapBalanceSheetLocationAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-5"
      unitRef="Unit_USD">71300000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <kpti:ProceedsFromFirstInvestmentAmount
      contextRef="P01_01_2019To12_31_2019_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</kpti:ProceedsFromFirstInvestmentAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_10522752"
          xlink:label="Fact_10522752"
          xlink:type="locator"/>
        <link:footnote id="FN_40312" xlink:label="FN_40312" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents capitalization of operating lease right-of-use assets, offset by reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522752"
          xlink:to="FN_40312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522753"
          xlink:label="Fact_10522753"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522753"
          xlink:to="FN_40312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522754"
          xlink:label="Fact_10522754"
          xlink:type="locator"/>
        <link:footnote id="FN_40313" xlink:label="FN_40313" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522754"
          xlink:to="FN_40313"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522755"
          xlink:label="Fact_10522755"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522755"
          xlink:to="FN_40313"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522756"
          xlink:label="Fact_10522756"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522756"
          xlink:to="FN_40313"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522757"
          xlink:label="Fact_10522757"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522757"
          xlink:to="FN_40313"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522758"
          xlink:label="Fact_10522758"
          xlink:type="locator"/>
        <link:footnote id="FN_40314" xlink:label="FN_40314" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents recognition of operating lease liabilities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522758"
          xlink:to="FN_40314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522759"
          xlink:label="Fact_10522759"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522759"
          xlink:to="FN_40314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522760"
          xlink:label="Fact_10522760"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522760"
          xlink:to="FN_40314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_10522761"
          xlink:label="Fact_10522761"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_10522761"
          xlink:to="FN_40314"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6644381168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember', window );">3% Convertible Senior Notes Due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Long-term obligations </div></div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.00% Convertible Senior Notes due 2025 </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On October&#160;16, 2018, we completed an offering of $150.0&#160;million aggregate principal amount of our 3.00% convertible senior notes due 2025 (the &#8220;Notes&#8221;). In addition, on October&#160;26, 2018, we issued an additional $22.5&#160;million aggregate principal amount of the Notes pursuant to the full exercise of the option to purchase additional Notes granted to the initial purchasers in the offering. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule&#160;144A under the Securities Act. In accordance with accounting guidance for debt with conversion and other options, we separately accounted for the liability component (&#8220;Liability Component&#8221;) and the embedded conversion option (&#8220;Equity Component&#8221;) of the Notes by allocating the proceeds between the Liability Component and the Equity Component, due to our ability to settle the Notes in cash, shares of our common stock or a combination of cash and shares of our common stock, at our option. In connection with the issuance of the Notes, we incurred approximately $5.6&#160;million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs between the Liability Component and the Equity Component based on the allocation of the proceeds. Of the total debt issuance costs, $2.2&#160;million was allocated to the Equity Component and recorded as a reduction to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and $3.4&#160;million was allocated to the Liability Component and recorded as a reduction of the Notes. The portion allocated to the Liability Component is amortized to interest expense using the effective interest method over seven years.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Notes are our senior unsecured obligations and bear interest at a rate of 3.00% per year payable semiannually in arrears on April&#160;15 and October&#160;15 of each year, beginning on April&#160;15, 2019. Upon conversion, the Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>The Notes will be subject to redemption at our option, on or after October 15, 2022, in whole or in part, if the conditions described below are satisfied. The Notes will mature on October&#160;15, 2025, unless earlier converted, redeemed or repurchased in accordance with their terms. Subject to satisfaction of certain conditions and during the periods described below, the Notes may be converted at an initial conversion rate of 63.0731&#160;shares of common stock per $1 principal amount of the Notes (equivalent to an initial conversion price of approximately $15.85 per share of common stock).</div>Holders of the Notes may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time prior to the close of business on the business day immediately preceding June&#160;15, 2025 only under the following circumstances:<div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(1)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">during any calendar quarter commencing after the calendar quarter ending on December&#160;31, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(2)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">during the five business day period immediately after any five consecutive trading day<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>period (the &#8220;Measurement Period&#8221;) in which the trading price per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(3)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">if we call the Notes for redemption, until the close of business on the business day immediately preceding the redemption date; or</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 4%; vertical-align: top; padding-left: 0px;">(4)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">upon the occurrence of specified corporate events as described within the indenture governing the Notes.</td></tr></table><div style="clear: both; max-height: 0px;"/>As of December&#160;31, 2019, none of the above circumstances had occurred and as such, the Notes could not have been converted. <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We may not redeem the Notes prior to October&#160;15, 2022. On or after October&#160;15, 2022, we may redeem for cash all or part of the Notes at our option if the last reported sale price of our common stock equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending within five trading days prior to the date on which we send any notice of redemption. The redemption price will be 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any convertible note for redemption will constitute a make-whole fundamental change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that convertible note, if it is converted in connection with the redemption, will be increased in certain circumstances. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The initial carrying amount of the Liability Component of $101.2&#160;million was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> borrowing rate for similar debt. The Equity Component of the Notes of $67.9&#160;million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Notes of $172.5&#160;million and the fair value of the liability of the Notes of approximately $104.7&#160;million on their respective dates of issuance. The excess of the principal amount of the Liability Component over its carrying amount is amortized to interest expense using the effective interest method over seven years. The Equity Component is not remeasured as long as it continues to meet the conditions for equity classification.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The outstanding balances of the Notes as of December&#160;31, 2019 consisted of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Liability component: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Principal </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">172,500 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: debt discount and issuance costs, net </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(62,643</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">109,857 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity component: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">65,641 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We determined the expected life of the Notes was equal to its seven-year term. The effective interest rate on the Liability Component of the Notes was 11.85%. As of December&#160;31, 2019, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted</div> value&#8221; did not</div>  <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">exceed the remaining principal amount of the Notes. The fair value of the Notes was determined based on data points other than quoted prices that are observable, either directly or indirectly, and has been classified as Level&#160;2 within the fair value hierarchy. The fair value of the Notes, which differs from their carrying value, is influenced by market interest rates, our stock price and stock price volatility. The estimated fair value of the Notes as of December&#160;31, 2019 was approximately $251.0&#160;million.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth total interest expense recognized related to the Notes during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 74%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 18%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/> December&#160;31,&#160;2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Contractual interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,849 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">344 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,368 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments on the Notes as of&#160;December&#160;31, 2019 were as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 74%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended December&#160;31, </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Future&#160;Minimum&#160;Payments </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024 and thereafter </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">182,850 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total minimum payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">203,550 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: interest </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(31,050 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized discount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(62,643 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 9%; height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior notes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">109,857 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-size: 10pt;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred Royalty Obligation</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In September&#160;2019, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we entered into a Revenue Interest Financing Agreement (&#8221;deferred royalty obligation&#8221;) with HealthCare Royalty Partners </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">III, L.P. and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) whereby HCR will receive payments from us at a tiered percentage (the &#8220;Applicable Tiered Percentage&#8221;) of future net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties. We received $75.0&#160;million upon closing (the &#8220;First Investment Amount&#8221;) and have the right to receive an additional $75.0&#160;million (the &#8220;Second Investment Amount&#8221; and together with the First Investment Amount, the &#8220;Investment Amount&#8221;) upon the achievement of future regulatory and commercial milestones and subject to the approval of both parties and customary closing conditions. </div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In exchange for the First Investment Amount, HCR will receive a tiered royalty in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits based on worldwide net revenues of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones, and royalties. The Applicable Tiered Percentages are subject to reduction in the future if a target based on cumulative U.S. net sales is met. Total royalty payments are capped </div>at 185% of the Investment Amount.</div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If HCR has not received 65% of the Investment Amount by December&#160;31, 2022 or 100% of the Investment Amount by December&#160;31, 2024, we must make a cash payment sufficient to gross HCR up to such minimum amounts. </div></div>  <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As the repayment of the&#160;funded amount is contingent upon worldwide net product sales and upfront payments, milestones, and royalties, the repayment term may be shortened or extended depending on actual worldwide net product sales and upfront payments, milestones, and royalties. The repayment period commenced on October&#160;1, 2019 and expires on the earlier of (i)&#160;the date in which HCR has received cash payments totaling an aggregate of 185% of the Investment Amount or (ii)&#160;the legal maturity date of October&#160;1, 2031. If HCR has not received payments equal to 185% </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Investment Amount by the twelve-year anniversary of the initial closing date, we shall pay an amount equal to the Investment Amount plus a specific annual rate of return less payments previously received by HCR. In the event of a change of control, we are obligated to pay HCR an amount equal to 185% of the Investment Amount less payments previously received by HCR. In addition, upon the occurrence of an event of default, including, among others, our failure to pay any amounts due to HCR under the deferred royalty obligation, insolvency, our failure to pay indebtedness when due, the revocation of regulatory approval of XPOVIO in the United States or our breach of any covenant contained in the Revenue Interest Financing Agreement and our failure to cure the breach within the prescribed time frame, we are obligated to pay HCR an amount equal to 185% of the Investment Amount less payments previously received by HCR. In addition, upon an event of default, HCR may exercise all other rights and remedies available under the Revenue Interest Financing Agreement, including foreclosing on the collateral that was pledged to HCR, which consists of all of our present and future assets relating to XPOVIO.</div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have evaluated the terms of the deferred royalty obligation and concluded that the features of the Investment Amount are similar to those of a debt instrument. Accordingly, we have accounted for the transaction as long-term debt. We have further evaluated the terms of the debt and determined that the repayment </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">of 185% </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Investment Amount, less any payments made to date, upon&#160;a change of control is an embedded derivative that requires bifurcation&#160;from the debt instrument and fair value recognition. We determined the fair value of the derivative using an option pricing Monte Carlo simulation model taking into account the probability of change of control occurring and potential repayment amounts and timing of such payments that would result under various scenarios, as further described in Note 2. The aggregate fair value of the embedded derivative at issuance date is included in deferred royalty obligation. We will remeasure the embedded derivative to fair value each reporting period until the time the features lapse and/or termination of the deferred royalty obligation. </div></div></div> </div> <div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effective interest rate as of December&#160;31, 2019 was </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">18.4<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the deferred royalty obligation, we incurred debt issuance costs </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">totaling $</div></div>1.4<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million. Debt issuance costs have been netted against the debt as of December&#160;31, 2019 and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short and long-term classification of these costs, as well as the period over which these costs will be amortized. </div></div></div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of&#160;the deferred royalty obligation at December&#160;31, 2019 was $</div></div>71.3<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million based on </div></div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> $</div>75.0<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of proceeds, net of fair value of the bifurcated embedded derivative liability and debt issuance costs incurred. The carrying value of the deferred royalty obligation approximates fair value at December&#160;31, 2019 and was measured using Level&#160;3 inputs. The estimated fair market value was calculated using an option pricing Monte Carlo simulation model with inputs consistent with those used in determining the embedded&#160;derivative values as described in Note&#160;2. </div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6661246528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Investments, Classified as Available-for-Sale</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The following table summarizes our investments in debt securities, classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> as of December&#160;31, 2019 (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized&#160;Cost </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Gains </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Loss </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,110 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,004 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,990 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,017 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,121 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(44 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,114 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table summarizes our investments in debt securities, classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> as of December&#160;31, 2018 (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized&#160;Cost </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Gains </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Loss </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,254 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(178</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">44,001 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(23</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,131 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(17</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,000 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,007 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,393 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(227</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,179 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6817773904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">$ 13,122<span></span>
</td>
<td class="nump">$ 15,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee-related costs</a></td>
<td class="nump">13,630<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">6,172<span></span>
</td>
<td class="nump">4,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">3,583<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 40,878<span></span>
</td>
<td class="nump">$ 32,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6641870336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6661455104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model (Detail) - ESPP [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6975123168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal', window );">U.S. and state net operating loss carryforwards</a></td>
<td class="nump">$ 150,909<span></span>
</td>
<td class="nump">$ 116,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">11,914<span></span>
</td>
<td class="nump">11,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences', window );">Accruals and other temporary differences</a></td>
<td class="nump">4,212<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">62,374<span></span>
</td>
<td class="nump">49,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles', window );">Fixed Assets and Intangibles</a></td>
<td class="nump">5,893<span></span>
</td>
<td class="nump">6,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">3,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives', window );">Deferred Tax Assets Royalty Embaded Derivatives</a></td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(224,943)<span></span>
</td>
<td class="num">(173,247)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">16,411<span></span>
</td>
<td class="nump">15,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization', window );">Convertible debt amortization</a></td>
<td class="num">(13,431)<span></span>
</td>
<td class="num">(15,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsRightOfUseAsset', window );">Right-of-use&#160;asset</a></td>
<td class="num">(2,462)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetsDeferredRoyaltyObligation', window );">Deferred royalty obligation</a></td>
<td class="num">(518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(16,411)<span></span>
</td>
<td class="num">(15,538)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsDeferredRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsDeferredRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Fixed Assets And Intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic and state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets royalty embaded derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsRoyaltyEmbadedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and other temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOtherTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Convertible Debt Amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxLiabilitiesConvertibleDebtAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>222</ContextCount>
  <ElementCount>463</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Product Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/ProductRevenue</Role>
      <ShortName>Product Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - License and Asset Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreements</Role>
      <ShortName>License and Asset Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Long-Term Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LongTermObligations</Role>
      <ShortName>Long-Term Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/Investments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Commitments and Contingencies  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Product Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/ProductRevenueTables</Role>
      <ShortName>Product Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/ProductRevenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Income Taxes (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/IncomeTaxesTable</Role>
      <ShortName>Income Taxes (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Long-Term Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LongTermObligationsTables</Role>
      <ShortName>Long-Term Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.karyopharm.com/role/LongTermObligations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Organization and Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/OrganizationAndOperationsAdditionalInformationDetail</Role>
      <ShortName>Organization and Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Financial Assets That Have Been Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFinancialAssetsThatHaveBeenMeasuredAtFairValueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Financial Assets That Have Been Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Summary of Significant Accounting Policies - The Changes in the Estimated Fair Value of Our Embedded Derivative Liability - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesTheChangesInTheEstimatedFairValueOfOurEmbeddedDerivativeLiabilityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - The Changes in the Estimated Fair Value of Our Embedded Derivative Liability - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesWereExcludedFromTheCalculationOfDilutedNetLossPerShareDueToTheirAntiDilutiveEffectDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure -  Summary of Significant Accounting Policies- Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAdjustmentsInBalanceSheetDueToAdoptionOfAsc842Detail</Role>
      <ShortName>Summary of Significant Accounting Policies- Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, net - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Property and Equipment, net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Investments - Summary of Investments, Classified as Available-for-Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/InvestmentsSummaryOfInvestmentsClassifiedAsAvailableForSaleDetail</Role>
      <ShortName>Investments - Summary of Investments, Classified as Available-for-Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/InvestmentsAdditionalInformationDetail</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Inventory - Schedule of Inventory Current (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/InventoryScheduleOfInventoryCurrentDetail</Role>
      <ShortName>Inventory - Schedule of Inventory Current (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/AccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Stockholders' Equity - Controlled Equity Offering Sales Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockholdersEquityControlledEquityOfferingSalesAgreementAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Controlled Equity Offering Sales Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Rent Payments Under Lease Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/CommitmentsAndContingenciesScheduleOfMinimumFutureRentPaymentsUnderLeaseAgreementDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Future Rent Payments Under Lease Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Product Revenue -  Schedule of Product Discounts Returns Allowances Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/ProductRevenueScheduleOfProductDiscountsReturnsAllowancesReconciliationDetail</Role>
      <ShortName>Product Revenue -  Schedule of Product Discounts Returns Allowances Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationAntengeneLicenseAgreementDetail</Role>
      <ShortName>License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - License and Asset Purchase Agreements - Additional Information - Biogen Asset Purchase Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationBiogenAssetPurchaseAgreementDetail</Role>
      <ShortName>License and Asset Purchase Agreements - Additional Information - Biogen Asset Purchase Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - License and Asset Purchase Agreements - Additional Information - Ono License Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LicenseAndAssetPurchaseAgreementsAdditionalInformationOnoLicenseAgreementDetail</Role>
      <ShortName>License and Asset Purchase Agreements - Additional Information - Ono License Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/NetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Stock-based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Stock-based Compensation - Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationScheduleOfTotalStockBasedCompensationExpenseRecognizedInConnectionWithAllShareBasedPaymentAwardsDetail</Role>
      <ShortName>Stock-based Compensation - Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity for Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployeesDetail</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity for Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Each Employee and Non-employee Stock Award on Grant Date Using Black Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfEachEmployeeAndNonEmployeeStockAwardOnGrantDateUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Each Employee and Non-employee Stock Award on Grant Date Using Black Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationSummaryOfRsuActivityDetail</Role>
      <ShortName>Stock-based Compensation - Summary of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/StockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOnGrantDateUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - 401(k) Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/KPlanAdditionalInformationDetail</Role>
      <ShortName>401(k) Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/IncomeTaxesScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseComputedAtStatutoryFederalIncomeTaxRateToIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Long-Term Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.karyopharm.com/role/LongTermObligationsAdditionalInformationDetail</Role>
      <ShortName>Long-Term Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Long-Term Obligations - Summary of Outstanding Balances of Convertible Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.karyopharm.com/role/LongTermObligationsSummaryOfOutstandingBalancesOfConvertibleNotesDetail</Role>
      <ShortName>Long-Term Obligations - Summary of Outstanding Balances of Convertible Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Long-Term Obligations - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.karyopharm.com/role/LongTermObligationsScheduleOfInterestExpenseRecognizedRelatedToConvertibleNotesDetail</Role>
      <ShortName>Long-Term Obligations - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d853399d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Long-Term Obligations - Summary of Future Minimum Payments on Convertible Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.karyopharm.com/role/LongTermObligationsSummaryOfFutureMinimumPaymentsOnConvertibleNotesDetail</Role>
      <ShortName>Long-Term Obligations - Summary of Future Minimum Payments on Convertible Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="d853399d10k.htm">d853399d10k.htm</File>
    <File>d853399dex211.htm</File>
    <File>d853399dex231.htm</File>
    <File>d853399dex311.htm</File>
    <File>d853399dex312.htm</File>
    <File>d853399dex321.htm</File>
    <File>d853399dex44.htm</File>
    <File>kpti-20191231.xsd</File>
    <File>kpti-20191231_cal.xml</File>
    <File>kpti-20191231_def.xml</File>
    <File>kpti-20191231_lab.xml</File>
    <File>kpti-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g853399g23c59.jpg</File>
    <File>g853399g25t47.jpg</File>
    <File>g853399g76b11.jpg</File>
    <File>g853399g91m71.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814793776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 128,858<span></span>
</td>
<td class="nump">$ 118,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">133,098<span></span>
</td>
<td class="nump">210,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">7,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,289<span></span>
</td>
<td class="nump">6,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">278,570<span></span>
</td>
<td class="nump">334,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">294,963<span></span>
</td>
<td class="nump">341,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">4,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">40,878<span></span>
</td>
<td class="nump">32,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">9,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">46,350<span></span>
</td>
<td class="nump">46,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes</a></td>
<td class="nump">109,857<span></span>
</td>
<td class="nump">102,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredRoyaltyObligationNoncurrent', window );">Deferred royalty obligation</a></td>
<td class="nump">73,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">13,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">4,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">245,189<span></span>
</td>
<td class="nump">158,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 65,370,448 and 60,829,308 shares issued and outstanding at December 31, 2019 and 2018, respectively</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">923,142<span></span>
</td>
<td class="nump">857,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(873,338)<span></span>
</td>
<td class="num">(673,748)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">49,774<span></span>
</td>
<td class="nump">183,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 294,963<span></span>
</td>
<td class="nump">$ 341,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredRoyaltyObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredRoyaltyObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6641881472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations - Schedule of Interest Expense Recognized Related to Convertible Notes (Detail) - 3% Convertible Senior Notes Due 2025 [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 5,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">6,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 12,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821560688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="nump">$ 162,243<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 528,617<span></span>
</td>
<td class="num">$ (274)<span></span>
</td>
<td class="num">$ (366,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance,Shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,887,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome', window );">Cumulative effect adjustment for adoption of new accounting guidance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and shares issued under the employee stock purchase plan</a></td>
<td class="nump">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of stock options and shares issued under the employee stock purchase plan, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">20,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">74,885<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">74,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,308,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(128,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,984)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">129,464<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">625,017<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="num">(495,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance,Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,533,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and shares issued under the employee stock purchase plan</a></td>
<td class="nump">3,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of stock options and shares issued under the employee stock purchase plan, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">17,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">145,705<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">145,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,525,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of 2025 Notes</a></td>
<td class="nump">67,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt', window );">Equity component of deferred financing costs for 2025 notes</a></td>
<td class="num">(2,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(178,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178,407)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">183,170<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">857,156<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="num">(673,748)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance,Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,829,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and shares issued under the employee stock purchase plan</a></td>
<td class="nump">4,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of stock options and shares issued under the employee stock purchase plan, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">15,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">46,191<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,712,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(199,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(199,590)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 49,774<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 923,142<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="num">$ (873,338)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance,Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,370,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Deferred Financing Costs Related To Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_EquityComponentOfDeferredFinancingCostsRelatedToConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the effect of a change in accounting principle on net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6668701392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Asset Purchase Agreements - Additional Information - Biogen Asset Purchase Agreement (Detail) - Biogen MA Inc [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=kpti_BiogenMAIncMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_PotentialCommercialMilestonePayments', window );">Commercial milestone payments receivable</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=kpti_BiogenMAIncMember', window );">Asset Purchase Agreement [Member] | Scenario, Plan [Member] | Maximum [Member] | Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Milestone payments receivable</a></td>
<td class="nump">$ 142.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_PotentialCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_PotentialCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront payment received under research agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kpti_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kpti_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=kpti_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=kpti_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6645349136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,291<span></span>
</td>
<td class="nump">$ 17,275<span></span>
</td>
<td class="nump">$ 20,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,457<span></span>
</td>
<td class="nump">8,686<span></span>
</td>
<td class="nump">11,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling,General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,834<span></span>
</td>
<td class="nump">$ 8,589<span></span>
</td>
<td class="nump">$ 9,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6613316768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations - Summary of Future Minimum Payments on Convertible Notes (Detail) - 3% Convertible Senior Notes Due 2025 [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 5,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">5,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">5,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">5,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2024 and thereafter</a></td>
<td class="nump">182,850<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">203,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less: interest</a></td>
<td class="num">(31,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized discount</a></td>
<td class="num">(62,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Convertible senior notes</a></td>
<td class="nump">$ 109,857<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6668930496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3. Property and Equipment, net </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; padding: 0px;"/>
<td style="width: 3%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 3%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 3%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful<br/>Life Years </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">593 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">593 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">654 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">607 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Office and computer equipment </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">598 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">559 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: center; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,443 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,397 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,288 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,156 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,242</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,293</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,046 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,863 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense recorded for the years ended December&#160;31, 2019, 2018, and 2017 was $1.0</div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;$0.7&#160;million and $0.7&#160;million, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6634486448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Related Party Transactions </div></div></div></div><div><div style="width: 100%; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We paid consulting expenses of $0.2&#160;million for the years ended December&#160;31, 2019 and 2018, for consulting services with certain related parties, including a family member of management and a board member. At December&#160;31, 2019 and 2018, there was </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">less<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; font-family: &quot;Times New Roman&quot;, serif; top: 0px;;display:inline;">than</div><div style="font-size: 10pt; letter-spacing: 0px; font-family: &quot;Times New Roman&quot;, serif; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $0.1</div><div style="font-size: 10pt; letter-spacing: 0px; font-family: &quot;Times New Roman&quot;, serif; top: 0px;;display:inline;">&#160;million</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and $0, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively, included in accounts payable and accrued expenses due to related parties.&#160;</div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions disclosure textBlock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RelatedPartyTransactionsDisclosureTextblockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808310192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Asset Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=kpti_LicenseAndAssetPurchaseAgreementsMember', window );">License and Asset Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">License and Asset Purchase Agreements</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11. License and Asset Purchase Agreements </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Antengene License Agreement </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Effective May&#160;23, 2018 (the &#8220;Antengene Effective Date&#8221;), we entered into a License Agreement (&#8220;Antengene License Agreement&#8221;) with Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong (&#8220;Antengene&#8221;) and a subsidiary of Antengene Corporation Co. Ltd., a corporation organized and existing under the laws of the People&#8217;s Republic of China, pursuant to which we granted Antengene exclusive rights to develop and commercialize, at its own cost, (i)&#160;selinexor, our lead, novel, oral Selective Inhibitor of Nuclear Export (&#8220;SINE&#8221;) compound, (ii)&#160;eltanexor, our second-generation oral SINE compound, and (iii)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;KPT-9274,</div> our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> orally bioavailable small molecule that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competitive </div> dual modulator of PAK4 and NAMPT, each for the diagnosis, treatment and/or prevention of all human oncology indications (the &#8220;Oncology Field&#8221;), as well as (iv)&#160;verdinexor, our lead compound in development for the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>treatment of viral indications for the diagnosis, treatment and/or prevention of certain human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-oncology </div> indications (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-Oncology</div> Field&#8221;) (the &#8220;Antengene Licensed Compounds&#8221;). We licensed the development and commercial rights to Antengene for selinexor and eltanexor in the Oncology Field in mainland China and Macau and licensed the development and commercial rights to Antengene for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> in the Oncology Field and verdinexor in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Oncology</div> Field in mainland China, Taiwan, Hong Kong, Macau, South Korea, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam (the &#8220;Antengene Territory&#8221;).</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pursuant to the terms of the Antengene License Agreement, we received an upfront payment of $11.7&#160;million, and could receive up to $105.0&#160;million in milestone payments if certain development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>goals are achieved and up to $45.0&#160;million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty based on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, upon Antengene&#8217;s election and the parties&#8217; full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the &#8220;Antengene Manufacturing Election&#8221;), we will grant to Antengene <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> rights to manufacture the Antengene Licensed Compounds and products containing such compounds in or outside of the Antengene Territory solely for development and commercialization in the fields in the Antengene Territory.</div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As part of the Antengene License Agreement, Antengene will also have the right to participate in global clinical studies of the Antengene Licensed Compounds and will bear the cost and expense for patients enrolled in clinical studies in the Antengene Territory. Antengene is responsible for seeking regulatory and marketing approvals for the Antengene Licensed Compounds in the Antengene Territory, as well as any development of the products specifically necessary to obtain such approvals. Antengene is also responsible for the commercialization of the Antengene Licensed Compounds in the Oncology Field and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Oncology</div> Field, as applicable, in the Antengene Territory at its own cost and expense. Until such time as Antengene elects to manufacture its own drug substance, we will furnish clinical supplies of drug substance to Antengene for use in Antengene&#8217;s development efforts pursuant to a clinical supply agreement between us and Antengene, and Antengene may elect to have us provide commercial supplies of drug product to Antengene pursuant to a commercial supply agreement between us and Antengene, in each case the costs of which will be borne by Antengene. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Antengene License Agreement will continue in effect on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country </div> basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, the Antengene License Agreement may be terminated earlier by (i)&#160;either party for breach of the Antengene License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii)&#160;Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days&#8217; prior notice or (iii)&#160;us in the event Antengene challenges or assists with a challenge to certain of our patent rights.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We assessed the Antengene arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Antengene, is a customer. We identified the following material promises under the contract: </div></div><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;exclusive licenses for each Antengene Licensed Compound, (ii)&#160;initial data transfers for each Antengene Licensed Compound, which consisted of regulatory data compiled by us for the Antengene Licensed Compounds as of the Antengene Effective Date, and (iii)&#160;obligations to stand-ready to provide an initial clinical supply for each Antengene Licensed Compound. We also identified immaterial promises under the contract relating to information exchanges and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Antengene, including (i)&#160;additional data transfers for each Antengene Licensed Compound, which would consist of the transfer of additional regulatory data compiled by us for each Antengene Licensed Compound after the Antengene Effective Date, (ii)&#160;obligations to provide additional clinical supply and related substance supply for each Antengene Licensed Compound upon request by Antengene, (iii)&#160;manufacturing technology transfers and licenses for each Antengene Licensed Compound under the Antengene Manufacturing Election, as detailed above, and (iv)&#160;options for a backup compound, which represents Antengene&#8217;s option to select a replacement compound in the event it elects to discontinue the development of the Antengene Licensed Compounds (the &#8220;Antengene Transfer Options&#8221;). The Antengene Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Antengene License Agreement. Finally, we also identified certain other customer options that would create a manufacturing obligation for us if exercised by Antengene, including for commercial supply. These options do not represent a material right, as they are not offered at a significant and incremental discount. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In further evaluating the promises detailed above, we determined that the exclusive licenses, initial data transfers, and stand-ready obligation to provide initial clinical supply for each Antengene Licensed Compound were not distinct from one another, and must be combined as four separate performance obligations (the &#8220;Antengene Combined License Obligation for selinexor<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div>&#8221;&#160;&#8220;Antengene Combined License Obligation for eltanexor<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div>&#8221;&#160;&#8220;Antengene Combined License Obligation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274&#8221;</div> and &#8220;Antengene Combined License Obligation for verdinexor&#8221;). This is because, for each Antengene Licensed Compound, Antengene requires the initial data transfer and initial clinical supply to derive benefit from the exclusive licenses, since we did not grant manufacturing licenses to any of the Antengene Licensed Compounds at contract inception. We also determined that each of the Antengene Transfer Options represents a distinct performance obligation. Based on these determinations, we identified eight performance obligations at the inception of the Antengene License Agreement, including (i)&#160;the Antengene Combined License Obligation for selinexor, (ii)&#160;the Antengene Combined License Obligation for eltanexor, (iii)&#160;the Antengene Combined License Obligation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> (iv)&#160;the Antengene Combined License Obligation for verdinexor, and the four components of the Antengene Transfer Options, including (v)&#160;the material right for additional data transfer, (vi)&#160;the material right for additional clinical supply and related substance supply, (vii)&#160;the material right for manufacturing technology transfer and license, and (viii)&#160;the material right for the option for a backup compound.</div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We further determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of $11.7&#160;million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the four Antengene Combined License Obligations for selinexor, eltanexor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div> and verdinexor. In connection therewith, we also estimated the standalone selling price for each of the material rights within the Antengene Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the $11.7&#160;million transaction price amongst the Antengene Combined License Obligations as follows: $9.4&#160;million for selinexor, $1.0&#160;million for eltanexor, $1.1&#160;million for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> and $0.2&#160;million for verdinexor. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Upon execution of the Antengene License Agreement, the only fixed component of the transaction price included the $11.7&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment owed to us. As referenced above, we are eligible to receive additional payments of up to $105.0&#160;million in milestone payments if certain development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>goals</div><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">are achieved and up to $45.0&#160;million in milestone payments if certain sales milestones are achieved, as well as a high single-digit to low double-digit royalty on future net sales of the Antengene Licensed Compounds in the Antengene Territory. In addition, we would receive cost reimbursement in connection with Antengene&#8217;s election to receive additional clinical supply for the Antengene Licensed Compounds in the future. We <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">expect to receive </div> the next milestone <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">payment </div>under this agreement, which is $5.0&#160;million, upon the first NDA filing in the Antengene Territory in Multiple Myeloma.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The future <div style="letter-spacing: 0px; top: 0px;;display:inline;">development a<div style="letter-spacing: 0px; top: 0px;;display:inline;">nd </div></div>regulatory milestones and cost reimbursement for providing additional clinical supply of the Antengene Licensed Compounds, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price at contract inception and/or through December&#160;31, 2019, because the amounts were fully constrained as of December&#160;31, 2019. As part of our<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside of our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Antengene, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property licenses granted to Antengene and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Through the year ended December&#160;31, 2019, we recognized $9.4&#160;million in revenue under the Antengene License Agreement, as the Antengene Combined License Obligation for selinexor was satisfied when the initial clinical supply of selinexor was delivered during the second quarter of 2019. Revenue will be recognized for the Antengene Combined License Obligation for eltanexor,&#160;the Antengene Combined License Obligation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274,</div> and the Antengene Combined License Obligation for verdinexor once our promise to provide initial clinical supply of each of the Antengene Licensed Compounds in the future is fulfilled. We currently expect the initial clinical supplies of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-9274</div>, eltanexor and verdinexor&#160;to be delivered within twelve months of the balance sheet date of December&#160;31, 2019. Accordingly, and as of December&#160;31, 2019, the remaining $2.3&#160;million of the upfront payment represents a contract liability, all of which was included in deferred revenue and is classified as a current liability.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Biogen Asset Purchase Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;24, 2018, we entered into an Asset Purchase Agreement (the &#8220;APA&#8221;) and Letter Agreement with Biogen MA Inc., a Massachusetts corporation and subsidiary of Biogen, Inc. (&#8220;Biogen&#8221;). </div></div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">Under the terms of the APA and Letter Agreement, we sold to Biogen exclusive worldwide rights to develop and commercialize our oral SINE compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> and certain related assets with an initial focus in amyotrophic lateral sclerosis (&#8220;ALS&#8221;) (the &#8220;Transfer of IP&#8221;), and also granted Biogen: (i)&#160;an exclusive worldwide license under certain of our intellectual property to manufacture or have manufactured <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Manufacturing License&#8221;), (ii)&#160;a technology transfer package, consisting of information and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how </div> regarding the manufacture of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Manufacturing Technology Transfer&#8221;), (iii)&#160;a right, at Biogen&#8217;s request, to have us provide transition assistance regarding manufacturing and other matters (the &#8220;Transition Assistance&#8221;), (iv)&#160;existing inventory of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Inventory&#8221;), (v)&#160;an initial supply of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Initial Supply&#8221;), and (vi)&#160;a right, at Biogen&#8217;s request, to have us manufacture and supply the active pharmaceutical ingredient for an additional supply of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> (the &#8220;Additional Supply&#8221;). In consideration for these rights, we received an upfront payment of $10.0&#160;million, and we are eligible to receive additional payments of up to $142.0&#160;million based on the achievement by Biogen of future specified development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>milestones, and up to $65.0&#160;million based on the achievement by Biogen of future specified commercial milestones. We will also be eligible to receive tiered royalty payments that reach low double-digits based on future net sales until the later of the tenth anniversary of the first commercial sale of the applicable product and the expiration of specified patent protection for the applicable product, determined on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div> basis.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We and Biogen have made customary representations and warranties and agreed to customary covenants in the APA, including covenants requiring Biogen to use commercially reasonable efforts to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KPT-350</div> in specified neurological indications, including ALS, in any of the United States, United Kingdom, France, Spain, Germany or Italy. The APA will continue in effect until the expiration of all royalty obligations, provided that the APA may be terminated earlier by Biogen, subject to the requirements that Biogen (i)&#160;negotiate in good faith with us regarding an assignment or license back to us of the purchased assets and (ii)&#160;not transfer or license the purchased assets to a third party unless such third party assumes Biogen&#8217;s obligations to us under the APA.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Biogen, is a customer. We identified the following material promises in the arrangement: the Transfer of IP and the Manufacturing License. We also identified immaterial promises under the contract that were not deemed performance obligations. We further determined that other promises for Additional Supply and Transition<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Assistance represented customer options, which would create an obligation for us if exercised by Biogen. Since no additional or material consideration is owed to us by Biogen upon exercise of the customer options for Additional Supply and Transition Assistance, we determined that both are offered at significant and incremental discounts. Accordingly, they were assessed as material rights and, therefore, separate performance obligations in the arrangement. We then determined that the Transfer of IP and the Manufacturing License were not distinct from one another and must be combined as a performance obligation (the &#8220;Combined Performance Obligation&#8221;). This is because Biogen requires the Manufacturing License to derive benefit from the Transfer of IP. Based on these determinations, as well as the considerations noted above with respect to the material rights for Additional Supply and Transition Assistance, we identified three distinct performance obligations at the inception of the contract: (i)&#160;the Combined Performance Obligation, (ii)&#160;the material right for Additional Supply, and (iii)&#160;the material right for Transition Assistance. We further determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">10.0 </div>million constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on their relative stand-alone selling prices. In connection therewith, we estimated the stand-alone selling price of the (i)&#160;Combined Performance Obligation, (ii)&#160;material right for Additional Supply, and (iii)&#160;material right for Transition Assistance, and determined that the stand-alone selling price of the material rights for Additional Supply and Transition Assistance were insignificant based on various quantitative and qualitative considerations. Accordingly, we further determined that the allocation of the transaction price to the material rights for Additional Supply and Transition Assistance was insignificant. Based on the estimates of the stand-alone selling prices for each of the performance obligations, we determined that substantially all of the $<div style="letter-spacing: 0px; top: 0px;;display:inline;">10.0 </div>million transaction price should be allocated to the Combined Performance Obligation. We believe that a change in the assumptions used to determine our best estimate of the stand-alone selling prices for the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations.</div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">Upon execution of the APA, the transaction price included only the $10.0&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment owed to us. We may receive further payments upon the achievement of certain regulatory and sales milestones, as detailed above, as well as tiered royalty payments that reach low double-digits based on future net sales. <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">We expect to receive the next milestone payment under this agreement, which is $2.0&#160;million, when the fifth patient in a Phase 1 Multiple Ascending Dose Trial in the United States of a Product in amyotrophic lateral sclerosis is dosed.</div></div><div style="width: 100%; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The future development and regulatory milestones, which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of December&#160;31, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such milestones is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Biogen, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We recognized $10.0&#160;million of revenue during the first quarter of 2018, which was when we had satisfied our promises under the Combined Performance Obligation by transferring the underlying promised goods. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Ono License Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Effective October&#160;11, 2017 (the &#8220;Ono Effective Date&#8221;), we entered into a license agreement (the &#8220;Ono License Agreement&#8221;) with Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan (&#8220;Ono&#8221;), pursuant to which we granted Ono exclusive rights to develop and commercialize, at its own cost, selinexor and eltanexor, for the diagnosis, treatment and/or prevention of all human oncology indications (the &#8220;Ono Field&#8221;) in Japan, Republic of Korea, Republic of China (Taiwan) and Hong Kong, as well as in the ten Southeast Asian countries currently comprising the Association of Southeast Asian Nations (the &#8220;Ono Territory&#8221;)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(the &#8220;Ono Exclusive License&#8221;). Pursuant to the terms of the Ono License Agreement, we received an upfront payment of &#165;2.5&#160;billion (US$21.9&#160;million on the date received), and could receive up to &#165;10.15&#160;billion (approximately US$90.5&#160;million at the exchange rate as of the Ono Effective Date) in milestone payments if certain development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>goals are achieved and up to &#165;9.0&#160;billion (approximately US$80.2&#160;million at the exchange rate as of the Ono Effective Date) in milestone payments if certain sales milestones are achieved, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, upon Ono&#8217;s election and the parties&#8217; full execution of a manufacturing technology transfer plan and satisfaction of other specified conditions (the &#8220;Ono Manufacturing Election&#8221;), we will grant to Ono <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> rights to manufacture selinexor, eltanexor and products containing such compounds in or outside of the Ono Territory solely for development and commercialization in the Ono Field in the Ono Territory.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As part of the Ono License Agreement, Ono will also have the right to participate in global clinical studies of selinexor and eltanexor and will bear the cost and expense for patients enrolled in clinical studies in the Ono Territory. Ono is responsible for seeking regulatory and marketing approvals for selinexor and eltanexor in the Ono Territory, as well as any development of the products specifically necessary to obtain such approvals. Ono is also responsible for the commercialization of products containing selinexor or eltanexor in the Ono Field in the Ono Territory at its own cost and expense. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Subject to the Ono Manufacturing Election, we will furnish clinical supplies of drug substance to Ono for use in Ono&#8217;s development efforts pursuant to a clinical supply agreement between us and Ono, and Ono may elect to have us provide commercial supplies of drug product to Ono pursuant to a commercial supply agreement between us and Ono, in each case the costs of which will be borne by Ono. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Ono License Agreement will continue in effect on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div> basis until the later of the tenth anniversary of the first commercial sale of the applicable product in such country or the expiration of specified patent protection and regulatory exclusivity periods for the applicable product in such country. However, <span style="-sec-ix-hidden:hidden10185021">the Ono License Agreement may be terminated earlier by (i)&#160;either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party,</span><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(ii)&#160;Ono on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div> basis for certain safety reasons or on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country </div> basis for any reason with 180&#160;days&#8217; prior notice or (iii)&#160;us in the event Ono challenges or assists with a challenge to certain of our patent rights.</div><div style="margin-top: 1em; margin-bottom: 0em; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Ono, is a customer. We identified the following material promises under the contract: (i)&#160;the Ono Exclusive License for selinexor and eltanexor, (ii)&#160;initial data transfer for selinexor and eltanexor, which consisted of regulatory data compiled by us for the licensed compounds and products as of the Ono Effective Date, (iii)&#160;initial clinical supply for selinexor, which consisted of units of clinical supply for Ono to conduct its Phase&#160;I Trial, and (iv)&#160;an obligation to stand-ready to provide initial clinical supply for eltanexor. We also identified immaterial promises under the contract relating to information exchanges, and participation on operating committees and other working groups. Separately, we also identified certain customer options that would create an obligation for us if exercised by Ono, including the (i)&#160;additional data transfer for selinexor and eltanexor, which would consist </div></div><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the transfer of additional regulatory data compiled by us for the licensed compounds and products after the Ono Effective Date, (ii)&#160;additional clinical supply and related substance supply for selinexor and eltanexor, which would consist of supplying Ono with units and substance of selinexor and eltanexor incremental to the initial clinical supply for selinexor and the obligation to stand-ready to provide initial clinical supply for eltanexor, as noted above, (iii)&#160;manufacturing technology transfer and license for selinexor and eltanexor under the Ono Manufacturing Election, as detailed above, and (iv)&#160;options for a backup compound, which represents Ono&#8217;s option to select a replacement compound in the event it elects to discontinue the development of either of the licensed compounds (the &#8220;Ono Transfer Options&#8221;). The Ono Transfer Options individually represent material rights, as they were offered at a significant and incremental discount. Therefore, they were further assessed as performance obligations under the Ono License Agreement. We also identified certain other customer options that would create a manufacturing obligation for us if exercised by Ono, including commercial supply. This </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">option is referred to herein as the &#8220;Ono Manufacturing Option.&#8221; The Ono Manufacturing Option does not represent a material right, as it is not offered at a significant and incremental discount. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In further evaluating the promises detailed above, we determined that the (i)&#160;Ono Exclusive License, initial data transfer, and initial clinical supply for selinexor and (ii)&#160;Ono Exclusive License, initial data transfer, and obligation to stand-ready to provide initial clinical supply of eltanexor were not distinct from one another, and must be combined as two separate performance obligations (the &#8220;Ono Combined License Obligation for selinexor&#8221; and the &#8220;Ono Combined License Obligation for eltanexor&#8221;). This is because, for both selinexor and eltanexor, Ono requires the initial data transfer and clinical supply to derive benefit from the Ono Exclusive License since we did not grant manufacturing licenses for selinexor and eltanexor at contract inception. We also determined that each of the Ono Transfer Options represents a distinct performance obligation. Based on these determinations, we identified six distinct performance obligations at the inception of the Ono License Agreement, including (i)&#160;the Ono Combined License Obligation for selinexor, (ii)&#160;the Ono Combined License Obligation for eltanexor, and the four components of the Ono Transfer Options, including (iii)&#160;the material right for additional data transfer, (iv)&#160;the material right for additional clinical supply and related substance supply, (iv)&#160;the material right for manufacturing technology transfer and license, and (vi)&#160;the material right for the option for a backup compound. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We further determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of &#165;2.5&#160;billion (US$21.9&#160;million on the date received) constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the performance obligations based on our best estimate of their relative stand-alone selling prices. We determined that substantially all of the total standalone selling price in the arrangement is derived from the Ono Combined License Obligation for selinexor and the Ono Combined License Obligation for eltanexor. In connection therewith, we estimated the standalone selling price for each of the material rights within the Ono Transfer Options, and determined that such amounts were insignificant, and, therefore, immaterial for purposes of allocation. Accordingly, we allocated the &#165;2.5&#160;billion (US$21.9&#160;million on the date received) upfront transaction price between the Ono Combined License Obligations as follows: $19.7&#160;million for selinexor and $2.2&#160;million for eltanexor. We believe that a change in the assumptions used to determine our best estimate of the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">stand-alone selling prices for any of the identified performance obligations would not have a significant effect on the allocation of the underlying transaction price to the performance obligations. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0px; line-height: 12pt;">Upon execution of the Ono License Agreement, the transaction price included only the &#165;2.5&#160;billion (US$21.9&#160;million on the date received) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment owed to us. As referenced above, we are eligible to receive additional payments of up to &#165;10.15&#160;billion (approximately US$90.5&#160;million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified development <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and regulatory </div>milestones and up to &#165;9.0&#160;billion (approximately US$80.2&#160;million at the exchange rate as of the Ono Effective Date) based on the achievement by Ono of future specified commercial milestones, as well as a low double-digit royalty based on future net sales of selinexor and eltanexor in the Ono Territory. In addition, we could receive cost reimbursement in connection with our promise to stand-ready to provide initial clinical supply for eltanexor in the future. We <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">expect to receive </div>the next <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">milestone payment under this agreement upon the first licensed<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product in Multiple </div>Myelomna<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of &#165;</div>1.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion (approximately US$</div>1.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million), in Japan.</div></div>  <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The future development and regulatory milestones and cost reimbursement for providing initial clinical supply of eltanexor, both of which represent variable consideration, were evaluated under the most likely amount method, and were not included in the transaction price, because the amounts were fully constrained as of December 31, 2019. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of such amounts is outside our control. Separately, any consideration related to sales-based milestones, as well as royalties on net sales upon commercialization by Ono, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to Ono and, therefore, have also been excluded from the transaction price in accordance with the sales-based royalty exception, as well as our accounting policy. We will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As the initial clinical supply of selinexor was delivered in April 2018, the Ono Combined License Obligation for selinexor was determined to be fulfilled and revenue of $19.7&#160;million was recognized during the quarter ended June&#160;30, 2018. The transaction price allocated to the Ono Combined License Obligation for eltanexor will be recognized as revenue once our stand-ready promise to provide initial clinical supply of eltanexor in the future is fulfilled, which is the last remaining undelivered promise associated with the Ono Combined License Obligation for eltanexor. As of December&#160;31, 2019, $2.2&#160;million of the Ono License Agreement upfront payment is included in deferred revenue and is classified as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liability.</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_LicenseAndAssetPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_LicenseAndAssetPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643274144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Segments</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AccountingPoliciesAndGeneralInformationLineItems', window );"><strong>Accounting Policies And General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange losses</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">10,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">14,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AccountingPoliciesAndGeneralInformationLineItems', window );"><strong>Accounting Policies And General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AccountingPoliciesAndGeneralInformationLineItems', window );"><strong>Accounting Policies And General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AccountingPoliciesAndGeneralInformationLineItems', window );"><strong>Accounting Policies And General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents capitalization of operating lease right-of-use assets, offset by reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents recognition of operating lease liabilities.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_AccountingPoliciesAndGeneralInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies And General Information [Line item].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_AccountingPoliciesAndGeneralInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6985308736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Total Stock-based Compensation Expense Recognized in Connection with All Share-based Payment Awards</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with all share-based payment awards, total stock-based compensation expense recognized was as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,457 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,686 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,208 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,834 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,589 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,197 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,291 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,275 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,405 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Employees and Nonemployees</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes stock option activity for employees and nonemployees: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px;width: 92%;font-size: 10pt;border-spacing: 0px;">
<tr>
<td style="width: 53%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 5%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Options </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(year) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/> &#160;Intrinsic<br/> &#160;Value </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in<br/> thousands) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,917,084 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.78 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7.4</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,197 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Granted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,325,390 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.67 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercised </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(394,358</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">7.18 </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Forfeited </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,005,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.36 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden11073498">9, 843,094</span> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12.40 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7.0</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82,134 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,391,153 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14.65 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.6</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,879</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, we granted <div style="letter-spacing: 0px; top: 0px;;display:inline;">1,065,970</div> shares of RSUs under the 2013 Plan. The following is a summary of RSU activity for the 2013 Plan for the years ended December&#160;31, 2019 and 2018, respectively: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 15%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of<br/> Shares<br/> Underlying&#160;RSUs </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/> Grant&#160;Date<br/> Fair&#160;Value </div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25,000 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.87 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Granted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,065,970 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.25 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Forfeited </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(286,150 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.24 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Vested </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(17,500 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.96 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">787,320 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.28 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model</a></td>
<td class="text"><div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the option component of the shares purchased under the ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%; padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended<br/> December&#160;31, </div></div></div></div> </td>
<td style="padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">61<div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div>-104% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">48%-61% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">48%-78% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years) </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.5 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.5 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.5 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.4<div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div>-2.5% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.3%-2.1% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.5%-1.3% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember', window );">Employee and Nonemployee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value on Grant Date Using Black Scholes Option Pricing Model</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The fair value of each stock option granted to employees is estimated on the date of grant and for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> on each reporting date and upon vesting using the Black-Scholes option-pricing model. The following table summarizes the assumptions used in calculating the fair value of the awards:</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Volatility </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">79%-81%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">79%-81% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">79%-85% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.5-6.0 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.5-9.8 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.5-9.6 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.42%-2.58%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.50%-3.05% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.76%-2.29% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dividend </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kpti_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6641008064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following as of December&#160;31, 2019 and 2018 (in thousands):</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%; padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,122 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,903</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Payroll and employee-related costs </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,630 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,103</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Professional fees </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,172 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,931</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">I</div>nterest</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,371</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="text-align: right; padding-left: 0px; background-color: rgb(255, 255, 255); padding-right: 5pt;">&#8212;</td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,583 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,556 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40,878 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#160;&#160;&#160;&#160;&#160;<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;32,493</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808344736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13. 401(k) Plan </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have a 401(k)&#160;retirement and profit-sharing plan (the &#8220;401(k)&#160;Plan&#8221;) covering all qualified employees. The 401(k)&#160;Plan allows each participant to contribute a portion of their base wages up to an amount not to exceed an annual statutory maximum. Effective January&#160;1, 2011, we adopted a Safe Harbor Plan that provides a Company match up to 4% of salary. We contributed a match of $1.7&#160;million, $1.1&#160;million and $0.6&#160;million to the&#160;401(k)&#160;Plan for the years ended December&#160;31, 2019, 2018 and 2017, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6641881472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Schedule of Financial Assets That Have Been Measured at Fair Value</a></td>
<td class="text"> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and liability </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%; padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-right: 5pt;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">206,494 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,114 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;&#8212;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial liability </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivative liability </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificate of deposit </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">289,060 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,179 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Our Embedded Derivative Liability</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded<br/> Derivative<br/> Liability </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Addition of derivative related to deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 11%;">&#160;</td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative since issuanc<div style="display:inline;">e</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;">&#8212;</td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%; padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></div> </td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,843,094 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,917,084 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,019,083 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock units </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">787,320 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25,000 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">253,100 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842</a></td>
<td class="text"><div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 8%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> Prior to ASC<br/> 842 Adoption </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 842<br/> Adjustment</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> as Adjusted </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated balance sheet data (in thousands): </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div><br/> assets(1) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,711</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,711</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">390</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(390</div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3,922</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(3,922</div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities(3) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,175</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,175</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease<br/> liabilities(3) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,848</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,848</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> </div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 12pt; margin-bottom: 0px;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(1)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents capitalization of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, offset by reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(2)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(3)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents recognition of operating lease liabilities.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821327856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges', window );">Impact related to provision items for federal rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets', window );">Reduction in deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">51,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carryforwards foreign</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered', window );">Period over which certain cumulative changes in the ownership interest of significant shareholders will be considered, subject to an annual limitation of net operating loss and tax credit carryforwards</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered', window );">Operating Loss And Tax Credit Carryforwards Limitations Threshold Percentage Of Cumulative Changes In Ownership Interest Of Significant Shareholders Considered</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties related to uncertain tax positions recognized in statements of operations and comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">224,943,000<span></span>
</td>
<td class="nump">173,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">576,500,000<span></span>
</td>
<td class="nump">427,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife', window );">Net operating loss carryforwards indefinite life</a></td>
<td class="nump">576,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">58,500,000<span></span>
</td>
<td class="nump">46,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">502,300,000<span></span>
</td>
<td class="nump">414,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife', window );">Net operating loss carryforwards indefinite life</a></td>
<td class="nump">283,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation', window );">Net operating loss carryforwards indefinite life remaining</a></td>
<td class="nump">292,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carryforwards foreign</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Net Operating Loss Carry forwards Indefinite Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredTaxAssetNetOperatingLossCarryforwardsIndefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforwards Have Indefinite Expiration Date Respect To Foreign Operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_NetOperatingLossCarryforwardsHaveIndefiniteExpirationDateRespectToForeignOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss And Tax Credit Carryforwards Limitations Period Over Which Cumulative Changes In Ownership Interest Of Significant Shareholders Considered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsPeriodOverWhichCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative changes in the ownership interest of significant shareholders that will be considered, subject to an annual limitation of net operating loss and tax credit carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_OperatingLossAndTaxCreditCarryforwardsLimitationsThresholdPercentageOfCumulativeChangesInOwnershipInterestOfSignificantShareholdersConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Income Taxes For Federal Tax Rate Changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ProvisionForIncomeTaxesForFederalTaxRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017 Change In Tax Rate Reduction In Deferred Tax Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6821982400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (199,590)<span></span>
</td>
<td class="num">$ (178,407)<span></span>
</td>
<td class="num">$ (128,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on investments</a></td>
<td class="num">(1,382)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">15,291<span></span>
</td>
<td class="nump">17,275<span></span>
</td>
<td class="nump">20,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of the value of debt discount and issuance costs</a></td>
<td class="nump">7,193<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(4,663)<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,301)<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">8,512<span></span>
</td>
<td class="nump">11,255<span></span>
</td>
<td class="nump">10,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(9,362)<span></span>
</td>
<td class="num">(8,027)<span></span>
</td>
<td class="nump">21,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(190,822)<span></span>
</td>
<td class="num">(159,117)<span></span>
</td>
<td class="num">(73,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(2,363)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">257,145<span></span>
</td>
<td class="nump">137,510<span></span>
</td>
<td class="nump">115,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(178,489)<span></span>
</td>
<td class="num">(242,811)<span></span>
</td>
<td class="num">(98,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">78,450<span></span>
</td>
<td class="num">(107,664)<span></span>
</td>
<td class="nump">17,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts', window );">Proceeds from issuance of convertible senior notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">46,191<span></span>
</td>
<td class="nump">145,705<span></span>
</td>
<td class="nump">74,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the exercise of stock options and shares issued under employee stock purchase plan</a></td>
<td class="nump">4,505<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ProceedsFromDeferredRoyaltyObligation', window );">Proceeds from deferred royalty obligation, net</a></td>
<td class="nump">73,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">124,305<span></span>
</td>
<td class="nump">316,109<span></span>
</td>
<td class="nump">75,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">11,952<span></span>
</td>
<td class="nump">49,250<span></span>
</td>
<td class="nump">19,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">118,737<span></span>
</td>
<td class="nump">69,487<span></span>
</td>
<td class="nump">50,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash end of period</a></td>
<td class="nump">130,689<span></span>
</td>
<td class="nump">118,737<span></span>
</td>
<td class="nump">69,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">128,858<span></span>
</td>
<td class="nump">118,021<span></span>
</td>
<td class="nump">68,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Short-term restricted cash</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash end of period</a></td>
<td class="nump">130,689<span></span>
</td>
<td class="nump">$ 118,737<span></span>
</td>
<td class="nump">$ 69,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Cash paid for interest on convertible debt</a></td>
<td class="nump">5,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">11,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 2,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ProceedsFromDeferredRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Deferred Royalty Obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ProceedsFromDeferredRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible senior notes, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ProceedsFromIssuanceOfConvertibleSeniorNotesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ProceedsFromPaymentsForCommonStockIssuanceNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from payments for common stock issuance net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ProceedsFromPaymentsForCommonStockIssuanceNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6824163872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2022 </div>
<div>d</div>
</th>
<th class="th">
<div>Oct. 16, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 26, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs allocated to equity component and recorded as a reduction to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument convertible threshold consecutive trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription', window );">Description of debt instrument convertible period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">during the five business day period immediately after any five consecutive trading day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_PrincipalAmountOfNotesUsedInConversionRate', window );">Principal amount of notes used in conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock', window );">Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible notes recognized as debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of liability of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentEstimatedFairValue', window );">Estimated fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Expected life of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=kpti_DeferredRoyaltyObligationMember', window );">Deferred Royalty Obligation [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Deferred royalty obligation at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kpti_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ProceedsFromFirstInvestmentAmount', window );">First investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_SecondInvestmentAmount', window );">Second investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kpti_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement [Member] | HealthCare Royalty Partners IV LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RoyaltyPaymentsApplicableTieredPercentage', window );">Aggregate Royalties Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kpti_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement [Member] | HealthCare Royalty Partners IV LP [Member] | Royalty Due On December 31, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty Payable Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=kpti_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement [Member] | HealthCare Royalty Partners IV LP [Member] | Royalty Due On December 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty Payable Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Note Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Notes converted in to common stock, amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted in to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Notes, conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember', window );">3% Convertible Senior Notes Due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt issuance costs allocated to equity component and recorded as a reduction to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes', window );">Debt issuance costs allocated to liability component and recorded as a reduction of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod', window );">Debt discount and issuance costs amortized to interest expense, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Notes, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_PrincipalAmountPerNoteUsedInConversionRate', window );">Principal amount of notes used in conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleLatestDate1', window );">Debt instrument, convertible latest date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Notes conversion price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Notes instrument, trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument convertible threshold consecutive trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent', window );">Initial amount of liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible notes recognized as debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember', window );">3% Convertible Senior Notes Due 2025 [Member] | Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Notes conversion price, percentage</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Notes instrument, trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument convertible threshold consecutive trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DebtInstrumentRepurchasePricePercentage', window );">Notes, repurchase price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible threshold maximum percentage of product of last reported sale price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible threshold measurement period description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentConvertibleThresholdMeasurementPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument non convertible initial amount of liability component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentNonConvertibleInitialAmountOfLiabilityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtInstrumentRepurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument repurchase price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtInstrumentRepurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs allocated to liability component amortized to interest expense amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtIssuanceCostsAllocatedToLiabilityComponentAmortizedToInterestExpenseAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs allocated to liability component recorded as reduction of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DebtIssuanceCostsAllocatedToLiabilityComponentRecordedAsReductionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_PrincipalAmountOfNotesUsedInConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount of notes used in conversion rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_PrincipalAmountOfNotesUsedInConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_PrincipalAmountPerNoteUsedInConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal Amount Per Note Used In Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_PrincipalAmountPerNoteUsedInConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ProceedsFromFirstInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First investment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ProceedsFromFirstInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RoyaltyGuaranteesCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment percentage receiveable on future date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RoyaltyGuaranteesCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RoyaltyPaymentsApplicableTieredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payments Applicable Tiered Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RoyaltyPaymentsApplicableTieredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_SecondInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second investment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_SecondInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleLatestDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest date when the debt instrument can be converted into equity, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleLatestDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=kpti_DeferredRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=kpti_DeferredRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kpti_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kpti_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=kpti_HealthcareRoyaltyPartnersIvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=kpti_HealthcareRoyaltyPartnersIvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RoyaltyPaymentDueDateAxis=kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RoyaltyPaymentDueDateAxis=kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RoyaltyPaymentDueDateAxis=kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RoyaltyPaymentDueDateAxis=kpti_RoyaltyDueOnDecemberThirtyOneTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6817749920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 40,893<span></span>
</td>
<td class="nump">$ 30,336<span></span>
</td>
<td class="nump">$ 1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of sales</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">122,340<span></span>
</td>
<td class="nump">161,372<span></span>
</td>
<td class="nump">107,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">105,421<span></span>
</td>
<td class="nump">48,847<span></span>
</td>
<td class="nump">24,870<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">230,168<span></span>
</td>
<td class="nump">210,219<span></span>
</td>
<td class="nump">132,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(189,275)<span></span>
</td>
<td class="num">(179,883)<span></span>
</td>
<td class="num">(130,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,422<span></span>
</td>
<td class="nump">4,028<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(15,647)<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(10,275)<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(199,550)<span></span>
</td>
<td class="num">(178,381)<span></span>
</td>
<td class="num">(128,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (199,590)<span></span>
</td>
<td class="num">$ (178,407)<span></span>
</td>
<td class="num">$ (128,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share&#8212;basic and diluted</a></td>
<td class="num">$ (3.22)<span></span>
</td>
<td class="num">$ (3.14)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding used in net loss per share&#8212;basic and diluted</a></td>
<td class="nump">61,955,420<span></span>
</td>
<td class="nump">56,799,699<span></span>
</td>
<td class="nump">45,899,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 30,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=kpti_LicenseAndOtherMember', window );">License and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 10,353<span></span>
</td>
<td class="nump">$ 30,336<span></span>
</td>
<td class="nump">$ 1,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_LicenseAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_LicenseAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6729346144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Securities</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Securities</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear', window );">Number of debt securities with unrealized loss position for less than one year | Securities</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Aggregate fair value of debt securities with unrealized loss position for less than one year</a></td>
<td class="nump">$ 63,800,000<span></span>
</td>
<td class="nump">$ 180,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses , included in accumulated other comprehensive loss</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments', window );">Unrealized losses, other-than-temporary impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear', window );">Number of corporate debt securities with continuous unrealized loss position for more than 12 months | Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Aggregate fair value of corporate debt securities with continuous unrealized loss position for more than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses , included in accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities accumulated gross unrealized loss before tax other than temporary impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments that have been in a continuous unrealized loss position for greater than or equal to a year for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6647111840">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies- Schedule of Adjustments in Balance Sheet due to Adoption of ASC 842 (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems', window );"><strong>Adjustments For Change In Accounting Principle [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease and right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,617<span></span>
</td>
<td class="nump">$ 11,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,848<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,202<span></span>
</td>
<td class="nump">14,848<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems', window );"><strong>Adjustments For Change In Accounting Principle [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems', window );"><strong>Adjustments For Change In Accounting Principle [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease and right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,922)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,848<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents capitalization of operating lease right-of-use assets, offset by reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents recognition of operating lease liabilities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents reclassification of deferred rent and tenant incentives to operating lease right-of-use assets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_AdjustmentsForChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Change In Accounting Principle [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_AdjustmentsForChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6817896112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Controlled Equity Offering Sales Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2018</div></th>
<th class="th"><div>May 07, 2018</div></th>
<th class="th"><div>Apr. 28, 2017</div></th>
<th class="th"><div>Dec. 07, 2015</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 07, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,191,000<span></span>
</td>
<td class="nump">$ 145,705,000<span></span>
</td>
<td class="nump">$ 74,885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_SaleAgreementTerminationDate', window );">Sales agreement term date</a></td>
<td class="text">Aug. 12,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,525,424<span></span>
</td>
<td class="nump">3,902,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,712,359<span></span>
</td>
<td class="nump">10,525,424<span></span>
</td>
<td class="nump">7,308,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.75<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after deducting underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,700,000<span></span>
</td>
<td class="nump">$ 37,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kpti_JefferiesLLCMember', window );">Jefferies LLC [Member] | Open Market Sale Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,712,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kpti_CantorFitzgeraldAndCoMember', window );">Cantor Fitzgerald &amp; Co. [Member] | Controlled Equity Offering Sales Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,172,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,405,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Jefferies LLC [Member] | Open Market Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares', window );">Percentage of commission of gross proceeds from the sale of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cantor Fitzgerald &amp; Co. [Member] | Controlled Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares', window );">Percentage of commission of gross proceeds from the sale of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission percentage on gross proceeds from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_CommissionPercentageOnGrossProceedsFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_EquityOfferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_EquityOfferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_SaleAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Agreement Termination Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_SaleAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=kpti_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=kpti_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kpti_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kpti_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=kpti_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=kpti_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=kpti_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=kpti_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001193125-20-049115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-049115-xbrl.zip
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MP13Z[WT+1 P>NU3KF8H4ZX](.I=@Q-SPY^3>.S"SX*-)JB4H/'9GW4E\WS3
MVE Z*+9K\\"QHO/%\].//E,9[U@C$83!;?N[V_>])V[=Q=F+%R_BW  <@5ZS
MY\%W(C_^RT 5']SZ\.D/;A;?0%C.?D610Q:^VC/::L_HK<Q^X< 25L"%*Y(J
MA6;V7>>?(DC%(7K?+6;_>O=X6C\^T*RN67T'6#U#[;O%Z"LRX?_)?4O;\$LD
MX6$ :R-^JXWX%;'M-7O)+Z.?HQ'/#ZRI#RZ>DCP%N.Q.])^Y]1^X_X1YJ70A
M[)$!B)(P&USY$+*0-J!^+2S73Z;,J0"X4UR<1P-QB&*89N9\US@JBI-J1DAO
MSA<F#2B,SX(P4IRUF3*HV"9'(47"YC'E[JG6>1IU%9CDAE>:.=5Z9:^;B<@Y
M>@46$9%+-2>*C,=KS^6#:^;_Y.%EY%H959%?#5)8'":.X(1EJXOR][V9.+QD
MMO]/YF!24C\*@V^H]&J9G!UUP9=!_/%W@#)JR0%=+AR2[:.%Z7:>HHL)L%Q(
MF&W'2/,,XR[448P'M^USWO<"M?+7Z&K;:E[65V<P%=5-P-1FDMX"JJ[RA$']
M#8)URRAY(4+UU9R>#6"LG:YJ'*HDGH:?MHP/BDQXN=C9&4+3@EL+;LT_$]S#
MU3###E0/:Y;2Q<QS>[JZPXAV<E=/=8O2"]M%O9L@T#4S%3F.OOWD_6I ?-.P
M_ :QM_U8WNBJNWN0B;YMAMRB W><[17</WS?CO2"5*;+^$UN)MY^Y\P)NR;S
M^;TW@(^#.^:'.$OJZNE;7^S XO8WWF'.!2V73!#=D&*.AA2O+@-GD@U!7+U\
M"G1I.IR%#G_(UYU'_-8]YR9=3TT-!K?N:-\G^$(\\NO=XU6\4FK* T_ SL6:
MN-=#W*^^6.QO LK2%\Q*#IKIELATEU[D:Z[37#=*#YO)=GG&?T-[1&.!LIE8
MCOO["=J^;3EVAPVG7']A#K Z?^AR'G[SQ"#(L<'";:.1<9M74N$5""[B$&7G
MJ91TCLL<J8)DM=+5_4,VI&QZ/?[(7II1V/5\6/1&M+Z:N.SDHHD V$RL4D58
MT[60JYQ_1+X=6+8Y+'M&P;.!&!T^<IV\\<W$YOC"58WG6?'\ZA*VM+YQ3CG_
M0Q7Y97R[O+GU&TA;B]0*TSN$$X W7%FYR80W$^%H@;9X@;9K!(<'Z/WA,)1J
M-X(E\"& .;YH0VJLIUN_NGH(!)N)Q\O(=^TP\I$K+NT7_!3L+DK'0V,SL2LF
M]FE>_9 +B,W$*<U;['J.==6C1E CJ6F[A=D)X-A,_)YY;A YV#0:<]5D4X]X
MXJ8PD8=ZGSA@U5AXH#!X])D;,#,5XRLNGB>OFV*3,\!B,Y%];;MC@@Z/SUXH
MSV-"@!QFPGC47Z,/;-&CZS-,O\F=\J?>ZZ(C#FGH;R(!G>A2]")4B10XL?AD
M>:2GA] 6(JN]^.7:Q:9!+04U(2Y #^LA\IM.G84<(K]$DM65SQM&H 4H-5ZJ
M!-53&K<%EWI*XRJG-"X1D7K<WP:-^ULB'6QA$\UB=JU<(@YU0]7E9BAO>T/5
M8H=Q='.TC6W\41#W:G>B4SKP5"C"6W57OF(1FA;<6G!K_BF>(;1=9[.;P$[Z
MJ'C5[J]N&+M#[%40;;7EIS@%:-VI+<'MY*W=3+/3_3L+T[^S^-;)]F-YHX_1
M]*#050X*76;NE*Z@7G7KCR5B4[?G65M[GN)B53?CV.IF'$LD/-V,8[FJ1!/<
ML%FI"_Q75]J_3"=0-^-8=S..)6)7-^-84S..)>)4-^,H0#..I>:SZ&8<Q6K&
ML4AD5VL_JJ(1QZ,W-)K7$U4<:=22O8JK1AX(!W!5WW/CPZM_\'8;7LV#;]_.
MQ%V!'YYA/0#W^PC5V*^\[7-7Y.T^,(?OPC"7B3M>@)T_$3-#B4(9Q,[Q;NP?
MDH=>M>=1>E@T4P#A^R'V^!<M1JHU^%_\J/BWA&2LY-H,"ZE?%LE"WT 6N %:
M;LT@X.%=!"("5$.,^B!F$5 P5F2&M[Z4((6E=$3XF,6*Q)WIMKQ+5/#8A;W?
M<1\ $[(.!YWQA*>S+8<_<-?VL,2:!^=1SNP)^XFGY2'F1VQ0-DSN<D6UX/P0
MV24"RN>DC'TM?T31;E.^P<4+%NV#E8*9=""=>\E/I'Z_V%X'U%'SRC5C(73-
M_O#\LR@(O1[\75CZ$EVR<Y9*M#6RL05HUIG!JQ8S"7.[1,%CSG;/X<E/+ 2F
M3N3$O1W\+"SI):)MXL(3BVS)Q[Q%QKF>TKE+V'Y[3H?N\;C@'H]%S$?93M(M
M-/EI]!=9<OWX)U:8N!VQ <_EHY?+*PI/:-LIYZ9^?19-]/))N-6LM5K6"I\]
MS5I;REI#N-TEUFK")6Z'N_RQRWW6YU%HF\$WNV>#*S(AH!.'I%4L JM4AH[N
MQ%$68/<<,\T].N=,'6FH,Z]'[X[[;<_O77K^;0BK"#;D,'=1.XR/>\>#=,Z3
ME?%1KM?1OTO,L!JB_G'K>G==YO>82?!F#AZQ,7?P.ML5DA\F4]A4FUV C"\$
M-VX?2S0MRT9=C-T@;.O*/6-].V3.U"?YA:3864^Z)P)AEZA!'/DW?<ZNF8VJ
M V=A[UZ"EDS@&0N+W2.)V=)["DT"2TA_V3ZLZY;$2V])7&3TO]%K+"3NM8,T
M/=YEQM96I9NE5'^RMUU":I)J1^[05B%W*)<PM<%=PG FMJK2B+9*2;^RPUU"
M=M,THUY$]0=$[FC ^KR+4,0T(RPCW2U#?6J [!*5_+OO/=G>]LGZ]+YV"9^R
MSP"U'>!!*!OGN9U=*(B9<N^[1 YO*KJB"+GG.-P2/]]2S8W;P3*C8!<(:18
M+.#(0D>:IJ#D:_:2/].[D&26.Q<[O8-=0MWY!6P_)O+?N-?Q6;^+9X D;C8/
MLV/W BNF857^X,/YQ9R']9I\8J^UQ2V+6TF11$X[X,SQ_+;7@<P"D9VB%-T%
M9,G]/XJ,?=WG9SU]?HI,$[H[T"J[ Q69$G1/H77U%"HR562Z[_QN!Z'79R&
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M$%QGDC!&B*T6R,+$Y?JR 8.(D0@;''<8@BH,5?#,Q';-?LH.[K$_X#I8#AK
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MX\0>FL65.@I*15#H@(%<U*'LRWB[F*R7.D#&.2B(Q.&,S<3"E5EL0\E0N/N
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M6H>FWW2:2=<20]M [8Z[38VF$;];'-R^(/29[*_'P@*11R;A+JE?X"]4G&2
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M;8R:?+,9[;D-(#Q>[4()MNQAK"&KT&M2;F1=)J-T@G2);&\+MG'[7*8JO6W
M\:_OG]VC*KNP#OI@&)V?O#YY3P8A'/1'FIGCJ 0/4^((<*I(["T2FOIXF,SD
M8Z0&D;YH1)\)88%C%\_\J /2"K-DE_0GCDV8Q-MYMC>?]AIY-S_2P%X$AQI6
MG"Q?8'?L: Y Z+OM[A;XQ&7.@HY&0I.;&M1[PY#L*=0!'W))FTJ@*H%M*C:L
MM43)NQC5 ,=5XC&=_QAQ($B< I*I"6:%[$R$RA/@Z),-9+_I3^P:&$O=K X#
M]5RPS5O?,7U25M+G5Q(>CBL_1G1]"<=T# P@?6HA\:@X6%OVN\V+D* 9,6R'
M(4'QPI@:)*/'-4>@QW7!ORQLR5I<EN1/LC#G2:5KD7O"FFN995D75REMK7[T
M\V(<FRH=C0S:V8QEZM%XO5'D1H8.^WHC1@9^X&-%2VT#*>S(OCO] /=/%@K7
M_8N\?MGH^R]Z_%CC7TCPLO5F/,$^0+P0AD5A[@!=%!<CYRBV9BWBM=O%!]TX
M%$PK>#IA$-;^H!FI&VN4G:&7N#(MZ-JBK/PB#UJ!DE5;ZK"/P\1!?=29-:"V
M&=Z/XW8/V]=^<4S?MRS9B;9 M_W!<_>].UXZRJDUJ[6M(1=FHR2"24;;$YXP
MWD[=Q3 <C/&K*N&09K3+)+6*=YS2?R#E/L?C5&!37/I[E2;7NKT^DT6!V$1*
MDT)//'CFQB_OP73O[!]$IY]%5@T.4&GP1 (UF<$.#H[[!]_13.!@CE/=X?O[
M'0D?P"#$@K-N+CWI_+48-K'-J0")2&>.D99\R>M3&BJ]ZN!Y?X]>Y? [\:S,
M/9'AP33+=LHF23DH\,/IJXVDNH'8HV<[^$2U7$@0FI7#]Q9OJ3OXZ$5C?!M!
MW=*(=G4L.C)DGPX.^B^^LQ$I;U#/#NYC4)U3Q0,;[/6??<?1/K.9..)7)'(:
M)A#E;F-EM$L00;UF(>8_IR9Q0;)$#<UL[ 4G2^\))(G2A-,:M,D-=AM)QW57
MGGU^5(EP+]OX^M-G&FB1E_8$!U$GR3L.3+H/T^*.2R6 "6!61J.:1 W9*..9
M ?MST'*<C^IYH&%$>B_HC[L 'W/LK/ %CH<5WH%A5=[]9CK>?6$!CQ]LL*R9
M)-;2@D:RV&5A=?%=M.U2D\++)"P9:&6@[,Y0^<);B=Y.VR0Z\RXLK=B#1<'A
M7S$C13$Z'0@=8"5<@&Z0(."AS=B:= $LGI9>]]#_BQP)<'IIEB-MMT//^:]9
M]=*%!YXT4N0FL;;>VJ7]PU?Q]'@*V=22R$ DA\\A^"8<XU&=(W"*!DJ<)4[3
M[A#4NF<!-)'@MX*O_U'TND-<NPAR 5!&R9X#_OI7AK>WP.Q'@WX(9R<+X-BA
M52RH_;"_$3BZ'4\;5G/PHG_8!M;L]8^^,RD(A=(<X+JN=8-P:;H:UD$JDW_7
MM'V21W5"'BAD0<; 1_*\YD,2KG!*9-40B#/QM[?PMB](.GU1*()(^$"0=L;.
MUCGX>C;^"D[^N:<N2C&*62:;^?E4+! .?EW4TV""R&LP4TGBC3\OK'Z :D]9
M+A@GSR!#G,O.,02RO=B/X+*^\B,]4,.?>#8]ZW4RX@740,V!^*\]ZP!ANY>5
M^ %=P50N&')F/YQ^I#S=8O*=MX^$\K>N#$WV? VH .ZU<4H;&IZDLT1KQQ:+
MF<I93,#;9%C4<;%4!QX]7?<&>[P[S"J=X:% UXF79N:F0K"6C"\:6XF'(>"
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M8.G*!?6K!\X\M7%4R/CY'0X<BPH\=J__['G/.<H<^8X.#KZC7['>YBY&;4#
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M3^:="\>=G\XN=H^?[0V>/&[:V(<"Y=N9Y_B=*+%=:>C#HN;\W<<W+*GR.I/
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M4$4S+?O!QL9O, 7,9NIQC\:94J#"6K:8"#%N]9G\UDF59$K,@:O33%C*VQU
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M")N:[=BS]&+R)T::<2=B:;3@M2SB3@QU:14+2'9F<3FG?>!HQEQM*SJ:XT&
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M4"F$7%U%<6C-BCCGUT[G;?V>]NCM?-K0D#3ZF?NAPGAD!]/1<-[R>GH#0ZR
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M^E./F-#;J/3!7M!0P70!68!$O#!0W:9M(5H^;!LRKD?F\KFVY+&J%_6D==4
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M6B[(Y.LH61@G0_5$+TI(LN7+)%%)+4T@!5E?.L BO5EX*D6%C+D,E78U*:$
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M=>)7M]@OF<="44E"3I'@@Y3<5@F9NR?"&=?"SF4V%+@&JUAZE(,5DY]5TTA
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ME5?Y5PL&Z4K%2E4K*9) CRQI-UOE\1G_C+/[.K B-3@''GJ"\MG7E[E-624
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M-E@XYN5\YI05J!$$O<W9IEF7BW[MM%S<>EF*D.6ZBF6,$(;S<DRU=?LZK"'
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M%4>V:%DJ7.<"</+D6] /TCLY)[!BY]^(,1<^00(HXG+_HP_76)1)SSB-$[%
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MV51/=W4+?,G9#,LTI"9Y3%=;5"1TAFA%S3YQ;DEQ\Y/+ER(&4>_A=(=5$SZ
M.T7*83L.V*9=#ONSN9>$*)ZBVO8-ZS6WJ(^#PS8%[<1:>33#K1! ,LB(XSVP
M$(1)" OAV)7\[]];9["<3&'FDAK(P(0**8&98K].&"(H\5S^4GU+_. /M7J
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MJQ>BDLY(6!<F./Z6E@7" ,<MZP[V(3S%8JI186A4\X.%A$"*)6)1BEFUQ48
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M0*/2DQ \QRKS;569OSQ6F6^HRGQPNCZDYGQ;G_USU[*[OHH =WIH*BZ9:2M
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M^;!:(UAI,RRI4^P:&W%UJ0T^16ME #DI,G)NTY!Z=> JZGY5ZW4OC@B=V^C
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M) //7T9ED_CR](5&@<,U^7249KD)(3Q7)571'8&S+\DZ.T'W4X<5#Y7C1OR
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M@ $9BJU MUA3Z\I2!)Q]O6L0.7:9X2W2C\7.:O#9&HI6Q\]O2N:JG@ZQ]V\
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M_M(*"$E%:M$V.V%$\BZ9BH\C_6>7)6'%T(K#LRB[W+TGFP]:<)IVO4P8FTY
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M31R_PG.03ME4R,<9'^%_(;@KVZKP,>"V;PV@"N^(TJ2GLS-I6YX289S[^4K
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M;L!ERH.ZVS)B%ANDAMEI$E)W"T#->,CZR*C#V*19*XS6L 3GS=):H))^6'9
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M.O#9W/AGS[Z? 8#3W#IB>9GW#K$TGT4NE^0#+:4ZBI.9&;NZ- K[P:M:2Q9
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MA&?!^6"GWQ.5G1)+>69UD$@ =:>#,5?IV^KSR,%6;<[[MA/_3BB 0,$ 223
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M&_=O/8?\;[V/?(.O9[TN#K^_7T01[;6JO,M$J_HJ1XPUW3?T7?N3^U-/JK
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MTKS:G8+BU=WO)/]\S>V@J,QX:_[H@B+?<%=YH?VUV\6O>8%BS9.N+>@_KY$
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MDP$.Y#Z>.5H1N*E<W$,(X)=7-1EG+JQS9ITME_,G84M*=<]ZZIL^@W&AN8Y
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M.=WZ.Z+7*,3_,P[<?@4LICMPX?CM&SIA.VSEYBC$RYI"O[A')#ES)8R&<X0
ML1GZ-8!=7(D7#:2Z_]Y28*W^"IB4'0:([RCX2?8LXR'F"^NW=QJS/T!;)L07
M5<J/1T+XZ,'B5\S'7IR<FK(S=-=/YW>7MOO]>5$A+TUKW\+JQK[,G7O?/G@L
M[]&:PNRW:.#7<BJ)WU??W7WX];6C&F4!OWOPZ.C.=W?N+/4Y.1U"SW%F5J0C
M&/,=+-W9V=GQ>[<?QZ0_C\F!6U-(BH8B:,;PNUAW4M_2#8B3V7%UU7V\*HN#
MJP"GDIRSO 7V&LVVZE!]J-K%"EWD9L?Z-3APJX._IF#Z6F2M3LJRXSP\0V;I
MM#TGJ?I$BWCWSM$_KI0.FK7A.>-S3Y.\X)3M'T 30F0E,VC:4&:V;;O_KV^^
M&9.77]'Z^)ZDP[WGNI8>./++:S*ZUE4*Q0 _)W*BZ\]UHJU*^#<YA72)XJ"W
M;C[]O?^7O;?V='ZF.S\Z^D>@!LGXE)G0*;!2J1KCGF.=,_B>O/&N+@6LL._J
MID,MD1MZI3M87^C^5XDTV=Q]\%7VM;6)]*$.^'HZB,\^H,Y&>W^2L@:\^_C^
MMQQ8\#/ @U6 2?A!?Y3H+\&S^8,U=I(0Q%5 TB&Q#T^2/GFP3BI_*UG3TM'G
M%V2*4O)]N?Y'G\$[([NX=7<"L&$9K$+\U[82>,L_$>D'+RNU:WV/)^BP;!JN
M$B!_].P)4Q: 4DMA-W@QI AP  %+#%^&EGH/USW$)-*GDYIA]_BDQ50LQWKB
MFU[SK];HZ<W)P'1ULC%*J@%,.]VK=_LEMT7DJ3X<WC5\$)N/E;.P0+M BU.#
MN.D>7!>],O_[[O>\W;0W72W0EO!2R:KJ6KK]S<YC?$YO.>,U<A$/16E9EPI\
MZAG9_[0)(; _^O;N'[N<L?EZ#MGSV+)^<[[JB<1C3X*68'+<XH;QT6O+'W;[
M(N=_/HF:A_DPCC0?DX\$') 76N390WEMIXV)+8]-G2A[],2CUD^-/;I^X1B@
MV/0]LGI8CUT"E?_OS@"7)E8JK?8'(0,XZ'*12&15VHF>)%_L#%).JT3B8I^'
MG+#"(L,O].:77\8_7U_HGR]9D0U&ILVPANN#-3R>80V?']8 @D>^U*JJ2>S_
M^R]W_D*GJRB4UM+]6[>1_ZV7EF_P=EI/C5?H^T5TT\\;_TQR0LK3'C'=T+ZA
M"]J?W)^BD_J7'E/PI7GL]=T?_VU"-8TYK%>-S5Z\>_92G<M (WF^SCPC=?'A
MT8/[]Q\__O_O_^7+1*)74#!7"T3/_?2;%V__L7A^\N3=JS=OXZCQ3\&=^1%[
MU*LO72ZRO6K+'#DR@!R@#2C/M,/ 9F]69K')R9A;>I]U!=P/O(0Z;]XOUHFR
M\N3>\;<?I:5EW(7WA=$AA)Y+A59.I7JNOPT8,7$0'M+=Y>&\^\,-M10^<*3$
MJ&^.\YX]X5<SITG1B0O9-2[19@.48W67\.=<7$#4._#"\,D0B%0%&';("M A
MLR!-TO]80_IVZ)3U5ECNU@%5VB9Y*5%8BG0<A2U52JJ[6?:B)8J0FCVYC_3C
MVI6@:',SWX=5&S1\B7/K>TI2N^.T708($\WQ)1G*#@;_6J\-B*".&4(JSY>9
M)JWS%=)Y%*2=L5N,G!_0.TQ_P%T0"_-AFW0-YQ/YFOHI/BA()LK%UKRA")=8
M0L(SAL;QA>$&8 5[D2#Q6:/_*L-1BP0.+DNA99-S'%V!4 B\9A+D[>C(M++;
MS.>7"#"8=VR5EPXL8V\*1WJ;G#K?_O<O\YQMO*[)DGQB.$"14\9@;<M!L(Q;
M922^&X*B$)*B.[_QC*!//,_AE5.7UZSO+]S#:S,"?X@=_Q5E!(KLT3.?G.;0
M@!%P#AOZOU^_^M>+5Y^+G-:Q7'S-:OQ,*B==F:CN\8B^XA"A\HP^*%1/]"'-
M=7G^#.DW4MLJ>$*%PS:<=\OYMLS.(?U(  4R9);.?4;2<>#NO:R"8FVJV%J0
MJ2N*GLI'A \5/SS\-RA[_^5.(%L#R2UR"3]<;G@QJEBPRI9A@G$=SD:05>!,
M86/3C)-,A7J9$>Z4I3\?4GQ,M#F-SMR&&\5;7)>S,(W'1G/_-9)8K/'8"K84
M%K7*G2F>C7A&RO[(D.N.EE"/RKGR!R\R"WO6ZP!VJ!C5'APD4,7A&TF_DX1)
M]Y>*UG$9Z?,8G%DFGC\]62XV=<( XH2>K3!2<71/ :%2"<S+R/BS\Y>9#\G.
MT (UJ.?:'E%>*T>JF9%M7^SI2^Q :J<@1Z5<7@@)J-%=OZ>EW]F>(636WKQ\
MB8;'2DZ4!X6TV/"F%0;>O>!6.-]F,_!G7,_0'5HPS-_=BO;?7: ]JT9YLH'J
M##_##*#5KLK<7FWP2DN+,E'ZT/N/%N335FDAT!<A$CU,'S^Z-2=VW3$,#Y"Z
M4\'!&3T3ND76XZY6<((YD^L5(NF']T;2N[J[#)Q<*AG!A )FCI?+*-D_1+/
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M9MF.^J0P9JS(<'Q#Y?!:]^7FL7X(KU56,;%>DFYSPW1XG.7:5;6-3AKC2/-
M!LFT? 4784O##'N@W"N*I319@VGP?,XJ9@;!$!+?SGDI-JV1@[.T*3R^;8_J
MJD?E>(/)WJY"V"?7OAZVMW?"466I#,G1/,TQ3KX'FN3"A$Y[4<Y%&>6S6'>M
MN,':1V^]W) ?$:29.C&"?=8"YR:;O ?(W9OU02\3N]<.7UU?/Y,H:8$C<%#I
M 1G'LXUQI]T(UC0W]7Z=Y 6V!#J864072HC9M(E,9ASC[3E>/!G9#N%Y,AA9
MF\B.USSFIY2J<6_?SXQ(]B$V"7RES*1D<)?"GJ4+Z[GL<S#KH2^R<B0-0>-U
M_Z!4]5C?"0_>L)QW>E'FCO0H7PTJFV[58$8:8C Z[QFK*=L(?D:.TA'ZI7F\
MW/"4<O?W&$X?$2ER.S$Q!%<9,*&"%6?&4]X0 ^XU+EP(QHTU9P(.)/-^C%JM
ML41E>=VO;QPOWBI9$]AL,?/B2':Z_^19981!=6>24MY#I;>@ V5Z<XC[W[8K
M&V"O5R9-\&K]E:#G '%G/?$<V'0<TO[>-!U:Z.%UV!R9KJ3P;2@+J&B')+5^
M2M@L_V54 FAR]Q@*L4U.)4*O-B07X(JSA^J<;3D6IKM@^7AGF#BNV59GB/ZK
M7=X(J8$HU0LV&@O<M-@O+"D/]?0FN#$M7!^^" 0!DR1XE,_TWA\O3IPP%@?I
M7B8W.P7SW'@/F.S<!8\X:D]ZE)_GG"/E!0:T-M^%]B;I?=(1$I<&ETUJL!M:
MC@2U8GDI[(VXQCS.A1S#<-@/YZ=Y(/GH\HJS3Y??T7==M10#4^VFG,E95%(=
MRU?!UX+ND)U<<]9,DW+GW,X?'3Z =+F$70N9 LOT0/$7\H:5.KBND5C,=$(3
M$V-X.E>]HT0K:H+Z5V(_5=YB1$<?+YYWF*U<,SO E(E8(^10XNRN9(-!FKT@
MD0PH1,[4DJF(V&?4(O48]:::A]V P5P]XY5QY*\G=H@A7 &>M9I[PM*)"?<Q
M90HX*MF2;L":R9;#\IZRX'OGGW19R99=]!FK(]*+4PK);M%0UD$TJ3.P//YM
M4C/F]+&!$INY'KUP*VMHPXV+0DBA+N,JCMA.25W:, T6PQEFT%,YVVR7?V7:
M,T,;E>6\T1B[IBY;P' 32\4BZ_ALTYDT-4*/$?I'F4HF9Y0%$8#&BIQ,#!#3
M6RGI;B,X*Y*PP]X9%"7>"-PN6(]LJ^,IU;/(*CU*&UKW,DCW]^[I8QR=GIK5
MU1Z3P!+R939]G2'#R'*2LE9<5(VVWY-/XJ$EY#._WB:-T:&KR_!?]SGTY<\-
MG#)19)[8C DUO4OEB-):]LPM0T+$8:9;&GA?YVL:^JN@9$;S./,<ID_6<7-W
M[KCYLATWG]9.3!\XYU:,^12!)VUYB,18YFLA,[1I/0D>]^0L8YJ\*;-]E9=B
M,B-E,Q)MB_*)0@1K5-]]Z82,9!?R)N'!*X(\ZJS.#IPZ_)*#!8HW6I?E9LI(
M[F2<BF(&;D3D&D<3]\YY0)VK&:6S+/7XT"$.K&/@]^!3.=O#!&QWN00O>WH\
MO(NPH_-.G>7\,*>Y.;.)?O]=81%H)0F;890]?S=Q]DWXL@>NKP2E3:^$3<9
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MX35,84N7J1IEHBB#Y(;.):>+OI\#D5E5W295-9CGJ*PLDB6PJ0!(C *@PDP
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M3;HU65>8H/GN>/$V<)OZ7+CR,OS*0@#7;#%P7N@$E6M>J>3BP8M.*LP'QSK
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M='8Y,-AM,6U?=BX4GSE1OK8C"I0<79T*6<:^JRD^)9F7$4T=YBWU-I:!LUF
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MVM_!889Y 5@%,;TL-% /I&<2*:<I4C9^^>C9(+H#_:,XI:B.O92ZOU6;UC8
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MTYO.N,!97<SJXE+J(N"GXIF7!ZEPO *W+3N=SS6[<M* &O:)$N;776&BA*G
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MQAC+J@74)XU'7A$N=XTA0#O@L9! +';GH]'FAK/*@Z<B,W%J6CW(M9>(H>4
MC]U%?%2;G5= U3S9\FRQSI9H<!'/13SOD+TAR\32%.G8*I(_DE*QRS08O>_9
M$I+_A]Y_%4'M &&J)G4>J1-$+]>Z<K<>VH[#2C'&95N<$?;T8;7W>]1V=FIH
MCC#Q)AU<6,B!%P%?!/PN8P!H;WP/J(FE]7^1MT7>?JF\1=LX,^LFV ($A[((
MUR)<BW#]XBY(B%5O&V(Z_[@V/,S -S:-$_TO=#:]_1='71>I7:1VD=H[CPB,
MP<L"M]!T@L?$@=N[B.DBHHN(+B+Z+]"-$2585797,:E3,Y8@%^NUWA(PKJ@4
MDA3UD[0LT53,HDPL<>4BH8N$_L*.<97-]5!6!9/$T BK=8*;]C*O5=ZD;E@$
M@;W5-Q96[IX1.Y%VO:.971IQ%D%>!/F]$D194CDQ8[-:]IR?G&WI("]=-O?5
M9?,GM\F'+@#4U8-7I<W0^64F5@7:E<CCB(1YUS6;$A#!Z$;97^7M+M^X@<E5
MM;,J\8V\YB1DT:&&AB#,XXT7='^-ZD!)^:(D*%O"8):.DC9TF5BHSX E"8WL
M:M!_E%M<'GTB:W^;<(.9AA,&IP^7V31#%?$]J?5$GC/8C?5!(9(!R(5BG W@
M!F\HV@B@ZEKJ%YV4$QX$Q]B?I#.]D1PG+6E02XP,=7#3#AFSGEGIKZE+R!$9
M9TW;1.CJ+=Y9%&]U6"G/M2RO- 7E@$/U4:CSCQ$8$$: 22=P)X(%-F.\I[ZP
MP G_VW]ICU;'+6 UI(7%2[:SX]T,T/SHJ,HK0:[E3^![Z<=F(><^/2#T]VCT
M@W[A;K],2:.S55-;M05(4.[V41!_3<V.\<"#0SD#3']L?VRKWOGJK\T-=<YE
MW-47>XQ.81O.7[8C--Z?!4U\1Q()U0_$_U0S>!-&AN"MVF<FFS#O*<CZ."7Z
MJJ-.0*.CBV;5-0D6#0#)1=D$0^3>Y53!Q?H-M7G5T,3+RR:L;<Q"!86\<ZX7
M=2:1>^SH.#X>?L0#7B;O[SAY_^4R>?_A)^_?@VCJ5WZ^3(MTTCHY\D-Y0 9L
MXZ2-0"Y.JJ#UAFRC6K[S6FS#H%CU:F"5Y[42.I8CF#GC1QZG=_"GT+OUF:K7
MJ"^-O56 _"QXJMU Q'@E&L(()[8S-L@8GM,]T@O\?(2?CQ1<L!'!C'I7PQ =
MI&1=XT9YP4<C^Y.P7+7>R+27_@35H ,Y'F#\V5]&(HGBR(>R(^:P&SHDET"=
M(C%)VB]/K 5*M\%4QWE=4VR\SKM2J+<,"^-IAP;!3^'D1G1PK_-J<.J.RX"9
MD"<@4/*_*-OQG$.;>W>.&H^)*RY&]%/051LJR*1,9N=I @%12)\;^-8X!7>^
MNJ"GIFU7@9M];GYF'WXU*XEOJ8^:")6NO")V+<2M(G\4U$4M/#H)@DO:@6O7
M]<P"\X@9_=Z'NI&O_:NF] -=31ZH.6C2P^MV91()[#9798=P@(1LE[]U% D5
M):E;"F:@44<'P=$98N(*9WWXY& J\1CFKC$<@T^1T#$1X'7YZZ#X^W@Z&FR
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MA!=OGC\0^38_D])O_PAK\=!WTW-"X12Y*@?)D!"VHA=E,I&\.3@^) #!8#!
MD!3HFIT_(%QKWYJ\BM$PI3EIGTW4R.>S:H<>B5'66AY91P9,E-$D_!%C!70
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M/K2_='HP8F[2[X=@-)A>"]E6AFCD"(SU8V)U5+(NM"%/'X3Y G:N.$B 8^9
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M+UK3L@:%R1E&%]JH_<9T_=D5G9D(\4Y=/Z $QCF[Q,KZGXL[[!%Z*>-O=3J
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M[3@XJLK\:;FZ(:=SRT1?)/O[BKES PE7U&UH)V#K+1U;ED50>P@BN,CHJ;9
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MM;CVFLN?';YN[74O"C6S"N20)-<EL$Y>-%PNG)[<RA[A<;=42*.?J +$.#X
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M@(#@BNS'16 [OX[>MJPBTZ4[>EB$):-U92]_@5LOGD/91D42[BQ*4\8BYQT
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MC!,GFT&8,CZ'2U7SWJN:7R]5S4<]V??;K51^1(4^&U53"R\=U_ZJ17"A:3W
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MO0AA?+7<?V>8"M#G]-;Q>/K/+&L1F8LF),3/V'B9?(SB][)>70R77E<*EB&
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M7EW\N8M,',?<:SX=93LN,;7''3I,SY,_<-ERIRU89L>! $/4,F:I 4Z]0]C
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MNML/A#!>^X/!F CKH0=8/7$G[0 %I-@Z@<S;:W12:^<K@5@D#/:JN>$^W\#
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M6G[K5$>Z:]$]Y7NDM)"PB1*3AQ)5-)NX:%JF^#I4%8VZ8S_FN\7ZP:_Y!__
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M_,:\8PVXJ%H:9PJ\%>D(8XTHU2AJEL&]:=A*/RWW.Q*;&0X5-9F -#VR+B+
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M9[?820L[95#O2L8XARU']D-##;M5NSH8<XP)F@GZ>.-<3-U,W<=+W>Q*.SB
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M"\Q7S%=;X"L)!\<<8Y*54+GD6)D9BQF+&6MQQI*I&C&&7Q,T+Z2M"%L&*HO
M:22>P)H'1(71WV</7E@.UIC?F-^8WQ;G-V0C;=I,6.FF1RTS8R3'+>OJL3/W
MS"*^IPBL9O1,'(SSB<4.BQT6.PN)'6<(Q)=(G2ZM5,7M,XS4-00&<R9S)G/F
M0IQ)+GL19RT@=/C9]$CCK] 7C=[@$O=I+-!W^PIDPFS';,=LMPC;Q6XX$G;&
M?7;&>C)>H4 ZJ3],?@GA4][P<I'QGQ%WLZT,L;[!7JD<[&"265%]4O0<PZ)L
M13/W,O<NS;W(/XXR&<$L!6Z#;?/B@7(&>Q0V-:Q(C-9C@+ /^Q3)0+T,O7M]
MM"8=G]$J,QXSWH)J,W5=!*L3OAKB,M-;0RGY%G!C*#-IDH$7]62*&*LZYCCF
MN 4Y3KM<P]SOXKB4!F-MHS0:6REZ+N8\ZN3]#*I*;)P(=Q  S3TQ&S,;,QLO
M%_<9SVGUQ1.FHI9&? #@JHH6V\(B&96A*A^61K(PMIO"S\E[E-<4.BJ?T0#)
M8+<^.YZ/]V?)NO+=* !2-#[Q-F9G9F=FYZ7"N,!96,*&D<\^L)OR^XRB,,8B
M-$HB=DB!.Z,1*%8)E.W,3M4WB "3ORF)*274#)0FW 3S?>%9(]B(-]EO,58Y
MWWVA<]9++GVODZ5<W_&&\<61\#67%F^JM/B22XLW5%H\A:*6KR;>9*%%Y2CN
M#C_+Z[^1/ QQ$S'2/!Y<5J4"O=25@M-PML<)@")]R9A3W<-R(,P' 447Q.F0
MA+$LW,+H--Z2!B[(1?0+4K%OK%P5B?,'/!-K4&-5U#""+Q-C16-KQ,')$X+I
M+HX[\,2S*,39I2M%%CH86*TK*/U.A@.':LU]3X(36>] _LPQB*>SSG6 _\+Z
MIR[<Z +2"\JN*=8V&YGI"!3_)_6I5/O:QBNH"H,J<8,086P:406+$^O4()UA
M$.E<0N4B(JRIWB<K^92#R-P6_87R:W!S8_AQ!+M$AV/X:N<4>IDU*A'VU@F#
M0J57UH,#N]BHE^-&9C@Z[/Y;4($6',Q-3_PGQ>TJ?8+^!M@2!\&UK@%+Z70<
M.-Q18KJ;98$0?<(_Y0Y0,:-9]Z;*7%3[K=QA+0F+>,-3_FR4H7B43U0#1T L
MTN "-QMWC([>IV^$OU+ZE%'ZA'5/>40J*W[*BF[&RJ N3!!PG+7)&W&@W/?[
M[S\Z/G*'VJ7'@8##NXDBK)J?K$*N1/TQ4"2(-J)GI!/;;%:@6_>-L.P0-& O
M8^->2'<HVO'?U+W(]AO?UQ#VM5O8UYCVU3'VE=I( 3:FLCG9DT'!;N2B1T#D
M46XB?];C3&]!)GNR34"4@AC<38.Z8ZZ\OPOZODQFY7+[L7)[Q3):+A,,\;+M
M&@#]#IP>X!FS+-T;P@L2K?.5+B4=8.8+9:7)<"^J9OQCA#_@AA(;.KYOPI5B
M[@[P#T@81")I0"KR(0J#$%%FI;M,R ] ;*+7/2JN6T):Q":(:G+1*6$-YF[W
M1.Q&7E>6)6.#(:M!!?9 F& >T6 N\CSD#58>\YIFZ=S,9+-NY2*1!?5SZ<B:
MZ&G5SCOON+(H^1ZD#W$NPV[*L;BN#_%ZBC-PRE#;Y80)TIVDP*N;G!)RYZ+7
M X9][;2;S>OKW^N-=_N1G4N8]#._]O^DV/\"6%*;QO #7_\;&R;Y(=AV")&Z
M89KH3E;?O/@/<V<.WI6X;TF\K\:486*(=99[+/>0&SOSQ5[SP,5>*1Q!\?>8
M CO0OYWHS?KD) [+N0W*N7O9/RG'A66];K"\\$E0GHE*%4,/I<1]?140DXY/
M1*^1>/)BD'HX0T#V@#+P;-^+AC:*./+I FI$EE,MI>O-)CP:MNII8-6;E4&:
M149K[8G1#MTVRZ79-: XC-1$H2]9_ %=_CT"-4O;9>MN.3TXW_&YQ[ $8I"/
M7KAC>!4/[?.SXZ>.[I&7H\\ESJ]"LFY_3B5R[6>)\()*KO56NN96CO*M!$,>
M=DA&341 EVIG%-(E'8KJM]6382G]5-V23 OI/.^WCP$G#$VDW:&7&%UQ,U_K
MC9M@O"X2&,-!3[**Q^%?XW0(^PH[T5/!+WRXRI12+Z26@]H?'8^$Z_4]8SFI
M[@F#GR =ULI9T7VC*Q9P =.L!LRG<M-A*K,H9%QR.$PQ[*AZT RS=K-FSI8L
MZ(-_>R-J%D<Y(!ABPJ@+[,49^4D&GNC#N_4O[^4OS]4)Z;MS35FX^U$$'FSQ
M;_ 3X R!*!+7(!^:PQSU4'KF=^SD"0<<G5,AOX/=F6DK_3?LZN[%Y#4$O>I$
M9L-4DXRJV#,0L85Y##FYQ2G0R+.7G6>&*F2'4MA>+7-FG(>$AVOLMDWN7"%E
MG)#]ID6_+\.+@<JBI^#R?&X],P(;0.W?D-*WU?JOZ;ROM\_$N3IK7,GFP5"[
M5WA)N:@XQWB.:I)(;?[Z1D#*HJ(\S=M[Z(^HXT1YYVF2:T\!D+*2B1@)FW^Z
M-L;40>1BP<0 6),&H63RF=(Y1[*CG$U!>#55 CZ1QK(X<2@;D.9A>8R]4W1;
M"24O*@2V[Q<C.E(K72&"@K+0;U_EQ1]I $X8R*P D:E_>ZN,B!^H',]T*@OR
MW LF/60,B\%[J?-*/MO'6E!%K/,;NG,>VZ;RV*XXCZUJ>6R[MIB6H,HCL)A*
MIAQ,J+T[Y/1 CC9 P6;=@YXT9*2\$@5TI<VI(KR35H/J%^7+ON.9Q:.SJ M9
MU3IYR]/;H>2\A;#!0->1W@[*'I'-I:BG]"3BV@(.DF"KOPNPE;U$P2@3:8%J
M%JZ3RJ(2CT*UF/,'^XZ-QQ.=6;;P7F;9<2-*5Z"\LIY(L,$W&EJ9Z^_"NO'C
MD,S ?\N^ZUEMJ2@X!XK F=IV4Y::-@8Q-@UFY[]5?WG2U%[\AVHGKC6\C&Q3
M?B6L65-(-_]T8[1)GFU'N7LR891&S^!$%[H8\T4] @!D88Q"'W/K*#/#P!'X
M4OQV6&A$;?'O58K_8CM)Z:TZ;34#8N7&CC(H9IF@\XS,>0@O-Q,E&H(-R/NW
ME:U?C]J1E1(%RZNT\3EQ]JO:G?PQHS0:A;$\&H=20/.-__7B\4(EM_HX>H)R
M+Q$ZFXD.],D+IW?MR(;=DQKY=053N=SCL2ZYR;[RF/)-ILX8UT\UF1=GGZXV
M.=3HGJ;5CYRAP*&T2$H3RI+T:OT#_OQ)=O'^DE\O\WZ4,XF<1K#O) L>43.%
ME#-Y'STY@>KFF)FO:(ST $ :KB;#'*+I*_F7:^8&B9,MUC:588E!L_B.X,Q!
MPZR99;14U.NS5#A(6>) KMH)4RIVLMRDF>,6MA,64ON+[B)%8@[-"D& HQRQ
M>A%+';6M$KH\X_.ZP@]?]C*#>:,QJ"/ \K<YUIB00N%!0O;O5"="?I,@'!\3
MMP3BD=5"RK,_/I*'=$(N*S-G-4AE!.G;]8KV=@'4>S. NA+X+N7*],PT?<"R
M$7H09XZ*I;O)KX>SI[%^"O$2*0/T+F*-2F0 OS> _W]@F( B'F,WV,L=*WO
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M* ,@+$TW)$V;-9:F&Y*FQ@ZNG 2Y@AB^+!7#G$$YE_8?;KY]M^[N[O8K<6?
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M78PR4^\FZ-V:AM[RL='7V/LI\'PXUR@5N!-C 1B&T\PC>X736^&%\KCE,KS
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M,F^NQ9O;F@-W?5R\R7[DJELDRH7,)@D+UNW$[#2E[:7A5]N^/((60N=LC'"
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MB&\B+X9?F9X,&L_XW7E=,)[HNNDP]9U$]*8M9'^CM*^OCG:2=H,G:3-R8.3
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M#[@ 1A K,BU/Z%$$0/E  NG0V'5B%=AQ<_=E6'.12*;ZH^0+_G6N:_BNV X
M64SOA4E]B0*<=[*2PS??>^\:0!4?=2?-^BC\J]UNG5V>=2YVZA7N-< KW#FU
M[K(1#&*"&VULAE7LAJ6WH]9)/&]S?W,2/[D=5#9V(G\VV9M_!,YIVAO<=#,
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M-:F9[G0*KAPC(BVJ_X 1II9+.F<_ST3PU,O%D^K.1Z.<'LJ+ >E3OE(,0DT
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MY0SP9@O/R+2B&<N/!D0T@B6I[(/<?+D)I]:')ZQP\%,P1BBY'HC4QQ(.Z3<
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MD9T*2D4::8L><0] 7]8'#"B$$8&M-P60IU)C^H9E=.A&D):OQ-[84,Q)(S"
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MV7L,5H?D[QJAEX-64-XXIB1-Y'2]V>0Y["-ZV"I+!PUZY=^ &;HR,DV#4_I
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M*I757%8ZD?6TC(K51C\2)><><:SK,0]/].YC[_9\.YK=J?V+]FS4!!5L7<Z
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MZYBQ>')LD<]']E35)8KZI(0TFG/:W"(SG*,K_K__S]]34A?Z=$39+Z]:P+\
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MB[A#1".@0.V7I3?,,G>LV:BPRK2_4;>UT-5G3.G9J]H:/#K/]WQ*KT4D^8?
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M.,C]41L#$FJA*4Q?'&"\>1S2!I_V3]-%>Y(/0+A<2K\"[FQ3DT;3Y?Z?[-S
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M'71Z_1<7]=?B28LGG5>@N5=S[W%R[\Z,BX.'"=N;W=%_$3:'!@G38JN%8NM
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M=I7I[7$XNDKOL*OTSK=41710^]&ZVJ J94!U*H :H1S-ZH?-ZMLJ&#RH_3@
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M\I[OX]WZA=O:SKV0DGZAWD[]0BULC_F%3<*AEZ4>Y1]8$^2\A:#2:V."[PD
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ME2WERL/"[=1LV0*VW,0-^DOI,;MF;,W8]=AHQ^#F:\6%CC94<NM[CS:"'JB
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MB9;Q27/3#VT6B M@4# K]@PN7.S\@)IVHPDL8^1CA"!DXZG+33 @"C< G6$
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M3\0U0D05T"K:U&PN!#1[<\G'H$IWE;+ I^&,S%J_2%], \RN]<NH'XB?QD^
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MF#U*:!_0XE)QG%9AQ;B@/;+?&8V5K8W6SZRK\:+_!#Z'>)\;OZ\(:YI#<LK
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M]2@N'9P-)SG> FQW7;&W?-]C#\6^T;#+ 0\Y[N7&\!P>@>%:*ND1S/8+5HA
M%JG:I*8M5+3)L6-!Z+>9.C86+=YOSM%+\]\FLR%3/2DLG=PIAM-#)CTMVK=W
M;.<Q_()I\DF2DG7L\,""H#B] =CWJ&R=MWY3T%]7=B:S^-'B$;Y"I#S)<#+J
M2?Z/5V\O7F<@)$;/45^>X\VQB?:GLXRY\H_?QH :A4PP345:V:C#_^):ZL6[
M.]IF'?90#&N@Z?OK:^5=QB8:=^53G/_>;T[OW"S9CO/%<IS?*%TBMBM]PH$Y
M #N;R(>._H)H0-AIGE[Z8Y@OL5454JW8;RB?$_A#&UT-6(7"-6 3B<E/?"^B
M3C8%W0,LUOZ2FD"6YP >=%Z]R87EF'=$^9AUS?OK!;(!,0R>@A3\S>=,_XZ)
M/=68D@+&.GL=S@JS:08G^*WY8@2XH'.PWV5UHI^DV*& X#W&*SW) 7%;9CP]
MT5N>YC)E/75ZU(>*)]6P9!.Q9)UYDEBR+CR)YGCNV]Z^QN[V;QF[5#4$6M#D
M/KU@U5J*EG^AD$:^]14\.>BC.QP<LY%N)U=M;X?I_N]0%1'^"X-G']$+^.O"
M?OTN[0G,PGE)-FR$W82^."]]<=2^VYU<M ZH"_0(5%()IVB=+477F4X@AQ]V
M4SEU5$6(DQ"G6L5IWGIQ$K(C9*>=LC-[/K)3B(:IT9V+ADO68J]:<"GB4:WD
MD#^?4DN?> RWF/TRB>=S"YM?&$0O19'0JYRAY(YTZ'R7&(0O=O'NE_3TT@BM
MTHC=/E[_LDS&",;O/MG6^CT+H<' -T&^02JNQSFQEI-M8?DZ_ U&A<^*TQI'
MO=%DD,H:V2$6$0U3=B4J2$A&F<B+=Z^.*)R3-@IG9O5,(;$ME-A*V;75)7;>
MF\ZO,A*_B@2V]4PKQ%N(=T?$N])IY,KB/9J >*<WY+,0[]UV4.FP@+!Q2H@&
M/?$@#)QB[9<W1Z%4:U6J'^ 7!ZAW&C-G.)OVY(&P<\X)" G!;87@-FOM#,=7
MO>F5?)YX2$BYD/*.2'FS1L_5J">/LPZSG8&0%QH]E6R>\OR=&=#:2W>,BY3'
M"294:%94F$_Y!Z>BQT]9T>-63BHSI)T_TRC:9?]57J1,2-LB]BG<"P7[U,$^
ML5#]$9=8\)G@LZ/SV2$>34GD=C3D][RS7 "BPO,I4CM.;%7]KL/$='?KMSR\
M-K7X*!__[<'7OQ-W9<$W#W )+9MV(B?IU55OTHUDD+*[F'"B"$GOI*0W[%6=
MS7NC^9DZ7(1"$ KA_!1"LP[8H3SO7664N#P+A= *#^RP;1[8?2=T<@_L:/,D
M:9:'96I:Y-O(F]5IG1M5%[E5G'9R)YK@-,%I@M/.BM,H%O![%6:T (Q@R!W-
M!-.5#]MR0[*!8=7BC*%?&M$5.R6:4PFR0M6_G:4'TU4%*Y0@E(]95S /L!YF
M@WR(U(O'WG)VK!4#;<A!UEB\W-Y*FKZ$BXFI$BP Z#X2PFJ<+Q1'9U7FL^OR
MTWX!Z3X-]+I(2>B-9V\LASC]^CJ%)MFE(T47"QMPW:HKHGD&N5FF*N^#N?<E
MI/OAI3L+>W,-)O)X/)ZS$I%H[NE+T*VPK/%RD5B:.+-Y@\T*2]JZ0S2__P,K
M'0DT2A:/3-<B3NN&$F5&@SG74',2ZWS64'0RTSI\2MJ OAET5:%B73/5)FLL
M"M?9H?8H']C9=SULJ+:4Y.I4*8TCUS\IJGLR/6;=DTXM4@?JG;2B4E\K*_1U
MBM-:I Z.6@:I4XO4 770B4I\W2@9)F3D?&6D_>7UCE :[&0)I&CAGDD":>I)
M92<95$D_Q)G'_2S)MALB(?69G/4K<JB7468UT[F)&-UYIU4)7NT8KYZDT$P7
M]LM16_=+6JH&HU T)B69Q/5;-)KWK,^5JMCV=FG9CXJMB;,=XFS'7G&\K#;;
MJ=C=C<]XF*KY/LIV_BGY:U.C/6LQRF<!_1(1O6OGQMSSG$91CN9DT+L:I"O_
ME3N>T4(M+1"%$-E6BFRU Q=%(CN<]N31]'Q$5K@KSA-^W;J6^O-RH6 ""*:"
M$--AF1L"9SU+,[ )S>UG3:64-_SB?_;Q"5F/O(^P("CLWXA)EKKKW*X4F_R&
M3!J]X+WEN,<!8,/>U7!\/LI<X"\ARMT2Y1J!64^6Y^<CRL+AU37$=:VJMH=5
M2M#I9;DKDI?>+1"84-N-VLYIG?V= %,_$$QB]]D4?KU!)KWS>?1#R*)' 5_C
MGCQ,EX'MK,(6V$L(<6>$N#;8->I-!Y/S$6+A#3M/;(:BH]CJBF(SC3P0P]K0
M8W(JB!<8+P*3"75^#%/Z/66W6#C#9\VC8*ZIW!O-A,-+@"XAI?5+:6V@:GS5
M&PUFYR.EPI?5-;ST7MGH+I *ZQ38>=A)8":AC9O6QI_-;[8%QFR@@,'B_1#R
MX'&BA+U!1B&]SFIC@9F$E+9'2NL+ /9&<Q'_$YZHEB.K3_H38*I(,2?==!7S
M7E\8(C(H='73007*?4$]J\\AZQT%2$UZ\ZO1^:AH :2$<)Y<.&O#3]/>6#ZC
M<+SP.74-&04'[&VP'$R/"#0D%&[CEJO_ >OD<"QWTD2XDP0*$D)YN%#6AGXF
MLHBW"=]1RQ'2)\N&"9FBEH)0TJ=7TOD'M#F;'B>)_'RTM@!20D;;)*.U8:O9
M6;J5\A"0;L; SMO$E%"0XSS WH/>&?WO;1H&I5!*%H/%WNL]/'1AZX X%-.Y
M9+#CU"CF"U$<$O0PV9;N11PE;'FZ^OS1'PP&PZ10^B72HN_LDRRDV*D)EM%V
M)9=,229*4(G+@R!4#80:!)2*;$E\1\JB742!I110FI9O4X.>FKI50AE4QOUV
M.=NC(,%1;SQ.!Q?+,X/<!S(*N:FDAR="#PL]?&I"/3<]_'_^,I>'\EM&Y*JD
M%EHN2:K*B+Z<AW0_W$]=CQG^S\S"OI4IEJ1Y3=T-;6NK& #DL0&.IA$\)&#K
M#V!W/A!&Y^(^$GD(OUXZ1^S$IZ;HF;!1GU),5_SJ>[UO"9EM\2MG.'-*QA^.
ME93SG3'WQ_5" =;^$'#VD3+F1OF0MHBRZ#()M/QS9*Q(%T&A1LY^M9M[Y2QL
M*66 RYR6-!7\C+FTR4*@G#@'Z,"]4>3S42\G2R',IJCR$@A)J<E_#)+[8&=#
MZ569]Y^*P?L0*]C36#'54V8+5EFN]D?>ZGB;@V)T^W)_]Z)Y+RN&\P*VO_:Y
M_B@@5);'O:L,WVJ7@GA5F.K5*8+R758BCRO=)93M"4K&HZUDTT5HEO/0+/6=
MV9V->O(XG7E9K%C.B,U?[0::E7!F!5GP/PI-G<E^ *BT2[1\MM,QIGW461^X
M3R7GE.YJ^Y35U;;#4\]IR)OW/EE8XYA,U3W^+^T9ZS 3=7CJ9\__)9PK1_*K
M%,<6VN=3F33C4[FS7,4 $)?J<MPZSTIY#=5VKTKY-VG [BGF^^[9/!5-GK_9
MEG.<(-YPVAL/NWWBLVZHT+SG1"@)H22.H"3J<X5,>I-1M^N7U8T"N^OYJ.;3
M;)/WH[&9-^"I[Y 5>,#TS\$2;+T\U!2 Z01#=7SZST(>1.K)P6Z2W+SIFK*>
MT4'B'V+4B?.F=6Z2;L2.19CX(&LH.E<P).YI9!(8-?KYQG)T-";>2#I8*'KB
M+C:-K&]LLB&*F_V=XKJ*NEI3X<[ZW@*JZSE/5 U]$WYST67CYC!X(/)'A X0
M.N#L=8 (=;4L??B]95+Z+0PB:63A2LK:@C__PU**VX;CA"=;>+++I_@E3[%]
M"4V4"-M_ *Z_CC#]<>)@H]YX]#SB8"U*(6Z_^C@HKU+HE"[JE*;#9F>80)RA
M9$0(38306A"$:2(6\!R<_*?FX+,(>K5U7L^"@_-JYX2C[:3/F[TK9K(*3G S
M_Y.1+O)!E/(QMT)V=<V,BD8[2D.E?!6G+G'T'2=_:2TO/8>P[-T=QM7^"U6A
MLFE0X.C\BD<=2LP,0%BA4(*@;!YE#R-BN3IR7:L;5]*XXV6/<,HWRS\<0O\^
MSCGSWGB:+A4M9*Y^5GC5U+90H2#H61"RA<I+$%'L +F$KECSJ2K58W6A!!NW
MH;[H_E82&C1U6$FG7I=4G5)K 10K$^L]3F72<V;^0VOV9;O,$XG"@_YL GJ'
MY0HO#!A7Z)Z:R-\TI<]SGZUD:?D?\$*S-X%R.DZ!V6'5X%E=4OS<1'27S76<
M^K5G0<JN:CM!:;&O'-5^.U[-WG/F=G$8JT,U:R)'LEJ7R2M.8SR#TQA'*=S)
M.J/'4_%$+1M1"OCDRD.4 GXF&D5D\(H2P*($<.OKB'9XZN>00=EJ_A<E@%L]
M];/G?W$NNF6U;;X25Q0 /O&)Z%]*&3H1IG<E=)T/V']O)9\AAI,S/;68'4P\
MM-#GUZ9R7/]#;$M3G%7@O3]#WXFH RQTA= 5AWM&=NN*\U85K7""#+M[E'GO
MJ9_#0="D534"JTJS/*SQTSJ+\)#YG]8LK,QBW92(LS@:+23BC"2"[HWP0X'7
MCR$@U2"*36>\PLW]*<!+.-N@L)ZXH:,W( )$K*F;K$%GUB>)#R1=^^O%'8#3
M6V(0BANO-QMB:C^&P\%L/)$'/V2&7^$&HEV[.RX>5?*&C5\D9"$A!3M,@:&<
MB5&?ZC,\JCK%_B322GD@$GF@/5+1,[8B$JNG"1\KIB:9!#.VZ34 2;$9^0*6
M%D:7O TL!UX/D-70_\,BJUO)6DJ69V?YVOK2;XH#G\!M>,5*=US+9C=LB U/
M@4$-"RYU>M(CGQDLI6IX&IV9XDHZ_-^1UI9-P'[Z28PM?@Q&C>6R[W$Z"V*2
M)5R8/Q'8"0V#WK3P9T^TOG2MJJ"481;&-IS QK;PQ35)D98>W/60T9X=[)S,
MQR@.3N(#4<EZ06RF\$9#4(*#X14E+EI4?>D.)ITUK&ZJ,#FD6%K #EYZ90-O
M]@1FFXM4_*783$RWT$T:CN]A&>[)9_-Z#<H_:4(.AC\&S-5T9Y5W.TT"4W*Z
M(\V_G^ZRVP3)0"(-I(WF4?Y'7MN"+$B@46"-<I;9M781M^E6Z&7I*,OC_E6*
MD+&\T0/\[R?2<'S->M+2MM8-K\1.YTC9E1C.1OUTL0"V$GLPX;P'6@Q&MH'>
M<!]!GL3[[D%1VDSI@)HRB9O2P_V$_S;)!%7WRT/<:$^96V?<C49WV&2N<PI2
M1%Z FT3#P>!%>@(7N9?FHP857IS8!\&$/$_6@<W!3B-_P^DADYYEL%_ A#D?
M9QP19C'%)$G).N9S6Q"02/2Y&8_*U@E!ZLK.9!:?Y4;X"A$?X' RZDG^#[!S
M7N?N02#C\PA7LXGVI[.,N?*/V6GD1_[DA66@;_!715K9J'+^XEKJQ;L[-*)0
MGM^CGC)=Y]?7BO\J3*%\]=;$UM6$[KM55T3S#'*S_+A<(EA^($':W'< "=\)
M0C& >%2(Z%,06?]F6.K/DML] >6W07FQ/7*Q![(?54'VXQ8B^ZKL?PW@-$IU
M7%:=+@I%F>0)7ME!C+S>> C>.0!V7,7U*+1>$@T4NA&]"?0[W0#"CP@%JL!"
M2$D816>H?JF;L.'I<#>.1[ 4OH/@&ZY=6K@=)MK"H!^"\A[S;/SU8@#+10R#
M^Q2"O_G;T[_CQVPH&24%ILX#'$S>YN,,W>S[3V*TO"APL/O?:@EIGJ$[+)9G
M<9$1?8@XDW=>>X0+(IX\,9V=T95Y'=&5]'CIG"+8,1DIJ@*$LGOP/#@J]A@/
M'!X4<BR9^Y+T&\;?O/P+A31*>3%A'P6!-O]Z,0R50]D%226>N:43SSJY:DE4
MP<>FJ*!^]#??!_S]"PV3CVB8_+JP7[]+&R=9\"[/I5TKNPE]<5[Z0A;JHOOJ
M@OK+JJB$:)1K?X)5X]OLQ=]-TKA/0LB.D)VZ96<N9$?(CI"=O61G]GQDYY"*
M'V7S'O<\Q#*3BUSK9WT\Y5/:4^>[]Q0WXM&C[KL3G5F9O6AAAGG)4\L-';7O
M5LIXU>SP,I& :Y>S[JW/H[&+]\H$V'@VB09.PZ3R2[DXA#WL#\[KM/W%NQ?'
M/94F)%Q(>"T2/H](>"HS0DBXD' AX1V7\%E$PF>U2?AH?*X2?I):B\_8ID)N
M)A&+JL=RW)9!6H2?*2SL*:&+VZ*+*=->F]H7"P@67)>J5]:P(9654GT6.EB@
M+"'9'9'L9@RH@9!L(=E"LD\JV<T83I.,TSMG(=DB8M5&Z^H;@4%,>"E)TT%&
M;#P;>K)R:L*4.CNUO*.V<QF]_-7"W%,/+EL8Y",+IS9@1SFP$O#;#M@U.3?E
M_$K@K@8$O&1%L]-+MY2>_-'+E]6M!"J97'(N,#NX+F+K&5J(OMC;N[.W'V!O
ME=G;1^=G>+T2$:M3V%3?B4,46UW1XC :>2"&M<&#MY)J$TT$JH0&;I'3"SY\
M3[G2\;GVN"&JZ;FF"0A4)62Z]3+=3'!JUC^S9EE"IH5,=T:FFPE+S?OC\Y1I
M$99JHPGUR;)A.),=E/(C4RZ6,1+&DU#*K7%?<3:-7?$APJTG"E/)(DPE$)@0
M]I8(^P%&5CF_]=DA,R'L0M@[*NP-!ZFNSE;819#JN!86*_6/96*SFA8(*TOH
MXM;H8K\K1?7"_D<SN,XP:UN ,"'XW1?\AHTO>9[1XD,(OA!\(?@G%OR&#;&A
M,,1$0.R(YMHW;&#GH#2YEF03U[/!7-/^UW-<UM)#&&Q"?;<E5^&;K5LV=@TX
M6>&+07]Z;MI9@#(AU9V1ZH:J!IX?YA)2+:2Z,U+=3&;AV98"%1&MXYI(-^Z*
MV,(0$LJU/7XLRI+7H9E^LK(59P><A)-:"'='A+OA$-09^CJ$< OA[HAPBS"3
M"#.=D0WE-["BYZY4EB(H+"JAE]OBKO(3 SZ:, 3-"ZBM/=4AA< ZKI(%W!)B
MW2&Q;JJD^DC(M9!K(==-)/*5$^RF*_R-SC99M]":JA1J*L_>F2V.]T+Z<I'N
M.,6$:II/^0>G^HD_9?43;^6D,IN<Y\\TJ_OV$9>X57Q6N&<*/A-\)OA,\%D%
M/A,9)\?UE@8(.-*>DKE.A<]4&&&G<ZZ\A[GKI@?CWVR(30VQ>E)/A(]4^%*:
M:I.2:(V2-X_3RW-[6Z94D7O1)$4(OMB_N[]_5_*9/OO]6_A)A9]4^!6$_TKP
MF> SP6?/E<\H"H ?RL(@[RC041GB4AC2B< ]U2"*36>V0F#R%(!#CDT9'&KA
M#1R^??76Q-;5&'J3?DT.R?E_.!B\2 ,TAF&C%))T[:\7=X!%;XE!*#J\WFR(
MJ?T8#@>S\40>_!@SN HW$.W:W7'QY*+29,I[FL<O:O,S#^52)@.][$"#H1YS
MI^ICKQW)6DH?B$K6"V(S81D->Q*Z!6DC._03]*1'(JT43?JC?]N7ECQ9V"2N
M9#%#Q;R7#,MQ)%6Q[2W8%X^*K=&!E<W&MI[ #'&)L95^*;:*;OS!OL!8[Z-#
M):R@:^?&#+V7/S[#5[:I&-_) P'.NR7V@ZZ2S]]O?Z<OY3DX>F!I77ONRK)U
M=_L5'G[]I#M)Z^F/VP]1X^ER$EA/T\(\D\ELFE& GY$4EM*@I5:!HHU08=X6
M*HSE6<;)[A@5>I)-G TS@(UM#XTY=05"MI461$+EC,6.K.72 09;>BX8L]%
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M7^,=[RZIMH1WURT-9T">5/1)PQ,+@KPQMR[@BDSDX7P)J.#<P1,=G/$W8JM
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MI8KB#RQK6T:46T!_[<<J*2S&AXF.HAA;1P^!V#\\8QN#1!.F'@-*&EN.-O,
MF<,VS#A'/2*0,'286RS4[YD>K#*=IK?1%!_E[9YF@>T/!%SJ]IK0[1>>\8@_
M -2D.8"M3OJ-^T!-2E2V^G2MD5M\2D97F(D*%:P(CDNO9R^QYQ<EE5<("$0O
MS0\5H/XA]D%X(>_D7;YY=;0)=-"F&TZC#TY]/2_"ASM@8PSD85V3),W(.G:*
M<4$PA/4&T.FCLG7" P(K.Y,=_4SV$;YAI+CV<#+J2?Z/5V\O7J=)RPDVZLMS
MO#DVT?YTEC%7_O%;>OLC?_("MGF<IB(!=(!=^R^NI5Z\NZ,[$"A#/!R+%=E_
M?:U$'"W5CB=,*D7=\&!+P^<(#H7E;,NAFI>["NK2W9+F$7\#3F]BX6;J]'-S
MB4YFZ("6OU%="[815/M3^@Z?KF]_ R3B>/!JU[=_Q()YF8>)JRX%/NER..61
M8=\7 !L7)H 2))C)O3*^80J;.M_D<6$(A2H4AX,58"N70"3=W7*[%3XPG25%
M_Q388 8)7(<VAF5OJ>=<X1L5L[PB<6M8-+;' \Z7EK:UYA=$'N(/3WWC)G]F
MUI.8B\%Q+%6GN[J_Y:*#),)UR%W(4@NTKE4+\#PBS<<58?MO^#A5]1" _8EV
MG;5QZ>8>)1Q(]3\4D&^;;^7<@=0#P(B&&PZVMC3FBK$)\*:/H*4U 7./.@\8
MLE B!M@E(W;"90#W*Q27 2@T*0A0G,#MA""F+_VQ07L?9\H07^SU\*@:?@[K
MFB6!5;,04ZDU8+-FN(C#RAX_KE45D3A,_9;3S_F#HB_DS>$TZOJ-M+CX9-D@
M<^&]WVS+M- /1+^MTR,\O,HHQ!K/3>0*#:%=Q+D#;VVC<60Q%U^6ZZ5%ZN<0
MA?XG\;4Y9ZO0)4"]( 2XBV;"V<2@ @A\F^VSH]Z%B!8 [4Y #U0-LA7SZ!]F
MR/_ I[\1$TP;UPD""]_\^5Z;FF_@?V03V:M 38+S/G_]E&/%HS\$V>_1 B$@
MYJZ,B0;>H] 9L?][F%9&A8YDZ1U%56V/FJ"^.\FNQCK(!F!:.1YZ1;G3F%K%
MU-$;TJJ%F_^!T@>4LDP*.!%)H7FL:[IB(]V6NA&O^$? BC0#+QXN+%"51MZ<
M'B6A'X]A?AO\Q$\K^]](2(Z[47BF4B_CZHR'HJ>4Q3/0=1/Q23)95RC<H&OI
MN[GQ"^KOP$@)3#13 TQW6.(P588)83&I*YY[2V+0\I EB%F=*:XZV$"+>74;
M&+^7(+7N;VG4->832'H$9!%&H] 'X;@<+P5A,0^Q1F0E=[F[?<:!Y?;Y)N'V
M]O$\7[O  T@]&]PCQOS"_1U.C93I6L'+$3N@GL(\"_>#[JB&Y<!DT);[S;#4
MGZ5T[ ]T.9/0W0P&(RTT /;C+3%U0#D6".8'C]P]6G<K$$N0L+M'N';["2!A
M%!SA+#Z;CFO3@!]#0 34\P;U&BC6HD/N:&Q.!N.KT2Y3\P##,F8V^]7I8NIQ
MGJ,>FS^USJ=%C?G6>&4F?>F+9=Y?HA-:LA:P#%PW[A>O.W3IZ,#ARNU<SFFI
MS2XR--CFAJ[6N5I523[J@_A+$1&4F Q*5 BI<T$>R),6!$SSB7L3N!&X[3GM
MA=@X&G1'4P64&5@F !MV6G51W?))44E^\L_@QW#*++M&55MI:+K#NIL,=AW\
MEY3[>YO<LR 6@!I] ]M8&#Y"Q%6%>CX2Q]IY'SQ<@&]T]TK0,J0C;!<GH6DR
M]C@NVYP(Q2A%TA?X>H%<.4RNS+A<O<1]'DOZR8.W]$7H[\.WKV@,Q/=4]-"_
M$N-Q.<KCW%VFF%'71JW\+7>(OV5Y=W6/0O;&)6'J#_C!\90P487FUI G>'_=
M(?ZES,F$E\#EZDIQ2'09V$#WMF)R4X[Y].!K^-*_P0Y3#+B&8J8&NYEZ61Q0
M_0P PI0?*'[TE1D,&N8Y84*/[GK\Z0MORP<'8U*G:4 PU>^>0;BJ'(^O>3 <
MGWY+5(]#T&O592RHJF#2TCL?=7=%_V;^)^G>T]D7:+EHL*#L"L;TCI]SR;R3
MC$@.95>';!2;N=;X:)$D'S]JS:)]8.(!]5]R ?D2?/?>_\X7ER#=!WE,0[,I
M,@V^0OXP'__M98\16WOT9QD :EGF"<^H40G1,(O*?23<19HQIV NR0?U?&<]
M*E#_-OC3@4T;\PB#9Z,'7W%6/99/XO@Z%RBRMC"5!* VF@_H;ULO?+,#4UC@
M)A8NSKVOA_F'^"$C"EUC()7)4#%;0<JB#G*^2F)$8=K&!"9!G^E>7M)/-'0+
MFL/)<Y0>RU*HZ51+1KF-N+(! E+A""BJXKO[:0@@S0!J  ]1][_.$BV73"8?
M41;-^QZ@J7O44($T =V7Q'&8C"^)[\;@_,HB[PY_T-[<&L\ \64AK)SABT-0
MW,>U7.I2SWC7'<P1\7+?6=>!\ORFZ-IG\[VR09S,IA?,[F89X09<WA;8GC45
MK=CM?,<<T'"MK>SEPW5%#Z"M\:Q1%GKT-ZO('E5[C&T#"P>XGX?85+: 136U
M>%T>("EG'*H?KOUWO+,"Q@W>[SM_M6OGN_]:,9Z@*WDV3#'*:#1>@BGRY#V/
M+Z+*GD&0C64'$9R=0V/Z[QIO^ ^[+O!K\Z!&)!I((KU9^$4L$LC2)C.]3WMP
MR;4_G3LK$0_@WU"5EFF.G()9DA$%S;.#B *FMYG,79FL'MFFJ%J(6]'U39WS
MS/+Q@.B ''!+B7AVD!L7F.@:QL]<9$F&<(696<;,W(# L&1A9:LP6W.M!^FB
M:#0 \D(O-Q#P&@"'P<$_2RV,^TXF2'6B #+!$7NP-K#$)O69)&[V PTTUAZB
M[5X$Q_JY!5$[&-;9:A[=^F[>?H[GK=BIUZQW->9,NTL1*Y97KY$U,UYBJ)WZ
M Y!$2YAFD$/#ED26>RR:81DTQ@"_@[GETK,;-$D(@_-,]C3BJ+:^P Q78EB/
M+*L?R.V@)1FS0'%JP)08>( G[PP-A.S_.]X$"OE#NJULMAS&^1^3(F!QW96F
M;)$?(Q'B1IY^-.V>^68)2:2K.4E7"H[_C0>-:+$:&,30B>T+&Q[(0?XAF(EK
MX0$?W]O _ @)NQY80P<+G-AKA^9M^RS(^$$)X$%P2B)D(WH<Q[,#,YDJW11W
M1?4"K^@1S)3J?#-PBT1,]_+[P/O@IO?^L"']Z?D$YS/UDPW+<4+"O(BN[>T*
MH,,=D J_N-MN,DN#,B55+GL@J>>GH.AGHW01&\89H?J+J4S<!4HX_0KIQ'R
M1Z)0Z>2*E <[G4E1[,=[B4?4'F!DTS\.E,%J, 1S=U3T:T3E/$*2D,[?<. D
M31.!@QIH^0,8X =E].R6,CMH.NG/TVY3RE24WY+L]JH?"3I'U5.U//K<[/46
M)-9W,*^],*M].+T2>>UUYK6WP=PZM#I1<6)^F"51JE\ O?3'\.+=W_TCD,O$
MKL^W?'0G4 !K;@,/ [M6MWU7,X",M6>X^L9@FUV1Z^B;K_[9!@8 #@?YP\&]
M+53$W],PL#4.YUIW/VH&,6):@?F M':![>*']C"%A_+W GTS]( I<_@&?P-
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M?"N_Q3<[+1B>"M3M,$1'[^KA22;=7,*OILK/L2KV3^+&=VX8D+939=W>:#T
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MXQW (E9@2A:XHH,#"5PA<$4+U'0^KA#^!X$K6LBP->&*R?"*X8KYC.,*[GW
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M![@C.RPL8%[^MP=+M=1I9S$$!S?,5@^S#9AQ7@-\$/D&G=BLVS>0@ \"/K1
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M.42Q?8$YVLBG#45-Y"CHH/F2L)>7R,SX1!9VN WS<,JD\=0,N0AKB-0,,9
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MSR:3U]IX /OLSMR*A/."=>F=E3J*^DDQ'LBVR1P+-J<#$BV2KAE9A$>Z-Y#
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M@[NT"EL;BQP;VD*;C0AZB:S4>8 <P1VJ/P[6$)QY3*]Z9K)X_]TM"WW7L65
M3-ME^&^G2NK?#_?+D@NOMG/[A<)>)4<,]1CU6 V\<L70]K$\[F5^=W.=FWR!
MHI\A<)#<UXG@<2QE(@?SLNACPOMC)Q!6Y =++U^0IC:@J>U^X'B6,^;NK+K*
M-\NKM9Q.ZUPKK',MN)9UOU@UW1N>KE<-A>O_FJQ37?DN?,)ZU&,1A'(#B3=9
MRDIOEED30Q>0IN>V.#Z0; )^ZR??VG(+XW3+R8M9WS*[OWOIZ*F"]?8J:U+=
M968W1>:4C+V<>KJ;XT[=NJ\+=%?:@0 =RZ,X$ _#PR)Z7.L!0;*-Y[>-2R=R
MR2[(+LK6#S:S9%B/U 'J"7JQ(4H*4%<K.D8K426QEZ3_IS/ZY&,ZK4\^P(PK
M>?-@/(9,H<JF,+->G[YY8-'^Q;K]BJEVE0@XC>9*JWSY4"WI>X6%09J(J"5H
M'8@4^+^2S<>&HIN/:5(B*V@OL6Y+Z%!.".;VX_V@+!D-A Q5TO63RLP34:B;
M.2RW+9MF>-70:H;NWP]I',J'EN7'7H0+[L3^B?W76]"+]5;U9?P?>2 \#%P=
M^2/XFGQ7[:"+EA1JJUKBFG74*KGD#=%)ZC$BX-46]&)=>'T)^+GS R/%Q[X;
M1H*<??W@G/AW;55+_+N.6LU[9-K(0UQ<B1XC+JZ6H!?KSNO+Q3\WV,"")\*H
MN(NK>^3NZP;NQ,9KJUIBXW74*OEDHN"J]!A1<+4$O5@?7E\*?L2#X(Z=--C'
M0 BO_)@Z^:XJ SHQ\-JJEAAX';5*+ID(N"(]1@1<+4$OUH77EX ?"S%V?G!V
MT6!]_L/A'H]&E)JFAK!./+RVJB4>7D>MEGMFVIE"K)Q8.0DBAUYG5G[.O= '
MKG;!_^7LW G@E1Q^[0">&'E=54N,O(Y:G?7*R6YQ&L!$QI^5C+][YD) )=)R
M%7S$S>S3B9O25F0+P<SO_-(J <N5%9K7Y6JZ'KW3+7,RR[W"8-@?^O8=?!Q%
M-^[[_P-02P,$%     @ +3I:4.XAP"8K @  /0D  !$   !D.#4S,SDY9&5X
M,C$Q+FAT;>V6WV^;,!#'WROU?S@A;=H>2*#:I(D0) @H8:-)1-"Z/AIP$FL!
M(V.VIG_];'XT).TF58WVE!?PG<WY<]\[RYBSZ#:PS)EGN];UE1GY4>!9W@_U
M1A_HYK QA7_8+@#36;CWX$PGBV 1CI6[F1]YBIP .;F$570?>&,E0VQ#<I73
MPM */H+6CBGG-&M<:YISM22/V- /]AIE9+<W(I+A$N;X-X0T0[D"=N!/YV.%
MD<V6*Y;I6-[#EL2$O\_CLAA)6#"'CF4.EY+V)0S]YHP<"<XY9C7(JHI+DA+$
MB%A)U_ -L3TMMHAE$&TQ0P6N.$E*\/-D\,384ZJWO20\$>X9KV(U*==19,%L
M)_!@X@7!:FE/_/ETK&A*;2]MU^WL.]^-9F-%U[1W"CB+T/7"VM\R-!Y5U#2P
MERO/Z ;_%.-4N6?B7%^)EI"(H=4.W [DL^ 00D3N8>9[^W63Z@&Y6W@<X-.7
MSB\>86^K+J4";; :,XQ^JB07!<(&^D5)"J]+R3J!$V4YQCFA?BK.WU=\K1@I
M4Y)P0G/9+Z(O*"LH0XV#P8)M4$X>:_N0X7_+KM>:<-R,\.+Q:5T[O.:&/M T
MG(V XP<NP%+1"(;:.5]SSJS>*5KA1$C&Y?&:"*4&LO/?5H);5)8HV58EYKR\
M2)R!5S%:8)AF\>SMZDXQ$_'W%UU/+H /CA"F2M%'"'AZABYNPUUTSL O&<*[
M,^G:!.O?+>(E;]GZ@Z'\_Q$3]6_3'U!+ P04    "  M.EI0V)D?3FP$  !E
M&   $0   &0X-3,S.3ED97@R,S$N:'1M[5E;;^(Z$'ZOU/]@1>KJ5&H@%PKE
M*D%)6\ZR@ !MMX\F,6!ML"/;:9?]]6><A):E%UJZ76F/>(EP[)E\MK_/,QYJ
M5^,OW4;MRFNV&X<'M7%GW/4:WC?3<7-V+9\VX7T^&X!JK7[[!K4NS_O=_K!N
M7%]UQIZA.Y#N'*#1^*;KU8T%%C/*3,6CBA6I*LK:$ZX47Z2OIIPI4]*?I&(_
MM*=X0<-E94P71*(>N4-#OL#,0,UNY[)7-P2=S971J+4:WH\YG5"%-$Y4R[<:
MM?Q  WT*@>W\1@@^88J(!,,Y9Q):B$]1AP4D(O" YI#,J(0Q)$"#>!)2'S5]
MG\=,439#%U0L_@C>QC5!?@90<:3F!%'F<Q%Q@17E#$V62) IP&2^[DI&3'D8
M\CN-,YU$-G2DL"(+\"0K:!/W Z8B0-K8]T=S,!J?V$1&5>T%:;XU6UUOY:K5
M'[:]H0G4ZC8'(Z^R^O'B1#=7Q4"IF[IA&>C<ZW8'S7:[T[N\;X\&S?-5^[K3
M'E_5#=NRCHP4SQ!)M0P)JB,CPC-B3@3!WTW*) U(!=]R&F0#VROCPM'#I,;M
MC<[3(P-]S9@#BW+/HI!,82WLW+K)>M<O1HTU8:%?5QB]ER=5M('IZ8U'_UQP
M3=R+?F^\@G(WIXJ8,L(^J3!^)S @'9EG)[6\'M4 JH<$9K;-I,=SZ?*YKFO:
MY4*I4#Q>N8B(4)@R3<B,PXYE6P"+^]]!<UJ+]):@08B95N%G+)8\FF- .IX3
M\$YB17VI1^9.M*F[HREF06KN+:*0+PG)_ QBX<^Q?,K-X<$C/]5$/,F6PV.H
M'YK^Z]N[5]/N:G+^&C7)7>6$>ESF,K/#@Q<,M98<RRD5G'O[K1]+;.QBR7VP
MT;Q_G9WC%DNG+^MV-_%5=?:Q5\V'J<;=JV9# 9;CV#L(H%PNV1\A@%V"SUY&
M?UI&A;]&1J]7D?NN5,YQBI9[=KRN)$%"  '7(L%E1'P52\"_C?Y3+A(!B?79
M@%% )@I)XL>"*DKD"=QV%@OHDEH<)RA*+C?Z$I:]N,-"8#A%TFPN9E3)YQ*R
M_?WF]XCB]'\HBO?=;T 41;?\3)CHL"#V4SCI"=^/$I1-H&X T6]$(D [(4*'
M@Q(RT;]QN-2_SXZW'O]I)-NS_0/97MRS?9/MKFN5"SNRO1G/8JD2>J]1O?P*
MJF^G^=JR%Y^IM66O]#)6"D=OK+T!1!X+"%D1%Y"W!DG4NR 3$0/P='V<HJY(
M.!8$)JKF,#2)B*ML45?N>$A3PREEF/D4A\#F^USX-5DC>#H\(-,I.(9LDQ&9
MF%%=P&3@#3ZB! \1OX4CY>$C*6J]2UOK(I3Y81P Q*1^2"5J,A:#BV'B8CO!
M$AZFZV%;YN=[IJQB_I)@@719-4!MXB=G7\8N.ZGGE'./ZI&OJ:.N[^WI*6RN
M(C\4' NZ?%LQG;?N=E[FD2>85"FV3W@15=$-CV$%X<#:">&;OM_BD.*P$_0%
M2XG].615"@B2',H?5I%O/,UFM H%>?T_ 6@O^7OA/U!+ P04    "  M.EI0
MY9^=#^H&  #E%P  $0   &0X-3,S.3ED97@S,3$N:'1MS5C;3N-($'V/E']H
M9;4KD'(AS.4AA$B!9"":S 0QT5X>.W8Y:6&[O=UV0O;K]U3;)AX( \SN,LL#
MX'9?3M6I.E7N_N7\TW30OQP/1X-ZK3^?S*?CP?CWUIMNN]OOY(\8[Q031/]L
M-OI#G%V<SZ:SZ]/&;Y>3^;C!+P2_O!)?YG],QZ>-2)JEBENI3GI'27HBBN>%
M3E,=Y4.!CM.657]1K[M[#F2DPFUOKB*RXC-MQ+6.9-P0P^GDXO-IPZCE*FT,
M^F>#\>U*+50J&*?H=\X&_<X5 ]V'H'O\+T 83)KBD_)6DD)QT18?918$&,=@
M>]1NBJN5^^.1256P%>E*ICWQ/9A2NDU;*O8I3GMO?WXAQFY;3,1*KDD86BO:
MD \DRHIA'&<R%->4:),*'8L/VD2B_V'V>5YBVZQ42BV;2(]ZL=X8F6"[H];'
M?H=G#80.8+/9ZF0EL72^(LR@+%6>%9/8:Y^\OK'';7$F+4R$/=%6W !U2/Z2
MFKG-)C?6UU@5ZU1XV$NJ6,AX*[(X-1D)F\J4(AS.UDD 3,DH^"F0'H:,T!$B
M+-7YO <38O+(6O@$4^JU2-X0#JYL:C'?!QJ<&7+<\B$\P5/&RR),B[$>4'PR
M M[W5L)F_&NW?D.&BDW8@DC9D*2OXJ78J'0%"VU"GD/(^R; IGW8N<8R7RRV
M53_\ '[>?(,?$H&*X0!VYL[@)LC!=+PVE?<J#A"M,E781\5>F/G8$TZM6-<$
M(\J$6Y' )\PG\QR&=X35:X6O[+VS$12^XIV;[,TLQ 2PI.%*=YYU@#QI5R((
M]<:6%!I:*IL:B9,D#^;  ;-98<*6:![ _0%DO&USSE: __)3]^W[$UMXN] M
M#BT=! J/SJ*)D(9<G,$7:A$2VR@(C"U"95<\G:=%R"O.+7[VE?5";3.LXXPS
M.LR=F!CMD8]A6Z\=P&D^@87<,^-;R&J\)#%$,%]G(9 _+4UO9*O[[H .2WWB
M,YY>]<[/5WVU#.#)Q'DT,&#!&50)DIPT-NY)X.#TF<B#[T(>[) S$_=C$3NQ
M^G^S\KQ_)+R*H9""/+S^4;@=R$,Q(JN6["DG:T_'19,EUY.9??X2EKX%@9+B
M)">F]9K.#'9 %JZ5=;F-:12[C;@P[W2\*BV&0NE(+N1TY]=F(3O\4D$A ,;J
M4/DR=4@75OE*&L46J%STG=C%O%-F68A=DEFGVDX)M"4 2J$\O"B1B"XO"R4K
M&.QR(':"CA5Y>:B6-?RW()X(C<%Z\D^X2[L:[._!7H?SQ7W.GYU8#ZA_?DIR
M[7T0 F)?!"!LULIG8J75L60UDQ9!P768V9;&+SV/6%!RH4*5;EGR]YW+@>A(
M<O[/0^BKJ94Z[D3SMK HR4P"_JVK49ZGC>\ N(J^I!B5)T08X TE'%\\!>U*
M3C7B4"60F6\6D-<AVSL4X[4,,Y<$[ @* A18M88)=D^A+.O-,Y(Z?]Q?.IG9
M>@TKD9 VK] +G:6/(WB.[LB[V<3]1_!T.R4696?CPI5R3P#/22[G/YH='ZF8
M&_[0@]P %W7+O=G'T@ORCP55>UYFV$NY>M5K^W>-M$TQ['&'%@ >-OHS@_AA
MZX/]*P+0C;RX-[F C;Z,7.?.3;W[P,EA'>:@5M+>*3UGE(L.\IW6.&\4,K!%
M>WY#(;?Q#^<W7^*@>FV/AW81L5^;_YM^[]UW]GONX]$O0Z>YBW-6U"I_NY#'
M#O7:"Z3^07TMH4F4V%0;>Z>M;@ [1O@.2XD>%Y6%AGCS:U\!GMOC "PCA2U+
M!/YRG2_5G?[,%-"[*,QBSS7ZA_^/GFF(CQ8N9 J<<$?'S::G"#XL=/&N==F0
MO&&=RPN)4SI7 MUW:_G]PBYY@AG^-"IS.6\S\I9_3W)('RLMW>7&8S06A1,K
M0 ;J6S,76PNEM5D$G\$ASIA"D/9^ZOU/A!0]S1!Z&1C$8A,.(I<^\+'[("_(
M:.:"H^*U#M?$JA/+97&Q8(J,HR@)]9;P=K/2>9K)KZ@&-:4@,R??K<CM^UI3
M,9BEYM[5W ,/-@:_Q N;G+A=^$IP>#8=B_/Q=/KE:G@^^7QQVCAJN.>KX6A4
M/O\V&<TO3QMOCWYNB+/9]6A\[88+"/E(ZWPVG0ZOOHQ[Y3_?]/Y]JOB:L5YS
MD*X'Q3^C\N#N$4X>]#OS$?^ZKDPM,22@I+5 8-\@&M"R4T^NM?+%"S$4Q_Y:
MW$C"C8W!"''0$Q]H85"@MKG[CM\WQ?'1\=$.TM=P*OM6MKT<3RXNYS#G?=68
MUS+D'EUGL_E\]@GX;H7[WA$_';F?QJ!C._LN0U\7<1ZRC4?*ZK]Q[3QXZL+W
M\:J^Y_CNBX_O3P;G*T4HK^-;\C)N;<4L+]?]SL1=>5<C'G\X5YV?.GQ/CQ?N
M>O]O4$L#!!0    ( "TZ6E 7)0JF+P<  $D9   1    9#@U,S,Y.61E>#,Q
M,BYH=&W-65MOXD@3?4?B/[18[2J1()#,Y8$0)!*8"5IF$F707AX;NPRMV&ZV
MVX;P_?KO5+<=+B&3R\YF-P^)W>[+J3I5I\I.YW+\9=3M7 YZ_6ZUTAD/QZ-!
M=_!'X]WQT4FGZ6\QWBPFB,[Y5?]/<?[YXFIT=7-6^_UR.![4^('@A]?BV_C/
MT>"LED@S56DCT_-V:YZ=BN)^HK-,)WXHTFG6L.I_U#Y>WT<R4?&J/58)6?&5
MEN)&)S*MB=YH^/GK6<VHZ2RK=3OGW<'=3$U4)ABGZ#3/NYWF-0/=A^#XY =
MZ [KXHL*9I)B\45:G=9%0"93T4ID,YFU!0/8[X&/CQR?T5W64&E(:=9^__,+
MX1P?B:&8R055*X86BI84 HBRHI>FN8S%#<VUR81.Q2=M$M'Y=/5U7&);SE1&
M#3N7 ;53O31RCOU:C5\[39[5%3H2OTJSTO.9Q-+QC#"#\DP%5@S3X.CTK6T]
M.1+GTL) 6).LJI5;@(XIG%+=FVR\K:'&LE1G(L!F4J5"IBN1IYG)2=A,9I3@
M=#9. F%&1L%-D0PP9(1.$$R9]O,>3$@I(&OA$IZ2R%O"N1M[6HR% (,C8XY0
M/H,G!,H$>8)I*98#24A&P/?!3-B<?ZW7+\E0L0D;D"@;DPQ5.A5+E<U@H)U3
MD%4K.)XWG@.;#F'G NM",5EM^N'-Z7FW18_88H=$I%+8SZY<VUL'-9B.QV;C
MN4HCA*K,%/91:1#G(?:$3]DVCG(VK@Y"E(E78@Z?,)U,<QRO^2I<97?.1DB$
MBG>N\XP\Q@20I.%(=YYU@ )I9R**]=*6#!J:*IL9B8,D#WK@@%G?X,&68-9P
MMZAX1);^$2[>'W&^;N#^Y:?C]Q]/;>'L0K(XL'04*=PZ@X9"&G*N@RO4)"8V
M41 (F\3*SG@Z3TN05)Q8?!\J&\3:YEC'Z69T['TX-SJ@$,-6'$C0%A)(\(X9
MW$$^TRF)'E+J)H\QY6E9>B<;QQ\.Z+#4)C[CZ54?0K]J:QG DTE],#!@P>FS
M$2.>,S8.R,5W@8/29R*/7H4\6B-G)G9#$3NQ]+=?$U[%4$R1#Z^_%6X'\E#T
MR:HI>\J)VM-Q46>]#61NG[^$97="H*0XR4EIM:)S@QV0A ME76IC&J5N(Z[)
M:U'85!9#L70D%UJZ]FN]4!U^J" 0 &-UK$*9.:03JT(EC6(+E)=\IW4I[Y1;
M5F&79-9IMA,";0F ,@@/+YI+1%>0QY+U"W8Y$&LUQPI?'#9K&JXFQ!,A,5A/
MX2EW8R^5]Q_+^627\V<GU@/JGY^2F:Y6'H2 V!<!")N%"IE8;M,DJYFT" JN
MPLRV-&'I><2"DA,5JVS%BK_O7 Y$1Y+SOP^AK:D;5=R)YEUAT3PW<_!O784*
M FU"!\#5\RFE*#PQP@!/:,[QQ5/0JWBJ$8=J#IEY5?WXL60'AV*PD''NDH =
M05&$^JH6,,'NJ9-EO7E&4OO;_963F:U6L!():7V!GN@\>QS!<W1'WL\F;C^B
MIWLI,2D;&Q>NY#T!/*=>SO]M=D*DHC?\H0>Y^RWJEGNRCZ47Y!\+J@Z"W+"7
MO'JA']V[:Z)MAN& ^[,(\+#17SG$#UL?[%\1@6[DQ<[D C;:,G)M.W?T[N7&
MPSKTH&;2WBL]9Y2+#@J=UCAO%#*P0G-^2W'1P^_,K[_$0=7*'@^M(^(-6^\/
MKVSWN'LH4X9==1_F+*B;]*TC'CM4*R]0^@?EM80F46$S;>R]M+H![)C@'2PC
M>EQ3)AK:S8]#!7ANCP.0C RVK!#XRV6^%'?Z*U= [X(P3P/7YA_^-UJF'MY8
MN(XI<,(-'?>:@2+XL)#%^\YE2?*69<[7$2=TK@*Z=];R[85=\@0SY?N3>Z5T
M78;O^/?DA@RQTM)]:CQ&8U$WL0)DH+S5O=9:"*W-$_@,#G'&%'JT]T7O/Z*C
M:&EZD,O((!;K<!"Y](&/W=MX04;=ZXU*%SI>$(M.*J?%1P539!PE\UBO"$^7
M,^W33&Y1#6I*/69.7BW(1[M2LV$P?^_:^0+WP(.U[B_IQ,Y/W2[\Y:]W/AJ(
MB\%H].VZ=S'\^OFLUJJY^^M>OU_>_S[LCR_/:N];/]?$^=5-?W#CA@L(?J1Q
M<34:]:Z_#=KEQ7>]OTL5?TVL5ARDFVYQT2\//F[AY&ZG.>[SKYN-J26&.2AI
M3!#8MX@&=.S4E@NM0O%"#,6QOQ4?'N'&6K>/.&B+3S0QJ$\K[[Z3CW5QTCII
MK2%MP]G8=V/;R\'P\^48YGS<-.;-#'GVA]IC'IH@M\FLA^Z$>RL2/[7<SPM3
MK6F;V]]1.0#_!1_L8'CS\Q^1N\>^EF_*W?%1JT7)MN0URL$7D=$9=K]1JK3Q
MP?P;.@1_=8U^6?'&=7]_,5,4^<M/I1;YVRO?5_@;:+F_&'-E0=-M.LWA]S[-
M/Q9S_YBY!]?^Y0I2>F^(*T&]]?M78=)AB7U3;O"'A=)1VN3_A>"!^Q?*_P%0
M2P,$%     @ +3I:4$VNG@2!!   JP\  !$   !D.#4S,SDY9&5X,S(Q+FAT
M;>57;6^;2!#^'BG_8435RI;\ DZ::QR"A V.41UC&=(V']=XL5?%"P=+$]^O
MOUE>8B>7OJ27-B>=91GOS+#[S#-OH(_]RXFACVW3,@X/=-_Q)[9A?VH?]3J:
MWBV7*.]6!J /7.L:!A=#=^+.SY6/8\>W%:D J9R!YU]/['-E0](5XVT1)WTU
M$6=0K1>Q$/&F%(4Q%^V,_47[VFX=D@V+MGV?;6@&4WH#\WA#N +FQ+F8GBLI
M6ZV%8N@#P[Y=LP43('&"WAT8>G<F@3Z&0.L](X2 <D'3 L/0GOO.R!F:ON-.
M/9A=S;TK<^J#[X+V#JXZ7F?8 <\>2C5H1V_5UO>0/B=7>T!-#TS+G?FV=0_D
MRX"I"3E53\ =@3^VP3/G W-J>VWWT\2^!G/H2TU/57L_'5I!;T6;\26>VS]^
M_330AL,AB#FG@6 QAQLFUB#6+ .3\YQ$,*=)G I U2A.-Z"/7.2SPG:S9H*V
MLX0$M,_CFY0DBJ&I[?=Z5UH9$(?PGJ3;.%D3O-5?4[2@N6!!!@X/.M 0:WIX
M\.:5=OS'V3#>)(1OY>+=61,AIPB#PI:2%"BZM@2+!G2SH.D;OLB2LR.MA:1I
MIRT@&80L0H,*.P6/!GG*!$-'"5^"?1NL"5]1P#,V+,NDG_B5EDLB*" NBE E
M&BC!E$Y76%I 2;"6SDB#'+&D&5MQ/# .0Q;@JM95/A0;+K: *L%"1-&")$^S
MG' !(MZ5R^%!(RMI;U85@ZZ099P(W'O_CIV9S*/J,(^D"\)IUG9O([H%,Q!2
M(_.HA7I2W"CM%C0K-#*FGS%*R-2*]N$;>7;RE32K1!$-RS3[5VG7T)HR(^K\
M"O,H0L:0P$B&[2Z4*?TS9RG=X!D%S5[)1)D#VE&#- $S17O;6#;OB-E%_R[R
M%3O:Z='QF<P)V>5GQN,]_/>XWRO=9QPS?4.*VL,R%(3)Q&)E=M;<$)8B.4E*
M,TE#2ZI)%"$@;#,,:Q05"?*2M8J[0L8)#Z0<-URR8FM9!FB51R([/$ BX@1K
M46H>YFX''A"SYY5L/P]:YC]H4HPR-,4N<L::@XD-0WLR\6;FT)E>G"NJ4JQG
MIF75ZX^.Y8_/E6/UM0(#=V[9\T)<02@E;9S"$W/FV?WZSS<I?A@/.;=Q:DM(
M<Z/Z8]4':RJ>C*W7M^3/?,^TQI"0%6TO4DH^8\@SMJ1]\B5F2W@BANK8#]6D
M0!H5P\(P+OLPHHLTQVY9\M<[D>VMI^XPW<>SM_'>OF/;N1C[Z,_)OC>_S9,?
M?B;2I&@1I]A*=Z);R.((@;Q2B\\3"ZJ;=>&28;G3""XZ.'?R,$2%S,,78.(1
M)"VX[%B=%LS6>'D!2+IC#->,AM@4L4$*]H6"6\XOO>M\E:/_0Y[M-W:MHZIT
M<[^YMVOA3R?D)<GBETK%/;+@/EOPW3'W?&S\QYCX@2?_7\,#5J%'.<-GE@]8
M>C##H<SD=BTHBW-T-[RKXBQ&MX]\9'E:E^I3WF*T7^I+8Y8RA)L@WAURB=@,
M@CCG@O%5[4BSQKX_9O$B'Q"*<'7EVS8JBI?TOP%02P,$%     @ +3I:4"J
M]\6O#0  $S0  !    !D.#4S,SDY9&5X-#0N:'1M[5OK;]M&$O\N0/_#0KT4
M*2#;DO-H8BL";$FUA2JV(2E->]]6Y$K:AN2R7%*R[J^_F=E=/B3YE3;) 9<
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M2UG0@(@%CQPM*3UD:/?[T;/]YA_ +02JLRQ=*E1%G_5X+%,XEU&T!W#G]9>
MG6O06UX0Y%F""&4 <B(-EDKZ>-QJ-5OFKX$9>ELQ%!3EJSV#8A(^FGL5O(R]
M5Q"L7MN!L)M\=AG%OHJD*J?[%M+I#+M6\]\+D0(ZX;'S=Z%Y1SQ&_"'N+E4
MD*K)")<B\-%8D)D^6CFX%;F(R"8!U;@'-NIS-,JU3)<E#*O7'C;Z0V=8'P&C
M4Q&Q2($+$2S,=,IF\)/+ /8! Q8<0*%$' ->R-1^7"F@"Z:R0&CT'1S(I<42
M%BHX [UYW0+Z-QJ6G9MW]CP6)T/'''2BH&V:@ 9."!JET8,F"$& K[>Y+W)L
M@L=$(!OP-UZOA?Q/Y7P6\D-JG0&AJ-HJ2W4*OZ"3L,J]<Q">@J>!TUJ*R()@
M2)8*A)B_,I5D(8@\(1K2A$>:>\[)SS(M(V0"+%(6+0XMB_:030 @Y98";(\"
M_F]0#!X/D$#<$WUOG $J:X'\P!DSQ>GH]9HO@0^I2G331!M++L$YYM&''9C8
MCU+,F;@%_XPX#6/ BXCD$-VTB%.$>+N[@N')6FKKW7SC#$I.#S2I^:![Q7V?
MXF!S?P1G9R(PT85&H<'S#,W RTFIU^(@ ]\*,C=^$\<0V2 NH>^9R9RN-!V3
M4 4@ON!H )NJ-'8T!7<0Z&>!7<S/(%PB:W6* RM6S3EUSM5I$3@MH^KI(< $
MX0+[ZE$K[/R;(H+'>"'02 6H 1J\M?5M)R&KO%"181LIJ &*90%=A7%&)!>(
MUE+D!DR<F7D00L;P<;8!SU&QD7O<PY?B1%^BAD>^Y<(DF_T)JN="&+HQ@77%
M:DT"!56+\ZB(3!CMLPPR6Y[/J*?(3<Q95+T&R@9JCU;RJ%C5=W0Z*P6M#GAB
M82[FD@Q="]P%!I)H8KZ!2#MUWJ0B4J 9=PD@A Y C_D*D)^,FVM81.-B\PRW
M6R^%"2R!^GS/+21B.1 =?A-U'LF_,ND7,7 ?/( *,GS^4F*5AJ=B10R>F^ \
M*-$!#/0+,@Q>1B0>XN]:6G""6"V1LPRM I2#@;RY([/D[W!V67[?Q%:N"6'+
MH'%I**S7BMMBH6)+OL(HP7 ;SG2R37.Q/P9B6TF/'?H;71-[TB*8:SD['PW<
M4N?7X_Y@?-"['HW.;B:#$_?+O8?:YD"#F67>-5H-UAN,1C=G_?[PZB)_GMR<
M]=SSQV%_>OFNT6ZUGC4,/6- _PU8T#O6B/E"',P2P3\!O]$>3_A*2=\.[!>3
MGQ6GFO:WOAX_:[#?;,X$N)+G3P(Q1V9 3/UVW[3VUK0]&Y07JHY%Z52^6OZR
MJG38W:'Z(UG=A2AK!8A7Q$!@4J#W9'BD9RX3<4IJ0^3#/V/\!R5? 9GOFO1_
MK$F$,X4: 4@+$0K_N]Y\UYM[]0:N57!C@FL.]WV)3MKE4"A7^EUYOBO//<H3
M<G!7W$2!,L'0#;.<J$08OJ\CB(J6,D:?!E&EMDG*^_7IJY0K*A&:KV  YG$(
M0KTLS ).R8&5N1^:.-FD:/*8N10HF\ 9;B9PC1!Z3YJFFFJ$*Z+. _%FO8;3
M[6V&^Q ,:($WD?D<!M =HUD*UO<L7B0K,6C0(I'F:2M6QVP47,0%;94GTVRZ
M76<BCV*K:^Z$LT@^\BH1$.0GYB8<\D\5^'"I6 AN3%2/F0@;J]=KJ+ZQL;*J
MM$6X(VQ\53)#DT0[X<&:;S16##N78S89_AO4YD7#+4E5Q9,?WM*?JHD[J^@-
MKJ:#\9<O.6(F]J92&\&D=:]ZQ1T^O7AQOEN- 4'5:UA) 34%0;\'*5^B.I]%
MJ3R8@H 4J!8;D%KI/".\_^A?*B%\[B[*?7=1-O>GZX>2: 53'I/>=6RQ60:3
M0-QS2[?9!+K31X(G8'8"ZTYH?AINQ5I+3 500)XN$P'8$."]5=LT$3U15B@P
MMHJ!.S I"9FXC66"V,%-:,\K:>^=%!FEC.Q=.EU*H',#])2*JB1=>H=3,4WK
M<H,&EJ(LG)F,57$Z3X6 2IKV P;O.3^0/I>WF&)-5,A2D!C=N?'G_UAJ8RQ"
MM0(&EG4':9R4N/AD77JR)F']C:?-$GQO07,)EN\%XR:F8(43V1W20:"F8C0X
MA@3/;W/A'L^T 6[S%;0U0G\AJ2*\LDG)74?!L5"!"=Z?7SUSGQ]3&, :,R5Y
MK,:YN5LJ\96S,),L%LG!>U?S,*E<HP)H$(2$5FR:+4P1.M@8+T@6N8=A15[<
MGM'6]/8RA21LLKIH2&5_2)5]6*VD=ACHO3[5#]8*GEPGR"*J/OV-S1X#J459
MPC1)>'AA,$%+TQT=B5B FT:&@&RPOP4\]QU9QZ=9R^>T*+B0RG99P'$3$0L>
MY,637-9._'?8H:T<?::%F<(*J1V59[:+G6N5 ?8#H645HSJ,-"IF74?9^DJ6
M-XSRP*OY2#(AXOS:=.XWD%PD3>(QO/85U@>B3;FA!+66:OF88L9B;]-DQPS9
MU<Z3APH(]9KI3IKE_3MF#8G[KQ4V4O %*-/R&V%:J=!\I4(9<<?)/0'3$^VA
M7G/AD)%QI:I-A6\L@L\W+$.6LS5V+YE(A6RS-#BJ4,9S*=.U ,,H27P%I]0^
M=L7O+#6%<@('^O;6?K+,-]@ JJM1 2*)]R">E,0L/$%>"H,@AV_5J.HT+RLU
MS1FEQ?!RO7TK$,/V&7^%?02$"D79WE).FNF+@&^V![QV RAVHI"L3#?NV71]
M!3:8*C/1E $QU *GY/H.M,*]< W8;8>;N 1PM#/Y<%-@=J%B;UZ!QF$N&50_
M.. !7/!.*!N0+CM',*>+]%;9[1CCJ"]S!N.++9%Y 9;?R^5^6U(S8^##\]N?
M3)X"W[XUI/[3A )PETA\OBGMV/Y;.U:B;7H#QS.5:RM'%_C<P[8U-1!0^PB6
M'K-9(#T<HS+0L=!6R1Y:A.)RM(20^Z0]F6[6:T2*P%N<\KPLL6.^"5!=*>Q0
M1 0XW^1--#T 85CP"6$X50L_,Q8W)K[CIM#KH]IRCQH9UI8VS]#&7*Z%(F<<
M VM0!X/M-2FWI52+\E_N0#P NR^?JEFJE!==*+G_-"5SN(7L::79X8>'?3#V
M$F'/.-O<$>DT[VZ=N;-MIAQ_U&N?$Z<)N(" E>@E76,,&#N# ZX ,F>)N<.7
M\9,RC1I89Y%TEJ@,ZZNVS0J7NO?*C:5K+\C(I9BU"'*=9R-F>G@Q0CO5IL7#
M13:F"75? ]*WZ=UPK;;G#I9[*IPY%SU).?9P&:O\*+;2C]7^Y>/6B[Q_%^Y/
ME=#=M1X;U406@;QW9H.?QE8 :DHE['/-03F199,AURFB!5\0ZH',;.-D[F"\
MXB2V?YO:_3 D,2-=9MEU:!KQVK&F6PT3-Q@UZ!V$3T5Q'[3]=C/A07"*^K-_
M93BTO7'AI/UC %205?@RH_9!D( VA%,($J.QFV2&Z8[?N;CMOX64-M['( IF
M:&W;(TE-5C;:!66)T',D]]+M68C)+PAO\@M"O;:'SG+ZP";+71%[ITU0.F<J
MTP>Y?,C.'M8$8\ "3)F'"BV<ZN7I$K'0)%B2A3DRHK\*7$N*C%8J6"&MF7:I
MTQUMJO1DV0W=6( =PO\B&&RWGCGT-8TM!(PVZX#WE<=H*XH/])KN5QN*'IQ*
M1@+05E+^0JTCI+R-<K%MIG;C.V5!74O[%L:K8B"II=8TT6)C/:;LP4P(,A/F
M'HW;,(G'K67RO'[G"/];3[=S1/\9Z+]02P,$%     @ +3I:4,TTD'Z=(P(
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M6[A;UOXVW#3+<NZU_&O%-<-/>NR?O '700LUV)W'X9IU]TI/+92-X*-7/R@
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M? OT_\8"0)S.G]3^"TMPA@,\NVZ#H+!KUE (F/9;O71VLJ&%0VB!SLZ.=I;
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MLR[6V8&)C8&#@HB$C(H 0$/')R DQB BI=.+C1LGX;NAK6\8'3,\,D9&KFL
M=$F8H&=@TO&)BG]2/KI#P<C,+RBL\()%0$A$3E[1"+2+*2-K:0-W?9B=T[G
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M=%B]KW<K+X0KQQV%TL*\0!MPB'Y [I.EO?4H9:!5=<6T0X.UIKW K ^)3YJ
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M0Z0GKN.U<<@/KA8V(-K3B>T/RS=V0#?T,SEFTF=6" LLX%3IKKS62\HC4RK
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M)I_;3L./Z8B<6NX.\K9VVT0ZAJ@<.,X/CK=CDQF_!@0EDA2>!'0HG\,I=VA
M:0D&J2/VL5K:MK14YDK2:EI48J8-V=9AY'#N)RG&%:=LW&-QEU!A4=>8D,!)
MIM:-F$*!QQ]&*N6],:)JA=39%Y;N*W=WEAORF(/FS14_A)(V^JWC#MGX#;Q)
M,>323$A9?Y<:^O)AJG%[OF\JU\ULR"YHXQC3;98XC0B[XB'>[=7@%'YF,<[#
MI@OHY@+IXI81&X/]^P#$3SQ*\?O^"F6M,-W/2,P\!KML8WA'9?HU1^Y ;6Q)
M=[A"@GJ%7.XEFW[.S<B-Z[?>*Z^DX171=C#SAM[3<V)D%@V8YE+Q;'%+LWT+
MAE@N6C$F.RZ"*;D&Y^S\,GL)! LQOB"&]H71D@>V-A!>48+OE? <<F7ZE(.
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M=F_V#)QL,:'F 7OU)V?': XWRRE<"E58$H= B#\2WQ/EUQTG5#P#DBYUYC_
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MJ,/J62NV">UE6,"-UI>0YLSZ+!,-&=LPXE^PJ$YB#/=$5,6SUB Y)]_7N9(
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MT2,5IU\H(00XV$V9&+W^!+Y!\[W0K]]MC ;UY-^H094;LAD;_9ZA;OH<XP]
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M&OYB_?8,]6:72LU+?HL!^:NJJ $)4B^7=J^@.Q^S!M0PV5*X.Z,6HI=N>>G
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MW<R)BS^?WQ[(.O!4G$KJQ4O+ UU]UO* O3)\'.5C^M*5#A/Q/3]C !8?UW^
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M0L;H [8U9ZVY5E<'\/$AX4*CA+:L3LB<8-2 659ZP")3JN 6L \[+#6KB38
MZH0+O8B<%F.-D&%)%5PW<SQ_F6*2FL[I47=J>PW<V\I7CC]LX(A'#YCZJJRD
M(M//IZ5[T4Y%G*(7:A@2#M*&+*UF*EQF> VWMHA(-4@W7#=LZVO=@@J>;)A
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ML>\K*@LF%C&78A>Q>>V6AD=7R10G]@*]V.5B-[AW+LA[7$/UY;B;C$;4L\#
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M3+1LB%JB):BV>CD';TS7U[6V,C*:"P>G^_A\9KIW>?(H5:I0"63T-=2?,/@
M+R8%SD&S$DQA0F7S$_G@V_A>9B6UY.:3&/M55"?M(M".1#)DG,)@M36Q]@77
M00Y-6QF91"]D,=R.L#4DD/7]$LO3IA[>D /BJ%_T^'+&V'8""Y;2FT$I;1R^
M$I=5531SEM=XJ7O5Q89 UR^28?=<Y>;,HA)BK!)OYCI\K?+9O:*^SL[3E0;S
MEE9#R8I\EL%UK.4L+.[!)2^]%[2Y++.9CS.Q@>/L(VZ@+X E27S%M/ED9$7M
M[E2E3XY''Q&DPH7D\\Y%(:<0DX$R&7PZ!Z_FMJB&3&]0*0YS/EZ!6,M#O\8R
M[](;PFJ,U\AC6/G.S7$Q]@DZ3-:T5+;=<1Z6V>;<CX]%F)7*HY>+)#+MD:77
M0C=%*2<<</-,Q8P*$H_ZWE@)CJNYBK)Y-@9#:[U$<F('?#*!$U>V9CW@:!)J
M&C35D!I=*M&J:"4)"TDP.']@U6.*7--.#Y'@R5,CK/CG[UZ5>!4$2;\U@Y;?
MW?A&#,*MI[0Z!-B>:]>?"%V0V.;S$8^G5*CB=*IQ<6C,;/H.(G%D8#:.V*&/
M,-?Q]T9RO4GYZ81C7#0[ARZ_^<$C?;7@Z-Z8T3'1M9$5,TW7L]832&6]\ FD
MU,P>5;#!M(B=[6B,OHD2B.+PBAR5@_BSK69EHR&Z,^=Q? @S*Y,4%+_@+?'I
MS]\]O)'Z%+UQ;6.*)2C>!HH$<4IKNNLA*./"<M]BJL69,R+'"O(9DO# F<2J
MD^,J^3C[0.]9V\AG@&Y0-0>KS(XK.JR4Q^F5APJ+XSNDRO3ZH=8>8Q[))-Z(
M?AJCX1.AA1H;!<LCND073 IE#C!/OG)3GDY]';>[>J-R#SD31O*QUHC6-S]Y
M[8*DK35<DN5V1^<JWKV!=GGOK^]H)2GL&.T\;4[HU'>68'$ @UE2OH@?,8O1
M1!@<\X;T;W"D@E6J7G2[[L3YBBZ0FZ(Y6S$:<B>AP)396ZY'FEAP6CR$M[)=
MS=*U68Q$3<'%V<EID+>BJPXAM=M:]= $\M V1> F1+,2#CKR4<-+1<![+6WO
M_0J-S][0Q@,.I0;J*T6H*R)SHN\TA:4HBQ&I5!Y^G=7%<.22_[2L:9;Q86%'
MG[\C@\"_9N@MZDA+@TUY8N2WM^;9\/'BF@UO97T.@3%.;1\5)!HM]B?7$Z#M
M6R42=\YQL<C$XF00]JT@D,0VF-5XPL.GN+<UD1;?J#AD6<VF4"<9B:"9G(,%
M[)K_B45C0JEUCEF8M)+6XMN2"3_]J\A.JB;5/=*0)D,HQYY%N@F^370\K=H$
M\H_/#0G$DA1D]N9B$=]@QQ$_%G3>,6U@OV=^W:?#AYN:RC65TTMX;%E07$9P
M *:?>J@=?5L9+)JJE^ZI,@6.:C_0B2BB2'UKYR$\1_ *K0+;W*1<+=.;BYTW
M+$O3QAVY9RXHC$QZ2'B=0B<QPP4+T?;HD.47/_+R^.W&\4VOP\W6=Q(-ALIM
MSUTK%&(D51F2@?61XE[*HLL(-[-N*DKT) W!93S7[5XT4BZ$V2P9&]63T##9
MM"KMTJO0;"N-E:B,1M,L5LBG;^Q?':'LCLQF2!CY]:5JHD4K[UCTHLOPSS1W
MBZQU0MHCM&PK&]]IAO4 (>;O%) DE4#A0!R"!AQHVK2AX>!&S^:Q2*!Y#>7G
MIKXFNI^^OXUX/U^?W&T#B1VP%>QZ2<\:^AQY&VWA9_S"9]XJ><-YU90U653Z
MR>$IQ#,\(JTY2%5#*I-*HZ,MXNMBH;GI/MR7>!Q\E5!?]]$J(&P-MI5EIV-B
M;K9LI>]C;IP\]J;R4T5L<!%UL7(-QV5L@=%8<^.*I$=I\%O)*Z4PT&/9AH5Z
MD[%MO7!#OO @WDR]T0\+=,7S2 >^< (1S,H=,G_$DN,/'VL4OF;;"1IU3(5^
M[R,T#C$IE*PA\<ZL\319D.,@"VX<XDW9[M5,FBH9.<C:?6KN'3'79M<B6MF_
M'H'8I("++%=AE8L+CR?1W&3 <KR8JA.D6F"R)4Y)=[2BJ@>JRSR+/BM&:,],
M,;G!AM&*^HHAF(.M)((1RCV&CC'@1S(AU*PA[;KIY/-B+ HM=&"O2_1]E(;9
M1F]N:437OA]BZ(M49(W7]?@%3I8G+I9B5OB*6>/U>=X>CX*RI%M!-9),BH6=
M(54^6G/Y@^ ,MQP&VV4*?<C@5'V^YI@(W5I/(OUZEF2R[7RGM'6M_=Q'M.!+
M.X54?%D%I7*YO-J(&,[Z/!ATM#DBA!_5!8/"+IX,2;JC2J!9V__XLT932AMS
M^=H13EF?N60-$$6VD2,'2Y_WZ&XK"X6[2.?^"661(R1<LF0%^VE_$1.:$%WX
MNAS9/#BBMDQT!",2K[1HH1'OP8[;?TJ3.D24RM6VE&I/$P_"WU)J)<',.:HH
M\+%J!M5JMA+GGAH>W&RHA^WV?K_Z36.*+M<]T89!XFP50LI"+0;$N&ACO6:3
M<[^"3!>L7?$:G40X@6;\<PTJU>E'UK3W[;@7<2A$T\$QR;.?^=][J'TBC\(+
M$V'F*0#&3M26RY5J4-J9E+*/FP88MQ2MO%5JW<_?@LTLI%"X-U2HI 2WXC2\
M@9L)HRF*#0L=Z=\LG!:V[D]M+X-ZR($>,25P6V"6%,(5 9H6S):."=<OB-;N
M1)>BV1;EO[_F_-HZVTQKI*6(UBXONWMK<&@X^9&U.8A1D^A??4EI)-:UFOFJ
MI\B%H6*#FA0\-!P^=/A2;B290Y.](>O$'EB@5>XH.L]OC%UEC-E\4VL%TF92
MFL4$UMTK-BU!E#S!-_J0^E)5]D$\*"R)0K'E7I\@WTV5:&;+0,,JVSUQU=XG
M )V].0]GUMX ^DX!J,C(=*"UZ9_9%L)G7G&N+?-1^/1@D)QA*[RW ,,_HHQB
M >A<D&^&0S<.+(QCCK8T$^#*F4AE?7T F\?Z0G?)?<E[U+B1YB#8*YDLV 2"
M'2U35XI4,OU(V;R,B5Z3>C_VF'3H,E"D#R+5D(YD1451%Q8Z.MS53M2^+Q.B
M2TMK\8+7K0AZ;NK:4^]A!9EB4>'%CF:9EI^F6?J"?FYP1WI4>KK[B&G.^@X\
M+&-=S4X6T15C5<TD,1JD$LVGN9^HSU^7.WW],;,>6Z/8+!N;0!1K_O 2^)V7
M%PW4UAR'I-08I)T;I.U2@!E9Q>XMW:K#N!8'>>2N%'.NT"TGJLMW[JMO%>]R
MS;4A,:!I88U->\L/\N >IVBT&/%50B/8WJOM=>HS"MK=-X2:^T (1I2[>-AZ
M5Q3JXD9H](=#>Z0BNVWQ$T?H%5%UZA%+95E07V5H3BB%&.]GVLX7C/PP]%&%
M-QC%X,.*C(@0$PJW &A.3(L&0F8PZK\O&O3FAR25%8.LS(8?6?G:2["3?$(:
M%)X;$!Z&H8/4L4>^],?Y_G1QK8ARDGRI-U*ON8W"X.-@02?4$6C.;HBX8S%W
MNA##S,D)Y%9*YQ+O4 DT)L3#N;V1[I)")JW,O5-N&$M/S22TT2-HQ4":;--^
M$6F(!B$&$FU'9KNP\T/SZROM0&L&( 20(IT,JU-SPM+Z3,_OS^?O$$8=NRAG
M3GWT,Y - 1OT=EBGQ5MZYF@IO3TC,Q"+"AP*,**]&X)2;,";16%8RWIN[WR9
M6?V9L%EY)_B3@O306[N];"!>(\$Q 86=J_8 43+1/LX%04\6XNJ7MZ"$#&)S
M6WB,26-?RI!<4BD=_&L()A+WH0L=$K]ZWC>50G,>O\*A7A;S/2U_;LD.Z[@4
M!RF*WNN28Q"=GOX( RO69S,; TJV6"@R-)G>%1]Z\/J0A&1N$ZAJ8]-)G^SC
M)1<]\I$Y54!.K01'6OXB&$?*P:*:X34_]8T"$T<0N63;^W@C2B(;1!S=^[S/
M.1I8'4X#TV=5+'8MZZ$1=M?S^X74:;M1_:)A,=KE8VUHZ@IT%LRIT<9V/TG]
M!PW!&PO@*W:-=.@E10L+O4Z!57!64FP9\/&(7J6^D6UN=)<=F[W!B(^9NS8>
ME;0@D3=2JMF*!<^U-?'A\%W@?1*839!WQ?&("1A2OV%C%(^5)O*"UM%>FV+H
M7[O"18D)_YVQ,"3R5&7A,T9%G=J+C^NA+6YE,HS<HJ/Q1]S!T+K%EY%L:-1B
MG2WHZ59D_-JN).H@N6&6N0-S^82CG.ZEY%"M7T>.[/7UE/KFYB!;"*Q HP^^
M "^B\&B"KET51J2ZH*9I.M'WU:LG0X\3#.&59C7\T))R2>&!#5L6836:(\/*
M?#0Y:-LP![UL==$02PO@^U'J,=,M*I_XD6;0H35RO7%+"N?/+(*C+$8:,KJP
M(FIU(]:00EH-5DP63X*L_MYF':'#:5KA;PY-C+S5/YSK-3@N/N=G9;-#\T)"
MPZE[,@\->^H="#E[>(,V;.E)J<U4J861 M,(/3 IWAYNK!A^>?W@> CY35KN
MU[I\9OY>I[%/\F7J_:EH096V'/KK0IY<-D$IQB2SA9!"GB1,SE2^NWO@SJ 7
MNKR2D)W[U6X?%-9>7AY0L$V:()54AL_J,@Z25A567_GD?$AX%$ROBZ9>$VV4
MGFK;E.TRA[PWH_7KT^P\/:W"$9P4^$I>Q&#7 9ESU:ECU;"MCDV=_WB5=)2C
MI)WFZ^C+,:FA/:MI=_@.NH;DE/KMG5J3%[71=NFC1SYE8*ZO8M!CE5T()1RH
MA%8"+-/GH3DE9(>?O!)(SACBWQYZ4A-A.0A&5GMQ/VR@&=Q^6K^LE^HN;#CL
MB48J ?7X<D0O\%C(4;2]\Y71#/',V)ZVX5]?B4^J<]OQP*J;99+DVXZ&(ZON
MMU223L(V!^UE1^*@%_.^6S;43T #ZJS6P*AO?FQKA30>NT#/Z4JN(X+Y1.CI
M+L=#CNJ/02L)13-#XFCCL9$SDFB*R MO/N>JW _SCRS[WTP!%0P("I)M*L6(
M:(Z$<)R^;HB[82Y-((1T?G;X^:J5VVG'4H.\V#&?HI=7WOG0^6;.OT_LG;%S
MWTA;M54_);ZSXR?XGQ&A@917O)N]#JP@W$=<X/]B9%_8@SY$O?0HP5G-K<S>
M?< P/LM8UC5VO/6!V9L9S64951Z4KDN_8NM 5[_R0D\W2Y;_8\@KF<?N-#6!
M>146%[LT,'>$#QLU.G,-JLSH$/U<<P.\APBNAZO6LMF2O72Z4.<$+:N3G$/R
M&&2[D7\S3'33OWSGDS)66H6FL9B;+=E$%J"/D=K-R#;9Z,$]=>(-UNVDU+@N
MLL@PL&RGPD=0^5C?FC'7X(/$A#X77."K'1]L5X_8JD1*3Y<6FA2*ABX[9<#$
MGC(V&D+/DN"9E:?X(\*HK<J6@IW=#,N(">6*:&Q)4&GYS4,X)\<OBD;E=4,6
M2),]_=U<[PWW(*Y"^=F%Y;:#P5#)]*J*:PXA5,X*SZ+VDJ,R9=76UJP#TSA+
M6]\WY^1*#IZDE,I="[K@'DY-M4T2XA'7S#-U 3)8V>X1,H-EF!!4OI"1<.PJ
M%(#9U8@)!<];S9;#1JLJQZ5!7X\(/L:3@NN#88A11NA)I&8B2E]9[9?'>C8,
M;0Y7F9665G!PIRIEEJDL7_3&;/-OG;%PU.CJ&J@H?M%/3V8>++ TM,RD9^?1
M]QE :A=QM+L[+:HB5DQUT4X?&7OLC4J"J')QF29IA6B-,(GSH::E,LM%!EV#
M4:>FT9S?PNB<[[C!//;O$LSEC&$1R?2LCEG/ $$H-D+N"%$VDNXH\ #XA$J.
M>#KI5J]N!_<QC'R79A ^7H6)XB(-R['RKH25G<?PUR'6%B[2=-"GOV\*V.X>
MJ][5M18^O$US)<T_P-:U%\T3OAH;Y,3LX&U-*G<IM42B7H&-"SN"!X)R0"!8
M!Q"J*8"&@JI';>"#K]H;(:URTA,_E0P$%0^C*1=J*M<G+R'DEV?YLX[9&I&'
MMUOQSSH)XJZBAQ ]B?A4ZMCGK"=%<329MQEBZ*'PTLDMZ7D&?0%!*Q;-ZV@:
M0'"#V$&4 1*'\GX4!5[WFH*WH@_M?"RQ J4CJD,M"N8FJOX-!7]^%5L\1^.T
MTLJ5QV"OH)I</$(<(SG:HV9%,Z,J]4NHY(FU[B2Z:6DRV^N^^I(JPH\SV7I
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MM4B,]#R\4,M/AO=!7G:.6@E;].&)-/%3$<[.,=,,DK3L&S:ZYN3O-)FVW?E
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M A!HLJUP6TG2MR# SZ5,B@6;ZY85]T*M:Z71%*D_!5$Y6\PQ&SD#8LA0K%V
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M#7(G*6$Z7 I2BV$S+/&3<#"': 5O<NOV3#0CNDN_!8ON_G"%D(JYE1DT+-+
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MS<)FX54CD%L/T9A+Z"2T]"62,^.:DISC:6N6M2TTJ_3MQQNW8D-#YYMILP&
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M.'(GE5"]<6"RAI-5C5(K!M!SX_)=-8\STHBF99OATO^T:N:,)0?0S]C1R:H
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MOAUG25HA23L[(ZL3]:DSQL-LMZ2$8 $XWD"_F*A9J9^VY*"@.:L9+"OFF@)
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M![Q4.I-E,2:.-;2JB/IH<%O5^:WQM;R:A%3&,H<CY&0MOIE'DWL94=EE\=<
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MM4BDF;SU^>AKW]2..BH >0&(>9+0P*#VO%_CNKGJ[19_-/BEJ;3Q A@E%O$
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MD1:FJUNNDSFEGF*!-]9R<H]9\&7E.W/[*4U*L;SP!+3+N;)"$"PG3I^FFD:
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M<YQ?8N]57XU%4=GW&G 2U N+V?MX*@X"1[(#ZZ:^+XS#%<9N3#:'<<DJD/T
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MAS:8B[T,!WI0Z6U#[L.]&(83Y>ZL_,31% /%K+G:#U)ZQM%;ZA&;>IHY><^
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M0W3(97M.7_M<6C^%O3%+T@V6>]?M[7R1,Q9\>8A*W/";KXMMW?TF!/8LG5S
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MB#S:NXN(/R9&.!O5,T4B,->@1Z4@L1@/R#:=VJ3RJ;<S07.TO2X"<F'[JF/
MF3:(;[FM1*1*!_*U+K=^[*!.0M8GTO&*3<[: E24B9%VVK>$PU"G0K7;'G!-
M/P]I*P\DQP^+;U$Q6T=+.LQ-S7I+/4A&T[+3PV7N_"KW3I/+_+USNQ7=0 8U
M) ;A?<5W<WR&!5!=4YU[[ 0(^0>3^Q!7-OOD][,-Z+*!E:YC(AF=C=W<R90_
MNUJQ2V<O\<PG!CMF2Z/O^64=3(D*8YOR([1WY&R3J.R7PBA>U@YBKO6B/@.B
MVS%ZP9EZ'N.23E@IT,5YI,62UH7>U\YOKF:^KCG(,&39V%:)^>L6&83ABFA
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MFU,)]Q&DAE/'2,>@S'F!.2@6'M:%O >Y^ )3&RI1@O,@"M6S458/K&5.H")
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M9U$&QY-$&[ZM\X6SA?#[?M8&JAHL$X &&?/UE?L\+VA#0+OG]5"PT7N40U3
M=;"PG>N=.TEIH&8$(:2AL*-;V= Y\[E*K(,<9X4WU3:#,@&XG#V!%+B2[:Y7
M*:'3?)2\*IA]W^47PQ*U-\5&N20<X$1]?_64BU)XU:YBEMWIBQQ7ZB:[DD_\
M/9-[I<[^.??TL3(WYNI;$C/"'&U"-/*-4M38OVT>4KZ"1:00])X/>#S#4RM0
M['H=)BAY?!3/%T 7%)L/>K^'G\TH!?B[!H ?2/;*7Y+2*:MT[@IC.>Q_CYWV
MHIZGK%'R/TGT;,)MQGWGB3EEI&:_F7M69>O..9BUE_OJBCICR:"#!"I]VV?5
M]C\V?5D*N";F>A\Q#QE>M"F;0T.*1#R%HI:DISB:XEJ]Y@;^8KK?3TN]*C-O
M$)T0*7#F82GX7(J3=+*BM!& +]C [T^4]H"2%HQB5]8L8;"\42?I_!TUV-;.
M^DF#BJ.#:S<_"0>Y3V"@0/A?3 -\C"'-TI<9]XWA,>F"F37QM_X B-5V3C[<
M]O/E5I!W=/L,<&9RL PU-*(B"VYMAT:[F N2H/M!B+\U@%G!; 10 BNT;>H\
MZM:RLCHOR^Z9%>]^:E]+;P8H.R:6\;8H(Q"QW;!:T6KI[+6:WZ6F.:^@=>H+
M>1PJV&O[W;$Q5,0KPI;PREY) A=0",K/+!>7=Z><@>$WP&PM8\D7(MSNRV$<
M.34R":X,R)[H0/1<M2HP?BXWJH*!N.1*K%Z:B6NTN^=LG[F$P5;196!HY+D3
M+$ETB!18!+5NKC+'5Y"[RA@>-%+QA+*3;/"1RD0K4\$Y%*]LS0<^D>6+C:GG
MKW!G?N;P9':PCMG@*(C7*=6M[547&JX3;39 @LJM*T#@VX8Z -/UYS4:HW1
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MV:-0JJQ( <<"8DND4[*2I."0E(\JZEN8?QY3?)HMETO40843G>)=>@.=A&L
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M]=TA4%Z9Q3:_D[^P7)Q89.)DAPFI]>I_^&?2_UP\31]_DM;WH_2$[V]:AMI
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M([;;YK!Z!:B M1QL*F"&>&JXI.]I/<S"QBM9]564=-+<?;9\!"LC(G2B3]5
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MK$.J-:$<&X?(D>&3,8F^2R2PT.U\=)9G@.18PIMYN#W?9R!R40M/;Z. ]\:
MR3E_!1"FHF^?0HWR?ZS.<=-0LTE4%SU$W@COUNG[H6J>U_VMG=5=_83_"]9E
M[Y:+5@_ECZJ^OM3K1N;^(S X0UKJ=XJ%NJ>5;8[5C-D$6UU_-#5E74,1'RX*
M]V5X:JS!S9!0T>I>+B>FUS-+3"96T2WC)HS.P(!B3@R!98P_MMT?)6D[6YU=
M '\*!+T"RNVURU*6(;4:/J@<6,P0MC'DV>"CN 304]YS0 6:XC$YCF(9!44F
M_3 SB)=$RM,?YDH(R1OX:,'XH(V+8'X\9&]UL%)U%[YBF@Y\E@O5FSV_=$*P
M=VQ^62Z2 0G8$!>?B+$L&HJP+&M -]>J(XU@HDAG23*S#.Z6V/^(&D3B?8J2
M]<'#P=%Y+-\>]8(/_$E]'REF&4%^U[W*6AR\D>W8J:WH=F!6/]&1+E/D?HZN
M,6U\;IQF6B#UGLE!IU'6$!Z,HH5GZ"M*Q))H4>Y9SZXE.34)U"RRH[W@P3F^
MLK=^$$#,MNAIWQ_:;GIR_T$2LJC#:=R(IW@+MDR29NNY[=H0:8+0)VY=9*2%
MYQVA@O>M0 ^=8D%]][2.^(9=OA)STCP4WN\-O9']UTN9YK:(663P;><K0%5U
M>C<$S6(6FU6!A=$)>%?654CTOID".4LJ%FI$>;9]41\@KA8JKR>D)&X4K#)S
M9+.]3R,MP&2,%*5/LN*AU6A7<?&5%X^K>A.$_F5!3&ZV B'_;&29$M?HDRUV
M$@@G4Q%#%%6<FY;9N;._8)L*C1,'.>F44G<PG_5JJ>MK/RHC651X,_48+/M%
M>!9IO34@;SZ\M&Z4M]AHO#IXL%6LY!@=7^L$WG$5R<[-?!DJCM56U,IRJL1Y
M/RA&W=U'84TV)5%6KON]Q?AABC$]R5P:OCE>/1UL*M&^H&X+++?S!+20YS(W
M=]-+&[VGT(=/J_ KINO:B_![W QEH51MFHY3B6,0-RXL59S=@E]8)/2@)A2^
MX,5B_J]JS?*K"<=1XW0)@]$M,D)@0ZD!$M(-2L< '9V3$4/R"X+T@!%*=Y?
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MAD4RFL77R[S49V&!/!5A>?5N0A8H-+JMT'([I35V.E_4_>%35=.*R&*3/_A
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MWR$YDM_LJ+ 3T DK#",)I@(^L+P!3BL^%-K241:4#2YG$O6^6SHIW+W'F_1
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M:YBH*2AMFE0C#SCR54["=M)G3W]^=T^441;\\"-FT6.M&^/\%_]?4$L#!!0
M   ( "TZ6E JQD6QVE$! $NA 0 1    9S@U,S,Y.6<R-70T-RYJ<&?LO 58
M%&W;/SQ+ES0(4BLL?=/=74LO8!!*K8#$$DMWJ,!-AX2$2(.(("4H)8*$="@A
M" H"+AW2WX*WWOD\;Q[O\?V/@U-F9\[\G==YQ<SLC'OR[F0&((6J:J@"(! &
MR!OD#0 G*(;'>K8(),+-%N$,%N+E!\05-;2QL  T,<0UNMO^S@(*]"!C )..
M58T> P P;IW08^@!V,IP!Z0%/08VP*)M9^6*<$/<0H*O(ERMP3Q@07X!";
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M9X>@[_,=B_*,.^W0L[F,=6H/4)3^5K"'Z,T3?3@# -/H3J.(!6@ T,F[$Q1
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MUM*[WY*9+#*TGT_O:'%TF:F[83.P% KUV)1,T5V<&WI^\)C>RA!R C@VI9T
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M+@QWVUD60A^8#F%*=XW-8]E<7^)7ZSEV8;>28"-26&W_=7Y7^&Y@4ED KH;
M/KRH4EDU4#PC5IYD4ES7+<-O2,XFS;05\^F1T+ YD\&Q:T+@,Y<6([=?TYM/
M@-$;31)8[97#-]PP#V>5'<$]*%E%]HP7:)SN>3S9]&X8>[?<A3<(.L?VA8S)
MP47 C3T5UUQM\7XN.=:G[%ZI_;T@MV;<C(S1##>^5$R73'A1%/$K,9;MB<_-
M$?/3HF9RVVD]6,&QZ)P.=U@VXWN^6B=.KOD_L=V\RK3QH(=9]=.RMFJ '<MF
MQH49%+-"'\;S7D;K(7S/=.,]2*#\LK9R?GQJ&&&\_OZ1/\74PCUAP]P9-[J;
MK4:R+/4=>@MO[KY^\P:R4-HED 6R23^<K9-,JN@)L):=?8.O=*D!IN,</SC5
MCFN;G;3.LKC[?,_'&&,ON<=8N0XF+?387:D\3EUN:>(Y8R+3&#/Q'+!N*5R3
M/ ^7U-=WF[?AOU+$H%IKO'258N(6=K\H,3%U?G0+W;K X V^*_&S4H^K'>V/
M9+@\<@UN$)JQV$)+?7!\P]R]B]9+#]N'>P,>)1P5W6#_B)=?;YH)3I!?]C;"
M^K2+Q=2 :U>ZE^D"NCU<VVTDP%]XH]$49BD(S2C&4/-:.O2Z<FOYNBVGZS/3
MI>Y,>=*"]\-BRE7JDU3IC9E1BJ0D=G-C>RG%792OZQ>]X(^!:C->*I)XNHL,
M_J]DUG#\VKVB1 *EBK?@0LG[W>F+0[_DL*I<O'#M2$8?'R0OIIK>YZ4/)F*M
MNPKSC8+I6 08:E/D'\W&JMT0F6\HMR_#*U)9F;.O2@$N<Y-(&-9F.BEWF>A>
M >_,WG-CWTCQU;-'#@]<VZX>4AQGY()>JS!=P7DA(H=GU+D[HI>L#$WG:6$B
MPHOLV:UJJH(K1;I_\-_,*+-.1FY*&5>EL6F)3J'PU#-:8;B@0 D2V]B=[=[8
MW?PG<G,O;#;C=L)/ (3IEQ/ QWCN6*K]/V' =&:0@9Y!:!.FS56Z0 D^6Z\.
M6>^^C(5TXT^S4H'9H$.O=[[J!TJI3-T=DLR6@<D\;K'E"YUSB 4&U(7C#\\'
MH@)'[S\_ 6+6T>-WG.[HQ68NT^&B??8W=##Q5=OP[,]SF60+AT7+L=\6& /%
M3P!;Q,YF;^!N+CJG#-_#N:.<VN,;WOTXT]NY3XBM3H!"U4,O_]R7C]CI]Q8D
MZ-[,Q]0EIDYLSN-F!TX_W8DZ:P']@MSQ<'73H6>4[$!C_ZS<YX6,3V2"$KE/
M\%9/@.[4_<-O%VX,- [@.OF[9?@$<DG.BDT?^Q]-U8WMM1\HGP"UC6XGP$L>
M] ?]G!**"45*[+W=&W$"+*N9!G;XB_<M7$:1G3;L>*NZX] S^EZ59Q6LL#!;
M>I'E!"CC<3D!&.8"%ZA0%]$V?<=;VVB;6MK#V9>/3H"),8D3X$-6W6DU2E[F
M^C^*@VPN9](*G #&QC,GP G@&2V7<:]*[<!G0>U@<(QI_8/0WAM?Y<#:)\C
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M"1"X)IOAPQF7V>_LFRKKF_E4O _[Y;["WL*W_87H%Z(;/A3L@W(VW=_ZZ/(
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M9Q=&187MK9GGBH/F.0:<$S(L,AUNP4=AQ-)XAB%Y\5CJG(*@Z?5)U,18S'$
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M-[$NC+)\QF6HW1":KL4(@X  OUY?U:/C:XRF!$'XH1,R01+CX(4>5!9N1[P
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M21R8'7S;LN4C^_.+!GZC/@G;12O)O&4=I;R[!.D+D</66UZ]/#QYJ6%@5A8
MA'EW*[_B/5VGG#WMH;6357?/MY(@K&"6GEU&K\V.2]_:VH[,._J^91[637R@
M$,!=11WT'-91<1.02RGW,@?&EM.M9]C0MI\]_M-JGHC"9P<'L$2_LEZ04Y"+
MG6I>M.U1TTV3BACW/1*7'((&)4&*TMYH)-;V==?B#*C BF08P%\-+<$KJG/D
M'JCFXX\P'+P>=;+&=\S$S""R$/!"="*B.'L[ @.?7,M;V0&_#_6!A"Z2(/X$
M\%=\L:8:\ AKWZ72[F8< >P6B6$0BY<$A (3K-O?S,\Q<\=/QD1+G=$+['%P
ML$-/Q!E/6BR.Z84#IM>-8\S*<**Q569WK'SL;6[)[LW0LP96)\-@ 8CP-H+#
MCU=3:&5BX_LLV80FNE>C'-MC6<H(@)8(+'6A20\FTUB-&-:RBX>)$W9E8YI/
MBL9VS'1U4KK;.PO+DH>3NKV)*Y]I&NDCX4[;@W4PZ#O%N"MY!7@$L]?=TGT8
MVHV@NZ(2%08Z<X9?)=-?XN>5O%6182:=XI$Q+EGZX%J9E7&YNO(M=,JQ-FY*
MT6 57S/(^(:S[;Z1X+6%BV(8J0I*4#>E1;6DI.T<1V@)UR3LY7L[G"B.(AC5
M+P8XH;\FT7D\_:Q2+4;9OWDQ#6HT^HF/JCTW95RGXA7R K5*>]I2U^YD3NE:
M3B6*H#BY'TC%O /EM?KBZZMN&?O =-KB;GT]S24UG;+X$4TU9=T0U%O'HLC;
M!*(3L#C# 7/) :5N]]?%!IM6R@+:-W6\'_3L)U^MU;IH9/1P*W<[6DKU0!=F
M) :KGUTLRUV#C5RPZO(H&._4JWT.U9#FW\Y-UTSE&35%&<\9WW:\ZE!;MT\[
M<H407E%?3^!)?80(-4"4N>M>2:B]G>4R;XB"=DVZ?_ZELWR=HBZ562T5)?0I
MX%YL8.#<H4VT?$</\;O8%+OL)H&.!N^,O<0#G7?'[%$1TS7*>PL+6WO1N;&6
M+A2' 7VOH@<CR*U]/(\.">X3+[ ,:S#"1/<S,G=Q0_$M58DZ+*KP-A)D;SX+
MY;@M0,IFA2N;/>[6$G99F[+N#O6DPSWR+U>A<56,>75X,0DA&/4%"A2"XCPJ
M)1?+F5[<U%<O\3#R+GN8JX?-5B&LN<95FL"OR+6B6/T)P)"_AD\*><Z]:)]^
MZ[TVTGG8=/%+PI21@K[Q_6GCM\S4E1JP=P4PTDIG218ZS/&KVL=>+P6O#'9?
M\-(>><RIL99N$I;_:@ +R"OB2 !P(,ZLH6J\)4?.PSL[@Y^U,],C"3R-"#TF
MM^$R(Z*EZ8JM<?>3#:ENDY","KD\-V&PO0<8Z]O9=7H_>WJ-(YD(4L9Z6>U%
MB!IJTF6+^RM&2;<GNPAV=<'H6Y&&&VSWDUEQ*+N\W;I3#)<TH)$)FRLOOAC&
M^?2XR._=>\NU6TW]Z-%3D15'YDUW.Z,1$)=_;^126+%6E9JF@HH<0<IP42J0
MQ7Q@%'E0PJUAD5ZR.WG-8"290-\1!#,L-+O9G/4)0L6QHS$[M='TW@GE9R8#
M[PRYCLW%9WC9$09*W"]X0VS8AJ>_>%M(((;O5M)GV;@!HLIG.J_=W?"Z2Z&$
M6AQX1\:2?FP=Y6V/2:\*$!MG0F\S'$Y;YIKYSFQY(8LX\F\Y2QL'X\>Y ,D^
M'C-#EQ0KG[*5&IE:8-UY]![ZY&XS(*^'Q6-5:W"'@U^+H<[#(*>$S8].6PA)
M^5%@CI*$,D2(26!*BK83A;'YZ[A8XF3D0]?:FTO[!/;W%,QD$C+GEU>W(V6@
M\K='N^_,PUYD4Q>VV@L-J]$C%IH^R\TSUE"-ZL#T D+>31$+[*V4%A3J#0L:
M'5>DR*WX>IOXXL354@PK7&^MF]=>V?,;KEZ=JF88_^A9-R)>>*.T;D3*\.!7
M%Q7H99U?X@@B@L-3@]C#^JL@?IS?FAZ[L3.]D[.Y1,61!CE:B 9B.]:%VDEO
MJ74O;+:S2"$ZBJ$1S>R#HIL3?3MK7'8CD!*L3^3LG\EB'_?ES!@^&]1M,^_(
M:9GXY!^P@C/7C_^.4>;+U>[EH\2.E[@]+K5WV9]O;,XH5^6&/4P+KF 9]/6<
MT=>IRTJ@F,<A6<%E;+J'49!:@A-@=2@;UD;DO0:OQ[VX8\)&I"&(/\%FCMD(
M1L60/+/S"LMK!3&$1#!:S^'V),33IKW7?B"D@5DL-)E05A.!.?1<8$$F]E&4
ML+JBHEI '*XYD0UBV6>UB>X2O 4<#+08$GFN1A?*^;G4-I0NT+4FX@[UL:^O
MME^"T\9\4*8/K4+(M4C;-&3,6_G%?I +D%K/6BE*E?-*W(J=Z,A:*6?UWCM^
MNSNQVP%LX3'=5AV\@T^J"E'8ZTNA(6='J<5Q<B8FAGCNZV8'\.<H51T^.SH!
M B^1^H5+M>".=5GY'Q9VTWZ6B@\E9Y--E3CT6MOS*\"U6/SD(=46T3+W.H>;
MU)HD;2MM@F:?1$<:2LY,C@-NGG8F2HPG%V+OQG*IP]=JE9^VH)6[G+$0M27K
M%='GA<KF=_95GQ/*K#ET:RK<72N&US=8-^B9I>F&UTN&2=88JJMH8B4-PQK(
M+@P_+:2Y+L5JO2)^?=3#HTRLFC>LN)MG-O/7SW>^99./N<I[%_2= $RJZQXA
M94R[)24V#]B+:6]C%:4NRCRK2GRG(^-Y="\8DSLB'(@SU_$776T\=)RAP,PW
M"P_&I&6(\FNRH<L/I0AEM$YDK&,9X]?M"Q[2RL<7!(TK^V]FUP>8.,/KD7D.
M1@M1 ;0=?8M91&P9'$%D@FX2^[NHA>6)X"'H(Z(+N1@LLGIXAU[BD<Q$@$:H
M!);W+?87N]/W;L0-*1X5?Q6]>LGD[12OX3!Q33_7S5!8$_YK]7>LA%R]6.3.
M^,13FMU<T:#RC('H_L,K8U\HAV08\(K@H]>\C? !+*55S@4\7$*(1@>Q+/(+
M 8JIA),4Q1*M9X82ODAG'ZF8D%RYC&]01,@)-9S32:"/8*&@2,-,\"LL&4[W
MA4V]5K2S7^9,J[EV;9UB1/\J;,W1]1TKE+6Q\K+@.X(;N$0'Q"%%DC$#W:++
MC'DC/H5&CV+U19OUM1_H+'8-7->:LE18TJR541QI+'M:%617YO11^W$BBH_-
MOECBQ2IO^0J!:-ENA>9UPZ?7UQ>5(DQ44_D*BXT<DHJ?)!1!(W?H_85\Q>S,
M2*P^=_'4C-K%K^P*/S/%9[A5D]YAE8?=BL=J&9D5+0-E4.'4D':]J'D@]*'Z
M1M&+D=&GM32N1TA7#1-#!<)R?WDJ4LKU13U6GD-!K1+/E^G<"9?$5 R>HJR(
M1D<,\F6(DO(,JAYB43YCP,U;*/[PK#(\_M7\,X/<\DW']-01.6S\PD>Z2P-
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MB1^G<!59:+I48\/(WE1AY;_#5%S56C$*N=*@HL-.%IJ%G([PLH\%U>JF?P2
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M\7@H?,6P2I/!Q8_<4<^?4N[.R9$*I6?V/>CU!)^4LLG=DB<*JL#+B:$AYWE
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MO=@OAGZ8P_\!4BER/U##/*WU%35-/_O3W4:XN75;]FN:G9DN F!,5.I<%+T
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MS,K!]<F.N@$L0AZA>88+P:<%&]$A8TL9#=OIVN:=:^8O-,#(454-"G6%G-(
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M=0HMZQQ/,.1==6M.XJER&I=+:\N_+5LTZ'AKFY#Z.B+.2?3 LGC]RP#W=FB
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MZG:HML%E+=[9#OE':I]:UTP7#<+>&DW.?4S0^F696-9DR=X[^MHU/;;BZ3]
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M7L'6*0+.LPIA+RMK<87=\"K)SB0C[8ENO-=]"4:LL  FDS0[NT$,,G">4R8
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MW5-<M?N4WI_S?#[4HPY%%ETCN1$(0OAL&U@(LP69"8JFYQ!+'8^NUH(FK7O
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M%*[D+X3M>"55N$G$(6J*+=T=LVK]G9676)R'IU=1E6_,NZ!*=#G&,Q>#XS.
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ME^/3BF-I%VH$+BW[\')C9\Y"U4WPAB[. CQ@"!7J^4RJ0/9EN-@_X!&6:[B
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MO&H!DJ@M]S#'.D>^<F>6.R8/[[O\\]G'-N?J*7:V:_SMQR_ K9L]2_\0*D[
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MA1A Z+(VPUW@,!*R)-(]S'+CBJ]E6'_NK(W$L[<AG\PD)0WKJOYGB.R$*O1
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M*UW73:<M%!$_UZF<V2!T/)37*+DF5<OG71=\_?;L'?L!&GM'PT["AVNNF'\
MOSM>'VUI/_YNH*9F[(?< WN'4.2]:+!#8YM]DF]+ZUEC[JA. EA3TSN_Z>1L
M(LEK(0^=T=H_5E1RJE=/:@N\Z=>FJ0'6>NUI?]V<KN)AHT;+B'UUAI;,I.3W
MH%8+LFJEIP=G/4T02'3%85)):V:+NW'OXJQ0A/=6U:EG=XY.QYFU14L1"EG:
M#,WRM//KMUE^W]UX*4=\6RPI#\X0?S:K=E7_-E<HORS(9<%=(V8G3M%8L4;@
M%2*5I7,M%7,),_&H7V4O5C=I$2-LJ]>#P:8N[189J(#5D_'OD8*JA00:6-VI
M,6M;4,Q5;IC W+I@84KB1F1>$H=>?GA%I#+9]]O:[/>&TI/?)CLJ[174GLO;
MGX\/%4\:0<JW6F*K:[6*IRS.[N/[K."-B3!L8:VI<*QID;ZM4_4]9DOYE8/Y
M<A*FL77U.8M??>.]NK4T7%UDQ]/T>=2Z#Q>2 &./5HW!!I=_;]P+,'7U!K9Z
ML]@.4+]QU";G%T)0GXI 0DE%U>=_:7<DUPSNG+HZ[$>4$["(^NX$-M3A'A!R
MU_%&;C:F>*YQ$@]4C@3C2N7<CW4#[=]:+42]3,#4)Q\UN;B7K57@NIG1@K>1
M629W,E:U[HFF<2)I<!QKLAAOFTI;:W,O/4(\NZGXY$10/ #LM<K%1N"&RK#/
M+ CI??V#?]X'M2Q'8MG_NY %R$R&'$S_5+NA]GKZB].&==?;G\ E133K76&O
M@L$++QC2/CH8\-CIJI47-^02L)!;KS+_;OR#HOM(5062^7K0AE5?3NHZ!?"I
M3TZ_44FAT+"6N\;]O_M?^4R 30GRO/WJVC_%\JY+L(;V%JQLTE]J&UC&'3HU
MYC0F&,SS9:4\_VJGND>]^,KDW4D>4:>@M&Q&X%0O9K8K]O:A6;/&7OR\ VI.
M?8],KGI3[@5/I7(@SB:39@_+YIRR>RJ;?>;O:XNB>F#XV<::L;"7SZ<-S6]_
MWIR/W @_V'@3Z'SVT5M'Q>OT8P,#OS_4(#R9QLC(@;Q^ -^;^2C,<,1APHAT
MV>E\?\NN/O2#]MK89U"7CUVWG*94?9).?'90C'$T5S-'\55M<RPN#;#3BEB!
M?)N;Y'BMSD@G_[K;TG,+LQUT6*R70RI#X;0L%^+]XI\:S<TZ=:5I.#J !'XS
MT$"F,$I8)Q.#+G2+G"XQ!0%,:02E6N0G]C2!3. E80)?<OWP?X4U?F@1F_?O
MVMZ)4!"H_(;W=$4+&/<.T^$GUKRR6B#9_,7TUH0<5XJ\1,#=^WMO!!Z!%([?
M2G5N>^I%?;D^!OT'N/S((S:C"JTG\3#G,F?0 /'$?O]#*(U9C."ID,&^2.G[
M\2JI8./XR\N'C2EKE8D^$$"R]LK)V 3_0Y_8@<\7;=]/\$$4?,NTDPU%>K;?
MY+%Y"UP#GE:&=#A1FYG+]O3$2+%]F:V_842ET-*"GJ.0922[!ZCT\IGKAO '
M([]BHU4G955E#O=CT_7^SE3_C1,WO5M $W!@_^6I9'3M,ZL56_H[WMRZKR,*
MN;,/@O/JIK4N7HE(4;MQ(3/GS7N#5Y"+-^0CQS2Z/W3:HB9Y:50ZM62A&=_L
MO?E7A!_9=Y:#U'4/7<GR.4U6!<*9Y/?9Y[_)N0.#6V;WFZP[;D#ADIAB8J$P
M7D&4<+FX5A$Y[W"EE\?*A=>FK.'@M9+ZGF;L[>X)%SYO#[-['\M?E_-,M,3)
MR@*;78.U3CZXH&)!^68YS>>6;6;XGF_^FEHV: 7K5N"<7:4H7P)"4>>S72J>
MMFICK/(_A=J@'%!U$RZ-Q1,SZ8W,.$4".I) Y.0\Q0\]$=\XRN[]ON*.'B-&
M'@\LIMG6O9&((A#FY]4@],CA/L7%R+K9'@QPB1^H-!+I >*["G0,C%0L@5'N
M++0';>\%WNPUI*LBNXNW*A4MRS]E@6 C;HJTW#1)/$NNKN;;%7\C7_\OUUJ[
M=)M<=]K.$P.<:!1WY8[(-E?*J@<L *6^NPSN/Y>81NS;A0TH"[UV.*KXT_)W
M.JZ\KOWI=U)7^(,[Q.YNR]<-KRQ+>X:?_*\"2WR%$W^#JW$/ABX@*G-K!-GR
MRO8CPGM*AV=C]U??\7O==NO_Z%_<144VNM9VO1<KG"+/PP1L#>2!J8E&-]>2
M7+-!U1?)DV$.9UT\$/Q1K%Y"1A2E&;\OS_E/=)NVI7T:<:\UX9-9H4VN#F8Y
M;>P11 6IK_IX3\_7Q%G=HPI'C67RFLN]/PQO'M@$8FH!>,;= _33 L6RCI34
M@;K*Y"-?COWP/"IQON7+@Y2U=O<N\RJNMK-NS +] SB@.!W,W&^+X \$N24!
M;;:P:QHHM[Y 1HLC=E_B>_Q<??:*O<LP3O8X?A7\NP5[ZN]Q9$[<T)RG=*1[
M[4JE:<WNN>X3?E<Y\#LY<4-XLOB>"GQ /V6/1D&G6>U(E+DA:_]!FI$9K&>/
MW#^9O6L=K+4;,%O;=KP4AN7082!8SHX6XV5A4/AZU8%1DW@)8MY%0ZM"E_P)
MC;,3;VZP=50DEA379F>(P<G-P$NA,H0>$ JB:-*I;A;44RRY,QM;WFI@%ON^
MG%2>-;F.TB1H1,R77X:ZP_8$NQ?WQSV$UP^ZIL\/ A&"[47G?0M<WL8M4Z_U
M!V+\4>B>F[6TKH@VHA]_/T[<-05B3M289W_*?*^.U6?LV3-GSO$7P99F6QF8
MPA H,E[>Z+<YUX\OG(!J:1<K4R;8DQ08JV+K\K$/(S'D'Q$1<86_-_0U/V%P
MS32?>@5?<BG>2[:1 EL/TB5.7GJ;W@VJ7IW*B1OW^E]/+ZI78:*;3:X\?]#;
MA05P <.7T9QA#+Q@S+"N5;[^DPU-.> !?U%M-ZK.4*)'.[FEG2X?U-0N9A&4
MIHR'^K\$5'*IN@7-CC[4^BN) ]YP#M8O.%!Z7K;ZS-580@HJS/ONB\CC7R\D
MMECC>C.[CW(IY?UIV>[(QH#%K')GRJG\^0>!FJ_4$$7 ^TD(:K7PB#",JQ1G
M<Z'^#W,3Q]'18>5'IV:G"Y)<3A9%Z_JM/8W/G8ZF73GHN@TS,7MD:AW0],G^
MM5+VGG?L]K+>0?VJ&]"?Q]'!!O3QJY0,;K+M\*"YD*BN3@1Q2D*<G IG,I(J
MW[']/!;9ML?Z*!K%^*P'.@[7874GJ#RP9\(R!3J%O.M&SS+K_KI2&'>:>QWP
MQ=S(;"\?88@#T$Z@.HRSR;M-.ZC6-1A,QK;GF_",\[#)*86$6/GI";UJ([C8
M(@5O*7^EP0N-A0N6N)*Z3JIZL6!:VG U=M1$H46Z*.?WWM)>9<A14\!!W= [
M@?:$YWKV9P,HFIFF/F=\I9ZM*#R.&QF_@9(=BQ5>S]47EP(KOF[SZ"HZ@I]K
MH"B=/-$KFV$]-Y>HJ"#P07[XVV$NJPO6I-"+181A%#TAX%G)+W'8Y_8B]U6*
MP5OAZ+U1"QOVG&<T^YF &B/&J%F&#$!5(5!":OI;5B$@4>OBI_(:;D5N%GBT
MTX?OWXOR;&9JV$DKMYJ:;X^H?AF]K+K8N;*UP:#F5?RH2*\=5V#FV#Q,V")1
M'P<\K(A>#].>*?ZV%#V>LK7T1?+F-/)[A:7_WOD'O1\UO;6J:%>6KM*TNIWG
M.VV-Q_H6 QUI DZJZ^:]]'A'=V\0C(E^]*C)#$5";A@K4\*L+"2FXOL[2LFO
MM,WPDH-GAIC%Y<-/?Y:H")8KD ON6%G;C%[TGBBFNQV:PK!881XG&7>#@+J.
MYQ37%E(A78XY";N)(AP08-R!_ ))TFHLP% X%L<A*<0?Z,( @]H_'F$MTG;C
M(4'%Q/I=ZZABF-5@";9Q]US706\)>N2WI2)GZE&@* Z;8WAJ:Z"BPHO4^H(Z
M[/^PDU@PAX 9*[2R/X9M>O>$D8V"P@FS7.J%L04&T'<1LA@@AZK5;<B/"\ P
MA8(R3NG&D- "HX&=3:YIF^I?/P3ET:J>PU'KC0E%BC),NZB1?&4-#ZF_P@,]
M^2MQXR=EZRV1$:?&V!09FR#.RF,1IOZ;/PI !0]C+]_)^81OZZ2'+V64L/V9
M"@H"&^?VC'P3WK?);U4UY)YCOC&FNU3(O*D;\OJ<,*VIEI.9NS6X/M5_$_K8
MZ^2N51EGL.S'!_<X> &ZQG(R,WLINRM*<^$CX_>X#&0VS=FDPZ KS]^--7$6
MP9ZRP('5#.6Q\$T#@3/$[9VY]O+L-W[9M5H;,+>O3L/-B'-K$BX7$PVI:4"9
M4G6!,SON]])>.SA1&/MSBUOBMC D:@T./R]MP#>17M?33)+ B0Y2\T5E-RN-
ME5>_'M4\[W:V]^QTNKSQL+:Q.<':G>0/9$H_1_<DW,R6J%^]1]B-B;3E&*9@
MUX37[<38"1:M-] S\==O0=N[Z 6_]XX*6]ZT8G))9>\=89R[?K>D98X]8?EL
MHJ?*@F?]("I"%QU^^ZY$*&E?U72C4GK K%-'H_3-]\&],<F-Y!7+4]MNQV!U
M/"?072P #*[; -+)>8*)BQ7EKJ3#Z!\_MW ,N/OAD.5CRJ*%X[D].0D+'K[1
M=5-*<?;D0K-PXVUB$Q<^"''+BPC66:RZM29(6Z0Z?U]Q(Y4XZ6*=R9\(=XQY
M.C_N39E!(Z5 CC<$GF"Q!",);^-DKFI00C='4-[@#9/F^P_W; V\/Y#*CS'-
MMUQ%^5-QXMEB'&U7%7W9/6L+9'C+0ZW];:_RH'IPBOXRQ#%18B%!LFJL=H\M
MPU&,U97;A:);:W*#FU.^9_$5I%2J]TZ0C"*;4-&3RBRIZ=-LSW='6HMAA2%R
M"7Q# L5&DB$M,!QY/9C<).YJH1(8V$QXU:9$!$'9E44MN714+8W7WFRW^UTF
MD@/+\3^#R*GUY3^Q8D!*31JPM^X&*)%S""]&,G(3?6AXQ;$S.[).H/-3[^0(
M^!KUX*=]),O5\T)I[?*74?HO%N:F)' LX.[4UM2U!^L&3==K]G /_2^G6'S/
MWO"KO^6X6^ITM)?>;'P<;Q30'/8M#IW,B?3OB$I>L?P&_5E^UD0U-L;E"-2Y
MG2,USG"?W@W&Q^ZTJV BI2969QFXL_?M@*(VNCLL:$S!$T$J KZ"H'$BL#$1
MX?\ YA]^40F7NNC 8E!;KM;?ZO[TDOG@7HX(RM.,6QP0V]!L*]>?KJ%71\<@
M0C-7S1?G)Q/0D6@O0D0[L^K\PV[F6>=,Y'Y)E8%3]J:^%RN\QU4TTB)%@=!/
MQ^;;A,ZJ,/(0Q4"T!/+8OZC9)[T 7^*N$FG2=45.M'[5)?FBB7!WV0??9P]?
M_9VB2592F',N]07EN6A,?XB_I$O^]XCN NJ\O6_#S?%>1SSA]VNX@Y$("BR8
M?@?9LY!TTIO%"BV]K!3S5R!?*3FRZQ3*7.+[:OA>J<LJCN_;8 $8TY@LV"<1
M:2P,%;1A*2U4OVY8<6$&N=RF==;==N[PCK5_#[+./ZJ]\[\GHXBB9]Y>):+&
M/^&+J'J(E)Z5^HVM/9TVR+(3;J.?! 3;<U[HPT0J1ASS'/4GNH/;KJ_!WP^R
M&R"!Q.8@5ZAW_9,-:,\B;2UY"8:OKC_G51B&:E"'EET?CKJQ9DQFC !!4L"+
MH,RJ]<][Y#-:[Z(>P"DOSA@:^R9L;PW^=^IC'E)G&T=HBM\\1TW+]JUL;&Z1
M,N"*K\Z+"00?QNS+58*!]VE=C92^X.9F97:5C.L!!SV@6/GUVDC@6>^C"IA_
M7.CJ$]<[L$FP]M^AH%[70#!4%B:K;ZB!XW94MPC7..CN>#+EWT8A8AK#JHFR
M?JZ&"KW5A;%2L#SX;=^U)*"KX)0J7QV0U7+A0YQZM$+9VY&#I)?#6?^-V^-3
M2F4"#,W&[P:_[$L!F?M 1GZP6E'BHZHE/\M$)!KAK2:-$JI'XG7<&KU9U(W5
MU!AR"J^2H>HAT3/B [,X8QOC<4&3O^R9XP;?<H4J<W$J;.J LAKYPTK^WUEJ
M+\.([M9?5D( 'WBM)F<NW19FDO/L[8WN?%U5'#'YJ,HR(C7-"/RH;G(2 K4I
MK#=)M'?8C_YLU;%^8>03[D5:8S'>)$WULU3>27=5:EF2H5O<IX.#^96D&W9-
MM**\ORZM[']>C1]6_13,_22@;N>[P9YW0Z0K*";_8$4ELKJ#.F]@VQ1H.LSP
M?_BT&B^[^1KQL8?R?HY>7XZS>G7?ANI,U3&U-%V50WA*;#CUA@UIO;[U2(ST
MK/VO./%^<<*X( F+BWGDG'[G,FX-.#J9RAI[-^7EU>0"QQ)QF$",3T$P7:Z4
MIO\T_98+;M8M%,(C"T213%$V$)&7#2[:P77M072S5A7-6[7!(_>WREHP!4T5
M -UE5E(E8KD1_1;-'W&=)D03XDP1=[5>BF3CF-+==;8F@!X=SIV_&:EBQN5B
MYGA%MZO<)569R VTSHSG<6 &-*PI1!ID(!CG[CQGJ("G=4^R*WIE;>C 41[3
M26MKC+6W\HZW,3NV$2F?GE =)6SC5:!VO>S'[]X7$L;0T_<WBGY\O"=SM-[T
M#U!X6',>&3Z2E#=U<OUB@4K_R)L'T6/C6[ED%(4HDZD@;"S#QD;Q%;K^T?"O
ML!0^( MXZ<I1IA29_5C=ZJ%NPN?_*=Y$CKDPC//[H^A$;I&_.3NR:IF+AE7'
MZ^GEQ+0J1R*$[6_^[4;]YS<<K3Q.U[^LLE-[(1>G^<_8KV2)D)<D+7B24E+8
M2U/(7PU_I%3_D<1@%2J%?=15#>Z6Z13JV5D]Y$__- []P&HCE*QU<#I@)=[_
M'@&#>2F_A17)I*AKR0][<5_\L)&^M9V;$E:_$=G4XO,^O/E6<UVW3M%-_^5,
M4@^BWSKHQM=)V@X7;$1%44F17G\_DMB-I,6]WG#J?X8!%;<P0LMAQZ KN(@(
M4!@?6Y?]^0*;+@6\OADIT"Y2F60/J2R9_KVB\JLLO"?\<N8..WT1??7P;%AG
M2=MA#O7I>O#2WB%?WR?]PG6@HQ74^G&&8)/A!_TPU\6!\HC;B_TE3G?ZXHK=
M)#NZ#0-++OLQ EW:KM XKY+Q3H;KUSH#[Z?'2MQ/[>_6CX/G\1;&U#F\B[>:
MC$\(UP#VW2QP(F-4 KJM781%\01'6ZTNE7IB<<TWX8P"19ED4[N8H6+^R.\K
M94L]+=3^G9ZKN9JPU082^N.C*=Q7RH34/0(:L>0!@B!D! L,W!7L17.W?.^-
M!;%HBS,H[9$3S?BH58I8\%.-]7=4444I9=?N[L22&AFS0(U4O%BAZSLD1Z^;
MTQF9:=4H>VP*0RA%$DC ?SZC)/-"(2?US<<05=^'?+)U*8]-='0>Y\='&45S
M[NR<U-88Y#)UKO\#G+P841/2OXJDB"F+R @HYT%RIC^M)]Q*6XR-&&&14RU(
M4KBG="FO1%BKF#X_='4-:882L^O..Y=-NMT0XBDMA%(T9V6MV$% 7BA\\^R:
MUPS0K.-;ZF^EFV>!=F-32>:BAIS9XZ"_C[+@$I%'JWK5_65; ;JW.QWY'&]N
MGX^JM7#4RQFDRQ]'(1H'K2I<Z@3Z<;6'!;.$U%)0KERPCW3"#D-]+ZYX/AJU
M\\.AN:Q[1V7OKDL;/_*COYFM9@@) IXEX;:$\W=?\P'/"N--&W9F*ERNE;AU
M4XJ#3+>EKN1 V[X<W9F*Z 8[/*#;4O;)PMDY9G<0BZ*W&GPZJ0C&SGV@&9^"
M5A]'7%A1:4W1]+.%L=(3^7*7DE)N^G'&Y^,'WA92!CP[PG/U_4]VZ3C_^XN+
M3=(-/CD3)"<J!5<RFT%;&UV56?[\IHWI7R7!K!]BS%&[(FV::XD3D6F=*@ @
MO\8346J]3*::S#?J/X"W$0;/;(#6WLC_';7G;2=D%31@:*;17P"45<;4DB0(
M@PJF7LK70RY)>/#_3'*_T:5@^"$1]51&4<ZKD-=8Q#!436GKI;/[#S;C[]_+
M(F/7G6]&3*)-#/="V_S<JNU?6:4%^/7=9N*J2YL A3+_A<X88A[$H6/%4/"P
M#KN!YCL[H?@[W7*WZ\A:@W57J8LN"']0OV_;,\1O/N4Q5Q6VW,C=7-_=:=^E
M$M>6;@[W\=ZGC<VF?\X&@KP.>JQ-%VRO0RS?<IN,A8X:]-.X>& HJU$<2%74
MBSTKGWL\Y6@@\.5:,I4==IDWXDWX18=%_E\I&_IZ1/"0 7"GDA5PD7WZHZ7>
M&\OHY8ALZ_#;W]R1ME9VU=@2S(I/6;[]O=U)LWB$6MG2IDZP6RFAL:]]U2MR
M2R6(EJ/;N#=#I5/GNDJD@L?<=<QV8*+=RE<)W7772 @",; :FZ-)N)I>_/7:
M',C;<;Z]NW$Y]*@8KPF?#6SOUA$E+WA<$H%X7T;9CXK*0/H?)DT96$'H[F'^
MD@WU08\-9AM'U^OL])\0FG% B)0RE,O49!1;'W/S5+6G:]7^\0(\[QF]Z_YQ
MHH>EUNHWS^>:;BY\S5=@86)*72G"X8_S#8Q37O5@.&8ICU^-'P@!QT*3!;!_
M1F*0&MV"@ \I>DE=;)TC4O\ S]..\O%-M<F.A7=Y62]SYVQJ?U+*EV_.!,H(
M^\J47LA=6)F0U]<FJ>*,2QW4+NE[2E0&;XF\##R,!+NG0X28H;]CK%N$+?\!
M?+?ZY#W*#D]XOU;CDV5R?RH(<N87%2;<90"^#=BF"7$KJ2F,JZH:C0CR>QTC
M'?O$4-T0-6!3I'E!89SFWJ4[]BL_+I_$!BT6B$B)/T/6R]F<W?!+V9 UO+D^
MKL3ZH%'KQ>\?ZDJ#TM]>%37T];0?\+4WOB=T7*I @_Q!_LN0QJ;[-)H3 OG>
ML:VITK1X$>.W@]Y9@4'XM1+36.@ROC=>=*R0VEJBF(S)CJX!STC<>R2HK.5!
M]GT+DN79VV+JA=(ABG.F;C QBBA[J+BBOREE#656Y^'GQ *CQ/:G_TV]Q[(/
M21ZPN'/SD\9C5V45E1:0"7(SGX8:ALIH%%<B9A=%N\5TX 6T5AQ _A%'73>F
MSXE\A[X8V8BN.:ZG.L6*0UHB.Z)(QS#&(P$2$DYF> ?(0EW!8@8\4ERH6^_V
M,9A<_SN2@TRE0H:?@>BY"42G57"C22KRJ10RMX6@M!:Z)4H0Z3VCDY-VG5#_
MP\^ES#2_1(K+(;#G/'T6UZYKBN/9@>Y<YA8&?!+6C0:\?3%M9[>N;HC<ZLMM
M? BC96A:Z8_VG#L]!Y#_NSR?(/^\F.'#Z>E>>Y:=("^SGG EI8B-5<Y823Y5
MEW&?!09@K>06Y)6\I*[_[:=G;N$#$?D&7&SF1:5?9OW5+_\!+A^4ZJ0L2:YO
M+'V[[JB: .T6[V>7.%Q1^-^6=&@I%]_5&.F/<67B;_U63M$#0/9#Y*7>;!V%
MJ.)C2I/Y?SVV^R7SY<='G_ 7<X$;BB!XT08K"^"_W%^+\J$ZDI+'J"Q5%I20
MG)7GC4O/9E)M34)[T+_=O1<W3V[B\0&]/:+&"'H^ Z*D$DKE-E6'R@#NQ724
MAV6OOFOY74[ZZ6CA60NR?5H6NHI$)LMZ7#9EUJB[H6R461)UW"A*I0^GHPT2
MWET..(QTJ_0(QD0NE;NXQS(LOS..F;HD5(T4=^!ALT:7?)T--I*_'M(4&<V<
MF7"8%KT3R3?78_9]P&IV^?.1MH@;*79BPOF%(Z*Z&:5M1RJD\BJ],OUS#F+\
MDX:ZM^=1?QC][$)__0N[H,K!**+3;\LV,ET;==K6U8]G_YBCO!-J?UB,0Z(F
M).(Y\6/V0CY#L[HJY?T^-<BE"T^13)A7>6()&Q?F\T1AG"\1U6P=_,=(Q 3J
M[":-8]4A'NIRFC%4BI#0+UWK+Z_;O?9_K/4+SH'>-C_4JN6Y;2P3(<)Z]YSW
MFZ<[C@\1^]C6;KL+%IH&8)#1>&4769C!U8!JCM!(32SD#M''@7U?%;THV6M3
M97M\Y8;-?T >=C'^916VS\W'0L+\#T)879A&G.V ,^S'!K553?.SDN@"&9O*
M-[/&2_>T/]O]^+[JDUMZ)4U9L&QDK_07WUC)RNCO0!;!>_K/N;Z_VXK_\Q]/
MSR @%N[TE LFS(J%++$,/ZCYU-M:[(J;/>^^Z\TJD)B<_XT]3IT?*</_DK.'
M)W!G@"HF"_EVWLZYLQ#!?C?_WMW*(\9S ;9[YR7B;=N'SD85$SEZRD! \Q1E
M-U96)TJ=GQ(0SNX5*HPQA"P=RN"[M*V"@D=:"#OT -UR%X++0@3XC7_;,H^
M6QG,%+V+=IJX;?-S#V?:>Y*RX=N3=SEBN)2*"V)T0.?.G:K<H^!PW5I'I/W;
M7]!D"F.N:^DL!H'XY6'?[Q(*<IF#7N?,W%ILJAKLW;3-?AE'[<]R;BG?+4"\
M)N+!)7Z,R#1-E I\#>)?QV.?#F4B\O6 ;@ASIH(.-G6VHP4/</KZYHV,/-L$
MOW[/>L)%YOQ"<R"6BJ*VJ?C4X71*9N&Q%;*T@W^ %A20!P \HPM9&Z']M@K_
M3J;:>SI?[^93["_'B<9K]5SH<4*I+YHB5*YJV&C>@0]GFK@PO:&71"M+8<Q#
M;\]<YZ46?Q5FE0.R6[-; $73(<03@%O8]4<(.DY,N4A./MW6&_ENL)B2:5U[
MT%O'YMEI=&4]^,:J*\2EVV"SD=RV9Q1.>.(RD^7\D&06X%KAP1]QWNEW-DLQ
MK=;4Z1.W@;J"L;J[LSI8$V5E$\:D:/+7\Q$#;FTO?TM[RTM[\MKV[40/I7!9
M4[?2N@-4P VKL.' 'DI+#?:W#*Z YP4H$K)/EP.CM??H-C*]I&@L1;#V5'T)
M@BC_.2%JDXB_H):DK&F.'8-I"<D(W:@Z5E>[OC*9O3>E^\![P,&E6_KIO=4(
MJ@:=+MJ8794!(J+%FYH"T6=P?3Q1]74F$TU8?7-U;)V!\F4WMX&A'4;UDW;\
MQFN#ZRY!/?:==\)4FHB$1D)_]\VNAF7*\:M129]FC77>5*1X88]@X=;C!GTZ
MO@M'+LQ?NVA-0L4)/\5_Z4^4*5C*4LK<_+1A^_J@:S(;".)6#F _>,6FP/]>
MNN\3M=_BS9_S#-D@'0"*C=4R=LB2Y<.W*]M#AI^48?DF)B)4&>4OAJ&#-G__
M7O%NG,.3:U*36<VY4Y/F *_BK!JC5G8$8B7B #!S05FKA[]DDJ3#-Y0V1&X;
MU-V7;>J6I6B[)WCAA^2:EI:\[77WP 8.LG+E]7WXJSDEE'IA,FU;60<E:"4\
M9#4P9%->7.T=T=Y5PFBVSD3"O*&[UDFS[<D+)DQ^FX@7S*1BJ<C-=Z-W+F^8
M[YA(@3OAD_N]#?GI%:9S3>=0QMSF!315/0UJPE-Z\KKC.UF/$J9DT_U7VHB7
M&DRYNK$/2FVU$YEG\W5CD_2R>'(WS&*\Y_TN"<AFG+6+.VO"LPT; 88JPV'Y
M3[HNR$)E34W69U/?57TCOXD;&*L>]<IY$EK<;ZR0\#GOVLW3JK^#P*>PBRT(
MNX.9X.W%Y]+$BQ*!SR^I1L*#=2NKZ"W=3J$7AYV#]3[E; 7$_DP"L;.QK>D5
M+>79O,TY#8LITP#_ UC =R9:O(^*\]VJ!YST;FXXEI=O#DPUDABV5D%DI-OM
MTZ@:+48VIJ6JK=[UVA44@0Y^#ROF;7U3?^3U#.6V(T%U=B4(EY%J@PB'1@ZN
MB'6QJ\4M!?"U.!Y+T**MD3$!+68[9>PR[NH!UO-YL@%F$Y^Z@MYT;>CH=6VY
M<O0HK6U@8)^B9'N[F=3VSIV)\&^SZ6E6 1_+'!J87=.AB\-[SE,I-^TP#$_Q
MGTPI([0M1]WA[%3UXNA"(+G( C+U("*@+;@WEX1%&7YPS14FL!+*%.K=F $[
MCI%G'7O$&S'MEL]>A54^+?<[R_:J,7PM]%!Q%->F8 P%Y->R=4#\IK3=[W<!
ME]V]FST.?V;W.')0^IOR"QUL47>D>5P0&6_:>X'LO 6CY"?4@W,5FI3T6>!\
M .;9"NDM,<+Y61@80)4MQ,I&!&BM?J7@VQZ*U*T(LY/XRLYX)?-_MV3??S"]
M9MB90K_VUH:%KG^P)&12__4Z>_O>3K[:]PM[8WYL=TNW;\@)M']8.OI1HY;$
M,@ [AV,MNU!Y<?I_M-_7.F-W1F<[HW-#(N [Y6\IA#E?HOC*\B3:FGLIP3D7
MA,$H7D-B+B5;;3'Z\2.7?J1939*CY8_87SDHQY?M 5B,[CO/ S*7'G^-;(%-
M$&92K6(*/86U\Q@,26F+OBZ%$0YSGRBAC24[$SG(&<LH>;=B/_0*D>1Z!:G*
MR-/_\8C+[ J9I[B;Z/"5 "!:/K#4H[A;$3'W!TBOQ7B6&V?)2K0N(B+5N3]9
M=Y>IU(CP@#9X%18S%%\#UDN?Q3UY[[@XUY]+]6G4((MSR*I$CQJ*3T 4Y]5.
MYHN5ZOH,Y!4"SY]UPOPU1E>)-/=9D(@JW:.18KGM+XD'?\O(0U$M%E+QNN7W
M->E3HHR];BB/]9069LK,[@Q]M5$WYE?!9I/BX5;GLYXAZ]KVQ0SGWX;N5S&P
M=AQ68.'0,B-H&-\=5$L_8)D'F/<N2T3WGY?NGF\#!A%0^[VI8KN7=)4Q&D/6
M=&==O>[TG<"'58M6SNM/F;>]XP/GJ+UN@0*Y==S O*?DMS+5-T[=HX:<4*"%
MQHZ@&$W-P^U[2W!WC8C]0:8++V[20UJ(A5.*71$MDUC;^Z:D;PA2X;[<K>9L
MV340W.)]:' 32U:T.(CC..A3M.8]SZ.%B#7_2G P@9J8E\?^ _ 0^K-"L5U/
M[N!)W :.6-BXU6V#M0+X) .;1F!77_'JJF<*2OIP1\J(/OV-9K%X\P_P(TB&
ME4"NYX$4ZM[]UGP<;O/:_7IF;&Z;BKO>]J@SY>GB"W8.CJXU:W\[]J9F5ARK
M]64"M@V(2&1,^$3G,B[N75 (^=:3^%T0SL)^-XD9GB@O")%Z%=*W*MLX1P!X
M*.#,;>RHWUG-[<ODT_8DT$U];OE-W,?U"&!*5O$HME9D3F 4 4VY\6'K$1!#
M 2/NI'4X?+AC81O.;:M'JT('@EPX4T_.+7"!25[5'S@E56XTWGPBUSA7WX02
M;1+L86\SL )TK"GA\^.^ I9>NBZ]"#51KGFDRCO-;U)P49C?QQ*BE 'FZ ,A
M["&&#XSUL%GP)=X"&:ATI<%V\TBBB(0"JY;.C?&W$D5J2UFK#"OH$VZ1/(?#
M7_<O_$]D).*?M0%![+QV7)<% KRB](Q%)/5V C]P<;.QRO@V]:G;_7P[K388
MXK(71;XYEO[;$><HRS(3WN,PY(I"V"C"S* [ <HI'/0&$C>;O@BU/_DML01!
MOX$ H2_Q.KNV"'UR=M M-.0IMZCN&I<AQ(-,V %>N>>6^C"/'#>K%N-YIT8I
M4PX-#6WU9.KRK2;(%;&E0V%0S?&;[07T:YK.<F<^L]P[\,F:)+3,Y>7,HVC-
MJ_2E)SXYT*<8/5O_QU>SI^F-DZC3.@AFR_:.&=+BB^&-.'$L@E[\1VM4Q%!!
M&O2WZ @^?//^LXA^*=?X9W,4\8S//:X2N51:7?E1M1D$/<N\Y9.#(,66WS/^
MFF0"E;PU[;@2/ \ZA>(U$0L=P^@>"9=@T7%CB\6L^7.4VW%(O"HH?PT0"<T[
M%_LIW\>.=E!R66/CD*$N6O$LJGS#E2X5KYG5=,OC_Q@N$T8F&#@.3^2,)%+N
MFTU3[BMR'W/O< Q=B-$P&3F3,\HU<X9<FVVN$G-W*(2<,V(DY)HH<H34^WZ$
M__D\O]L@56"PO(DQX -.JT(+E!& ,I!UNC^%;V &L#;3L8&O@DFF(R\V82E?
M*-,&YM_ HQG_+ZX51( _2P @+(H[TGX[-M!9D308U=Z\$&8G.\3B8G?/G5<]
ML,I] (@$H)OIR0M*IKG*^--8C RX0UZ43Y?4H-5Q6E22'$;<O&EGT:,.)H1L
MFGL:0[A&F+1):TF^;QF"N0.B*>U0_Q@PS)P4>O+09G=*U,Y4<Z(9K(1SINUN
M@9OE+G&ORQ',/K+K9),C(C3@0>6XEAM0Z#'$FHDVXSIV-<HI#N3<*;2T1^G;
MO2ZF$E.ZSJ;>>O[J<4'QYN>@SUP+7^CGP2RC6>Q+7.R^J@6]T9VKCQ_.\/T#
M4';G03\:_)[YV,66M[.YDBG L]8O:;-%)'.[0[HBV;PC2@F:Q<_]9$M-+GSE
M'T#^2NEPNR7DE\KRL/Q,H AUYC@O7=_OS1@<X3R+7F^^^F*EA!A62',)K>_L
M<)S#OI-&V+8RN#"]%Y-4?N_$/G&[H6M*2'J+5-H\T ="[@D/HK'FYF!J>1"W
M/[(H&VD'-1BSLN9!=4;++@!^#M)GGS0AM%UN/F@W?(:MSZ(S+L\@L\,$7WG:
M]T/]Q>L#*RC+T.0)1Q&"35VCB36&1UKV,??< &.YO3#MN+=\XM-Z ',HE:N\
M4V<O0+!%GC#9[O>EJKJ.K*FMH?5"8"W"3E#^*_/<-C)&,JB..NU>W5IVO/J4
MF0_]58)MKI.3;O?OB..RN>?<WLTO0?0F4V+QU%PK*'09+%5#ROAU<?TY/DSW
M[_=@I9.^?:\$-!'(Y!PYU*=1N=!F$=]]IP!]@8:W_)]^T=1P. '35>=ECCWW
M=+*B? .U@KPN_NY@_7SFZYF[=ZX]>FK;4MZF7JN;<*?^S?J$4WN/?(Q=<[O+
MY-'-VMHJ0EEM;$E2>1)-?D\]A""(WSO[XB1JP-- 1/+! V^>?(6V5&_T05">
MQO2S.W-NH<R&MIF5\C3VT3T;^/J=E\OZ\+P\#\%WTO1R%2!0NIK;9EW\DFG$
M>/M[YRDZ^ /JS1!^PEE$D4S#=B)F2V'^6,[['R(N;-Q7VMX B=X>VY8'Q,/9
M9V#V;UR@;U%3=?\ ST5J*ZL@SVH\S=7KN+814/KUY#S3<DZWFRF3N(I($YV0
M+Q$WZ^KVC_R?G+0-,&+LE+&7/2\0@5N"@DS,/>*+N@.G'UK5$NBW\2T7<@G*
M,&-"$I^TMM/7UTNW42[Q3 8?M9QGS<G8/:"OVXB-/U:*S$CHW;Q_^;I] !/>
MX^IGR,BH0X6_1X-;)A 3L>SC>1_X]03.\Q<34Y]&]YH]C6/YL;Q.G5ZB_ /@
MDN28L5&9_P!&8_I!XN&INN>O.Z@<A[7E]<J=,CIUZ]MW#N)AKWYV-ZG"NE!=
MSAC .?*I7R'8R.&$?"WT[+1)-GAG:S\KBSS9<M[ Z1_@\>[7S^<_\WX]?-1W
MJ5E>A)TP(25;0SD,%U\T[RX[QSJXH?[NPEH>Q,11H'25R,D6$8AIB0[+.*OP
M!3_B!/I]5S:HFR_LY,_YR *J-<?%A"_VG[_?Q:SW**Q.J?EC>;^&-%AWDFW(
M]L3ZVP_/\./0J<B[ BR@FG@MWN]6"^&YT6UA?T\,"U^5J:*K(*"@*1^^/'Z:
MMW!Q!(T%W'P:R"-;AWJ4R ]>!K1ZKCTT:7-NN8R\4P JW:Q=7]:<DI>!N3YS
M+SNM0<MR1]R!B]TPE9.3^_F#]H?:A.KE?Q_ZD5?&@Q,:64+"0D">"/>:?,F(
MY=S+K4P\Y&F_8D9TK*.AO_LA;-  @G=R5Q$6O\N(U*)[MZF]WS_.:=%,I'>X
M61UY!%*2Y^T1"/B%F?'GO/I*\8;AV//(._,V]UZM?9M#W4"P7F 2"^NP_P##
M!Z<Y8VMA2K4P84^,<9Y(UB#01,!';OO*SG53U(PVJ'8F8V6S\5<P^L;6,D('
M.EW#*=_N0_Z,;2Z6E^-2%"U5=S* $8+.NM4W!<V^3W-$[<8WJ\7Y-*?&X\P$
MNQ^Q<4IMBCG/%M;4P V6%&NE>]IGX;1X(_G]D=YR>:GV6-E3'C=TQ!DN[?GK
MO,//NT-A$[7RG]&V'QVQ50T@Y"-P#8NQ)-=F-V_/5$/SQXIF:+.#M=6\J9]/
M&4-P:$]@B< ;E^6)[#2_A;,/6QC^DM6D,)-!H4J2@\N5L3W\7S$/QTSXI!75
M9:SG4TZ#XV:@R?\3"'M:J3"AJ5_G'T#B#TCF,:*=)CF%X7);EP-4J%/?7GJN
M,KW8CWIM.\-TJ^J WA1R@./5WIQA2_PC+E?&5_O'^JJ78;2]4'LW;C)Y[8<M
M]<3FC'Q1%,Y(V<2Q&$#Z;/:I>.GCMM!-+$^X0BGIUH,1I;B9Q[.LLT\_6$2/
M !C "SONR#%NQ],F(5?/. 05]*=_^AGM#]8,(A^ :NID'0BW5;2$ID8)2E($
M?S/":7G+>MMRN5S+"+7D#!.^LXY,:_Y@VWBK['-981E_KJ.U&L[Y_19LK#C%
MGSWAX3S&JJ,/N-::N];D.:>A,BM6CJ7<%;C02)P4Q&,#R_FSM''>*V8_&2W^
M-3PS=9'&7/5":TX^0O5.=5H#E*:K1?E^Z\P584=:P&EK)2X>F\?63I;GQ1/R
MWY0V3&QJ8CS3F<EB2 _B[<::.E-C>Y4\\H$CD^'>M'9Y/"^K-&%?VI=D''8#
M,JO)T72:8VV(-T;*#C'\"CKYVA-S8Y$X-:G"=PDZ22G#J]U XA>4XO2D;J1$
M.--SV[4ILP@#<]#[] G-B?%OT>J3Q?A:@0M)_X<2?J.OZ2HIXS.HA?"7T\#_
MB>&!00@9 ?OREI$X?X\ 4M9T]*,E($ X$C99P7'VR$?79"BJS@F*T VE4KX<
M@0JM'=&0;5%L2CM\67]B2V I4,NXW^3U^0^HJB9>A5QAO>0X4GVG,ZB^L=R(
M[*3870VARS5-01^SLR#3*NS%@JZC"4A&34,+#,Q+GA(EU1!1O3-6N$4&YD,=
M.(N+"7S\0]1BTOT &%'NT27IW\$('':CS+?"W2_YH%4Q9PP%UE'+U.1ZC=!F
M2$K,7*"68)F@'ASG&YG<0QP+KKF#UP-3CXKRR,_N*7XX0&+!9Z2!%WG6($:L
M@*]>8B$!SOXWO (H)_>'C@UZJVW=5?C4K:O7W2*>B5^J#I5^+H1C1?"QO]V^
M\4!83.%J9DK&0-2%"76;\F;T<%IQ<P56BZ@MKGP/>K9#390H..5+<I-]?R?W
M:'*)@)<G= ZF6659EP31E2I;0<3TEU]USL), .RV2IP?;&_9L_2/\(9MD?W)
M,RG._-5<O[T!:L'>F8VJ)9TIYRQ*]HG+[)05H7#ERWIU17,8*PK5K26*8!.*
MW0OE0FZ0UE1XC*KK2!4^U5](/DE SS,&"WMX_LNF:'TX71IK)5L^AG 8-T4H
M(:6-[?1*"8H5/B!6N02Y[3.>,06'RJ$3:&;[B:@E#(/^,%&>J[/64K<RX)Q2
M4L6FM7XL;VQ&,)92XI>":#:H0P8NHGB;!I5LT!KCT$3IIC)IWO*FN,1R+GX\
M  "( RQ40G\[@11C:5?50F)C^LYTF0<0N\:)&:\^\%90DIN;M2I21,D59'-W
M'NO-[:9393[<4&_;GUHAL;]..GTO=2=X_<%1C'OT*SL?UCA_SD[XW9]A>)/2
M=[@*>\MP9I)ZKZ_.?!<PEHCZ^U<KB M0(%K<AW\\?UVU4)61PEL#\W=7 _]_
M@#5K[LUSZ3NS12[<3G8/?JYG!4Q;67.3?ZZMPR9,RL': .^< W! [9:XG4=#
MN$OWZ*)@6H) &A4^2(9&RWV,+?&WF!<0C(SA1[>XYU:0G)$;-\LI1E+Z]LW2
MYB!) <Z+4$%MDW?V;Y\N6HT?$5\>X:\[.4&7^S,(P%_!G#9K,>O*&B/M],M-
MMLK\2&B<R:MNTLJR&W5N,YS"_H.O"WJTQCJP06S1N4'"*"2];;B4?.X'C^'6
MS) ^0=K_'KF/NQR((Q@EJ//+V)XHW I*%<4LX-0P!7T/=3;EMNYG/]V.\PYD
MN;0I.O(\?^Y-K%[;H2(;,R.J^&/9F.GP0[>P7\.K!QA&I#=D1TY>+OM\CJS!
M\5^)3N5'+%<Q269O'_]X>>IAV+4CGN^U\1DWOG"4-K:>.Z5ZF&F?.<?8[U_*
MRF=*[J;]J:I4.,!*O<NF!Y-T^@U6;Y=^2)#/#G*,8ZM1,(H[<XXMRRJC._BJ
M62E/AWU33+F,U>=%PU'#A$_/92QT:E^/>WP-R)WQ?((F6$4A_<M.Q.,+^9O'
M&K/.NT>2[V$%7T(D(,!EV;X:)'\A1$RF?@>6+_QL.<#/&L-HGK.I[_*LX5HO
MJ\+ZS%!F*$G1X-PD8  (N'[^W+F>D>:Q:JC6O$I;<#Y*PUPVU9Y$5X+0W&HW
MW U45&V_.KAK62 6-4J3DA!_S$RX-EJ0(2/&Q#K\_HR"X_^XDN<Q17'QM0L
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ML(>O+\?=_1'B*/?!W(MQN)1(H'E_ -P_QUB4.[J4\!RH^@'[R=/G]O)D=E<
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MN=V^2V:"IHI<XIGQ@J_S1>!A,LEO4T9G"M9ONO+XM8Q3)V>R)_(%%H,=R]F
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MA_@*< ]P7[ #U3@&0-[,E#=.8$Y?RCC"5%H:R%H&.AM#%X->"72X=\+['3U
M]]S(&]KP]&>C.ZT9B*6,%W69AIL(Y,X%GN;"#+B?)MN7,UN*_;B3\-"K]<VD
M[>V1.NP^=37\:M"?@16AR8I?9*S\NQEF7PD4/\B)\7YE;C;^TL$2,F^C\5T+
M3^ MX\19AR#1ZQ!H!0 2?,ODZ26 Q-^J(TL2?2.W5E:*TXI=ROB=Z.I@V]<
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M"8_+T+]V$@\1I >1!SDH-</QO::5,Y![*_I!+7<X^TQB4KIR]JI?N<^^:]M
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M[/\ S]2CH5R1YOI(RD'EIK,=\C-E^\>N.%YCD+SW09/)3FZ,#!Y;ZR(SL/\
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M-36S;]P.RXA*/AQ3RSX<H_3$C1\^4!U^ #7$O&DSZAOF6L3FAX$<FA,22VE
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M_)1K\*;Y7?]]H/K7@.8&T2_Q4><H=A_% !#;2(OBR@+^>><Z6G6V1[9C?\R
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M&5 <;@)41,L R?8QW!#=K[J!FE)M"7%W0M2^WX^^/Z)_\'YF$??!!TD[>LF
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MT2XTU#'=LK[CH..RY5GH?R&$)+(]YF:2SAV2K/:\FR47*OF?;#UO?W6G*V!
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M-'U@>1/R\#L%JDJP-B?((J 86,12:Y*6#@\[C3E-GMY:9X[[/O%&78A$A@
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MQ$+K5,L%"#??YR6KUP1!,[5;ZY.!G&3#405^RY Z/@);HI<;DP&Q&$Q*M3)
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M<NZJH1#]XLOXE5P]G%?W+4T:E_QVEX-C153!%/N7^>%+N[JT;*K>0498[+L
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M<7-K8#+VV1\1KNJ-#&'E4K+6K_HH^7J12,FB;L<./G[0VENH![S/6_%Q5SP
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M\UY"6%D$J_;RI91ZMR_XMQBP&O%AV^-M+O96 %C.'T; +)' ]BQW":G*V@N
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MT=C?V>3 ?>BG8(56OA!VI@RCBRYW6M%!'YBPBT\N]M[7F3NX6K+LH-CI+F?
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M+Q?$ !BN955?GA507 A;MT)WE$@$I4J7R9FD%$U_B>P<G</J?FC!M$8O 5F
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MX973OLS*/>3_0XDULOCIV; E'_N?B7<ZV88WA,<I,1H$/&-J2DU##QAJ:%3
M.R-%,7BH*!E?P(J6(HR(RYE5;V]*[PVV"U8&S @[/H&&=-7W;+V0"$>^(U_Q
MR<AV((&#P7&7B>1M"X;^%"C\U#B7*P8:8Z M<KUHHB?8KCR<FM3P-9T1ZG/+
M#H7#$9S.5U7U=@FG?OA/42$ZS,X?K7P0RI'U1.JK].E#"<2_SGE[ZHI3TG.^
MFHM.=)P*FZIL^1KXUTL1X?@N?GI]P=77 2N1GH$<P)]"LUW$\8R#ZB9:,RW2
MS7%D:B_BR#&2Q<RGQK%6]TO:+.OF'P[%B9Q?35K]>8^<,]*,>@V8/)7+7O;7
M2F_8'[VK)T@?S&>EJ2\F172[D: -:AZ<%K;V**)&\ 9_&'"\X.MWZ7<=#_[,
MOV.#03=^W?+4;=FW9=$CHQJDM]Q0-VU6X+:#2[P+_O+:G-2DV_BK"8&ST*;:
M^<7[S]W)5@USJ,7!$J4Z!]+P?;_=Z<J')7YC!0?%O]Z1%L P>WL PQV <+*:
M__\ $T#LO\A?2L%05\)Z5*N2+"UK?"-]\ 6M??@D=Y9IGTTRX;A1(Z /!<79
M((SU8W*@"D@J%@=AW[$>R]HH1^1&@F9DD(E(8KWBH0+H2I6JJXL!/H$J3]?+
MBIE392FJU([J]_F'_P#R7+Y&^3OOL?+@=K\27.H=6@T^0J)-ETV9'B2FU=*V
M9+K*T-+2H6Z5)6H'JQ8_%BW%2/9O]E#4-1HVO]0ZF0X:XM^909-*-64Q6GFG
MW&GA+BQ$$/3F7W@T\M0>)DY4AM8!(E2B\HJL_I*O:'UC4)LFF1*Y?2YJ;:7Z
MG3H;#!:=:D%]2E.->,X^VPVM0<;0"4J #9$HZ?T+2=/PM,P(]6U!*BT L*7$
MDS4"+)2T@MB.$,--+5$2G[C#RG0#9*NH"QE2'2J?(0OIEI<47"&T^,U'>;9Z
M$]+A;D)2AUP+)#B \G8%*B";&<#3K3,9KJ:]]CAM;SDEA*?%*K (:;1U62XE
M*BKI4[TD)4";@$YR($=E4EQF*8R4)9<:=4X'?>T.KZ4@.)2$@ILKJ0FY;4E:
M%DJ!/"-MLJM?;UQ<&^^//!M?([=U);&=_,F_R%B, XV&Q.^^,>BQQW.3VN?/
MRQ;&]]K@\9>&1N>_;)L2+C^N_;RL.-@9!L;=[F^XMZ6SM;L?IQ>;DUHJ'2-"
MO*J,5MV3K",M53:>0D$TAYEQB/"7U GPG8[JWUI5@EU)(N 1Q YY<IM>>PWS
M3?UQ3-#R]?\ (ZKU!<J+4X");8H:0\X_3/?IL)N7*TGJ;3[LA3$&M)8>@5)A
MMB0E*7'9<)!95?TJM.;T))@Z<K$Q^LKA/1VI&M)^F1*I#JVU(255"EO-S:N[
M'^%2%KH$)]Q6%HZ[DT!Y/\KM>>TQK^J5^K4ZIHT#4)[DW5G,"O-RH[M>7*DA
M^I4_3;4U*9,^74V08#E57=FGPW75I27/";X[7PX4>&PQ%CM-LQHS+;$:.TGI
M;8880EMEM"4X2A"$I0@ 6 2!C@CB5.(A,:CKB>]29:G7(C2VNI*GV>@O):>2
M.I!>CJ42PH&ZF0XW=25#AXTI)1[PNC5IN53J7-GJ8D74 _#?3U-MO-=:?"D,
MK2I'4TX$^*BR;-.)LF9#RTK^@M=4(PD1JWI^K(C/SW$% C.4QQM9DM/QG%K*
M5%8;Z&5%1ZC="OA!$]KINF^MDM4>&W%@N%V VZRR\[$41?PVG5(ZTM!5U(;O
MTH-RD).>,*IJ1F(W9UY$=L@@)2;K4+; )((L+V.,>M^(ZD:CJ%:DI@T:.ZI3
MJN@.)2IR0O) Z4I!(*KC:^2!GM/6A>4$>B1VM6<QJO2-)T=!2ZY4=43XU/;L
M0%V"IKS0N1<=/5U$FP2=B%>W5H_EM[5'L:<U>5O)'F;I^M<Q-*MTKF-I2+2I
M;:_M"L:$DJJ+]+\.R"^S5J,[5J8T\PIQ#4J5&D$E#:DJ_(?R,YMZTTRYJ;3M
M.ERZ'6ZC+ER)3D-;D*2^M/AM5&F2U-J0MQJ\:XCGJ"74K %U'AZU;K'4LNK4
M.L,R)CE1I4B6N5,2\L2_LIYELRPXLW4ME'0HKZOO!:R;]1LY.<J]%ZUK;U E
MS$R'JW2O>*%68MEO4Z:ML36TK1U)#BA9UJ0R2G#8*% F_#12.47,6AK@:&KD
MV@HI-1J:XE+GMU9I]V6E8 <;CTQHKGJ7(CME2F5M-I04J4XZE+95PQSN7=6:
M=53H]'2S5:!)9JL)N&T4M3-,54^+"G,+7\2VPVMI2RI2BE2UI5\22. 76-!]
MVKKB5J9>=+;1>\%:74)<Z1=!6W<%2;"X)N%8/GPSL4N]@E'2 !D #M\O+&2;
M?+AX9HQ.>D["^+X-QG%A?Y_NX>6*,K8(LD7OC^P6'S_+S>6* 5]-TVOZ"U]K
MVMG<"XQZ<'VGN7T>H/H,TV;-BK )L1;N,D&UKW!)%^)LTOR4H+51ILQJL.QG
MH3WO+2PV@E?0L.!@_$!]X!(VN,=LVMYJ5S3',!W1M=K[33]5TQ3F*0CW5H,*
MD0H(!9,AQ)ZE*;* 4DD]-U6 '$'ZRYBMLT\T>D,B/%4IQSH:) 65DV*U ?$H
MBV2">Y)M<U[6Q)G2 0DE2U$J(S<DW-QWL;BQ(^9-^)MT+IF@J\,51A"U!(Z7
M2E/6EQ5QU D*L +CMO<]SQ/^CWZ#H^EUJCTD);C5]*VYH(0LO,D$.-%1%NGJ
M/5T_47[5*]I;[*IO)R;1Z;&Z&CJ>A/I<403FK-$VV&;VN!L/GQSR*NM15V23
M;O<VW/SV&;VW\N"W0VL*CH74T'4U(1'<J-.:G(8$D.^$CWZ$_!6M19<:=ZD-
MR5+;Z7$D+2DW%N#W4_.C6^K850I]:DTQ]JLPV*?/?;IK34MV$Q/9JB6!("E+
M2TJ9%C.]%K(\!"6_#3<&*&Y;U-F,U".PS*<9"R&'0GH62TMOK 5\)6VI:7$!
M1L5(%\YX7"OUU5-D0EU>H&#44-+F4UZ6^ZPM]I0=:<#/C%H.M*ND+"561=*<
M$<,A0E0^( FQO;UWXTF.+&Q(WMG;R%NUK;_NN2=99S]]6^VW[SB_J+#'GP_Z
M1:OK/12<GKU71Q<[#]LK8#?';OGR/'2J(PA!&V;F]@ 3>X&P)M\A<<$Z9Z8\
M52E'I0A(4I759( W*@>^?3.;$GCJA[-M9\7DMHMQ+[I2I.H.D@&UDZJKB1:^
M;6&/3BH]43:J5&U_]_S<7'_C*Q8D=@<]_E<91I2%9!N;Y&<BUK7..]_6V<WX
M4QG78B_&BNN,/GI_:LK4TZ2#C]HGI6" 20;X!-C;CQ:U+4I:E%2EGJ4M:BI2
MEJR5J4K*B2"2223N;G?8RR75;?#>X/8GMF_?.?+UMP],1DMV*@-MB"23N+D6
M[WN#<9SM;AZCU&5';2TV^ZVA!6M 0M20%K";A202DH-L@I^1&Q>7JDF;'892
MH MI25H0V6FT*2FUT)"U745%:S:R07#BY)/C"B4]-MMK8Q?O?/SP3GOQOV_C
MSL/X^O&003O?TM@?4W_C'UW6 O8#/\6^7\6X)=(44Z@U'2:58EF1+;,DBY"8
MK1\60LD7-@TA0OZ]SCCH; =;2RAMH!"6T(;;:2 E+;3:4H0A(P$H0E*4  [
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M4GT[>>/KQU+]FUI">2NBTMN*0@#402D"X &JZZ+7[\5MJ;:?M2HG>T^9<_\
MVAW)/?MZ#Y<)!VQ:X!QMM]/X OVX\%R,C&18W)_$_7(\_3A0RRE6^VUO,8))
M^8%L6N+V/#LVR0 4ILD6L-ABW8[#M<;G.>ZP7/5@6OCN0!YF_>_E^8XS"2K
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M:CJ.MJR*A6GA*>CMDW]WID VIU#B"Y"(T!ELI  *20"9[HFGH$!*41(B&2H
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M;6/#JU#4JW62;[)&WR*CMWP-[ CL>'-F*A*19(&<B_?M<G<>=SMC<<+VV4[
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M7QY%MMNZ"99<+C$F!7*LS8CH6D/(B.*:=;7A2%@$*0M)RGJ'24WX-&H-.TU
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M*189  L3@"^]L#<D"^0-^'\U@I((<-TF]NH9P1:PZ@!Z$=[7 WTPJ[)34'%
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M'*C2H+=S>NWR/^4M8\['\AQSWGN!-5J6,+J,L7V/^^'?,V];C!S>QXV, J4
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M(H=*E@OU"JPE-T@^&E+B6YTV3+A16W7@GK3";<><+) 6ZE:E-(D?2GM6NKJ
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M@DJ4HD ](W-R!D@ 9'>XM@ U;U7/KU3:TKI-M3JW5(;>>:MTMI4H@K>78A(
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M-,:3AU5,;22]1O42G$M0)&H:F9<Z0$JZ?>G(\9F'#B=:;>&RS'"TH-G7%J4
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MPE+TN-)E@K#WC*;;\0*"@I*@(;U5S%U7RJ>JO+;5=&2#74NH9BR8ZI-/JGC
MLQYM&6EM9#SJNCH+2NI*N@N#IL>*;OT_P)#ZUCJ?<>67"LA:^KJL0HC!Z/NC
M>UL6%N'.+!2A(>=N#V3;M@_+:WKGRX=$!:RDD%"<$ ;VSA1L=[?+RS>S@RC/
M[\7WL;GSOW\O0<.L5ETK2M!*.A22%"X4@@@A25#(4E0!24V4" 0=CQ8?1G,]
M^+X,'4R7)K Z6T59H=<UD)P#*;Q[X@"Q4L%,@"YNZ;IXL[2'X-2C)E4Z9'G1
M5@!+\98<1<@&R@+*:6=RVZ$+%E7&.#^!I$:AA^XP3!1/89JE44_-<+3:&(U
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M"/WD<#4M)P3<[@Y.#DYQY7((/?@=EH)3U#MDC.;@I[6-[#]_;AJZ3D6V-@2
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M /J_4+&IJHW46(28 ]T99=90EM"%2$J<4Z\E#0"!XG6GJ)'4XI)<7\2C8_\
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ME(!)(3GCEMSEYDJYT:^5IK3TA;O+O1\HH<FQ[J;U#5F5%,J8T!AV*TZ50Z<
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M2:14)E,F-K:DPI#L=U"Q95VU$!5KGX5ILI.2"E0*38@\(>)N]F0#_9)<A?\
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M .7HUO6^1\K7MOQP>CLOR'&V8[+LAYQ=D,L,K>><L+V0VV%+5:Q)Z4FP!)L
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M$I3<?$>]\7^GH+#/<[8P=C:K&UC8IL?E:U[GS&/+\3Q;?EJ+Z)HASM4=B?\
MRM.]1^X?+BL=2@%,N63U?[Y?WQ@O*-[W[V%K^7KF">?'-2D\DN7E4UC4PV_.
M64TW3E**[.5BNRFW#$AMC[RFT!M<J6X$D-1FG%*-RD'DQRRTC5=45VI<X.8B
M5UFN:@JLB93J:\XI!KE6)'AM)4H%4>BTI!:$IU">EB*TB,T?%<0!?+1&E0A<
MC5.H%"=/G%L..E'AB68Z U&IM/:!*8E&I[82RRPR A+:" 5/..NF3@\'2Y*D
M])8;(;#+8"4O.H%FX;0L$HCL_"'NG?[MQ?'$W])5[?*M%IJ/(SE'54/:]J3#
MD36VIX#J2SHZF/H4A=$IJFC8U^8A5GWDK2FF1@465(='@_GMZ5--FY4MQXE;
MBU$J6M2CU*6I2B5*6HDJ42;DDDDF]U]%92Q)$D7*@;]9&!D$9M?/>X_?P3SZ
MT_*6EI2E*:;Z5R%%5^EI)%SDW&;!(M<[<7,Y3Z%TOS T,I^E59VC:FIDWH86
ME:4QY<;I2LN+22@H6VKJNXA5R>QO?BS>BO;$YV^S4G0M$Y8:C@4][EQS'JW,
MV)-<I[%0<J>J*WIFE:.JJ*MXQZ*C0Y=#HT&.Y2WDJ8+J%OA27% IW1_TCGM!
M4^/%ID5OETV\:?IBEUZH_J9#55=84'2=(U#I^AT'54I<@_:%(8H&J:U1W8S3
M<4OPY*0XM3[2'@\Z._2&<_=*MMT_2T+E]IW2R85:I8T51=(MTO3*Z/78.F84
MJG.,0ID>>IIO]4*),8E?:'VC[\R_)>F/*DN]9G0?;H]H-VC55=3H.AZI!GLF
MF5#4C^C69-;?H[?,.)S0BZ>74U22INCP]60V9$5I"$2&XUXZI*PAI2 /7W.[
M6//C7\;7/,.!37G#2*)IYA%(IY@QFJ70HONL%MU2W9,N9*0TI7CSJA*E3)"R
M/&?4E*$I]KD&FI++L)M*&5)3T,[J1ZD[DF^0>XOVMP-->$'%(2D=8.;C.W:Q
MWO\ 0C@GI4-;ZDV22GX2=]^V2+  7OV!)^?$F4V E ^[ZV_UB,Y/D ,8P; #
M@T@PQ=-P-K@':UKC!QW/D1:X'![2*<I90X< $!(M<;CXB+6MOZWMVN.)&IT,
M72H@618YL02+_(WO?'U[C@R@( (4<D[#-D@ D;6P>_J;#:Y,(CP2E-SC L3G
MRP+[=]L6[]B&)+4@I'5=)P+WS_A8_7MBX+(3Q)2GJ!!Z;'O;&#N;$XMZW[6X
M+X#161B]RD9ON-[GTW([B]SP3,L!-DI3U':Y'H?+;&/4#/"],)U0V \D@YWM
M@6)M^'YCC88#@[B_U/G_ .:,X\^]^$2T*;44J%OZ^,4.A#J;*'4#>V^ 1OQ)
M>FWBXH$$'J(*L>EC@G:P-A].V)8ITCJ;\-0NFUSU#%ADWO>^!Z[7\^$,GPVE
MNJ9/2EU5EI\B;FX. 1N+$9^G#2J:VDA!<2"J^.J_P@][6S@=\7.?-8S*%P1F
M][GS_=?S&PS<GC8^^AU 3O?L3L,_,8M>W]O )6$-I2X ,=0)V]/38YN?+-R#
M81K4D#J4!MX9)OD@@D9VO8@?AY<!4T?'?_SE8\KG\.W;^\M2A8D?QG/"MA/Q
M(!OBP\_Z)SZV(^O%3OT@2;>R]J0FXOJ;1A\SFO1=]MR/QM?-^.-/*#FE4>3^
MK4:MIM'IU<>53I=+=@U%^;#'@3'&'5NQ)].=8FP)(5&0CQF%W=C.2(KB5,R'
M ;":@]L1G4CD^54>0')YRHSF51OM%4.JO2(T1*YRXT:.F3)?"4L>_N-..K4M
M^3%9CQUNMEI+P;%>U;3"ZIS_ &/?)8))=_9BD2_"5XD(Q M8+EU/-WNAT$)$
M;^:^#XA,OA;*]L674:*BAU/DIRAFQ(\ZIRJ:C[$<C,4J)/G/3&J7#B10TS[G
M%2^N&5.%<R7#LAV4EWK>5C4_;!?ET"L4*E\E>5>F_M>GTVFJJ5$@S8T]B/ K
M5#KJ[++BD.+G3*$S[R4)CI5[S(64J64%+KJ+VVJGJ^5/J>JN27)^O5F>I856
MIM)G+J<2/X%688CP)+DAT1A$^U2ZPHM.I\2.%N-N*=*FU ]L^D1J/36*7[.7
M)NEUR,Y5HT^?#I3C<.=19]"I%':BIC@&6W-"XM6>D2G9KK99JBF&V0OQ'R(U
MG5E-YMR-&:MU#I;EMRLT-I>L33*B:2B(9J.H9@?AR7$U!@I7+>!$=F!'=?+4
M)IA4A33*G2ZI;1RBU0_K/VPN4&HGPPDU'G#IUQM,=OPVDLA]U#00+ D!"18K
M!40;^?'ZJMB;&Y-QZWMOVL,^9VO\O4V!!!( (N-[F_F#;N!ZVN1;BV?+;&BJ
M+_Z1_P#S:=Y<01J&1$I J]3J;S$2FP!,F39<A8:8BQ(Y<=?>=<6>E#;;25*4
MHD >1-AQQ(YDZOE^TOS3EZKG&4SRJT;*=I>D8-EI557%N'I>B122VNK5T,E]
M1L#$IC04\M"&3U6(T/I-#ZQ5JFVS&B1&FXR8["0F-!B,"S%"I*+ );2;+G/)
MLN3)6Z\Z5.+ 3+Q>7.>2T@B.PPV@+4@!#5.AC[K;21\*9#B+I2A-K$W5\74H
M\L/TBWM^4WD-1I7*/EA,;E\W*]2G(ZI$=U#C?+ZDS6G&4528I"R$ZDD@E^FQ
ME)*F"$37P!X25?FC9$RHRI-3J<J1/GS'G9<Z=,>7)E3)3ZRX[(D2'E+=>>=<
M*UK<<4I2U%14;GCZ192D@&QWW/XC:Y]1V[VX=8J VVG&2+_/RVM@9]>QXLC[
M/>E*!-KDBJ:H@QZE "2E,24@+:6!<$J0JZ5"]K Y!&XMQ8G7^H=(Z?IJX&EZ
M?%HC8ZE!$!#<=(4=U7;LH$FQ).,9[@54->J%5J?[$OO6<Z5/J)4>D^I(OO@$
MWO;@FIM#D/2W90))^$+ZU7589 L-O/I!L+7QQ(],IZE]#24A1)2F^V#?RN<#
M(&V3; '%Y>4D>%#TVFG36V76E74MIU"%-J!%U!04+'<9(.1>X(X*-2O:4@4]
MQAB%":4 >@,LMME*E9ND(2""%$7-P?KO7I^4])G!#"U%GJL;$BP)L+#RMOG)
MM88 !-2].2Y,I!:2I;1MU*5U)%R;FUP;^6V]N)CI>G_=D(2$&]D_%;IMBY!Q
MC%@2;Y_#@TB4\ IP+C>PP+]QC/UQ?UW+:;3>HH*DD)N.V59 %P01TW[?X<2!
M!C!*4I L +$;>EKVN/3UL!Z%#".AO&YO]T7[;;7P3];9MMP\Q5E* H@"U]R,
M6)[ WMFV.%WOR&_O$B^<$&UAO8V%\[[CAP@5IOQ$H)"@K O8D@>E[7[_ (7X
ME:A@R VK<6-_*P(M8W(OL?SOQ+%,B$-I 'Q* /E9.,G'D=\X';@UI]-4Y:R+
MJ)RH[7%OG8BXL+YM<\%\:A@I!4D':Y(W-@=L >1 O;A4JA(4@V0E).UA97X]
MOI?\. BN4IZ./NW)/PE()N,[&P(]-KV%P-^!)FAR79(<2'"L))S@'.Q OVW^
M5S;B5-'TN0E?Q)&X! &;DX[ DC!N1B_IQ,46 66P.DDE.2D>8&!VQDY %[@9
M-N!RL-.-$@(-E7 M>QL/S%CMV-^ )^"M0*UK<4ZI2U) 4?V9OL0,6-@;@DD"
MU[[N]/4^$E#ER4@6[&UA<9&18';Z>7"UZ0&T$_=LDC!N?[AY[]R!P%U22'">
M]KWWL,8'T!%]^PP#@ G.W4ZJ^P([?$3O^(QZ?GP'3%$K&=QD&W\=R.QW/?A$
M4@F_\7['A5%3U+OY%(_$Y [7L/PSQ4W](,+>R]J(>6I-%^F^H(W\9N!^?'$+
M05-T_5]<:-I.K9Z:5I6HZCH\/4M5,H0OLV@OSF6JM4$RE,2DM+A05/R6S[M(
MZW&D-!I:E@<7AE<J/8B;E"DP^<5>G5!+8E,3W9\:GT"72C5UP79$RI/45Y5-
MKC-&4UJ"+IYF+,5+<3)H[TR-(0PZ_2OFEHW3)G"'RPU!5M0T-BB4.L5.<X&8
M-8;ZP\*ZTU'C*44"(^(G6TR\J4Q$?<="RIEPHC:GR8;R5MP1,6S'\%HNRW7I
M"5NH;2B0694A*'G[NI6MSK4\6U.!OQ5E)"7$D#^,\8%9[#'K_CQ\%YR+>9_C
M^,\; XHIZ HE%^HIZCT]0QU=.Q.;7_/B</9CM_LE.0AV'\J>F-S_ /'N]\&Y
MO^7;C];9.^!GY=[$'MVOG?.>/18[8&+CO>^.V<"_;!)OVXMGRWO^I=&R/^,=
MQ?\ XVG8P;8XY!^VSSB>U9J*5[/NAJH&&&G5U#FS7V%++%,I+;WC-4!;C25*
M6[(NAV;'9*G9"C'@)2I3JTF).76B&%)@L1XJJ=3*9$M&0Z$A=.AN!'BRY022
MVNN5,A!>Z%+4PV/=VUAEL]<_('BF-!I[:&F&4E,1HCI0VTE-W)TBY&393@+E
MUN+LHC* :">WU[;^G/9-T$K3FF7XU6YOZLA/_JM1U=+Q@I>"V7-85YJY"(45
M?4FE0WB#.?: ""PEQ1_*S+K&H];ZAK&L=85697M3ZDJ#]4JU6J+BGY4N9*67
M'7'%J)Z$@GI;;1TMMMI2VA*4( #[TI9:LG%A:^^3OO?UWX;F&B\^I9!*1L3W
M^8%\#MMVOP518?64I( !MV-[6L;X-K>G<V.+@S3IRKJH<#I8(0&9$V;L!4D7
M(/2.Y))P;A)N-R+7(W' ?7=0OUN=[LN2I*5*/4KJ)L+G-QML0 <@?/$H:2H?
MN;$:4Y ,V %A*G6P%**L7*@+D[FU[>0%C<3"_0Z?&83-A -MR4I*VE?>3>PR
M+D@Y)-[$&U]\N%#BMEY!(%@01T@;@X-[$^>^+>G$WT^M.4^-TM+*"$6( (WM
M:V!\R=AVP>!^HU:1/?2AQ:E>(JW42JV03<[Y["V_SOP<Z:T\T\XPMY"D-A:+
MR$I4I!O8_%OD6SC&-A>]BJ/I5NGE#CZDKBR4CP7>D=.4@Y ";;  D]SMGA]5
M 2VH] 2M-R$J%B"+XM:XS8D G;S/"Z)"3UI*@!8W(&!Y]OZ\B^PMP2QDI"@
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MR +D>F/P]!;/'JE=*2HVQYGA@J,D!*K'XBDI&PR=SGO\Q8$?B!5%:0CI-B0
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M;]P%"X)(%SMC<6N.P&+=^#VGJ!21WN+)-C?'D<G& ;VO;%N'R,^65YR"2,'
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MC?\ <1P=TWDQSD0 %<I.9J5 @GJT%JI-P<WO]E#OC8_NL<1>4'-X(05<J^9
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MT]3;D8+3U)4E0N,I((N"#Q__V5!+ P04    "  M.EI0<P-J!K9F 0"!NP$
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M:__T6D'URX%/ZP;7/"-3"VO:WG_>$%,QM/:ZGE94VSXXLTD)X.!@HP4?Q42
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MEM6<ZDLX.[>ODI361+EG7;($F$;VNX8/W. ^I2XKO/97C;U$AC>:$]48GF&
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M-;XW;$R$661M7E&/3ACH3T5X)5+=]<HF)U5_^8RU08;82!L@3ALUN3"%/_&
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M/Y$(CRQ["3&5) /(U+5=1*)DX4V/IO56/ZKVDTWGB2S;72DMC;-EC@BJM#*
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M\S3 ;WEBV"QGH);-4U'A1EC==E3Z^I1JL=R0!B5,CWK*!&61X%0LH1L[.U3
MK<=7Q@$_N?DYK3B@+75(84I:;GROM@=-$,/%YC<11OV%1#Y4=%%*-:$]6 \M
MFP&.5K*6O;.8U>607)Q(;$'XFN5R4NQ^;I0X(]%DTM.)KMAALBGI%>NG9& U
M%;-0:S>5Q0_6;UVL:.8@5&3# >]6PL ^Z$_9)!S9F?Z",^",'0P@V%R,) 3.
MS'S12ML,8B8IB& $MR)#]GJ"2KAFI>F=,I2"09D![_H5Q*';*FY0"^^/8Y>O
MG _,;;CR[;6K?GU(J<HEW5?!MRP=65%1R!!00<%$5=O)$JD>*I--=0G'7E^G
MR;<RW7.U(U;]G#ACBO(!?,7TV*LW(G@P! <A_)SL=J6>235I]K@";#%%1(Q8
MCRT=M_<QFKWX3!LE=7\=![N 992PMFU9O4^$S2,='=DW)C$=2-&^X"W4&V-3
M$?UJL@< 35<!7[D3==_;=*EVDF>7-1=>=OA-\9(-\](^&!2TX2VXEC5WVJX6
M\<ZV-S:%AE5!@$B&5<!"O#JPT_3-H)/KI>H(&:U;"C8/"^\Y#1KD]4T-:%_Y
M4EK*K&78BN8H'#%#>7"]O PABZ!(_Y;^;$Y&PY]&+^Y]_<+G3VC]IP5;9K?;
MHXRKR<WB<^6IK&4@"?@#;DT?G19]360<GR>U.900ZVL@3KZA8A?J@U^WZW!1
M#[_K<I?@5"?<[8[JE]3+QM&5QE=>6$[I.H97Y J^_8!7@Y B1(0[CU\7\2Q1
MN)Q775&_$U=_&TY#%<X(]>Z1A\M_@U= 0<,QEWJ];MW7LY-\=Q%N=LM#J%\R
MI <^N)D)-5L+SFC78V9&Z56=K D8>Z,T("Y/)()'J-45!JPG)=6'+XY'*C_[
M;!KZ*>5NF8[]@J%MY5M$3=&5P-E+PSQ7@-R;1OIG^O7K N>,S*O+X1!PJ/BT
MH5P0_!ZQAFG.M$R,<W8:W<'@U?1S51$PE3CGZF:>:.Y:NQ[$77]!1C<ITU6Q
M]"M]#5(!@T.EJR7V6:Z:T,&!IPLRXHBHI=F2FT_Q&>1EN"_8J*K212^]P",*
M83)NI<<7<H_=&F]B1B1KM5I D]L(<K^R]\VT/<[$<2&,2N($XN8_->=54W("
MZX+K:#PJ7X1O;3S!A,+:P74<MJR7E&R@/?]&A'_=^=MZ.%!N%0=' 1>5('7+
M0#Q>4#![#[AG9GOY861)-'D&[N;,REY=S_7/@:Y[6R,B7[1Z6#I#<*T=GT;.
M[$@[T>L,:?4%??$2GT#IU-U?2W^]""BW/_V*[RYW8_:NJ@2^C/(241L&R#XP
M5<:C2R?465'OF9#*]$UGOD(V4#TP+9J;W;<4E\FXE]\22Y/^*-'J0EGC!,EV
M<89<^(;X1YT[NJJAB RF5W@Z3W'QA;<29%7"IA+RM\^D2U#WJO1\03)M?:B(
M@GI1*#G+S!#L9 O0J49',=NR7*+&GA5Z&FHLS;CD"+F6<9W>-3&?8R,8E=)Z
M\80N^\,*?:P =Q\SDK091_BI3YQ$+,WI*H,G<)X[>>5N"7 /G((:1GT)8T)X
MCJHK;TEC86)NK8I>+D6!?%@SZ7!V<0Y^UHPO11'M9%7!6DUX:$$I12 -;K]^
MA::F<#/Q742-XU4B-AS"5U3*[V38-$%4@AD3 P8Y#3IO^ZZ4\GKAVYS%T6"R
MKWK(>?OA2[6;-H]6$B;%3Z:.('!@<VIV""MNKG .T25(.!\146R*%;Q#^2/4
MD2!LO>9605T5W\GZ.:'=P+.RR_!YT[.7\-IVWJ9P0^*)$PFIA!-:6$!VK*Q%
MBC4L9:8P<7JMSJ"\+M<TF])THV&?-&,C(G@BVE[Q;3&XP"R?0EY(F>P#P]*E
M AA404ZCR6M9MJBF0@DGJ4;J8(N+.6O?^STY*DHV7&%[N\>QM0>7(RVU8YRT
M7)U5]4)L>'%-A(0,$6(BN*!E%APJK\- ][%PI^/MR?$;R=RM0@7A]1,X!D8.
M926]\?!DBL3\?"HSW&8%GA4!SQ7</MQ-="7:Y:,@94T+U+_5FFGF22S3#M_T
M0.'&AX<Z%[/G^E)O==R$P7G7<T7K$V.22T_Y2_;?X)$EBEE1WB\J=3A5%G.W
MG+TMK]A807Y==/6:WHNO]\G2Z ,2KQN[4*44R.=G$(17JN,@[PDRNRAU$S8+
M/EF3U:DWROD(SHA =CGH"XA*.4I(2#O<=JP/QA&X!ENG#)N78+X#>@' MAYG
MJK*DK:]-H 3!=#V9'O0RA20^*KW"+<FZ9Z;SXQ!RX4K^]\(<>ZFI0O%7\GHS
MY%C!:!=VV\F+HC.W\'.%IM+)\&^U$+20H];7:$/ZIE!DN8D*L]24+R*+U/IU
M/WX=3-5JU#49,.A([.-;?S?PKI[BT]FY&\8WK=Z74N3CL:I>PJ>AR3Z%,H@_
M>#M>G@JO,GBG?Z5T]IW*^9<U5ZSX7MIEN0:<)79\%$<HFI+"BZ0 $CSW[TNH
MCC9=_#*J550<^*[LT0FGG+IW@KW7W_>^H%G[]K0 T O60J1*:8)[J*C'>E0'
M&KN?#RJ^E-LH??^QR2C]+!$9_PMXJ2W=)?6SK8X\JL*]>O($T&4U'U'T;:D[
MT9<>UAC=<OQ4YGO6\>N5$J9K>8,F4(%+CC9X&K0MKJ^)OH!#KXG7!/8]K7PJ
MUFG$Y%&0IOGF(&UO],&5Y,<&&UG/ZL,-Y2X2G3!!T$P6<8-I^AH-D)"E20R0
M4"YV_]F=<ZF<)A9AVK9M2=Z5MR,>#3[;BLD3.3G(Z KCIL7-9[6#G/^"=Y'-
M_$7'O%RUX=FJWG,GG6"EE9_[$[0\[/5G>3BIX=#(Q-[%D.=I%(&;6JUW]>XG
M>C?<MDZ\;0S7TS,P%-$RUBOM2 LSK[J;D5@THO/%9H\'4MR1UG]7QH)YDU07
MIG01[TG!TV6\FA*;.R<N?PTOSEW+$W#OEP<66@Q0HRM;>!K?<HW/J)_1$9I<
M?I^4[M/_6D=[/YG*CWK\>GG]L'-552HORE810: [+S\/M2R%I3!V%??DWN!]
MYOBPZBI_N<>I-\XEY:E2 <+VKD.W4HSHF;BU#-4TJ*?JGP+)HA%GON)[3WO)
M80!X5F'R%=0BN\.#D;GKM^!9QC[.S;F.VOG>&SLX%QXJR-B8*"*2<'2HVYF>
MA'4=F+L;+2VLFMKY91U4?BJ!7311NYE?1,S#2K-68(JKD1N?' ZA 'H"Z5S"
MO_K>^)JP%!:6/<.4RRPXQ8T@$N?"!:R7NG#7T*Q%')QL1&S@&[*NXSNQ!&K
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MC^$W%NM-&W#MC'M9[&&5[.1'D2TS5UZZ[GFCG&0;\ [_%3TA-F-PR\Y!-L3
M?YQAXJ))DUN?S-[_TMZOJ4#8 .KX59K>S0$5H*%S3_%335;66\R"IX$;]%FL
MG@&8?S@V.3,U5UF39-_2MO.N5$9-JDXF;_JOY5U-<6#Y$,H^]H7EB/)E@:A1
M#@QA6J$/P&F/L\Q+2Q^CL%GO8"&FF?QYSJ 8# !P*%!"JP_0U"5C9GK!(WV2
M KGM5$RI+B@X$_Z3B99'$@&*9U(*QL-=J_9Z:2MPUKD[WKCFE14F >9)B?B+
M@UW,AI&6T9\SZNW*7%I*8R5B)E^0J,^&( 57NNY\_D'OE'WOZ;.-#,^Z'.7#
MC?("<T!<7MNN*(_2#Q$@3BA7QCVBDDE/WU,#2"8D7Q72?ESZ-XGW<3:SW7BG
M2D3E4Y<BPXF99<LF82"_1^,\1/BI5B3KLK+%J--%Q,MHZ8F &C#F/+MFV3-,
M!C[[HYHT5OF$Z<1I7$10%_C'C_-X+?M(]!^ YK2Y'H_GA8;*F]I!.-CRE,KK
M._ [N^[W6+:+6SX8#F?F\\:RTP)86;D#3N-/?YP.G_;@0K)S",U__/>T>C]@
MJ\7:GTU^*8%1WL]3?#IOC*7E!Q\F)FRG.P]5CWS?DOCYRQQ296B/<\!7>!)R
MNJ*S><KMP>RT.R <%A- >4V44F!IWF#_/3?/[F6+RZ\VQ\HT[L,;L93WZ#CX
MV$$010N@"$_I"],(F_D,V/#"))MFR4V.HF<;B"QE1'(I8L@;%*WWB?Z<D=O6
MSUK*.V!M$SWIB(?)%:G(D@3AY'8>[.G&L+^G^@F<J[\*K!YM"+9^$T$U!\Z8
MK5J(S^M^#G G@YK ("2TXEPV"7[3%, 2R/S9(7"XK&J[9@IFUVTANV6\2FO;
MH9D/H/F2L;"U&;BN/F5<0E!>H7N:I($)>/E-12QJHSYMF=M?RZ)61K;L!Q1F
M='$0$C]$M6H&.DVIV_K@8>(H_[\\?G"X\ADQ; H8Y"G^OC4F<)"N1_?6[.1N
M#!D%Z*_V?LOZ]L)]"?62!EB]JE9+OM>LT]:G-X''_2;&L]$(X\WGMW-Z^,Z]
M4=+5Q61$0\YT8^,)<BKG%49*AF(RVKNJ6UV7/;_D.<5$HN%IP+%#T#\ =P3W
M.$63\7J,+G7A<J'<WQ2*RPYZ?;Z>?HE=JN=_]KLK*](E^/8%A(>!UZ'>3V33
M;N=<KU]<_>$42U>'0;ERF(^ZQS%GREQN:(-O$O5#>R=%#P-[>:]XW9+ T6V@
M5UP]8ROK'DSA'8RO-817R('!*=9[0FK<A^E?/?7U;:<4)"@4_MZ^"(N!)=PC
M2WW2"^!ST4Z07PJ4Z/[*N.;#N5>T+BQPNU_^,#+412B"+$7=>/%UT$J2]J?4
MF!-VR//PHE2E7+XQY09Y$'):^&%(\E#_NE=U"(I73[L9PQJM+[] S_L/H+PO
M(2D_,F(>>X_6<(4^+9X\K"$LZGCE1(P?1IXHJ ?RSP_F^9!TIBSRQSEB @\,
M[]G?98+^C=#E[=@,C-Y MRZ<C%4T;9_2P?+<:@[<W?1OZXA1. 0$T%D"#KZ9
M%@QR/PRFWF,NZ2P++M,;KGWT=:=IT?,I=IBKD]B/]&ABF&C8_54UH&-0)WG#
M@V!]LV$BP"BK![:J'.!D? E&S*--.VWW.QKQ>C1V4'./AVM<\(NO^J#*F,A(
M[#@BZJP5&Q1RQ\T VY\49W!\/(6F;U@5LLQ:-$?:.V_<\U.X]]"$=EN3F4F
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M=YLU53:-F8K*2[;RF1OI(H:%_K'G&@OMTJI9_GY&M%/,*5(VBD4I><W%\!_
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MHEYA1006_]K6=KD$YU.+R586CN&CS12#FDK*P[<\FS<I&T8])D\[1=ZL6]0
M1K=W"V3RQE*8>6^\M7(09;,I83PY?KUPPY9D K-8HCCUVY3-W3C-(!W?B;H,
MR-TU6ONQMSF]X23Z-%?4ML]"D2=8K/D2KJR[;(#4BH]C$7 3^Q+A?JV".Z_Q
M;?EQN?>,*EKKC?M>^=QVL[E%<R9_J_AQ>4,!(8: 3\QBX42*E_##1!YS>&6P
MRUS]+7,;<B>-.6PC[7P;FK)VA/(:S::H>,MHGT1JB(C:II@>6.8PX=9+%?UT
M3+<O M]92.EBFU/3,TONMQ@3R6!<L.@0&V3;M@&8$I:,#6!55D&^&L=)'^_A
M5D&9DK'\)6FT:3=,,_/3N()6!T7 >VR>]B<,PXE#GHZ",X4U+_$N>1Z4L,P*
M1$P%!E3)W5-4Q*97M(SE^O;\V\5H6$A?(/<4J5EJ!6'3B#608?B *-;DJFHM
M)+@Y@U)2,/(EU*M"U-P4IQW7XKP3^;\GEZA2:[CK)X)8[HV7X[G9]XFM:'[#
M!?$=&(37LL<1\WYBO%N/>[D%4I<GF[@S-[RU4XNE\_E].>QS"$^)E[=<2\S*
MECID%:@L]\F:^WFC;F(*YD-W-D\9$7-F"GI]40**2DU?UI=ZR,0HMX[R4Y_/
M"^R!QV@NH;*YX=I#;$GF3_HMV(IS>X Y/.N7=XJ:9OX3Q2G29!0L@T=?B,Z0
M87#G%17(13ZBWGCN@0&N7)_M3)LN1I"<=0T',=+2Y&-LJ" SIN[778^E8Z!T
M,/&M*6DU5_)RG-/C<:O%H>6,FRU3]Z02O"/1@J3,3U&F"X/QG):Y0E,&CXH8
MC*00)V3FSW$0VYO6IG!#L/ 37:6KU]B&YH?%@;^3QI:>4RF_U=[[-"];F*ZO
M^]4Y,H,W-V,K?_T)=-6BW1> 9C'Q!J8S2OH!X\][5.VESM.)G%_GHHS82V N
M":6:F6@V%?\2Y'<8@IU8O@"G*2)@A=N4]4@ABE./+J7] SGP.\O6GH7HQ&>*
M1V,YVUI&<B1L92X9&)A[-$Z^("W#4%XS=Z/\'<?%IJ(6"=WH:8YHU-\AZR^@
ML7/&>&"BJ6>BM8RL72CQ;W576M0<CE3Z/W]-ZYF1-KK!UG@RMMT]Q0#+2@P9
M$,E:E-&<B'W]"'RP );@ATAP[O>H_5R,<T1BF)Y\A@-Y9\?7CY6=D>TT_P"+
M"!>YUV63]5)=3^+[A5,BGM_WN_N,./X/,,GY6Z4X+6T.V,.Y:A3"_'IO=.E6
M.;<1;HMMQ$K05%G$<L<9C$$<OT[\]![.AJ5(&J==-[1)5#9SK3@@$)35/[UQ
MM(L) )A/JX.$\?JL/*V?"?!AXNJ\CA)C)K\V.#HV:YH%P\(FR1;-QOX>R!PM
MKU1>(WOITCS!SK&CBX3\'P =0.*_'=1,T[CS,I<4P[35(<:4I) +:H'4B"#
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MEAH@R4KJE3U5#H'Q%2CTID]*0)X;3?B1\3?21,D9!\Y&X@]1\AG?'!XTCC9
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M9%.R_K%#K=.%=8IVG&ZQ:&0HA/6&4*#85TIZ@GJ '%T7J=:NJ(C.0<]H!)Q
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M8VXDO2S+%&%A:4J0Z %)4!!!! C$3D^ORW+WL[-EMUS5<&*1IJI+:F^M*$R
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M=SPTX&1@F?3RSC'UB,#>1QC(.W>< >LP>PV&3,0<;<>(V .,X/D9,Y@=SWD
M?,#,>D8RD=_J,"8[;_A"GI3_ /*!R\V _M73P.__ #6J_$#:>.C<J294>H'
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M8=^Y]3Z_CQC/GY F-O7'I$XC]W!MIJ/UBAD@=(C8"<XF22#$B?IP?;84N"<
MX&X,G8[1 [R1D1GN?13I202 < ;F)'[^^P&-^#382=@)C8^63U&0)G& 3Z<#
MI2"2)\HQT[1'F#G_ +4^@X'VQ ^DB3_#'>=^!F@C[Q]>V?D1@B8WP8R#P,B7
M5I2$G*@ !L9@  P-]I^78"9FIPBEI4EQP-,4S32%N+(  ;0E ZE">Z3 DE4B
M!L!I;=1TEPK%T@2IF8%*ZZ0$U,#(()_5K(!Z4J)"C !!('"E=G%,VVL<!A08
M6$S_ *RAT@'>#G;!GB(&J,!04O\ 6*'Q0)F3_K$Y/U/T[\&DMA/[$3M]?($&
M3'8F3V[\+%#;T+4A;Z2I).&$J(4ON.N,I3!!(@SC82.)$H64M)1X@2 !\*4H
M'2@8!2!L3 &29)W('"T_>5-LE(<]U9$ ):2"MS>!(  QW)WC>!!BVVBXW>D<
MNM=54VF-+4QFMU#=W?=J;S+=,7?UE74K)AIIL.+68*4Y,/2PW!QC_)^5MH31
M-N2BJYEZLHQ45E0@R%?V;L3XZ6^HCJ:JZQLH3 (8)(4)-TQRZ9:JUW>Z.UMW
MO-6>NKU!?5JK[M4K/W@QXTHH6!_T;3*&F4 PE! Q,UNH:2C0$4S()(A;JC!5
MYE3JA( @GH:^$;"-N'%2@+*4MI\10RDJ!2RB3GI;C]8H?ZZSM!"9X8'.'GQR
MF]GW3SFJ.:FK:"RM>&I=#:_$0_>;JM*5%+%MM2%>.[UE)3XRDH800.IQ.!Q\
MZ_MA?I4>;/.X7'0O*:IJ>5W*YY*Z>L5:W/#UAJE@%2>BZ7QI27Z"@<1TDVZU
MJITN!135/U ^%/*NDH+K?ZX4]&U4W"OJ%*5DK==<6H!2EN+62I17/Q*4HF<F
M<Q-6G?9\NE4U3U-Z]X2^^L%-HHVP:IQ  43/5 )B.D GO.>)-;Y;Z,9HTZ=8
MLK35U>ZE.+KVG#<F"@%)^+J2E*1&1G.8QPS'=#M6>I73M,DEI7PK!,I@X[@)
M/EZQGBV'LMWJILNLG+!5!9M.J#24M<^H!0H:EMX)I:UPR.EGJ=\-U1!$Q, 9
MO[6VVP\J^8-2_6W&V5]MUY;O<ZSW=XIMM)J*W);53W'WCI2/%?H@&:E2/@\4
M#J7\7$?4]%6WOF-6NZ2935Z;J:NT76\WE"?#M=/>;8T[3.N4;KB5FLJJBD*6
M'@PM*8Z5N0A(ZF)[6]B0;3H.^H:'BTMPU%87%1,,U+%MNU&"3(@/IN*D"#\2
MU@Y,FDJ:91^ZE,$>1F,G$9&)[>OR&31+,[_"08,$&?2,R-LB/3@RBD;$!4R<
M_C!,CL9QW$>G!E%.B3",@[]CY8/PR.^.#*6O*0!N D1GUCZF/+@5#,'<DDX$
M3OZ@&(Q$#^/!YJG&Z@9[#<]AY2-B3!'\.#J&E$"$D)[8^F/J1^,\&FJ9<09W
M,Q*CV[Y_?P>9HU$X!GL2-S$F($XW@[3GA11;U$?%F,@*QOVV!'X$9SP<11(Z
MI4K804@3'IU1&#_V3Y=IX-HID)  03$9/<Y,^0B<*P8W[\>JTU#-)4O4S*JA
MYFF>?:82?B?=;;+B&)@?&ZH! ([F"<YJ7S_YHV.]\M[_ &*WH<:>J;+;*6Z,
M/,K:J*:]4^HK6ZI+J%@.-E:4.,N-KD)*4$'IRFLA5!B1.V\P,1DF#DCYB"8B
M.,2<GON<X[@=CZ1GU$"#P_[?S,YB6VU4%AM&K]16VT4#54Q26ZU7&IH:;HKE
M!54VMNC6RFI\8@!8>#F,2!CAF5=7752FDUE14OFF0IEE-0XXX6&U*4XIMM#I
M);27%*6IM( ZB3]Z>%G2.J;QHK4EJU+8*AJENULJ4KHG7D>(UXB_U82ZV?OH
M*504@A60008'$E\UN:/-G53CEDU]JM^\T:GJ>[BC8JF:BV(J7Z=*V2DM!2DO
M--.]"J=Q7B,*44*;24F80W&_D(S'RV,[$#?SWW\#D?" #M S@3V&8,3^&>WO
M+OVR)SM$2/4F8Q$YX\#).(VP#DF>\?AF,F#DB%;2B2>87+I(_:U93&>\FEJL
M;")\NY';CHV:5P?>!F9&X(!.,$X)C (!/X<:BF5_VH)CY]X.VXXR:8B/A401
M. 3\MC(^7SGBP6I/_6._$8_SS==XS_EK^!!!B,X&_;R3DP$A/^L)G.^.Q[D&
M),GY[':"-OB,[;$SG>"#$["(R([<#,MJ)"B !N!O('I P/7;MZ**$P1@J).,
M';^!_KSX-)9.ZC'>!!(])V/Y\#ML)*@$ID[R1,>O?:(!&<<*2*9"/B4>HIR,
MPE,2"=^X)SC< =X%2ZE2@E!*CW,F!,8GN<1,=^W!D)P9( DX&^WH1C\?+@4*
M0D0-@.P.Y]-Y/F?E/ C;B<DPF8&<&?7$QL ?RX'GY_A_7GOMQLF0H0//U['M
M!]>XCS&X4J92&G6'%CK0AUM:P-UI0H*(\\CTSW!R.)^T7RZO7,=TW2YN.672
M%,M1-3X9<75^&)6Q;6%! JJDQTN52QX%,,G,(5,[F@>6NOM,,T6B'+535E S
MXUGN- ]XM2TX'%ME-Z/4'ZIFN>9<0MYY*%T[R.NGZ6VEM*K?J$W2T-UVG+]2
M.TUYI76V70L'H>;2L$.I5LM*T@*0XDD+2>K[PX9/2E ,R9@2)_ '.!MM._ ]
M*@+<E'Q*!RLDEM,0>KM*L1$[[GAZ6RE(27B<))EQ1 )&YRF( D@?3;()_P!Z
M?JJE-+1-+?J%GH;;;!<48*05F)F 04DCI1!)Q'"M;C3TM4EFFLPUMJ53A2U;
MS5*9TU:'$2 _>:QDJ56+:41-!2$*7T$.N@GB4;1H.OOE;37?75R3JBYTQ'N%
M$IGW32VG$G[C%GLK44H6A,)]YJ$/U:X!6ZI4 3I;+71T?0H,AQ]"8"^E*6V@
M,@-MG]4R$@1U*!<\@(PZ*=U*CT%?C9PE"B$ XRMS=Q0[@$)Q]V,\;WC4%BTO
M;'KYJJ\VVQ6>D1+U;=*IJCI4 24H275(ZUJ (0AN5*) 3)QQS)Y__I)&[=1:
MHTKR)M@1=[4PII>M[_3I]S:4X%@O6.WN#PZAQM0"FWJM3C1D*#*\<?/?S#U[
MS$YL:EK]2\P=57C5-XJGEEVKN56[4#*E'I:05!IEI!/ZMMAMMML0$)2@B&_;
M-./UU6Q2LM+*G5A(2A)DD_"(!!(R1T]X,$DDGBRG+_0];IG5]LM=39*]E58N
ME4FJJ:)QM*TK=;ZBER  B"<XG(C.>E//#E;::1_1NJN7]:U1U2;=0"],I$LH
MJD-HZW6XD2M25!:<R9))VXAC4]FM=;7&YO):J+VFF*':E"4MJ2>DD@!/2,]R
MKSF3Q7RXV]HU3REI286J2KXCO&-OKMMP]N5ND*35>M;1IYVYW.RMW(OH%PL[
M[;%<PXVRMYI3:GD.-+3XC:2I"TD*[%)^(= K9R1T]XE)4:NO&HM>U5$A**;^
MTMPFB92GIZ8MU FDIEJ( ZO'#X7'Q@G/$PTU)243#=+14S-)2LH#;5/3MH::
M;0$A(2A#24)2 ,?"D0-^_%=?:EMR7^6%*^$=?N.L+.Z.H3T^\VZ\TJ@G$ $=
M&#O&?N@CGJ6C$G /8C/[\<;!G'<#>9&T3V$_Q[SP(FFF" HC,G)[;29'UP?+
M@P*8C]D>>^<[R9,_P[<#-TY)S)[0"3\L]OWD\'V:0#<=,Y)C)'E,2<;;1^?"
MHS1?#UA)@$23!5YR!&(F9WQV&2JM6\$ JE(P0(R(WA)!QCR!)(,G$GDTC2,
M>H[1('EGS.X&<#)X,H9"0 !TR =S.(WR9(GY1CMP-X:<$R2/I_7X\;I1GX1
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MD)"G%9'5 C('ID$*D$9C!SP"TA^I4%/*,$C$PE(B1@#.W<D;'?A5;2EL? (
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M7AU:@@:@OI&YO-U!!'8U]0#!].G]_"2D)) )$")GTQ&._GY#MGA2:"<1B!@
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MG&/B)G\-_61PH(B/KG@PTI"22K>#![#;MWGTX.Q)[ 8R-LC'RGC&,?23^_\
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M&IK<M^(XJ$HI^HEIG*\\-W6',U#E)9KKHFW4;VNM(,4M=[G2!+;6IT4H0ZX
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M4K%(1Y7#T0<_+^J_@M'9>!"-0T 40)Y3)(/ZH'<H(:1M/#[3RQL*H84D6M"
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MF+2IMI(I(I [KY_CFN+16B?[M)>ZX@W6!8%]7\H(D+Z@SK:LX,2.EO\T3CO
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MQQ?FL-/,CPS2$9WCSQ9 7G5Y="?\K0Q\BC3T Y)>2@I1HLTLU8]1"89O0FC
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M6D@O@+[P_P.(_\R]#!NJ=9&"6<#&.Q_>_4]-!,9WSN=*[),;HM2!L$ATU)R
MG2<+',Y$#UZ/^S,7?CRFY8%0KI$H\8-N%G!4$UNT<F5.-D!+89^-'!,K;>U
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MZR6MN?;A(A/C,0,P=.=L=?^2O-$C&IY(IWUVFC*VNKT8^0(HM5O]_648D\S
MYP-VQI]:CNB].\_W#3SI.-.98L0T#<]&SZ@:] 6NQ669@==5DNYH_"FI=?_
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M6>CDUR7&**P,]&9>!"+"\&JU-E^N)[ _\@B:6RP<CW;06EJL^KHXWS'Y=YL
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M)'.AV(9N-.A6''HH['0+$ >Z5Q?M6#3@TV.X9*-1*)+Q<Q=X(/;CC7U^<AA
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MY5\CN>OL5T,B&<9W\ HVMCXS(Q95=OXOIE?<%<F-R?I&)6MW(BS&4G+;]TJ
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M&JOQ6D]^Y4\(9XL@R3>(UR=6;OS'%-3<%@G6V-=\@4WC_!]I9Q&-<N#KP%H
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MNW-_A-7%4AKT#T!^!!3+^+9M>-/K0-4]OF?DOX _]#P.05UFL?_Q&ASY[A\
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M3%99NT1LM5CL[A'V)&I)G4L]ZZ.K[9* T[G#W%91(D-(__JE'D2-(+XZ1:Z
M883[E=_APQ]5IPFE_P"'V79\&>6.'[6^/=K3BW=7\[W#4 #Y!Q#ZQC9V%B8A
M_C!G-;P[YEA;2\0B0_\EH!!XMJ02OI9TPG1,%7 NZYUS)1+PC<\1AO##@J7K
M-\<^:OU? ,DB-MWKSCBH2A#;:5.$E0&"3QQ2YE:JNGM4<W'GJ-YVDY8Z/J'J
M:UND+##]*TZ6ZB]*:V757$)Z*%H#K+1:$2XH<7>Y:\OV:)FUTU'0^ZHI&NFV
MT2TCIH::(76UJDB%5SZ 5+)GHD-), S8CK8M],:.F(2PW\50[LNH=P#D;DG
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M5#JF1TF"8)!CCFGST]AV\4-W>YI<HM4W2Q7"T-.5-#9;.A-!76\A)#R[=5L
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M> \%>*DHB%%SQ%J6H@E1.3Q5VQ^Q!I&BU<Q7OUK2]-T=_5J.@M[#!17A\/\
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M)($A+K3*5IGO"A(F>W#]HAU*@8F(^D>4CA9'EOC/TD''EM@9\SG. -AGS_\
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MX ,8@@9[F,Y[$C@1M(*H(Q"O/,=49WCX1B8WD<+-(D2V/K^>WRX<;)Z>J,1
M^D3PO4RU )$]P)[P1,?B._;!X6F'%'H,P21M, _%D DB?7OWGAP4BE$I5.20
M#@;=1'EY8]03,SPNI6IL$))V49),@^D1O.?.!.W#<NM6^DPE?2(&PG98\YCO
MM&YX/6YA#K:%KZBHJ3)ZB-SZ?/\ (<27;:)AMRE4D**E!)45*F<^41'TXL5I
MUI"&F2D1(G?O']P].)%H%%)  &Q.VQ^$R/6>^_K'#@:6H$D';SCUWX4V%*(
M)GX0<^ICYQC@XVI0."< QG;8?U].%NE4KX<G<CZ?U]>%2G_TV#&VV)D9!['Z
M\.N@)E/J /Q,X[?W</"@6?$1M^'H.'O;R0XH XD8^>3^/[L<.NBF%9(R1@^?
M3.-N%UQ1%-(W COL"1\^WGP'3I2K"A(@GZA0(VC^_O,GAUV9""OJ*025 29V
M!F-_Z^?$P6U*4H:@ !202/4_/,?,GA]4R06T[_=3CM'E&T8X7*%2H(ZC'4!$
MXB)B#(WX6@HH) V'GF9!.?P[1W[YX-!Q0"<_M)'G@@$_*?2.#2'%P<]_Y=S)
M\N_ Z"2$Y.3VQN8_@.!D*)3!.)_EN=S]?X#C19E1V[;8[>G\9X)5.!(]/XCA
MJ7')![RD'O(,"#,F/D1D?.6Y5G!$#<9[[D?N$?W\(#N"D]R%9SV$C:-I/KP6
M6GXR),$9$_+SS^T>_P H@<:1F.QW'G(/_=!QZ\%5)3D0,B3ODS'G&VV,=N"Z
MV4&9&TQ]/IWC^4<%BPV>RN_[1[_7;@RVTA*3T@CI5TC:8^<3,@'?TVQPH)2$
M],=QG;L!&P'E_4GA:H4),8W"?7=03WGL3^.>_#KH %/]*@"$@QN)R$Y@CL/H
M<C.>'I3)3TI/2,CY8*9C&0),[\*3:04E1&4D1Y<'F0%*3(_9GON/K)^IX-Q]
M1Y'/[\_PX-L@%$D"9(V';;@5YEL() @P3(QDIZM@ #GS!]>$1]M*D]1P>D&1
M ^6PC$2.\[D\(%4RV21TC( )QWDG?$^L>G#1KV4-N#H'3)/X"<>@R=N$U!)F
M>W?Y_P"&PCC('J=R-^P)@3O_ !^ACC )DCM,>6(5Y;;;B#QK)@JG,#]Y&VV
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M)IB#W[G5^*>'5#@B]!@@<-2 /<\\&E 5BOD5_,X4$@9!Y%<3<94X1,2'4&@
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MS[Q13PZ^G ^,U&O!*EIK$C1%/1.V:&'LMZRH\,UY8\4:SG270/#&];)YCBX
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M]O@0L5M'.+M O/%>M"PB;"W8OJRZ4(*?X:\T"S,H?$7P2FHA+4\DB=+L/BU
M8RS)\_?T>9:6>9!,GK]#V_>;Z$V<A\K6T, %5%\-^4KB:,[6,*.KU-M.&NQ
MZ)U.3:\X!SW*/<KH]<=<>6!BKCRP:ZYLKV]W9JX\\+*R_)?]PAI*%#Y8CBU9
MQ0Y\K"S/F&QJ##MPF#$=13#8BIH#":DT-2/M6J"I_><B?8M2N<I5;\-(._2S
M2#R;U!SUB4N_.^7W*9R121F3T71)+34*T0P0^2,IRBS)AW&<?J?AL3DM49*$
M41PQZR+;967F,IO#5PSSS;S&5Q"<X$;7A5FXTL5N+9N>ZL1G9P='"+EN-I/B
M/F4U,<ED)WO:-Q!9/@R+Z"TJWI4KS,JXX]-#WVJRK.0C4+S;H_7'OKW&PC(U
M[:VO>H:U%M.BZ># +=]R8.G.C7:0O;&I;P"M,V]6F@0?'SU50O;3:+JL*/8;
MF52YP%AZ"[-Y8_F;(+R3\V/4FM,M9I0K9GCS7L!;/ _!.S/ATJR>]<5#$P56
M@/.\G%>_:[4Q-?]0Q4C?4FJ:[U,6..#-NT9CZQ\%XB9KAK'U3RY /MT6K7\8
M'O!QD% #O^+IMMZL0NZA]6\E$*[TN B\2;ZPHD[Y%+C=L *"9?.3LE8NA1WR
MO4FQT$X.V"8^6P)1V?6,\B"(,C>*LLK+37V*;@S "6KF1<$4YQB,=+'X4Z.)
MZBDT$X/BM-AJQTY51T6!W1T7? C^U%427$5J218NWOEZY@99,M'>[EQ\KN(J
MMH\17] "#= E%_PI /5QYI8O![(GDTQUKIN5MU(<[%62EZTSKKK=ZAWPBNX5
M(ER[DLO=0*(NZ')&420+)SZAGZ]'I\<H=?BV\FQKF]JD_0"*;Z&[C+G\O5 #
MBH5W'<4S>3J]30J2D;RX_D&7.=D8>9<YT8MZ3G3FZVCV4M[^"\ +WZRA'+$Z
M >WAN\W7H"@S$ ')1]/5'FBTA$V' D[XYB@A6=7-T/GS9M(T0,G17<<X0$DB
M&0[%%NW;Z-$630*4W%A76P4H[2N(*@3>O#=8C7YQ9%5J&: D?$"2 _'F+<*R
MB'RY@]N3E>H:;:,DB^\!2KA7;_E*XBB=UC#+'T2Z<,HLYW/X]6CZ%(&R/(W"
M ";SIH!;&D<AJ%.;DEVWR33-YNSR?44K:AM4.1),3<[7DLDO)"'9UM=D5^U&
MX]!"4U_.$'2(FS0CP.S+,LM($K[7DA7_ G/N+LWS"P+DDN?@AV2/-!B%E=1R
MI'@H5E@[R?#WTB;(O7'7'(&>%E!6W)$ [JC1ZZP83;_EA*4(D8A;VH\Q[.,(
M6 ^K-Q?U;7+OHN EBJ/B75N8ZQX,FBLE%%N,^RB]N8'?EY0IH^F:X*?J,BJ[
MVPG[5/!07 9<"%&-TYN[^4.6 I'%.WT"*0 TS>:_H+3"UC$MX[MH*K.N:/1F
MD$]1-%47HC5!["YZ3!.4R#AF/$;%E Y-9S9%UQRM1;-;>QN"5L#L(WWWE$22
MK_]>840L:=A"*EO2Y:-RY<RH+P3A_7^G146RHW ?K9#Q?>X).+Q#L*OZ3,YX
MC&T%:\YLJ_60FC/]:_ CFI=S*=NWVE3DH]RQ1+-VG]U\BIVY&>IQ&ABEY'2]
M#:/["UK(O2:GN13[XW0WG/RCS NFJ=^DV3WY7CN?LC2!'\-E\2R%[ZW)../3
M@[/C 6+>:5LG<3OT-KSAK!;AG*1R3SE9\PH55MKJ=H+@"U6*4N'EUDO982L+
M'0M1Z9:*8)O8('TJ@F029)/\VV(2% 3:GQX,U-4V=?I7^%&C5:1K2[#'&D$3
MB/3$MQ>SC5/2390$21@%,3-?Y\^SH/AK\$8N" '^!#1U\F18W 111J-T2?6H
MUKE'Z_K[%9%P8*[LM8!E1>8H>21AF=':F)73<+;ZYT601[GLA<[)=\:#<X28
M/AL05*Y>UKX!+$*H;>A RH*G0+M\\BKSHKF#=Y#/ "#]'S7EO@6QAGXO[@0L
M0;2IN9(P=QJIF.#-4^,F2Q&?9/YOE=I%FV''1P>.7,6U+P<J\?&%WAZT-P^8
MGDX+7^X=.//#:C9+2R<$=5*C&FM!/>2OR"+-(W6U2DFO\=$A:IQ(^S4L.!!4
MD+UQ@/Z:)N3]:Y#]2HJ;,IFH%S6_ Z!"C>-R)4@96F\\I-<ZSL7[^L>_1B0#
M'L[>[\@;B15*G-X L-EY$'S0B4)GPA!ODL6L*5URH3*4[9&O])XW&@<6#W;4
M@XFP%.+61^SJQ;<_4O=%.T,0O_LWZ.;3X#99E$7.<!\J#W-)+\"):@ENL"85
MTA5A]">+#H]4M6U?T@L HF;/=2K$+8S^O)SS2#UJ),1EK_'QZ<'Q.>H]R:D<
M=V'Z\_R]?GK1#MD5] "6>%!8L!O56<8!CU[':=3/E&2;RAB L/;8MJ$^IV^2
M.?]/2JW*YF> A8ZR*NBKVC+A"A[:K7/ GU?YGDXB;S1W_-FD]/5 ,,E=IO,Y
M;.I \D, N[O:OLIK/SXZQ'7DL+[L!996,7B!1#%2&*1SDA=1>)EFBS0+"I8]
MZHF>J\NC5R%AK?X &C7I3E<2-V"&8 8@V.:^/?V2OI$L87O<*TFHBX_A)- =
M J"CWOFZF@=F_!!,!02#W2VK&,32Y[PK4Q?O-P:6(#I(=WJ5$($7R!+!ZK9-
MX25L1J]I%OT6:'G<JCL#7&S':9$,="0FAB1PB$$PN74@05_4;1>B5.G/ QN9
M+U>I^#8DB4]+>0<X"U 3!>FNCVV1Z& 2L!\C[^0LS0I=<:D[ 3Q'.=E=BDP7
MET!L" 8QGA*VXWI^$<2T7.C3C)#BERPM%W"2Y\,7:!Z$LMPS;8<&!J-.@>[<
MD:TP2C"G,*)6&,F;V(0HIZ[/P"W)9!'V@07CQH:N.PNL"(<O> 5H@401;%/#
MMR"*J=Y^DV9/ 4U7M[ILR40J[ 3P4.)T.Y&I K5 J CF*;YSG-FRU1X#6(9:
M[->ER V9()@!&*YC,J;4#CLG&H#N^+02^?DIJINI'YJ ,<,$$PW!^'4-_)U,
MR.2*9+ \BNB-K%E*R]ON_E$G&5[3(2ONX+I56)4R?R:U9H]@\JPV<6\B9I]G
MY')&<V_DMPG\?)T7T9R6;:C!'969!#%VZ*Q\*V%[Q[<D?<E)]D;5"N9!0XM4
MP&R)(V6.6Y>?H\7K!@<(M@:+8+1#:BU]BO+L\!RAT+#3"2 XS5SQKM\!MYL]
M:+/_/T;YK\JR$.)N%6<\*(;L3N3\1V$=GG@3AKNA]A)F+CW$J6U1HZR!N%L%
M$KOTLI885!*4@/,F8M:=!'UY+7(K2@^#6SF*,D<]5[YDF Q3'9NH%C"M9:=]
MLU C]2;PE>?2_O>HF.T=1OGV:?2X<YE?7AY6];*U5&_+GZR8B_JPB:E4NN*F
M?_&]EI#">DTGMTF8T;SZ5Z3Z?X?SEOO]BNU^6/?Z.XGEK/4Z5%D'=B[ S<9R
M,(.EWZO8ZD=<EO\S5H^5/:EGM<G.]Y#"1PI0>>+WJR@NJ1:T>>C[.\G(]8\P
M+H&*&Q >-5$&<5C&C".C*>M!)O>DH%6'8/&R^MRT[E<*3:-L"".O1KV>3DE8
MF-;,LO3J"W1,]M#5D=&2XV6QA'4=9 FU4*\ Z9@E;7UB?'2"\2S>COKAG,XO
M=]RIQ@?6H#J&VQ6QX-'='J.\,1-N-IN6Z)0%@JU^"+B(8-WN8I*YX)-%2S:"
M07/X/<@F&N$,6^T N!MUWZR8L0MA\O>F??#>V#,9 E#,R(1B!)X%E3 R^J#*
M[#@7[YLV#\$[B[JA@#:HD@FM!*55H-?%YX"CV.'1' D+=A!G^+TQIWZ0&>6+
M.1Y]:JDL]@A:]R;IWU.1AK]^ \'DCT_?#/*2<OJ-CTY1#?+NM@;^?-%@AC>&
M4"</Y@>'9T<>)&?I3@_18H<WID(G+ZT4I*.0$DMOY4LQ-'E@78+S)D.A.PGZ
M<CB[%:6'V0:I=WOQOJ)8_2;.:5Z!0WVTU%I&@K=O&2)_$@JR(WVD5P!JKVV%
M!_5%3LIF@?XKA*%($>CAXT*MX-5M4G<"9T\$JRI)T"X/OQP/3-\&1 65MZIL
M52[5MTF]U%:4A-$BEIKU&XXT/CPQVLW:0I!7A38:97SHZ-X@*0K=D+_;"Z<Q
M5J^<;_4JY<)=)RB()(\CIQ6 1;P>-)?.EI"%N%R9D$WE(50'N>V =BSU7<A)
M*</K9+LR^KIG.;:^W9;W[KU.C;>A]<J6%_ 6]P!<>$6E^1-<OO5PZ7=E4]22
MQU-(DB"+TH>,O$5IF<?OCV219@692(6BZ@;(4-[;C22C!\(C"^"49!F9/ *P
M2_A_5%R6\&^I\X2P#V!#N=U85-XT,7IDS=NE\SY-P@8BW'0#A"@^>)U(<1>F
M-T:]$>BN 45X1SU,=>*T!3T %TK:4@?BDR+TQG8GH%)K'2K[ E:4M,/=27,7
MJS_&OFV"'Z/763&:?LNK7!7:0MWI!R!1;+3.!<K%B6\B?,A2(+-X'R83:OQ<
M4/#WI*@Y'/,;X#@&KXBAS\U%G2*9;5"_,W,+Q_#GW6?W'I'ZSI3R(1C&8X0B
MVP;L%UC:31%Z93"T-]<OWC4\'S5Z5WSRH,2BN6"Y\\,$LC>>K&+$.F_6&KVK
M185=,]%$-H;2Y4#UQLVU*^EB&THQQ.QC2/^*6"T/A5K+"A)JNE&3]<47G0B3
M-_Z;-V4&;"TSZK!X$_V@/ZGS*X@[50!1,P6W%YH&/&^,L:/I- J)_B+CMJ]@
MH?H!M9>:')DWUE=V\9VE\>1VOLC2-Z*7T432JX*(ZB+47G@Z^+RQNPKA?LO)
MM(SOHJGL4JK1NX*,6DFJ]<W4!*8W=EDAT>M,EBOJWZ199HS&J=B FI#9G;2E
M@/VQVPKI_R5+\T:29AT94D>N2^BBW4;H3_'G81B6<YK?@:;%6F0DK))?P,\Q
M8<Q/)L-YFA7+ B)"?!*IV_I$Q3T_%2_=^6&=%_[4GA;2>B]]S)%UJU"B)JQQ
MMR/4\2G*3'?PC%,K][-V^J[][C(.\CR:1F0RS'?K1."\Y-2<SH5U*W0>=8S&
M&1]A%#L0$U;;3M@!\RW)2!!'O\$_87)?D&E*P^M^R#;GMF./CW!C8AK(3[ U
MV^&$-\\_3?#0K$ZN9LW6V, KU$LXZJSA<,*;YR0)GDHOH6'>N53=TQL!<*-:
M/KN8 ?MXO7E8$E.]79*XD:"WAP#DJ"I<!Y+F ?;F46F;N%T0*K<0C=[ ,S=+
M6>H.8DVLV@@MNH,@/%[Q:WTIO$#$G8 E'B2AT)<=5_0J>-Z\7&V2GO!)YO_6
M(+&,^;# (>ST52KQ\87>'K0W[V.>3@M?O$EPYH?*KP3A$>Z2@")*P_<+DH^F
M5V21YI'Z^5O2"U0<5$-]^S4L.!!4D+UY?>.4KE"<Y8(>P XW!IPN#W(I-G]>
MSIZS(,FG)*.%.)](]A:%4?(ZFO+*D%!O@)S_)Z7?G\W/  L=!85J'_-2X?+G
M@WT.^/-DU]-)Y(M2X,%L4FD(&,]WE^E\#MLUD/P0P+Y]GQ:W297 CQ9+:*A(
M-A\43EN4N#QW&XA X6C)(<7+89=FIG0.2ED47J;9(LU @=H^TI5S1:L_@$;U
M].IJ6A@P0S #$ R-WYY^2=](EK M]94DX9YE5#D)=(< Z*BE(;J:!V;\$$P%
M!&/CQG5 (]1LOS&PQ(-,^RWO)")8 BDA6!6W*;R$;>8US9:N1\JEJNX,<!T]
M_&A?'40RT)&8&)) @@@&P XDZ(O>[D*42D7<R%8G2.YXER:OSR2;U]RIA**1
M=X!='C75N^[ZV!:)#B8!^Q'L:D^S-"MTQ:7N! Q!=59O)C)=7 *WE=4D[=9O
M<3B91!4EM\DTS>9+S]K?D7/BL5\.0SZXF3E*3^#&]>18J$M:XH0%YT11!N.V
M!(Z*&<F>9T'R3.;TRIN]W\X7092QI2TZ*=U^=7SD*NU!1[.G,Q[UP'V1YF2/
MDC(M=V ^T!<^>AR1/&<@OY/XC7R%UK-\73JVT1[5ZHL@3E1#5P<[EP7^],"=
M4H6RCFZ443699&[GG?2+P%=4PYH'\TZ#/][X=JY1PEZ=;Z&\3?CH\O]5PB\+
M5D7D*LJILV*9D?N2BH56AUZV^@7Z%M6V/\JN_PE]GM-10OZ+!+)[$ 8Y(!'4
MER+[,[9SYGGCHRKF8$L6K,X2@RGLF 3@?)^\XIMLM"X8YHU'K@[_#.I7R\<
M[&Y\M&QZV(NGB"%.BW[V""9YBXYYQQYXV)O*CCL!I B]\9+MI6/5L:,XRO;>
M><="#VO['/#&+;>G<\B71SX/)I/R31#!;[BI3Y7"?0@W8:3]78 _0328@)]&
M_9$P.^Q#D!7OC#%!R)1@CQZU!"3JO&.INM)$*&<G"/:3C78C$L#%^]9?M#5Z
M@_$J]&[6HE3!UQ:+2JUO K;?R=4%B!6:OJ17Q1<W<=0-%?Y&4N7.%!W<WKPA
M"8A5ZF32?A5,1YERM'5U'3D827 'G#?O,2YEZ(NN[%:85K.C"YP&+F$S@4^
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M: P-#U"E<[_V&-6C$:IWORW!-8(M$"6"*8>I"R('U_U&,!-12KXW=JG;H5S
M>(PD0M0P<9OG)9E<E<SI%E"ED\I[\YY\9W^2V[AU!@#8CFRAC@1F@$H@3 Q3
M#I]JEC:PA2RW^U=7K7YYM!KA$L@3P6I3]ZJF1 9)" I8S:(HD:6R[_CDX. <
M)W%A4SGJ8Q+(T,B((_)(KBM&-#-]E%0Q*$$A]BZ6]('3^&R XQ;5S&U8!XO
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M():. (BM!$9[E8DF)*I$ C_L2@-^-;XCKT%\G111\2XX8#BM8/<^^'+NQF?
MR=$BPV K+9$QZRM:A/O4;I.*8*RB.3(.[O.:2[>M+#\=,1K[#&C-<=6&?VPC
M/N6O)(B+61ADY#%]AQ_?'X*LH)G<;M_N%G*3F4;7"@G*Z[=P&G,,829(!+*P
MX92P_O@[51NN2D)=O@6[NKP#I?;\P,V+J),-7A..@/DV/ VX'Q?N.:HN%<58
M%BI-;NJ*8 >20 A&]^HNA8!]$+B4AO*,L!$4LB0#OC]*KDC(]L/G6905[Z-D
M_W$ ?B$_-QH.5R'&2U.MLS3$,FR,5B!7&^FKS4B[2<O,IF WXU58\1*F=B)9
M#ER!:!%<$"Z"F+I?/LT(*>[H9RCWY2]GHBX,G:-X5Z?O9TI  G$A>"/P2%4^
MTH@[50@=^<]I/Z<I^:\OMAU8 L$A)"YV(SAL!<>U!)5*CIW CLH3?;FK;]+.
MRL\\1;<* 6IDH\8"X1QNNK@$*=$07 O6F20NWM<__C4B&;!K]GY'WDBL.-'T
M!F#('25$<WJ^&<(3"!;!'V%-;2V12[X/0;F/&HU3\0';F=)09@K!&^$6R!_!
MM0%3_KX<K6@3077VGB!$CZQ)ODT699$S^$=*CQ=)KPHK:@!)LT6JD+,$J4":
M&/7,X .CZ3#+:"$9C< $;OO*/-_#4UF.1B EA-B1&H6T$L@]$+3YS3/\E <L
MWC97KD/#D2I>8!_$<C'Q1=L4J$#H"&8A;*'[<OIV)WWE<6MD;1+9?>% 2.CI
M4"53J&*O:?KKUXPP\A1F7KWN%2+40[7I"N09>PU!"\1G(PJF'C=Z$V5Y<9N\
MD:KHB#!%H5Y'1OV7?B6!U0<E$(D-X]$3"5-:'DM/#OS6U=3I5XHE!1)!6G4;
M?BO;;S;Y<+&(HY J6\\1K2RHSGJE/4"%IC?)R1J"$XC*HEO++V4 .VY!2$Y3
M+$=5D21M.2EZ5V]J_5H\AL@$$O(JY^KU=$I"FH^]06I Q3B5Q?D#)6&5813(
M&L/64BDZ0;S*MA21G%/M2F9WT1NALDST9@4W12>0K$\EA=:)TVM%%;17L6(<
M&EY^@!LF[:86!0^C0-8KZPU.$<VG<CZ'EJ/IJ"SR(D@HU<LGPGP_61I.=<UM
M=J\EI#T):S(U\PW]L,6Z',41-LI,L",=PQ6GB]9"_4RM=+N<?)4O\+<@U$R'
M+>X/.%"C<0VDU@"7-X4Q]?./[27I.D911QLPF[_&N'B\*FU9RTV3)&40KS/>
M+6^VVMLEOSL@1DF':DV"^B M5++4V@Z_)<$J72_5?EE>PHS,HW(.JD8]FZO>
M[J@]'*#$<PUO(\KVH#VM2JE*$LAI#7C<V-FD.0);:R<UVBUF"$3/1-<@0>"Q
MF_N[T0N\6#8Z6^@:AJ>%)%NFGCO&]O(6L5M'.+M +)1X]%)$OCQ[VY.5ZEG;
MQAN<[\D!726,:9L<\)CO &X-LZ*X(I(5+)R121F3T72GI 0M(?":4-7KD<15
MG8$/9Q/#\-FLE^H832EI.ZJMS'E(U1<@H3X,23G-WRTU,5FP8KF0W]K]A15L
MT!;==C= Z*=54E=J/#C>F+4L7,9.W!A'FEW&Q$(1TF[Q,H9O_S*_C*UC-7R[
MC)T(LSF*8%BP7GFHZ9\X<BIJ=1D[T31Z[ +QU K56D0^7\::R4IU&;-1DM+W
MR]@IJJ.)?"6YNHR=^F35VKEV*5[>.*V!5QY=J+44%2$*;PQ9' JO?X1Q.:D>
MW->ZKYFHN$, <M2BE7;D)X$FMW0A.__<E$69D:_PO7DY7[D)CY(/9^KPP+%N
MRU]%W[]GJ]OXY,Q1!%S+Q7*J^:["@^.-;</"5?G4S5[6[*JL*Y0:[38KFV$+
ML,%5^=3-LUC[J_+I7K)8%0Q/[1<M[V&GV,5>1.PVO7Z=VO'%\5)$/E^5F\E*
M&8[[.[@JGWGTM+*[DEQ=E<_$,3C8JY3C'*:]7#E] 2MJ:&-K)4:(R3M3!URS
MZ*%^6689<]:D\>AA]0^-^[2D-^!%#;-O($-M5-Z81E:W:86EJMX,$/AIXA#+
M99]\"PX[]@5PJ5PVG-: !\7;VY(XME HG&J0Q/(U*,J,A4 ^DL7*J#3=E*F?
MPJ+_+Q)D]*C5E)W)D, :/P-F] 1L#E4P"Q!,* 8X;I-[\J, G2L&?2M-BIGL
MLMYJ7&"\1[JK[?D@PBN8% AF&2,P;&:GI2R)5*/Q8*5X]-9G?Q)LXQ0('\'\
M8PR"7=QL2I\-"'SV\YG0HOAK0 7R1[ MF:/XGEJ5_O<46.*G@Z%-V:]@"B0O
M23;PF5+P$N3D7_\_4$L#!!0    ( "TZ6E!X*&,"6)D  #D&"0 5    :W!T
M:2TR,#$Y,3(S,5]L86(N>&ULY+U[<R0Y<B?X_YG==\"-]J1NL^1T5;4T.SV2
M=HU%LEI<L2IY)&M&<VUKLF FDHSIR(B<B$A6<>[NNQ\>\48  <3#'5EK)DT7
M23C"'?BY W XW/_EOW_=1^2%IEF8Q/_ZF[>_??,;0N--L@WCIW_]S3'?G?W^
M-__]O_WO_]N__!]G9S_3F*9!3K?D\95<?KC^1/[C_=T-N8ZS/(@WE%PFF^.>
MQCDY(\]Y?OC##S]\^?+EM]M=&&=)=,S9![+?;I+]#^SO?Y0?)'<__O8-^Y']
MZ]WOSC[0Q_08I*]G[]Z\>T-^>?ON#S_^^(<?W_Q/\O_<?OS_SLXX%U$8__H8
M9)0PKN/L7W_3^,[7QS3Z;9(^_?#NS9L??R@;_D:V_,/7+&RU_O)CV?;M#__Q
M\>9^\TSWP5E8B%)1\6[ZZ-[^]--//XB_LJ99^(=,T-\DFR 7XSC(%]&VX#^=
ME<W.^*_.WKX[^_'M;[]FV]_P,4B3B-[1'1&?_T/^>J#_^ILLW!\BSK;XW7-*
M=_T\1&GZ Z?_(:9/?"9Y_S_Q_M_^CO?_=\6O;X)'&OV&\):?[ZZUXOS4ZJL@
M^@&(QUN:ALGV*A[';)<:ENO[/$CS"7PWZ:$X?TCR(!K%<Y,2BMM/=-SXUG1@
MX\I,(1TWK@W*.;G-54Z=![,UBA'_]PW[?HLS^C6G\99N2]XXI<%RBHZ%Q15=
M)IM69Q$WO4FJRIFQSD1'&=W\]BEY^6%+0];AVY_X/\[X/\[>O"W,Z]^Q7_WG
M1<)6P_/'+$^#35[V)R007_G/GC:UD"V>4IHEQW1#G024P];^:O#8]U6V1+$6
M?)FF\=GG^]_\-_%W\DO9XG_^B^RM8NX\;8]9D&[*+[%_#G!7M/AAD[#U\9"?
MM1C=I<E>.SK%)Q.M(#\L.Z'EMN2!]:N9SW83H.GL\-6=S6HWQ?^.-95]8]><
MR;Z!6WPBJ[7[DEG!@1GMM 6>VBZGVCF6#0EK27A3[.GN'>&^>>\=WL4 \) &
M_%QR_[I_3)2A+T3HM &:\"YGW8DN_DYD ZSI[1V_YK3V#MYBTWD5YV'^>D>?
M0KX2Q/FG8*]3Y_ZF0).KX;,[Q[(9J=L1WA!KKDV#VYQRT\@N//,?PHBF%\QP
M/"7IJW'B.RU!Y[W+I6;:13-2ML.=]=Z!52>]=U07GO/[?1!%[X]9&-,L,\YY
MIR7HG'>YU,RY:$;*=KASWCNPZISWCNK"<WZUI^D36U9^3I,O^?-%LC\$L5G?
M-12@&-!QK<%"V9S(]J0@P 6%<>15<!B'?6&0L*_MD_@^3S:_WC\';$K7QYP[
M8_E^Q(@5,R$H9 9DT"!'4A%!MB*2D#0H<2%D,R\JDFPF96E '=.4G5#NZ"%)
M<[ZIS8/\:%YR="2P(-+QK8./;$\J B(ID&%C'/T>P!B'?NE-R3.-(IMUJ=T0
M=DO2YE&W(^&M_%A[^@:U9S_2,Z*+S?;YGL9;[K;X$ 6Z1:73!FB.NYQUI[?Z
M.^$-L":V=_R:<]H[>(O[ S^$V2:(_DR#] /[C<[$:UL#^P15;K5>0=F4\+9$
M-,;V"VI&NL\SJ!EF(#!(OZ0]'%KM40#1YG@($H6_V"-0](RX'A8]P[WT;I!]
M.PVBZWA+O_X[-:_R2EO8_9_"J6[C)QL2T9*PIL@[OOX1[MGJ]0_O<A>Z<FM9
M&R3SS9&^.=0UKYY?Y<:WV/LW%PKL.Z2AX6Y=! ^,]<)&X4]L[_GO<?(EOJ=!
MEL1T>YUE1YH:C8.6!M1(Z#G7& M.</8KIR E"9$TN%9C8 I4ZS$P_@LCYO;X
M&(6;#U$2Z$)#>MJ!(J/-H08-LA$1K7#GOV= U3GO&<V%Y_F/272,\R"5=R1F
MKY'2%G2^54XU<UXUE%=5R/XAS0"K<Z\9W<7/$>=Q? PBZ8\:.$*TFP*?'CI\
M:@\.LEWA)>S._61.\T8HXO+L0I]P^K#0=[CI \+R86UI$&<A#SNW JO:'#K<
M3>57'_I6M44'[JQL@X?O:3#2&\JG 0A ,,BGX_YQ8/O=; 8>!E+Q9X@!(;(1
M/%!G81,^3J4]Y_U!*NT)7QB(U_$F21GPQ4L>?@U%+Q*V TE?+Y*M.3QM@!(4
MKD-2:*#1(EN)FT1*DI04Q(138T$;4"18-;!"G*H95G!;6%D>@J_76[9HA+M0
M/GVS,.%:&E %T7.NP1$C(&T*9%._G 2P\!_ D K\ 0 M#/GS[99-:E;\YR:,
MZ5LCW'O;@T*]GV,-2(I6J_(?A+<GZQC-["_#/2S$#9A1X6T # RT+]@_U^E#
M\B6V 7:S-0:L6]P.P8(WYHL_;^X%)-2QU@)"'6@8.(BMQ3J]39.7,-Z8M\ Z
M$@Q@J'P/H:/:&Y8TR#9O 0E00*Y!D!;I&OC P/TVR?(@^K_#P^!YKY\  ^I=
MGH=@(ML31H!ZHEN&>Q2(]Z)&"_!>R"P7 ,$_G-+  .AV$ZA AS9?2G"#F'3V
M=R2,3F(/+-JB9VY;$18]$[L8T'C^F^CV.8G-GERU&1#@>OCKSJIH0D0;M./]
M+&Q" 5 WYTT0ZB9\,2#>T\TQ9<A_^^[Q(<PCG=53FP$!L8<_Y<4X_SU)=N3M
MN^\>OR<E!3P:Y^,5"I*ZV6]"4C?UBT/RZNOFF8T=-3QV[V\*#,T.G]TI+YN1
MLEWO8W<X=,["+C1 ^[#0!](^("Q^"\:&/MCDX0N]#/*@"-0<N/[J)P&^]]+P
MK;T=JMKSJ-F@?$Z'=\GEQ']_<^SK+!-T^NZQ3+BQQ7D)\UV0/0KFC]G94Q <
M)-9IE&?E;[J@+W[]G\+KP",@UKL/81S$FY!M6A(9"F'(!^9&#J ,CO(HIK(D
MXPMZ14A*2N3\8F,FJX3<F)F"@]]YEM$\LP!:MR$@I!0>E7>*HH$!(\O:44<^
M,0'</]U=J/;/-30H!\&( $+K29V.N$;Z4G>F1/)3$GB"-S/.L/!5+/G6MD]I
M#XX^E>-^,*ZJ] Q^F,1AODM^)6+_@ ]9#3CZ$:Q!!A*@;8&,!^!AX&*:4SV3
MTJIN6ECU!JI6$$6 YDL0,G8B^B%)[X.(%MZ%D&:7]#&O?[( KVM/D/!VEE()
MXV?M2-UP1:HNSW9)>I:Q3A?4#BM;/EG&^^<DS<_8Q_8DC%]HEO/C$*X&C4.G
MHF/CH FGA1=!]GP>;_E_KOYZ#%\8CVSDS_.+($U?P_CICT%T[',,.](#:IRM
M1,I.@Q&0(-X2\8\&Z8H$.2FIB2#'T;/)DFWX/VA-BJE@3L#KJI43ZN"4Z3:E
MAR#<7GT]T#BCC,%U_DQ3VSV8%36@(ME)TP5;044*,H$[04@6W\G9Z- TH:@D
MRX14B9#*GTV? _JZ^N0 /3AMNJ,;RE2;+9[9)YH/ZX^F/:#&Z#CNPJG1;D58
M2V2=L&7[?+/A+WHRDE8$F'@WXJ.+<",XX#!]S7:W,>O[E3%A@'*[&2""._QU
M$5#]6< 6!ZVV+.)X"@:XDXZ"4,<CI/KT0;&K-7TXA%P LCP--SG=3CVE./<$
MNFBX2JDN)V4/Q'"(66J)>:'I8V*SR,PH)C_(8*V54\5H^#I2LT2PB^DH75.7
MV5&*YI_7\1,;MMD<C\W.//0]MF0=Y7ZL>_#; VF4]":)GT[2!ZEB=:P;4@4J
MG&:N#[R:+[,,-S3(Z%WX])RO=Y_9:92?0@U*.$ 'J&]#$G0!5[4G@F!%!,E9
MLCMC1-)=,KLZ'41@T<N@1HV7)>($)"U%.7(?T#*1$)8[C_E%P3%R4^7@VT*+
M:8&T<%8ZWS5F5@H/Z?1-&$/YZRT;_)SM>/ANY\#7#O,1WTP&ZN8U\J^Z0F7S
M%1$$ E45":);8*08@G]:\Q\OP;^-XV Y_F%]T,/*H#J?AS7!'Z>#U<' I1./
M7 W&[;&=EV'!D\!,C@9;(?WU,5B>8D[(NS!\@G'7*#B3<1,&CV$D#E",,5%E
M[#F)MFRJ.8/YJT4@J7T7@.;"02X%A35IM4-@BQ5VU.F,$F4-XG\0*S#."].Q
M(.PJF"L" 4.4DIB9_CQ\C"@W;@_,MGU*<IK=!J_<I6$*3AJBA Q+&I1""=NI
M*8AH2HJV^/ZV:<)D- Z3E,2< C4$R0Y82O"1':K@%.22[B@#P_:.X>&"_3?,
MK3:I9C) U1C@7_5(R^:$MR>28%&5L/69C94C+4]N_(EC&4\D"D\F2E8XJ%WT
M%%F89L=GJ/9I"O>8%LE&D[OFR$:-,6S1"XV/U-$0*30H5DCEW&""1&/\%7D4
M]VG)O9WMP=$$#8[T:J !$<IYT.[(AW6J,Q]S</R@9O9D_%2D9Q+IR&5QJO+/
M+S'!'^&5'\+:_X".:%OV%9B?I,MAK*L!55/L'W^;B'"T8_@Y=:.Q/V_!G20H
MF6XH!^JK\&'H&."/_SZ\".DO?!<6;VTU!)!A;3J>M>\5*K\9[C-99[X/LB5J
M#)H1($J<F1$=H+!.CW2K:IH9V3H:6'!K.>_!"6]+^HPZ&L2=N2_?U"%E=G#@
M6.[*2KZO-'P#:Z<9YST*:@8YIM=Z6$<--*C^:E/VACYG-:J2CF+?/\_H -('
MH8+F$W6!>9L SQMJ!?#"F>@)N&WY+IR@?H"[#R #GDXT6#OMKI"W55;K.\P^
MRM%E-+0=*7WV_OE$!V#LPQZD'4I><O0Z#.<A0K17)STR##X[J6B0;?<$2>0+
M!T]TP Y5YF<-.D@!Z@9/ >)DX[44D-J@Y5H!CTC?XL_9V95SSPS_ %P4M)NQ
M@KX$6 4N6-#B+P3&4 #36H ?RC]-(F5- (NQFK+:&87[5 =6D>2D%K_A  YK
M98(LP3 BE-^3X'VGX/;[ULUR$:Q_GN=I^'C,N2>?Y FY#;RX+9P@F+PR1[TN
M= _,]RD4_WRS.>Z/49!3F2'N(MD?4OI,XRQ\H=?Q)MG3FR3C&;;6NX?@J_FV
MQ:TGV#L81RE[[C;*'HKDAZT^B.R$?,>[^5X\FN7+$NL+[=IF1H&+O(@M@2-&
MCGQ1,@:X/=<G8U +J*#;K:@;$T2W0;B]CB^"0Y@'$>-SG\3"DIATTH(84@UM
M9%& 6!$13D7"F!1T*R(IB2!%4K2)(O$DG6=,I(VD0]4H:Z0I2F0-,\@W9M7'
M!S->*TU!7Y$I?*HOK6J4KV2ZZA6YSK(CW6*=X^RYSB37_^7-;]^\>?.6X3TE
M+YSBGPG[Z.J-_'^2/;.M:$:"8_Z<I.'?Z/:?R>_^:?7C?WVS^L=__+T(E?S=
MF]7OW_VT^O'-[\O&H1@!F;CWF&<Y^P<_.P4YN:0;RLO DA_?K@C'AVC$_O'[
M%7]#?:"B%ER$&FJIPZ?Z-JT?G* YL.7UE)4R];:&S7'=PVU/^N?BLM GK7+E
M7:];_V32K)@7=>[7'N1LUSJ<]62WUH$,,J]('H0QW5X%:<R&+FML)2_I+MR$
MYGPBP\2@>40L9%%3:T@B4E*1[YJGAH+P>ZR4&R,D:K*_E:UPDVS8(DQ-KF$+
M+TS?FY//#=G7-LW'AA-TX/ RQ>8ERF2F#S0-$V:S@S2?A?7W]"F,.;[)8\#^
ML)F_BHOD^"K>SL+OE=RA:IC%=5K:.RM=+,>OAUS6 '_[KK &_#=UP%/R&D3Y
MZ_HQ"I\"?H(T7M+9DP)8"@<Y] %VDHS4=&BOCN<0)RW$22HZ#(B[ JP$/ JZ
MM@E;EUFGXAO8*(-USH0R'3-/_)7$_):0QAOS^VHC%;#+1L]]GQ^D:"TS[#7;
M8R7[F2+ IMF>?,<SY9"?E%T^M"]E $Y];I4!+*'X*MEV<9V*^O%;<:R]I>D]
M/\';N2_UU#@>38,T9B<G(R1)2B2I=,X01DP$-9[2C!:K\-14'AIL;;%$F\$9
M.00U%.T1'&3GE:_+3FM4*AQMZ>'>K"62@-04Z)IA+T*A$8I[TA/-T"')H!$Z
M&"%J@G1GNVA!28&I 177-NA?S&<_#OI#O+=A'_:RC@KY-F0&X=[&"R+4U_4E
MA@O>6V28H&_S;X?\M?[B!@G^5E*T=<"3VR<;0 UJ0P^:L.YI1QPD;#M N\UU
MV'<K%[P>GBAF$,ZG<X4;_LQ7NOZ<+MI\.1PPA@C1M,ABCZYHCR<GC0F"^'C>
ML,.665/P3QU]_ P>/$Q$R)JAW<+KM +S #)2 -^.(<,8LM$"K,-('R]VYY%!
M2F1=,._G=0J!?BZ9(HJ7IQ-+A-DH">H91;ZH$!N[O5U.3BT%H&;HN59KU8MG
M0%53P]LZ2/@,#+M:)-XXYI A8P4+#P-U8;H-04/%.CRJ86(5&$03M%>64_F$
M#5#JFWDU.*EOVA'P>1/&])K]TQ2^T-<8 Z=-7@T8X,V(:(<-V.D,HR!7P806
MO0H@X!!<!@B7#I;W019NSN/M91@=<^,);I 2$-O#4BBAF&7(>N4#7!%!)4)<
M"CH<W+L+PU\;\_>XY,"$$1O7O_^[W[][^^Z?'RN)MOT202J&)=2Z6F*),^@]
M+'\5_(')*$.'CHS#(MU%$F?OZ2Y)B]?##\%7FEU]91NH)&5[[B!]%9K.(_ 8
M)1L_QM_3=<R00;/A??!"7P7?2R\U>IK]N'R63S@F2?U)4G^3/(J/EL_XQ6=E
MOISZ,Z3\#DXP/^S \>^4@Q+*0<EYE_BGF$45K_\DM*C601LNQF21Z/H]C>G.
M^$I-2P%N,/JXUB@[:UJF\B;?%:UG?(3VDV0[ID_\=LI.:QVX9UI&#FGR$F:(
MM0)'<5VD?<>W$%J$]VNW%MYPFLDV<+6E,>ACIQV@%G8Y[-N"MA=;GQ["V7#?
ME] &9L,_ECM(S>I%:%>?>N&)D/C12I=Z6V,D=S3.?9W\L*5=.&IDQ[+8.HJM
M=E+MDKS(7S@,8 ,FX&#\)QH^/;.MQ3E;K(,G^NG(4YFL=^+PV[B\L??4C.T0
M4!E&R]P%7]D1*7HBLBN>C$V]G/3&Y3.[^&=!(7Y<B;\I@B^5>TURS*A(JQ6?
MA!MIFGIT-7Z:;B"L;661(HNK4P,-QCK7P[E^M2L;HR<G'<=^60(+-3/I(&:T
MRY\.,( W:U0X2WYF)[(TB)CFG6_W81QR=GCNKH)!TVV;90>0-W"V,BF77))P
M10I288K;Q*7"(%W539;LJ2%9T")&O<MS0J%RO^<$0<2UQ&4-P5T[K-8,Y,.1
M@5>9:R=1E@FO5@GKU0$CY5I&F7C/?"=&7VB4'/CU^?!B,$ 'FFC-+(&:8TVV
MEV>4F@+7WD^28EM3X"97L\"2FE?- D@(EOPBR40B"Q>+KM)@6/8>SO467C06
M(%K.UCL="BRXYTWX^3L+(D\,O0XL6H.O0PK@!4D2)VW?7,&+Q3'8@A;R(L5"
MDIXB,8GB!R[(OD<_(8^12)90* (+OBNV0=^CGI:M(:;<>MCB"_*F7\88#.^,
ME):@-_M=+M7;9=EB_MV.ZRV^-:=>W(+WSKYZ^]T[]9 H?6&?YQLHJ39647 Z
M$E#<:OE685$V+>SV:L$H,AMC[<1[ 6EIIG$1;4:*"FTS3#S8N(S9L/BQ47'=
MH""%?#BP7[AEQ)ZDVHP4L!<E!KW<ESCO1Y JSHY1@2%"Z/JS+FB2>UM@E;"N
M1^LNB0<[&CL<]5:D]4@;[N@+C8^TC"3F1X,_A?GSQ3'+&5NIQ5'6N@=0CZ:M
M5*I74%#68?F\'?G"B$E)C7ZXG2R=>@4\F7'+(%ZLB8%UXCJIE.K.==(G;TS%
MU==-=.1Q*>=91MG_;<VE.4?UYH\)T4@[ K4K4O5%RL[PBG3.([;<O*:%M?%8
M&4V@=51,$V)'*VF6Y@T%93]UE9/]ZC]OTV1[W.3K])ZF+^&&GG\-^RY;]$T!
MU,K IYKV1#035RI%2V;965O@Y781EB&P/X2)$MA#@ !!+;_#*;Z=72;[(%1*
M3K0EZFL/B]]>CJT0(5OCP7AVSH'1K,=*#Z3U0(%,PB58^2@J?QHV0YUVH FV
MVASJT/"+;(%TXK'ELMAQX-7*M&.SW!7J!A4VBU</1-6<73WXG%!KZX8I);^,
MC&6!<ZU^F!I#U=/2\:H\,9+M"&M(I),*1V=&,2U*K@JF-2H$ <EA:+3J8BV/
M"ZM*6./Q49B!W^+4NZHR_:QWT@<I:@[M#RE]9GR&+T7^  L/H'-/&!FFK*74
M9W-*=J1%6KK0_7 [C9Q/;0(HM\D$OK_IX8@_C/Q$&=OLW'V;I%QEF\^]'Q+Y
MV-OFC=)<7X"^$9IE5/HO7'J!+]_]K@A_#,Z4@WUB18J/:)[:H_O.EQZG36N<
MRF R_H(1-Y)L9JWIO=::3V5 :[9T>2[Y-5@((Q5LQ18#]SVE3NQTV*<T&5-$
MQ$Y080&NGO(M0\CR8ZG]D*0T?(HO1,G6S>M#&L09TV"NX/%6_!2);?/Y]B]'
M&?9DH5=+?="3A7C2F(U8EXOOD?*#I/%%<>1K?)/4'VT: RQ7"M@PEF.T*<<H
M;XQ)4/7@WV[%AU'P90<SW1BY;&BF6R)\$_XY3FD0\>(L_Y9$_-;RYR",N7#K
M^)XR%(1Y2+/S-,S8GR[9C_'3+4W#9#O!B$__I =F?(9Q&V'(ZZ[9YNPE"".^
M,SO;)>G9?1#1%:FY(@5;A/-5I3V3_!#)$)$<K4BP8T8(+]0 <(@;X_,DQD4<
MR BS;6$5E3W_LSTF6%9Z#W\^AML@KNE/<#Q\,/9SF2U;<S^7S4)QZXH"*\^,
M;Z:-5W\]AOFKFS/71(_CPC5*9'3<-BG_@4A:_QRWPS-F<-<.3Q<""B4C7+.2
MF!L536R2)1T&ZC02*,G[):3J=B@Q2TMSCZ(7)@QI]<$$(,!2%FTNM %. ^TA
MRU9H.!Y"#%)TTV)L@U:A,*%$J3UA@@@<LL\WF^/^&/&7RKK-TV#8DT,?@!K@
M(ED77N?KBVOMU1=J"-4DJ6I:8CJMRE.$#U%-SNCL:IDS- $U;[L-^9$RB&Z#
M<'L=7P2', ^B86TSTT%JV( $"OZJ]H03G+$3:T&"K503!;D>%@14:VR0I6B*
M#:Q +W3W22S.0H,:T=,6]O)6X;3G/I,G2!:-D+$^&[O -[#]:.BY=^V' N3[
MNISMY.BV+"XV"%\= >@K.0W/ZD,XV9!41>YPT6S->'/O<TEWX2;4[^1@'[:9
MT**^73-!!7+O4EZ)90^)9N40><X?@XR*N$.VXQ(.]#O*SCU9F-/B38?TL][1
M3?(4BU[^&$1'4_J&Y3\-NH-:?!S5O4OU27ZHZ6QE2+TG*TJNGXE/D^:W5Z3Z
M>O6T2'Z?-!C VLJ!CZA8;8IAVC0Z]"&[!92BJKM)&"T%=(6+XA;7678T%D1I
M-X-T=+?Y4T J_KPBLL'\=Z1BEN[S(,T'?=IF1M_3IS#FBQMY#")^U;J2! NQ
M?!4/9N@;8/A*5CHQ<POJ<.]!JN)?[X$IY+42LYCRX\W;5LG4U?X0):^4BD:W
M;%:?F8FX98-KOG :V2/H5=18J7M7G$*5N]$@I:*7'1:GN+)+(OK$NLV::P"N
MOM)T$S)I>/)C(5]RD,5V>3AD48<HE.-SC+<T)?DS);0<$DER*(?DP/I>D>\D
MV?P)M"Q#)><;G>+X+J4,RC@CLDM2<@A>Q55Z2N51B.T >7U-GLGD649&X%X5
M3K(+ZB7B)*/@B3V\HUF>AALV6Z+9^9<@E7$I'Y)T1\/\F!ISLL_0MR\VTG(D
MQEC+NNO"7HK.JPCJQ@<\-)TCQ^6/C(R/!9,OK<675N.[L"SGIMA#;PR"BV(X
MF087K4 W$N(X)/ZVEDM@N38:3RGN?>$; :.D+DHO.EH5BE[T1:K.O%)P)YGG
MWQ5YJ/O#>+?4]6&P^Z';G^@7\9<1BWR7WA,=;DHT0F\9N6PP_UH\;:L^*!S_
M W<2-&NF\J[\,SF+39$O%D31*A>KH:@4NJ60&Y<)ID+I -]6J#*-V=E[:RV&
MQ=.9"[$[OU_(6[&ENU ZVBW>NLPNFDB)SW\9E@TVO$"4AU9$HW%.!PU$.\(^
M?;[9),>8'P%OTR1F_]S(%PCIQ3.;*GH=-QN$\28\1/1JMZ,;=A*23=8Q.Q;)
M*#J#Q9G_4Y"E*N8?)Z7"!;-0=1>D]1&2I$3VP6]F6ZV*+ZV(_)9(:R1;,F7B
M?HOKWMHJ,'L+@&&[D/$</'"5RA&H'S@+7V>PE<<?/C(Q&^.@'KVGPK2A%M]8
M2 .5FAT+J9]?T2:=<'K&=Q*S]3D/'R-Z21]-3^7FZ=ZSJ!&+\9@0&:(\OQ Y
MU:H/$/X%K.W60J-3B+QIBOSNS;M_(I^2',LKO)"H_->=#1@)(J'@\LJ(=L>"
M^Y=2NDG2+6L0L-;L)YYIE%M?UCZHH70H K\WDCO?8V-LS<J8^!=;FS(A0:OR
MB4NZHRF;FP]AS":WK+]Z)V\#'Y)AHSE/MU!)7Z?+/_CP;+TC9:>DZK6H)EST
M2QZ2Y:WC<#+9Q0:C91.WY6#LJL&0%H1OR83!C/L,)EABVIE4HI7"UB=]L$IV
M>QIZ,<'P5<=NOH2)C^IL65]+*//4RZ7>R266XXL^?PB ];#BM>G6*?PY^(Z<
M 4"T-'EA-%@II]5(W]$B+4TF+O&"IZ=4U!L6P\P3EAZ%YFU#MBW+HU=9JXBW
M#!M3%,3E5BZ365!>D9)8/[ /K'?G:<K/FGR !O)+:-H#GL%T'*NQ6!$C2U+I
MJ&BT%WOFYL_R16[.CMND3829@,)63-Z.(ZHKX*<D/@L:OVLD6?,A-X41=]T]
MO1%T@-Z0F@%>&X6-<&. F^,[_)+8M2=('X>SE(H[H]&#!191TU[X(BWH\7L<
MCI63]C@03]A;BJIQS$+3K=STKG=LF\LVMSR'7W;.UF'Q:7,Q%+<^H/:CCI*I
M:UU)7CH(RPZ(Z(%476#65,$7$FS3.P:IK>WP&)BBY,B["++G#U'R)7-+C==#
MAI,1KX]_<P431D $A7_I[[238<AZIYT)P)03C 7^_QSJ+PS@<=Z(!.9_8,M+
M^Q>-E@:\3>P7,I7%Q!%0;"5KL9)0;31L1=N+/_+]2O=W#0*\IW_+#,B&RT?K
MAL7U226__#LOY;4CDE7,]YJ(8Q#DY+%Z#JH=#-!$)'/8""5IR1P&XD3LI Q_
MNHXW*0TR>DGE?]G/LNCRU=>-B#>X8PN#C$!8RK".8.14+/&8,5[(=*_*Q! E
M-^2[DI_O5Z1BB90\$<Y4$=&$5*@&>^1YZ%98CI:X*;>UER=K&$<;A5DMZ6B+
M )B'M@C*:O*RCI?:N"[R-<@<N(N,EG+S685?MHU8$A-?][]VJ7B!1X^6HY<6
MHW<:AF]!E512!B^GCY"!YSGGX39-7L(MW;Y__9Q19G2K$('S31Z^R'H,PZZ<
M,9V!!H^/D+5O/R L0MD->7PEW_&>V.[@^T9L1=T;>GG.602O)0NJYK@!VV.1
MJX9DCX6MCWHZBWYZJI?SZ"/.26:RE&+I/32DW)VL1D[71'@-9$QM*-UF'YC<
M93C0>B=?CGWFS_?9T82MX>$+K^TM?OV^FTQ/Y+.I3C#-Q^X&I5WXNX!ZOO0(
M=I6F_![A4"7-8#CYS2+K0O55L9?59=F4F;J:3I)6P@J<A1UW1$6Z"N<D%[XF
MN #1[Z[! U'N"<$53?YN9;(R7JBSD=>[Y)J9;EUTA6,G4.$5KK)IE8%W0,H>
M>'(JTLK87AD>U@WT*ZQY!15:'_K_5GP\=%OA%GBXM0I,GG=:#R5^^<.05GJ#
M:C[9_#H')%O8E?)=PEWR&D3YZ_HQ"I]Z!>^;60,QAATQR6*V']7KC(*4U+0(
M45F391*8JAX?I85,244KK(47MF$0?EJ; (,]9UNP" :74/QZP]-X=G1/XS!)
MQ2M>D>3/ZM70U%XQ3,4HZ<WS5^TTUNWWW[)7^31:Y*)@?T=_P;3<6/1L4^JQ
MR.18B%>//F]9QBN'UEXA:X:S(?,+%4AOL30NL6M147RF"QIC9_B.8+.LC@[A
MJK,3N*!Q$[R6S&MWL 5R+=W"%K#U44]GT4]/]7(>??3J@L9>2N6"YKMC*65X
MLKHY72<1KFH*7\9#<K[YZS%,Z7E9=>%#DO+',O?R?35C;B 9E7-/D-<ISE(J
M>Z/2Y\/S2\D^1-8'4E.N2-7KV2Y)SS+6[WSJ^9.4-!9OY0?#_V<0N+ALR,3V
M3D!UWQ?2!7KO, ZLRDW".*0B*B4S'0>V_W[E%QCY>2S>M!UX$Q=]-'2"J8HF
MV6RTL*1?B6O'?"5NTZI.O%% )S&;NG<H"(5<5"<7JAH.PG-0 P>QB1.\P(T!
MX^9CD(L<(^N=WE)8AB4X]8@4<. FM=F+P)L+Y):]<4B#+IQC@P3F'(6]["3T
M:S6=!G33_?P(E*,?/]?,  5SN8F,G>$?1\VR.AY+J\Y.P$WD)G@MF=='40OD
M6AY)+6"+E#R9E]&--V%$JVS.-TG&?C^?)B_S.:SDRO.-UT"RY>I#C<SMY#O^
ML>_YGT_-;N ,8EH-(K]/B=A'^&_CTE%6^,9(TF./_N!-(N*95=28F'AF_00T
M:IM-2OFMWOD^2?/P;^*&;[V[##.1QYXG@KI-Z3X\[K/K>IMH,ELC.X0T3&-E
M5K2F[(A\U^SJ>W&F*'L3IXVROQ6YUF^VH7P!L\G/+6S0Z$.Z!R2E$'M;#0+[
MHR?'C&F(5ZS )+@#ZGF+O79R8L9CQ:])LZV[@-1E>[D4[>T@5W@!VK$U L15
M'T@[@/DDY%'_+[SLFDPOSL0M%50(BA]*,Q:MBE8Z0A5.#R]YMN%-*#ACG#09
M-:B>D0I0V\S<J]4OZM8KIEZ'2"Z6(E]O@W3%4VP>TJ2H<X&C9N-%$_(TET&L
M>BTSBD#H5_Y*!;6LDX6J=/7>0D\ DRKVOODQ:+F. #*1HHYG)86BYJT=4@%6
M:[;YLXB"[4WSB: '>#?C1<GX: 0+',K5+#_5^;:HSF/AZW+I!% ;G&138_J4
M/%W<9U)[F8HNT%U,DZ2L2RHVG$%91HN]<Q0&CV&$[QAR1VE7W]PABJF#11G"
M[#9XY;=<3JJGT*)JG"J)I:*5A*2@]$6YA@6J.#_T<XZK.!IH#>N+!E?(:I(>
MZ?:FME)LURC*AU3*W?B;JQ8Y=8VM9&[C8*^#O%_2(!;+@JS04B^%C;][I*;3
MAJ24O=A92L$3(7BD%Q==MT?H@Y7JCU"&"6\5#:OU#?_9K-7N74"]0G232ZNE
M)7E[0RIZP-/%&02L98F$+,B*-A:*K6> 6#BT>O,W$QZW#3PF^CF<ZR7S$-=W
MX=-SOMY]SN@Y/\J,M1!*-[Y8"56^84MQK5H*T0U_D,PZ(J(GZ!O-F:3MFHV4
M4YPEN[,C^T&>9KTU'QJL.IF0)8$ZBQEQ *S)E(AYY7=?U;PBO0Q6Y;U-*2_H
M7:9QN)*;QG*7)*1V.W_8=8AZZK"4V?*L4?1&BFX:YXSS7@V&BK:83>Y2P)X#
MA:A1RF]QT6S5/,@>/DFXP-H#?;XSOXD:H/-!.^_ZGP0-*.$=XE,G5U&JU#DI
M\CLF*Q19J\@=RFLEE1U1^2[8Y'\*\^>+8Y8G>YJ6QX)7)]T8Z E56X:DM-2?
MLAM99;KL:%4=RE^Q8@NF2]Q0LQ<:'SWS:ENA=%CWK"#JP\70'=W0\&7TW5"3
M'-MSK<KC>D-4$_NS9ED)5DF0:B5 =RAKX&9_7Z1B#5.!>!1OS+[F>A_4HD-5
MF;8$EKK2(/)'1X8DD7]5UDQ<E>@!T+ N]*#'QP>J!HUPZ<3+!ZD]"!OQ$-6K
M_$CV4@X^^SJ-9Z@ZA7,')VC^AUV8\^=D!NUJ-H+-TE#SUH>;UOO+9@6&6QZ9
MF[ ]6)ZGX>,QY\L[?V/XB4UY42J=-[N.<\I+E*&E7S"+QU]&(J=,Z&"C)PM"
M!QAPR%6*IW5*IED$AMIW 8AZ![FZH.FK5]@M4H@>$#I)/OD.-JS>'-G7'F0_
M'YA58#]QYP=;9_AS)=9=ED3AEF\0R6,0B?=)V3-%=G.[0KNKEJZX!GRU<#P<
M(BIN["+.U(<H^7(=[Y)T+U]5#.NL=0^0[QJLI5)>##0HI:IR6M(@1M?7F83C
M;P'9@G9,D6.U'1&H/(QP@]^$,!*Q90S"[8<D/=\+5X7<W_"MXT=V;F,CR=E8
M[YQCS^;H&2K89)91Z"N:3GBOHB9/T2\I.^;!*(VN>0B*7U%LRXV)N%WC=5Z"
M8DS"<DR*!7/?&!>V_!JBJ=!"6N;3FU:4BV=*8Q7X@@04>Y @!<AT G[6CWD0
MQGQ0RHK-;,#ZA\1TI3BI5\@#QB3IE3UY&<U6A>F1LD>.A:K6.@>+SHS.?^]H
M=Q*9=2 LPOQ(TA@9VAP9SPSIC(JBG$VF:PED/H7'O%5'A-E/'@RUO3RFC#WN
M3F+6<)W>!FD>!E'Q\T,:Q%FP&<RZ,+EOT-P,TT="O;-74Z*4W1+9+RDZ(DQ'
MBJZK7S4ZQ\N),/^HM-?7L'!1\A1'S;HT/+\*;OJ$F31#3;(PDUK 68EU^A3$
M12*(B\JC))-$W++)*[=I5:Z8(+IGOQ$;)!LWY4S] UJ+N49$66,;_:Y(J^<R
M$5K5-]]Z5KV3NGMTA\J)#@ZD=9E5H[H69E9U.A$K<UEYWQ[HU_P]8_/7I0Q.
M[Z=.Q?;TC],BFE9_BOS"/T;$U^:W299;&>!ADP\HY#Z??>UDC8U!L6:U.P:M
M DWGRKT];!MVRYC?6&::-A#!IF75\ZZ)?)2A!+(U^K9A00& $Z0.8*@G">H
M@ #O+\.G.-R%&UZW16'+9FFU[0#R]M)6)N5^KR8DO8!;<EFSN[L<+=IQOP]2
M4;YE0$K4NTPG-"I7F4Y0! U)ZZ^.9+'86-#"!K -2M)32J=9X*M=WPM]$8*4
M"#C4S0YS/1%P=H#S0'_<#H%NW?B@57:G$#,</3N5S21K6TA1Q]Q+;7,X38V!
M)^3+GBH;/W=H%_SEKW4E,*N\I?:=@+[Y<9"MOQ:Y(%[)G/@E-!E*ZQX\61;<
MIU%];.,ZAR@@O8X+[CX&Z:]4Q,LK?,;;"Z9P01@_I &/LI?I$-P6E>4^B:,
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M;,HXDWR)$JFW3&W2BL%R+AP?GH[N$O(1ZGBY%1>*[*I14KC=6PUIK_RU/H\
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M-"O+W=:7UG<TXJFE\Z3!BQA,M^>S<WP!^@7M+*.B6Q7%,BA[[PO'J#Z@HGC
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M795)'8GHF51=&VXM@.S.DF,2H.? GPOZBD68"?>  0:"J9ZK)E-0@9X&,I#
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MMG9(U,?/VL$03L>T_+Q_[9:TZ%$O*VI S;*3Q@E^*_SB*-!206J6 _ZZ2N4
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ML. >!YET>"J)":,F#7+Q"B$K$881:C-!N$HH;K"W#:$VG XO0,85@^U8%Q0
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M4SW:E[V0NANRCHO*.F5/A'<E*_&4/E6,TCGSR-P05*23K4: _20KE!Q*L46
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M ,Q_EL!<_/K7B\L> ,M_= #:QEC:K_F7R_L/9Q__X1J&ZC'1=!_$KZ@(Z[[
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M,3QQ#/G#>T.X]9'>)=;&,'[\ZY$"0*F^34I#&KU0_L*2F&R.^3&E_-RC%]G
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MQK^PS_\E7\S)7_^4A;-Y1*?-?C=-R?BO?_I]GH?0__CZ^(3W_F\W"3#Z.9A
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M8GIDD7BH9JRBU^#\\A(M39A395T/$3\2W45<:H6G;15%VW]/TZ##CVEW$EW
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M\9(XX,7C&L4@5_76<71UA;R<K AK>.7@J'[$*P<@]R4!QS8SC*\<',&/?>4
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MO)()W7I>R#Q)JPB#47]F#L$VJ%83!SM\';@H?<U(?WR7Y>$,3B65:K3=D),
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M>WN6YB4YAW_MRCC\BAEI@IPHTCH*6@%B).M$9?9L<UF*R;]( ELN2HT*PG:
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MI"K'@RMA,1R1$PK9!MWT$6)& 1\KO>W#<B0?.I)<GAVC5ZEO0"C,8#N*E#W
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M?6MP=NR[7:^^^+HG&&X>5UF&[/4Z'):P!ANL[XMLW63.L084:\RP)N-@'9G
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MXG!9[R2)7"E8+,'$879BU0R 9;[;6'W9G_5DE$B^]6-1"VP)4H.C2:)49VO
MW2R @>T/TJNS#ER34K(6#E2ARI-5L)<[&VLA6$T$&(C]\N'W6JA 3<ERZ-:#
MG8YN@GLZUH*PG HP$3OXR.\E48F>DD71*E_U'^FF\/-YT149)9)?\=6Q$_8=
M).DWG &P[>?;I"LR2J2_70^6:W=DRPRCVNWBA5 W,?C]31(S_^8BB-Y(.CO1
MK8+#S@98V>TG4RR22E9'JU(UUB7>/WA6OWA$XWQH!OVWA/[*GJ:J.C+^3!(8
MW_T'7H\H+5EB/T9VQ_W]Z6 E^:3?')Q>_WPFKDXX29!*NY)#UMPC2AKH-HF:
M/ +D'P7&=/_QN$'*242Z_BNR)PG1>EE6S#@IOF;T0+O+\G!6+A[8'],B0HJH
M$$[.>%UV\&L&V\.G*!C^#I^!.62<U/3B!7_XDHQ(A!,:7%D2U[0H40L(\87D
MTV241,ED81 _?("OLUR6/^.,=6$HC$IM570K2(-DYW1.3Z^2Q65I7I)?^->N
M[,*O!B\4H20 >>OO#".Z"Z%SCFU+AABQ5Y''YER5AG[NM. XD70D,<4E7-F9
MKU>YV8SX\@6NPK-BIN3,5AN.%<DQ3$;W?>Z(Y^Q?:*P9DX+O>B:5VW# 2%Y+
M%DP2SKD#6<JJ)=(XO[P\\B>1:3/GF1JYHX#+GQDU*F<@8)Q ?LP7RX9K[Q0#
M(C@*GFQ9:@V*_L)WC]<Z;-V6I$JTJ1O\Z,$95=\&V&R.#9J^#]W9]$"GH4-R
MU8UK]/P(M3'![#S\_2.)8+0HS!<O0=[(4Y;U)+A88 NY.^%S+-W5Z>DJ2-*#
MG#-5'E)$A%N_CS?E^J#]*.=.^SU%#:2]6?JY"J/T0+I=;0LO8?;[?4KH@R$!
MP<H/N<6+OLUYU7XON /N[$HRNHJ?[)#(K_:&V_ C')%X=$B1%WV;\ZK](<,'
M%'DE&5V%20I$WH_4Y2]9L4I9_C,O>3EI]=G)Z4]_ ?5]^NP$V5#N@L5-.P$P
M(OVP><G/3K OUFX9:?*0PC![Y1WP0[ZBG)T@1X0)I.* [R<,OE>^$-92^ (7
MD#2DNAE38K[&89Z]O'XUJ5 G[S<X._7]1EB9W6+Q,B"'?SX9G7M*.3O!-KH=
MXB1T1:@.^)]4)H6V1OE3$G^PB*OF<N[9S@&XYONN:BAYCN6Z&B%_)CW7TFT[
MX17*&MB> G"NK;[SR$M 1,<NY$QOC&#+;#YDA"K^>[, 71([$J"E*T!"RA\[
MO;N6:CSL''4-;$\!N-;^H%*4!2"BXX^=';Z=MX#3]C\]^G$+.)4_/OXX6>;-
MR;;CD;:.N5X_^.(N#^WT@.&^>WO[OG(,:>S*;^O'N5O[N;8LYPC,QWZ);.D"
MJT1H5ZYBG;Z_TVR\?BXNFPD"P['C)5NZLNRI_$-D[7=TB?1S95G.$=B._6S8
MTL55B= _1!F G[<M8';[LT7[?]N2IY*V?L@7FC#:DRKN9Q(X+Y+ G5]=G_]T
MZM8%29]?'[75EZ."-#3M_[VBIU=)X*QE>.5MJ''^+C>C,33'W7%Z6_%1+"]"
MX.WV 3?VWM[+\ 'HD=4K(3O4G-N9/9;GM";M#--%GHMT. 4II5,W2S<CZ<;1
M(GLM21BPS2TK-/YY,SM/N@E[$;:S6<,[JQBQ?W[!C63>/+\^1O*D$I-=PIJ=
M^3KR6CUX9L<*Z3<!L#?I-SGQ]UDDGK-_CI6-I=\$P-CY:_5,$L[Y9VJS Z0V
M U+_(+<3A^3ZF=JL7:G-SJ]/VN^3O1(^Q])=G9ZN///0-^AW/=G>3<CF16*S
M\ZOK]C_K&,AZL_1SY2"'+MNNM@0/TYK!8=]^1^L#[NI*,O[0OFHM26H&6U-;
MWZ10!%Y)QL:\R [T(/]W:O/MC48A1_ 0CY-TQL;'>3K?XA?0FN1ARCBVR4]E
M\ 1N,0JS=%\@U#.[)6.0YA&KVAJ^%\QS 7BQ-,RG7X(<5M&RJNOJ[R0= @@%
M\.J#<CH@GX15^";> 1P0H@.)QC14H%1-"0.8+LJ->K.DJ"-GFH$YB9&#= XF
M:Z;$</3$C762/,3P(WD+OI/,H_-D/2NK\T/1BY[\1U=6KD^2=VC!1Y@!4N:?
MI._$YX:LW)G03O @;0;,T9Z,FS5Y#;57Y-,D#?.%QA5(W($3!>GIVH)GXDU3
M@\G19N@;H[4.0+(NC##8A>,U/#-E] XB1^Y!R)G0@1DTE> C?"+ZKR(-LU$X
MI)"T&18U/3F9D.,MM3R47,,-H3ER,O)ML1LX><H[4>(<8UDF&]C=]W Y<C_R
MD>D5=ODMKST@$/+ER(!_-HS?0>;(N0F;]7#3@OF_D \2%^25I!_AD#R\O&IW
M?$U/3B9D=PHC/LI$P R>(^\I7"GHC?Y=9#GS*KE/TB?RK3<<TEM]&$^>TR2&
M'X?<YT27ZMUF'$Y"I/?9VF=#-:B.W+API87FF^Z/>Z-$7=Y4U9P3!/F.7XV%
M8G%0@G3D(H6\1ZR) PIQ/ K24?9U/@+5&-I?'%]HQ<"H/R<9LB.[DI>2W< *
MG"MG(22?.=@P;V"*87X3I.EBG*0L$[WZ9)#V843!\LJM?0KH876C*J 0I]$E
M0=.3TPGYP4[/10ON"[!UHTS>"_ &Z#HUJ;91:LBI@'P3-.64F,\20 V6@FLX
M=H*9M*AJ\YDDDS283\-A$"D"S:3M.2V0['J5=V\S2*Y2O[@YI<WX2B:[D*0;
MM+(])P)2%B\S]@A8JD7C*OE()99F*YYF9/CG2?+Q&U,9TP5EZ^7J'Y2KER6N
M+G\]N+T3L'#S1XX0Z2YM1OMM?@FF+F$.KD'-=9SN]='E$=*RJK5=[D.0L,O:
M\G7 [=$RZ)8"15Q2^R27L&5GOA+&6!N9#LB8"K&<%"R2G4!&^'WVB.<L85#S
M(7/F+CR/BI!+;1^^HR,9]RKO<N:P)%X=;3'?W(W'A!9X)FNPU!?\A0R3>!A&
M(6=4?D\ 51!1/:R B2RV&BLN?PY&YX3VS"5H7PS$=T67^"6"=B#G7<EN\9PF
M'V$&4[I/TI*W)/QK"6J)XF9*MTCI!F(Y#*,)5N!J59FH!53"_(,9C23LIY:4
M(J<YU/XK><]ZP[P_IE<6/ON'>"WOHX+YR#S$M\O)TE?8+".Y5"+JC\QIYYFW
MB9&0.,0ND9N6>:*M"4GCEN*,?"(Q&8=&WL[;/3A=D,R/=0\3'28)KUOF<T9#
MU3A'HBCY%L1#LBO=JW6@C>BP'8I3$LE+I:YT5 8K$9N6>:WUYW!ZTB?7QR3+
MRG9]U3NDO!.C#E:YPKJB8 !+PO2#F=<D^L2NR#Z17 [F(1[1**4P!\*,I=$E
M-8;DU/+,0&>D0;@ +1&1@SFS241$">5O ;UJK># .1FF/%"+Z4L9#7I^2T#9
M)N$D7HZ2B)Y#&OH2IVW+[K)-TT(B9RUS@]M3P>7D6E)"<2[9#\:H>>:9XXSI
M>54#KD1XK*VGF!'-8H<3G7*KZ,6ITU(]U@27)+S*VN;J^&C:$ENXO0NA9(_A
M+.3<R'CQF3Y,XY_3<#B]*68%S2?VL3+_/,3];S%(YC2<KU+3],>O(/_A.!P&
M<<X2?DR3".!G-S!>"#]L0IQWSS-/IL>XB)65H=8AZ!L!)<O@8-Z$KI;!&PR7
M49C+=!7!A/3'OBV&)B?).>I9\$,S2^(@9)0LC):Y6.ZI1:"$VRB-T)Q3Q+/'
MU\IJ81F0A,4M,VQ_C5,R3$"L_V PEQ;=;$VT9P+H\I#0I;5:"$OKKT(2:HS*
MZ'O94@.Y"]P2N6J9$7UOZ>Q;AVUVDOW>@XNCB]/3KMPW%?@D\E"_I,3A4QAM
MTHG3/%%)3(/9^F/>@![?GPB<UZ34 2]=WO;D]IZ\:,:I,"Y [5B;DS+#%'HU
M1F:N0FM/E(,_?U(6W<,:$$UQCW5Z&U/U01D=L-.&N^*EZJFU%G$ZE-;)B@ZW
M\$.6AT.WHK<:E9,7Z=SQ5O;VJ-.A5%-6A/@2QBRQPTJ[8XI>>11>P987?'Q@
MM6I93+=;8:TZ"\X^#_*5>B7<M:GI*!E7GN1!Y(L&5[*%E!E&?P[B1;:GX>*K
M<GM3HDFTPN"=5L^@5S([]<UP-)"!R[-U9@EDVXT!1%4WC@4Y&T(='IA;>?8@
M8U7'-71343Q8KHYFH,U6ZCA3=Y4*0_.-#\EMQ8JM!IXK=?!W0@O:(P@U>2Q_
MMSR6=](^K^Q>XHH!-TEFM0,Y^!QG"'+MG0H">1":(*<*-=WA]B'3/ CI!S.F
M]H;#M @B^F,_GY+TC< ID8(N<QN.H0^)A_+0#_=?XJ1%3B?E;/]S1XY.I"05
MT4?PXKA*TF&YTRE&XF1$5K\<;V(F<#N1TW0/_$/\G":P.-9X807=D@\2)7-Z
M>;01&\U0C)!8GN1-R(TI7N2,J*8'VWWXG8S6]Y<'X$T\"=\CBP-+.@(G!;(]
MQ]E!I(?9B>RG M,)_P6WP]CL#-L].9F04U^YW @D\#J1U=0#=^ZC4^0,^2YE
MQ1PQ<GI4TV/CD<"M;F7M6AB?%=O=!N=7U^<7R*]9S@X("3;<8LBF_'Q)%D&4
M+^YF[\&(@#Z3AA_,(=%<#9".0'U)CH[;IP%6A=F%"L'-.U"Q_:Y#-C$%Q-H9
M3Z^Y0,1D$N3+MAZ(Q.<4SC(;*6 =.%4Z9$?81N6L>.SN:RL.I^U>*-4=&6&Q
MSX%&'_!4H-$2J.HU@-*T;Y(8-,><WFMOR7O>FR7PCS^48<+6 [&U@A6K:<DU
MM49@B;=VPM6:YX"Q+AA.IGE__#4C[-_F&N!V/ZX!^V/^J<YG-;S:J5H/Q-;5
M+Y8:;/\]"B>F*ULS J>%/[:=NJS6 ZV=\-4KG6[M8U4BG,$Y+^K&=[LVKGHK
M=+7SRF[S_\T/=:].G-W1F0?5OYOWS5I#=96XUBN_RNW4G/L>L)3&!<AK+U]G
MZUPF;MQ*VOF6H(?1B%./BCQNWX192?6W'4=?X *%$%;3BM2W1^?(%T;77!;O
M-"ZIU8G(&Q.";'D]EC:<FE(I&Y83&/G>ZH\X:LG4"?=3$TH\)?3PI<EHX?:O
M#T^O.B0G++)F[8_\*4G4B0+T)E18>[&9N/Q5&Y 3%5FY]T?N% 3JA(>I"0V6
M3@M;+58NMWDHC.YP.3PG.+)[B#\2:4RN3OBRFE!DE>JYWC.VXR]Q-B#')?DC
MM54HA^Q3>S@!?D[#)/T7G"[NKC6B(3EAD;TP_!%))8DZX=UK0@4625,J!U]3
M[G:'XP1%=@#Q1^:DY.F$'['-07 7 T79.># M"@>E!'WXJ=%T8Q(R*[(AWX'
M<&+JY\3[@8TT2J(X\X5&>C-[3.+)&TEG&X> K#<:A1S/0SQ.TAG[+<Z3UVOQ
MGI'_% #Y[H,>)09O6+(N@_.CH\.OU9W9L *5YI-?UK,\0HY\5I-4O)3D2!P]
MYN#ZDK_G#S$0H: *CJ0RM+PQT 'YS47.'9G;@!B#HP<1?WCY%,P(+VQNS-%-
M%Z )NI>0F$\F7-W%X2K)ELL@'YIKG&SRC)=<5%])##?=IR0GV6U!WKXE;].D
MR()X]/8-VB[NX5"7EI]V-330#3T*0,51@9^@,]2.'@HP=X+7:9+F5!>B5'R#
MKVDV=F%[H :R%=]V;U? <&1=]XJIVMU=T@,H@FSH5C#*D+-E)(X,SYB\W8E0
MD.[ORO:#\V-L94S%)C%G%4@<&74=\C5+\Q)/X5^[_(1?#9CO#3VT7N$H"M(P
MD6R^TK:#LXNKZS._;DK2O5>/PI&MU#JVJ@8'ES"^QK0^8#@.R4BZURK;<QH@
M:5)ZS@@XJ47BR.Z(P$WZ$C\,,OGF*F_,T&,YNYKQ1<Y+"117YCY<"S(]9/KC
M7II28[F!"4/8GEI_KJZQSTY+95>-Q%6> S?KU)JM)5@T.N0)4&Q^\P8_9<&0
M67BUFI+E2)R R+8/-6O%XE 59^W\!XY#GU\(2']!5@G5[\,XB(=A/.E-X'I/
ML:AM'X;=.7QDM\FJ+!,8/VQA.\N$4%FWSE:;1$:&?YXD'[^-2,CW!_AA=UN
M7PT>R22([N(\S!>2/5[0B@-&JC9KN[.KYH^6H: 2KS@ J<Z\VX2C1/)T4E%]
MGS_":=?.'>!X#_T;":)\.@38RQCIYR#-:<G*AX_'N7K_-.C*82-=3Z4\$&R*
M-EAJYPEHXHU@/>T%W<)O"T*+UDLV/W4'BO/Z"/F\,]T'#:'4CO)WK;F(9BS=
M W5=.$PD.ZTA!TS9MH.H=GA^,XR#R?;C6S)D&\/;-$SS13_>?RZ"7VA4T&K#
M<?(@J2K&O).SO#)>9['Z#6R]AJ#NDR)U*12;\3B5,(LD'T0J!( E#AD'2LWI
MQHSQ*8AHB,3KE)#\D7Z&\DUMH))U870Y1C9,V-JHM& D3&Z+F4J$3_LJ*^_$
MR8*LI6EY9L[J'5029J.9FJ2)I-1;N:8;AXOL.6' #<&>;8I,PL@#6H_J+]W[
M($QI,!OYM%C_^+>0I#1F>/%(2T9H-FJS 1C-L&O"VF[;EM DXG 8VY1#2?A"
M EJIG=EC]W%K]W6K<3CQD(]S2SYKA,4*MD1FFC>9.9:9AWA>T.SR0*M3[5N4
MHA<G#/+17XV5&K%08)4(0:L\MW;VUL<P)@\YF2F]+25=@"[(T;[6#I=*)!+V
M8CIPU?2IOP^&I#=+"DT1+G&7P;EGU[<==HE9K$8C8;&U*<^'<@K\T930 IB&
M639W>@!)_+*P&S)8 4;"WP/9YASYDFSBM]^2343@<Q".'N*;8![F0<3+M*^3
ME-)BY5MNJ2H'$P?# [']<K4WDAQWR"4!.MAE>&#GR[)BO2IHRI,A3PB\KB2T
M1D:C=&':HU[VPA.?T0RM); L_$1N4G#^*2 LMI._A4@U2P6)>!TH4-.)>"UK
M%M _KIQ\EFGURM4,GDD:)B,W4F;S12"S7SXVKH7-GA@2F6MQ0.D*.,M@5J1A
M/)&*F]T 0#"_[CT5%&,U-HDPM,I@NHWW2Y #RGQQJ\X&(^\$A/$KPJ4"T_?Q
M2!C=JN!1BI&?HQE-0\-/5%IQ807[=0KTS>CF24;'&N:;#P0$1 XYKBH0MA@E
M0M*J8%0M;FXEJ"4>RR$&YR?(2:$:$8PM=!*1:)4E='MO+&GB&S(\I^&0Z&3"
M: P@FU^/:A6.#RT\B50<R( JN;? !.-A. \B+L"@YM";UM>,RO8&AB1+G.4(
M0(86F4PK@9/PN&465(E8/P+,+*?J4:5%7^H.Q&JE;=44F40,6F5HW4;[0D9D
MQ@"Q+6V3F<58$J0C ,E::"ZU B=)0M,J[T>I]--4/=DTB49O:3""J_)ML#!/
M.Z89AV:).L).7N1TKU"BE,A)BW/0B9##[S(R+&@^RQ(1*ITINC%A^;7(E.D(
MKD2*#F2L5!G(E9A*;BK<VG9+LF$:,AQ*(WCE48%<+3)5.@,LD0_<#'H[FG9_
MS%Y\:EQ$%", &5IDK:P$3L+C YDNJ^\!P?=P5LPV^E-__)PF]$&P/WX,,M"S
MY@DUO+P&$6&:%GTDG,UHB;1D^'N-7:+6=X'D+5)1#D@2B10>R#9J)(4 HTB'
MTR C^HN-3??!^6F+[)SVR"2LQ0VQWDDSNK;44L%^B$-:H6FU?^Z_"ILQW')0
M(%:++)NN\$J$H\6^HF7K;I"F"YJ-94F$MRG9\8NJ9!+7C@JD;9'YU!E@B2RU
MK#H+')U#0D;9/1#5W!M1T0N(TT(3JA:0A-NMLISN %O'3MR&V3!*Z.5,91\S
MZ VD:J'%U!B8)+NS!_ZCZWWL+LO#&74O6Z,PTQ[V^P'D5GIV:B%)N-AB6R9-
MA6Q\M-/&0(C66Q\W."0,Q34KE@^4^S#-8.8?A+NQ2T-[S#JR9%)7;;O7F\.2
ML!/7"OA*JV.-3'DH;LVS@+7M\JW!(N$6KCUO.YE,UIO/HW!(HPS?0@(3TMM2
MC ?@=&B1TE,1GH3-N :S)8S/19 &<4Y(1NU\(0\5,N:QIC=/%-2V16N)3<+=
M%OL%EAWEUT4**SB':,;AN4I:]%97#Z5$3EIE/ELF+0ZBE8TP))G@RJ>0$,,1
M>/Z!%NT<5?%)I**^;R%>1<_78C:#EOUQO\BS/(BI(\,RV5&V'_Z'4^J3+N$-
M-PP*?8H[P!WJ&GNWUE7Y%+0>G)\A:UTJ<AI=8#<P?E;X!#H@[Y12YICP<@/A
M9X'/[3**9\B/ 3(^F7!U%\?/ I_VI2ZQRE*9<51P=7*&N@,%/K>)MU8>C3>"
MDKIYYE6A7\OM?0<':I5/HV<@06H!N7YHU1\H@.PWHF2-]E5(AZP#53YWCKPX
M+H)H[::YM/F9*V?"[D KS)H!=BPU4N 4,!T5"*WJYV&TX+_&P2IW"+V3L)C
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MKO^-SNH]R,C_^/\!4$L! A0#%     @ +3I:4#F!0[[&HP0 M7(T  \
M         ( !     &0X-3,S.3ED,3!K+FAT;5!+ 0(4 Q0    ( "TZ6E#N
M(< F*P(  #T)   1              "  ?.C! !D.#4S,SDY9&5X,C$Q+FAT
M;5!+ 0(4 Q0    ( "TZ6E#8F1].; 0  &48   1              "  4VF
M! !D.#4S,SDY9&5X,C,Q+FAT;5!+ 0(4 Q0    ( "TZ6E#EGYT/Z@8  .47
M   1              "  >BJ! !D.#4S,SDY9&5X,S$Q+FAT;5!+ 0(4 Q0
M   ( "TZ6E 7)0JF+P<  $D9   1              "  0&R! !D.#4S,SDY
M9&5X,S$R+FAT;5!+ 0(4 Q0    ( "TZ6E!-KIX$@00  *L/   1
M      "  5^Y! !D.#4S,SDY9&5X,S(Q+FAT;5!+ 0(4 Q0    ( "TZ6E J
M@/?%KPT  !,T   0              "  0^^! !D.#4S,SDY9&5X-#0N:'1M
M4$L! A0#%     @ +3I:4,TTD'Z=(P( CI@" !$              ( ![,L$
M &<X-3,S.3EG,C-C-3DN:G!G4$L! A0#%     @ +3I:4"K&1;':40$ 2Z$!
M !$              ( !N.\& &<X-3,S.3EG,C5T-#<N:G!G4$L! A0#%
M  @ +3I:4!,_0*,Y%P$ MV<! !$              ( !P4$( &<X-3,S.3EG
M-S9B,3$N:G!G4$L! A0#%     @ +3I:4',#:@:V9@$ @;L! !$
M     ( !*5D) &<X-3,S.3EG.3%M-S$N:G!G4$L! A0#%     @ +3I:4-3/
M3H-:&0  X D! !$              ( !#L * &MP=&DM,C Q.3$R,S$N>'-D
M4$L! A0#%     @ +3I:4!H"C($?$@  SP@! !4              ( !E]D*
M &MP=&DM,C Q.3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( "TZ6E".P7U8U%$
M (\L!0 5              "  >GK"@!K<'1I+3(P,3DQ,C,Q7V1E9BYX;6Q0
M2P$"% ,4    "  M.EI0>"AC EB9   Y!@D %0              @ 'P/0L
M:W!T:2TR,#$Y,3(S,5]L86(N>&UL4$L! A0#%     @ +3I:4'\1)NQA<P
MJ8L' !4              ( !>]<+ &MP=&DM,C Q.3$R,S%?<')E+GAM;%!+
4!08     $  0 /T#   /2PP    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643078640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Each Employee and Non-employee Stock Award on Grant Date Using Black Scholes Option Pricing Model (Detail) - Employee and Nonemployee Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.76%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.58%<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6647014656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue -  Schedule of Product Discounts Returns Allowances Reconciliation (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionDiscountsAndChargeBacks', window );">Beginning balance at July&#160;3, 2019</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks', window );">Provision related to sales in the current year</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPaymentsForChargeBacks', window );">Credit and payments made</a></td>
<td class="num">(1,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionDiscountsAndChargeBacks', window );">Ending balance at December&#160;31, 2019</a></td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives', window );">Provision related to sales in the current year</a></td>
<td class="nump">2,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives', window );">Credit and payments made</a></td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives', window );">Ending balance at December&#160;31, 2019</a></td>
<td class="nump">1,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns', window );">Provision related to sales in the current year</a></td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionSalesReturn', window );">Ending balance at December&#160;31, 2019</a></td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns', window );">Provision related to sales in the current year</a></td>
<td class="nump">5,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns', window );">Credit and payments made</a></td>
<td class="num">(2,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns', window );">Ending balance at December&#160;31, 2019</a></td>
<td class="nump">$ 3,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionDiscountsAndChargeBacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition discounts and charge backs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionDiscountsAndChargeBacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition discounts charge backs fees rebates other incentives and sales returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionFeesRebatesAndOtherIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition fees rebates and other incentives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionFeesRebatesAndOtherIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionPaymentsForChargeBacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition payments for charge backs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionPaymentsForChargeBacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition payments for discounts charge backs fees rebates other incentives and sales returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionPaymentsForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition payments for fees rebates and other incentives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionPaymentsForFeesRebatesAndOtherIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition provision for discounts and charge backs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionProvisionForDiscountsAndChargeBacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition provision for discounts charge backs fees rebates other incentives and sales returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionProvisionForDiscountsChargeBacksFeesRebatesOtherIncentivesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>revenue recognition provision for discounts and charge backs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionProvisionForFeesRebatesAndOtherIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition, sales returns, reserve for sales returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionSaleReturnsReserveForSaleReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionSalesReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition sales return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionSalesReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643875680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember', window );">3% Convertible Senior Notes Due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Notes, interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">11.85%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6660872784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations (Tables) - 3% Convertible Senior Notes Due 2025 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Outstanding Balances of Convertible Notes</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The outstanding balances of the Notes as of December&#160;31, 2019 consisted of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Liability component: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Principal </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">172,500 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: debt discount and issuance costs, net </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(62,643</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">109,857 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity component: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">65,641 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock', window );">Schedule of Interest Expense Recognized Related to Convertible Notes</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth total interest expense recognized related to the Notes during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 74%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 18%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended<br/> December&#160;31,&#160;2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Contractual interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,849 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">344 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total interest expense </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,368 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Summary of Future Minimum Payments on Convertible Notes</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments on the Notes as of&#160;December&#160;31, 2019 were as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 74%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended December&#160;31, </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Future&#160;Minimum&#160;Payments </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,175 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024 and thereafter </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">182,850 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total minimum payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">203,550 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: interest </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(31,050 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized discount </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(62,643 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; width: 9%; height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Convertible senior notes </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">109,857 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Scheduleof Interest Expense Recognized Relatedto Convertible Notes Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ScheduleofInterestExpenseRecognizedRelatedtoConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kpti_ThreePercentageConvertibleSeniorNotesDueTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6633694672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Minimum Future Rent Payments Under Lease Agreement</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">As of December&#160;31, 2019, future minimum lease payments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> operating lease agreements for which we have recognized operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and liabilities are as follows (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 83%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="width: 9%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Years ending December&#160;31, </div></div></div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-left: 0px; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future<br/> Minimum<br/> Payments </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,200 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,277 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,447 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,718 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024 and thereafter </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,735 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,377 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px 0px 0px 5em; background: none; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,529</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Present value of minimum lease payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,848 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643163520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - The Changes in the Estimated Fair Value of Our Embedded Derivative Liability - (Details) - Embedded Derivative Financial Instruments [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Addition of derivative related to deferred royalty obligation</a></td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of derivative since issuance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6641102240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5. Inventory </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our inventory of XPOVIO&#160;at December&#160;31, 2019 and 2018 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%; padding: 0px;"/>
<td style="width: 20%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 20%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December&#160;31, 2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December&#160;31, 2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and work in process </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">273</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Finished goods </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total inventory </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">346</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2019, all of our inventory was related to&#160;XPOVIO, which was approved by the FDA in July 2019, at which time we began to capitalize costs to manufacture XPOVIO. Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO and related material were charged to research and development expense in the period incurred. At December&#160;31, 2019, we have determined that a reserve related to XPOVIO inventory is not required. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6642265376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9. </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are party to an operating lease of 98,502 square feet of office and research space in Newton, Massachusetts with a term through September&#160;30, 2025 (the &#8220;Newton, MA Lease&#8221;). Pursuant to the Newton, MA Lease, we have provided a security deposit in the form of a cash-collateralized letter of credit in the amount of $0.6&#160;million. The amount is classified within long-term restricted cash. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Upon the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> we recorded an operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> asset of $11.7&#160;million and corresponding lease liability of $16.0&#160;million related only to the Newton, MA Lease. As of December&#160;31, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>, there was a balance of $1.7&#160;million and $2.6&#160;million related to unamortized deferred rent and tenant incentive allowances, respectively, for the Newton, MA Lease, both accounted for as liabilities. These balances were deducted from the lease liability on the Newton, MA Lease in arriving at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> asset upon adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> on January&#160;1, 2019.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Newton, MA Lease provides for increases in future minimum annual rental payments, as defined in the lease agreement. The Newton, MA Lease also includes real estate taxes and common area maintenance (&#8220;CAM&#8221;) charges in the annual rental payments. As these charges were included in minimum annual rental payments as part of our accounting for the Newton, MA Lease under ASC 840 through December&#160;31, 2018, we have included such amounts in the calculation of the operating lease liability, consistent with ASC 842 and our accounting policy elections thereunder, as specified in Note 2, &#8220;Recent Accounting Pronouncements.&#8221; The operating lease cost for the Newton, MA Lease for the year ended December&#160;31, 2019 was $2.8&#160;million, of which approximately $0.9&#160;million was charges for CAM. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In addition, we are party to short-term leases having a term of twelve months or less at the commencement date. We recognize short-term lease expense on a straight-line basis and do not record a related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of</div> use asset or lease liability for such leases. These costs were insignificant for the year ended December&#160;31, 2019.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease Commitments </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">As of December&#160;31, 2019, future minimum lease payments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> operating lease agreements for which we have recognized operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and liabilities are as follows (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 68%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 83%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="width: 9%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 8pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Years ending December&#160;31, </div></div></div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-left: 0px; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future<br/> Minimum<br/> Payments </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,200 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,277 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,447 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,718 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024 and thereafter </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,735 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,377 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0px 0px 0px 5em; background: none; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,529</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Present value of minimum lease payments </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,848 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;">As of December&#160;31, 2019, the remaining lease term on the Newton, MA Lease was 5.8 years. The lease has a renewal option for an additional five years, although there is no economic penalty for failure to exercise the option. However, because we did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard, and the renewal option was not previously considered in our assessment of the lease term for the Newton, MA Lease before adoption of ASC 842, the renewal option was not considered as part of the lease term in calculating the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and liabilities as of January&#160;1, 2019.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As a discount rate was not directly observable for our Newton, MA Lease, the discount rate used to calculate the net present value of future payments was our incremental borrowing rate calculated at transition based on the remaining lease term. Upon adoption and through December&#160;31, 2019, the discount rate used to calculate the operating lease liability was 11.0%. The incremental borrowing rate is the rate of interest that we would expect to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. In determining the incremental borrowing rate, we considered<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;">(i)&#160;our estimated public credit rating, (ii)&#160;our observable debt yields, as well as other bonds in the market issued by other companies with similar credit ratings as us, and (iii)&#160;adjustments necessary for collateral, lease term, and inflation or foreign currency.</div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Litigation </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time we may face legal claims or actions in the normal course of business. We have been named as a defendant in securities class action litigation in the U.S. District Court for the District of Massachusetts. A complaint was filed on July&#160;23, 2019, by the Allegheny County Employees&#8217; Retirement System, against us and certain of our current and former executive officers and directors as well as the underwriters of our public offerings of common stock conducted in April 2017 and May 2018. A second complaint was filed by Heather Mehdi on September&#160;17, 2019, against the same defendants with the exception of the underwriters. The two complaints are related and we expect them to be consolidated by the court. Both complaints allege violations of federal securities laws based on our disclosures related to the results from the Phase 2 SOPRA study and Part 2 of the Phase 2b STORM study, and seek unspecified compensatory damages, including interest; reasonable costs and expenses, including attorneys&#8217; and expert fees; unspecified recessionary damages; and such equitable/injunctive relief or other relief as the court may deem just and proper. We have reviewed the allegations and believe they are without merit. We intend to defend vigorously against this litigation.</div></div></div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6668649920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Future Rent Payments Under Lease Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">3,277<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">3,447<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">3,718<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2024 and thereafter</a></td>
<td class="nump">6,735<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">20,377<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(5,529)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="nump">$ 14,848<span></span>
</td>
<td colspan="2" class="nump">$ 1,175<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents recognition of operating lease liabilities.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6822796192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Asset Purchase Agreements - Additional Information - Ono License Agreement (Detail) - Ono Pharmaceutical Co Ltd [Member]<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 11, 2017 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 11, 2017 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred Revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LicenseAgreementTerminationNoticePeriod', window );">License agreement termination prior notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LicenseAgreementTerminationDescription', window );">License agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Ono License Agreement may be terminated earlier by (i) either party for breach of the Ono License Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Ono on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days' prior notice or (iii) us in the event Ono challenges or assists with a challenge to certain of our patent rights.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_PotentialCommercialMilestonePayments', window );">Commercial milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,200,000<span></span>
</td>
<td class="nump">&#165; 9,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Development Goals [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPotentialFutureMilestonePayments', window );">Milestone payments receivable</a></td>
<td class="nump">$ 90,500,000<span></span>
</td>
<td class="nump">&#165; 10,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Sales Milestone Events [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_RevenueRecognitionPotentialFutureMilestonePayments', window );">Milestone payments receivable</a></td>
<td class="nump">80,200,000<span></span>
</td>
<td class="nump">&#165; 9,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Scenario, Plan [Member] | Sales Milestone Events [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">&#165; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Government Research Grant Agreement [Member] | Scenario, Plan [Member] | Clinical Development and Regulatory Milestone [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,500,000<span></span>
</td>
<td class="nump">&#165; 10,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_SelinexorMember', window );">Selinexor [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_EltanexorMember', window );">Eltanexor [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember', window );">Up-front Payment Arrangement [Member] | Government Research Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payments</a></td>
<td class="nump">$ 21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,500,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_LicenseAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_LicenseAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_LicenseAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_LicenseAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_PotentialCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_PotentialCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_RevenueRecognitionPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition potential future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_RevenueRecognitionPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kpti_OnoPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kpti_OnoPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_DevelopmentGoalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_DevelopmentGoalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_SalesEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_SalesEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_ClinicalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_SelinexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_SelinexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_EltanexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=kpti_EltanexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6678105168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity for Employees and Nonemployees (Detail) - Employee and Nonemployee Stock Option [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Aggregate Intrinsic Value,Granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning balance</a></td>
<td class="nump">8,917,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">3,325,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(394,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(2,005,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending balance</a></td>
<td class="nump">9,843,094<span></span>
</td>
<td class="nump">8,917,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
<td class="nump">5,391,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding, Beginning balance</a></td>
<td class="nump">$ 13.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="nump">8.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">7.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited</a></td>
<td class="nump">13.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding, Ending balance</a></td>
<td class="nump">12.40<span></span>
</td>
<td class="nump">$ 13.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 82,134<span></span>
</td>
<td class="nump">$ 8,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 39,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kpti_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6724435552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Were Excluded From The Calculation of Diluted Net Loss Per Share Due to Their Anti-Dilutive Effect (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Outstanding Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from the calculation of diluted net loss per share due to anti-dilutive effect (in shares)</a></td>
<td class="nump">9,843,094<span></span>
</td>
<td class="nump">8,917,084<span></span>
</td>
<td class="nump">7,019,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from the calculation of diluted net loss per share due to anti-dilutive effect (in shares)</a></td>
<td class="nump">787,320<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">253,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6633725392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Operations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (873,338)<span></span>
</td>
<td class="num">$ (673,748)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808226176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=kpti_XpovioMember', window );">XPOVIO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock', window );">Schedule of Product Discounts Returns Allowances Reconciliation</a></td>
<td class="text">The following table summarizes activity in each of the product revenue allowance and reserve categories from the date of approval by the FDA through December&#160;31, 2019&#160;(in thousands):
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px; width: 92%; font-size: 10pt; border-spacing: 0px;">
<tr>
<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Discounts&#160;and<br/> Chargebacks </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees,&#160;Rebates,<br/> and Other<br/> Incentives </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr>
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance at July&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision related to sales in the current year </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,657 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,318 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,209 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Credit and payments made </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,655</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(499</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,154</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px; background-color: rgb(255, 255, 255);">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="margin-left: 0.26in; margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Ending balance at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,002 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,819 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,055 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of product discounts returns allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ScheduleOfProductDiscountsReturnsAllowancesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kpti_XpovioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kpti_XpovioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808327184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4. Investments </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The following table summarizes our investments in debt securities, classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> as of December&#160;31, 2019 (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 7%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized&#160;Cost </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Gains </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Loss </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,110 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,004 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,990 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,017 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(255, 255, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,121 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(44 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,114 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following table summarizes our investments in debt securities, classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> as of December&#160;31, 2018 (in thousands):</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 6%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized&#160;Cost </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Gains </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross&#160;Unrealized<br/>Loss </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,254 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(178</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">44,001 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(23</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,131 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(17</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,000 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,007 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,393 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(227</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; padding-left: 0px;">)</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,179 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2019 and December&#160;31, 2018, we held 27&#160;and 79 debt securities, respectively, that were in an unrealized loss position. The aggregate fair value of debt securities in an unrealized loss position at December&#160;31, 2019 and 2018 was $63.8&#160;million and $180.6&#160;million, respectively. As of December&#160;31, 2019 we did <div style="letter-spacing: 0px; top: 0px;;display:inline;">no</div>t have any securities in a continuous unrealized loss position for more than 12&#160;months.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2018, 8 corporate debt securities with a fair value of $14.9&#160;million had been in a continuous unrealized loss position for more than 12&#160;months. The unrealized losses of less than $0.1&#160;million related to these corporate debt securities were included in accumulated other comprehensive loss as of December&#160;31, 2018. At December&#160;31, 2018, we did not intend to sell the securities with an unrealized loss position in accumulated other comprehensive income, and it was not likely that we would be required to sell these securities before recovery of their amortized cost basis.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have experienced a credit loss and have the intent to sell the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>investment or if it is more likely than not that we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The unrealized losses at December&#160;31, 2019 and 2018 are attributable to changes in interest rates, and we do <div style="letter-spacing: 0px; top: 0px;;display:inline;">no</div>t believe any unrealized losses represent other-than-temporary impairments. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6661556896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8. Stockholders&#8217; Equity </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Underwritten Offerings </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On May&#160;7, 2018, we completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offering under our shelf registration statement on Form<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;S-3 </div> (File No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-222726)</div> pursuant to which we issued an aggregate of 10,525,424&#160;shares of common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $14.75 per share. We received aggregate net proceeds of approximately $145.7&#160;million from the offering after deducting the underwriting discounts and commissions and other offering expenses.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On April&#160;28, 2017, we completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> offering under our shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3 </div> (File No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-214489)</div> pursuant to which we issued an aggregate of 3,902,439 shares of common stock at a public offering price of $10.25 per share. We received net proceeds of approximately $37.9 <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>from the offering after deducting the underwriting discount and commissions and offering expenses.</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Controlled Equity Offering Sales Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">On December&#160;7, 2015, we entered into a Controlled Equity Offering Sales Agreement (as amended on November&#160;7, 2016 and December&#160;1, 2017, the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co., as sales agent (&#8220;Cantor&#8221;), pursuant to which we issued and sold through Cantor an aggregate of 9,172,159&#160;shares of our common stock, for net proceeds of approximately $89.1&#160;million. The Sales Agreement was terminated effective <span style="-sec-ix-hidden:hidden10182875">August&#160;12, 2018</span>. Under the Sales Agreement, Cantor sold shares of our common stock by methods deemed to be an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;at-the-market&#8221;</div> offering as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). We paid Cantor a commission of up to 3.0% of the gross proceeds from the sale of the shares of our common stock pursuant to the Sales Agreement and provided Cantor with customary indemnification and contribution rights.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2018, we did not sell any shares under the Sales Agreement. During the year ended December&#160;31, 2017, we sold an aggregate of 3,405,763 shares under the Sales Agreement for net proceeds of approximately $37.0&#160;million. </div>&#160;</div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Open Market Sale Agreement </div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;17, 2018, we entered into an Open Market Sale Agreement (the &#8220;Open Market Sale Agreement&#8221;) with Jefferies LLC, as agent (&#8220;Jefferies&#8221;), pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $75.0&#160;million (the &#8220;Open Market Shares&#8221;) from time to time through Jefferies (the &#8220;Open Market Offering&#8221;). </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under the Open Market Sale Agreement, Jefferies may sell the Open Market Shares by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act. We may sell the Open Market Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Open Market Sale Agreement, but we have no obligation to sell any of the Open Market Shares in the Open Market Offering. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We or Jefferies may suspend or terminate the offering of Open Market Shares upon notice to the other party and subject to other conditions. We have agreed to pay Jefferies commissions for its services in acting as agent in </div></div><div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">the sale of the Open Market Shares in the amount of up to 3.0% of gross proceeds from the sale of the Open Market Shares pursuant to the Open Market Sale Agreement. We have also agreed to provide Jefferies with customary indemnification and contribution rights. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, we sold an aggregate of 3,712,359 Open Market Shares under the Open Market Sale Agreement, for net proceeds of approximately $46.2&#160;million. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6645281136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12. Stock-based Compensation </div></div></div> <div style="width: 100%;"> <div/> </div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During 2010, we established the 2010 Stock Incentive Plan (the &#8220;Plan&#8221; or the &#8220;2010 Plan&#8221;). Under the terms of the Plan, we granted options to our employees, officers, directors, consultants and advisors. The exercise price of each stock option is the fair market value as determined in good faith by the Board of Directors (the Board) at the time each option is granted. We granted service-based options under the Plan, which generally vest as follows: 25% of the shares vest one calendar year from the vesting start date, 2.083% of the shares vest on the first day of each month for the three years thereafter. The options granted under the Plan generally expire in 10&#160;years from the date of grant. We will grant no further stock options or other awards under the 2010 Plan. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2013, </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">the Board </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> adopted and our stockholders approved the 2013 Stock Incentive Plan (the &#8220;2013 Plan&#8221;). The 2013 Plan became effective immediately prior to the closing of the IPO and provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Plan is equal to the sum of (1)&#160;969,696 shares plus (2)&#160;the number of shares (up to 2,126,377 shares) equal to the sum of the number of shares of common stock then available for issuance under the 2010 Plan and the number of shares of common stock subject to outstanding awards under the 2010 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&#160;31, 2014 and continuing until, and including, the fiscal year ending December&#160;31, 2023, equal to the lesser of (A)&#160;1,939,393 shares of common stock, (B)&#160;4% of the number of shares of common stock outstanding on the first day of such fiscal year, or (C)&#160;an amount determined by the Board. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In January 2019, 2018 and 2017, the number of shares available for issuance under the 2013 Plan was increased by 1,939,393, 1,939,393 and 1,675,513 shares of common stock, respectively. As of December&#160;31, 2019, we had 2,373,779&#160;shares available for issuance under the 2013 Plan. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with all share-based payment awards, total stock-based compensation expense recognized was as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,457 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,686 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,208 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,834 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,589 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,197 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15,291 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,275 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,405 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Stock Options </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">The total stock-based compensation </div> expense related to employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options for the years ended December&#160;31, 2019, 2018 and 2017 was $12.6&#160;million, $16.4&#160;million and $16.7&#160;million, respectively.&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes stock option activity for employees and nonemployees: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px;width: 92%;font-size: 10pt;border-spacing: 0px;">
<tr>
<td style="width: 53%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 5%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="width: 6%;font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 1pt;padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Options </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(year) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregate<br/> &#160;Intrinsic<br/> &#160;Value </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in<br/> thousands) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,917,084 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.78 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7.4</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,197 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Granted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,325,390 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.67 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Exercised </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(394,358</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">7.18 </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Forfeited </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,005,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.36 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden11073498">9, 843,094</span> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12.40 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7.0</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">82,134 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,391,153 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14.65 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.6</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,879</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The total intrinsic value of stock options exercised for the years ended December&#160;31, 2019, 2018 and 2017 was $2.2&#160;million, $6.0&#160;million and $0.4&#160;million, respectively. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The fair value of each stock option granted to employees is estimated on the date of grant and for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> on each reporting date and upon vesting using the Black-Scholes option-pricing model. The following table summarizes the assumptions used in calculating the fair value of the awards:</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended December&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Volatility </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">79%-81%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">79%-81% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">79%-85% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.5-6.0 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.5-9.8 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5.5-9.6 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.42%-2.58%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.50%-3.05% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; text-align: center;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.76%-2.29% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; text-align: center;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Dividend </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;%</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We use the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment</div></div>, to calculate the expected term as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term for options granted to employees and utilize the contractual term for options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. The expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to us, including early stage of product development and therapeutic focus. For these analyses, we select companies with comparable characteristics to</div>  <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">ours including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the options. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. We account for forfeitures as they occur.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Using the Black-Scholes option-pricing model, the weighted-average grant date fair values of options granted during the years ended December&#160;31, 2019, 2018 and 2017 was $6.01, $8.91 and $7.22 per share, respectively. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">At December&#160;31, 2019, the total unrecognized compensation related to unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option awards granted under the 2013 Plan was $26.7&#160;million, which we expect to recognize over a weighted-average period of approximately 2.66&#160;years.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Units </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one share of our common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of our common stock on the date of grant.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;">We grant RSUs with service conditions that vest in </div>two<div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"> or </div>four<div style="letter-spacing: 0px; font-size: 10pt; text-indent: 0in; top: 0px;;display:inline;"> equal annual installments provided that the employee remains employed with us.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2019, we granted <div style="letter-spacing: 0px; top: 0px;;display:inline;">1,065,970</div> shares of RSUs under the 2013 Plan. The following is a summary of RSU activity for the 2013 Plan for the years ended December&#160;31, 2019 and 2018, respectively: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 15%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of<br/> Shares<br/> Underlying&#160;RSUs </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/> Grant&#160;Date<br/> Fair&#160;Value </div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25,000 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.87 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Granted </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,065,970 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.25 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Forfeited </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(286,150 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.24 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Vested </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(17,500 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.96 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">787,320 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9.28 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The total stock-based compensation expense related to RSUs for the years ended December&#160;31, 2019, 2018 and 2017 was $1.6&#160;million, $0.4&#160;million and <div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>3.4&#160;million, respectively. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019, there was $5.8&#160;million of unrecognized compensation costs related to unvested RSUs, which are expected to be recognized over a weighted average period of 3.12&#160;years. </div></div>  <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We have an Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that permits eligible employees to enroll in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden10168480">six-month</span> </div> offering periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first or last day of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month </div> offering period, whichever is lower. Purchase dates under the ESPP occur on or about May&#160;1 and November&#160;1 each year. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In 2013, our shareholders approved an increase in the number of shares of common stock authorized for issuance pursuant to the ESPP to 242,424 shares of common stock, plus an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2015 and ending on December 31, 2023, equal to the lesser of 484,848 shares of our common stock, 1% of the number of outstanding shares on such date, or an amount determined by the Board.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">During the years ended December&#160;31, 2019, 2018 and 2017, $1.7&#160;million, $0.9&#160;million and 0.4&#160;million, respectively, was withheld from employees, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> basis, in order to purchase 415,257, 98,770 and</div>  <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">57,582 shares of our common stock, respectively. For the years ended December&#160;31, 2019, 2018 and 2017, we recorded stock-based compensation expense <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">related to the ESPP<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>of $1.1&#160;million, $0.4&#160;million and $0.2&#160;million, respectively. As of December&#160;31, 2019, 404,332 shares of <div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">our</div> common stock remained available for issuance under the ESPP. As of December&#160;31, 2019, there was $0.4&#160;million of total unrecognized stock-based compensation expense related to the ESPP.&#160;The expense is expected to be recognized over a period of four months.</div> The fair value of the option component of the shares purchased under the ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%; padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 4%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended<br/> December&#160;31, </div></div></div></div> </td>
<td style="padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">61<div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div>-104% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">48%-61% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">48%-78% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years) </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.5 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.5 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.5 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2.4<div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div>-2.5% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.3%-2.1% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.5%-1.3% </div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;% </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6641980912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Segment Information </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. All of our revenue to date has been derived in the United States. All of our material long-lived assets reside in the United States. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On an ongoing basis, we evaluate our estimates, including estimates related to our net product revenue, clinical trial accruals, stock-based compensation expense, interest expense on our deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div>&#160;other reported amounts of expenses during the reported period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Although we regularly assess these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. </div>&#160;</div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Principles of Consolidation </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements at December&#160;31, 2019 include the accounts of (i)&#160;Karyopharm Therapeutics Inc., (ii)&#160;Karyopharm Securities Corp. (&#8220;KPSC&#8221;, our wholly-owned Massachusetts corporation incorporated in December&#160;2013), (iii) Karyopharm Europe GmbH (our wholly-owned German Limited Liability Company, incorporated in September 2014), (iv) Karyopharm Therapeutics (Bermuda) Ltd. (our limited liability company, registered in Bermuda in March 2015), and (vi)&#160;Karyopharm Israel Ltd. (our wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div>owned Israeli subsidiary formed in June 2018). All intercompany balances and transactions have been eliminated in consolidation. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist primarily of demand deposit accounts and deposits in short-term money market funds. Cash equivalents are stated at cost, which approximates fair value. We consider all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. We do not hold any money market funds with significant liquidity restrictions that would be required to be excluded from cash equivalents. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We determine the appropriate classification of our investments in debt securities at the time of purchase. All of our securities are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> and are reported in short-term investments or long-term investments based on maturity dates and whether such assets are reasonably expected to be realized in cash or sold or consumed during the normal cycle of business. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div> investments are recorded at fair value, with unrealized gains or losses included in Accumulated Other Comprehensive Loss, exclusive of other-than-temporary impairment losses, if any. Short-term and long-term investments are composed of corporate debt securities, commercial paper, U.S. government agency securities and certificates of deposit.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Risk </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents and investments. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments, including cash, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses, are presented at amounts that approximate fair value at December&#160;31, 2019 and 2018. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes </div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">valuation</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%; padding: 0px;">&#160;</td>
<td style="width: 1%; padding: 0px;">&#160;</td>
<td style="width: 86%; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td>
<td style="height: 8px; padding-left: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#160;inputs </div></div> </td>
<td style="vertical-align: top; padding-left: 0px;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our cash equivalents are composed of money market funds. We measure these investments at fair value.&#160;The fair value of cash equivalents is determined based on &#8220;Level&#160;1&#8221; inputs. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Items classified as Level&#160;2 within the valuation hierarchy consist of commercial paper, corporate debt securities, U.S. government agency securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In certain cases where there is limited activity or less transparency around inputs to valuation, the related assets or liabilities are classified as Level&#160;3. The embedded derivative liability associated with our deferred royalty obligation, as discussed further in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations&#8221;, is measured at fair value using an option pricing Monte Carlo simulation model and is included as a component of the deferred royalty obligation. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a component of interest and other income (expense), net. The assumptions used in the option pricing Monte Carlo simulation model include: (1)&#160;our estimates of the probability and timing of related events; (2)&#160;the probability-weighted net sales of XPOVIO and any of our other future products, including worldwide net product sales and upfront payments, milestones and royalties; (3)&#160;our risk-adjusted discount rate that includes a company specific risk premium; (4)&#160;our cost of debt; (5)&#160;volatility; and (6)&#160;the probability of a change in control occurring during the term of the instrument.&#160;Our embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations.&#8221; </div></div>  <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">and liability </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">that have been measured at fair value at December&#160;31, 2019 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 2pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%; padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 6%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">89,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">39,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;">&#160; <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,016 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;; padding-right: 5pt;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">206,494 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">71,380 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">135,114 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;&#8212;</div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial liability </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Embedded derivative liability </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding-left: 0px; padding-right: 5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about our financial assets that have been measured at fair value at December&#160;31, 2018 and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px;width: 92%;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 7%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices<br/> in&#160;Active<br/> Markets<br/> (Level&#160;1) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level&#160;2) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level&#160;3) </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial assets </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Investments: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Short-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">143,079 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">43,978 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">U.S. government and agency securities </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,124 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Certificate of deposit </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,997 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-term: </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none; text-align: right;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt securities (one to two year maturity) </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt 5pt 0pt 0pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; background: none;"/> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">289,060 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,881 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">212,179 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div>  <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the estimated fair value of our embedded derivative liability during the year ended December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;width:;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Embedded<br/> Derivative<br/> Liability </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); height: 15px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Addition of derivative related to deferred royalty obligation<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 11%;">&#160;</td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="padding: 0px 0px 0.375pt; vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative since issuanc<div style="display:inline;">e</div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; width: 11%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black; height: 15px;">&#8212;</td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px 0px 1.25pt; vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 83%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 </div></div> </td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.25pt; width: 11%;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,300</div> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding-bottom: 1.5pt;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our <div style="letter-spacing: 0px; top: 0px;;display:inline;">L</div>evel 3 embedded derivative liability, as well as the estimated fair value of the deferred royalty obligation, is described in Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>, &#8220;Long-Term Obligations&#8221;. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, net </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:hidden10173497">three</span> to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful economic lives of the related assets. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and any related gains or losses are reflected in the consolidated statements of operations. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We review the carrying values of our long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell. We have not recorded an impairment in any period since inception. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred Rent </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from landlords related to our operating leases under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 840. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense. Tenant improvement allowances and other incentives were also recorded as deferred rent under ASC 840 through December&#160;31, 2018. Deferred rent and lease incentives are recorded as a reduction to our operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets as of December&#160;31, 2019.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We adopted Accounting Standards Update (&#8220;ASU&#8221;)<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2014-09,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Revenue from Contracts with Customers</div></div>, as well as subsequent amendments, which were codified in ASC 606, on January&#160;1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. The adoption of ASC 606 did not have a material impact on our consolidated financial position, results of operations, stockholder&#8217;s equity or cash flows as of the adoption date, as no transition adjustment for any of our contracts with customers was required.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements, and financial instruments. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects </div></div></div> </div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the consideration which we expect to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div></div>&#160;</div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Revenue Recognition</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Product Revenue Recognition </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, we began to ship XPOVIO in the United States to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited number of distribution arrangements with such third parties. Our specialty pharmacy customers resell XPOVIO directly to patients while our specialty distributor customers resell XPOVIO to healthcare entities, who then resell to patients. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with negotiating and executing contracts with our customers, our policy is to expense incremental costs of obtaining a contract when incurred, if the expected amortization period of the asset that we would have recognized is one year or less. However, no such costs have been incurred to date. In addition to distribution agreements with our customers, we enter into certain arrangements with group purchasing organizations and/or other payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of our products. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the context of ASC 606, each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the product is transferred to the customer. Accordingly, we recognize product revenue when the customer obtains control of our product, which occurs at a point in time, generally upon delivery pursuant to our agreements with our customers. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are reported. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Certain of the amounts noted are known at the time of sale based on contractual terms and, therefore, are recorded pursuant to the most likely amount method under ASC 606. Other amounts are estimated and take into consideration a range of possible outcomes, which are probability-weighted and recorded in accordance with the expected value method in ASC 606 for relevant factors, such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contracts with our customers will not occur in a future period. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following are the components of variable&#160;consideration related to product revenue: </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash discounts and distributor fees:</div></div>&#160;We provide customary discounts on XPOVIO sales to our customers for prompt payment, terms for which are explicitly stated in our contracts with such customers. We also pay fees for distribution services to our customers for sales order management, data, and distribution services, terms for which are also explicitly stated in our contracts with such customers. Such fees are not for a distinct good or service and, accordingly, are recorded as a reduction of revenue, as well as a reduction to accounts receivable (cash discounts) or as a component of accrued expenses (distributor fees).</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns:</div></div>&#160;Consistent with industry practice, we offer our customers and other indirect purchasers a limited right of return for purchased units of XPOVIO for damage, defect, recall, and/or product expiry (beginning three months prior to the product&#8217;s expiration date and ending twelve months after the product&#8217;s expiration date).&#160;We estimate the amount of product sales that will be returned using a probability-weighted estimate, initially calculated based on data from similar products and other qualitative considerations, such as visibility into the inventory remaining in the distribution channel.&#160;Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Based on the distribution model for XPOVIO, contractual inventory limits with our customers, the price of XPOVIO, and limited contractual return rights, we currently believe there will be minimal XPOVIO returns. However, we will update our estimated return liability each reporting period based on actual shipments of XPOVIO subject to contractual return rights, changes in expectations about the amount of estimated and/or actual returns, and other qualitative considerations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chargebacks:</div></div>&#160;Chargebacks for fees and discounts represent the estimated obligations resulting from our contractual commitments to provide products to qualified healthcare entities at prices lower than the list prices charged to our customers who purchase XPOVIO directly from us.&#160;Our customers charge us for the discount provided to the healthcare entities.&#160;Chargebacks are generally determined at the time of resale to the qualified healthcare provider by our customers. Accordingly, reserves for chargebacks consist of credits that we expect to issue for units that remain in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare entities, as well as chargebacks that customers have claimed, but for which we have not yet issued a credit. We record reserves for chargebacks based on contractual terms in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. We generally issue credits to the customer for such amounts within a few weeks after the customer notifies us of the resale to a discount-eligible healthcare entity.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government rebates</div></div>: We are subject to discount obligations under state Medicaid programs, Medicare, the Department of Veterans Affairs (&#8220;VA&#8221;), the Department of Defense (&#8220;DOD&#8221;), and others. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses. For Medicare, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under Medicare Part D. Our liability for these rebates consists of invoices received for claims from prior and current quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in distribution channel inventories at the end of the reporting period.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other incentives:</div></div>&#160;Other incentives offered by us include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance, which we provide as financial assistance to patients with commercial insurance which requires prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> by the patient. We calculate the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on estimates of claims and the average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance amounts per claim that we expect to receive associated with sales of XPOVIO that have been recognized as revenue but remain in distribution channel inventories at the end of the reporting period. Such estimates are based on experience with similar products in the industry, as well as actuals for our product sales to date. Any adjustments to such estimated liabilities on units in the distribution channel at period end, as well as actual amounts incurred on units sold through the distribution channel during the period, are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses.</div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue reserves and allowances: </div></div>As noted above, cash discounts, product returns, and chargebacks are recorded as reductions of accounts receivable and distributor fees, government rebates, and other incentives are recorded as a component of accrued expenses. To date, we have determined a material reversal of revenue would not occur in a future period, for the estimates detailed above, as of December&#160;31, 2019 and, </div></div> </div>  <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">therefore, the transaction price was not reduced further during the year ended December&#160;31, 2019. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product revenue, net and earnings in the period in which such variances become known. </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-style: normal; margin-top: 18pt; margin-bottom: 0px; font-size: 10pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">License and Asset Purchase Agreements </div></div></div></div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We generate revenue from license or similar agreements with pharmaceutical companies for the development and commercialization of certain of our product candidates. Such agreements may include the transfer of intellectual property rights in the form of licenses, transfer of technological <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> delivery of drug substances, research and development services, and participation on certain committees with the counterparty. Payments made by the customers may include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees, payments upon the exercise of customer options, payments based upon the achievement of defined milestones, and royalties on sales of product candidates if they are successfully approved and commercialized.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize the transaction price allocated to the license as revenue upon transfer of control of the license. We evaluate all other promised goods or services in the agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. Optional future services where any additional consideration paid to us reflects their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations. If optional future services are priced in a manner which provides the customer with a significant or incremental discount, they are material rights, and are accounted for as performance obligations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We utilize judgment to determine the transaction price. In connection therewith, we evaluate contingent milestones at contract inception to estimate the amount which is not probable of a material reversal to include in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore the variable consideration is constrained. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate </div> the probability of achieving development milestone payments which may not be subject to a material reversal and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect license and other revenue, as well as earnings, in the period of adjustment.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We then determine whether the performance obligations or combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. We evaluate the measure of progress, as applicable, for each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded within deferred revenue. Contract liabilities within deferred revenue are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based royalties, including sales-based milestone payments, and a license of intellectual property that is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Our contracts with customers have standard payment terms that </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">generally require payment within 30 days for specialty pharmacy customers and 65 days for specialty distributor<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customers</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. We analyze accounts that are past due for collectability, and periodically evaluate the creditworthiness of our customers. As of December&#160;31, 2019, we determined an allowance for doubtful accounts was not required based upon our review of contractual payment terms and individual customer circumstances.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Prior to regulatory approval, we expense costs relating to the production of inventory as research and development expense in the period incurred. We capitalize the costs to manufacture our products incurred after regulatory approval when, based on our judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Such costs are generally recorded as costs of sales upon shipment. In connection therewith, we value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. Raw materials and work in process includes all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. Inventories that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO that could potentially be available to support the commercial launch of our products were charged to research and development expense in the period incurred, as there was no alternative future use. We analyze our inventory levels for recoverability each reporting period. In the period in which there is an impairment identified, we write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value, and inventory in excess of expected sales requirements as cost of sales.&#160;The determination of whether inventory costs will be realizable is based on our estimates.&#160;If actual market conditions are less favorable than projected by us, additional write-downs of inventory may be required, which would be recorded as cost of sales. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of Sales </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs, as well as third-party royalties payable on product revenue, net. In addition, shipping and handling costs for product shipments are recorded in cost of sales as incurred. Finally, cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_DeferredRoyaltyObligationPolicyTextBlock', window );">Deferred Royalty Obligation</a></td>
<td class="text"><div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Royalty Obligation </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We treat the liability related to net revenues, as discussed further in Note 15, as a deferred royalty obligation, amortized under the effective interest rate method over the estimated life of the revenue streams. We recognize interest expense thereon using the effective rate, which is based on our current estimates of future revenues over the life of the arrangement. In connection therewith, we periodically assess our expected revenues using internal projections, impute interest on the carrying value of the deferred royalty obligation, and record interest expense using the imputed effective interest rate. To the extent our estimates of future revenues are greater or less than previous estimates or the estimated timing of such payments is materially different than </div></div></div> </div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">previous estimates, we will account for any such changes by adjusting the effective interest rate on a prospective basis, with a corresponding impact to the reclassification of our deferred royalty obligation. The assumptions used in determining the expected repayment term of the deferred royalty obligation and amortization period of the issuance costs requires that we make estimates that could impact the short-term and long-term classification of such costs, as well as the period over which such costs will be amortized. </div></div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are charged to expense as incurred and include, but are not limited to: </div></div> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">expenses incurred under agreements with contract research organizations, contract manufacturing organizations and consultants that help conduct clinical trials and preclinical studies;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">the cost of acquiring, developing and manufacturing clinical trial materials, including comparator drugs;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">facility, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left; padding-left: 0px;">&#160;</td>
<td style="width: 3%; vertical-align: top; padding-left: 0px;">&#8226;</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">costs associated with preclinical activities and regulatory operations.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are accordingly reflected in the financial statements as prepaid or accrued research and development. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Loss </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources, and currently consists of net loss, unrealized gains and losses on investments and foreign currency translation adjustments.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Transactions </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The functional currency of our subsidiaries in Germany and Israel are the Euro and Shekel, respectively. Foreign currency transaction gains and losses are recorded in the consolidated statement of operations. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net foreign exchange losses of less than $0.1&#160;million were recorded in other income for the years ended December&#160;31, 2019, 2018 and 2017.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. We have evaluated available evidence and concluded that we may not realize the benefit of our deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets. We recognize interest and/or penalties related to income tax matters in income tax expense. Our foreign tax provision pertains to foreign income taxes due at our German subsidiary which operates on a cost plus profit margin basis. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) resulted in significant changes to the U.S. corporate income tax system.&#160;For additional details regarding this act, see Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div>, &#8220;Income Taxes&#8221;. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accounting for Stock-Based Compensation </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We account for our stock-based compensation awards in accordance with FASB ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees,</div> including grants of employee stock options, restricted stock and restricted stock units, as<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">well</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> as modifications to existing stock options and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;), to be recognized in the consolidated statements of operations based on their fair values. We use the Black-Scholes option pricing model to determine the fair value of options granted. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense related to awards to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. Forfeitures are recognized as they occur. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Share </div></div></div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Our potential dilutive shares, stock options, unvested restricted stock and restricted stock units are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect at December&#160;31, 2019, 2018 and 2017 (in common stock equivalent shares): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%; padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 3%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, </div></div></div></div> </td>
<td style="padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; background: none;"/> </td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2018 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2017 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Outstanding stock options </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,843,094 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,917,084 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,019,083 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted stock units </div></div></div> </td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">787,320 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25,000 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">253,100 </div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We have the option to settle the conversion obligation for our 3.00% convertible senior notes due 2025 (the &#8220;Notes&#8221;) in cash, shares or any combination of the two. As the Notes are not convertible as of December&#160;31, 2019, they are not participating securities and they will not have an impact on the calculation of basic earnings or loss per share. Based on our net loss position, there is no impact on the calculation of dilutive loss per share during the year ended December&#160;31, 2019.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Standards </div></div></div></div>&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In February 2016, the FASB issued ASU&#160;No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Leases (Topic&#160;842)</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02&#8221;),</div> which supersedes the lease guidance under FASB ASC Topic 840, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div>, resulting in the creation of FASB ASC Topic 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;).<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>The FASB also issued amendments to ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> including ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-10, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Codification Improvements to Topic 842, Leases </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-10&#8221;)</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic&#160;842) Targeted</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Improvements </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11&#8221;),</div> which we collectively refer to as the new leasing standard. In summary, the new leasing standard requires that all lessees (i)&#160;recognize, on the balance sheet, liabilities to remit lease payments and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, representing the right to use the underlying asset for the lease term for both finance and operating leases, and (ii)&#160;disclose qualitative and quantitative information about its leasing arrangements. We adopted the standard effective January&#160;1, 2019 using the optional transition method under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11</div> and, therefore, prior period financial information has not been retrospectively adjusted.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Pursuant to the guidance under ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-02,</div> we elected the optional package of practical expedients to leases that commenced prior to the effective date, which allowed us to not reassess: (i)&#160;whether expired or existing contracts contain leases; (ii)&#160;lease classification for any expired or existing leases; and (iii)&#160;initial direct costs for any existing leases. The new standard also allows entities to make certain policy elections, some of</div> <div style="text-align: left; text-indent: 0in; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">which we elected, including: (i)&#160;a policy to not record <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and leases on the balance sheet for short-term leases that qualify and (ii)&#160;a policy to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for certain classes of underlying assets on contracts entered into or modified after the effective date. We did not elect the use of hindsight in estimating the lease term for leases subject to transition to the new standard.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">As summarized in the table below, the standard had a material impact on our condensed consolidated balance sheet as of December&#160;31, 2019, specifically through recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets of $11.7&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and lease liabilities of $16.0&#160;million for our existing operating lease for office space in Newton, MA on the effective date. The difference between the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets and operating lease liabilities is due to the change in classification of deferred rent and lease incentives through December&#160;31, 2018 from liabilities to a reduction in our operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets. However, the standard did not have a material impact on our consolidated statement of operations and comprehensive loss for the twelve months ended December&#160;31, 2019, as expense for our existing operating leases continues to be recognized consistent with the recognition pattern before adoption of the new standard. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please refer to Note 9, &#8220;Commitments and Contingencies&#8221; for further information</div></div>.</div> <div style="width: 100%; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 9%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="width: 8%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> Prior to ASC<br/> 842 Adoption </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 842<br/> Adjustment</div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1,&#160;2019<br/> as Adjusted </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated balance sheet data (in thousands): </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div><br/> assets(1) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,711</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,711</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">390</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(390</div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current(2) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3,922</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(3,922</div></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities(3) </div></div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,175</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,175</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 57%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease<br/> liabilities(3) </div></div> </td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,848</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,848</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> </div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 12pt; margin-bottom: 0px;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(1)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents capitalization of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets, offset by reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(2)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents reclassification of deferred rent and tenant incentives to operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; background: none;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap; padding-left: 0px;">(3)</td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-left: 0px;">Represents recognition of operating lease liabilities.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We implemented internal controls to enable the preparation of financial information upon adoption. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In June 2018, the FASB issued ASU&#160;No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation-Stock Compensation (Topic&#160;718): Improvements to Nonemployee Share-Based Payment Accounting</div></div> (&#8220;ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07&#8221;).</div> ASU<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-07</div> largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of Topic&#160;718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. The new guidance was adopted on January&#160;1, 2019 and it did not have a material impact on our consolidated financial statements.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In November 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-18, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and Topic 606</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> should be applied retrospectively to the date of initial application of ASC 606. We adopted this guidance effective January&#160;1, 2019 using the modified retrospective approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements, as each of our arrangements detailed below within Note <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11</div></div>, &#8220;License and Asset Purchase Agreements,&#8221; were previously accounted for under ASC 606, not ASC 808, and we have no other arrangements within the scope of ASC 808.</div> <div style="width: 100%; font-size: 10pt;"><div style="text-align: left;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;text-indent: 4%;">In December 2019, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2019-12, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Simplifying the Accounting for Income Taxes</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12&#8221;).</div> The ASU removes the exception to the incremental approach for intraperiod allocation of tax expense when a company has a loss from continuing operations and income from other items that are not included in continuing operations, such as income recorded in Other Comprehensive Income. The general rule under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-20-45-7</div> is that the tax effect of pretax income or loss from continuing operations should be determined by a computation that does not consider the tax effects of items that are not included in continuing<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">operations</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> incremental approach). Previously, companies could consider the impact on a loss from continuing operations of items in discontinued operations or other comprehensive income. However, under the amended guidance, companies should not consider the effect of items outside of continuing operations in calculating the tax effect on continuing operations. The new guidance is effective for public business entities with fiscal years, and the related interim periods, beginning after December&#160;15, 2020. For other entities, the ASU is effective for fiscal years beginning after December&#160;15, 2021, and interim periods within fiscal years beginning after December&#160;15, 2022. The guidance in the ASU may be adopted prior to the effective date. We adopted this guidance effective January&#160;1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-13, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> requires that credit losses be reported as an allowance using an expected losses model, representing the entity&#8217;s current estimate of credit losses expected to be incurred. The accounting guidance currently in effect is based on an incurred loss model. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019. We do not expect the adoption of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> to have a material impact on our consolidated financial statements. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">In August 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-13, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement&#8212;Disclosure Framework-Changes to the Disclosure Requirement for Fair Value Measurement </div></div>(&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> modify the disclosure requirements on fair value measurements in ASC&#160;820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> to have a material impact on our consolidated financial statements</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">In August 2018, the FASB issued ASU No.<div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2018-15, </div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40)</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15&#8221;).</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> updates guidance regarding accounting for implementation costs associated with a cloud computing arrangement that is a service contract. The amendments under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> are effective for interim and annual fiscal periods beginning after December&#160;15, 2019, with early adoption permitted. We do not expect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> to have a material impact on our consolidated financial statements.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentrations Of Credit Risk And Of Balance Sheet Risk Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_ConcentrationsOfCreditRiskAndOfBalanceSheetRiskPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_DeferredRoyaltyObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_DeferredRoyaltyObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643966336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our inventory of XPOVIO&#160;at December&#160;31, 2019 and 2018 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%; padding: 0px;"/>
<td style="width: 20%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 20%; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December&#160;31, 2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt; white-space: nowrap;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">December&#160;31, 2018 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and work in process </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">273</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Finished goods </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">&#160;</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212; </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total inventory </div></div></td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; vertical-align: bottom; padding-left: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">346</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px;">$</td>
<td style="text-align: right; padding: 0pt 5pt 0pt 0pt; height: 15px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); padding-left: 0px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-left: 0px; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^;L O&'NP_-KX*=BW\NHON"U!+ P04    "  L.EI0F5R<(Q &  "<)P
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MGEV>VK:^K.-E]-)V,R V/8)/$&Q$1+;O48 C@0TG=/Y>X)XBQ'O$EB(D'H*
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M3*/M4.(;.Y233O?C1:X/37LZL^=5OZ_N+QIS'OXSB,8_+M9_ 5!+ P04
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M"RJ6B[GZW\-;J*-\=!)S/+5U/_U=/+WV0]O,HT0K3?7C\GLX3K_G>?SW,#T
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M"[%&SQP? VQ\A):/D*T/ 9AA(=E$Y>! /CA WH%B':C!@7IP0%BN1XP>,-6
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MZ\XZDN+9E?9DL_WMH;"'KK]-W'TS#O#C0U>?IS\GHML_)*O_ %!+ P04
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MGMZCGP[JXM#_1C ]_U#Q\!]02P,$%     @ +#I:4*P;&.[J 0  W00  !@
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M*_^$PR>8^KFE9&K^"UQ A?2H)-0H4;GT)67O/.J))4C1XG4\I4GG,/%?8>L
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M\6S'(1L-;[KI_[#Y$^?O4$L#!!0    ( "PZ6E#EC"(?M $  -(#   9
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MR8R?8*[GEI*Y^"]P!87A00GF*(UR<27EX+S1,PM*T>)EVF47]W&Z.1QFV#:
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MKS#7<TW)7/QWN(#RX4&)SU&BLG$EY6 =ZIG%2]'B9=IE%_=QNDF2&;8-X#.
M+X#;F(=-B:+RS\*)(C,X$C/UOA?AB?<'[GM3!F=L1;SSXJWW7@J>I!F[!*(Y
MYCC%\%7,?HE@GGU)P;=2'/D_<+X-3S85)A&>O%-XO4V0;A*DD2#];XE;,3<?
MDK!53S68)DZ3)24.79SDE7<9V#L>W^1O^#3M#\(TLK/DC,Z_;.Q_C>C 2]E=
M^1%J_0=;# 6U"\=/_FRF,9L,A_W\@]CRC8L_4$L#!!0    ( "PZ6E#,)OK
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MV&PHJ%PXWOJS&<=L-!QVTP]B\S?._P%02P,$%     @ +#I:4)#E,27M @
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MV'LU'->'AI'=^"F23-]#Z[]02P,$%     @ +#I:4$(Z7>?> 0   04  !D
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M?S#;"=V_GVT<1#.T%^Q[?<[Q.<8N1JG>= =@HG?.A"Y19\RPPUC7'7"J[^0
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MZUHU$?UW3>9'E>PO)YDZU.UAV!R7_<9C?U+KT["IZEUV=C?_ 5!+ P04
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M?+,F(?03HHE^0[#N(%MX[':Q,< .11:;N^E^@>4) 8IA]XL- MC8 G7W3L/
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MW!2G@[V\E&Z$[.RVD^*#&Q2CO_!FS/S&U2DK=? BC1V0W!ASE-((6TQ\9X_
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M =TU*8708%+T'LPLU>:EF0P&I;;;C=G+8=X&0XMN?$K(])YE_P!02P,$%
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MKZU'\<X&MM/%YO10Z6T_W,[L?7L\PA\?>K.?/D]$IV\DJ[]02P,$%     @
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M2JY)5(\#H\+\>H>+D*R=7!1*2S[&:].9ZS#YW\K<!=%4$,T%8?S? CP58*L
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MD7J[4WL^#I#Q(%DWS48T#^C\'U!+ P04    "  L.EI0*L=786$#   B#P
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M]]V]%4)R91!-E,&=NK">!P7?RO8U5N]U?VOK!U+L]8TT.%^+Y_\ 4$L#!!0
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ME'1&2=*8P)0,I&0 Q=G'ZVQ&B<+XT8O)04P.8&('D\\PGPB)'NQE%,('-P1
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M007CCDR$27"2!"9) ,&DDP1AICC)!":9] E(U$G28,8W#\RQVE.88@I2$$Q
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MFEZ_&2A9MN>8\'J86OX%4$L#!!0    ( "PZ6E"Z&X\W&0(  +X&   9
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MB[J#IR:.QU?U%Y.\2N9 !&P9_5,>9;%VEZYSA)R<J7QE[5?H$XI<I\_^.UR
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M ;)O=D,.QITC )<G(/*$/@I<2!"-.*#A0F+(7@>M@^V# 34BIA&B@H5!-E0
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MG O,: $8'9NC#4&.H1:8S0*QV<Q'@#(XY(RY4L*L%V!5C\W3/0ARB*' TB"
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M^-Y0_7=^X962ZYDHQE94G?GUMN=.BGK(HJ92%Z_]M6S,]3KD?PO# \@00,8
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MHDWBU#:P_?O:3LB"&5!>B#TY<WQFF(PG.S/^+@X TOFHJT;,W(.4[:OGB>(
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M@/(N\WSOZGBISJ4R#IRG#3G#+U"_F[W0%AY4CA6#6E:\1@).F??DKW>QP5O
MGPHZ.=HC4\F!\U=C?#]FWM(D!!0*912(7BZP!4J-D$[CK=?TAI"&.-Y?U9]M
M[;J6 Y&PY?1O=51EYCUXZ @GTE+UPKMOT-<3>Z@O_@=<@&JXR43'*#B5]HN*
M5BK.>A6="B/O;JUJNW;N9'6ES1."GA ,!#_YDA#VA/"#$'U)B'I"-"%@5XKM
MS8XHDJ>"=TBXO]L0<XG\=:2[7QBG;;8]T^V1VGO)DWB5XHL1ZC$;APE&&']
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M+O1>]).N/RC>#D,<C?\DQ7]02P,$%     @ +#I:4&*:U'H1 P  8 P  !D
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MC/*I]<9%$T+5E(3[I!!!3#GXNP^#"<$F#B7@P@DBN);DE-X!+G@0*IXD_DT
MH9C-@'$6)(7AWLD*EST(=4\2_SZ 4--FE*=3QP97-0AE+?,O90@5:R9@*B-<
ML@#1+.)?*Q *T@S=.1ANNL@4URZ*:9>OHR/HMM7P1'_]+F0@DMRT>EWO_4TU
M^Z)NHV=C7=?8]W8[8ZQV[LB#2^O@VOWKH-0[V[U*]]X,/>\PL.8X]O/)]4_%
M\A]02P,$%     @ +#I:4!-N61>Z @  !0L  !D   !X;"]W;W)K<VAE971S
M+W-H965T-C8N>&ULC9;=CMHP$(5?)<H#;.+\ @(D0E2U4BNAK;J]-F @VB1.
M;0/;MZ_MA"Q,)MN](;;YYOB,X]@SOW+Q*D^,*>>M*FNY<$]*-3//D[L3JZA\
MX@VK]3\'+BJJ=%<</=D(1O<VJ"J]P/<3KZ)%[2[G=FPCEG-^5F51LXUPY+FJ
MJ/B;L9)?%RYQ;P//Q?&DS("WG#?TR'XR]:O9"-WS>I5]4;%:%KQV!#LLW!69
MY20T 99X*=A5WK4=D\J6\U?3^;9?N+YQQ$JV4T:"ZL>%K5E9&B7MXT\GZO9S
MFL#[]DW]BTU>)[.EDJUY^;O8J]/"G;C.GAWHN53/_/J5=0G%KM-E_YU=6*EQ
MXT3/L>.EM+_.[BP5KSH5;:6B;^VSJ.WSVNG?PO" H L(^@"2?!@0=@'A>T#T
M84#4!40@P&M3L6N34T67<\&OCFA?;T/-+B*S2*_^S@S:Q;;_Z>61>O2R3(D_
M]RY&J&.RE@GN&-(3GE;OIPBP*;)@$!X\3K >$DGXB.1#A) 1%R&::&@%PH=$
M1P0B5""R M&# $@D&S))$H%D/\'D&!/C9F/4;(R8!4N:80PTBS$Q,(LQ"6XV
M0<TFB$ *S&+,!)@=,DD ]G*.Z4QQLREJ-AT*P$DRC"' +,: [91C3(B;G:!F
M)X@ >,49QH!7O,:8!)C%F!0W.T7-3A$!\(HSC)D"LP@3PFV ,2.G ?'Q@]-'
M).!Y@$+@.UPC4!*#[9(C4#P9^<K(R%%/!A)1!'<# J4A/!50"!X+*#2VQNC-
ML2(!(I% QT-H\-FO4:44.L:@R8AC_)8A(2(QA8Z'$.+X$U#^'ZAU[-W5 A43
M1UMG26?'S[4R5^K=:%_+K0)32X#QS-1XML9XEVD+Q!]4'(M:.ENN=*5BZXD#
MYXIIC_Z3OA].NB;M.R4[*--,=5NTA5G;4;SIBDZOKWR7_P!02P,$%     @
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M)X.#U$X060FBCQN-K02QQ6BX,3IAHI51/\'1_YPF5IW$HA-M=)([G4\QCL/
MKI-:=5*+3KS12>_]>%D:)7:=S*J3?> 'R>Y_D"@._8T,6MT</9B^$WYN>^&<
MF%27T%R5FC$)BM%[4$TW:A8N 85:ZFVB]GR:"%,@V3 /.[1,W.(?4$L#!!0
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MTG51ICKR.OFE/?^W[K=HASI!U7%E_@@7:Q>OU.\C6#FF['_YY\O)>/+](JE
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MXSYG"+H2L# PE!!+[W^P].Y$Z<1QSCY>I:VA2W&3DFD=J<O(,.SS8!Z6B3/
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MHVB5//'@#GHQJ6C!O.OA;D<E1UY22(=)A. =Z@E<[[2 Q*");%V,&UD8Z39
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MZ!!#TY.J8+N!@7-FVU2RM_7/T,55N!)PY;>[_;(U,35R\MNBG;9DIP#^Q3U
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MJ ,J.8?X$[&CIK6D>1/[6.L$OC!F]"#;/B+,O9-([( ^SMK@=;%CN+A<B(\
MA;#U &$8P*HN6XA%?(@&T%P/G^)UK3E<$XY"U@P!E))]CZ'@.2?.I@RO)O%>
M<(E1*!ECX3QCZ.S8IO*H*#2(HGAJC7_1U-+($.#7(!+7B>'7[YVH($D]W"YT
M#E?1PE7JGF_9ZP]/F&-;2Q>XU(B1ZZ*Y8XM(>MITP^%H6KF]N]'T#-/N1JU1
M#A4V_4B2.P=]I.#-</P"026,*H>KH$9.@V=%B,&>O$H$SYPX>"9#E2Q"Z;8L
M<OB\9%/S4&6>3QW#)1-[[^I9PT:O78,\61/OR(HY*Q(5*0FY\\AXE/ MI0/L
M!NBID>CFL<$+36X$J;2J,K!/X?"8;KZDXFIRN302DYQ+%D6J:07Q9\WVG>62
M0KS" J@<[4CVM@ UG#C3AK(!64E[#_0F!6P<^T8I5B9E@J#B2=QP_%\ L/P/
M-4#AL@0=O*&F3X"=CPA4,AF-\(\Q?KRXP(\3U-IF]'%*M_4E?IPI!A_X "7/
M.X\OIG,QFO<,] 5,)YY"JPB#>:G^ :T_[W,!G<[C^>0J.CNY#9Y :U9?PP)]
M[5W!FO*';*6ZFT'J"!-O43B2X1QHETQWS"[YK0>I$INGCU0?USDUD]S&TE$!
M3GH9#>MHK+TW*=% UG;)_SB<\8F!TDFVP9VFH#3$ E0VYL/4W%BDRP3O$:/'
M$X^@I_<L#< %MJHH47F6:X(1E=7,"JP5NE0%6@7:/%TY.?(BI8\.OQZ[8-_&
M0J@C4A/);)YLP)+DO.:$/HI;[!A.YXZ(AS*\;F\XSN# 2$SWYIIH=$KA+<+"
M984.@J2OI=@;!S>2SUG[<^43BP4J$'06-0ZG+?G4%*!LVZ$$->36D7 W6?RZ
M<5Y\OB!W#!X3];7YM.^+HBS9JU!RKFH71(?<SV]R$/3==5)$XG'+SP30?6U>
M'3^QWFN29C,>@ZK$I^_ I#CYN.076OMXX= -[FOYHNJ'FC:U$FND;B!(2E8B
MRI23N+H<N YQY.L(IW_;<]IX3TX^SU)N7G2'/<V_9' )NPQ8S31$_;,4 [$C
M9@Q1"4OM[/:@OB]5\N55C;F>+]6Q]O1(^(BG+-VLPAQ!K#<O0&]VDHV82<1N
MNG@R: 0N0<)E1V6>0=\DE^TE*QO7!O9,'@Y+B@Y9JNXB&79Y_6-#=)I!;ZVR
ME0_=UO006'^E5JO%FY:A1.QG:U1W-J!T;KCZ'4>PB4RE%; T[QSH*YQ5'U,1
M4$%.5:,)ZI(G6X&14? #,$0V"!@T!6D2TGZT\>/36K((WOHA8XT"1(!]Z64M
M]S4,(%#*0$YF!P$*W70ZUE3^KU _\53/GCB1KS<PX8<T?\(><CA1KS4:5YT;
M']-:$=5W%!(>NSP'>Y'VPYHQ&GZ2< &V+27TH4JL7U+1,TLMBH5L$#/#-')0
M[=63@D]J%E2FW,+Y54RP+ADU)0,27R'B.$$T(?:$#AC!Y> 6% +K;2X3+,H?
MTX2(]WWZL,IPW;Q**W;A*[\ ;(C9IGZ/*ULG3^M.R%UB9R4U$AX+/XXJ2&-)
MN 1?7/R!,YLO&IB0A1;K!NH81J\*2C3EV\/-32.X9#>),_>M4XQ5WEA*I&P9
M0?J^E;-0M!S]6H')6:)N*:A]$MU]N/UX3?FEV-:&?E'X6B8O3RVBNT\?/K[G
MQV(Q5J<8V>JU%!?S7U QOVUR'WHPE7=_;P$XDJLI[T[WE=306)X^.:K6!_%0
MI9CWR0Z@)*Z#,IH?P/=B/P3%A++F8*>_R_*_4K8;1A1DZ3IRQ6WE[Z3R&\1)
MB$"YCJ@8%6?FPKO-\P[&2Z4L-M'VF<1?IO3:DRO[CA'H<,0RMN-Y4!E3).S]
M?5&RC.6)%E%3CM\,.R(#;'7L9WZ._O,]G8[C'*CC4;OZ]B<N3\QUF"D.O8)/
M2RT&%&1R=8E#'/41FY3T_.LF:D81,"[MJ52&\@G>+8"F&:?> A%+,BI. YQP
M@F:"I31&:3+"B#T-,2<(/;OGI+5N]"L11QS4QF![>@6G-K0C*#7XAA)9?-2B
MR!\Y*7]$6E< 0WZ5WF=YSOEW.&021"%:C6D0.WC@$X([)#&*81.:U9=)7ZX#
M,@-,XO/Y!?QWBF%<TUDT!UWRZD2BDNA J&BT359I=#J&Y^<8VS"[ EW/H)SC
M\7P&RM]KUE;-^-NKA:&1HQ$A6.)+^AM[IB")^=RO74?Y:*EG$.:/.J;.K50?
M31E,+!OATVZ9J,=FTTGDJD]*VP$&HFV6/JJPW#>]U'>R?P\"]Y'U[*Z1'6$N
M,?>\]Y:^=LYKNIRGXKFVYF+_NG_X!UA,[PMMPQ/:'9VV6FL]$_ID_8/ #\ID
M1R7U*GB+<DUR,1A&$;.X20D:Y<IV:6*\5X)N5]C+/Q;P]9_Q/ZT1N?X9?F,2
M!J$"ZX9S8[J]*6 3ZM7PFX=#EW):[#:IP[Y^3)V0%=T\9'G2XVR6M"]F9)2M
M@T#'4MN/;B "DSF#L%8_2 FHB,XS3.B.]W9,BDJ5HG7LEZ+DFV!#*?MST*XV
MF&80>.,=6SB_8#CI0[;($(P!(_UQO]P@;WG]"Z72U\6]>_OC:V]DQD.UQY)'
MI.JDF#[3=\42X4"2WO$J8G_0@GG3:RA_OOTTN)I<S&)73&# PCS9UU!ZJ3,:
M)^7-RY=8OO#)Y\S(!Q_T.VTI"KYM.D."1(<'R%BKVVCUKFB_@YN&"AP_J27E
M!9Q>$X7%FX.JK[RG7O_QR+K]R;S>JE>6K;L36H:9,"G'CZ./Z]"^<G V_D>.
MHT3/@\,P<WD]TM0U 0@YJ^XWQ8(TN##A:6^'G(\*MUC P)Q!+=$:8(HB-_G>
M)4=F)4DR6>-H=2CWG^$F6(T*EV1HOJ0B4IC,F"MU4U$:$(BYC)8O-4(I35'+
M)FG6E6M3A?#@K/H'$BCVZ,6WVQ@*-U68,\(KYBA2+8@&V.FA8VM,DC:O.5-G
M66^6(3UV3N[(O$%#!2U3<)(^'28QWFR)2+&) 34#-<Y\L'@:R$=TR\!57S[A
M=_*1W*YDK!2QW?=G$I%V)2W3>ND=R?=X820A,-=9+,F780Y%3,OJ9%F6_WUA
MTA N[*#74EZSJ\X=IS3Q1U4+LG*- Y1W#VR)<-8,4S)@:BM,NZ&ER(YM@2^8
M /1LS@ UB=Q55?7]D?2?=!S^4*"PS-V6U$-9EJH.@J*Y>K*@" H>X:GZ@X])
MA)^.FBN75B%/JBDENSUFEX)"238CA>8GE9S//BU20944O1&5<"QUK3G86";%
M& @JE0=*QPZK_'(.#(+J/K;'JGS?E8'2U%9L3Z4;18N[MM)-[>GJ4.<%[:6E
M:J>U4X8=DWKPVVE*!L24Y;)0F=*ZIILC2.ZY;J56U&&2.^V@-D=>IFAM@[QL
M0 4*BC4GNSF>]A@GA>$-:/\.UYZ/0!C+X2HP/YG%YPRM7\$?#"7[I]X'';T6
M![9@$S#/)(HQ"Q !]8!^.7.$1NZT"+6U_<Y(:;S?I4\4$PC9).;:Y&CD#T-7
MW6Z3B'=7V]([!I5ZE%?9><:B+2J-<FF0&M^^-@]RI&XEYY/2(U<UKCPZ)KS&
MFL^9W->4IEI]0.W2O17;C@@Z0894=O&$-8'9FMXN"DS#,+7CI1W-V^3NP/Y2
MP)TTT+J432&9 XQ'7 Q'L)]F:-*W\2+-ZRC!UWS>:$FJU/7N_/FZ!<URT'X/
M-'W=-VS#V]PMNN9^%\^0NS::I^>Q'0PE)NK&71_WW.!BJC6788@#5<;U:RY%
MIB=;6YP-9:AS)#EMN%3O0?/IPM0;1P,^*W)\:?428/?!N]%VE!8_A#3B--,H
MAO^ISJ;(&*\-_N1/0]=J[W<#5L><UN=?);^IN$D.B,!6.R+/*)I+U]DO8C5W
M=B-WO84%F+V,F8:*H!];0WGC)/A2,CJARX/4P]E7:8=2",K4YS;-ADI(] #G
M),+TWIMTL,KN,]+Q0(JELI;N.U=BQ>'=T/OM[,"_0B=J XD> _V8-,(RS;8+
M= &J;&^J%(4V)'?K*#R+0YBXK0/7_-=H=KP")%-Z![;VH;K_)_=@J*Q'M.&^
M4O4G,3L_!]T*2^FNHA=7PYFE"#6&'\7SE2]&WW(H'RG81ROFNISN?:P(RV $
M[Z[@KR_$A$WB3?$2(DI6T**:<I.GY1.MNQ5H;]ES<S!VJ*][T3,.QTM>906\
MVFN,Q?@639LXF1T(<.EM(."=M]>!S?(=8VJM8@V'0(;T_AJSJI&E,D006[NE
MH/.-W9/?CNE=9]7C+[M"0T(CV>UUY[@\Q!PF*\/SER#H0)O5(UYC1U@QV5W5
MLA/2ADSG(_?OSWGQ.'@ _M7\H?EO@_/V6!K@(1DW6<+(3>(A^4[R,&[#1S)#
M^#H*#N#O7\/<!GEBL*JP?F$M'_V=HZ+Q.QD%%7JQ5AP209U;-ET#N88KJ?,-
M[29HR_A'F$N4BGZ5K42QR7Z +^F+3T:#?'OK\&ZA6B-'^->H_#X%#4E''+/4
M(^,,#XDA$@^C72$KN?9WT)W7,#]YU)<3#<:CX8C_TR.M(-$\(WF0P,+BQ\A(
M$*Z/SBN,P6V_U&TIPRT6;J\YY%J3\,7$9B1S5\,Z6V,A)REU1"@LQB>,H_<8
M5[W#V)%JJ5C8HL*MY@R@['3.J>K87:W)D1+GU::HK:>B+HL=#"(2O%)4+3=I
M65#U6503*LPKT'<CAWS 2TTMY98+5[K"[IJ#/I8,ZJ[@AZ>H+0HOD@!&\&E:
M!":Q G@S$WQK1SVZE Z&(-U%(=P(HA-1SR*>=R%NA]890#"U5B4KUTK=A+;E
M>SC'F$0(#UI1!F@/(G4BGAW7(47#M)$^,T[LCXR^T,+TQ2:T>7'F<IO9O^G@
ME@H5=G^,(.LKM&)0FI--R?;2-GF#UJF,JD.P<'3K[#XLYRZ7^[*AU=L#KZ'R
M" I=%1A'1TE)Q:F$4!$J6+]GYN,R-$I$/^OY/C",Z[6TLO)WG?46ZV:<E%\S
ME=X=1"I$&':%-Q!;H[6QPNI/H0@:\!2R'K<* )/'KB'67=HT*[38%-"Q,E*E
MU.%N<F@GI]T:9FQDM86WF;D1T-N;)PZUI18EL<P09+3BH*?\ Y Z(=$DB#J,
MH867C_>3;]2!WQV^W#60T$N.CP#3A#DOR4$.5$21][_**?VG9&=JHT 7SX0]
MJR<:!_-K?=!>*:!!>M%<Y7J03._S@C"_5 =8N375&R)24]:%67(>]EC[QWE_
M)?E4RPJ!(R?GE2VC0,L0!_[X/\-Q3.*VBSXZ_91DCTG.<KC#& 0'2IDX$/8=
M,+X'$,]JX+U9DHN427!4QND0Z]["2785MJZE_J',K=G"CSV3<@IUH"@<ZQ?N
M),"8OOYM?,$]N_T/<0$'R\&G_->[??LFT-7G/];/*_/Y.@^OZPYO7PDD\%.R
MNK&=$;MYNZ;8/,]VQ^!F#T/A\<T^WX.6,EYCBN#JH6$^$.K!BJ;&^P+-8I-L
M3R;*$]9%EI\@H97H0Y:;)6T?CV/*FBQ=H-;0;*P?"$XJ 3UR%KB&&!EBF[9J
M.W#%*\JP&V-I&KF?&8UB(9=)E;KS4ODP/I5G%@C Q0L1WF+9M_NV^RU<\KT<
MA-9LD09)5)(2%J?$D9'[.ZM]R@#<T$5IH9[=K0IJTV8;\'3+_J-"RY16Q>8+
M%\6$MI/\YW*_JY<N?X)I(NZ8[;=A$OY1NC7O_S\"A*!+_=K=#[KH!UC?(0C"
MX?>^'7BP4:/L,@ 1.>[FL0=M\4S=K8=\)@84US%(K@>%@1 =KV*'5 "8"T/C
MDZSDOF5EUOA40Q=]/^KAH'='E_,?BFV(_SN"&X1/>O4T/0AM.(96?V- PU&D
M[# -/:1\]JM@"U\[87X5UY.%0N!B4@ OMST<$/6L=]4IQ4<<16?G^^W.# EH
M6&C->6R/1&)8(,9!L=!D23D@_/R6P LK OW#(1=R;6O4;IN46^K)0;!%UQ/_
M'6$6G>)*)X/^_P!7T6"#G6B*S-$*:4A:]A?D6U@$%%S836@V,B1EWJL@:T7?
M0]&J2*MC\!J9RP+]7PK6P"NC4R;JP6QH7.RQ'(TX^-=W\*N8()Y<QZ)^#?P#
M(RF_"OV!$SW:Q>P2OPGC_XHVW/0L@V$W@%C0V<"TP-C-WCL0>Y*$Q%5P486"
M XGOC24F*UB9??&ENYWMMEO"KC)2"WS2"#*R-4Y[@/WKM:747K+#1B5!A7*?
M)I$W]:P6 S:72^*)I'NW39G.FC!:VAO3 ITRP_ZJ[)?G6G2Y8-Q4GC%6A4!6
M??!HHA.9ZMCWK"R1J^;%B1\9%U0=6MMPM-IOR SYYN\16F,6$IY_ZVL$P\.-
M?I5P)(+,E_Z9D41G4K4T19R#CM7:XKN8"28;Y%R8(-%EU13AR:=+-!381W1\
MZ?KRM<&]XVTCY(8#17L9^,^,KZ'MJ!&9M]>/W.WE[2'V8_V^__+/X_/Y]Y/A
M/%IH2M'/=R\F8Y/=269#L;$:S736BU!KNXN/\Q*S*\Z[A)S,N/.>7.<,IK14
M/'0_[C!!%<Q"9W 6.R/^UWMYQ0;3 IF1U9FN4XZ!?_Y"C?E2<9:X_]]O_"U^
M8Y?%[7]'IS&)U/^U'F-UP8DQ^;^9 _DZ%*>^ BMHDXQ(9<BONMZE.;OX"SH$
MZXS\2<P@V']-<9M7!J[+Q4+<=AO_MGJV&;5)%48Y%2<F/_G4N=YR;:0KZQXY
M6MSH(C\:G0R=KA7$9AO-0%2?K]80 KPKGDBW7 ;SP_YDXI^:H0H9F>Z;]IV(
M6S-=>1+[JHGWEM2*$78TL3B$?L]!,T(7-0/#0TWA9$DM@2I=U2Q59VM+=U9#
MD&-C:PPWGS-):=&W;*L1:Z4+K'H'#(MK#B]LS>&OKI\QGD@IA8Z1:;Y@6,L1
M0Q<J3,7!)7AP*?$'?AO!H9Q*@<J8!AH>?J&*FXAW\@N];W[NQY'B0[$%&CA[
M""<2T0(HF 9,,AO%/JU1K(4Z$I?$>_4EJPI-_^/2][F4ZZ0"<3HC;P8ADL<B
M6))G2W(A!MP#G=U%L<+G@);%'_6*RG@@B;I$2Z?N^S-59R@%%NM>KDN9+O%,
MG;JDNI8-TX7P,H*L%1U##J7'^QQ+7'%\!GJ!JI?19/Z=KJYDJ*='4%R#8X]9
ME$K&G;L; G\G]W"-=S[GBID,1Y?3GH:,4+=*GMRR4F)/)^G7#W $I>A*[3)4
M#B7/*<]-9Q[.T4P.9,^,ZP("07%;K=0NU(B_?%B91F>Q:!)VMRN?/RAYI"K1
MOFM'M&134B00?#N-S693ZCVY/9CK^G(EOH*4M#=]_A#14^%1^:0OT\,HSFU3
M4XHB S%EE;%,O--R4B23 7>1Y.WXY]O;#^I?\(F,\0=>(<K1I\,*U@B30N28
M<7A/DG/C-_X39^I*WJI=UJ1GEJ=HC3M^0$>"[H#W(E6&7_&/O!@@4DHA'5]R
M(<A,)ER/(P0P2QX)-L'6RFK"T0OR!59[2DU[.CZ+KLZOXO.K<^UCMP$9]G3"
MVFQK!*<<IC.)QY-SS*8JWY]UMM[90G,.-4J4KB;J@9DPD3H;Q+,-VY3\(%^C
ME$!@EU[Z%V,1';W85 A S;H4#_HC<M6*+D02^X$3<]I;_ AC7Z<$X"TP3]=.
M0AW4'\9L,4,02G:/D8A^HLRGFW@)MG!QSFEM3.P*O$M3\K!*7FK-U1UKT8G5
MRIFI.KC6&JYE> N9"^I.FK')B2SF]\[<O;!L,W7KH_>$Q:$ZVZAY6)2?^,C6
M,%%/(Z6EEKH^O3Z+QO'5](IJM79O=QR=OCJ+9M\=37>6)KH6B72T8)%@4T]O
M>,594PU+93A>27S4A<2XFM:T++X246N QYP!.<V/A+WC[::^W>K$9J&POW%\
M?C&/Y^/^93NJF&NLP-4)'/II?'%Q]?6CIF5IAK,E6D]&V)^*J\I!:TKI;!GD
MT@ITML:X:JA)9<2"5DJS_Z",/JW(,U^XCK:HOWK=B^@\GLVQ4/1E?'Z))1G'
MXW@RNCRY8WM<K+>XB&687A7E5[IN+N/+Z0S^.[^\PNI.5Q>2LIIJX$VNL 8U
MD,?D8L[9JF>C^0E?I&JH)CWK\)(0^E&DQ^?RS@4"H4M"1\J(RI\T#6C3??'R
M1 ?S4XJL*%T-S*=K5UT#%MX]&?#?COJUL"17,/'1Y8SJ @XO+J.+X8S6&!?I
M#R(N3>/I!,O:CZ++X?G%R6OG SR=7LWBZ1PK6E\,QY<G;QPC/L5*SW,L/XX%
MJ*?#Z?FQ@\(=BBZQ.O85C6HRG(TBK/D$HX+K;SIS#8FTS?7ENAK",8_C\9SJ
M3,^&Y_-H/D3*@7-Z>7%UXC<U0\AL7F5+GV8YE.*\V_.HZGX-QJ-)\2<^<N7%
MN0&VXW,O1C[:LLD</JF^X$;75BN,U<;3$$H?+E.PM<*J&,MI[8HRH-Y*,L<_
M?UK_0GE(*7'SQ=5W@\OQ=^&_\^].7I,U%P>&*;>1*]#*G<%6S >X"/COU?!2
M_CT_^9A5/P_6*,N[E,[D QP/9Y/O!I/A_/([4!;FH^\&T^$(5(_Q\.(<OY]<
M?7?R0T:E@5>:5_"[C@\_<:IT$I<RF#$KW6S\)!\\=+DLLX6_7$RI)URNUP)=
MXBS^E%84 X?6:UMTX=4>1).:RC,,09>X4"7[E56RPU4?HGQ?&>LE ?P1N)WR
MQF-QD>IGE*\QN2TP:5<[6@J7L.%KM0>^)ZE8B=<_ ",$T8=L, ]41$&L<AZ.
M5>U1V:7@*2PDBS5D"+81;)XB&G?B3D"R+'MV*S/Y9Q-"UX/PAJ!Y&-M>2D(7
M+A&[+XRJD::]O0?GDEV/O.J<2I\9$*6Y5:,HV4B'T6>'?W^U28"%WRU!BTH5
MG3# -2%(8['"_'3XW*-RUP0+1=^K(K,*:\%+\>90P5R%!9*^CE' J8"?7UP.
MX6(BUG Q!#:Z0X4%MZ\E.G26S*T=<\.*X^Z6#JXL8\O>4^GJU%> U?O'WVD?
MO5+%E^-G0F==]VA;&O/Q\>ZS"Q@P_EZR92O*7QT]Y%\C$BTZBMR1U5QM!T(.
MT'HO?X3? CJT.JLST+1ZZ6*3WFR"C6KZ<S:?1*;X&BDR9+3(*&TYR]5.3X!K
M;[-AZYHK>N13=^@ZLY6STB_D$.^_LNR64N(X'IW/XZN+T<F/3O!U8L,U$_;)
M9]W]3B$![O[1".]?8-->*' -P]>3>7#U7Y[#I3N"BQ]^F9W\A9L^!4%C/L)O
M@;#/#W9Y%5U<7H#,P7U.+D^.$+^\1.IHFK;JV^_KL:\9%0?7,Q_*?I&]=O5S
M7\Q](1R&]_8=Q58);G<@<19JA<.3X;EBT3#22]T"95N1LBU?RGXZ'$^TN(GF
MA9?#[/(#D*+C*LCEAY_30_[Z[O;6G7(BZ1UJ:!A.LP&=FP+'G52"(@H%V5#^
M_.R7 1OR_"?05]@,1@8OY <M@Q>E:V-%S&7R?T[S3/9PQY<NLX,W C2R<^)D
MR-@RF\2SR:Q7@R-;0-L.\ UF "E&)"JQJK!,4'/&X#B%^7CU?79)]7$.5K$=
M=RCN5D#7=R5(2/)ZE\<HXS]\VQT8X\F["$[>57#R>@7EF,,]@5L^8% 1&6ZM
M/3^G4:-5>% GOT1SX$>7DX.K$UZT;[Z!E;BD*I0/^FNXEZ-$&)85R _(X.?C
MZ#O8]>\&YV/^]^+R@  ^&L[U_[U"-RA?$8K84Y2PH5%X]KL!_GF4J-WT2,U&
MX].?SXASM NYNZ(4KQC5=L #]?M;6"PE!ZXO?PO\L^QHPU9F_(09!UYM8 N.
M=&E-AY$9LF>*^JWI4 S?T.< "8I$C*;IW;1E\AA_X0JH:)#!8\SJB%$*\.ZS
MHTC8OD),Q(5-,/-RM3IQC)@[V7LKLY+D(#@A]X0_D'*2<H81Z4'5I["2IF%I
MWBB_37[!&EQ#$R80LJDQ!UZHMR*Z2]9I],>D7,"A\49>YQM(R$&(\ K00& F
M/"(V(U;))BG9O>]GM&(H+P,*&QQBW*I-[Z]N/4IV";]%)F@R@R9)OLWA0*?1
M)RR9V/_;<95"QS.TV?GVL(04O?TNO<\JJ8KSP5P%DXFMM8X%U B'IJP]S&Z!
M<+-4PL8WR2,]@8W?[,6G^:=B046-W>W^Z>9/UPVTZ\:,A++GBQ.*JC=HI#A5
MD&1&XKQH6CU ZS9-8<_QK@7F0ML"+_"V>-,XQZFT"HX/N2 7ER_1J:9Y0LP.
M)L:1GRGEXR>@K>!A6$EPCGCL$3'XM>; Y%)4J.V[N/9NW-*%GQ7.0NNPE!*K
M+%"^VJ3?HB+(:]TJ7V$-9U]J#4*I&^+$.M+JX:PLW21Q/T3JJ1KU8]8(\6$(
M/NZV+S6K-XLI!$.&X6>4B<OP D.QRPWE!=X>>LQ:166PTH+#@Q"W!B+<LD >
M+!5;4PS>HUBO,6,52!,)8<@BCP9SA3BD/%BP+,B*T<R0:@P)7NA$D,=LMA A
MDY,'O+G2$!1LV]%.T2X[/+'<Z>NG56I=.9V?8!,R9@EN8Z/5/O7KK<.TU:;:
M!['!6'Z]2,.".+:(7;@BF6LNM@E,/X\<C-*5Q)/H/BG#]8<4P:H81[_WE;ZP
M-4\Z.PYFH5W2)WRW&'*Q)QLP-L[-V=QCO 7<*0NS"2E< Y+@^=I&+ 8P'*:K
M$&*]P8+=4H@PZ)28RU$^CZ;0]D;F\ *TY6D\)649/Z-OXXH_3^?P&;X_H9T$
M[?D<RW1BZ93Q#!W':%@_O9K&D]D8'B)_!M;$/!U?7<5S;7!\<1E/+\?R!S1_
M-<&G?S!T;&J6V+1W(($ Y6"$848Q,CF"G35<'$F&BYXB]7>?)SKG;6ZD3DJE
M&%"^=D6E@HZ%0H>;0$6LNHYQF6I^BW2EG,"[7H[9DF YI-V7O.R2([7F;)2F
M;"&2Q#(IRR>8)CNVT9<TBJ]&5)]F#)LU/3^YZY/W05RZ&L_(A36Y/+G&HC"X
M?1Z:T+W^LQ@$ZV@:GX_F_9XR+L=71>?H,YQ%0"S3T<7)3;++:JES6/:].HZQ
M".P82.;RY TE(36;"P(#,&K4Y:MH'E]>3=$C-YGXU5-(&[0R'T?SB2?S9Q=O
M%EU,3MXU:D%B!=JI*TSDNU&H*# ITK$I&H8=??.I?^$O;?8*)VPRBZ^@53Q&
M%WAX+O3P=%(7[.-L/$8OX7S:H!-#ZR]/;HH<Y/@Z<W460;"&/P77>SJ&J4S'
MU"FU!'U^M)5%J3?TF<W.)[XJ4GO*)C3K=#Z^-(]V3,$>QE.9B!W!CVG=.>>N
MJE JEG@H.1XS]C]\$5LQE3:C9U#X7*:4<(70"8K+Q]KBL":RO?V'VH3ZX!/L
MO^ 7 B)**U^INY'D@$/\MLBR!>5.5Q$I.FIQU?"I ]R%$%[XTD)'CQBZ:P(S
M8T;;I\XR]GVW._'$3B;6;4K4*U> OETM>C1"0PB9VV3 J^,,QY0(&$Z(-[C$
M+.*^@+-B +#'-7>)^2XR='G#>(RH8JORK#M80TI%+_$^@JMCX_,4=8@9R%/W
M6M;V(37ZJDJ8YB66@XKP"B=@\WJ3+HW(URE#9Q;=</!J;_>LPTUJ,T*VKXR'
MH^@[_6<ZPW].2$\S[\>\2+[2HQ(N;C':9/"_<]BT[TYN2?8AV=!<&Z<HJ)\Y
MPPP\?3J%Q\^^>^X2B<YI7!?#2_CO)=J"'$NGX6LG!/0^G7 OT/:,_KVB?T]N
MV%L*B]M%P*>3.0T%A1\@,?PPYO=\)3I2VTB?L*5D4<G_SEFH<.'8%'0ZDO[Q
M =/>F[;2859D-)S2NDQI$"?>S-&D(/]*QZ>^6N3N)#M #XD7NJ'/WH]M)6-^
M<6ZT+[)ZS"87-CEFPS1*,K!DRR'(!&H5K)(H_-[/U-P=():S4.7%>#NV/MX5
MF^<UAL>^1A7548@'?HBA LBGUZFX5EQ4!+)?P>0F'.6$D3XK$N-5L9Z,IA>]
M *J>A3]2INM8]M$$""5T!!VUX@ZNU5KVJG'<@XM;DEX]MP#1E1T']ZP.G&")
MH[66^#MRN9RJWL<I<,3"+9Y;O&A^V:39OL4+UHL-3+I>C272Z1ZW2O^%G<],
M3(+3;%U@PENTNR,V5?.1WQ0K*17?0:8$QNU;>%2)# B72]"RA1K>)1G5\U%U
MVK3ZOQ/WME>!2&!A'QHSAA^_<F!\%MB(X<?GS<T;+,@8U,QVJ;9\!I\M1EA2
MWGXICB2/%H\@5F!=6._"0%NR42@#3Z(X2SEJP"0VD^WN$PC51IG48I>NN"@M
M%_*U_&J?[RM"@CC!9^DN0HDU-!.NFD$ Y_3*F^N[5UJ&_?KN,_TP&)_;T#=1
MV_VL::/37.(. Y>RKB(IW@(>H@5L"RM?P5$Q2%#*FOJE+[]N#(PV"0,T??%U
M;YR@F:,5*7?H#6?H(:M#M@FO;*GXVI7GF2%2>F"9Q@4/1R+.7T',K5;9TL"=
MA!O&'4]W=(H'T<>6&)+G=4Y<\@(?Q.+,W]TR]7G46T1XB'67&3;%,"K12P)J
M;1S(N-$IK!(?!?S:OX362)':$2J78(R&Q @R(TFE!I69TW-\19>P"$U^AK_H
ML9'Y[-')^7>6TA-EQPQM:%6\?E?D]X-/Z._TL7XMK\STN\BJ[7=ICK$M/Q9X
MIG_8(X!Z,O_*8MCS841=,V#-Q/Q/AZ/1@>Y6VMT'SP- 8_?'C&K IQP'Q$EK
M! /U8CRW*9(3!P,&U2M'S^!&?7QR6G@D2S.2BD>2AR.QCDL:I'< !>54"L.U
M[(B%:26Y314!RJ45  X.%OOGU6GB,TB]=J%V 2J1' Z*4#$=<T,&(\M028Y0
MU1=*?Y?("O.AYY?)V$N5)C).7(DV)_\H-NK]MXCURNJ]]+[8/TGC6$2>\S+D
MT<<]+/YX-KLVH'T#-;U><K*A9N2TB8.^WV<K8U=8"':2-]<YR-F@Z.*IL%Z&
MBW#7U@RPV=O?? $B=02^<[_=Z&]!,F#&L8E9S@Q#-L>AA?ZV[VXCV'9TE$C^
M"Y]@"1W4H1VZ8TQN+,V.8KV.*:!<7J,<9G6]24W?>$<GU4-\ !U"*!A)6>1L
M%/@22TP'4"7BIR@D>TY'= 91I\*3[*+PT<K)B=HV^1BO-SFK%K5O9<FAOLS>
MO5VFD7T2Z/ 1Z0_C*39P-C>&@M!/DA+<&;[F4N@4:N&#S<4=B4BV;]VA$*W9
MSG^B)."TTEH,GQUS#8*V*3RE&1??ZIT]I;9ZNW>LH:CJ.<HNR58#(!//( BV
M2C7+B)_N08B"?4I78<8AZ( 247MQC7+GJ3><N#-"?<FPMDN>.'0DW68L(V^>
MB/W ]N-]76C* D&)N;MC[G!FS3@S\XK*#9\Y&X6>UMB< TT%8.\+ @[\PT^'
M5M<:GF"LI%@<*1V'QA1K8@0#GO,9+5M/]0+HL$0]$7E.9DKJA\309A.8!$:R
M$7(R D38I)R)XP">>,UYLS:487TRPG0--))5\E1%IX\/*;-GNH#I.%)ZGB_I
MF36S&@CGR#X4MN;FV!D*2*,VS^N1"N-[87$XF5]S 2F('!,%EFQ*=_!FH(;Q
M=.1PA(;M\Z+HQ<(454AVZ0136"]9R?9C^OX$(V"#Z@ZH ^RK+$=W,HY:EL*.
MFK<=B6/-!=TZU^<$PS9A!Q^).C9F3&L*&UVE6\D\0N&4#BY.V^J&()PI&%+W
M"HI;7EHE@P#F+3@YG9UYEP@%)Y"9EK15SM1.EZ=Z[DD%KC@[@ :FA/$>\#O*
MPO>HTN;:,\V,M"64USDI(M89LG*5!G-[MD&(T@EF@*<#3.O:_)7N(&Q4&J1"
MFG2R85&+,LCZ+YS17GC?=(B(TBB8GC%JU6&2JS&VV4-P?O411-+J/WA*DG+\
M9'/6K>,9!,]S?$'N*U]4" ["CF 0L@R>>B38QE,3SU/9\WCD%^.P+*V@<2XY
MI1AFT=Z1:>QSO-G<]40\C\ 9@=2/!\@Q9',WH!+1.$XN_SM+Q)QG].=T\(CA
M-R#+ Y.1')MB'R$)2 QRO%J<=C#H)/:ZJLE3[\B 3HYE,47S"5J5[H;7XCV4
MGUCE[!+1+,_0K? ..7Q)K599N=QO.1.>6!)<>AQ4R&DI@]WJDIE(W1N-&T(-
M;,5RS_85D)@9 >6X9Q 4@YGFX$W@Z5[&IS5P>5/59&Q2Z=CU60/[I[J4GT+9
M[-&GKE7]? OB"M\4M7&PX;FFS#:F46S+(LX7R8:6J<%">HQ1@?QZ&/KQKJW8
MO#RY=:<%0X G&*%R\@[X^DL6*37MJZ3I">5+M,N>GD_B<\03D#N]N9G0YN@J
MOIQ?G(BDZ7O&@.8YO#I&WWJ0?-"$>)!+)%@'7&IW[2+*H\+[84#2(K8A>6B,
M]\K"N8M^@;S5RW@\O)Q_=R RW1@(LO7 'Q9!$0LB3Q(V'>1*71%<X6!LD($J
M")2M<E=D!!!BT S*)7_;4]9M2<](!$B2^0*--,@,8LTMS6E]-E+:0?]BV0G=
M4V1Z#!,SO4/'1S2Q%[ 9]D.6EN@CZ0S9M3H<\2UVGOH$,UGIZ4?B/2EYU!H^
MYDLYWIPP*-C5*O:)830!6+X*_O[B8@2$/EQ0<-^B]YTW4J-"M7,R'WL+U+ [
M]%U,Y\@W->":)]"12*"!)%4+V7$(A@-XKQN3UZ/5_XMH'H\OYB?7%K>C2K3C
M N?QY>RJ^YF0.433V4PP.1U=C2?Q]/SRY W;,#%3P7:_]766Y90^LQ%'8 \[
MK<C2ZWOI5?-]G8!H-W++,$$<F/LX\1^G_N-,E7A)M12-+R? ZT8R[]:T,+7"
M%*&)PF#=PIQ.$3&&4$?^89\+>DK@RK3TGM'R0XHCUS '12K=]%DV/2]VL*J/
M JLR">% RKE+=[7 ZC68LE%J34W9;W4&;Q@Q @1JJNN*56O5#^(*ZZ_],86?
M'VZ06>G ;D&41J]6]/;MVSAZ-[QE1.+!)_\B#ZJQ[8\W'WT_N%G 1N [YSZR
M-:6%&7'.G"2J,TZPEY:8MPE#"8.2P5Z\^L0/WKH'K47/E/,6A""1]/^Z_?"7
MMYPQ2O+GDHY G%FM^U*IPJ;T]"5]L4%-[<K9,$E^#?/OP;M!:LY\Y7-R#J7:
M(.6CC5Y<S(/ZI6@3D6!A.^LW%,GWEJ(S:9^OZ3X+S*#M,F:N/GAH#@^ZM+W<
M<;'JOF[XY!7WK+@X>;1G;,%5W3]RIY-*'7=%T<MF-*J8F63_C52W55B:2^N*
MD19=U!*TI&EQ?<5B66L?34TJA]:)<5:$WCFV:-K1KQX\N;"WV6K Y>BCMVMZ
M[2'1L@%""^<^I5VK)[R&FS&8$Q0AK!)VU%LSUJ0Q^3UJ1&@O0S5:4_&$.1GN
M2W2OXV@Y5$I*H#*/%8_I4+.?@EHMC:A4O*>+0&0OUFW0RNO2)O^&QRIN#(&<
M80*#J1Y0W4<QCE3YFN^G5;KSYCFYH7_3<_XI&)"HZV(W9&'2&3F,DYL=^>X^
MUKIBL*2:_GTEH3XLT"DI.3*RVUFQY,-*LW%]06OCRT/DAMFO-'T[F^2WJ(6A
M]*XY"H+!3\?#7KIV8_&6NX-]BP^W?DPW7U)6,D"OP[RKE=1TMWXT/<(<)/Q(
MJ1PV:"E_,J&&0:QRNT>V1[B2A8H,4?NXP  IML1-!DMUH@N?BKC(3/F2<Q%.
M#D>2J)6!HKD)A<&!BZ7+E<ZB)XX:U[!CY(?7[*O&YBTJ/19!Z-Z-'22)9+^Q
M=0AB'!L>&[P'1 \ B7Y#2*5"5O[) 2K$^45,Q+D<#\@GV)-6M^ML'(V/"U@P
MLH12BNK5/M7S_\6X;NSE8>X#D0&ZBW!SJ)"OUL>V)JY;KT4F/6CW*)E,DVB:
M:2SI7[3H<D=&LS.9@"BEZKI,MNG_1M3221LX"JHCJ?YQLLJ2G"!5=-G'A1;K
M((V<IXACEM**9(C?<+E )<T*:"4)%TKG0D-H(=JDJWM>+AADH_P=PP4W&Y4#
M7?T>1-BP "((+%M1CNG'1TV&X0E!XM\#9"[R3*M(HIB[JO[=(Z2=V-2(I8FW
M(!&=T&4[ZHD9:'O?;3)O6+.-0Y-@@WZBC0I$W1->U +6;%>V" 2$@Q0:,XGB
MX7-DNDU6=':8T3,MMODJ0>;SSC =,0M*^9M%!M,17N&S[88+R(3@C15B+V#;
M>-N"UC9KF-[WE=S"A;>EXS?O8=QI!&K5IL!=W4MX,V6$BNKD9R[34!<NXY0X
MI!<FHJ6]"LS/N4=$8-8"E_=;H.R9A'J@)D;VD(#GA0=?KDL"GOF\.O0:*%[X
MD<L/^*(FRL H$QDE=&#CK9,_VBO5M6&),7"L)+]7=UKSUNFR6$6)S^WM!J,[
M_7B('[.'B$R(++9YYQPQY>"@;I)=1=:OWQ6E2R1KT ,'AWG(<'K('#:FP(A>
M',?!^]6B.;K,2$YF?.$-;#]T/.>ADB M$TSL'L-E:\,)#J YD8TM4K%;B^&%
M\+%U8"NT:=BHS;U+J=:Q;JZ<B"($"ZGWJTAKB2 E]V$(Y35%;H#I[[<[CYW(
M\MV^%HG>_K:OE!!YV]W U)3>T$>:3#*(U_/>]MH"<31'DZO:E=3L"OW9KU*E
M7B4\J1J^_2"*#\?(.I:NIN4 X5(Y]X*I?U$;" #NBP-I.KR-NI_<!DH@<V!0
M/NHN[$K'1;FLG*'"6>"#" ]%YOAHI19G44:/3H*.T^^]4GQMM<E<S\HW3\Y;
MKBL[OLY)4_Y$F+@PK960.[L I@$E-NSI05K_AH_NFRX?8B;<84>F1!0Z>NF_
M8YTE;6& *##W0ZO>!.6MI=OMSJ#I3;++6ZS'0F&F^NFLV<@KC1:_9<&NJV)%
M-ZBV\TT^_\LEYY A(;0K:,^SQ1V>?ZGR<@!1*6XJ-#)XX#;\GNY,?&!#3UF#
MI)1B>DUG<J40HS]<7]]ZS&QK4=-[8D9O?1+.HU:CX[WH@PO!J/A7QJ)1U ^[
MK<)0>A3*?&K19%'L:^$HKN BFMU!UPZ3A&;-K-.F3)-8"M!R:*-T5Z#&D[L=
MF22G\M:O!MO$EW".F7:77 OKH7@DM)W ]5#B 9U@F>H5(#5312C06F<D:%"H
M2R/%!+X$3Z#]FC1*A>Y@CD8,(V@N7Z/TC(?^K-D=P1F;8HV"4M'.UG.BN9?[
M>P:Q(VR*\]5+1<>@-.LV^2LN"^Q%PK&O7@O2B'J1M;U7D@M =E-DT((KBT?7
MSH9><HI4Q75ZNIIHTNMG5FQ>ZS7WW.]T0/G0N=NM.ZZ6I";<0V3\=![=\?%W
M+6_?5O/3AC<NW=]&%F"?KV;?23W(2 7MHC=IA<)25T'M'&,L[7NO-J >,;GV
M9>+I&Y)SCHCMD<MQ&L=G4Q0FF!;>)/E]P<@)X)3LK])J6(2DU(6R.KM?/>-N
M)7B&L;;*B&)?PZDF6DHD7T7\;$*[N.W^E*#^9_3Q5L8WSY@++&:D*8_:?//0
MHY+<Y=E\25WB@*@[XB%9NFU#6_"?X7XL=@\)"'700YGLTGV=+2O,M3.4JI_F
M$0/RORG*G7?5_?GV[D:N##:W(49J\S3 T+95]!YH#S2B/8+5*P<0Y& Y!Q<D
MEN#S@HW&TS,M/6Y&\'J/Q=ZB/VP7?XQ.6QU) IUW&)R6KAIH$;ANXU:'@<MT
M=B95/OM6Y?05=+!?)6?1NQJ(F :PD<["Z /JK,148^I_C>1=_/B>XE$Q1>:9
M*09J>GU;E0E(3[X7GF8T:)+,C0*3Z0-B=;X@_+5NLKGN.[GW[<C]0IZ U/RB
M=>\]$I^,>%N6?"DNSE.9^9(8)BD3K$-LX09SL!#T\@#OOFEVEFB4\8HK^%;N
MBNL1B#7W'M4])+/<0W;_ (/<9- L[H-:B207LK@D,C6685 EY7(E.RY9D%IU
ME%R<#F,2FTO$9IV"<6D8=D/) EO3E5S,1C#E,2():6)J?RNP!641IH1;I(TJ
MANVAM#/Z^06PUB?O\82-I3P#+1V/,WGYUTGP 56G,EGF31TOLU#!Q6X?+]-F
M_3@5TP9PL0X(6WO=^JIU" HJSZ12$_).#N+%Y* <7K!>#UXQ/"^Z>\ D\?C3
MKVOGC6/ WMA7:9B*&LM,].2>1"H)+Z9\^)U'B>,36L>.Y4>W^&Q01>)B7;JQ
M+T+T9>.F,,%=[&J,4?SEHI0Q<S*F W^WRWCA#F2A@L*>GTC\[&R7U,K*-X$4
M =10B6F? '82BTH1(:R@4M>5MQ+CT<%KM\S8STD>%!X))UHA9D(AMP&K*23E
MC00UIYIWNJCXP& [0:8NLQN%IB449N3'@J%R T%W-FGF#;*>OY"^_-[G\&M)
MF3V/=1.1%7>8'$RB>OZ"!-3,2%L^VDGQ12SPQ7Z%-":'I$X!3NO[<<3E%4A1
M96ZK.\A"J6>W1YD?./?/3ZED:/,L2^334#_CO"I](JH7.6O;-]?>RI,%.]9%
MM;+8 ;$[]%D87+NF)$(+_^B0D0R"SVHJ@^/51^DC"/[RB,TH)_LN#XAG[6TO
MG;T0])M<][[:;:NWKYB17PO/(!@23$<E42-1^SD]'!0;JOA+/U!6TBNY,C>H
M41+#: [VY0G;G<8Z^'\/8*Z9E!%*Y6YDLRH7(T>Y77-5EI8D3A3-*DV^Y7]Z
ML;3.X"\^4AU1!\;6^;,XLYGI]^D9^.U):%\#O=2T*M]95#DK^X]Y:"DFFT;=
ML!&+V&"2)FLQ]CUGD5=;7/? *3UE^T:1_(.%I!_L$L@P",=[/AKW3' <NX##
MK2ZS;CRTQNCRKBA23(_*6TJ^^BR:V=.=IU&]8(NU17WM0)ZGU/4:J-208F+6
MXSDJB?U<]P@D""07,8:P@,3"HPBZM&JJI39\>NKCK)3<!63LVD5KE/'7A16\
MW12AF86 "$0XS<K5 ,GCR9&"&)[T/FY\K4D)(JVZPT61,;^17T@RX0:W$<'@
M)%\$&Z=P$EJ($N\(T/-P!?$4B:".]=K,E2LGX2N1[9CC6Y>T072.JSI%5X^+
M3-G1&>;!&[#OK41',.'P];Q76#L4JV*+5]S2 Z4$*)4A5CLL'5UA;&J^?,#.
MHJ<LW:P$O251Z\VSST:^A-5W<< 2<W+I]V#OD24<V$PJ"XDN)A=S0K! VB:Z
M%&(A#*H'9&SYHL1H.'38* -9D\W3W[6^C&"A$AL)1$5@. KHK8D/0LL?HW,9
M4(UG7%5B5Q].-2G""* U&T]34H)\L7*<L?"$IS@<-N]TW@ =JH.P7_%K'/;2
M- IN/V/6(8\6"B[[B@JIB8]:/0_C: [_^]01/>!J!EEAAUD\@7F<\-<A^4B$
MDW<$.&].* ;UBF!X?);BV.L1-N3.;\L7FK$$!3:G(7)]2]].$[C_ _EDV#G$
M2'JYZF^9T*T/QGP^>=-8AI.F&>#ER?NV]OPBNL!TKR/[H9W^TZB[+T_NG/4!
M\Y[V</_H\BH>75RYML(_3VX:]PB6Y$,8K3X>_GG2NDGPK+5NDUE\=77AF@C^
M.G%I60Z-^13U,906'PN.,E&DY5DTB3'YCK8=_'6"@0WG\8S*%;I%'$_G\7@\
M,XOH-\@1Y\GK@P?L!9;]''5NB?OMMS@PWWQ$+O\/.2+G\>7EV'[X38[(&(M<
MFC/2^+M]2.#WJXM+3^'!GT<>DO%5/)[,?)_!GR<W7A@SLE@T#4[6]+<^6:.Q
M/5G^+SQ9R#C.1W;MX9=X?'%EUK[K#)B0LT1*KSHR;,!-^J+AR'ER\(!^:U2:
M'OL3M8)UHW,NS1RO!?O)V^+&8KPWASPJ0^86)A=K.%738I517F$&7D0NW^DS
M0[UR# FUI'?1O.V503^K8#O01KYC5ROZFX+?4OW-I:7G9"QJN&8XXE(2 7+T
M@"L-C^@H4R@^JWP#'JR$55<H^_8&F8U4_NS .X$HN-XCM_[B,: ^4:2S#'F@
M "GQG;G(WI'C]9K>.,JGT'J+8Y7(O5VWL"\NE4K;RXN"N4O[B("DK)3RFS#L
M+P0A95Q @,(* M8=@_?XT4:@LUL>Z5133DA].JQ#!]T/H^O\J6.(7*V+?> P
M5&3/91K8J[!I.-T<?%&'H;)N!&6@(1*9*(@.N,%F$]I%FR5-9%G0D)*[C YR
M%G+$?Q!U-3?7AQ+"RP=_C$R:?,:O.]@S?9%B.3B!GQF@&D;3,.(=!HFE[_AD
M:/ID:[',R.Q.Q.K XZ2OP+E=;0K,]]?P]9K<G80]$$RIOR8-QN=.%-N*R[LY
MGR5FJ'0A9)W/WQ0K[P#1UZZ=I_,LNIR-AKQ&9A$:I4)].FN76DH"A1J3\)!9
M*@E"@=#VN/-B:X[+3U^_MAQXNZF*(%'4*MA=7D>8(\XMZDO9>#EL$ 4I+E+2
MT/47<L%62JJ.?62@O]06:!=:8TC)1P^@/HHA=;Q'AFDI^-6Y\Y]WI*7[/?>5
M8-%//!A=Q2[8@"A50[3%JW=#T8$8U8I+>3XZ=W9=1@<QQMH_O]3G8_*1[#CS
MBW_(&2J-P:M:HB<<V2=MM-IO$-M CI%*SD;,7A8DC)C#&Q;J?@=.A(Q3G X$
M5._R1PPE_Z_,Q971X?2M"O6A*!K*?R.3$5M$Y0'EA+7<4KV3^Z)8$>N38K0T
M3!.%8BVEE41F6%N8RS[#.%D;JIJU@B_1\M[JD-*.>M%=IV'P^9Q^QZR10\[Z
MU_HVQ:Z50+U8R7#2'J79J>IT5[TD* ;;O-=/.EG:^M-*8JP3MZS?,RPC>-R
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M/C.@HS$JHR5?I2;((OS\IO!1R$W1&QK?)CI +891T*PS<AF91>VI/QVE^OF
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M&O1>M<>0#Y+VAIES9H\9JUJ&WJT5SZ@4K@<?.E.-9[[Q.4S4ZBI.-U>P@O@
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M#3O9JZP_?M4<=OCO:/RJ<6;S^-#LA0R;DC"/LW9K8/YK7,XWOS=O0>(M(6O
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M<B_0=I_^3NBO"M2)80T<=0<T%+SF6EWZT.'WG,V&4!ZHO-=415.T05-Z9:5
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MMD;D]$>+0&%B8U=<(W8*36RWHC!0K.BA9/:\S/?#958,NXI\%P0 8AA6Y+L
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M7G-5"@8@$P0R.2#DCP1 I@AD>A#(><#QNP+(#(',#@@YB&2.0.:'A$P!9(%
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MK[< O86OMP"]A:]W 'H'OMX!Z!WX>@>@=UC@K 0=EO#U#D#OP-<[ +T#7^\
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M60V*K 9%5H,BJT&1]?2(LD['LK?M\%V2)^<VG_/9]*?)J[]02P$"% ,4
M"  L.EI0'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    "  L.EI0)^B'#H(   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "PZ6E#GD7;D[@   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( "PZ6E"97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ +#I:4/[&RTMS P  Q!   !@
M         ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( "PZ6E"/+D6(100  ,,4   8              "  : ,  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  L.EI07MM<)$ "  # !P
M&               @ $;$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ +#I:4-?$F</L P  +1$  !@              ( !D1,  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "PZ6E HU&F>40(
M !8'   8              "  ;,7  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  L.EI0I1BI3.L$  "T&   &               @ $Z
M&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ +#I:4*P;
M&.[J 0  W00  !@              ( !6Q\  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( "PZ6E $?_Z/>04  (0;   8
M  "  7LA  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  L
M.EI0'SIAG[$!  #2 P  &               @ $J)P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ +#I:4(%&KLBV 0  T@,  !D
M         ( !$2D  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  L.EI011F7W;,!  #2 P  &0              @ '^*@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "PZ6E 88BR[M0$  -(#
M   9              "  >@L  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ +#I:4)(WR4ZU 0  T ,  !D              ( !U"X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  L.EI0Y8PB
M'[0!  #2 P  &0              @ ' ,   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( "PZ6E!-L3#]M $  -(#   9
M  "  :LR  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M+#I:4$^U\/6U 0  T@,  !D              ( !EC0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  L.EI0L%^=B+8!  #2 P  &0
M            @ &"-@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( "PZ6E _%/'/L@$  -(#   9              "  6\X  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ +#I:4(LIYY:S 0
MT@,  !D              ( !6#H  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  L.EI0A7&=$[4!  #2 P  &0              @ %"
M/   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "PZ6E"=
ME^LXM@$  -(#   9              "  2X^  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ +#I:4+WS*I:T 0  T@,  !D
M     ( !&T   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "PZ6E"P+7>_N $  -(#   9              "
M 1A+  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ +#I:
M4)O.&02V 0  T@,  !D              ( !!TT  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  L.EI0<MJA);8!  #2 P  &0
M        @ 'T3@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( "PZ6E!;*12,N $  -(#   9              "  >%0  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ +#I:4#:U*?&T 0  T@,
M !D              ( !T%(  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  L.EI0NSO&$^X!  "G!0  &0              @ &[5
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "PZ6E"AW+)N
MSP$  )P$   9              "  >!6  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ +#I:4/Z$WS+( 0  6P0  !D
M ( !YE@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  L
M.EI00GHOY+@!  #7 P  &0              @ 'E6@  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "PZ6E#:Q1K[Z@(  ,8+   9
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M970T,"YX;6Q02P$"% ,4    "  L.EI0KZ4?9]8"  !+"P  &0
M    @ $F;   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M "PZ6E 9>99)\ $  -L$   9              "  3-O  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ +#I:4,'->\*D P  +Q$  !D
M             ( !6G$  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  L.EI0F9:SRC@"  !8!P  &0              @ $U=0  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "PZ6E"(+>YIU@$
M +H$   9              "  :1W  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ +#I:4+T^J6@B @  :@8  !D              ( !
ML7D  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  L.EI0
M=MC#\P@"  "L!0  &0              @ $*?   >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( "PZ6E JQU=A80,  "(/   9
M      "  4E^  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ +#I:4$%/ 3V. @  00D  !D              ( !X8$  'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  L.EI00:]H&)\"  "Q"
M&0              @ &FA   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( "PZ6E!P60D(9@(  $@(   9              "  7R'  !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ +#I:4 9OO KF
M @  6 T  !D              ( !&8H  'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    "  L.EI0NAN/-QD"  "^!@  &0
M@ $VC0  >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( "PZ
M6E"R138:10,  (0/   9              "  8:/  !X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ +#I:4&_)&4:K 0  T0,  !D
M         ( ! I,  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
M    "  L.EI0$1>SY]4$   ]&@  &0              @ 'DE   >&PO=V]R
M:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( "PZ6E 0VJ:54 (  $P'
M   9              "  ?"9  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
M4$L! A0#%     @ +#I:4,B:7LST @  # L  !D              ( !=YP
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  L.EI0]FC-
MM)$"   !"@  &0              @ &BGP  >&PO=V]R:W-H965T<R]S:&5E
M=#4Y+GAM;%!+ 0(4 Q0    ( "PZ6E \JVUU80(  *T'   9
M  "  6JB  !X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M+#I:4&VXAVA_ @  3PD  !D              ( ! J4  'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    "  L.EI0E)>?!_\!  ! !0  &0
M            @ &XIP  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( "PZ6E!,MK.]]P,  *P3   9              "  >ZI  !X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ +#I:4-FS,2PZ @
M508  !D              ( !'*X  'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    "  L.EI08IK4>A$#  !@#   &0              @ &-
ML   >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "PZ6E 3
M;ED7N@(   4+   9              "  =6S  !X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ +#I:4%./R4^H!   O1D  !D
M     ( !QK8  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M2P$"% ,4    "  M.EI0)DQL%7D"   ^#@  #0              @ 'M9P$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "TZ6E!;X0,X* 4  $XN   /
M          "  9%J 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  M.EI0
MFK<(.TL"   7*@  &@              @ 'F;P$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  M.EI0X1^AO@0"   \*0  $P
M        @ %I<@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ )L5
(  ">= $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6818164688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 14, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Karyopharm Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPTI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001503802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,548,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,517,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">EntityInteractiveDataCurrent</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3931704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">85 Wells Avenue, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">658-0600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6975159392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (199,590)<span></span>
</td>
<td class="num">$ (178,407)<span></span>
</td>
<td class="num">$ (128,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (199,383)<span></span>
</td>
<td class="num">$ (178,434)<span></span>
</td>
<td class="num">$ (128,927)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6668381648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, matching percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, matching amount</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803303056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed at Statutory Federal Income Tax Rate to Income Taxes (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.90%)<span></span>
</td>
<td class="num">(28.20%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Provision to return adjustments</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Federal rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(33.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6645937616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and Operations </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div></div> <div style="width: 100%; font-size: 10pt;"> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are an innovation-driven pharmaceutical company focused on the discovery, development and commercialization of novel, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div> drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Our <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">S</div></div>elective <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">I</div></div>nhibitor of <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">N</div></div>uclear <div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">E</div></div>xport</div></div> (<div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SINE</div></div>) compounds function by binding with and inhibiting the nuclear export protein exportin 1 (XPO1). Our initial focus has been on seeking the regulatory approval and commercialization of our lead SINE compound, selinexor, as an oral agent in cancer indications with significant unmet clinical need. We were incorporated in Delaware on December&#160;22, 2008 and have a principal place of business in Newton, Massachusetts. </div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2019, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved XPOVIO<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">&#174;<div style="font-size: 5.476pt; line-height: 4.05224pt;;display:inline;vertical-align: top;"> </div></div>(selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (&#8220;RRMM&#8221;) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Following accelerated approval by the FDA, XPOVIO became commercially available in the United States in July 2019.&#160;</div></div></div> </div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2019, we had an accumulated deficit of $873.3&#160;million. </div></div> <div style="width: 100%; font-size: 10pt;"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have had limited revenues to date from product sales and have financed our operations principally through private placements of our preferred stock, proceeds from our initial public offering and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on </div> offerings of common stock, proceeds from the issuance of convertible debt, proceeds pursuant to the Revenue Interest Financing Agreement (deferred royalty obligation), and cash generated from our business development activities. We expect to continue to incur significant expenses and operating losses for at least the foreseeable future. We expect that our cash, cash equivalents and investments at December&#160;31, 2019 will be sufficient to fund current operating plans and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. </div></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6644852528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kpti_CommonAreaMaintenanceMember', window );">Common Area Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Allowance for improvements</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=kpti_OfficeAndResearchSpaceLeaseMember', window );">Office and Research Space Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_kpti_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office and laboratory space leased | ft&#178;</a></td>
<td class="nump">98,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit in the form of a letter of credit</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kpti_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kpti_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kpti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kpti_CommonAreaMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kpti_CommonAreaMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=kpti_OfficeAndResearchSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=kpti_OfficeAndResearchSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6644459136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory Current (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">73<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6643583232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,288<span></span>
</td>
<td class="nump">$ 7,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(4,242)<span></span>
</td>
<td class="num">(3,293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 3,046<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 593<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 598<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life</a></td>
<td class="text">Lesser&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,443<span></span>
</td>
<td class="nump">$ 5,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
